id,summary
0,"[/INST]C0C0C0C0C0C0000000000000000000C000000C0AC00000000000- aB0000000000000000000000X0X0C-,C0C0C0C0C0C0C000000000000000000000000000000000000000000C0C000000000000000000000-,', a000000000- 1C000000000-aC00000000000000000000000000000000000- 0- 10- 1- 0- 0- 1- ', a- 0- a0- 0- a- ', a- ', ', ', ', o- ', ', ', 1- 1- ', ',- 0- -,- ',-a-a- ', ', 1- 1- 1- ', ', ', ', ', ', ', ', 1- 1- 1- ', ', ', ', ', ', -', - ', ', ', ', a- ', a- ', ', ', ', ', ', ', 1000000000rdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrd0000000- 1- 1- 10- ', a- ', 1000000000rdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrd"
1,"[/INST]

Pressure Ulcer Risk Assessment
-----------------
| Examine the patient's medical history for pressure sores. | Look for signs of unstable pressure. | Assess the patient's ability to tolerate a sitting position using the block system from the bed. | Determine the patient's ability to ambulate using the cube/block system from the bed. | Examine the patient's ability to tolerate a sitting position using the massage mattress with a cube/block system. | Assess the patient's ability to tolerate a sitting position using the cube/block system from the bed. |

Comparison of the Pressure Ulcer Risk Assessment Tools
-----------------
| Examine the patient's medical history for pressure sores. | Look for signs of instability in the patient's ability to tolerate a sitting position using the massage mattress with a cube/block system from the bed. | Assess the patient's ability to ambulate using the cube/block system from the bed. | Determine the patient's ability to tolerate a sitting position using the massage mattress with a cube/block system from the bed. | Examine the patient's medical history for pressure sores. |

Comparison of the Pressure Ulcer Risk Assessment Tools
-----------------
| Examine the patient's medical history for pressure sores. | Look for signs of instability in the patient's ability to tolerate a sitting position using the massage mattress with a cube/block system from the bed. | Assess the patient's ability to ambulate using the cube/block system from the bed. | Determine the patient's medical history for pressure sores. | Examine the patient's ability to tolerate a sitting position using the massage mattress with a cube/block system from the bed. |

Comparison of the Pressure Ulcer Risk Assessment Tools
-----------------
| Examine the patient's medical history for pressure sores. | Look for signs of instability in the patient's ability to tolerate a sitting position using the massage mattress with a cube/block system from the bed. | Assess the patient's medical history for pressure sores. | Determine the patient's ability to"
2,"[/INST]
Other: [Pediatric] Diabetes, [Treatment/Intervention], Quality of Life, Augmented Reality Glasses, [Treatment/Intervention], Anthropometric Values, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Anthropometric Values, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention], Quality of Life, [Treatment/Intervention], Augmented Reality Glasses, [Treatment/Intervention, Quality of Life, [Treatment/Intervention, Augmented Reality Glass"
3,"[/INST]
Virtual reality (VR) is an interactive three-dimensional image or hologram, which can be experienced by a person wearing special glasses.
Virtual reality (VR) is an interactive three-dimensional image or hologram, which can be experienced by a person wearing special glasses.
Primary Outcome Measure: Anxiety level measured by VAS-A scale before and after watching virtual reality with smart bracelet.
Secondary Outcome Measure: Watching video with virtual reality glasses.
Virtual reality (VR) is an interactive three-dimensional image or hologram, which can be experienced by a person wearing special glasses.
Primary Outcome Measure: Anxiety level measured by VAS-A scale before and after watching video with virtual reality glasses.
Secondary Outcome Measure: Watching video with virtual reality glasses.
Virtual reality (VR) is an interactive three-dimensional image or hologram, which can be experienced by a person wearing special glasses.
Primary Outcome Measure: Anxiety level measured by VAS-A scale before and after watching video with virtual reality glasses.
Secondary Outcome Measure: Watching video with virtual reality glasses.
Virtual reality (VR) is an interactive three-dimensional image or hologram, which can be experienced by a person wearing special glasses.
Primary Outcome Measure: Anxiety level measured by VAS-A scale before and after watching video with virtual reality glasses.
Secondary Outcome Measure: Watching video with virtual reality glasses.
Primary Outcome Measure: Anxiety level measured by VAS-A scale before and after watching video with virtual reality glasses.
Virtual reality (VR) is an interactive three-dimensional image or hologram, which can be experienced by a person wearing special glasses.
Primary Outcome Measure: Anxiety level measured by VAS-A scale before and after watching video with virtual reality glasses.
Secondary Outcome Measure: Watching video with virtual reality glasses.
Primary Outcome Measure: Anxiety level before and after watching video with virtual reality.
Primary Outcome: Anxiety level measured by VAS the intervention with virtual reality glasses.
Primary Outcome Measure: Anxiety level measured by VAS the intervention"
4,"[/INST]

How is the study designed?
| Designed by: [/INST]

How is the study conducted?
| Conducted by: [/INST]

How is the study organized?
| Organized by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study organized?
| Organized by: [/INST]

How is the study presented?
| Presented by: [/INST]

How is the study presented?
| Presented by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is the study structured?
| Structured by: [/INST]

How is"
5,"[/INST]
Other related Terms: [/INST]"
6,"[/INST]
Multiple Sclerosis, the Mediterranean Diet, and Quality of Life in MS patients.
Walking Impairment Scale: [/INST]
The 12-item MS Gait Scale will be used to determine the impact of walking in MS patients. The score given for each item is 0-10 points. A higher score indicates better gait impairment. | 12 months |
Quality of Life Scale: The 12-item MS Gait Scale will be used to determine the impact of walking in MS patients. The score given for each item is 0-10 points. A higher score indicates better gait impairment | 2 years |
Mediterranean Diet, and Quality of Life in MS patients.
Quality of Life Scale: The 12-item MS Gait Scale will be used to determine the impact of walking in MS patients. The score given for each item is 0-10 points. A higher score indicates better gait impairment. | 2 years"
7,"[/INST]
| Disease |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24 |
| Disease: week 24 |
| Outcome: week 24"
8,"[/INST]

| Other: Questionnaires |
| Botox |

| Overactive Bladder |
| Questionnaires |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Other: Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |

| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |
| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |
| Botox |

| Questionnaires |
| Interventions |
| Discrete choice |
| Botox |

| Other: Questionnaires |
| Interventions |
| Discrete choice |
| Botox |

| Questionnaires |
| Intervent"
9,"[/INST]..,........................................................................... B. B............................................... a. a. a. a. a. a a a a. a. a................. D. D. D. a H a H a B. a B. a. a. a. a. a. a. a a a a. a........................................ B................................ H. H. H H B H. H. H B H B H B H B H B. B H B H B H B H B H B....... B. B. B. B. B. a B a a a a a a a B. a B.
.
.
. B. H B H B H. H. H. H. H. H. H A H A H
.
.
.
.
.
.
.

























.
.


 H
 H
 H"
10,"[/INST]
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
Treatment of [/INST]
Secondary Outcome: [/INST]
Other Outcome: [/INST]
Secondary Outcome: [/INST]
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome"
11,"[/INST]
| Group 3 |
| --- |
| Group 2 |
| --- |
| Group 1 |
| Group 2 |
| Group 3 |
| Group 4 |
| Group 5 |
| Group 6 |
| Group 7 |
| Group 8 |
| Group 9 |
| Group 10 |
| Group 11 |
| Group 12 |
| Group 13 |
| Group 14 |
| Group 15 |
| Group 16 |
| Group 17 |
| Group 18 |
| Group 19 |
| Group 20 |
| Group 21 |
| Group 22 |
| Group 23 |
| Group 24 |
| Group 25 |
| Group 26 |
| Group 27 |
| Group 28 |
| Group 29 |
| Group 30 |
| Group 31 |
| Group 32 |
| Group 33 |
| Group 34 |
| Group 35 |
| Group 36 |
| Group 37 |
| Group 38 |
| Group 39 |
| Group 40 |
| Group 41 |
| Group 42 |
| Group 43 |
| Group 44 |
| Group 45 |
| Group 46 |
| Group 47 |
| Group 48 |
| Group 49 |
| Group 50 |
| Group 51 |
| Group 52 |
| Group 53 |
| Group 54 |
| Group 55 |
| Group 56 |
| Group 57 |
| Group 58 |
| Group 59 |
| Group 60 |
| Group 61 |
| Group 62 |
| Group 63 |
| Group 64 |
| Group 65 |
| Group 66 |
| Group 67 |
| Group 68 |
| Group 69 |
| Group 70 |
| Group 71 |
| Group"
12,"[/INST]
























































A
A


A
A
A
A
A
A
A	A	A	A	A	A	A	A	A	A	A	A	-
A	A	A	A,
A	A	A
A
A
A
A
A
AAAAAAAAAAA	A	A	A"",A"",A"",A"",A"",A"",A	A	A	A					A	A	A	A	A		A	A	A	A	A	A	A	A	A	A	A	A	A	A		A	A	A	A										A	A	A		A	A																				A				A	A	A																																																																																																		1-a-a-a-a-a-a-a-a-a-a-a-a-a'- - - - - - - - - - - - - -a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a'- - - - -a'-auauuiveoiveo-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a'- - - - - - - - - - - - - - - - - -"
13,"[/INST]-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-C-
-C-
-
-C-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
--
-
-
-
---
--
----
-
-
-
-
-
-
----------------------------O------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------"
14,"[/INST]
Primary Outcome: Frequency of adverse events leading to permanent study discontinuation | Secondary Outcome: Change from baseline in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Change from baseline in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Change from baseline in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time | 
| Secondary Outcome: Percent change in vital signs over time |"
15,[/INST]
16,"[/INST]
The surgery.
The symptobe.
The symptine.
The sympt
It.
It.
It.
It.
It.
It.
It.
It
It
It
It
It
It
It
It
It
It
It
It
It.
It.
It.
It.
It.
It.
== a
== a
==>
==>
==>
==========>
==>
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
This
This
This
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
















==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
=="
17,"[/INST]

Other: [/INST]"
18,"[/INST]
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. | the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. | the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. | the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-routine procedures will be performed on patients. |
| the mean body weight of 25 | Other: It is an observational study and no non-"
19,"[/INST]
The process.
The process.
The process.
The
The
This
In the
This
This
In the
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This   
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
S
S
S
S
S
This
This
This
This
This
This
This
This
This
This
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
This
This
This
S
S
S
S
S
S
S
S
This
This
This
This
This
This
This
S
S
S
S
S
S
This
This
This
This
This
This
This
S
S
S
S
S
S
S
S
S
This
This
This
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
This
This
This
S
S
S
S
S
S
S
S
S
F
This
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
C
C
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
be
be
be











S
S
S
S
S
S
S"
20,"[/INST]
| Experimental: Respiratory and neuromuscular function | 3 years |
| Other: Assessment Respiratory and neuromuscular function | 3 years |
| Experimental: Respiratory and neuromuscular function | 3 years |
| Other: Assessment Respiratory and neuromuscular function |
|
| Experimental: Respiratory and neuromusical function | 3 years |
| Other: Respiratory function |
| Experimental: Respiratory and neuromusical function | 3 years |
| Experimental: Respiratory function | Other: Respiron.
| Experimental: Respiron.
| Experimental: Respiron.
| 3 years.
| Experimental.
| 3 years.
| Experimental: Respilist's.
| Experimental: neuromat the hospital.
| Experimental:
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| Experimental.
| be| be| be|three experimental. Experimental.
|three.
|three.
|three.
|three. Experimental.
| three.
| three.
| three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
|three.
The hospital|three.
|three.
The team.
The team.
The team.
The team.
The team.
This|three.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team.
The team"
21,"[/INST]
This
In
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
A
A
A
A




















This
This
This
This
This
This
This
A
g"
22,"[/INST]

Primary Purpose: To assess the safety and efficacy of ultra-hypofractionated radiotherapy in the treatment of early-stage breast cancer.
Secondary Purpose: To assess the safety and efficacy of partial breast irradiation in the treatment of early-stage breast cancer.
Partial breast irradiation is a minimally invasive form of breast cancer treatment that involves the use of radiation to treat early-stage breast cancer.
Early-stage breast cancer is a type of breast cancer that is detected at an early stage and is considered to be highly treatable with radiation therapy.
Radiation therapy involves the use of high-energy X-rays to kill cancer cells and shrink tumors.
Partial breast irradiation is a minimally invasive form of breast cancer treatment that involves the use of radiation to treat early-stage breast cancer and is considered to be highly effective in shrinking tumors.
Breast cancer is a type of cancer that begins in the breast tissue. It may also affect nearby lymph nodes and other parts of the body, including the lungs and liver.
Early-stage breast cancer is considered to be highly treatable with radiation therapy.
Radiation therapy involves the use of high-energy X-rays to kill cancer cells and shrink tumors.
Partial breast irradiation involves the use of radiation to treat early-stage breast cancer and may also be used to treat cancer that has spread to nearby lymph nodes.
Early-stage breast cancer is considered to be highly treatable with radiation therapy.
Radiation therapy may also be used in combination with other treatments, such as chemotherapy, hormone therapy, or surgery, depending on the individual case.
Radiation therapy involves the use of high-energy X-rays to kill cancer cells and shrink tumors.
Partial breast irradiation involves the use of radiation to treat early-stage breast cancer and may also be used to treat cancer that has spread to nearby lymph nodes.
Radiation therapy may also be used in combination with other treatments, such as chemotherapy, hormone therapy, or surgery, depending on the individual case.
Radiation therapy may cause side effects, including skin redness, fatigue, and temporary discomfort.
Other possible side effects"
23,"[/INST]
901.
9018.
99999
98.
9999.
999.
999.
999.
9999.
9999.
9999.
9999.
999.
999.
9999.
The treatment.
999999999999999.
It.
It.
It.
It, it.
It's
It's
It's
It.
It.
It.
It.
It.
It.
It
It's
It.
It.
It.
It.
It.
In
This
This
In
In
In
In
The
The
The
The
This
This
This
This
This
In
In
In
In
In
In
In
In
In
In
In
In
In
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A"
24,"[/INST]





























 D
 D
 D
 g2
 g2
 g2
 g7
 gure gure
















 gine
 gry
 g2










 D
 Dive Dive D










 g2






















































 D
 D give D gna D give D
 D
 D
 D
 D
 D

















































































 D
 D
 D
 D
 D"
25,"[/INST]

Adverse Events
-----------------
Expected frequency of adverse events
| Expected frequency of adverse events |
| Expected proportion of subjects with the adverse event |
| Actual frequency of adverse events |
| Expected proportion of subjects with the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects with the adverse event |
| Observed proportion of subjects without the adverse event |
| Expected proportion of subjects with the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects with the adverse event |
| Observed proportion of subjects without the adverse event |
| Expected proportion of subjects with the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected proportion of subjects without the adverse event |
| Observed proportion of subjects with the adverse event |
| Expected"
26,"[/INST]
1. Introduction:
This study aims to determine the effects of physical exercise during hemodialysis on heart rate variability in patients with chronic renal insufficiency.
Patients with chronic renal insufficiency are required to undergo physical exercise training while receiving hemodialysis.
Physical exercise and hemodialysis are required to be performed by patients with chronic renal insufficiency.
2. Methodology:
This study employs physical exercise during hemodialysis as the intervention.
Physical exercise and hemodialysis are the required treatments for patients with chronic renal insufficiency.
3. Population:
This study includes patients with chronic renal insufficiency who will undergo physical exercise during hemodialysis.
4. Comparison:
This study compares physical exercise during hemodialysis with virtual reality for patients with chronic renal insufficiency.
5. Primary Outcome Measure:
This study will determine the effects of physical exercise during hemodialysis on heart rate variability in patients with chronic renal insufficiency.
6. Secondary Outcome Measure:
This study will determine the effects of virtual reality during hemodialysis on patients with chronic renal insufficiency.
7. Time Frame:
This study will be conducted from January 1, 2016 to December 31, 2016.
8. Eligibility Criteria:
Patients with chronic renal insufficiency will be included in this study.
9. Exclusion Criteria:
Patients with chronic renal insufficiency will be excluded from this study.
10. Device:
This study employs physical exercise during hemodialysis using a Stationary Bike for patients with chronic renal insufficiency.
11. Primary Outcome Measure:
This study will determine the effects of virtual reality during hemodialysis on patients with chronic renal insufficiency.
12. Secondary Outcome Measure:
This study will determine the effects of physical exercise during hemodialysis on patients with chronic renal insufficiency.
13. Time Frame:
This study will be conducted from January 1, 2016 to December"
27,"[/INST]
|
| 1. 1. 2. 1. 1. 2. 1. 2. 1. 2. 1. 1. 2. 1. 1. 2. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 2. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
In. 1. 1. 1. 1. 1. 1. 1.
It.
The 1.
The 1.
The 1.
The sympt
It.
It.
It.
It.
It.
It.
The.
The.
It.
It.
It.
It.
It.
It.
It.
It.
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
This
This
This
This
This
This
This
This
This
This
This
It
It
It
It
It
This
This
This
This
This
This
This
This
This
This
This
This
This"
28,"[/INST]
Other: [/INST]
Surgical Technique: [/INST]
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. | The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal flexor wrist crease and was extended to the end of the surgery. |
* The surgical incision was started just above the proximal w"
29,"[/INST]
This
This
This
0
0
0
0
0
0
0
0
0
This
This
This


















0
0
0
0
0
0
0














































































































































































































































































0


0
0000




















































































8
8
8















































0"
30,"[/INST]

Patients will have a central venous line placed using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Other: placement of a standard central venous line using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Other: placement of a standard central venous line using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Other: placement of a standard central venous line using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Other: placement of a standard central venous line using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Other: placement of a standard central venous line using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultrasound device
| Patients will have a right central venous line placed using an ultraportable ultrasound device
| Sham: placement of a standard central venous line using an ultraportable ultras"
31,"[/INST]
Device: Er-YAG Laser, Vulva, PS03 handpiece, Vulva Dynamis, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece, Er:YAG Laser, Vulva, PS03 handpiece"
32,"[/INST]


-
-
-


-
-
-
-
-
-
-
-
-
-
-









-
-
-
-
































































































































































-
-
-"
33,"[/INST]

Conclusion: [/INST]
Adverse Events: [/INST]
Patient #1, a 65-year-old male diagnosed with gallstone disease.
Details of the study protocol, including eligibility criteria, are provided below.
The study will be conducted according to the protocol provided by the research team at East Kent University NHS Foundation Trust.
Funding: This study is part of the research strategy of the Gastroenterology department at East Kent University NHS Foundation Trust and is funded by the NIHR.
Organization: The research will be conducted by the Gastroenterology team at East Kent University NHS Foundation Trust.
Time Frame: The study will run from January 2016 to December 2016.
Details of the study team are provided below.
Organization: East Kent University NHS Foundation Trust.
Scientific Rigor: This study uses the scientific method.
Gallstone disease is diagnosed using imaging.
Details of the comparison intervention are provided below.
Time Frame: This study will run from January 2016 to December 2016.
Details of the comparison intervention are provided below.
Ethics Approval: This study has been approved by the East Kent Research Ethics Committee.
Scientific Rigor: This study uses the scientific method."
34,[/INST]
35,"[/INST]
The   
The   
The   
In
The patient.
The patient.
The,
The,
The,
The,
in
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
This
This
The
The
The
This
This
This
This
The
This
This
This
This
This
This
The
D
This
This
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
This
This
This
This
This
This
The
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
C
C
C
S
S
S
S
S
S
A
C
A
A
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
C
C
C
C
C
C
C
C
S
S
S
S
C
C
S
C
C
C
C
C
C
S
C
A
A
S
S
A
S
S
S
S
S
S
S
S
S
S
S"
36,"[/INST]
How is the study designed?
| Experimental: Early Skin to Skin contact<br>Standard midwifery practices and labor follow-up were performed in the hospital (n: 187), who met the inclusion criteria, and were in the control group. | After 2 hours postpartum, mothers were asked to fill in a personal questionnaire and a traumatic birth scale. The maternal attachment scale was completed 1 month after birth by telephone interview. | Traumatic Birth Perception Scale was used to determine the perception of mothers and infants. | from birth to 1 month after birth | 
| Traumatic Birth Perception Scale was used to determine the perception of mothers and infants. | Primary Outcome Measures: [/INST]
How is the study designed?
| Experimental: Early Skin to Skin contact<br>Standard midwifery practices and labor follow-up were performed in the hospital (n: 187), who met the inclusion criteria, and were in the control. | Traumatic Birth Perception Scale was completed 1 month after birth and were asked to fill in the hospital (n. | Traumatic Birth Perception was completed 1 month after birth and infants. | Traumatic Birth. | Traumatic Birth. | Traumatic Birth. | Traum. | Traum. | Traum. | Traum. | Traum. | Traum. | Traum. | Traum. | Traum. Traum. | Traum. Traum. Traum. Traum. | Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum Traum. Traum Traum. Traum. Traum. Traum. Traum. Traum. Traum. Traum Traum Traum. Traum Traum. Traum Traum Traum Traum. Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Traum Tra"
37,[/INST]
38,"[/INST]

1. Provides information on the diagnosis of chronic low back pain. This is a measure of the diagnosis of one of four MP-related categories. | Provides information on the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | Provides information on the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories.
2. This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories.
3. This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories.
4. This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories.
5. This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four MP-related categories. | This is a measure of the diagnosis of chronic low back pain. | This is a measure of the diagnosis of one of four"
39,"[/INST]
This will.
The intervention.
The results.
The results.
The results.
This random.
This random.
This random.
This random.
This random.
This random.
This random.
This.
This.
The results.
The results.
The results.
This random.
This.
This.
This.
The results.
The study.
The random
The random
As.
As.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This
This
This
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
40,"[/INST]

Primary Outcome Measures
-----------------
Behavioral: Neuro-linguistic program | Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome measures include:  |
| Intervention: Neuro-linguistic program |
| Primary outcome"
41,"[/INST]
| Participation Criteria |
-----------------
How is the study designed?
| Participation Criteria | Participation in the study will be required to have: |
| Eligibility Criteria | Participation in the study will be required to have: |
| Participation in the ECOS versus control of psychological status prior to the service ECOS | Average STAI-Y between the two groups |
| Participation in the ECOS versus control of psychological status prior to the next service |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Participation in the ECOS versus control of psychological status prior to the next internship |
| Part"
42,"[/INST]

Secondary Outcome Measures
-----------------
Participants
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
| Intervention: Usual care |
| Experimental: Web-based health care program |
|"
43,"[/INST]
The
The doctor.
The
in
The
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
**
==
==
==
==
==
This
This
This
This
This
in
in
in
in
in
in
in
in
in
in
in
in
in
in
In
In
In
In
In
In
In
In
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
*
*
*
*
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
R
This
R
R
R
R
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
R
C
C
R
This
This
R
This
R
R
R
R
S
S
S
S
S
R
R
R
R
R
R
R
R
S
S
S
S
S
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
The
The
S
S















S
S
S
S
S
S
S
S"
44,"[/INST]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Tertiary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Secondary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Interventional Model: [Patient information withheld]
Primary Outcome: [Patient information withheld]
Interventional"
45,"[/INST]

* Drug: Ocrelizumab Injection [Ocrevus]


* Patient #1


* Other: Ocrelizumab Injection [Ocrevus]


* Patient #2


* Patient #3


* Patient #4


* Patient #5


* Patient #6


* Patient #7


* Patient #8


* Patient #9


* Patient #10


* Patient #11


* Patient #12


* Patient #13


* Patient #14


* Patient #15


* Patient #16


* Patient #17


* Patient #18


* Patient #19


* Patient #20


* Patient #22


* Patient #23


* Patient #24


* Patient #25


* Patient #26


* Patient #27


* Patient #28


* Patient #30


* Patient #32


* Patient #34


* Patient #36


* Patient #38


* Patient #40


* Patient #42


* Patient #50


* Patient #60


* Patient #70


* Patient #80


* Patient #90


* Patient #10


* Patient #20


* Patient #12


* Patient #14


* Patient #16


* Patient #28


* Patient #30


* Patient #32


* Patient #34


* Patient #4


* Patient #5


* Patient #6


* Patient #7


* Patient #8


* Patient #9"
46,"[/INST]
| 90 years old enough to
Colon
Organic
Organic
Colon
Organic
Colon
Organic symptoms
Colon
Organic
Organic
Organic
Organic
Organic
Organic
Organic
Organic
Colon
Organic
Organic
Organic
Organic
Organic
Collaps.
Organic
Organic
Organic
Collapse
Organic
Organic
Collapse
Collapse.
Collapse.
Organic
Organic
Collapse.
Organ.
Collapse.
Collapse.
Col
The
The surgery.
The, *
The patient.
The,
The,
The,*
The patient.
How
How
How
How
The, *
The,*
The,*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
The patient.
In.
in.
in.
in.
In.
In.
How.
How.
How.
The,
The, it.
The,
It.
It.
In
The,
The,
--------
--------
The,
The,
The
In
In
In
In
In
In
In
The,
S
The,
F,
F,
F
F
F
D
D
D
D
S
S
D,
In
In
S
D,
S
S
S
S
S
S
S
S
S
S
In
D
D
D
C
D
D
D
C
F
D
D
C
C
C
S
S
C
C
C
D
P
P
D
P
C
C
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
C
S"
47,"[/INST]
-----------------
Nebulised hypertonic saline, saline, nebulised
-----------------
Keywords: [/INST]
Nebulised hypertonic saline, saline, nebulised
-----------------
Nebulised hypertonic saline, saline, nebulised
-----------------
Keywords: [/INST]
Nebulised hypertonic saline, saline, nebulised
-----------------
Nebulised hypertonic saline, saline, nebulised
-----------------
Keywords: [/INST]
Nebulised hypertonic saline, saline, nebulised
-----------------
Nebulised hypertonic saline, saline, nebulised
-----------------
Keywords: [/INST]
Nebulised hypertonic saline, saline, nebulised
-----------------
Nebulised hypertonic saline, saline, nebulised
-----------------
Keywords: [/INST]
Nebulised hypertonic saline, saline, nebulised
-----------------
Nebulised hypertonic saline, saline, nebulised
-----------------
Nebulised hypertonic saline, saline, saline, nebulised
----------------
Nebulised hypertonic saline, saline, saline, nebulised
Keywords: [/INST
Nebulised hypertonic saline, saline, nebulised hypertonic saline, saline, nebulous, saline, nebulous hypertonic saline, nebulous, saline, nebulous, saline, nebulous, hypertonic saline, nebulous, nebulous, saline, nebulous, nebulous, hypertonic saline, nebulous, nebulous, saline, nebulous, nebulous, saline, nebulous, nebulous, nebulous
-----------------
-----------------us
-----------------us
Saline nebulous
-----------------us
Neb
Neb
Neb
Neb
Neb
Nebulous
Neb
Neb
Neb
Neb
Neb
Neb
Neb
Neb
Neb
Neb
Neb
N"
48,"[/INST]
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C












C

A





















C
A
A
C
C
C








































C
A
C
C

















C
Pure
C
C










C
C
C
C
C
C
C
C



C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C

C
C
O
O
C
C
C
C
C
C
C
C
C
C
O
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
O
C
C
C
C
C"
49,"[/INST]

Other: [/INST]

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy Volunteers

Inclusion Criteria: Patients with glioma who require MRI and PET scanning.
Exclusion Criteria: Healthy Volunteers.

Accepts Healthy"
50,"[/INST]
Second, and third.
Second, and third.
Second sentence.
Second, and third.
Second, and third.
Second, and third.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
The clin
Second.
Second    -->
This.
This.
This.
The clinational
The clinational
In
In
The//    //    //    //    //
This.
This particular// 
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
51,"[/INST]

Adverse Events
| --- |
| Extracorporeal shock wave lithotripsy will be given to the patient | Procedure: Extracorporeal shock wave lithotripsy will be given to the patients |
| Active Comparator: Extracorporeal shock wave lithotripsy will be given to the patient |
| Intervention/Masking: Extracorporeal shock wave lithotripsy will be given to the patient |
| Primary Purpose: Extracorporeal shock wave lithotripsy will be given to the patient |
| Secondary Purpose: Extracorporeal shock wave lithotripsy will be given to the patients |
| Tertiary Purpose: Extracorporeal shock wave lithotripsy will be given to the patient |
| Eligible for study: Extracorporeal shock wave lithotripsy will be given to the patient |
| Exclusion Criteria: Extracorporeal shock wave lithotripsy will be given to the patient |
| Inclusion Criteria: Extracorporeal shock wave lithotripsy will be given to the patients |
| Exclusion Criteria: Extracorporeal shock wave lithotripsy will be given to the patient |
| Intervention/Masking: Extracorporeal shock wave lithotripsy will be given to the patients |
| Primary Purpose: Extracorporeal shock wave lithotripsy will be given to the patient |
| Intervention/Masking: Extracorporeal shock wave lithotripsy will be given to the patients |
| Secondary Outcome Measures: Extracorporeal shock wave lithotripsy will be given to the patient |
| Primary Purpose: Extracorporeal shock wave lithotripsy will be given to the patient |
| Intervention/Masking: Extracorporeal shock wave lithotripsy will be given to the patients |
| Eligible for study: Extracorporeal shock wave lithotripsy will be given to the patient |
| Intervention/Masking: Extracorporeal shock wave lithotrips"
52,"[/INST]
| Tracheal stenosis |
| Tracheostomy |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |
| Tracheal stenosis |"
53,"[/INST]
=================
| Severity of psychiatric disorder, as measured by a clinical evaluation | Severity of psychiatric disorder, as measured by a clinical evaluation | Severity of psychiatric disorder, psychosis, suicide risk, and depression, psychosis, and HIV/AIDS. | Severity of psychiatric disorder, psychosis, suicide, psychiatric intervention, psychiatric disorder, psychiatric diagnosis, psychiatric intervention, psychiatric disorder, psychiatric diagnosis, psychiatric intervention, psychiatric disorder, psychiatric diagnosis, psychiatric disorder, psychiatric diagnosis, psychiatric disorder, psychiatric diagnosis, psychiatric diagnosis, psychiatric disorder, psychiatric diagnosis, psychiatric diagnosis, psychiatric disorder, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric diagnosis, psychiatric psychiatric psychiatric diagnosis, psychiatric psychiatric psychiatric diagnosis, psychiatric psychiatric psychiatric psychiatric psychiatric
================, psychiatric psychiatric psychiatric psychiatric psychiatric psychiatric psychiatric
================, psychiatric psychiatric psychiatric psychiatric psychiatric psychiatric psychiatric
----------------s.
The, psych
----------------s.
----------------s.
----------------.
The patient.
The patient.
The, this.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
====
====
====
====
====
====
In,"
54,"[/INST]
Conventional endodontic treatment combined with PDT will be carried out with diode laser, and the photosensitizer used will be methylene blue.
Primary Purpose: To evaluate the effectiveness of PDT in disinfection of the root canals associated with conventional endodontic treatment.
Secondary Purpose: To evaluate the effectiveness of PDT in disinfection of the root canals associated with endodontic treatment, and to compare the results of the photosensitizer used in both groups (before treatment and after treatment).
Experimental: To evaluate the effectiveness of PDT in disinfection of the root canals associated with conventional endodontic treatment, and to compare the results of the photosensitizer used in both groups (before treatment and after treatment).
Conventional endodontic treatment combined with PDT will be carried out with diode laser, and the photosensitizer used will be methylene blue.
Primary Purpose: To evaluate the effectiveness of PDT in disinfection of the root canals associated with conventional endodontic treatment.
Secondary Purpose: To compare the results of the photosensitizer used in both groups (before treatment and after treatment).
Experimental: To evaluate the effectiveness of PDT in disinfection of the root canals associated with endodontic treatment, and to compare the results of the photosensitizer used in both groups (before treatment and after treatment).
Conventional endodontic treatment combined with PDT will be carried out with diode laser, and the photosensitizer used will be methylene blue.
Primary Purpose: To evaluate the effectiveness of PDT in disinfection of the root canals associated with conventional endodontic treatment.
Secondary Purpose: To compare the results of the photosensitizer used in both groups (before treatment and after treatment).
Conventional endodontic treatment combined with PDT will be carried out with diode laser, and the photosensitizer used will be methylene blue.
Primary Purpose: To evaluate the effectiveness of PDT in disinfection of the root canals associated with conventional endodontic treatment.
Secondary Purpose: To compare the results of the photosensitizer used in both groups (before treatment and after treatment"
55,"[/INST]
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score | 90 days |
| Severity Score |"
56,"[/INST]-st-st-st-0-e-st-st-0-e-0-e-e-e-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-h-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-h-h-h-h-
-
-st-st-st-st-st-dis-st-dis-dis-dis-dis-dis-dis-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-dis-dis-dis-dis-dis-dis-dis-st-st-st-st-st-st-st-st-
-
-st-st-st-st-st-st-st-st-st-st-st-dis-dis-dis-dis-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-
-
-
-
-st-st-st-st-st-st-ch-
-
-
-st-h-dis-dis-dis-
-
-
-st-a-a-a-a-ch-
-
-st-st-st-st-ch-ch-ch-
-
-ch-ch-ch-dis-dis-st-st-st-st-"
57,"[/INST]
-----------------
Primary Outcome Measure
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of people affected by the earthquakes in Turkey.
Change in the number of the earthquakes in Turkey.
Change in the number of the earthquakes in Turkey.
Change in the number of the earthquakes in the earthquakes in Turkey.
Change in the number of the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in Turkey.
Change in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes in the earthquakes.
Change in the earthquakes in the earthquakes in the earthquakes in the earthquakes.
The earthquakes.
The earthquakes in the earthquakes.
The earthquakes.
The earthquakes.
The earthquakes.
The earthquakes.
The earth.
The earth.
The earth.
==.
==.
The earth.
The earth.
The earth.
The damage.
The damage.
The damage.
The damage.
In the
in the
As"
58,"[/INST]

Counselling

Other Health Care Providers
-----------------
Primary Outcome Measures
Counselling
Secondary Outcome Measures
-----------------
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Secondary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Other Health Care Providers
Primary Outcome Measures
Counselling
Counselling
Other Health Care Providers
Counselling
Counselling
Counselling
Counselling
Other Health Care Providers
Counselling
Counselling
Counselling
Couns
Other Health Care Providers
Couns
Counselling
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Couns
Coun
Coun
Coun
Coun
Couns
Coun
Couns
Couns
Couns
Coun, Clinics
Coun:
Coun:
Coun
Couns
Couns
Coun:
Couns
Couns
Couns
Couns
Coun,Coun, Clin's
Coun as
Coun.
Coun.
Coun.
Couns.
Coun.
Couns.
Couns.
Couns.
Coun.
Coun.
Coun.
Coun.
Coun.
Couns.
Couns.
Couns.
Couns.
Couns.
Couns.
Couns"
59,"[/INST]
A





















































































































































































































































































-










-
-
-
8-
-
-
-
-
-
-
-
-
-
-
-







-
-










-
-
-
-
-
-












-
-
-
-






-
-
-
-
-
-
-
-
-
-
-
-m-m-m-m-m-m-m-m-m-m-m-m-m-
-
-
-
-
-
-m-
-m-m-m-m-m-m-
-
-
-
-
-
-
-
-
-h-
-
-
-
-
-
-
-
-
-C-8-8-m-8-8-8-8"
60,"[/INST] C-
 C-
-
-
















 C-0 C-0







-
-
-
-
--
-
-------------------------0--
----------------------------------
-------------
-
--------
-
-
---
-
--------------------------
-
-
-
-



-






-




-
------------------------
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-------------------------------------- C- C- C- C-
-
 C-
-
-










-
-O-O-------
----------------------------------------------------------------------------------------------------------------------------------------------------	-------------- B- B- B- C- C-"
61,"[/INST]
|187
|187
|187
|187
|187
|187
|188
|187
|187
|187
|187
|187
|187|187|187
|187|187|188
|187
|187
|187
|187
|188
|187
|187
|187|187|1887
|1888
|187
|187
|187
|187
|1887
|188987
|187
|1887|1887|1887|18888888889|188787887878888888888888888888888888888888888888888888888
The,1,1,1.
The,1888888
1888888888
The
The
The
The
The
The patient.
The patient.
The patient.
The patient.
The
The
It
The   
==
==
The patients
It
The patients
It
It
It
It
It
S
S
It
It
It
It
It
It
It
It
It
It
It
It
It
It
The   
It
The
==
The
The
The
The
The
The
S
S
S
S
S
S
S
This
This
This
This
This
The
The
It
S
S
S
S
S
S
S
The
The
The
The
S
S
S
This
This
S
This
S
S
This
S
S
S
This
This
S
S
S
S
S
S
S
S
S
S
S
S"
62,"[/INST]
The patient.
The-old.
The-old.
The patient.
The Q.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The.
The.
It.
The.
It.
The treatment.
The.
The.
It.
It.
The.
The.
It.
This.
This.
The, this.
The.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
63,"[/INST]
| Other: [/INST]

How is the study designed?
----------------
| The study is designed as an open label proof of concept study. | One year of growth hormone therapy is provided to the participants. | No treatment is given to the participants as part of this study. |

How is the study powered?
----------------
| The study is powered by the investigators. | One year of growth hormone therapy is provided to the participants. |

How is the study structured?
----------------
| The study is structured with one research visit. | One year of growth hormone therapy is provided to the participants. |

How is the study organized?
----------------
| The study is organized into one research visit. | One year of growth hormone therapy is provided to the participants. |

How is the study designed?
----------------
| The study is designed as an open label, proof of concept study. | One year of growth hormone therapy is provided to the participants. |

How is the study organized?
----------------
| The study is organized into one research visit. | One year of growth hormone therapy is provided to the participants. |

How is the study funded?
----------------
| The study is funded by the investigators. | One year of growth hormone therapy is provided to the participants. |"
64,"[/INST]

| Primary Outcome |
-----------------
| Sleep efficiency |
| Outcome Measurement |
| Sleep efficiency |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Sleep efficiency |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Outcome Measurement |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |
| Primary Outcome |
| Sleep efficiency |
| Outcome Measurement |"
65,"[/INST]

| Primary Outcome Measures | Measure Description | Time Frame |
| --- |
| To evaluate the prognostic significance (recurrence rates) of iENE: Diagnostic accuracy of various radiographic features of pENE | Endpoints: Diagnostic accuracy of various radiographic features of iENE | 31 December 2023 | 


| To evaluate the prognostic significance (recurrence rates) of iENE: Diagnostic accuracy of various radiographic features of pENE | Endpoints: Diagnostic accuracy of various radiographic features of iENE | 31 December 2023 | 


How is the study designed?
| Primary Outcome Measures | Measure Description | Time Frame |
| --- |
| To evaluate the prognostic significance (recurrence rates) of iENE: Diagnostic accuracy of various radiographic features of pENE | Endpoints: Diagnostic accuracy of various radiographic features of iENE | 31 December 2023 | 



How is the study designed?
| Primary Outcome Measures | Measure Description | Time Frame |
| --- |
| To evaluate the prognostic significance (recurrence rates) of iENE: Diagnostic accuracy of various radiographic features of pENE | Endpoints: Diagnostic accuracy of various radiographic features of iENE | 31 December 2023 | 



How is the study designed?
| Primary Outcome Measures | Measure Description | Time Frame |
| --- |
| To evaluate the prognostic significance (recurrence rates) of iENE: Diagnostic accuracy of various radiographic features of pENE | Endpoints: Diagnostic accuracy of various radiographic features of iENE | 31 December 2023 | 



How is the study designed?
| Primary Outcome Measures | Measure Description | Time Frame |
| --- |
| To evaluate the prognostic significance (recurrence rates) of iENE: Diagnostic accuracy of various radiographic features of pENE | Endpoints: Diagnostic accuracy of various radiographic features of iENE | 31 December 2023 | 



How is the study designed?
| Primary Outcome"
66,"[/INST]
==
==
==
==
==
==
==
==
==
==
==
==
==
==
This
This
A
==
/>
/>
in
in
in
==
==
==
==
==
==
==
==
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
/>
/>
/>
in
for
This
in
in
in
in
in
in
==
==
==
/>
/>
/>
/>
in
in
in
==
mil
in
in
==
AAAA
fur
fur
fur
fur
fur
/>
==
==
==
==
==
==
==
==
AAAA
fur
==
==
mil
==
==
mil
==
==
AAAA
in
in
in
in
in
in
in
in
mil
mil
mil
AAAA
AAAA
AAAA
AAAA
f
f
f
f
f
f
mil
mil
mil
mil
be
be
f
f
f
f
f
f













f
f
f
f
f
f
f
















f
f




























f
f
f
f
f
f
f"
67,"[/INST]
A



































s
s
s













































































































































































































































































A
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A-
A-
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A















A
A
A
A
A
A
A
A
A"
68,"[/INST]

Head and Neck Cancers
-----------------
| Oral: [/INST]
| Pharyngeal: [/INST]
| Cavity: [/INST]

Surgical Interventions
-----------------
| HPV - Group: [/INST]
| Oral: [/INST]
| Pharyngeal: [/INST]
| Cavity: [/INST]

Alternative Therapies
-----------------
| HPV - Group: [/INST]
| Oral: [/INST]
| Pharyngeal: [/INST]
| Cavity: [/INST]

Risk Factors
-----------------
| Oral: [/INST]
| Pharyngeal: [/INST]
| Cavity: [/INST]

Patients with oropharyngeal or oral cavity HPV- negative tumors and negative diagnosis of head and neck cancers are treated according to the same protocol.
| Pharyngeal: [/INST]
| Cavity: [/INST]

Patients with oropharyngeal or oral cavity HPV- negative tumors and negative diagnosis of head and neck cancers are treated according to the same protocol.
| Pharyngeal: [/INST]
| Cavity: [/INST]

Predictive Factors
-----------------
| Oral: [/INST]
| Pharyngeal: [/INST]
| Cavity: [/INST]

Patients with oropharyngeal or oral cavity HPV- negative tumors and negative diagnosis of head and neck cancers are treated according to the same protocol.
| Pharyngeal: [/INST]
| Cavity: [/INST]

Patients with oropharyngeal or oral cavity HPV- negative tumors and negative diagnosis of head and neck cancers are treated according to the same protocol.
| Pharyngeal: [/INST]
| Cavity: [/INST]

Predictive Factors
-----------------
| Oral: [/INST]
| Pharyngeal: [/INST]
| Cavity: [/"
69,"[/INST]
A
A
A
A
A
A
P
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A





















A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A








A
A


















































































































































































A



A
A












C




C









C
A
A
A
R
R
A
A
C
A
A
A
C




































































































ine



ized
ized
ized"
70,"[/INST]
[/INST]
[/SUMMARY]
Alveolar Ridge Preservation Connective tissue graft, Tooth extraction Membranes
[/INSTANCE]
[/SUMMARY]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/CONNECT]
[/INSTANCE]
[/"
71,"[/INST]
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflammatory cytokines<br>patient with Essure contraceptive implants and in control patients with endometriosis or adenomyosis |
| Other: pro-inflam"
72,"[/INST]
Adverse events
| --- | --- |
| Autoimmune hepatitis, disease, hospital stay, clinical outcome, incidence of COVID-19 infection, symptom relief, death, disease recurrence, prognosis, nucleic acid negative conversion, clinical outcome, disease recurrence, symptom relief, hospital stay, disease recurrence, clinical outcome, death, disease recurrence, clinical outcome, disease recurrence, symptom relief, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clinical outcome, disease recurrence, clin"
73,"[/INST]
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectal surgery to prevent postoperative pulmonary complications.
Prone position training is a behavioral intervention provided to patients with colorectomy.
Prone position training is a behavioral intervention provided to patients undergoing surgery.
Prone position training is a behavioral intervention.
Secondary surgery.
Secondary surgery.
Secondary surgery.
Secondary surgery.
Prone position training is a behavioral surgery.
Second surgery.
Prone surgery.
Second surgery.
Prone surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Prone surgery.
Second surgery.
Prone surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surg"
74,"[/INST]
101 patients with the
1.
1.
1.
1.
1.
1.
2.
2.
1.
2.
1.
1.
1.
2.
1.
1.
2.
1.
2.
2.
1.
1.
2. 1.
2. 1.
1. 1.
2. 1.
1. 1.
2. 1. 1.
1. 1.
1. 1.
1. 1.
1. 1.
1. 1.
1.
2.
1. 1.
1. 1. 1. 1.
1.
2.
2.
1.
1.
2.
2.
1.
1.
1.
1.
1.
1.
1.
1.
1.
1.
1.
The
The
The
The
The
The
The
The
1.
1.
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
S
This
F
In
This
F
F
F
In
This
This
This
This
This
This
This
This
F
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
Pres
In
P
P
S
F
This
This
This
F
F
F
F
F
This
This
This
F
This
This
This
This
This
This
This
This
This
This
S
S
This
This
This
This
This
S
This
This
This
This
This
This
This
This
This
This
This
S
This
F
F
This
This
This"
75,"[/INST]
Study Design
-----------------
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 6 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 24 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 6 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 6 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 6 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 6 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 6 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |
| Primary Purpose: Prevention of frailty syndrome | Secondary Purpose: Improvement of physical function | Time Frame: 12 months |"
76,"[/INST]







































































































































































































































































































































































































































777

































8
8
8
8

8
8
8
8

7
8
8
7



7
7
8
8
8
8



8
8
8-"
77,"[/INST]
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
78,"[/INST]
Adverse events
Patients in the control group will receive physical therapy and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30 burned patients who will receive resistance exercise and medical treatment.
How is the study designed?
The study will consist of 30"
79,"[/INST]

Other: [/B]"
80,"[/INST]
Other: [/INST]
Adverse events: [/INST]
Patient #1: [/INST]
Intervention: [/INST]
Parameter 1: [/INST]
Parameter 2: [/INST]
Parameter 3: [/INST]
Parameter 4: [/INST]
Parameter 5: [/INST]
Parameter 6: [/INST]
Parameter 7: [/INST]
Parameter 8: [/INST]
Parameter 9: [/INST]
Parameter 10: [/INST]
Parameter 11: [/INST]
Parameter 12: [/INST]
Parameter 13: [/INST]
Parameter 14: [/INST]
Parameter 15: [/INST]
Parameter 16: [/INST]
Parameter 17: [/INST]
Parameter 18: [/INST]
Parameter 19: [/INST]
Parameter 20: [/INST]
Parameter 21: [/INST]
Parameter 22: [/INST]
Parameter 23: [/INST]
Parameter 24: [/INST]
Parameter 25: [/INST]
Parameter 26: [/INST]
Parameter 27: [/INST]
Parameter 28: [/INST]
Parameter 29: [/INST]
Parameter 30: [/INST]
Parameter 31: [/INST]
Parameter 32: [/INST]
Parameter 33: [/INST]
Parameter 34: [/INST]
Parameter 35: [/INST]
Parameter 36: [/INST]
Parameter 37: [/INST]
Parameter 38: [/INST]
Parameter 39: [/INST]
Parameter 40: [/INST]
Parameter 41: [/INST]
Parameter 42: [/INST]
Parameter 43: [/INST]
Parameter 44: [/INST]
Parameter 45: [/INST]
Parameter 46: [/INST
Parameter 47: [/INST
Parameter 48: [/INST
Parameter 49: [/INST"
81,"[/INST]

How is the study designed?
-----------------
Primary Purpose: Cell free DNA in serum, patients with endometriosis, patients with pelvic inflammatory disease, patients with infertility, patients with ovarian failure, patients with premature oocytes, patients with pelvic inflammation, patients with day 1, patients with day 2, patients with ovarian failure, patients with day 3, patients with pelvic inflammation, patients with day 4, patients with day 5, patients with ovarian failure, patients with day 6, patients with day 7, patients with day 8, patients with day 9, patients with day 10, patients with day 11, patients with day 12, patients with day 13, patients with day 14, patients with day 15, patients with day 16, patients with day 17, patients with day 18, patients with day 19, patients with day 20, patients with day 21, patients with day 22, patients with day 23, patients with day 24, patients with day 25, patients with day 26, patients with day 27, patients with day 28, patients with day 29, patients with day 30, patients with day 30, patients with day 31, patients with day 32, patients with day 33, patients with day 34, patients with day 35, patients with day 36, patients with day 37, patients with day 38, patients with day 39, patients with day 40, patients with day 40, patients with day 41, patients with day 42, patients with day 43, patients with day 44, patients with day 44, patients with day 45, patients with day 46, patients with day 47, patients with day 48, patients with day 49, patients with day 50, patients with day 50, patients with day 52, patients with day 51, patients with day 53, patients with day 54, patients with day 54, patients with day 55, patients with day 56, patients with day"
82,"[/INST]

Secondary Outcome Measures
-----------------
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Implant survival | Percentage of number of initially placed overdentures still in place after 10 years | 10 years | 
| Overdenture survival | Peri-implant mucosa condition scored with the Modified Plaque Index, score 0-3, 3 is the worst | at 10 years | 
| Pocket probing depth | Depth of probing in the peri-implant sulcus scored with the Modified Plaque Index, score 0-3, 3 is the worst | at 10 years | 
| Patient satisfaction | Satisfaction of patients scored with a 5-point Likert scale, score 0-3, 3 is the worst | at 10 years | 

Secondary Outcome Measures
-----------------
| Implant survival | Peri-implant mucosa condition scored with the Modified Plaque Index, score 0-3, 3 is the worst | at 10 years | 
| Overdenture survival | Peri-implant mucosa condition scored with the Gingiva Index, score 0-3, 3 is the worst | at 10 years | 
| Patient satisfaction | Satisfaction of patients scored with a 5-point Likert scale, score 0-3, 3 is the worst | at 10 years | 

Secondary Outcome Measures
-----------------
| Implant survival | Peri-implant mucosa condition scored with the Modified Plaque Index, score 0-3, 3 is the worst | at 10 years | 
| Overdenture survival | Peri-implant mucosa condition scored with the Gingiva Index, score 0-3, 3 is the worst | at 10 years | 
| Patient satisfaction | Satisfaction of patients scored with a 5-point Likert scale, score 0-3, 3 is the worst | at 10 years | 

Secondary Outcome Measures
-----------------
| Implant survival | Peri-implant mucosa condition scored with the"
83,[/INST]00000000000000000000000000000-st-st-st-st-st-st-st-be-st-st-be-st-st-st-st-na-O-O-st-st-st-st-st-st-st-st-O-O-O-O-st-st-st-O-0-000000000000000000000-O-h-st-st-st-st-st-O-O-O-O-O-O-O-O-O-O-0-0-0-0-0-0-0-O-O-O-O-O-O-st-0-0-O-O-O-O-O-O-O-O-0-0-st-0-0-0-O-O-O-0-O-0-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O--O-O-O-O-O-O-O-O-O-O--0-0-0-0-0-0-0-0-0-O-O-O-O-0-0-0-0-0-0-0-0-0-O-O-O-O-O-O-0-0-O-0-0-O--------------------------------------------------------------------------------------------------------------------------------0- a a a a-0-0-0-0-
84,"[/INST]

Primary Purpose: Healthy Volunteers will be favorably received by the study physicians. Healthy Volunteers will be defined as those who complete the study and accept the V-CST sessions. This outcome will be assessed at the end of the study.
| Participant Characteristics: [/INST]
Cognitive Impairment: [/INST]
Primary Purpose: Healthy Volunteers will be favorably received by the study physicians. This outcome will be assessed at the end of the study.
| Participant Characteristics: [/INST]
Cognitive Impairment: [/INST]
Secondary Outcome Measure
-----------------
| Participant Characteristics: [/INST]
Cognitive Impairment: [/INST]
Secondary Outcome Measure
-----------------
Cognitive Impairment: [/INST]
Secondary Outcome Measure
-----------------
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
Cognitive Impairment: [/INST]
Secondary Outcome Measure
C"
85,"[/INST]
|1950s.
|1950s.
|1950s.
|1950s.
|1950s.
|1950s.
GERD.
|1950s.
|1950s.
|1950s.
|1950s.
|1950s.
|1950s.
|1950s.
Conditions.
|1950195000000000000000000001950195.
|1900195019999901950195019501999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999
In.
In.
In.
In.
In.
In
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It.
in
in
It
It
It
It
It
It
It
in
in
in
in
in
in
It
It
It
It
It
It
It
It
It
It
It"
86,"[/INST]

Secondary Outcomes
-----------------
Behavioral: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Primary Purpose: Men who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Exclusive to Women: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Other Specified Diagnoses: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Study Measures
-----------------
Primary Purpose: Men who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Secondary Outcome Measures
-----------------
Other Specified Diagnoses: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Primary Purpose: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Exclusive to Women: Men who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Primary Purpose: Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
Secondary Outcome Measures
-----------------
Primary Purpose: Women"
87,"[/INST]

Primary Outcome Measure
-----------------
Diagnostic performance of CAD EYE, adenoma detection rate, and histopathological prediction of the endoscopist. Through study completion, an average of 2 years | Comparison of the diagnostic performance of CAD EYE and histopathological prediction of the colonic polyps with the automated system.
Secondary Outcome Measure
-----------------
Diagnostic performance of CAD EYE, adenoma detection rate, and histopathological prediction of the endoscopist. Through study completion, an average of 2 years | Comparison of the diagnostic performance of CAD EYE and histopathological prediction of the colonic polyps with the automated system.

Secondary Outcome Measure
-----------------
Diagnostic performance of CAD EYE, adenoma detection rate, and histopathological prediction of the endoscopist. Through study completion, an average of 2 years | Comparison of the diagnostic performance of CAD EYE and histopathological prediction of the colonic polyps with the automated system.

Secondary Outcome Measure
-----------------
Diagnostic performance of CAD EYE, adenoma detection rate, and histopathological prediction of the endoscopist. Through study completion, an average of 2 years | Comparison of the diagnostic performance of CAD EYE and histopathological prediction of the colonic polyps with the automated system.

Secondary Outcome Measure
-----------------
Diagnostic performance of CAD EYE, adenoma detection rate, and histopathological prediction of the endoscopist. Through study completion, an average of 2 years | Comparison of the diagnostic performance of CAD EYE and histopathological prediction of the colonic polyps with the automated system.

Secondary Outcome Measure
-----------------
Diagnostic performance of CAD EYE, adenoma detection rate, and histopathological prediction of the endoscopist. Through study completion, an average of 2 years | Comparison of the diagnostic performance of CAD EYE and histopathological prediction of the colonic polyps with the automated system.

Secondary Outcome Measure
-----------------
Diagnostic performance of"
88,"[/INST]
| 1940000.
| 194000.
| 19400.
| 19400.
| 194000.
| 194000.
| 194000.
| 194000.
| 1941.
| 194000.
| 1940000.
| 190000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000001
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
It.
It.
==
==
==,, it
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
The
The
The
It
It
It
It
It
It"
89,"[/INST]
| Assessment of PK parameter of itepekimab: AUClast | Time to reach EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: tmax | Baseline up to EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Terminal half-life of the serum clearance (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Baseline up to EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: tmax | Time to reach EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Baseline up to EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: tmax | Time to reach EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Baseline up to EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: tmax | Time to reach EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Baseline up to EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: tmax | Time to reach EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Baseline up to EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: tmax | Time to reach EOS (approximately Day 141) | 
| Assessment of PK parameter of itepekimab: AUClast | Baseline up to EOS (approximately Day 141) | 
|"
90,"[/INST]
The study.
The study.
The study.
The subjects.
The subjects.
The subjects.
The subjects.
year.
year.
The study.
The subjects.
The patients.
The patients.
The study.
The study.
The
The
The patients.
The
The study.
The
The
The
The
The
The
The
The
The
The
The
The
The results.
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The   
The   
The
The
The
The
The
The
The
The
The
(year
The
The
(former
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
This
This
The
The
The
The
The
The
This
The
The
This
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The








































s
s
This
g
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
S
S"
91,"[/INST] - - - - -0 - B- - - - - -
-
-
-
-
-
-
-
-
-
- - -
- - - - - - B- B- B- B- D- D- D- B- B- B- B- B- B- B- B- B- B- B- B- B- B- B- B- - - - - B- B- B- B- B- B-
 B-
- B- B- B- B- B- B- B- B- B- - - - - - - - - - - B- B- B- B- B- B- B- B- B- B- - - - - - - - - - B- B- B- B- B- B- B- B- B- B- B- B- - - - - - - - - - -      B-  B- - - - - - - - - - - - - - - - - - - - - -         - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - B- B- - - - - - - - B- - - - B- B- B- B- B- B- B- B- B- B- B- B- B- B- B- - B- B-
- - - - - - - - -
-
-
-
-
-
-
- - - - - - - - - -
-
-
-
-
-
-
-"
92,"[/INST]

Cancer patients with venous thromboembolism or atrial fibrillation
Secondary Prevention / Intervention
Apixaban and rivaroxaban are both anticoagulants studied in cancer patients with venous thromboembolism or atrial fibrillation. This study aims to describe important differences between them.
Apixaban is a factor X inhibitor that is used in the treatment of venous thromboembolism and atrial fibrillation.
Rivaroxaban is a factor Y inhibitor that is used in the treatment of cancer.
Cancer patients with venous thromboembolism or atrial fibrillation are eligible for this study.
Inclusion Criteria: Age 18 years, able to provide written informed consent.
Exclusion Criteria: Life expectancy <3 months Monitoring of cancer patients receiving rivaroxaban or apixaban
Intervention / Treatment
Secondary Prevention / Intervention Strategy Cancer patients with venous thromboembolism or atrial fibrillation
Apixaban is a factor Y inhibitor that is used in the treatment of cancer patients with venous thromboembolism or atrial fibrillation.
Monitoring of cancer patients receiving rivaroxaban is ongoing.
Data related to the safety of apixaban is limited.
Cancer patients with venous thromboembolism or atrial fibrillation are eligible for this study.
Apixaban is a factor Y inhibitor that is used in the treatment of cancer patients with venous thromboembolism or atrial fibrillation.
Monitoring of cancer patients receiving rivaroxaban is ongoing.
Data related to the safety of apixaban is limited.
Cancer patients with venous thromboembolism or atrial fibrillation are eligible for this study.
Secondary Prevention / Intervention Cancer patients with venous thromboembolism or atrial fibrillation are eligible for this study.
Data related to the safety of apixaban is limited.
Monitoring of cancer patients receiving rivaroxaban is ongoing.
Cancer patients with venous thromboembolism or atrial"
93,"[/INST]
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
O
A
A"
94,"[/INST]
8
8
8
8
8
8
8
8
8
A
A
A
A
A
A
A
A
A
A
A
m
m
m
8
8
8
8
8
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A-
A-h-
8-
8
8
8
8
8
8
8
8-
8
8
8
8
8-
8-
8-
8-
A-
A-
O-
8-
8-
8-
8-
8-
8-
8-
8-
8-
8-
-
-
-
-
3-
8-
-h-h-
-
-
-
-h-
-
-
-
-
-
-
-
-
-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-8-8-8-h-8-8-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-h-h-
-h-
-
-
-h-h-h-h-
-
-
-
-
-
-
-
-
O
-h-
-
-
-
-
-
-
-
-
-
-
ities
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-























-
-
-
istic
istic
istic
istic
istic
istic
istic"
95,"[/INST]
|1 year|1 year|1 year|1 year|1 year|1|1 year old|1|1 year old|1 year old|1 year old|1 year old|1 year old|1 year old|1 year old|1 year old|1 year old.
|1 year old.
|1 year old|1 year old|1 year old|1 year old|1 year old|1 old|1 year old.
|1 year old.
Stroke.
Stroke.|1 year old.
|1 year old.
|1 year old|1 year old patients|1 year old|1|1|1000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000001.
The increase.
The increase.
The increase.
The000000000000001010101000101010101010101111110101010000000101011111116
The.
This.
This.
This.
This00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
This
01
0000000000000000000000000000000"
96,"[/INST]
Terms related to the study. Non-invasive
| Evaluate the acceptance of dysmia.
| 15 minutes after the two interventions.
| 15 minutes after the study.
Terms related to the study.
| 15 minutes after the two interventions.
| 15 minutes after the two interventions.
| 15 minutes after the two interventions.| 15 minutes after the two interventions.| 15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15 minutes after the two interventions.|15.
|15.
|15.
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Symmeters.
Sympt
Sympt
Sympt
Sympt
Sympt
Symple.
Sym
Sympath.
Sym.
Sympt
Sym
Symmet
Sym
Sym
Symmet
Symmet
Sym.
Sym.
Sym.
Sym.
Sym.
Sym.
The sympt
The sympt
The treatment.
The symptoms.
The symptoms.
The symptoms.
The sympt
The sympt
The.
The.
The disease.
The disease.
The disease.
The sympt
The.
The.
The.
The treatment.
The treatment.
The patient.
The disease.
The, it.
The.
The process.
The.
The,,
The,,
The,,
The,.
The.
The.
In.
The|
This."
97,"[/INST]
Primary Outcome Measure
| Rate of broad-spectrum antibiotic dispensing as a function of the number of selective antibiotic susceptibility testings | 5 days | 
| GP characteristics: demographics (age, gender, diabetes, pregnancy) | Impact of targeted antibiotic susceptibility testing compared to of a standard antibiotic susceptibility test as a function of the patient characteristics | 5 days | 
| E. coli antimicrobial susceptibility profiles | Impact of targeted antibiotic susceptibility testing compared to of a standard antibiotic susceptibility test as a function of the patient characteristics | 5 days | 
| Rate of broad-spectrum antibiotic dispensing as a function of the number of selective antibiotic susceptibility testings | 5 days | 
| GP characteristics: demographics (age, gender, diabetes) | Impact of targeted antibiotic susceptibility testing compared to of a standard antibiotic susceptibility test as a function of the patient characteristics | 5 days | 
| E. coli antimicrobial susceptibility profiles | Impact of targeted antibiotic susceptibility testing compared to of a standard antibiotic susceptibility test as a function of the patient characteristics | 5 days | 
| Rate of broad-spectrum antibiotic dispensing as a function of the number of selective antibiotic susceptibility testings | 5 days | 
| GP characteristics: demographics (age, gender, diabetes) | Impact of targeted antibiotic susceptibility testing compared to of a standard antibiotic susceptibility testings as a function of the patient characteristics | 5 days | 
| Rate of broad-spectrum antibiotic susceptibility testings as a function of the number of selective antibiotic susceptibility testings as a function of the patient characteristics | 5 days | 
| E. coli antimobiles characteristics | 5 days | 5 days | 5 days
| 5 days | 5 days
| 5 days
| 5 days
| 5 days
| 5"
98,"[/INST]
The goal. The clinical psychiatric neuros.
The clinical symptoms in the first to know that the cause about 0.
The clinical psychiatric neuros. It is the reason. It has been proven in the clinical trials. It is the reason. It is the most effective treatment.
The clinical psychiatric symptoms.
The clinical psychiatric symptoms. It is the reason. It is the reason. It has been diagnast
The clinical psychological symptoms. It is the most effective treatment. It is the most. It. It. It. It. It. It. It. It's clinical syndrome. It. It. It. It.
The treatment. It's clinical disease. It is the treatment. It. It. It. It. It.
The.
The patients.
It.
It's.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It's.
It's.
It.
It.
It.
It.
It.
It
It's
it.
It.
It.
It.
It.
It
It
It
The.
The.
This.
This.
This.
This
This
This
This
This
This
It
This
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
it
It
It
be
be
be
be
be
be
/>
/>
/>
/>
/>
/>
/>
be
be
be
be
be
be
be
be
be
be
be
be
be
be
be
be
be
be
g
be
be
be
be
be
be
be
be
be
be
be
be
be
a
a
be
be
be
be
be"
99,"[/INST]

Adverse Events
-----------------
| Expected number of deaths or serious adverse events per 1000 patients | at least 10% of patients will experience a serious adverse event | no specific estimates of harms provided |
| Expected weight change per 1000 patients | at least 5% of patients will experience a serious adverse event |
| Expected to be a serious adverse event per 1000 patients | at least 10% of patients will experience a serious adverse event |
| at least 5% of patients will experience a serious adverse event |
| Expected to be a serious adverse event per 1000 patients | at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| Expected to be a serious adverse event per 1000 patients | at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
| at least 10% of patients will experience a serious adverse event |
|"
100,[/INST]-st-st-st-st-M-M-st-M-c-M-M-M-c-8-8-c-M-M-M-M-M-M-M-M-c-c-M-st-M-M-M-M-M-st-m-st-st-st-m-st-M-st-st-M-M-M-M-M-M-M-M-M-M-M-M-M-M-st-st-M-st-st-st-st-st-st-st-st-a-a-a-M-M-M-M-a-M-M-M-M-M-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-p-a-p-p-p-st-st-st-p-p-p-p-p-a-st-st-st-st-st-st-st-st-st-M-M-st-M-M-M-M-M-M-M-M-M-st-st-st-st-st-a-st-M-st-a-a-st-M-M-M-st-st-st-M-a-a-st-st-st-st-st-st-a-a-a-a-M-a-st-st-st-st-m-m-m-m-m-m-st-a-a-a-a-a-a-a-a-a-m-m-st-st-st-st-st-st-st-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M---M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M
101,"[/INST]
Other: [/INST]
Accepted: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Other: [/INST]
Secondary Outcome Measure
Accepted: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Other: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Accepted: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Other: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Accepted: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Other: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Accepted: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Other: [/INST]
Primary Purpose: To evaluate the change in pain intensity over time Secondary Purpose: To express the acceptance of the investigator after treatment Tertiary Purpose: To evaluate the change in symptoms over time
Accepted: [/INST]"
102,"[/INST]
Other: [/INST]
Adverse events, serious or unexpected events, that were reported in 13-14 year old females who received their first dose of domestic bivalent HPV vaccine or imported HPV vaccine, and 36 months (window period  1 month) after the last dose of vaccination.
Serious or unexpected adverse events, that were reported in 13-14 year old females who received their first dose of domestic bivalent HPV vaccine or imported HPV vaccine, and 36 months (window period  1 month) after the last dose of vaccination.
Participants: 13-14 year old females who received their first dose of domestic bivalent HPV vaccine or imported HPV vaccine, and 36 months (window period  1 month) after the last dose of vaccination.
Primary Outcome Measures
-----------------
Serious or unexpected adverse events, that were reported in 13-14 year old females who received their first dose of domestic bivalent HPV vaccine or imported HPV vaccine, and 36 months (window period  1 month) after the last dose of vaccination.
Secondary Outcome Measures: [/INST]
Serious or unexpected adverse events, that were reported in 13-14 year old females who received their first dose of domestic bivalent HPV vaccine or imported HPV vaccine, and 36 months (window period  1 month) after the last dose of vaccination.
Other: [/INST]
Secondary Outcome Measures: [/INST]
Serious or unexpected adverse events, that were reported in 13-14 year old females who received their first dose of domestic bivalent HPV vaccine or imported HPV vaccine, and 36 months (window period  1 month after the last dose of vaccine.
Secondary Outcome Measures: [/INST and 13-14 year old females who received their first dose of vaccine or imported HPV vaccine, and 18-14"
103,"[/INST]

Quality of Life: [/INST]

Adverse Events: [/INST]
Quality of Life: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST]
Adverse Events: [/INST]
Complementary Medicine: [/INST]
Quality of Life: [/INST
Complementary Medicine: [/INST of the art of the matter.
Complementary Medicine: [/INST of the"
104,"[/INST]
| Provided by: [/INST]
| Eligible for: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Provided by: [/INST]
| Eligible for: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Provided by: [/INST]
| Eligible for: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Provided by: [/INST]
| Eligible for: [/INST]
| Provided by: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Eligible for: [/INST]
| Provided by: [/INST]
| Eligible for: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Provided by: [/INST]
| Eligible for: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Provided by: [/INST]
| Eligible for: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Provided by: [/INST]
| Eligible for: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Provided by: [/INST]
| Eligible for: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Provided by: [/INST]
| Eligible for: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Eligible for: [/INST]
| Provided by: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Eligible for: [/INST]
| Provided by: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Eligible for: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Eligible for: [/INST]
| Inclusion/Exclusion Criteria: [/INST]
| Eligible for: [/INST]
| Inclusion/Exclusion Criteria:"
105,"[/INST]
This
This
This
This
This
This
This
This
This
This
This
This
F
F
F
F
F
This
The
The
The
The
The
The
F
The
The
The
P
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
P
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
C
C
C
C
C
C
C
P
P
P
P
P
P
P
P
P
P
P
P
P
C
D
D
P
P
C
C
C
C
C
C
C
C
P
P
P
P
P
P
C
C
C
A
A
A
A
P
C
F
F
F
F
F
F
C
C
C
C
C
P
P
P
P





















































C
C
C
C
C
C











C
C
C
C
C
R
C
C
C
C
C
C
C
C
C
C
C
C
C
C
R
R










C
C
C
C

























C
C
C






















C
C
C"
106,"[/INST]
-----------------
Primary Outcome Measure
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Changes of serum AST | Changes of serum AST from baseline to week 4, 8, and 12 of study treatment | 4, 8, and 12 weeks | 
| Changes of serum ALT | Changes of serum ALT from baseline to week 4, 8, and 12 of study treatment | 4, 8, and 12 weeks | 
| Changes of serum AST | Changes of serum AST from baseline to week 4, 8, and 12 of study treatment | 4, 8, and 12 weeks | 
| Aspartate transaminase (AST) to alanine transaminase (AST) ratio | Aspartate transaminase (AST) to alanine transaminase (AST) ratio at baseline and week 12 of study treatment | 0 and 12 weeks | 
| USG examination for Transient elastography (TE) | USG examination for Transient elastography (TE) measurement will be performed on baseline and week 12 of study treatment | 4, 8, and 12 weeks | 
| Aspartate transaminase (AST) to alanine transaminase (AST) ratio | Aspartate transaminase (AST) to alanine transaminase (AST) ratio at baseline and week 4, 8, and 12 of study treatment | 4, 8, and 12 weeks | 
| Changes of serum AST | Changes of serum AST from baseline to week 4, 8, and 12 of study treatment | 4, 8, and 12 weeks | 
| Changes of serum AST | Changes of serum AST from baseline to week 4, 8, and 12 of study treatment | 4, 8, and 12 weeks | 
| Changes of serum AST | Changes of serum AST from baseline to week 4, 8, and 12 of study treatment | 4, 8"
107,"[/INST]
The-1.
The-within
The-specific
The-specific
The-specific
The-there.
The-specific
In
In
In
In
In
In
In
In
In
In
P.
In
In
In
In
In
In
In
In
In
In
In
P
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
G
In
In
In
In
In
In
In
In
The
F
In
F
F
F
F
In
In
In
In
In
In
In
In
S
S
S
S
S
S
S
**
**
F
F
F







P
P
P

T
T
T
T
T
T
T
F
P
P
P
P
P
P
P
P
P
**
**
**
**
**
P
P
P
P
P
R
R
R
P
R
P
P
P
P
P
P
P
P
P
S
S
P
P
P
P
P
P
P
P
P
R
P
P
P
P
P
P
P
P
P
P







S
S
S
S
S
S
P
P
P
P
P
S
S
S
S
S
S
S
S
S
S
S
S
P"
108,"[/INST]
Primary Outcome: CD44, E-cadherin
Other: pterygium
Secondary Outcome: PCNA, immunohistochemical staining findings
Tertiary Outcome: pterygium
Quaternary Outcome: CD44, E-cadherin
Interventions: [/INST]
Secondary Interventions: PCNA, immunohistochemical staining findings
Quaternary Interventions: pterygium
Recurrent Interventions: CD44, E-cadherin
Secondary Recurrent Interventions: PCNA, immunohistochemical staining findings
Quaternary Recurrent Interventions: pterygium
Tertiary Recurrent Interventions: CD44, E-cadherin
Quaternary Recurrent Interventions: pterygium
Secondary Recurrent Interventions: CD44, E-cadherin
Quaternary Recurrent Interventions: pterygium
Secondary Recurrent Interventions: CD44, E-cadherin
Quaternary Recurrent Interventions: pterygium
Secondary Recurrent Interventions: CD44, E-cadherin
Quaternary Recurrent Interventions: pterygium
Secondary Recurrent Interventions: CD44, E-cadherin
Quaternary Recurrent Interventions: pterygium
Secondary Recurrent Interventions: CD44, E-cadherin
Quaternary Recurrent Interventions: pterygium
Secondary Recurrent Interventions: CD44, E-cadherin
Quaternary Recurrent Interventions: pterygium
Secondary Recurrent Interventions: CD44, E-cadherin
Quaternary Recurrent Interventions: pterygium
Secondary Recurrent Interventions: CD44, E-cadherin
Quaternary Recurrent Interventions: pterygium
Secondary Recurrent Interventions: CD44, E-cadherin
Quaternary Recurrent Interventions: pterygium
Secondary Recurrent Interventions: CD44,"
109,"[/INST]

| Frail elderly | vital, with symptoms of nasal and respiratory tract infections or not,
| Young adults, healthy with symptoms of nasal and blood | 
| Frequent use of antibiotics like penicillin and gentamicin | 
| Frail elderly, vital with symptoms of nasal and blood | 
| Transplantation with immunosuppressants like azathioprine and 1, 3 and 5 months later | 
| Transplantation with immunosuppressants like 6-MP and 1, 3 and 5 months later | 
| Frail elderly, vital with symptoms of nasal and blood | 
| Transplantation with immunosuppressants like 6-MP and 1, 3 and 5 months later | 
| Frequent use of antibiotics like imipenemicin and 2, 3 and 6 months later | 
| Frail elderly, vital with symptoms of nasal and blood | 
| Transplantation with immunosuppressants like imipenemicin and 1, 3 and 6 months later | 
| Frequent use of antibiotics like imipenemicin and 1, 3 and 6 months later | 
| Frail elderly, vital with symptoms of nasal and blood | 
| Transplantation with immunosuppressants like imipenemicin and 1, 3 and 6 months later | 
| Frequent use of antibiotics like imipenemicin and 1, 3 and 6 months later | 
| Frail elderly, vital with symptoms of nasal and blood | 
| Transplantation with immunosuppressants like imipenemicin and 1, 3 and 6 months later | 
| Frequent use of antibiotics like imipenemicin and 1, 3 and 6 months later | 
| Frail elderly, vital and 1, 3 and 6 months later | 
| Frequent use of antibiotics like imipenemicin and 1, 3 and 1, 2 and 2 and"
110,"[/INST]
Diagnostic Test: ascites, peritonitis due to SBP
Monitoring: [/INST]
| Cirrhotic Patients with Spontaneous Bacterial Peritonitis|
Secondary Outcome Measures
-----------------
| Diagnostic Test: ascites, peritonitis due to SBP
Monitoring: [/INST]
| Cirrhotic Patients with Spontaneous Bacterial Peritonitis|
Secondary Outcome Measures
-----------------
| Diagnostic Test: ascites, peritonitis due to SBP
Monitoring: [/INST]
| Cirrhotic Patients with Spontaneous Bacterial Peritonitis|
Secondary Outcome Measures
-----------------
| Diagnostic Test: ascites, peritonitis due to SBP
Monitoring: [/INST]
| Cirrhotic Patients with Spontaneous Bacterial Peritonitis|
Secondary Outcome Measures
-----------------
| Diagnostic Test: ascites, peritonitis due to SBP
Monitoring: [/INST]
| Cirrhotic Patients with Spontaneous Bacterial Peritonitis|
Secondary Outcome Measures
-----------------
| Diagnostic Test: ascites, peritonitis due to SBP
Monitoring: [/INST]
| Cirrhotic Patients with Spontaneous Bacterial Peritonitis|
Secondary Outcome Measures
-----------------
| Diagnostic Test: ascites, peritonitis due to SBP
Monitoring: [/INST]
| Cirrhotic Patients with Spontaneous Bacterial Peritonitis|
Secondary Outcome Measures
-----------------
| Diagnostic Test: ascites, peritonitis due to SBP
Monitoring: [/INST]
| Cirrhotic Patients with Spontaneous Bacterial Peritonitis|
Secondary Outcome Measures
-----------------
| Diagnostic Test: ascites, peritonitis due to SBP
Monitoring: [/INST]
| Cirrhotic Patients with Spontaneous Bacterial Peritonitis|
Secondary Outcome Measures
-----------------"
111,"[/INST]

Patient Information: [Patient Information provided by Study ID]
Study Design: [Study Protocol provided by Study ID]
Patient Information: [Patient Information provided by Study Protocol]
Interventions: [Intervention provided by Study Protocol]
Patient Information: [Patient Information provided by Study Protocol]
Outcome Measures: [Outcome Measure provided by Study Protocol]
Time Frame: [Study Design provided by Study Protocol]
Data provided by Study Protocol
Patient Information: [Patient Information provided by Study Protocol]
Data provided by Study Protocol
Patient Information: [Patient Information provided by Study Protocol]
Data provided by Study Protocol
Patient Information: [Patient Information provided by Study Protocol]
Data provided by Study Protocol
Patient Information: [Patient Information provided by Study Protocol]
Data provided by Study Protocol
Patient Information: [Patient Information provided by Study Protocol]
Data provided by Study Protocol
Patient Information: [Patient Information provided by Study Protocol]
Data provided by Study Protocol
Patient Information: [Patient Information provided by Study Protocol]
Data provided by Study Protocol
Patient Information: [Patient Information provided by Study Protocol]
Data provided by Study Protocol
Patient Information: [Patient Information provided by Study Protocol]
Data provided by Study Protocol
Patient Information: [Patient Information provided by Study Protocol]
Data provided by Study Protocol
Patient Information: [Patient Information provided by Study Protocol]
Data provided by Study Protocol
Patient Information: [Patient Information provided by Study Protocol]
Patient Information: [Patient Information provided by Study Protocol]
Data provided by Study Protocol
Patient Information: [Patient Information provided by Study Protocol]
Patient Information: [Patient Information provided by Study Protocol]
Patient Information: [Patient Information provided by Study Protocol]
Patient Information: [Patient Information provided by Study Protocol]
Patient Information: [Patient Information provided by Study Protocol]
Patient Information: [Patient Information provided by Study Protocol]
Patient Information: [Patient Information provided by Study Protocol]
Patient Information: [Patient Information provided by Study Pro"
112,"[/INST]
Breast Cancer, DIBH and left sided.
| the heart.
Breast Cancer, DIBH.
Breast, and left sided.
Breast, and the heart.
Breast, DIBH and left sided.
Breast, and the heart.
Breast, and left sided.
Breast, DIBH.
Breast, and left sided.
Breast, DIBH.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Breast.
Break.
Breast.
Breast.
Breast.
Breast.
Break.
Break.
Break.
The breast.
The breast.
The breast.
The breast.
The breast.
Break.
Break.
Break.
The breast.
The breast.
The breast.
The breast.
The breast.
The breast.
The disease.
The disease.
It.
The.
It.
It.
The.
The breast.
The.
The.
The.
It.
The.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
This."
113,"[/INST]
This
This
This
This
This
This
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
The
The
The
The
The
The
The
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
This -
This -
This
The -
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The -
The -
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
In
In
In
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
S
S
S
S
S
S
S
S
S
S
S
P
P
P
P
The
The
The
The
The
The
The
The
The
The
The
The
S
S
S
S
S
The
The
S
S
S
S
S
S
S
S





















S
S
S
S
S
S
S
S
S
S
S
S
S
S
S"
114,"[/INST]

Primary Purpose: Health Services Research
| Intervention/Evaluation | Eligible youth will receive usual care and mental health services at the enrolled clinic. | Enrolled clinics will provide usual care and mental health services to youth who screen positive for the app. | Following the step period, a survey of mental health services will be conducted and electronic medical records will be reviewed for completeness. | The duration of the step period will be 1 year for all clinics.

Secondary Purpose: [/INST]


Youth and caregivers at the clinic will receive usual mental health services and be encouraged to access the app for the duration of the step period."
115,"[/INST]
Synto be done | Synto be done
Synthesis
Synthesis
Synthesis
Synto be done the Synto
Synto be done
Synto be done
Synto be done | to be done Synto be done
Synto be done
Synto be done | to be done the Synto be done | to be done.
Synto be done.
Synto be done.
Synto be done.
Syn
Synto be done.
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn
Syn.
Syn.
Syn.
Syn.
Syn.
Syn.
Syn
Syn
Syn
Syn.
Syn.
Syn.
Syn.
Syn.
Syn.
Syn.
The|
The patient.
The patient.
==
==
The patient.
The patient.
The patient.
The patient.
in
There.
There.
There.
There.
There.
There.
There.
There.
There.
There.
There.
This
This
These
These
The patients.
The
The
The
The
The
The
The
The, the
The patients
The
It
It
It
It
It
It
It
It
It
It
It
It
It
It
This
The
The
It
==
==
==
==
==
==
==
==
==
This
This
This
This
This==
==
This
This
This
This
This
This
This
This
This
This
This==
This==
This
This
This
This
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
and
and
and
This
This
This
This
==
This
This
This
This
This
This
This
This
==.
==
This
This
This
This
This
This
This
This
This
This"
116,"[/INST]
Other Outcome Measures
| Successful pregnancy | Rate of vaginal microbiome, IVF/ICSI procedure in women with non-European origin included in the observational part of this study. | The total costs of all received treatments within the study period. | 3 years | 
| Pregnancy at 12 weeks after a first IVF or an IVF-ICSI procedure with an ET in women with non-European origin included in the observational part of this study. |
Experimental: Physician decision group. | 3 years | 
Primary Purpose: To provide information to help women decide whether to use hormonal contraception.
| Women of reproductive age | 18-40 years | 
| Other: Women of reproductive age <18 years | 
Secondary Purpose: To provide information to help women decide whether to use hormonal contraception. | Women of reproductive age <40 years | 
Treatment: To provide information to help women decide whether to use hormonal contraception. | Women of reproductive age <18 years | 
Experimental: Physician decision group. | 3 years | 
Primary Purpose: To provide information to help women decide whether to use hormonal contraception. | Women of reproductive age <40 years | 
Secondary Outcome Measures
| Successful pregnancy | Rate of vaginal microbiome, IVF/ICSI procedure in women with non-European origin included in the observational part of this study. | The total costs of all received treatments within the study period. | 3 years | 
| Women of reproductive age <40 years | 
Experimental: Physician decision group. | 3 years | 
Primary Purpose: To provide information to help women decide whether to use hormonal contraception. | Women of reproductive age <40 years | 
Secondary Outcome Measures
| Successful pregnancy | Rate of vaginal microbiome, IVF/ICSI procedure in women with non-European origin included in the observational part of this study. | The total costs of all received treatments within the study period. | 3 years | 
Experimental: Physician decision"
117,"[/INST]
The-1.
The-1.
It.
It.
It.
It.
There.
This.
There.
There.
There.
It.
It.
It.
It.
It's
It.
This.
It.
It.
It.
It's
It's
It's
It's
It's
It's
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
a
a



































==
=="
118,"[/INST]
Other Names: pioglitazone hydrochloride; Research Participants: placebo
Primary Outcome: [/INST]
Secondary Outcome Measure: [/INST]
Research Participants: pioglitazone hydrochloride 45 mg/day for five days prior to coronary artery bypass surgery;
Other Names: pioglitazone hydrochloride; SPHK1 - aortic appendage; Difference in SPHK1 expression in the aortic artery cells determined by western blot between groups;
Primary Outcome: [/INST]
Secondary Outcome Measure: [/INST]
Research Participants: pioglitazone hydrochloride 45 mg/day for five days prior to coronary artery bypass surgery;
Other Names: SPHK1 - aortic appendage; Difference in SPHK1 expression in the aortic artery cells determined by western blot between groups;
Primary Outcome: [/INST]
Secondary Outcome Measure: [/INST]
Other Names: pioglitazone hydrochloride; Research Participants: placebo
Primary Outcome: [/INST]
Secondary Outcome Measure: [/INST]
Research Participants: pioglitazone hydrochloride 45 mg/day for five days prior to coronary artery bypass surgery;
Other Names: SPHK1 - aortic appendage; Difference in SPHK1 expression in the aortic artery cells determined by western blot between groups;
Primary Outcome: [/INST]
Research Participants: pioglitazone hydrochloride 45 mg/day for five days prior to coronary artery bypass surgery;
Other Names: SPHK1 - aortic appendage; Difference in SPHK1 expression in the aortic artery cells determined by western blot between groups;
Primary Outcome: [/INST]
Research Participants: pioglitazone hydrochloride 45 mg/day for five days prior to coronary artery bypass surgery;
Other Names: SPHK1 - aortic appendage; Difference"
119,"[/INST]






























































































































































































		














		
			







,,						,,	,,	,,	,,	,,							,,	,,	,,	,,,
,,,,,,
,,
,,,
,,	,,	,,	,,,
,,,
,,,





			
		
	
								,,
,
,
,





	,,
,,
,,,
,,

,,





	









D
D



















,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,,,
,
,
,
,
,
,,,
,,
,,
,, .
,, a,, a,, a, a, . ., .,, a, a, a, a, a, a, a, a, a, a, a, a, a, a, a, a D,, D a D a D a D a D,, a . . . ., a, a, a, a, |, |, |, | a | a | a | a | | a | a |"
120,"[/INST]
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad












rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad
rad












































































































































































































































































































































































































-
-
-
-
-
-
-
-
-
-
-

-
-
-"
121,"[/INST]
1. Extracorporeal shock wave therapy at 10 Hz frequency, 2.5 Barr energy and 2000 shocks/session will be applied to the most sensitive point in the medial calcaneus.
2. A tape consisting of 96% cotton and 4% lycra will be asked to remain for a week.
3. It was stated to the patients that 10 represented unbearable pain. The patients' pain level will be recorded before treatment and again after a single treatment session.
4. VAS, translated into Turkish, with numbers from 0 to 10 on a 10 cm horizontal line; 0 means no pain, and the patients' pain level will be recorded again at the end of treatment (at 1st week)."
122,"[/INST]

Primary Outcome Measures
-----------------
| Autism Spectrum Disorder | range from 0 to 3 for each item, total score of 60.
| Higher the score, worse the symptoms. |
| Social Responsiveness Scale, SRS | range from 0 to 5 for each item, total score of 60.
| Quality of life questionnaire | 6 weeks |
| Autism Spectrum Disorder | range from 0 to 3 for each item, total score of 80.
| Social Responsiveness Scale, SRS | range from 0 to 5 for each item, total score of 60.
| Quality of life questionnaire | 6 weeks |
| Autism Spectrum Disorder | range from 0 to 3 for each item, total score of 80.
| Social Responsiveness Scale, SRS | range from 0 to 5 for each item, total score of 60.
| Quality of life questionnaire | 6 weeks |
| Autism Spectrum Disorder | range from 0 to 3 for each item, total score of 80.
| Social Responsiveness Scale, SRS | range from 0 to 5 for each item, total score of 60.
| Quality of life questionnaire | 6 weeks |
| Autism Spectrum Disorder | range from 0 to 3 for each item, total score of 80.
| Social Responsiveness Scale, SRS | range from 0 to 5 for each item, total score of 60.
| Quality of life questionnaire | 6 weeks |
| Autism Spectrum Disorder | range from 0 to 3 for each item, total score of 80.
| Social Responsiveness Scale, SRS | range from 0 to 5 for each item, total score of 60.
| Quality of life questionnaire | 6 weeks |
| Autism Spectrum Disorder | range from 0 to 3 for each item, total score of 80.
| Social Responsiveness Scale, SRS | range from 0 to 5 for each item, total score of 60.
| Autism Spect"
123,"[/INST]- a- a- a- a- a- a- a- a- a- a- a-C-C-C- a-C-C-C-C-C-C-
-O-O-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-A-A-
-C-C-C-C-C-C-C
-









-
-
-
-
-
-
-
-
-
-
-
-
-










-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-




























,
,
,












, a, a,
,
,
-























































































































,
,,,,,,,
,"
124,"[/INST]
-
-
-
-
-
-
-
-











-
-
-















































































































-





















































































-
-
-
























































































































































































































































-















	
	
	-
-"
125,"[/INST]
| Terms related to the study |
| Other: Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Terms related to the study |
| Other: Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Other: Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Other: Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Other: Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Other: Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Other: Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Other: Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Other: Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Other: Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Terms related to the study |
| Sinus node dysfunction |
| Other: Sinus"
126,"[/INST]
Primary care. The cost of the hospital.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.Primary care.Primary care.
Primary care.
Primary care.
Primary care.
Primary care.Primary care.Primary care.Primary care.
Primary care.Primary care.
Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
Primary care.
The primary.
The primary care.
The primary care.
The primary care.
The primary.
The primary.
The.
The.
The.
The.
The effect.
The.
The.
The.
The effect.
The.
The.
The.
The effect.
The    .
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The
The
The
The
The
The
The
The
The
The   
The
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
This
This
This
This
The
The
The"
127,"[/INST]

Definitions
-----------------

Behavioral: [/INST]

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------

Definitions
-----------------

Change in Pain Intensity
-----------------

Communication Style
-----------------"
128,"[/INST]

Primary Outcome Measures
-----------------
What is the study measuring?
How is the study designed to improve outcomes?
What are the inclusion and exclusion criteria for the study?
What is the time frame for the study?
What are the risks and benefits of the study?
How might the study affect quality of life for patients?
How might the study affect costs?
Are there any harms associated with the study?
What is the likelihood of the study being effective?
How might the study be monitored?
What are the safety precautions for the study?
How might the study be financed?
Are there any safety concerns associated with the study?
Are there any patient groups that might benefit from the study?
How might the study be financed without the need for ALPINE?
What is the likelihood of the study being curtailed early for financial reasons?
What are the alternative strategies for the study?
What is the likelihood of the alternative providing similar benefits?
Are there any patient subgroups who might benefit from the study?
What are the inclusion and exclusion criteria for those patient subgroups?
What are the inclusion and exclusion criteria for the study?
How might the study be financed without putting those patient subgroups at risk?
What are the inclusion and exclusion criteria for the study?
How might the study affect the equity of patients?
What are the inclusion and exclusion criteria for the study?
How might the study affect the equity of patients eligible for enrollment in ALPINE?
What are the inclusion and exclusion criteria for ALPINE?
What are the risks of the study for those patients?
How might the study affect the distribution of ALPINE?
What are the inclusion and exclusion criteria for ALPINE?
What are the risks of ALPINE?
How might the study affect the distribution of ALPINE?
What are the inclusion and exclusion criteria for ALPINE?
How might the study affect the distribution of ALPINE?
What are the inclusion and exclusion criteria for ALPINE?
How might the study affect the equity of patients eligible for ALPINE?
What are the inclusion and exclusion criteria for ALPINE?
How might the study affect the distribution of ALPINE?
What are the inclusion and exclusion"
129,"[/INST]

Adverse Events
-----------------
Evaluation of the study
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Evaluation of the study | Patients who score higher than six points on the adherence scale will be considered to have high adherence, those who score less than six points will be classified as low adherence. | 3 months | 
| Patient satisfaction |

Secondary Outcome Measures
-----------------
Evaluation of the study
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Evaluation of the study | Patients who score higher than six points on the adherence scale will be considered to have high adherence, those who score less than six points will be classified as low adherence. | 3 months | 
| Patient satisfaction |

Secondary Outcome Measures
-----------------
Evaluation of the study
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Evaluation of the study | Patients who score higher than six points on the adherence scale will be considered to have high adherence, those who score less than six points will be classified as low adherence. | 3 months | 
| Patient satisfaction |

Secondary Outcome Measures
-----------------
Evaluation of the study
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Evaluation of the study | Patients who score higher than six points on the adherence scale will be considered to have high adherence, those who score less than six points will be classified as low adherence. | 3 months | 
| Patient satisfaction |

Secondary Outcome Measures
-----------------
Evaluation of the study
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Evaluation of the study | Patients who score higher than six points on the adherence scale will be considered to have high adherence, those who score less than six points will be classified as low adherence. | 3 months | 
| Patient satisfaction |

Secondary Outcome Measures"
130,"[/INST]
| How is the study designed? |
| What is the study measuring? |
| Time Frame: [When was the study launched?] |
| Primary Outcome Measure: [What is the primary outcome measure for the study?] |
| Secondary Outcome Measures: [List the secondary outcome measures.] |
| How is the study designed to answer these measures? |
| How is the study powered? |
| What is the power of the study for Aim 1? |
| What is the power of the study for Aim 2? |
| How is the study powered to answer these measures? |
| How is the study designed to answer these measures? |
| How is the study related to these measures? |
| How is the study designed to answer these measures? |
| What is the study measuring? |
| How is the study powered? |
| What is the study designed to answer these measures? |
| How is the study related to these measures? |
| What is the study measuring? |
| How is the study powered? |
| What is the study designed to answer these measures? |
| How is the study powered? |
| What is the study measuring? |
| How is the study powered? |
| Patients with ARDS, and Aim 1 and Aim 2, |
| Patients with Aim 2, and Aim 1 and Aim 2, and Patients with ARDS, and Aim 1 and Aim 2, Patients with ARDS, and Aim 1 and Aim, Patients with ARDS, Patients with ARDS, Patients with ARDS, Aim, Patients with ARDS, and Aim, Patients with ARDS, and Patients with ARDS, Patients with ARDS, Patients with ARDS, Patients with ARDS, Patients with ARDS, Patients with ARDS of patients with ARDS, Patients with ARDS, Patients with ARDS, Patients with ARDS, Patients with ARDS. Patients with ARDS. Patients with a disease. Patients with ARDS. Patients with ARDS of patients with ARDS. Patients with ARDS. Patients with ARDS. Patients with ARDS. Patients"
131,"[/INST]































































































Y
Y
Y
Y





















CT
CT
CT
CT
CT
CT
CT
CT
CT

CT
CT
CT
CT
CT
CT
CT
CT
CT
CT
Y

Y










































CT
CT
CT
CT






















































































































































































































































































|

|
|"
132,"[/INST]
Other names: [/INST]
Primary Outcome Measure
| Secondary Outcome Measure | Measure Description | Time Frame |
| Gut microbiota signature before prostate medication (degarelix or finasteride) | Gut microbiota signature after starting prostate medication (degarelix or finasteride) | 
| Gut microbiota signature before prostate medication (degarelix or finasteride) | 
| Secondary Outcome Measure | Measure Description | Time Frame |
| Gut microbiota signature before prostate medication (degarelix or finasteride) | Gut microbiota signature after starting prostate medication (degarelix or finasteride) | 

Secondary Outcome Measure
| Gut microbiota signature before prostate medication (degarelix or finasteride) | Gut microbiota signature after starting prostate medication (degarelix or finasteride) | 
| Gut microbiota signature before prostate medication (degarelix or finasteride) | 

Secondary Outcome Measure
| Gut microbiota signature before prostate medication (degarelix or finasteride) | Gut microbiota signature after starting prostate medication (degarelix or finasteride) | 
| Gut microbiota signature before prostate medication (degarelix or finasteride) | 

Secondary Outcome Measure
| Gut microbiota signature before prostate medication (degarelix or finasteride) | Gut microbiota signature after starting prostate medication (degarelix or finasteride) | 
| Gut microbiota signature before prostate medication (degarelix or finasteride) | 

Secondary Outcome Measure
| Gut microbiota signature before prostate medication (degarelix or finasteride) | Gut microbiota signature after starting prostate medication (degarelix or finasteride) | 
| Gut microbiota signature before prostate medication (degarelix or finasteride) | 

Secondary Outcome Measure
| Gut microbiota signature before prostate medication (degarelix or finasteride) | Gut microbiota signature before pro"
133,"[/INST]

Primary Purpose: Basic Science
-----------------
Diagnostic Tests
MRI, CT Scan, Ultrasound, PET Scan
Secondary Outcome Measures
| --- | --- |
| Diagnostic Tests: MRI, CT Scan, Ultrasound, PET Scan | 1p19q codeletion status will be correlated with the changes in tumor volumes and to the clinical response | 1 year | 

Interventions
| --- | --- |
| Diagnostic Tests: MRI, CT Scan, Ultrasound, PET Scan | 1p19q codeletion status will be correlated with the changes in tumor volumes and to the clinical response | 1 year |

Secondary Outcome Measures
| --- | --- |
| Diagnostic Tests: MRI, CT Scan, Ultrasound, PET Scan | 1p19q codeletion status will be correlated with the changes in tumor volumes and to the clinical response | 1 year |

Primary Purpose: Basic Science
| --- | --- |
| Diagnostic Tests: MRI, CT Scan, Ultrasound, PET Scan | 1p19q codeletion status will be correlated with the changes in tumor volumes and to the clinical response | 1 year |

Secondary Outcome Measures
| --- | --- |
| Diagnostic Tests: MRI, CT Scan, Ultrasound, PET Scan | 1p19q codeletion status will be correlated with the changes in tumor volumes and to the clinical response | 1 year |

Primary Purpose: Basic Science
| --- | --- |
| Diagnostic Tests: MRI, CT Scan, Ultrasound, PET Scan | 1p19q codeletion status will be correlated with the changes in tumor volumes and to the clinical response | 1 year |

Secondary Outcome Measures
| --- | --- |
| Diagnostic Tests: MRI, CT Scan, Ultrasound, PET Scan | 1p19q codeletion status will be correlated with the changes in tumor volumes and to the clinical response | 1 year |"
134,"[/INST]
* Drug: Hydroxyurea and Thalidomide<br>Combination therapy for beta-thalassemia patients
* Drug: Hydroxyurea and Thalidomide<br>Primary endpoint: Change in hemoglobin level from baseline | Secondary endpoint: Changes in liver and spleen size from baseline | 1-3 years on combination therapy | 
* Drug: Hydroxyurea and Thalidomide<br>Combination therapy for beta-thalassemia patients
* Drug: Hydroxyurea and Thalidomide<br>Primary endpoint: Change in hemoglobin level from baseline | Secondary endpoint: Changes in liver and spleen size from baseline | 1-3 years on combination therapy | 

* Drug: Hydroxyurea and Thalidomide<br>Combination therapy for beta-thalassemia patients
* Drug: Hydroxyurea and Thalidomide<br>Primary endpoint: Change in hemoglobin level from baseline | Secondary endpoint: Changes in liver and spleen size from baseline | 1-3 years on combination therapy | 

* Drug: Hydroxyurea and Thalidomide<br>Combination therapy for beta-thalassemia patients
* Drug: Hydroxyurea and Thalidomide<br>Primary endpoint: Change in hemoglobin level from baseline | Secondary endpoint: Changes in liver and spleen size from baseline | 1-3 years on combination therapy | 

* Drug: Hydroxyurea and Thalidomide<br>Combination therapy for beta-thalassemia patients
* Drug: Hydroxyurea and Thalidomide<br>Primary endpoint: Change in hemoglobin level from baseline | Secondary endpoint: Changes in liver and spleen size from baseline | 1-3 years on combination therapy | 


* Drug: Hydroxyurea and Thalidomide<br>Combination therapy for beta-thalassemia patients
* Drug:"
135,"[/INST]
Primary Outcome Measures
-----------------
How is the study designed?
| Primary care practitioners | To determine the current practice for diagnosis and management of suspected venous leg ulcers in primary care departments across the UK. | Vascular Scientists | A Delphi Consensus will be conducted via online questionnaires to determine the current practice for diagnosis and management of suspected venous leg ulcers in vascular scientist departments across the UK. | 3 months |
How is the study designed?
| Primary care practitioners | To determine the current practice for diagnosis and management of suspected venous leg ulcers in primary care departments across the UK. A Delphi Consensus will be conducted via online questionnaires have been designed to determine the current practice for diagnosis and management of suspected venous leg ulcers in vascular scientist departments across the UK. | 6 months |
How is the study measuring?
| Primary care practitioners | To determine the current practice for diagnosis and management of suspected venous leg ulcers in primary care departments across the UK. A Delphi Consensus will be conducted via online questionnaires have been designed to determine the current practice for diagnosis and management of suspected venous leg ulcers in vascular scientist departments across the UK. | 3 months |
How is the study measuring?
| Primary care practitioners | To determine the current practice for diagnosis and management of suspected venous leg ulcers in primary care departments across the UK. A Delphi Consensus will be conducted via online questionnaires have been designed to determine the current practice for diagnosis and management of suspected venous leg ulcers in vascular scientist departments across the UK. | 6 months |
How is the study measuring?
| Primary care practitioners | To determine the current practice for diagnosis and management of suspected venous leg ulcers in primary care departments across the UK. A Delphi Consensus will be conducted via online questionnaires have been designed to determine the current practice for diagnosis and management of suspected venous leg ulcers in vascular scientist departments across the UK. | 3 months |
How is the study designed?
| Primary care practitioners | To determine the current practice for diagnosis and management of suspected venous leg"
136,"[/INST]
Primary Outcome: Future

| Study Measurement: [/INST]
| Future Outcome: [/INST]
| Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit. | Future Time Perspective; The Virtual Reality Avatar experience will increase future time perspective. | Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit. |
| Future Time Perspective; The Virtual Reality Avatar experience will increase future time perspective. | Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit. |
| Delayed Reward Preference; The Virtual Reality Avatar experience will increase delayed reward preference. | Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit. |
| Future Time Perspective; The Virtual Reality Avatar experience will increase future time perspective. | Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit. |
| Delayed Reward Preference; The Virtual Reality Avatar experience will increase future time perspective. | Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit. |
| Future Time Perspective; The Virtual Reality Avatar experience will increase future time perspective. | Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit. |
| Delayed Reward Preference; The Virtual Reality Avatar experience will increase future time perspective. | Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit. |
| Future Time Perspective; The Virtual Reality Avatar experience will increase future time perspective. | Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit. |
| Delayed Reward Preference; The Virtual Reality Avatar experience will increase future time perspective. | Study Day Visit; 30-day Follow-up Visit; 6-month Follow-up Visit. |
| Future Time Perspective; The Virtual"
137,"[/INST]

Adverse Events
-----------------
Exclusion Criteria: [to be defined]

Timeline: [to be defined]
Adverse Events: [to be defined]

Defined as: [to be defined]

Primary Purpose: [to be defined]
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |
| to be defined |"
138,"[/INST]

How is the study designed?
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention Model: Open-Label |
| Primary Purpose: Prevention | Intervention"
139,"[/INST]
Primary Outcome: [Patient #1]'s length of stay in the ICU will be tracked across 12 months following hospital admission with any elevated eCART score. Because death is biased toward fewer ICU-free days and is a competing outcome, patients who die prior to day 30 are assigned with 0 ventilator-free days.
Secondary Outcome: [Patient #2]'s length of stay in the ICU will be tracked across 12 months following hospital admission with any elevated eCART score. Because death is biased toward fewer ICU-free days and is a competing outcome, patients who die prior to day 30 are assigned with 0 ventilator-free days.













































































































































































































The patient #1.
The patient data.
The patient data.
The patient #1.
The patient #1.
The patient #2.
The patient #2.
The patient #1.
The patient #1.
The patient #1.
The patient #1.
The patient #1.
The patient #1.
The patient #2.
The patient #1.
The patient #1.
The patient #1.
The patient #1.
The patient #1.
The patient #1.
The patient #1.
The patient #2.
The patient #2.
The patient #2."
140,"[/INST]
Primary Outcome Measures
-----------------
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Primary Outcome Measure
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST]
Secondary Outcome Measures
-----------------
Keywords: [/INST
Secondary Outcome Measures
Secondary Outcome Measures
Keywords: [/INST
Secondary Outcome Measures
Secondary Outcome Measures: [/INST
Secondary Outcome Measures:
Secondary Outcome Measures: [/INST
Secondary Outcome Measures: breastfeeding: Secondary Outcome
Secondary Outcome: [/INST
Secondary Outcome: breastfeeding: [/Instead of the Secondary Outcome: breastfeeding: breastfeeding. Second: breastfeeding, Secondary Outcome: breastfeeding. Secondary: Secondary: breastfeeding. Second"
141,"[/INST]

Primary Outcome Measures
-----------------
| Participants in the Moodivate app |
| Other: Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be provided educational material about mood management techniques. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be provided educational material about mood management techniques. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Participants in the control group will be asked to complete questionnaires at baseline and follow-up. |
| Part"
142,[/INST]
143,"[/INST]
| Other: [/INST]
Adverse Events
| --- | --- |
| Other: [/INST]
Participants will consume Funk It Cycle Bites (Test product) once daily. [Time Frame: Baseline to Month 4] | Survey-based assessment of any potential side effects using study-specific questionnaires. | Other: [/INST]
| Changes in weight. [Time Frame: Baseline to Month 4] | Survey-based assessment using study-specific questionnaires. | 4 months | 
| Other: [/INST]
| Changes in mood. [Time Frame: Baseline to Month 4] | Survey-based assessment using study-specific questionnaires. | 4 months | 
| Changes in premenstrual syndrome. [Time Frame: Baseline to Month 4] | Survey-based assessment using study-specific questionnaires. | 4 months | 
| Changes in energy levels. [Time Frame: Baseline to Month 4] | Survey-based assessment using study-specific questionnaires. | 4 months | 
| Other: [/INST]
| Changes in mood stability. [Time Frame: Baseline to Month 4] | Survey-based assessment using study-specific questionnaires. | 4 months | 
| Changes in acne. [Time Frame: Baseline to Month 4] | Survey-based assessment using study-specific questionnaires. | 4 months | 
| Changes in weight. [Time Frame: Baseline to Month 4] | Survey-based assessment using study-specific questionnaires. | 4 months | 
| Changes in premenstrual syndrome. [Time Frame: Baseline to Month 4] | Survey-based assessment using study-specific questionnaires. | 4 months | 
| Changes in energy levels. [Time Frame: Baseline to Month 4] | Survey-based assessment using study-specific questionnaires. | 4 months | 
| Changes in mood. [Time Frame: Baseline to Month 4] | Survey-based assessment using study-specific questionnaires. | 4 months | 
| Changes in acne. [Time Frame: Baseline to Month"
144,"[/INST]
(the (including (including (
This (the (the (
This (this (this (
This (including
This (includes
This (including
This (a
This (a
This (this (this
This (including
This (including
This (including
This (including
This (
This (
This (this (
This (
This (
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The (
The (
The (
to
to
to
to
This
This
This
This
This
The
The
The
The
to
to
to
The (
The (
The (
The (
The (
The ("
145,"[/INST]

Early Childhood Caries

Primary Purpose: Prevention
-----------------
Intervention/Treatment
Children with early childhood caries | Children with pulpally involved primary teeth | Children with cavities of the anterior and posterior tooth | Children with grossly broken down teeth | Children with more than one third of the crown missing | Children with discolored teeth | Children with missing primary teeth | Children with multiple lesions | Children with multiple cavities | Children with no clinical signs | Children with multiple abscesses | Children with multiple cavities | Children with multiple lesions | Children with multiple discolored teeth | Children with multiple missing teeth | Children with multiple cavities |
Secondary Prevention: [/INST]
Acceptance of SDF by parents | Reasons for not accepting SDF | Parental acceptance of SDF |
Treatment of early childhood caries | Reasons for not using SDF |
Allocation of children to different treatment groups |
Secondary Outcome Measures

-----------------

Acceptance of SDF by parents | Reasons for not accepting SDF |
Primary Purpose: Prevention
-----------------
Intervention/Treatment
Children with early childhood caries | Children with pulpally involved primary teeth | Children with cavities of the anterior and posterior tooth | Children with multiple lesions | Children with missing teeth |
Secondary Outcome Measures
-----------------

Acceptance of SDF by parents | Reasons for not accepting SDF |
Children with multiple cavities | Children with missing teeth |
Primary Purpose: Prevention
-----------------
Intervention/Treatment
Children with early childhood caries | Children with pulpally involved primary teeth | Children with multiple cavities | Children with missing teeth | Children with discolored teeth | Children with no clinical signs |
Secondary Outcome Measures
-----------------

Acceptance of SDF by parents | Reasons for not accepting SDF |
Children with multiple cavities | Children with missing teeth |
Primary Purpose: Prevention
-----------------
Intervention/Treatment
Children with early childhood caries | Children with pulpally involved primary teeth | Children with multiple cavities | Children with missing teeth | Children with no clinical signs |
Secondary Outcome Measures
-----------------

Acceptance of S"
146,"[/INST]
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A

























































































A
A
A
A
A
A
A
A
A
A
A























































A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A













































































































































































C
C











C
C
C
C
C
C
C
R
C
C
C
O
O

C










O
C
C
C"
147,"[/INST]

How is the study designed?
-----------------
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Out"
148,"[/INST]
-----------------

How is the study designed?
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Outcome Measure |
| Outcome Measure | Time Frame |
| Outcome Measure | Outcome Measure | Time Frame |
| Outcome Measure | Outcome Measure | Time Frame |
| Outcome Measure | Outcome Measure | Time Frame | Outcome Measure | Outcome
| Outcome Measure | Outcome | Time Frame | Outcome Measure | Outcome Measure | Outcome
| Outcome Measure | Outcome Measure | Outcome
| Outcome
| Outcome Measure | Outcome
| Outcome, Outcome
| Outcome, Outcome, Outcome, Outcome, Outcome, Outcome, Outcome, Outcome, Outcome, Outcome, Outcome, Outcome, Outcome, Outcome, Outcome, Outcome, Out"
149,"[/INST]
1.
1.
1. glabit. 2.0000.
1.
1.
1.00, glabis, 1.00, 1.00, glabis, 1.00, glab.
1.00.0, glabis, 1.00, glabis, 1.00, 1.0, 1.000000000000000
1.00.00.00.0000000000001.000000,000000
The psych.
It is a.001.
The psych.
It.
It.
It.
It.
It.
The disease.
The.
The.
The psych.
The psych.
The
There.
There
There
There
There
There
There
There
There
It
It
It
It
It
It
It.
It.
It.
It.
It.
It.
It.
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
The
This
This
This
This
This
This
This
This
This
This
This
This
It
It
It
It
It
It
The
The
The
The
It
It
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
It
It
It
It
It
It
It"
150,"[/INST]

Music Therapy
| Music therapy is a technique of care, which aims to improve health and well-being by reducing anxiety.
| Music therapy is a complementary approach to standard medical treatment, which has been shown to be effective in a select group of patients.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation therapy, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used in addition to standard treatments, such as chemotherapy, radiation, and surgery.
| Music therapy is used"
151,"[/INST]

| The incidence of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle related donor transplantation |
| The severity of Seattle related donor transplantation |
| The incidence of Seattle"
152,"[/INST]
| Participants will be reported | The peak thrombocytopenia during the fitusiran treatment period (via the Hemophilia Questionnaire) over time | Participants will be reported | From approximately Month-2 up to Day 1 | 
| The peak thrombocytopenic syndrome during the fitusiran treatment period over the fitusiran treatment period. | Participants will be reported | The peak thrombic syndrome while the fitusiran treatment period.
| Participants will be reported | The peak thrombic Syndrome
| The peak thrombin during the fitus
| Participants will be reported | The peak thrombin
| The peak thrombin
| Participants will be reported | The peak thrombin
| The peak thrombin
| Participants will be reported during the fitus.
| Participants will be reported during the fitus.
| The peak thrombin.
| The peak thrombin.
| The peak.
| Participants will be reported the peak.
| The peak thrombin.
| The peak.
| The peak.
| The peak.
| The peak.
| The peak.
| The peak.
| The peak.
| The peak.
| The peak.
| The peak.
| The peak.
| The peak.
| The peak.
| The peak.
| The peak.
| The peak.
| The
|
| The peak.
| Year
| Year
| Year
| Year old| Year old| Year old patients.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The patients|
The patients|
The patients.
|
|
|
|
|
|
The
The patients|
The
The patients|
The patients|
The
The
The
The
The
The patients
The patients|
The
The patients
The
The
The
The
The
The"
153,"[/INST]

| Other: Questionnaire<br>

| Primary Outcome Measure

| Other: Questionnaire<br>

| Primary Outcome Measure

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Questionnaire<br>

| Other: Question"
154,"[/INST]

Exercise: [/INST]

What is the study measuring?
-----------------
| MMT: Manual Muscle Testing (MMT) is a simple and brief test of muscular strength or endurance that requires the application of resistance against the muscle. This technique includes assessing major muscles from the upper and lower limbs opposing the therapist's force and grading the patient's muscle strength on a 0 to 5 scale | Baseline and Follow-up evaluation (through study completion, an average of 6 weeks) | 
| EQ-5D: Euro-Quality of Life-5 Dimension (0-15, the higher the more depressive) Assessment of the length beyond the tip of the toes with the hand stretched out in a seated forward bending position, and measure the time to return to the left and right rear corners twice in 0.1 second units | Baseline and Follow-up evaluation (through study completion, an average of 6 weeks) | 
| coordination test | Assessment of Coordination Measures in Older Adults. Draw a chair at a point 2.4m from the center in both corners, and measure the time to return to the left and right rear corners twice in 0.1 second units | Baseline and Follow-up evaluation (through study completion, an average of 6 weeks) | 
| MMT: Manual Muscle Testing (MMT) is a simple and brief test of muscular strength or endurance that requires the application of resistance against the muscle. This technique includes assessing major muscles from the upper and lower limbs opposing the therapist's force and grading the time to return to the left and right rear corners twice in 0.40. Baseline and Follow-up evaluation (through study completion, an average of 6 weeks. | MMT: Manual Muscle strength or end the time to return to the left and right corners.
| Terms related to the study.
| MMT: Manual Muscle strength or left and right corners.
| MMT: Manual Muscle strength or left and right corners.
| Terms related to the left and right corners.
| MMT.
| Muscle strength or left and right to return to the left and right to"
155,"[/INST]
| Experimental: ABBV-552 Dose B<br>Participants will receive ABBV-552 Dose C for 12 weeks. | Drug: ABBV-552 Dose B<br>Participants will receive ABBV-552 Dose C for 12 weeks. | Drug: ABBV-552 Dose B<br>Participants will receive ABBV-552 Dose C for 12 weeks. | Drug: ABBV-552 Dose B<br>Participants will receive ABBV-552 Dose C for 12 weeks. | Drug: ABBV-552 Dose B<br>Participants will receive ABBV-552 Dose C for 12 weeks. | Drug: ABBV-552 Dose B<br>Participants will receive ABBV-552 Dose C for 12 weeks. | Drug: ABBV-552 Dose B<br>Participants will receive ABBV-552 Dose C for 12 weeks. | Drug: ABBV-552 Dose B<br>Participants will receive ABBV-552 Dose C for 12 weeks. | Drug: ABBV-552 Dose B<br>Participants will receive ABBV-552 Dose C for 12 weeks. | Drug: ABBV-552 Dose B<br>Participants will receive ABBV-552 Dose C for 12 weeks. | Drug: ABBV-552 Dose B<br>Participants will receive ABBV-552 Dose C for 12 weeks. | Drug: ABBV-552 Dose B<br>Participants will receive ABBV-552 Dose C for 12 weeks. | Drug: ABBV-552 Dose B<br>Participants will receive ABBV-552 Dose C for 12 weeks. | Drug: ABBV-552 Dose B<br>"
156,"[/INST]

Causes of Severe Acute Liver Disease
-----------------
Most common cause of severe acute liver disease in patients admitted to the intensive care unit.
Risk factors for Severe Acute Liver Disease include:
Patients with known cardiac cirrhosis.
Patients with known pre-existing renal disease.
Patients transferred from another facility.
Patients with known chronic liver disease.
Patients with known malignancy.
Patients with known coagulopathy.
Patients with known creatinine level more than 25 times the upper limit of normal.
Patients with known albumin level more than 25 times the upper limit of normal.
Patients with known electrolyte imbalance.
Patients with known creatinine level more than 25 times the upper limit of normal.
Patients with known phosphate level more than 25 times the upper limit of normal.
Patients with known electrolyte imbalance.
Patients with known coagulopathy.
Patients with known cardiac index more than 25.
Patients with known chronic renal failure.
Patients with known chronic gastrointestinal bleeding.
Patients with known chronic failure of other organs.
Patients with known chronic failure of the respiratory system.
Patients with known chronic failure of the digestive system.
Patients with known chronic failure of the urinary system.
Patients with known chronic failure of the immune system.
Patients with known chronic failure of the hypothalamic-pituitary system.
Patients with known chronic failure of the adrenal system.
Patients with known chronic failure of the hypothalamic-pituitary system.
Patients with known chronic failure of the hypothalamic-adrenal system.
Patients with known chronic failure of the digestive system.
Patients with known chronic failure of the urinary system.
Patients with known chronic failure of the vascular system.
Patients with known chronic failure of the coagulation system.
Patients with known chronic failure of the hemolytic system.
Patients with known chronic failure of the o"
157,"[/INST]
| 15 October 2023, bipolar disorder, and coping skills
| The minimum score, and maximum score
| 15 October 2023, and the quality of life.
| Bipolar disorder, and coping skills.
|15 October 2023.
|15 October 2023.
|15.
|15.
|16.
|15.
|15.
|16.
|16.
|17.
|15.
|17.
|17.
|15.
|17.
|15.
|17.
|17.
|17.
|17.
|15.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
|17.
In|17.
How to|17.
17.
How|17.
The sever.
The disorder.
How.
How.
The sever.
How.
How.
In|17.
In|17.
How.
The patients.
In|17.
In
In
In
In|17
The sympt
The sympt
The
The
The
The
The sympt
In
In|c,
It.
It.
It.
It.
It.
It.
In|which.
In|
==
The.
In.
In.
In
In
In|
In|
In|
In|
The
In
A
This
This
This
In
In
In
In
In
This
==.
This
This
This
This
This
This
This"
158,"[/INST]

Clinical performance of restorations with different composites, [/INST]
| Active Comparator: Zen Chroma one shade composite resin as control group | Procedure: Restoration with-tooth colored material<br>* Restoration of abrasions with different composite resin materials<br>one-shade composite resin as control group | Procedure: Restoration with-tooth colored material<br>|

Secondary Outcome Measures
Clinical performance of restorations according to the modified United States Public Health Service criteria, [/INST]
| --- | --- |
| Clinical performance of restorations according to the World Dental Organization criteria | Retention, marginal discoloration, marginal adaptation, secondary caries and postoperative sensitivity will be scored as 1) clinically excellent, 2) clinicallay good, 3) clinically sufficient, 4) clinically unsatisfactory and 5) clinically poor | 6,12,18, 24 and 36 months | 

Secondary Outcome Measures
Clinical performance of restorations according to the modified United States Public Health Service criteria, [/INST]
| --- | --- |
| Clinical performance of restorations according to the World Dental Organization criteria | Retention, marginal discoloration, marginal adaptation, secondary caries and postoperative sensitivity will be scored as 1) clinically excellent, 2) clinicallay good, 3) clinically sufficient, 4) clinically unsatisfactory and 5) clinically poor | 6,12,18, 24 and 36 months | 

Secondary Outcome Measures
Clinical performance of restorations according to the modified United States Public Health Service criteria, [/INST]
| --- | --- |
| Clinical performance of restorations according to the World Dental Organization criteria | Retention, marginal discoloration, marginal adaptation, secondary caries and postoperative sensitivity will be scored as 1) clinically excellent, 2) clinicallay good, 3) clinically sufficient, 4) clinically unsatisfactory and 5) clinically poor | 6,12,18,"
159,"[/INST]
The
The
The
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
160,"[/INST]
Primary Outcome: [/INST]
Behavioral: [/INST]
Secondary Outcome: [/INST]
Behavioral: [/INST]
Levonorgestrel-releasing IUD through 2 years, with endometrial hyperplasia or malignancy | 
Behavioral: [/INST]
Secondary Outcome: [/INST]
Levonorgestrel-releasing IUD through 2 years, with endometrial hyperplasia or malignancy | 
Behavioral: [/INST]
Secondary Outcome: [/INST]
Levonorgestrel-releasing IUD through 2 years, with endometrial hyperplasia or malignancy | 
Behavioral: [/INST]
Secondary Outcome: [/INST]
Levonorgestrel-releasing IUD through 2 years, with endometrial hyperplasia or malignancy | 
Behavioral: [/INST]
Secondary Outcome: [/INST]
Levonorgestrel-releasing IUD through 2 years, with endometrial hyperplasia or malignancy | 
Behavioral: [/INST]
Secondary Outcome: [/INST]
Levonorgestrel-releasing IUD through 2 years, with endometrial hyperplasia or malignancy | 
Behavioral: [/INST]
Secondary Outcome: [/INST]
Levonorgestrel-releasing IUD through 2 years, with endometrial hyperplasia or malignancy | 
Behavioral: [/INST]
Secondary Outcome: [/INST
Levonorgestrel-releasing IUD through 2 years, with endometrial hyperplasia or malignancy or endometrial hyperplasia or malignancy | 
Secondary Outcome: [/INST of the levonorgestrel-re the levonorg
Secondary Outcome: [/with endometrial hyperplasia or malignment
Behavioral-re the levonorgest
Secondary Outcome
Secondary Outcome levonorgy
Secondary Outcome
Secondary Outcome
Behavioral-end
Secondary Outcome the
Secondary
Secondary Outcome the
Secondary Outcome the"
161,"[/INST]
| Eligible Patients |
| A new technique of subtotal cholecystectomy | Three to four centimeters of the inflamed gallbladder wall was then identified and separated from the cystic duct using an electrocautery hook. | The procedure was safely completed using the current technique. |
| A new method of search was developed using the current guidelines. |
| The cystic duct was then identified and separated from the gallbladder using an electrocautery hook. |
| The inflamed gallbladder was then turned over and placed in a safe zone. |
| A new method of search was developed using the current guidelines. |
| The cystic duct was then identified and separated from the body of the gallbladder using an electrocautery hook. |
| The procedure was safely completed using the current technique. |
| A new method of search was developed using the current guidelines. |
| The cystic duct was then identified and separated from the body of the gallbladder using an electrocautery hook. |
| The procedure was safely completed using the current guidelines. |
| A new method of search was developed using the current technique. |
| The inflamed gallbladder was then turned over and placed in a safe zone using an electrocautery hook. |
| A new method of subtotal cholecystectomy was developed using the current guidelines. |
| The cystic duct was then identified and separated from the body of the gallbladder using an electrocautery hook. |
| The procedure was safely completed using the current guidelines. |
| A new method of search was developed using the current technique. |
| The inflamed gallbladder was then turned over and placed in a safe zone using an electrocautery hook. |
| A new method of subtotal cholecystectomy was developed using the current guidelines. |
| The cystic duct was then identified and separated from the body of the gallbladder using an electrocautery hook. |
| The procedure was safely completed using the current guidelines. |
| A new method of search was developed using the current technique. |
| The inflamed gallbladder was then"
162,"[/INST]
| Study Design: [Behavioral: CBT+VR, Re-injury anxiety, self-efficacy, and adherence problems in athletes who have undergone ACL surgery] | Experimental: CBT, VR, Re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery | Placebo Comparator: Control<br> | Behavioral: CBT, VR, Re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery |
| Study Population: [/INST]
| Eligible for Study: Randomized controlled trial of CBT, VR, Re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery | Experimental: CBT, VR, Re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery | Placebo Comparator: Control<br> | Behavioral: CBT, VR, Re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery |
| Experimental: CBT, VR, Re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery |
| Study Rationale: [/INST]
| Primary Outcome Measure: [/INST]
| Terms: [/INST]
| Eligible for Study: Randomized controlled trial of CBT, VR, Re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery. The intervention. | Experimental: CBT, kinesiophobia, self-efficacy, kines. | Terms: CBT,"
163,"[/INST]

Other Measures
-----------------
| PT-PENCIL | Intervention/Treatment |
| --- | --- |
| PT-PENCIL cohort |
| Effectiveness of Intervention/Treatment |
| PT-PENCIL |"
164,"[/INST]

Adverse Events
| --- | --- |
| The Brief Fatigue Scale will be used to measure the level of fatigue before the start of the intervention. | The SAS will be used to measure the level of fatigue before the start of the intervention. | The PSQI will be used to measure the level of sleep before the start of the intervention. | The level of depression will be measured by the Beck Depression Scale before the start of the intervention.

Adverse Events: [/INST]
Secondary Outcome Measures

Behavioral: [/INST]
| The Brief Fatigue Scale will be used to measure the level of fatigue before the start of the intervention. | The PSQI will be used to measure the level of sleep before the start of the intervention. | The level of depression will be measured by the Beck Depression Scale before the start of the intervention.

Behavioral: [/INST]
| The Brief Fatigue Scale will be used to measure the level of fatigue before the start of the intervention. | The PSQI will be used to measure the level of sleep before the start of the intervention. | The level of depression will be measured by the Beck Depression Scale before the start of the intervention.

Behavioral: [/INST]
| The Brief Fatigue Scale will be used to measure the level of fatigue before the start of the intervention. | The PSQI will be used to measure the level of sleep before the start of the intervention. | The level of depression will be measured by the Beck Depression Scale before the start of the intervention.

Behavioral: [/INST]
| The Brief Fatigue Scale will be used to measure the level of fatigue before the start of the intervention. | The PSQI will be used to measure the level of sleep before the start of the intervention. | The level of depression will be measured by the Beck Depression Scale before the start of the intervention.

Behavioral: [/INST]
| The Brief Fatigue Scale will be used to measure the level of fatigue before the start of the intervention. | The PSQI will be used to measure the level of sleep before the start of the"
165,"[/INST]
Primary Outcome Measures
-----------------
Secondary Outcome Measures
-----------------
Content, participant needs, and aspects of delivering the Survivorship ECHO platform explored using qualitative analysis. | Other: Educational Intervention, and aspects of the Survivorship ECHO platform, and participant needs, and content analysis. |

Secondary Outcome Measures
-----------------
Content, participant needs, and aspects of delivering the Survivorship ECHO platform explored using qualitative analysis. | Other: Educational Intervention, and aspects of the Survivorship ECHO platform explored using quantitative analysis. |

Secondary Outcome Measures
-----------------
Content, participant needs, and aspects of delivering the Survivorship ECHO platform explored using qualitative analysis. | Other: Educational Intervention, and aspects of the Survivorship ECHO platform explored using quantitative analysis. |


Secondary Outcome Measures
-----------------
Content, participant needs, and aspects of delivering the Survivorship ECHO platform explored using qualitative analysis. | Other: Educational Intervention, and aspects of the Survivorship ECHO platform explored using quantitative analysis. |


Secondary Outcome Measures
-----------------
Content, participant needs, and aspects of delivering the Survivorship ECHO platform explored using qualitative analysis. | Other: Educational Intervention, and aspects of the Survivorship ECHO platform explored using quantitative analysis. |


Secondary Outcome Measures
-----------------
Content, participant needs, and aspects of delivering the Survivorship ECHO platform explored using qualitative analysis. | Other: Educational Intervention, and aspects of the Survivorship ECHO platform explored using quantitative analysis. |


Secondary Outcome Measures
-----------------
Content, participant needs, and aspects of delivering the Survivorship ECHO platform explored using qualitative analysis. | Other: Educational Intervention, and aspects of the Survivorship ECHO platform explored using quantitative analysis. |



Secondary Outcome Measures
-----------------
Content, participant needs, and"
166,"[/INST]
Other: [/INST]
Adverse events: [/INST]
Elbow (Flexion)
Prone to degenerative changes: [/INST]
Active: [/INST]
Post traumatic stiff elbow
Prone to degenerative changes: [/INST]
Active: [/INST]
Prone to degenerative changes: [/INST]
Active: [/INST]
Prone to degenerative changes: [/INST]
Active: [/INST]
Prone to degenerative changes: [/INST]
Active: [/INST]
Prone to degenerative changes: [/INST]
Active: [/INST]
Prone to degenerative changes: [/INST]
Active: [/INST]
Prone to degenerative changes: [/INST]
Active: [/INST]
Prone to degenerative changes: [/INST]
Active: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Active: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degenerative changes: [/INST]
Prone to degener"
167,"[/INST]

How is the study designed?
| Participant Group | Eligibility Criteria | Device: Us2.ai (AI-enabled report) handheld echocardiogram<br>* NT-proBNP will be performed in all individuals randomized to the ACTIVE arm at the same visit as informed consent, and those with elevated NT-proBNP (125pg/ml) will be invited to attend a visit for an Us2.ai (AI-enabled) echocardiogram which will be controlled with a standard echocardiographic study if the AI-echo is non-diagnostic."
168,"[/INST]
| Expect to be terminated.
| Middle cere, with no intra
| Middle cere, and lower blood pressure.| Middle c| Middle age.
| Middle age.
| Middle c|s.
| Middle name.
| Middle name.
| Middle name.
| Middle name.
| Middle name.
| Middle name.
| Middle name.
| Middle name.
| Middle name.
| Middle name.
| Middle name.
| Middle name.
| Middle name.
| Middle name. Middle name. Middle name. Middle name. Middle name.
| Middle name. Middle name. Middle. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle name. Middle. Middle name. Middle. Middle name. Middle. Middle. Middle. Middle. Middle. Middle. Middle. Middle. Middle. Middle. Middle. Middle.
The middle.
The middle.
The middle.
The middle.
The method.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
There.
The patient.
The patient.
The patient.
The patient.
This.
This.
The patient.
The patient.
The patient.
The patient.
This.
It.
It.
It.
It.
It.
It.
It.
It, it.
It's.
It.
It.
It.
It.
It.
It, it.
It.
It.
It's pres
It.
It will.
It is a patient.
It is a particular.
It is a particular.
It.
It
This
This
This
This
This
This
This
This
This.
This.
This.
It
It
It
It
This [ ]
This
In"
169,"[/INST]
| Patient #1, #2, #3, and #4 are all patients with panic disorder. | Pre treatment (T1), up to 14 weeks after treatment start (T2), six months after treatment (T3) and after two years (T4) | 
| Patient #1, #2, #3, #4, and #5, six months after treatment (T2), and after two years (T4) | Pre treatment (T1, #2, #3, #4, #5, #6, and #7, #2, #3, #7, #2, #4, #3, #5, #1, #2, #7, #8, #1, #2, #1, #2, #3, #1, #2, #1, #2, #1, #2, #1, #2, #1, #2, #3, #1, #2, #1, #2, #1, #2, #1, #1, #2, #1, #1, #1, #1, #2, #1, #2, #1, #2, #1, #2, #1, #1, #1, #2, #1, #1, #1, #2, #1, #2, #1, #1, #2, #1, #1, #1, #1, #1, #1, #2, #1, #1, #1, #1, #1, #1, #2, #2, #2, #1, #1, #1, #1, #1, #1, #1, #1, #1, #1 #1, #2, #2, #1, #2, #2, #2, #1, #2, #2 #2, #1 #1 #1 #1 #2 #1 #1 #1 #1 #1 #1 #1 #1 #2.
The therapy #2.
The therapy #2.
The therapy #1.
The therapy #1.
The therapy #1.
The therapy #1.
The therapy #1.
The therapy #1.
The therapy.
The therapy.
The ther"
170,"[/INST]
The, the process.
The.
The, this.
The, this.
The, this.
The, this.
The, the.
The.
The.
The.
The
The
The
The . .
The .
The procedure.
The procedure.
The process.
The.
The.
The
The
The
The
The
This
This
This
This
This
The
The
This
This
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
for
for
The
This
This
c
c
c
The
The
The
The
The
c
c









The
The
The
The
The
c"
171,"[/INST]
| Device will be placed to record skin temperature using the FDA-approved pulse oximeter. A positive R value, with an R-squared value >80%, will be considered an indication of a trend.
| The testing period will be 10 minutes, during which the device will be placed to record skin temperature.
| A positive R value, with an R-squared value >80%, will be considered an indication of a trend.
| The testing period will be 10 minutes, during which the device will be placed to record skin temperature.
| A positive R value, with an R-squared value >80%, will be considered an indication of a trend.
| The testing period will be 10 minutes, during which the device will be placed to record skin temperature.
| A positive R value, with an R-squared value >80%, will be considered an indication of a trend.
| The testing period will be 10 minutes, during which the device will be placed to record skin temperature.
| A positive R value, with an R-squared value >80%, will be considered an indication of a trend.
| The testing period will be 10 minutes, during which the device will be placed to record skin temperature.
| A positive R value, with an R-squared value >80%, will be considered an indication of a trend.
| The testing period will be 10 minutes, during which the device will be placed to record skin temperature.
| A positive R value, with an R-squared value >80%, will be considered an indication of a trend.
| The testing period will be 10 minutes, during which the device will be placed to record skin temperature.
| A positive R value, with an R-squared value >80%, will be considered an indication of a trend.
| The testing period will be 10 minutes, during which the device will be placed to record skin temperature.
| A positive R value, with an R-squared value >80%, will be considered an indication of a trend.
| The testing period will be 10 minutes, during which the device will be placed to record skin temperature.
| A positive R value, with an R-squared value"
172,"[/INST]
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
in
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This


































































































































































-






















-
-


A

-
-
-
-



-
-
-
-
-
-
























-
-
-
-
-
-"
173,"[/INST]

Other Outcome Measures
| --- | --- |
| Event-free Survival (EFS) as assessed by Investigator | EFS is defined as the time from surgery to any of the following events: local or distant recurrence, or death due to any cause. | At least 2 years | 
| Disease-free Survival (DFS) as assessed by Modified Response Evaluation Criteria In Solid Tumors assessed by MRI. | Up to approximately 24 weeks | 
| Distant Disease-free Survival (DDFS) as assessed by Modified Response Evaluation Criteria In Solid Tumors assessed by MRI. | At least 2 years | 
| Objective response rate (ORR) in accordance with RECIST v1.1 | 
| Number of responders Assessed by Modified Response Evaluation Criteria In Solid Tumors assessed by MRI. | Up to approximately 67 weeks | 
| Disease-free Survival (DDFS) as assessed by Modified Response Evaluation Criteria In Solid Tumors assessed by MRI. | At least 2 years | 
| Objective response rate (ORR) in accordance with RECIST v1.1 | 
| Distant Disease-free Survival (DDFS) as assessed by Modified Response Evaluation Criteria In Solid Tumors assessed by MRI. | At least 2 years | 
| Number of responders Assessed by Modified Response Evaluation Criteria In Solid Tumors assessed by MRI. | 
| Event-free Survival (EFS) as assessed by Investigator | EFS is defined as the time from surgery to any of the following events: local or distant recurrence, or death due to any cause. | Up to approximately 24 weeks | 
| Disease-free Survival (DDFS) as assessed by Modified Response Evaluation Criteria In Solid Tumors assessed by MRI. | At least 2 years | 
| Objective response rate (ORR) in accordance with RECIST v1.1 | 
| Distant"
174,"[/INST]
| Other: Questionnaire survey and specimen collection<br>Serum metabolomics |
| During the 24-28 geatational weeks. |
| Fetus has a known deformity or genetic defects |
| Accepts Healthy Volunteers |
| Other: Questionnaire survey and specimen collection<br>GDM with negative OGTT results at 6-12 weeks postpartum |
| Female |
| Accepts Healthy Volunteers |
| Other: Questionnaire survey and specimen collection<br>Serum metabolomics |
| Fetus has a known deformity or genetic defects |
| During the 24-28 geatational weeks. |
| Other: Questionnaire survey and specimen collection<br>GDM with negative OGTT results at 6-12 weeks postpartum |
| Female |
| Accepts Healthy Volunteers |
| Other: Questionnaire survey and specimen collection<br>Serum metabolomics |
| During the 24-28 geatational weeks. |
| Fetus has a known deformity or genetic defects |
| Other: Questionnaire survey and specimen collection<br>GDM with negative OGTT results at 6-12 weeks postpartum |
| Female |
| Accepts Healthy Volunteers |
| Other: Questionnaire survey and specimen collection<br>Serum metabolomics |
| During the 24-28 geatational weeks. |
| Fetus has a known deformity or genetic defects |
| Other: Questionnaire survey and specimen collection<br>GDM with negative OGTT results at 6-12 weeks postpartum |
| Female |
| Accepts Healthy Volunteers |
| Other: Questionnaire survey and specimen collection<br>Serum metabolomics |
| During the 24-28 geatational weeks. |
| Fetus has a known deformity or genetic defects |
| Other: Questionnaire survey and specimen collection<br>GDM with negative OGTT results at 6-12 weeks postpartum |
| Female |
|"
175,"[/INST]
| Sleep quality | Proportion of continuous sleep | Day 1 to day 4 | 
| Sleep quality | Proportion of continuous sleep | Day 1 to day 4 | 
| Patient Agitation | Number of days with positive response to treatment | 10 days to day 4 | 
| Sleep quality | Proportion of continuous sleep | Day 1 to day 4 | 
| Patient Agitation | Number of days with positive response | 10 days to day 4 | 
| Sleep quality | Proportion of continuous sleep | Day 1 to day 4 | 
| Patient reported sleep quality | Score at specific scale. From 1 to 10 | 
| Primary Outcome | Number of days with positive response | 10 days to day 4 | 
| Patient Agitation | Number of days with positive response | 10 days to day 4 | 
| Sleep quality | Proportion of continuous sleep | Day 1 to day 4 | 
| Patient reported sleep quality | Score at specific scale. From 10 days to day 4 | 
| Primary Outcome | Number of days with positive response | 10 days to day 4 | 
| Patient Agitation | Number of days with positive response | 10 days to day 4 | 
| Sleep quality | Proportion of continuous sleep | Day 1 to day 4 | 
| Patient reported sleep quality | Score at specific scale. From 10 days to day 4 | 
| Primary Outcome | Number of days with positive response | 10 days to day 4 | 
| Patient Agitation | Number of days with positive response | 10 days to day 4 | 
| Sleep quality | Proportion of continuous sleep | Day 1 to day 4 | 
| Patient reported sleep quality | Score at specific scale. From 10 days to day 4 | 
| Primary Outcome | Number of days with positive response | 10 days to day 4 | 
| Patient Agitation | Number of days with positive response | 10 days to day 4 | 
| Sleep quality | Proportion of continuous sleep | Day 1 to day 4 |"
176,"[/INST]
The study
The study
The
The
The
The
The
The
The
Mod
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
Mod
The
The
The
The
The
The
The
The
The
The
The
S
S
S
There
The
The
The
The
S
S
The
The
The
The
The
--------
--------
--------
--------
--------
--------
This
The
This
This
This
The
This
This
This
--------
--------
This
This
This
This
This
S
S
S
S
S
S
S
S
S
S
S
S
This
This
S
S
S
S
S
This
S
S
S
S
This
This
This
S
S
S
S
S
This
This
This
This
This
This
This
S
S
S
S
S
S
S
S
S
S
S
This
This
S
S
S
S
S
S
S
S
S
S
S
This
This
This
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
R
R
R
R
R
S
S
S
S
S
























S
S
S
S
S
S
F
















S
S
S
S
S
S
S
S
S"
177,"[/INST]

| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Proportion with positive test result among participants with HIV, HBV or HCV | Sensitivity - Number with positive result among participants without HIV, HBV or HCV. | 24 hours | 
| Specificity - Number with negative results among participants without HIV, HBV or HCV. | 

Diagnostic Tests
-----------------
Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Diagnostic Test: MagIA IBC test in other matrices
| Participant Group | Intervention Model: MagIA IBC test in capillary blood, HIV, HBV and serum. | 24 hours |
| Experimental: MagIA IBC test in other matrices. |
Secondary Outcome Measures
-----------------
| Proportion with positive test result among participants with HIV, HBV or HCV | Sensitivity - Number with negative results among participants without HIV, HBV or serum. | 24 hours |
| Specificity - Number with positive results among participants without HIV, HBV or serum. |
Adverse events related to the study will be collected among participants with HIV, HBV or serum. |
Comorbid conditions among participants without HIV, HBV or serum. |
Secondary Outcome Measures
-----------------
Proportion with positive test result among participants with HIV, HBV or serum. | Sensitivity - Number with negative results among participants without HIV, HBV or serum. | 24 hours |
| Specificity - Number with positive results among participants without HIV, HBV or serum. |
Comorbid conditions among participants with HIV, HBV or serum. |
Tertiary Outcome Measures
-----------------
| Proportion with positive test result among participants with HIV, HBV or serum. | Sensitivity - Number with negative results among participants without HIV, HBV or serum. | 24 hours |
| Specificity - Number with positive results among participants without HIV, HBV or serum. |
Comorbid conditions"
178,[/INST]
179,"[/INST]
Primary Purpose: To provide a description of the disease or condition.
| Secondary Purposes: Relieves symptoms, improves QOL, prevents recurrence.
| Tertiary Purposes: Prevents disease or condition, improves QOL, reduces risk of complications, permits normal activity.
| Examples: Nausea, vomiting, abdominal pain, diarrhea, constipation.
| Patient will be able to return to normal diet and activities.
| Examples: Nasogastric tube (NGT), water-soluble contrast (WSC), SBO treated with saline.
| Procedure: Surgery will be able to return to normal diet, with NG tube.
| Examples: Nausea, vomiting, diarrhea, constipation.
| Patient will be able to return to normal diet and activities.
| Examples: Nausea, vomiting, diarrhea, constipation.
Secondary Outcome Measures
| Patient will be able to return to normal diet and activities.
| Examples: Nausea, vomiting, diarrhea, constipation.
| Procedure: Surgery will be able to return to normal diet and activities.
| Examples: Nausea, vomiting, diarrhea, constipation.
Secondary Purposes: Patient will be able to return to normal diet and activities.
| Examples: Nausea, vomiting, diarrhea, constipation.
| Procedure: Surgery will be able to return to normal diet and activities.
| Examples: Nausea, vomiting, diarrhea, constipation.
| Patient will be able to return to normal diet and activities.
| Examples: Nausea, vomiting, diarrhea, constipation.
| Procedure: Surgery will be able to return to normal diet and activities.
| Examples: Nausea, vomiting, diarrhea, constipation.
| Patient will be able to return to normal diet and activities.
| Examples: Nausea, vomiting, diarrhea, constipation.
| Procedure: S"
180,"[/INST]

What is the study measuring?
| Primary Outcome Measure | Measure Description | Time Frame |
| Serum HBsAg | Serum HBV DNA level | Baseline | 
| Serum ALT | Serum ALT level | 24 weeks after the treatment | 
| Serum ALT | Serum ALT level | 
| Serum HBV | Serum HBV DNA level | 
| Serum HBV DNA | Serum HBV DNA level | 
| Serum ALT | Serum ALT level | 
| Primary Outcome Measure | Measure Description |
| Serum HBsAg | Serum HBV DNA level | 
| Serum ALT | Serum ALT | 
| Primary Outcome Measure | Serum HBV DNA level | 
| Serum ALT | Serum HBV*s Agreement: The study is measuring serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum.
| Primary Outcome to serum levels
| Primary Outcome: Serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and serum levels and
Primary Levels: Serum levels and serum levels and serum levels and serum levels and serum levels and
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary levels
Primary
Primary
Primary
Primary
Primary
Primary
Primary
Primary
Primary
Primary
Primary
Primary"
181,"[/INST]
| Other: Continuous Suture Technique | Simple Suture Score-1 | Other: Continuous Suture Technique |
| Simple Suture Score-2 | Other: Continuous Suture Technique |
| Simple Suture Score-3 | Other: Continuous Suture Technique |
| Simple Suture Score-4 | Other: Continuous Suture Technique |
| Simple Suture Score-7 | Other: Continuous Suture Technique |
| Simple Suture Score-10 | Other: Continuous Suture Technique |
| Simple Suture Score-3 | Other: Continuous Suture Technique |
| Simple Suture Score-4 | Other: Continuous Suture Technique |
| Simple Suture Score-7 | Other: Continuous Suture Technique |
| Simple Suture Score-10 | Other: Continuous Suture Technique |
| Simple Suture Score-3 | Other: Continuous Suture Technique |
| Simple Suture Score-4 | Other: Continuous Suture Technique |
| Simple Suture Score-7 | Other: Continuous Suture Technique |
| Simple Suture Score-10 | Other: Continuous Suture Technique |
| Simple Suture Score-3 | Other: Continuous Suture Technique |
| Simple Suture Score-4 | Other: Continuous Suture Technique |
| Simple Suture Score-7 | Other: Continuous Suture Technique |
| Simple Suture Score-10 | Other: Continuous Suture Technique |
| Simple Suture Score-3 | Other: Continuous Suture Technique |
| Simple Suture Score-4 | Other: Continuous Suture Technique |
| Simple Suture Score-7 | Other: Continuous Suture Technique |
| Simple Suture Score-10 | Other: Continuous Suture Technique |
| Simple Suture Score-3 | Other: Continuous Suture Technique |
| Simple Suture Score-4 | Other: Cont"
182,"[/INST]

Primary Purpose: To measure change in gross motor skills in children with spinal muscular atrophy. Scores can range from 0 - 6 points, indicating no change from baseline. An increase in score indicates a better outcome.
| Completed at baseline, 3 months, and 6 months | 
| Change in Bayley Scales of Infant and Toddler Developmental Checklist | A disease-specific and performance-based outcomes originally developed to measure motor skill in untreated individuals with SMA, revised following Rasch analysis of HFMSE. Scores can range from 0 - 5 points, indicating no change from baseline. An increase in score indicates a better outcome. | Completed at baseline, 3 months, and 6 months | 
| Change in Revised Hammersmith Scale of Infant and Toddler Developmental Checklist | A disease-specific and performance-based outcomes originally developed to measure motor skill in untreated individuals with SMA, revised following Rasch analysis of HFMSE. Scores can range from 0 - 6 points, indicating no change from baseline. An increase in score indicates a better outcome. | Completed at baseline, 3 months, and 6 months | 
| Change in World Health Organization Motor Milestone Checklist | A disease-specific and performance-based outcomes originally developed to measure motor skill in untreated individuals with SMA, revised following Rasch analysis of HFMSE. Scores can range from 0 - 6 points, indicating no change from baseline. An increase in score indicates a better outcome. | Completed at baseline, 3 months, and 6 months | 
| Change in Revised Hammersmith Scales of Infant and Toddler Developmental Checklist | A disease-specific and performance-based outcomes originally developed to measure motor skill in untreated individuals with SMA, revised following Rasch analysis of HFMSE. Scores can range from 0 - 6 points, indicating no change from baseline. An increase in score indicates a better outcome. | Completed at baseline, 3 months, and 6 months | 
| Change in Revised Hammersmith Scales of Infant and Toddler Developmental Checklist | A disease-specific and performance-based out"
183,"[/INST]
|
|
|
|
----------------
----------------
----------------
Term
---------------------------------------------------------------------in
---------------------------------------------------------------------in-
-----------------
-----------------
-----------------.
-----------------.-
-----------------
-----------------
In
In
----------------.
----------------.
----------------.
----------------.
----------------.
In
In
In
In
In
In
In
In
Aff
Aff
Aff
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
S
P
This
P
P
S
S
P
P
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
M
M
M
S
In
S
S
In
S
S
In
In
In
In
P
P
C
C
C
C
C
C
P
P
P
P
P
S
S
S
S
S
C
C
S
S
S
S
S
In
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
P
S
P
P
P
P
P
P
P
P
S
S
P
P








P
P
S
S
S
S
S
P
P
P
P
S"
184,"[/INST]
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure |
  1. Preoperative mechanical bowel preparation |
  2. Intraoperative mechanical bowel preparation |
  3. Postoperative 30 days |
  4. Colorectal surgical site, systemic antibiotic prophylaxis |
  5. Oral antibiotic prophylaxis |
  6. Intraoperative mechanical bowel preparation |
  7. Surgical site, 30 days |
  8. Other names: Metronidazole, oral antibiotic prophylaxis |
  9. Secondary outcome measures |
  10. Oral antibiotic prophylaxis |
  11. Intraoperative mechanical bowel preparation |
  12. Other names: Metronidazole, oral antibiotic prophylaxis |
  13. Surgical site, 30 days |
  14. Secondary outcome measures |
  15. Oral antibiotic prophylaxis |
  16. Intraoperative mechanical bowel preparation |
  17. Other names: Metronidazole, oral antibiotic prophylaxis |
  18. Secondary outcome measures |
  19. Oral antibiotic prophylaxis |
  20. Surgical site, 30 days |
  21. Other names: Metronidazole, oral antibiotic prophylaxis |
  22. Secondary outcome measures |
  23. Intraoperative mechanical bowel preparation |
  24. Oral antibiotic prophylaxis |
  25. Surgical site, 30 days |
  26. Other names: Metronidazole, oral antibiotic prophylaxis |
  27. Secondary outcome measures |
  28. Intraoperative mechanical bowel preparation |
  29. Oral antibiotic prophylaxis |
  30. Surgical site, 30 days |
  30"
185,"[/INST]
Keywords: Carpal Tunnel Syndrome, nerve conduction studies, ultrasound, symptoms, diagnosis, electrophysiological severity, and treatment.
Symptoms: [/INST]
Diagnosis: [/INST]
Keywords: Carpal Tunnel Syndrome, nerve conduction studies, ultrasound, symptoms, diagnosis, electrophysiological severity, and treatment.
Symptoms: [/INST]
Diagnosis: [/INST]
Keywords: Carpal Tunnel Syndrome, nerve conduction studies, ultrasound, symptoms, diagnosis, electrophysiological severity, and treatment.
Symptoms: [/INST]
Keywords: Carpal Tunnel Syndrome, nerve conduction studies, ultrasound, symptoms, diagnosis, electrophysiological severity, and treatment.
Symptoms: [/INST]
Keywords: Carpal Tunnel Syndrome, nerve conduction studies, ultrasound, symptoms, diagnosis, electrophysiological severity, and treatment.
Symptoms: [/INST]
Keywords: Carpal Tunnel Syndrome, nerve conduction studies, ultrasound, symptoms, diagnosis, electrophysiological severity, and treatment.
Symptoms: [/INST]
Keywords: Carpal Tunnel Syndrome, nerve conduction studies, ultrasound, symptoms, diagnosis, electrophysiological severity, and treatment.
Symptoms: [/INST]
Keywords: Carpal Tunnel Syndrome, nerve conduction studies, ultrasound, symptoms, diagnosis, electrophysiological severity, and treatment.
Symptoms: [/INST of the cross-sectional severity, electrophysiological severity, symptoms, diagnosis, ultrasound, electrophysiological severity, symptoms, diagnosis, ultrasound, electrophysiological severity, symptoms, diagnosis, ultras symptoms, electrophysiological severity, ultras symptoms, diagnosis, ultras symptoms, diagnosis, ultras symptoms, ultras symptoms, diagnosis, ultras symptoms, ultras symptoms, diagnosis, ultras symptoms, ultras symptoms"
186,"[/INST]
| Patient #1 | Disease Progression: Multiple Myeloma |
| Patient #2 | Disease Progression: Multiple Myeloma |
| Patient #3 | Disease Progression: Multiple Myeloma |
| Patient #4 | Disease Progression: Multiple Myeloma |
| Patient #5 | Disease Progression: Multiple Myeloma |
| Patient #6 | Disease Progression: Multiple Myeloma |
| Patient #7 | Disease Progression: Multiple Myeloma |
| Patient #8 | Disease Progression: Multiple Myeloma |
| Patient #9 | Disease Progression: Multiple Myeloma |
| Patient #10 | Disease Progression: Multiple Myeloma |
| Patient #11 | Disease Progression: Multiple Myeloma |
| Patient #12 | Disease Progression: Multiple Myeloma |
| Patient #13 | Disease Progression: Multiple Myeloma |
| Patient #14 | Disease Progression: Multiple Myeloma |
| Patient #15 | Disease Progression: Multiple Myeloma |
| Patient #16 | Disease Progression: Multiple Myeloma |
| Patient #17 | Disease Progression: Multiple Myeloma |
| Patient #18 | Disease Progression: Multiple Myeloma |
| Patient #19 | Disease Progression: Multiple Myeloma |
| Patient #20 | Disease Progression: Multiple Myeloma |
| Patient #21 | Disease Progression: Multiple Myeloma |
| Patient #22 | Disease Progression: Multiple Myeloma |
| Patient #23 | Disease Progression: Multiple Myeloma |
| Patient #24 | Disease Progression: Multiple Myeloma |
| Patient #25 | Disease Progression: Multiple Myeloma |
| Patient #26 | Disease Progression: Multiple Myeloma |
| Patient #27 | Disease Progression: Multiple Myeloma |
| Patient #28 |"
187,"[/INST]

How is the study designed?
-----------------
| Participant Group | DNA Fragmentation | Sperm donor undergoing TESA-ICSI |
| High Sperm DNA fragmentation in couples with | advanced maternal age |
| Approximately 40 years |

What is the effect of the intervention on the primary outcome measure?
| Compare the effect of the intervention on the primary outcome measure with the effect of the control intervention | Approximately 80% reduction in Sperm DNA fragmentation in couples undergoing TESA-ICSI |
| Compare the proportion of couples with high Sperm DNA fragmentation undergoing TESA-ICSI |

What is the effect of the intervention on the secondary outcome measures?
| Compare the effect of the intervention on the secondary outcome measures with the control group |
| Participant Group | DNA Fragmentation | Approximately 40 years |

Secondary Outcome Measures
-----------------
How is the study designed?
| Participant Group | DNA Fragmentation | Compare the effect of the intervention on Sperm DNA fragmentation in couples with advanced maternal age |
| Approximately 40 years |

What is the effect of the intervention on the secondary outcome measures in the control group?
| Compare the effect of the intervention on the secondary outcome measures in the control group |
How is the effect of the intervention on the secondary outcome measures compared with the effect of the intervention in the control group?
| Compare the effect of the intervention on the secondary outcome measures in couples with high Sperm DNA fragmentation |

How is the effect of the intervention on the primary outcome measure compared with the effect of the intervention in the control group?
| Participant Group | DNA Fragmentation | Compare the effect of the intervention on the primary outcome measure with the effect of TESA-ICSI in couples undergoing |
| Approximately 40 years |

What is the effect of the intervention on the primary outcome measure compared to the effect of the intervention in the control group?
| Participant Group | DNA Fragmentation | Compare the effect of the intervention on the primary outcome measure with the effect of TESA-ICSI in couples with high Sperm DNA"
188,"[/INST]
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Participant Group | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Participant Group | Intervention/Tre"
189,"[/INST]

Adolescent Contraception
-----------------
Adolescent: Mother, we need to talk about contraception.
Mother: I don't know. We haven't talked about this since the encounter.
Adolescent: I know about sex and birth control, but we haven't talked about contraception.
Mother: I didn't want to at first, but now I'm glad we did.
Adolescent: I'm glad we talked about this.
Mother: Me too.
Adolescent: I'm glad we did.
Communication about Contraception
Mother: I'm glad we talked about this.
Adolescent: I'm glad we did.
Contraception is important to talk about.
Mother: I know that.
Adolescent: I'm glad we did.
Communication about Contraception
Mother: I'm glad we did.
Adolescent: I'm glad we talked about this.
Contraception is important to talk about.
Mother: I know.
Adolescent: I'm glad we did.
Communication about Contraception
Mother: I'm glad we talked about this.
Adolescent: I'm glad we did.
Contraception is important to talk about.
Mother: I know.
Adolescent: I'm glad we did.
Communication about Contraception
Mother: I'm glad we talked about this.
Adolescent: I'm glad we did.
Contraception is important to talk about.
Mother: I know.
Adolescent: I'm glad we did.
Communication about Contraception
Mother: I'm glad we talked about this.
Adolescent: I'm glad we did.
Contraception is important to talk about.
Mother: I know.
Adolescent: I'm glad we did.
Communication about Contraception
Mother: I'm glad we talked about this.
Adolescent: I'm glad we did.
Contraception is important to talk about.
Mother: I know.
Adolescent: I'm glad we did.
Communication about Contraception
Mother: I'"
190,"[/INST]

Other Healthcare Disparities
-----------------

Study Design
-----------------
| This study will consist of people with Vitiligo only. | Other: No disparities in healthcare utilisation measured. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people with Vitiligo only. | People without Vitiligo will be studied using usual care measurements. | This study will consist of people"
191,"[/INST]

Behavioral: caregivers of children with early intervention, online and aggressive behavior, and the role of parents in the implementation of the curriculum, and the use of the Parenting Stress Scale with the children."
192,[/INST] - acyrdrdcyrdrdrdcyrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdcyrdrdrdrdrdrdrdrdrdrdcyrdcyrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrderrdularercy 2rdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrderrderrderrderrdrderrd  -  - 2 2 2- 1eromeerononrdonrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdrdularcyrdularularularularularularularularularularerularerularerularularularularcyrdular 0rdulularcyrdularularularularularularrdularrdularcyrd rd rdularlyrdonularlyrdonularularularularularularularerulularerulularerulularerularrdulrdonularrdonularularularularularularrd 1rdonulululululululululululululululululululululululululululululululululululululululululululululululul      erulululululululululululululululululululululululululululululululululululul rdonulululululululululululul
193,"[/INST]

Behavioral: [/INST]
Primary Outcome Measure
Behavioral: [/INST]
Secondary Outcome Measure
Behavioral: [/INST]
Behavioral: [/INST]
Secondary Outcome Measure
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral: [/INST]
Behavioral"
194,"[/INST]
| 4.
| 1.
| 1.
| 1.
|
|
|
|
|
|
|
The supplement.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The supplements.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
There are|
There are|
There.
There.
There.
There.
There.
There.
There.
There.
There.
There.
==
==
==
==
The effects.
The effects
The effects
in
in
in
in
in
in
in
There.
There.
There.
There.
in
in
in
in
in
in
in
in
The
in
in
It.
It.
in
in
in
in
It.
It.
It,
It,
It,
It's.
It.
It.
It.
It.
This.
It.
It.
It.
It.
It.
It.
It.
It.
It.
This.
This.
This.
This.
This.
It.
==
==
==
This.
This.
This.
It.
This.
This.
==
==
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
This
S
This
This
This
This
This
This
be
be
be
be
This
This
This
This
This
This
This
simp"
195,"[/INST]
Other: [/INST]
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power, laparoscopic surgery, Ventilator-induced lung injury
-----------------
Mechanical power"
196,"[/INST]

Exclusion Criteria
-----------------
Patients with contraindications to MRI

Vertical loss of less than 1 mm

Not day 1

No need to perform MRI

Risk of vertical bone loss greater than 10%

Not all Molars

Accepts healthy volunteers only

Vertical loss of less than 1 mm

Not all Molars

Primary Outcome Measures
-----------------
Accepts healthy volunteers only

Not all Molars

Secondary Outcome Measures
-----------------
Accepts healthy volunteers only

Not all Molars

Vertical loss less than 1 mm
Not all patients

Risk of vertical bone loss less than 10%
Not all Molars

Accepts healthy volunteers only

Not all Molars

Vertical loss less than 1 mm

Not all patients

Primary Outcome Measures
-----------------
Accepts healthy volunteers only
Not all Molars

Risk of vertical bone loss less than 10%
Not all patients

Secondary Outcome Measures
-----------------
Accepts healthy volunteers only
Not all Molars

Vertical loss less than 1 mm
Not all patients

Risk of vertical bone loss less than 10%
Not all Molars

Accepts healthy volunteers only

Primary Outcome Measures
-----------------
Not all Molars

Vertical loss less than 1 mm
Not all patients

Risk of vertical bone loss less than 10%
Not all Molars

Accepts healthy volunteers only

Secondary Outcome Measures
-----------------
Not all Molars

Vertical loss less than 1 mm
Not all patients

Risk of vertical bone loss less than 10%
Not all Molars

Accepts healthy volunteers only

Primary Outcome Measures
-----------------
Not all Molars

Vertical loss less than 1 mm
Not all patients

Risk of vertical bone loss less than 10%
Not all Molars

Accepts healthy volunteers only

Primary Outcome Measures
-----------------
Not all Molars

Vertical loss less than 1 mm
Not all patients

R"
197,"[/INST]







-
-


-
-
-
-
teen
teen

teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
teen
----------------
----------------
----------------
----------------
----------------
----------------
----------------
----------------
----------------
----------------
----------------









teen
teen
teen



-
-
-




-
-
-



-
-
-
-
-
-



-
-
-
-
--
-
-
-
-
-----
-
---Y7
Y
-"
198,"[/INST]
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
A
This
This
This
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A"
199,"[/INST]
| Incidence of gingival bleeding | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) |
| Effect on gingival inflammation | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on dental plaque | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on gingival attachment | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on Periodontal Pocket | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on gingival inflammation | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on dental health | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on gingival attachment | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on Periodontal Pocket | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on gingival bleeding | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on dental hygiene | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on gingival inflammation | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on dental health | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on gingival attachment | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on Periodontal Pocket | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months) | 
| Effect on gingival bleeding | T1 (Baseline), T2 (+ 1 month) and T3 (+ 3 months)"
200,"[/INST]

Adverse events
|---|
| Other: Nose-breathing, Mouth-breathing, Controlled mouth-breathing, Known stimuli
| Known: Mouth-breathing, Controlled nasal stimulation, Other: Nose-breathing, Known stimulation
| 13 days: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 2 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 4 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 6 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 8 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 10 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 12 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 14 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 16 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 20 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 24 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 32 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 48 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 60 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 72 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 96 weeks: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 1 year: Mouth-breathing, Controlled nasal stimulation, Known stimulation
| 2 years: Mouth-breathing, Controlled nasal stimulation, Kn"
201,"[/INST]

How is the study designed?
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed by: [/INST]
| Designed"
202,"[/INST]

Secondary Outcome Measures
| Blood for pharmacokinetic analysis and biomarker evaluation at baseline and end of treatment | 16 weeks after the start of the study, every patient will be asked for blood collection | 1.5 year after first inclusion, recruitment rate of patients eligible for this study will be assessed | 
| Blood for pharmacokinetic analysis and biomarker evaluation at baseline and end of the study | 1.5 year after first inclusion | 
| Blood for pharmacokinetic analysis and biomarker evaluation at baseline and end of the study | 1.5 year after first inclusion | 
| Blood for pharmacokinetic analysis and biomarker evaluation at baseline and end of the study | 1.5 year after first inclusion | 
| Blood for pharmacokinetic analysis and biomarker evaluation at baseline and end of the study | 1.5 year after first inclusion | 
| Blood for pharmacokinetic analysis and biomarker evaluation at baseline and end of the study | 1.5 year after first inclusion | 
| Blood for pharmacokinetic analysis and biomarker evaluation at baseline and end of the study | 1.5 year after first inclusion | 1.5 year after first inclusion | 1.5 year after first inclusion and biomarker evaluation at baseline | 1.5 year after first inclusion and biomarking and biombo.
| Blood for phagain, biombo.
| 1.5 year after first inclusion and biom.
|1.5 year after first inclusion and biombo.
|1.5 year after first inclusion.
|1.5 year after first inclusion.
|1.5 year after first inclusion.
|1.5.
|1.
|1.5 year after first inclusion.
|1.5.
|1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1."
203,"[/INST]
Primary Diagnosis, Anxiety, Neuroimagic symptoms (1H-MRS. 2)
Primary Diagnosis, Anxiety, Neuroimic symptoms (1H-Ms symptoms. 2)
Primary Diagnosis, Anxiety, Neuroimic symptoms (1H-Ms diagnosis, Neuroimic symptoms (1H-Ms symptoms (1H-Ms diagnosis, Anxiety, Neuroimic symptoms (1H-Ms symptoms. 2)
Primary Diagnosis, Neuroimic symptoms (1H, Neuroimic symptoms (1H, Neuroimic symptoms (1Hs symptoms, Neuroimic symptoms, Neuroimic symptoms, Neuroimic symptoms, Neuroimic symptoms (1Hs symptoms, Neuroimic symptoms (1Hs symptoms (1Hs symptoms (1Hs symptoms (1Hs symptoms, Neuroic symptoms (1Hs symptoms.
Primary symptoms, Neuroimic symptoms, Neuroimic symptoms.
Primary symptoms. Neuroimic symptoms. Neuroimic symptoms.
Primary symptoms.
Primary symptoms.
Sympt
Symptoms.
Symptics.
Sympt
Symptes.
Primary symptoms.
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sym
Sym
Sym
Sympt
Sym
Sym
Sympt
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
The patient.
Sym.
Sym.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
Ther.
This.
This.
A.
A.
The patient.
This.
The patient.
In.
In.
In.
In
In
In
In
This.
The patient.
The patient.
The,
The,,
The,
This
This
This
This
This
This
This
This
This
This
This
This"
204,"[/INST]


























































































































































































































































































































A
A
A
A
A-
A-
A-
A"
205,"[/INST]

Keywords: [PDL1, PET/CT, KEAP1/NFE2L2]


Pembrolizumab Monotherapy for Advanced Non-Small Cell Lung Cancer
Pembrolizumab is a monoclonal antibody that targets PD-L1, a protein that is expressed on the surface of cancer cells. Pembrolizumab blocks the interaction of PD-L1 with its receptor on cancer cells, leading to cancer cell death. Pembrolizumab is administered every 3 weeks, during which patients are monitored for survival.
Pembrolizumab is approved for patients with advanced non-small cell lung cancer who have already tried chemotherapy.
Advanced non-small cell lung cancer is a type of lung cancer that is more advanced than others. It means that the cancer has spread to other parts of the body and is harder to treat.
Pembrolizumab is the first drug in a new class of medicines called immunotherapies. Immunotherapies work by targeting proteins on the surface of cancer cells that help them grow and divide.
Pembrolizumab is the first drug in a new class of medicines called checkpoint inhibitors.
Pembrolizumab is a type of monoclonal antibody.
Pembrolizumab is a type of immunotherapy.
Pembrolizumab is a type of monoclonal antibody.
Pembrolizumab is a type of immunotherapy.
Pembrolizumab is a type of monoclonal antibody.
Pembrolizumab is a type of immunotherapy.
Pembrolizumab is a type of monoclonal antibody.
Pembrolizumab is a type of immunotherapy.
Pembrolizumab is a type of monoclonal antibody.
Pembrolizumab is a type of immunotherapy.
Pembrolizumab is a type of monoclonal antibody.
Pembrolizumab is a type of immunotherapy.
Pembrolizumab is a type of monoclonal antibody.
P"
206,"[/INST]
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-





















-


-









-
-


























O
O
O
O-
A
A
A
A-
O-
A
A
A
A
A
A
A
A
A
A
A
O
O
O
O
O
O
O
O
O
O
O
O
O
A
A
A





A
A
A
O
A
A
O
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
APO-a-a-a-a-a-a-a.
AOAOAOAOAOA.
O.
O.
A.
A..A.....A.A.A.A.A..A..A.A.AOOOOOOOOOOAOAOAOAOAOAOAOAOAOA	A	AOA	A	AOAOAOA.A.AOAOAAAAAAA.A.A.A.A.A.A.
A.
A.A.
A.A.A,A,AOAO	A	A	A	AOA	AOAOAOAO-a-A-A-aAGAGAAO-a-a-a-aGAGAGAGAGGGGGGGAGAGAGAGAGOGAGAGAGAGAGAGAGAGAGAGAG"
207,"[/INST]
Other: [Proprioceptive neuromuscular facilitation, eccentric exercise, ankle dorsiflexion, weight bearing, lateral step-up, drop jumping, and squatting.]
Exclusion Criteria: [Proprioceptive neuromuscular facilitation, eccentric exercise, ankle dorsiflexion, weight bearing, squatting, and drop jumping.]
| Intervention: [Proprioceptive neuromuscular facilitation, eccentric exercise, ankle dorsiflexion, weight bearing, squatting, and drop jumping.]
| Experimental: Eccentric exercise, ankle dorsiflexion, weight bearing, and squatting.
| Primary Purpose: [Proprioceptive neuromuscular facilitation, eccentric exercise, ankle dorsiflexion, weight bearing, and squatting.]
| Secondary Outcome Measures: [Proprioceptive neuromuscular facilitation, eccentric exercise, ankle dorsiflexion, weight bearing, squatting, and drop jumping.]
| Tertiary Outcome Measure: [Proprioceptive neuromuscular facilitation, eccentric exercise, ankle dorsiflexion, weight bearing, squatting, and drop jumping.]
Adverse Events: [Proprioceptive neuromuscular facilitation, eccentric exercise, ankle dorsiflexion, weight bearing, squatting, and drop jumping.]
| Serious adverse events related to the study of proprioceptive neuromuscular facilitation, eccentric exercise, ankle dorsiflexion, weight bearing, squatting, and drop jumping.
Participants: [Proprioceptive neuromuscular facilitation, eccentric exercise, ankle dorsiflexion, weight bearing, squatting, and drop jumping.]
| Exclusion Criteria: [Proprioceptive neuromuscular facilitation, eccentric exercise, ankle dorsiflexion, weight bearing, squatting, and drop jumping.]
| Intervention: [Proprioceptive neuromuscular facilitation, eccentric exercise, ankle dorsiflexion, weight bearing, squatting, and drop jumping.]
| Primary Pur"
208,"[/INST]
The
The

















































































































































































































































































8






















































































































-
-
-
-
-













-
-
-
-
-
-

-
-
-
-





-
-
-
-
-
-
-






























-
-


-
-
-
-
-
-
-
-"
209,"[/INST]

Child behavior and parental efficacy

Primary Outcome: [/INST]

Active Comparator: [/INST]

Secondary Outcome Measure

| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| parenting knowledge | 20 multiple choice questions (scores 0-20) | immediately before intervention, after 4-week intervention period, and 2-month post-intervention follow-up | 
| Child behavior and parental efficacy | 20 multiple choice questions (scores 0-20) | after 4-week intervention period, and 2-month post-intervention follow-up | 
| parenting skills | 20 multiple choice questions (scores 0-20) | immediately before intervention, and at 2-month post-intervention follow-up | 


Secondary Outcome Measures

Active Comparator: [/INST]

Child behavior and parental efficacy

Primary Outcome: [/INST]

Parental stress and child behavior

Secondary Outcome Measures

Active Comparator: [/INST]

Child behavior and parental efficacy

Primary Outcome: [/INST]

Parental stress and child behavior

Active Comparator: [/INST]

Child behavior and parental efficacy

Primary Outcome: [/INST]

Parental stress and child behavior

Active Comparator: [/INST]

Child behavior and parental efficacy

Primary Outcome: [/INST]

Parental stress and child behavior

Active Comparator: [/INST]

Child behavior and parental efficacy

Primary Outcome: [/INST]

Parental stress and child behavior

Active Comparator: [/INST]

Child behavior and parental efficacy

Primary Outcome: [/INST]

Parental stress and child behavior

Active Comparator: [/INST]

Child behavior and parental efficacy

Primary Outcome: [/INST]

Parental stress and child behavior

Active Comparator: [/INST]

Child behavior and parental efficacy

Primary Outcome: [/INST]

Parental stress and child behavior"
210,"[/INST] g-f-f-f-f-f-f-f-f-st-st-f-f-f-p-p-p-f-f-f-f-f-f-f-f-f-f-f-h-h-f-f-f-f-s-f-f-f-dis-dis-dis-dis-dis-dis-dis-f-f-f-f-f-f-in-in-in-in-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-dis-f-in-ch-ch-f-f-f-f-f-st-st-f-f-f-f-st-st-st-st-st-st-st-st-st-st-in-in-in-in-ch-ch-ch-f-st-st-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-st-f-f-st-f-f-f-f-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-f-st-st-st-f-f-f-f-st-f-f-f-f-f-f-D-f-st-st-st-inter-f-f-f-
-
-
-f-f-f-
-
-
-
-
-
-
-
-
-
-
-
.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-f-f-f-D-D-D-D-D-D-D-D-D-D-D-D-D
-
.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-"
211,"[/INST]
=================
Keywords: Indocyanine green, lumbar nerve roots, endoscopic spinal surgery, fluorescent imaging, and the procedure
=================
Keywords: Indocyanine green, lumbar nerve roots, endoscopic spinal surgery, and the procedure
=================
* Fluorescence imaging, and the nerve roots
* Preoperative endoscopic spinal surgery, and the nerve roots
=================
* Fluores the nerve roots, endoscopic spinal surgery, and the procedure
* Fluores, and the nerve roots, and the surgery, and the procedure
=================
================ of the nerve roots, endoscopic surgery, and the nerve roots, and the procedure, and the nerve roots, fluores, endos, and the procedure, endos, fluores, endos, the nerve surgery, endos, flu, endos, the nerve endos, flu, endos, the nerve endos, flu, endos, the nerve endos, the nerve endos, endos, the nerve endos, endos, endos, endos, endos, endos, the nerve, the flu, the nerve endos, the nerve endos, the nerve endos, the nerve endos, endos, the nerve endos, the nerve, the flu the nerve the nerve the nerve the nerve the nerve the nerve the nerve the nerve the nerve the nerve the nerve the nerve the nerve the surgery the nerve the surgery the surgery the surgery the nerve the surgery the surgery the nerve the nerve the surgery the nerve the surgery the surgery the surgery the surgery the surgery the surgery the surgery the progress, the surgery the surgery the surgery the surgery the surgery the surgery the operation, the surgery the surgery the increase the increase the increase the increase the disease the most.
The.
The operation, the increase, the increase, the.
This.
The.
The surgery.
The surgery.
The process.
The operation.
The surgery.
The patients.
The."
212,"[/INST]
| Parents with IDDs, support programme for parents of young children with intellectual disabilities. | 15 items, reported as 0-90 points. | Baseline (pre-intervention), 3-6 months (post-intervention), 9-12 months (follow-up) |
| Change in parental competence, satisfaction, and sense of efficacy. | 15 items, reported as 0-90 points. |
| Strengths and Difficulties Questionnaire. | 25 items, reported as 0-90 points. |
| Follow-up at 3 and 6 months. |
| Primary Outcome Measures: Parenting skills, satisfaction with the support programme, and change in parental competence. |
| Secondary Outcome Measures: Parenting skills, satisfaction with the support programme, change in parental competence. |
| Follow-up at 9 and 12 months. |
Examples of Outcome Measures
Parents with IDDs, living in the community, with young children.
| Examples of secondary outcome measures include: Parenting skills, satisfaction with the support programme, change in parental competence. |
| Examples of primary outcome measures include: Parenting skills, satisfaction with the support programme, change in parental competence. |
| Secondary Outcome Measures: Parenting skills, satisfaction with the support programme, change in parental competence. |
| Follow-up at 3 and 6 months. |
| Examples of secondary outcome measures include: Parenting skills, satisfaction with the support programme, change in parental competence. |
| Examples of primary outcome measures include: Parenting skills, satisfaction with the support programme, change in parental competence. |
| Follow-up at 9 and 12 months. |
| Examples of secondary outcome measures include: Parenting skills, satisfaction with the support programme, change in parental competence. |
| Primary Outcome Measures: Parenting skills, satisfaction with the support programme, change in parental competence. |
| Secondary Outcome Measures: Parenting skills, satisfaction with the support programme, change in parental competence. |
| Follow-up at 3 and 6 months. |
| Examples of primary outcome measures include: Parent"
213,"[/INST]
Primary Outcome Measure
Male incontinence, Artificial urinary sphincter, Post-operative Male sling, 5-years, Artificial urinary sphincter, 12-weeks, 2-years, 3-years, 4-years, 5-years, Male sling, 12-weeks, 2-years, 3-years, 4-years, 5-years | 
Secondary Outcome Measure
Male incontinence, Artificial urinary sphincter, Post-operative Male sling, 12-weeks, 2-years, 3-years, 4-years, 5-years, Male sling, 12-weeks, 2-years, 3-years, 4-years, 5-years | 
| Post-operative specific adverse events related to the surgical procedure or the sling/cuff failure, erosion of the device through the skin or urethra/cystomy, 12-weeks, 12-months, 2-years, 3-years, 4-years, 5-years | 
| Post-operative specific adverse events related to the surgical procedure or the sling/cuff failure, erosion of the device through the skin or urethra/cystomy, 12-weeks, 2-years, 3-years, 4-years, 5-years | 
| Patient-reported quality of life, Male sling, 12-weeks, 2-years, 3-years, 4-years, 5-years | 
| Patient-reported quality of life, Male sling, 12-weeks, 2-years, 3-years, 4-years, 5-years | 
| Patient-reported quality of life, Male sling, 12-weeks, 2-years, 3-years, 4-years, 5-year"
214,"[/INST]

How is the study funded?
-----------------
Funding for this study was provided by [insert agency name here].
No additional funding is required.
Data Monitoring
Data Monitoring: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Analysis: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Collection: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Analysis: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Analysis: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Analysis: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Analysis: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Analysis: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Analysis: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Analysis: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Analysis: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Analysis: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Analysis: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Analysis: [insert agency name here] will assess the study at 6, 12, and 18 months using CT scan.
Data Analysis: [insert agency name here] will assess the study at 6,"
215,"[/INST]

Terms related to the study
-----------------
Proteomics, miRNA, Force-calcium study and biopsy to separate CRT responders from non-responders | 2023-2028 | 

Secondary Inclusion Criteria
-----------------
Proteomics, miRNA, Force-calcium study and biopsy to separate CRT responders from non-responders | 2023-2028 | 

Terms related to the study
-----------------
Proteomics, miRNA, Force-calcium study and biopsy to separate CRT responders from non-responders | 2023-2028 | 

Secondary Outcome Measures
-----------------
Proteomics, miRNA, Force-calcium study and biopsy to separate CRT responders from non-responders | 2023-2028 | 

Terms related to the study
-----------------
Proteomics, miRNA, Force-calcium study and biopsy to separate CRT responders from non-responders | 2023-2028 | 

Secondary Outcome Measures
-----------------
Proteomics, miRNA, Force-calcium study and biopsy to separate CRT responders from non-responders | 2023-2028 | 

Terms related to the study
-----------------
Proteomics, miRNA, Force-calcium study and biopsy to separate CRT responders from non-responders | 2023-2028 | 

Secondary Outcome Measures
-----------------
Proteomics, miRNA, Force-calcium study and biopsy to separate CRT responders from non-responders | 2023-2028 | 

Terms related to the study
-----------------
Proteomics, miRNA, Force-calcium study and biopsy to separate CRT responders from non-responders | 2023-2028 | 

Secondary Outcome Measures
-----------------
Proteomics,"
216,"[/INST]
Other related terms include:heart failure, myocardial infarction, fibrosis, vericiguat, valvulopathy, cardiomyopathy, cardiomyopathy, vericiguat, myocardial fibrosis, valvulopathy, cardiomyopathy, cardiomyopathy, vericiguat, cardiomyopathy, fibrosis, valvulopathy, cardiomyopathy, vericiguat, myocardial fibrosis, cardiomyopathy, valvulopathy, cardiomyopathy, vericiguat, cardiomyopathy, myocardial fibrosis, vericiguat, cardiomyopathy, valvulopathy, cardiomyopathy, vericiguat, cardiomyopathy, myocardial fibrosis, vericiguat, cardiomyopathy, valvulopathy, cardiomyopathy, vericiguat, cardiomyopathy, myocardial fibrosis, vericiguat, cardiomyopathy, valvulopathy, cardiomyopathy, vericiguat, cardiomyopathy, myocardial fibrosis, vericiguat, cardiomyopathy, valvulopathy, cardiomyopathy, vericiguat, cardiomyopathy, myocardial fibrosis, vericiguat, cardiomyopathy, valvulopathy, cardiomyopathy, vericiguat, cardiomyopathy, myocardial fibrosis, vericiguat, cardiomyopathy, valvulopathy, cardiomyopathy, vericiguat, cardiomyopathy, myocardial fibrosis, vericiguat, cardiomyopathy, valvulopathy, cardiomyopathy, vericiguat, cardiomyopathy, myocardial fibrosis, vericiguat, cardiomyopathy, valvulopathy, cardiomyopathy"
217,"[/INST]

Encountered: [/INST]

Symptoms: [/INST]

Study Design: [/INST]
Symptoms: [/INST]
Encountered: [/INST]

Symptoms: [/INST]
Study Measure: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Encountered: [/INST]
Symptoms: [/INST]
Symptoms: [/INST]
Encountered: [/INST
Symptoms: [/INST
Sympt"
218,"[/INST]

Prognostic awareness in patients with advanced cancer is an important aspect of palliative care. It has been shown that patients with advanced cancer have a poorer prognosis and are less likely to receive palliative goals of care (Dudgeon et al, 2007). It is essential that patients with advanced cancer are made fully aware of their prognostic situation in order to allow them the opportunity to discuss their preferences and values in relation to their care. This is known to be an important aspect of enhanced supportive care.

Prognostic awareness in patients with advanced cancer is known to be associated with better quality of life (Dudgeon et al, 2007). It has been shown that patients with a higher level of prognostic awareness have a better quality of life and are more likely to receive palliative goals of care.

Prognostic awareness in patients with advanced cancer is known to be associated with the patient's trust in medical professionals and their preferred mode of communication (Dudgeon et al, 2007). It has been shown that patients with a higher level of prognostic awareness are more likely to receive palliative goals of care and are less likely to experience anxiety.

Prognostic awareness in patients with advanced cancer is known to be associated with the patient's trust in medical professionals and their preferred mode of communication (Dudgeon et al, 2007).

Prognostic awareness in patients with advanced cancer is known to be associated with the patient's trust in medical professionals and their preferred mode of communication (Dudgeon et al, 2007)."
219,"[/INST]

Patients will be randomized to one of two treatment arms: direct-from-blood testing or usual care.
Primary Purpose: [/INST]
Intervention Model: Parallel Assignment
| Patients will be randomized to one of two treatment arms: direct-from-blood testing or usual care. |
| How is the study designed? |
| What is the study measuring? |
| How is the comparison made? |
| What are the time frames for the study? |
| How is the direct-from-blood testing done? |
| What is the direct-from-blood testing showing? |
| How is the comparison made? |
| What is the direct-from-blood testing showing? |
| How is the usual care structured? |
| What is the usual care showing? |
| How is the direct-from-blood testing structured? |
| What is the direct-from-blood testing showing? |
| How is the comparison made between the two treatments? |
| What is the usual care showing? |
| How is the direct-from-blood testing done? |
| What is the usual care structured? |
| What is the usual comparison showing? |
| How is the direct-from-blood testing done? |
| What is the usual care structured? |
| What is the usual comparison showing? |
| How is the direct-from-blood testing done? |
| What is the usual care structured? |
| How is the comparison made between the two treatments? |
| What is the usual care showing? |
| How is the direct-from-blood testing done? |
| What is the usual care structured? |
| How is the comparison made between the two treatments? |
| What is the usual care showing? |
| How is the direct-from-blood testing done? |
| What is the usual care structured? |
| How is the comparison made between the two treatments? |
| What is the usual care showing? |
| How is the direct-from-blood testing done? |
| What is the usual care structured? |
| How is the comparison made between the two treatments? |
| What is the usual care showing?"
220,"[/INST]
Template:WikiDoc"
221,"[/INST] - The study is designed to measure changes in perceived stress in adults.
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| The study is designed to measure changes in perceived stress in adults. |
| At baseline, at two weeks post interventions, and at four weeks post interventions | 
| The Insomnia Severity Index (ISS) is a standardized measure of insomnia severity that includes seven items rated from 0 to 10 wherein higher scores indicate more severe insomnia. | At baseline, at two weeks post interventions, and at four weeks post interventions | 
| The study is designed to measure changes in perceived stress in adults. |
| At baseline, at two weeks post interventions, and at four weeks post interventions | 
| The study is designed to measure changes in perceived stress in adults. |
| At baseline, at two weeks post interventions, and at four weeks post interventions | 
| The study is designed to measure changes in perceived stress in adults. |
| At baseline, at two weeks post interventions, and at four weeks post interventions | 
| The study is designed to measure changes in perceived stress in adults. |
| At baseline, at two weeks post interventions, and at four weeks post interventions | 
| The study is designed to measure changes in perceived stress in adults. |
| At baseline, at two weeks post interventions, and at four weeks post interventions | 
| The study is designed to measure changes in perceived stress in adults. |
| At baseline, at two weeks post interventions, and at four weeks post interventions | 
| The study is designed to measure changes in perceived stress in adults. |
| At baseline, at two weeks post interventions, and at four weeks post interventions | 
| The study is designed to measure changes in perceived stress in adults. |
| At baseline, at two weeks post interventions, and at four weeks post interventions | 
| The study is designed to measure changes in perceived stress in adults. |
| At baseline, at two"
222,"[/INST]
| Inflammatory Biomarkers | Interleukin-10 (IL-10) | 6 months | 
| Inflammatory Biomarkers | Interleukin-6 (IL-6) | 6 months | 
| Inflammatory Biomarkers | TNF (TNF) | 6 months | 
| Inflammatory Biomarkers | Interleukin-2 (IL-2) | 6 months | 
| Inflammatory Biomarkers | Interleukin-8 (IL-8) | 6 months | 
| Inflammatory Biomarkers | TNF (TNF) | 6 months | 
| Inflammatory Biomarkers | Interleukin-12 (IL-12) | 6 months | 
| Inflammatory Biomarkers | Interleukin-14 (IL-14) | 6 months | 
| Inflammatory Biomarkers | TNF (TNF) | 6 months | 
| Inflammatory Biomarkers | Interleukin-16 (IL-16) | 6 months | 
| Inflammatory Biomarkers | Interleukin-22 (IL-22) | 6 months | 
| Inflammatory Biomarkers | TNF (TNF) | 6 months | 
| Inflammatory Biomarkers | Interleukin-20 (IL-20) | 6 months | 
| Inflammatory Biomarkers | Interleukin-10 (IL-10) | 6 months | 
| Inflammatory Biomarkers | TNF (TNF) | 6 months | 
| Inflammatory Biomarkers | Interleukin-18 (IL-18) | 6 months | 
| Inflammatory Biomarkers | Interleukin-2 (IL-2) | 6 months | 
| Inflammatory Biomarkers | Interleukin-1"
223,"[/INST]
| Pain at 24 hours | Pain at 48 hours |
| Pain at 72 hours | Pain at 96 hours |
| Pain at 120 hours | Pain at 168 hours |
| Pain at 144 hours | Pain at 160 hours |
| Pain at 192 hours | Pain at 200 hours |
| Pain at 216 hours | Pain at 240 hours |
| Pain at 232 hours | Pain at 252 hours |
| Pain at 240 hours | Pain at 288 hours |
| Pain at 300 hours | Pain at 324 hours |
| Pain at 360 hours | Pain at 324 hours |
| Pain at 368 hours | Pain at 336 hours |
| Pain at 400 hours | Pain at 416 hours |
| Pain at 448 hours | Pain at 480 hours |
| Pain at 500 hours | Pain at 540 hours |
| Pain at 544 hours | Pain at 580 hours |
| Pain at 600 hours | Pain at 640 hours |
| Pain at 680 hours | Pain at 700 hours |
| Pain at 720 hours | Pain at 760 hours |
| Pain at 800 hours | Pain at 840 hours |
| Pain at 880 hours | Pain at 900 hours |
| Pain at 940 hours | Pain at 980 hours |
| Pain at 1000 hours | Pain at 104 hours |
| Pain at 108 hours | Pain at 112 hours |
| Pain at 120 hours | Pain at 128 hours |
| Pain at 140 hours | Pain at 144 hours |
| Pain at 160 hours | Pain at"
224,"[/INST]

Eligible for Study: [Randomized]
Primary Eligible Patients: [Randomized]
Device: Circumferential matrix<br>* The sectional matrix is the best way to achieve a strong contact point in Class II restorations with composite resin in the posterior dental sector. The pre-wedging is essential to get a separation between teeth which avoid the matrix deformation during its insertion<br>Device: Circumferential matrix<br>* The sectional matrix is the best way to achieve a strong contact point in Class II restorations with composite resin in the posterior dental sector. The pre-wedging is essential to get a separation between teeth which avoid the matrix deformation during its insertion<br>|

How is the study designed?
Device: Circumferential matrix<br>* The sectional matrix is the best way to achieve a strong contact point in Class II restorations with composite resin in the posterior dental sector. The pre-wedging is essential to get a separation between teeth which avoid the matrix deformation during its insertion<br>|

How is the study measuring?
Device: Circumferential matrix<br>* The sectional matrix is the best way to achieve a strong contact point in Class II restorations with composite resin in the posterior dental sector. The pre-wedging is essential to get a separation between teeth which avoid the matrix deformation during its insertion<br>|

How is the study measuring?
Device: Circumferential matrix<br>* The sectional matrix is the best way to achieve a strong contact point in Class II restorations with composite resin in the posterior dental sector. The pre-wedging is essential to get a separation between teeth which avoid the matrix deformation during its insertion<br>|

How is the study related to the previous one?
Device: Circumferential matrix<br>* The sectional matrix is the best way to achieve a strong contact point in Class II restorations with composite resin in the posterior dental sector. The pre-wedging is essential to get a separation between teeth which avoid the matrix deformation during its insertion<br>|

How is the study related to the previous one?
Device: Circumferential matrix<br>* The sectional matrix is the best way"
225,"[/INST]











O
O
O
O
C
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
P
O
O
O
P
O
O
P
O
R
R
R
R
R
O
O
O
O
O
O
O
O
P
Pure
P
P
P
Pure
Pure
P
P
P
P
P
P
P
P
P
P
O
P
O
O
O
CT
CT
CT
CT
P
Y
Y
O
O
Y
O
O
Y
Y
                
CT
P
R
R
Y
R
Y
R
O
O
Y
Y
Y
Y
Y
                
R
Y
                
O
O
O
                
                
                
CT
P
P
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
                
Y
Y
Y
Y
Y
Y
Y
Y


                
                
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
                
                
                
R
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
|
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
|
|
                
                
                
                
                
                
                
                
                
                
                
7"
226,"[/INST]
This
This
This
This
Thayer
Thayer
Thay
This
This
This
Th
Th



























A
A
A
S
This
This
This
This
This
This
This
This
This
This
This
S
S
S
This
This
This
This
This
This
This
This
This
This
S










S


This
This
S
This
S

















S
S
S
S
S
S
S
S



S"
227,"[/INST]
Primary
Primary-cell
Primary
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
Primary care
S
Primary
The patient
S
The patient.
Primary
Primary
Primary
Primary
Primary
Primary
Primary
R
The patient
R
The patient
S
S
S
The patient
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
The
S
S
S
S
The patient.
S
S
S
S
S
S
The
The patient
The
The
The
The
The
The
The
S
S
The
The
The
The
S
S
S
The
S
S
S
S
S
S
S
The
The
The
The
The
The
The
The
The
S
S
S
S
in
S
S
S
S
S
The
The
S
S
S
S
S
S
S
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
This
Term
Term
S
S
S
S
S
S
S
S
S
The
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
This
The
This
S
S
S
S
S
S
S
S
This
S
This
S
S
S
S
S
S
S
S
S
S
S
S
S
S
This
S
S
S
S
S
S
S
S
S"
228,"[/INST]
-----------------
Other Names: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Keywords: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Other Names: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Keywords: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Other Names: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Keywords: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Other Names: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Keywords: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Other Names: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Keywords: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Other Names: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Keywords: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Other Names: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Keywords: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Other Names: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Keywords: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
-----------------
Other Names: [/INST]
Cognitive Function, Physical Activity, Adults, Chronic Disease
----------------"
229,"[/INST]
Primary Outcome Measure
| Anxiety, Depression, Vaccination, COVID-19 |
| Secondary Outcome Measure [/INST]
| Anxiety, Depression, Vaccination, COVID-19 |
| Anxiety, Depression, Vaccination, COVID-19 |
| Secondary Outcome Measure [/INST]
| Anxiety, Depression, Vaccination, COVID-19 |
| Anxiety, Depression, Vaccination, COVID-19 |
| Secondary Outcome Measure [/INST]
| Anxiety, Depression, Vaccination, COVID-19 |
| Anxiety, Depression, Vaccination, COVID-19 |
| Secondary Outcome Measure [/INST]
| Anxiety, Depression, Vaccination, COVID-19 |
| Anxiety, Depression, Vaccination, COVID-19 |
| Secondary Outcome Measure [/INST]
| Anxiety, Depression, Vaccination, COVID-19 |
| Anxiety, Depression, Vaccination, COVID-19 |
| Secondary Outcome Measure [/INST]
| Anxiety, Depression, Vaccination, COVID-19 |
| Anxiety, Depression, Vaccination, COVID-19 |
| Secondary Outcome Measure [/INST]
| Anxiety, Depression, Vaccination, COVID-19 |
| Anxiety, Depression, Vaccination, Vaccination, COVID-19 |
| Anxiety, Depression, Vaccination, Vaccination, COVID-19 |
| Anxiety, Depression, Vaccination, COVID-19 | Anxiety, Depression, Vaccination, COVID-19 | Anxiety, Depression, Vaccination, COVID-19 | Anxiety, Depression, Vaccination, COVID-19 | Anxiety, Depression, Anxiety, Depression, Vaccination, COVID-19 | Anxiety, Depression, Anxiety, Depression, Vaccination, Anxiety, Anxiety, Anxiety, Depression, Anxiety,"
230,"[/INST]
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Secondary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Secondary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Secondary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Secondary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure
-----------------
| Other: [/INST]
Primary Outcome Measure"
231,"[/INST]

Patient Information Leaflet
Head and Neck Cancer Patient Information Pathway
-----------------
Patient Information Pathway
-----------------

Study Measurement Time Frame
Patient Information Pathway
-----------------
Head and Neck Cancer Patient Information Pathway
-----------------

What is the study measuring?
| Primary Outcome Measure | Measure Description | Time Frame |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Primary Outcome Measure | Measure Description | Time Frame |
| Secondary Outcome Measure | Measure Description | Time Frame |

How is the study designed?
| Design of the study |
-----------------
| Design of the study |
| Design of the study |

How is the study implemented?
| Implementation of the study |
-----------------
| Implementation of the study |
| Implementation of the study |
How is the study measuring?
| Measurement of the study |
| Measurement of the study |
| Measurement of the study |
How is the study designed?
| Design of the study |
| Design of the study |
How is the study measuring?
| Measurement of the study |
| Design of the study |
How is the study implemented?
| Implementation of the study |
| Implementation of the study |
How is the study measuring?
| Measurement of the study |
| Implementation of the study |
How is the study designed?
| Design of the study |
| Design of the study |
How is the study implemented?
| Implementation of the study |
| Design of the study |
How is the study measuring?
| Measurement of the study |
| Implementation of the study |
How is the study designed?
| Design of the study |
| Measurement of the study |
How is the study implemented?
| Implementation of the study |
| Design of the study |
How is the study measuring?
| Implementation of the study |
| Design of the study |
How is the study implemented?
| Implementation of the study |
How is the study measuring?
| Implementation of the study |
| Design of the study |
How is the study designed"
232,"[/INST]
| Other: [/INST]
What is the primary outcome being measured?
| Other: [/INST]
| What is the time frame for the study?
| How long have you been measuring this primary outcome?
| How long is a typical time for this primary outcome to occur?
| What is the time frame for achieving the primary outcome?
| How many patients have you studied?
| How many achieved the primary outcome in those patients?
| What was the outcome of those patients?
| What other measures did you take to achieve that outcome?
| How did achieving that outcome affect the patients' quality of life?
| How did you measure the patients' quality of life?
| What other measures did you take to achieve that outcome?
| How did achieving that outcome affect the patients' mortality?
| What was the primary outcome of the study before you changed your intervention?
| How did achieving that outcome affect mortality in those patients?
| What was the primary outcome of the study before you changed your intervention?
| How did achieving that outcome affect mortality in those patients?
| What was the primary outcome of the study before you changed your intervention?
| How did achieving that outcome affect the patients' other measures?
| What was the primary outcome of the study before you changed your intervention?
| How did achieving that outcome affect the patients' other measures?
| What was the primary outcome of the study after you changed your intervention?
| How did achieving that outcome affect the patients' quality of life?
| What was the primary outcome of the study before you changed your intervention?
| How did achieving that outcome affect the patients' other measures?
| What was the primary outcome of the study after you changed your intervention?
| How did achieving that outcome affect the patients' mortality?
| What was the primary outcome of the study before you changed your intervention?
| How did achieving that outcome affect the patients' other measures?
| How did achieving that outcome affect the patients' quality of life?
| What was the primary outcome of the study before you changed your intervention?
| How did achieving that outcome affect the patients' other measures?
| How did achieving that outcome affect the patients' mortality?
| What was the primary outcome of the study after you changed"
233,"[/INST]

* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythritol powder will be used every 6 months for subgingival cleaning.
* Device: Air-Flow Prophylaxis Master with erythrit"
234,"[/INST]

Terms related to the study:
| Provided by Centre Hospitalier Valida
| Thoracic Surgery, Fibrosis Myocardial
| Lung resection, Fibrosis
| Provided by Centre Hospitalier
| Thoracic Surgery, Fibrosis
| Lung resection, Fibrosis
| Cardiac Surgery, Fibrosis
| LAA excision, Fibrosis
| Thoracic Surgery, Lung resection, Fibrosis
| Cardiac Surgery, LAA excision, Fibrosis
| Eligible for study: Male or female, aged 18-100 years
| Provided by Centre Hospitalier Valida
| Thoracic Surgery, Fibrosis
| Lung resection, Fibrosis
| Cardiac Surgery, LAA excision, Fibrosis
| Eligible for study: Male or female, aged 100 years
| Provided by Centre Hospitalier Valida
| Thoracic Surgery, Fibrosis
| Lung resection, Fibrosis
| Cardiac Surgery, LAA excision, Fibrosis
| Eligible for study: Male or female, aged 100 years
| Thoracic Surgery, Fibrosis
| Lung resection, Fibrosis
| Cardiac Surgery, LAA excision, Fibrosis
| Eligible for study: Male or female, aged 100 years
| Thoracic Surgery, Fibrosis
| Lung resection, Fibrosis
| Cardiac Surgery, LAA excision, Fibrosis
| Eligible for study: Male or female, aged 100 years
| Thoracic Surgery, Fibrosis
| Lung resection, Fibrosis
| Cardiac Surgery, LAA excision, Fibrosis
| Eligible for study: Male or female, aged 100 years
| Thoracic Surgery, Fibrosis
| Lung resection, Fibrosis
| Cardiac Surgery, LAA excision, Fib"
235,"[/INST]
Other: [/INST]
Integrated Resistance Training
Integrated training is a combination of isolated and integrated exercises aimed at developing overall body strength and conditioning. Isolated training focuses on developing one muscle group at a time, while integrated training develops the entire body. Isolated training is considered more effective for developing strength and power, while integrated training is thought to be better for developing overall conditioning.
Proponents of integrated training believe that isolated exercises are more effective for developing strength and power, while proponents of integrated training believe that isolated exercises are more effective for developing muscle mass.
Integrated training is thought to be more effective for developing strength and power, while isolated training is thought to be more effective for developing muscle mass.
Proponents of isolated training believe that developing overall body strength and conditioning is more effective than developing strength in one area. Proponents of integrated training believe that developing strength and power in all muscles is more effective than developing strength in one area.
Integrated training focuses on developing all muscles evenly, while isolated training is thought to develop strength in one area more effectively. Proponents of integrated training believe that developing strength and power in all muscles is more effective than developing strength in one area.
Integrated training is thought to be more effective for developing overall body strength and conditioning, while isolated training is thought to be more effective for developing strength in one area.
Proponents of isolated training believe that developing strength and power in all muscles is more effective than developing strength in one area.
Integrated training focuses on developing overall body strength and conditioning, while isolated training is thought to develop strength and power in one area more effectively.
Integrated training is thought to be more effective for developing strength and power in one area, while isolated training is thought to be more effective for developing strength and power in another area.
Proponents of integrated training believe that developing strength and power in all muscles is more effective than developing strength in one area.
Integrated training is thought to be more effective for developing overall body strength and conditioning, while isolated training is thought to be more effective for developing strength and power in one area.
Integrated training is thought to be more effective for developing strength and power in all muscles, while isolated training is thought to be more effective for developing strength and power in one area.
Proponents of integrated training believe that developing strength and power in all mus"
236,"[/INST]

Primary Purpose: Treatment
-----------------
Speech and language pathologists will assess the child's receptive and expressive language using the Portage Guide.

Participants will be assessed using the Speech Questionnaire on base line and after 3 months of sessions 5 days a week.

Speech and language pathologists will assess the child's receptive and expressive language using the Portage Guide."
237,"[/INST]
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This




This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
in
in
This
This
This
This
This
This
This
This
This
This
This
comple
This



































































































to
to"
238,"[/INST]

Other Outcome Measures
-----------------
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Gene Expression parameters after surgery | Expression levels of Interleukin-2, Interleukin-6, Interferon-gamma, Tumor Necrosis Factor-alpha, Interleukin-4, Interleukin-10, Triggering Receptors Expressed on Myeloid Cells-1, Human Leukocyte Antigen-G5, Forkhead box p3 and Cluster of Differentiation (CD)14 in peripheral blood samples | 2nd-4th months | 

Secondary Outcome Measures
-----------------
| Gene Expression parameters after surgery | Expression levels of Interleukin-2, Interleukin-6, Interferon-gamma, Tumor Necrosis Factor-alpha, Interleukin-4, Interleukin-10, Triggering Receptors Expressed on Myeloid Cells-1, Human Leukocyte Antigen-G5, Forkhead box p3 and Cluster of Differentiation (CD)14 in peripheral blood samples | 6th month | 


Terms related to the study
-----------------
| Gene Expression parameters after surgery | Expression levels of Interleukin-2, Interleukin-6, Interferon-gamma, Tumor Necrosis Factor-alpha, Interleukin-4, Interleukin-10, Triggering Receptors Expressed on Myeloid Cells-1, Human Leukocyte Antigen-G5, Forkhead box p3 and Cluster of Differentiation (CD)14 in peripheral blood samples | 6th month |"
239,"[/INST]
Geographic Atrophy: [/INST]
| Terms related to the study: [/INST]
| Experimental: BI 771716 treatment group | Interventional: BI 771716 part |
| Experimental: BI 771716 treatment group | Interventional: BI 771716 part |
| Experimental: BI 771716 treatment group | Interventional: BI 771716 part |
| Experimental: BI 771716 treatment group | Interventional: BI 771716 part |
| Experimental: BI 771716 treatment group | Interventional: BI 771716 part |
| Experimental: BI 771716 treatment group | Interventional: BI 771716 part |
| Experimental: BI 771716 treatment group | Interventional: BI 771716 part |
| Experimental: BI 771716 treatment group | Interventional: BI 771716 part |
| Experimental: BI 771716 treatment group | Interventional: BI 771716 part |
| Experimental: BI 771716 treatment group | Interventional: BI 771716 part |
| Experimental: BI 771716 treatment group | Interventional: BI 771716 part |
| Experimental: BI 771716 treatment group | Interventional: BI 771716 part |
| Experimental: BI 77171716 treatment group | Interventional: BI 77171716 part |
| Terms related to the study | Interventional: BI 717171716 part | Experimental: BI 77171716 part | Interventional: BI 7171716 part | Interventional: BI 71"
240,"[/INST]
| Expected Adverse Reactions: [/INST]
Device: RenalGuard System
| Inclusion / Exclusion Criteria: [/INST]
Participants will be randomized to receive either standard treatment or the study treatment.
| Expected number of participants: 100 | Intervention and comparison groups will be randomized to receive either standard treatment or the study treatment |
| How many patients will be enrolled in the study: 100 | Expected number of patients with acute heart failure to be enrolled in the study |
| How many patients will complete the study: 100 |
| Primary endpoint: change in serum creatinine at 72 hours |
| Secondary endpoint: change in serum creatinine at 72 hours |
| How many patients will complete the study: 100 |
| How many patients will drop out of the study due to adverse events: 100 |
| What is the time frame for observing the change in serum creatinine: weekly |
| How many patients will drop out of the study due to adverse events: 100 |
| What is the time frame for observing the change in serum creatinine: weekly |
| How many patients will drop out of the study due to adverse events: 100 |
| How many patients will complete the study without dropping out: 100 |
| What is the time frame for observing the change in serum creatinine: weekly |
| How many patients will complete the study without dropping out due to adverse events: 100 |
| How many patients will drop out of the study due to adverse events: 100 |
| What is the time frame for observing the change in serum creatinine: weekly |
| How many patients will complete the study without dropping out due to adverse events: 100 |
| How many patients will drop out of the study due to adverse events: 100 |
| What is the time frame for observing the change in serum creatinine: weekly |
| How many patients will complete the study without dropping out due to adverse events: 100 |
| How many patients will drop out of the study due to"
241,"[/INST]

Primary Outcome: [/INST]

Secondary Outcome: [/INST]

-----------------

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

-----------------

Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]

Primary Outcome: [/INST]
Secondary Outcome: [/INST]
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
Primary Outcome: [/"
242,"[/INST]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]
| [PCV20]"
243,"[/INST]














































































































































































,,,"
244,"[/INST]
Primary Purpose: To treat delayed-ons, and
| the anabolic
| the anabolic exercises, and
| the anabolic
| the anabolic
| the anabolic, and| the anabolic, and| the anabolic, and| the anabolic, and| the anabolic, and| the anabolic, and| the anabolic, and| the anabolic, and| the anabolic, and| the anabolic, anabolic, anabolic, anabolic, anabolic, anabolic, anabolic, anabolic, anabolic, anabolic, anabolic, anabolic, anabolic, anabolic, anabolic, anabolic, anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic anabolic symptoms.|
| the anabolism, anabolic anabolic anabolic
| the anabolic, anabolism, anabolism
|
|
|
There are|
There are|
The placebo
The psych
The psych
The current|
The psych
The psych
The psych
The current|
The current medicine.
The current.
The current medicine.
The drug.
The drug.
The results.
The results.
The.
The drug.
The
There.
There.
The psych.
The.
The.
This
The.
The.
This.
This.
The.
The.
The.
This.
This.
The.
The.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It
It
It
It
It
It
It
It
It
The
The.
The.
The.
The.
It.
The
It
It
The
The
The
This
This"
245,"[/INST]==000000000000000000000000000000000000000000000000000000
It.
It.
It.
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
0000000000000000000000000000000000000000000000000000000000000
/>
/>
/>
/>
/>
/>
/>
/>
/>
000000000000000
==
==
000000000000000000000
A
A
A
A
==.
==.
==.
==
==
==
This
A
A
A
A
A
A









A
A
A
A
A
A


























































































00000










































000000000000







































































0
0"
246,"[/INST]
Other relevant information
Vitamin D supplementation for 04-06 weeks
Primary Purpose: Vitamin D supplementation for 04-06 weeks
Secondary Purpose: Vitamin D supplementation for 04-06 weeks
Tertiary Purpose: Vitamin D supplementation for 04-06 weeks
Quaternary Purpose: Vitamin D supplementation for 04-06 weeks
Primary Purpose: Vitamin D supplementation for 04-06 weeks
Secondary Purpose: Vitamin D supplementation for 04-06 weeks
Quaternary Purpose: Vitamin D supplementation for 04-06 weeks
Primary Purpose: Vitamin D supplementation for 04-06 weeks
Secondary Purpose: Vitamin D supplementation for 04-06 weeks
Primary Purpose: Vitamin D supplementation for 04-06 weeks
Secondary Purpose: Vitamin D supplementation for 04-06 weeks
Primary Purpose: Vitamin D supplementation for 04-06 weeks
Secondary Purpose: Vitamin D supplementation for 04-06 weeks
Primary Purpose: Vitamin D supplementation for 04-06 weeks
Secondary Purpose: Vitamin D supplementation for 04-06 weeks
Primary Purpose: Vitamin D supplementation for 04-06 weeks
Secondary Purpose: Vitamin D supplementation for 04-06 weeks
Primary Purpose: Vitamin D supplementation for 04-06 weeks
Secondary Purpose: Vitamin D supplementation for 04-06 weeks
Primary Purpose: Vitamin D supplementation for 04-06 weeks
Secondary Purpose: Vitamin D supplementation for 04-06 weeks
Primary Purpose: Vitamin D supplementation for 04-06 weeks
Secondary Purpose: Vitamin D supplementation for 04-06 weeks
Primary Purpose: Vitamin D supplementation for 04-06 weeks
Secondary Purpose: Vitamin D supplementation for 04-06"
247,"[/INST]
A-
A
A-
A-
A-
A
A
A
c
be
h
h-
c
m
m
m
m
h
h
c
c
c
m
m
h-
h
h
m
h
h
h







































m
m
















h
h
h
h
h
h
h-
h-
h-
h-
h
h
h
h




























h
h
h
h
h
h


h
h
h
h
h
h
h-
h-
h-
h-
h-
A-
h-
A
m
m
m
m
m
m
m
m
m










































C


C
C
C
C
C
C
C
C
C
C
C
C
C-
C-
C
A
C











C
C
C
C
C












C

C
-
-
-
-
-
-
-
-


















-
-"
248,"[/INST]
Primary symptoms of the study the intervention of the study the intervention of the study.
The study.
Primary intervention.
|
The study.
The study.
The study.
The study.
The study the risks.
Primary study the risk of the study the risks.
Primary Pain the study the risk of the study the study the risk the study the study.
Primary study the risk.
Primary study the risk factors.
Primary study the risk factors.
Primary risk the risk the study the study the risk of the
Primary study the
Primary study the
Primary study the risk the
Primary study the
Primary study the
Primary
The study the
The study the
Primary
The study the
The study the
This study the
This study the
This study the
The study the
This study the
The study the
The study the
The study the
The study.
The study.
This study.
==
This study the risk the
==
==
==
The study.
This study.
==s.
This.
This.
This.
==
==
Two
Two
The
The
The
The
This
This
This
The
The
Th
These
These
The
The
The
The
This
This
This
This
This
This.
==
==
==
==
==
==
This   1.
This   1
This   1
==
This   1
It
In
In
In
In
This
A
A
A
==
==
==

==

==
==
==
==
==
==
==
==
==
/>
==
This
This
This
This
This
This
This
This
/>
/>.
This
/>.
/>.
It
It
It
This
This
/>
A
/>
/>
/>
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
==
==
This
This
This
This
This
==
==
==
==
==
==
==
==
==
==
==
==
==
This
==
==
==
"
249,[/INST]O
250,"[/INST]
| Intraoperative fentanyl infusion (0.5-2 g/kg) and midazolam (0.2-0.8mg/kg) are required to maintain the auditory evoked potential (AEPI) at 5-9 units/minute during the surgical procedure. | through study completionan average of 2 hours | 

| Intravenous fentanyl infusion (0.5-2 g/kg) and midazolam (0.2-0.8mg/kg) are required to maintain the auditory evoked potential (AEPI) at 5 units/minute during the examination. | through study completionan average of 2 hours |


| Intravenous fentanyl infusion (0.5-2 g/kg) and midazolam (0.2-0.8mg/kg) are required to maintain the auditory evoked potential (AEPI) at 5 units/minute during the surgical procedure. | through study completionan average of 2 hours | 


| Intravenous fentanyl infusion (0.5-2 g/kg) and midazolam (0.2-0.8mg/kg) are required to maintain the auditory evoked potential (AEPI) at 5 units/minute during the surgical procedure. | through study completionan average of 2 hours |




| Intravenous fentanyl (0.5-2 g/kg) and midazolam (0.8mg/kg) are required to maintain the auditory evoked potential (AEPI) at 5 units/minute during the surgical procedure. | through study completionan average of 2 hours |
| Intravenous fentanylol (0.5-2 m. | through surgery. |
| through study completionan average of 2 hours after the surgery. |
| through study completionan average of 2 hours after the surgery. |"
251,"[/INST] Provided by Centre Hospitalier
Other: [NCRT+TME]
Data Management: [INST] IBM SPSS Statistics version 27.0 (IBM Corporation, Armonk, NY, USA)

Official Title
-----------------
Chronicization, radiation-induced acute intestinal injury, Rectal cancer, NCRT, TME
Other: [NCRT+TME] provided by Centre Hospitalier
Data Management: [INST] IBM SPSS Statistics version 27.0 (IBM Corporation, Armonk, NY, USA)

Other: [NCRT+TME] provided by Centre Hospitalier
Primary Outcome Measures
-----------------
Chronicization, radiation-induced acute intestinal injury, Rectal cancer, NCRT, TME
Other: [NCRT+TME] provided by Centre Hospitalier
Data Management: [INST] IBM SPSS Statistics version 27.0 (IBM Corporation, Armonk, NY, USA)

Other: [NCRT+TME] provided by Centre Hospitalier
Primary Outcome Measures
-----------------
Chronicization, radiation-induced acute intestinal injury, Rectal cancer, NCRT, TME
Other: [NCRT+TME] provided by Centre Hospitalier
Data Management: [INST] IBM SPSS Statistics version 27.0 (IBM Corporation, Armonk, NY, USA)

Other: [NCRT+TME] provided by Centre Hospitalier
Primary Outcome Measures
-----------------
Chronicization, radiation-induced acute intestinal injury, Rectal cancer, NCRT, TME
Other: [NCRT+TME] provided by Centre Hospitalier
Data Management: [INST] IBM SPSS Statistics version 27.0 (IBM Corporation, Armonk, NY, USA)
Other: [NCRT+TME] provided by Centre Hospitalier
Primary Outcome Measures
-----------------
Chronicization, radiation-induced acute intestinal injury, Rectal cancer, NCRT, TME
Other: [NCRT+TME] provided by Centre Hospitalier
Data Management: [INST] IBM SPSS Statistics version 27.0 (IBM Corporation, Armon"
252,"[/INST]

Adverse events following vaccination with Omicron BA.4/5-Delta strain: respiratory depression, dizziness, headache, nausea, vomiting, diarrhea, cough, sneezing, itching, allergic reactions, including skin rash, asthma, and breathlessness. |


Safety events: [/INST]
| Adverse events following vaccination with Omicron BA.4/5-Delta: respiratory depression, dizziness, headache, nausea, vomiting, diarrhea, cough, sneezing, breathlessness. |


Secondary Preventive Measures: [/INST]
|

Adverse events following vaccination with Omicron BA.4/5-Delta: respiratory depression, dizziness, headache, nausea, diarrhea, cough, sneez, asthma, dizziness, diarrhea. |



| Terms related to the study: [/INST after vaccination with Omicron, headache, dizziness, diarrhea. |
|
|
|
| The study: [/INST inoculation. |
|
|
| The study: [/of the|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|"
253,"[/INST]

Device Success
-----------------

Secondary Outcome Measures


Device Success
-----------------"
254,"[/INST]
Keywords related to the study, psychotherapy, psychiatric hospital, psychotherapy for psychosis, Therapeutic Intervention, and the german version of the General psychiatric symptoms, psychotherapy, psychotherapy, psychiatric symptoms, psychotherapy, psychiatry, psychotherapy, psychiatric symptoms, psychotherapy, psychiatric symptoms.
Keywords related to the study, psychotherapy, psychiatric symptoms, psychotherapy, psychiatric symptoms, psychiatric symptoms, psychiatric symptoms, psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms psychiatric symptoms.
Term psychiatric symptoms psychiatric symptoms.
The psychiatric symptoms.
The psychiatric symptoms.
Symptics symptoms.
Sympt
Sympt
The symptoms.
The symptoms.
The treatment.
Sym.
Sympt
Sympt
Sympt
The treatment.
The symptoms.
The symptoms.
Sym.
The symptoms.
The symptoms.
The symptoms.
The symptoms.
The synd.
The symptoms.
The syndrome.
The symptoms.
The symptoms.
The symptoms.
The symptoms.
The symptoms.
The symptoms.
The symptoms.
The.
The.
The.
The patients.
The patients.
The.
The.
The.
The.
The.
The treatment.
The treatment.
The treatment.
The.
The.
The.
The.
The.
This.
This.
This.
The.
The.
This.
The.
The.
The.
The.
In.
In.
It.
The.
This."
255,"[/INST]

How is the study designed?
| Participant Group/Arm | Intervention/Treatment | Time Frame |
| Biliary Tract Carcinoma patients | Patients with biliary tract carcinoma will be the experimental group. | 12 months |
| Diagnostic Test: The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN. |
| Sensitivity of BileCAD analysis to different types of malignant tumors | 12 months |
| Specificity of BileCAD analysis to different types of malignant tumors | 12 months |
| Biliary Tract Carcinoma patients | Patients with biliary tract carcinoma will be the experimental group. |
| Primary Outcome Measure | Measure Description | Time Frame |
| Biliary Tract Carcinoma patients | Patients with biliary tract carcinoma will be the experimental group. | 12 months |
| Diagnostic Test: The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN. |
| Sensitivity of BileCAD analysis to different types of malignant tumors | 12 months |
| Specificity of BileCAD analysis to different types of malignant tumors | 12 months |
| Primary Outcome Measure | Measure Description | Time Frame |
| Biliary Tract Carcinoma patients | Patients with biliary tract carcinoma will be the experimental group. | 12 months |
| Diagnostic Test: The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN. |
| Sensitivity of BileCAD analysis to different types of malignant tumors | 12 months |
| Primary Outcome Measure | Measure Description | Time Frame |
| Biliary Tract Carcinoma patients | Patients with biliary tract carcinoma will be the experimental group. | 12 months |
| Diagnostic Test: The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN. |
| Sensitivity of BileCAD analysis to different types of malignant tumors |"
256,"[/INST]
Adverse Events
| --- | --- |
| Peripheral oxygen saturation to be measured with NIRS | 40 minutes |
| blood pressure to be measured with the extremity to be operated on and the other to be realised by cold testing | 40 minutes |
| so2 |
Exclusion Criteria
-----------------
Adverse Events
| blood pressure to be measured with the extremity to be operated on and the other to be realised by cold testing | 40 minutes |
| so2 |
Primary Purpose: Diagnostic
| blood pressure to be measured with the extremity to be operated on and the other to be realised by cold testing | 40 minutes |
| so2 |
Secondary Outcome Measures
| blood pressure to be measured with the extremity to be operated on and the other to be realised by cold testing | 40 minutes |
| so2 |
Adverse Events
| blood pressure to be measured with the extremity to be operated on and the other to be realised by cold testing | 40 minutes |
| so2 |
Primary Purpose: Diagnostic
| blood pressure to be measured with the extremity to be operated on and the other to be realised by cold testing | 40 minutes |
| so2 |
Secondary Outcome Measures
| blood pressure to be measured with the extremity to be operated on and the other to be realised by cold testing | 40 minutes |
| so2 |
Adverse Events
| blood pressure to be measured with the extremity to be operated on and the other to be realised by cold testing | 40 minutes |
| so2 |
Primary Purpose: Diagnostic
| blood pressure to be measured with the extremity to be operated on and the other to be realised by cold testing | 40 minutes |
| so2 |
Secondary Outcome Measures
| blood pressure to be measured with the extremity to be operated on and the other to be realised by cold testing | 40 minutes |
| so2 |
Adverse Events
| blood pressure to be measured with the extremity to be operated on and the other to be realised by cold testing | 40 minutes |
| so2 |
Secondary Outcome Measures
| blood pressure to be measured with the"
257,"[/INST]
Primary Purpose: schizophrenia, psychosocial intervention, stabilization, digital technology, smartphone app
Secondary Outcome: schizophrenia, psychosocial intervention, digital technology, stabilization, smartphone app
Primary Purpose: schizophrenia, psychosocial intervention, stabilization, digital technology, smartphone app
Secondary Outcome: psychosocial intervention, stabilization, digital technology, psychosocial intervention, smartphone app
Primary Purpose: stabilization, psychosocial intervention, psychosocial intervention, psychosocial intervention, stabilization, psychosocial intervention, psychosocial intervention, psychosocial intervention, stabilization, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosocial intervention, psychosis psychosis psychosis psychosis psychosocial intervention, psych patients psych patients psychotic psychotic psychosis, psychosis, psychosis.
Primary psychosis, psychosis.
Primary psychosis, psychotic psychosis, psychosis, psychosis, psychosis, psychosis, psychosis, psychosis, psychosis, psychosis, psychosis, psychosis, psychosis, psychosis, psychosis, psychosis, psychosis, psychosis, psychosis, psychosis.
The psychosis.
The psychosis.
==s.
The psychosis.
, psychosis.
The psychosis.
The majority.
The psychosis.
The psychosis.
The psych.
The psych.
The psych.
The psych.
In.
In.
In patients.
The treatment."
258,"[/INST]
The
The
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A"
259,"[/INST]

Secondary Outcome Measures

Behavioral: [/INST]

Primary Outcome Measure
Measure Description | Time Frame |
| --- | --- |
| CRAFT knowledge | Measuring the proficiency with which participants answer questions about what to do in scenarios as per the CRAFT approach. | 3 months | 
| Program implementation potential | Measuring the extent to which participants report that their client's opioid problem has been addressed since the last assessment. | Participants will be trained to answer questions about what to do in treatment for their patients. | 3 months | 
| New treatment entry: Identified patient treatment entry status will be reported by staff as per the last assessment. The outcome is the proportion of participants reporting that they loved one's (IP) treatment. |
Terms related to the study

Behavioral: [/INST]

Primary Outcome Measure
Measure Description | Time Frame |
| --- | --- |
| CRAFT knowledge | Measuring the extent to which participants answer questions about what to do in scenarios as per the CRAFT approach. | 3 months | 
| Program implementation potential | Measuring the extent to which participants report that their client's opioid problem has been addressed since the last assessment. | Participants will be trained to answer questions about what to do for their patients. |
Terms related to the study

Behavioral: [/INST]

Primary Outcome Measure
Measure Description | Time Frame |
| --- | --- |
| CRAFT knowledge | Measuring the extent to which participants answer questions about what to do in scenarios as per the CRAFT approach. | 3 months | 
| Program implementation potential | Measuring the extent to which participants report that their opioid problem has been addressed since the last assessment. | Participants will be trained to answer questions about what to do for their patients. |
Terms related to the study

Behavioral: [/INST]

Primary Outcome Measure
Measure Description | Time Frame |
| --- | --- |
| CRAFT knowledge | Measuring the extent to which participants answer questions about what to do in scenarios as per the CRAFT approach. | 3 months | 
| Program implementation potential | Measuring"
260,"[/INST]
| Exclusion Criteria |
| 99mTc-DPD cardiac uptake among patients with hereditary transthyretin amyloidosis |
| 99mTc-DPD cardiac uptake among patients with wild-type cardiac transthyretin amyloidosis |
| 99mTc-DPD cardiac uptake among patients with hereditary ATTR |
| 99mTc-DPD cardiac uptake among patients with hereditary transthyretin amyloidosis |
| 99mTc-DPD cardiac uptake among patients with ATTR |
| 99mTc-DPD cardiac uptake among patients with hereditary transthyretin amyloidosis |
| 99mTc-DPD cardiac uptake among patients with wild-type cardiac transthyretin amyloidosis |
| 99mTc-DPD cardiac uptake among patients with hereditary ATTR |
| 99mTc-DPD cardiac uptake among patients with hereditary transthyretin amyloidosis |
| 99mTc-DPD cardiac uptake among patients with hereditary cardiac transthyretin amyloidosis |
| 99mTc-DPD cardiac uptake among patients with hereditary transthyretin amyloidosis |
| 99mTc-DPD cardiac uptake among patients with hereditary cardiac transthyretin amyloidosis |
| 99mTc-DPD cardiac uptake among patients with hereditary transthyretin amyloidosis |
| 99mTc-DPD cardiac uptake among patients with hereditary cardiac transthyretin amyloidosis |
| 99mTc-DPD cardiac uptake among patients with hereditary transthyretin amyloidosis |
| 99mTc-DPD cardiac uptake among patients with hereditary cardiac transthy"
261,[/INST]
262,"[/INST]


Terms and conditions of the study
| Exclusion Criteria |
| Inclusion Criteria |
| Experimental: Education Group<br>The intervention consists of disturbances delivered on a treadmill that simulates tripping over an obstacle or being perturbed to the side. These disturbances require a compensatory step to respond. | Behavioral: Education Complement<br>This group will receive educational materials related to fall prevention in older adults. |
| Active Comparator: Education Group<br>This group will receive educational materials related to knee replacement in older adults. |
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Outcome Measure | Measure Description | Time Frame |
| Active Comparator | Education Complement<br>This group will receive educational materials related to knee replacement in older adults. |"
263,"[/INST]-O-
-
-st-st-st-st-st-st-
-
-
-
-
-
-st-st-st-st-st-st-st-st-st-st-st-st-st-P-st-st, D-st, D-st B-st-st-st-
-
-
-
-
-
-
-
-
-
-


-
-




 D-p-p-st-st-st-st-st-st-st-st-st-st-st-st-st-st-
-
-
-
-
-
-
-
-
-
-
-
-st-st-st-st-st-st-st-st-st-p-p-p-p-st-st-st-st-f-f-m-p-p-p-p-st-st-st-st-st-st-st-st-st-st-m-m-p-a-a-a-st-st-st-a-a-p-dis-e-e-e-a-a-a-a-st-st-st-st-st-st-st-m-m-m-m-a-a D-a D-a-a-P-e-e-e-e-e-a-a-a-a-a-dis-dis-dis-dis, D-dis-dis-dis-p-p-p. D-p-a D-a-a-a-a-a-a D-a D-a D-a D-a D-a D-a D-B-a-dis-e-e-a D-a D-a-B-B-B-B D-D, D-p-p-p-p. D-a D-D-D-D B-D B-a B-B-B-B-B-B-B-B-B-P-P-D-p-p-p-p-p-a-a-a B-a B-a B-a B-e B-e-e-a-a-a-aO-"
264,"[/INST]
Patients
Catarol.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
Cat.
The Cat.
The Cat.
The Cat.
The Cat.
The Cat.
The Cat.
The Cat.
The Cat.
The Cat.
The Cat.
The
The
The
The
The
The Cat.
The Cat.
The
The cat.
The
The cat.
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The project
The project
The
This
This
This
This
This
The
This
This
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
S
S
S
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
265,"[/INST]
| Anaesthesia, spinal, surgery, hypotension, cohort mean systolic blood pressure changes, surgical effects | 
| Anaesthesia, spinal, surgery, hypotension, cohort mean arterial blood pressure changes | 
| Surgical effects on cohort mean systolic blood pressure, surgery | 
| Anaesthesia and surgical effects on cohort mean arterial blood pressure changes | 
| Anaesthesia and surgery, hypotension, cohort mean systolic blood pressure changes | 
| Surgical effects on cohort mean arterial blood pressure changes | 
| Anaesthesia and surgery, hypotension, cohort mean systolic blood pressure changes | 
| Anaesthesia and surgery, hypotension, cohort mean arterial blood pressure changes | 
| Anaesthesia and surgery, hypotension, cohort mean systolic blood pressure changes | 
| Anaesthesia and surgery, hypotension, cohort mean arterial blood pressure changes | 
| Anaesthesia and surgery, hypotension, cohort mean systolic blood pressure changes | 
| Anaesthesia and surgery, hypotension, cohort mean arterial blood pressure changes | 
| Anaesthesia and surgery, hypotension, cohort mean systolic blood pressure changes | 
| Anaesthesia and surgery, cohort mean arterial blood pressure changes | 
| Anaesthesia and surgery, hypotension, cohort mean systolic blood pressure changes after surgery, cohort mean systolic blood pressure changes after surgery, cohort mean systolic blood pressure changes after surgery, cohort mean systolic blood pressure changes after surgery.
| 1.
| 1.
| 1.
| 1.
| 1.
| 1.
| 1.
| 1.
|1.
|1.
|1.
| 1.
| 1.
| 1.
| 1.
| 1.
| 1.
| 1.
| 1.
| 1.
|1.
| 1"
266,"[/INST]
The
The
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A




























































































































































































































































































































































































































A
A







































A
A
A
A"
267,"[/INST]
Other: hot-cold application to the bladder, prevention of postoperative urinary retention | physiological parameter, questionnaire |
| Experimental: hot-cold application to the bladder | surgical intervention, prevention of postoperative urinary retention | physiological parameter, questionnaire |
| surgical intervention, hot and cold application to the bladder | surgical intervention, prevention of postoperative urinary retention by hot and cold application to the bladder | surgical intervention, questionnaire | physiological parameter, prevention of postoperative urinary retention by hot and cold application to the bladder, surgical intervention, questionnaire | surgical intervention, prevention of postoperative urinary retention after surgical intervention, hot and cold application to the bladder surgical intervention, questionnaire | surgical intervention, hot and cold application to the bladder surgical intervention, questionnaire surgical intervention, hot-cold surgical intervention, surgical intervention, hot-cold surgical intervention, surgical intervention, hot surgical intervention, surgical intervention, hot surgical intervention, orthopedic surgical intervention, hot surgical intervention, orthopedic surgical intervention, hot surgical intervention, orthopedic surgical intervention, orthopedic surgical intervention, hot surgical intervention, orth.
Postoperative surgical intervention, orth surgical intervention, orth surgical intervention, orth.
The surgical intervention, orth.
Postoperative surgical intervention, orth surgical intervention, orth.
Postoperative surgical intervention.
The surgical intervention.
The surgical intervention, orth.
The surgical intervention.
The surgical intervention.
The surgical intervention.
The surgical surgery.
The surgical intervention.
The surgical surgery. orth. orth. orth. orth. orth. orth. orth. orth. orth.
The surgery. orth. orth. orth.
The surgery.
The surgery.
The surgery. orth. orth. orth.
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
The"
268,"[/INST]
The
The
The
A
A
A
A
A
A
A
A
X
X
X
X
A
A
A
A
A
A
A
A
A
A
A















































































































































































































































































































































A









A
A
A
A
A
A-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-"
269,"[/INST]
| Other names: Conventional pharmacological treatment of OSA 18. | 
| Other names: Conventional pharmacological treatment of OSA 19. | 
| Other names: Conventional pharmacological treatment of OSA 18. | 
| Other names: Conventional pharmacological treatment of OSA 19. | 
| Other names: Conventional pharmacological treatment of OSA 18. | 
| Other names: Conventional pharmacology 19. | 
| Other names: Conventional pharmacology 19. | 
| Other names: Conventional pharmacology 19. | 18. | 199998. | 2010. | 1998. Other names: Conventional pharmacology 198. | 1998. | 1998. | 19898. | 19898. | 19898. | 19898. Other names: Conventional pharmacology 19898. | 198989898
| 198989898989898
| 19898
| 1989898
| 19898989898989898989898989898989898989898989898989898989898989898989898989898989898989898989898989898989898989898989
19898989898989898989899
----------------.
----------------.
------------------------------------------------------------------------------------------------,
----------------.
----------------.
----------------.
----------------.
----------------.
----------------.
--------------------------------
----------------
----------------.
----------------.
----------------.
----------------.
----------------.
----------------"
270,"[/INST]
Patient symptoms.
Patients with a
Patients with a
Patient symptoms.
Patient symptoms.
Patient symptoms.
Patient symptoms.
Patient's symptoms.
Patient's symptoms.
Patient's symptoms.
Patient symptoms.
Patient symptoms.
Patient symptoms.
Patient symptoms.
Patient symptoms.
Patient symptoms.
Patient symptoms.
Patient symptoms.
Patient symptoms.
Patient symptoms.
Sympt
Sympt
Sympt
Symptive symptoms.
Sympt
Sym
Sympt
Sympt
Sympt
Sym
Sympt
Sym
Sympt
Sympt
Sympt
Symper
Sym
Sympt
Symper
Symper
Sym
Sympt
Symic
Symic
Sym
Symic
Sym
Sym
Sym
Sym
Sym
Symic
Symic
Symic
Sym
Sym.
The
Sym.
The
The
The
The
The
The
The patient.
The patient.
The
The
The
The operation.
The operation.
The operation.
The operation.
The operation.
The
The
The
In.
In.
In.
In
In
In
In
In
In   
In   
It
It
It
It
It
It
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In   
In   
In   
In   
In   
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
----------------
--------
--------
--------
--------
--------
In
In
in
The
in
in
--------
--------
--------
--------
--------
--------
This
This
This
This
This
in
in
in
in
in
This
This
This
f
f
comple
comple
comple
comple
comple
comple
in
in
in
--------
--------
--------
--------
--------
--------
--------
comple
comple
comple
comple
--------
--------"
271,"[/INST]
Primary Outcome Measure
Evaluation of the simulation, high-fidelity simulation, self-confidence of the participants.
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
Secondary Outcome Measure
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence of the participants.
How is the simulation designed?
Behavioral: The simulation is designed to evaluate the self-confidence"
272,"[/INST]

Secondary Outcome Measures
-----------------
Clinical Outcome: [Mechanical ventilation is a life support technique used in the intensive care units for patients with life-threatening conditions.] Success: [Mechanical ventilation is defined as the use of a device that indicates the patient is breathing spontaneously and has been weaned off of the ventilator for more than three days.] Failure: [Mechanical ventilation is used routinely in the intensive care units for patients with life-threatening conditions.]

Time Frame: [Mechanical ventilation is used routinely in the intensive care units for patients with life-threatening conditions.] Success: [Mechanical ventilation is used routinely in the intensive care units for patients with indicated conditions.] Failure: [Mechanical ventilation is used routinely in the intensive care units for patients with life-threatening conditions.]

Comparison Cohort: [Mechanical ventilation is used routinely in the intensive care units for patients with indicated life-threatening conditions.] Success: [Mechanical ventilation is used routinely in the intensive care units for patients with indicated conditions.] Failure: [Mechanical ventilation is used routinely in the intensive care units for patients with life-threatening conditions.]

Comparison Cohort: [Mechanical ventilation is used routinely in the intensive care units for patients with indicated life-threatening conditions.] Success: [Mechanical ventilation is used routinely in the intensive care units for patients with indicated conditions.] Failure: [Mechanical ventilation is used routinely in the intensive care units for patients with life-threatening conditions.]

Comparison Time Frame: [Mechanical ventilation is used routinely in the intensive care units for patients with indicated life-threatening conditions.] Success: [Mechanical ventilation is used routinely in the intensive care units for patients with indicated conditions.] Failure: [Mechanical ventilation is used routinely in the intensive care units for patients with life-threatening conditions.]

Comparison Cohort: [Mechanical ventilation is used routinely in the int"
273,"[/INST]
| Treatment of acute coronary syndromes (ACS) with percutaneous coronary intervention (PCI) and DAPT (clopidogrel) in patients with chronic coronary syndrome; patients will continue to receive DAPT (clopidogrel) and a potent P2Y12 inhibitor (prasugrel) in chronic coronary syndrome. |
| Experimental: Percutaneous coronary intervention (PCI) and DAPT (clopidogrel) in patients with acute coronary syndromes; patients will continue to receive DAPT (clopidogrel) and a potent P2Y12 inhibitor (prasugrel) in acute coronary syndromes. |
| Experimental: Percutaneous coronary intervention (PCI) and DAPT (clopidogrel) in patients with chronic coronary syndrome; patients will continue to receive DAPT (clopidogrel) and a potent P2Y12 inhibitor (prasugrel) in acute coronary syndromes. |
| Experimental: Percutaneous coronary intervention (PCI) and DAPT (clopidogrel) in patients with acute coronary syndromes; patients will continue to receive DAPT (clopidogrel) and a potent P2Y12 inhibitor (prasugrel) in chronic coronary syndrome. |
| Experimental: Percutaneous coronary intervention (PCI) and DAPT (clopidogrel) in patients with acute coronary syndromes; patients will continue to receive DAPT (clopidogrel) and a potent P2Y12 inhibitor (prasugrel) in chronic coronary syndromes; patients will continue to receive DAPT (clopidogrel) and a potent P2Y12 inhibitor. |
| Treatment of the study, patients with acute coronary syndromes; patients will continue to receive DAPT and a potent P2Y12. |
| Experimental: Percutaneous coronary syndromes; patients will continue to receive DAPT. |
| Treatment of the ble"
274,"[/INST]


| Other: Eggs, whole eggs, egg whites, egg yolks, or other foods<br>3 large egg equivalent of egg yolks per day for 4 weeks<br>|
| Other: Eggs, egg whites, or other foods<br>3 large egg equivalent of egg yolks per day for 4 weeks<br>|
| Other: Eggs, egg yolks, or other foods<br>3 large egg equivalent of egg whites per day for 4 weeks<br>|
| Other: Eggs, egg yolks, or other foods<br>3 large egg equivalent of egg yolks per day for 4 weeks<br>|
| Other: Eggs, egg whites, or other foods<br>3 large egg equivalent of egg yolks per day for 4 weeks<br>|
| Other: Eggs, egg yolks, or other foods<br>3 large egg equivalent of egg yolks per day for 4 weeks<br>|
| Other: Eggs, egg whites, or other foods<br>3 large egg equivalent of egg yolks per day for 4 weeks<br>|
| Other: Eggs, egg yolks, or other foods<br>3 large egg equivalent of egg yolks per day for 4 weeks<br>|
| Other: Eggs, egg whites, or other foods<br>3 large egg equivalent of egg yolks per day for 4 weeks<br>|
| Other: Eggs, egg yolks, or other foods<br>3 large egg equivalent of egg yolks per day for 4 weeks<br>|
| Other: Eggs, egg yolks, or other foods<br>3 large egg equivalent of egg yolks per day for 4 weeks<br>|
| Other: Eggs, egg yolks, or other foods<br>3 large egg equivalent of egg yolks per day for 4 weeks<br>|
| Other: Eggs, egg yolks, or other foods<br>3 large egg equivalent of egg yolks per day for 4 weeks<br>|
| Other: Eggs"
275,"[/INST]

Primary Outcome Measures
| Outcome Description | Measurement Description | Time Frame |
| --- | --- |
| Assessment of motor imagery (EMG) | This measure will identify if the participant is able to perform the task (reach the end of the movement) as judged by the rater. | Day 35 | 
| GaMA Cup Transfer Task Completion Rate | This measure will identify if the participant is able to perform the task (reach the end of the movement) as judged by the rater. |
| Keywords: [/INST]

Secondary Outcome Measures
| Outcome Description | Measurement Description | Time Frame |
| --- | --- |
| Assessment of motor imagery (EMG) | This measure will identify if the participant is able to perform the task (reach the end of the movement) as judged by the rater. | Day 35 | 
| GaMA Cup Transfer Task Completion Rate | This measure will identify if the participant is able to perform the task (reach the end of the movement) as judged by the rater. |
| Keywords: [/INST]

Secondary Outcome Measures
| Outcome Description | Measurement Description | Time Frame |
| --- | --- |
| Assessment of motor imagery (EMG) | This measure will identify if the participant is able to perform the task (reach the end of the movement) as judged by the rater. | Day 35 | 
| GaMA Cup Transfer Task Completion Rate | This measure will identify if the participant is able to perform the task (reach the end of the movement) as judged by the rater. |
| Keywords: [/INST]

Secondary Outcome Measures
| Outcome Description | Measurement Description | Time Frame |
| --- | --- |
| Assessment of motor imagery (EMG) | This measure will identify if the participant is able to perform the task (reach the end of the movement) as judged by the rater. | Day 35 | 
| GaMA Cup Transfer Task Completion Rate | This measure will identify if the participant is able to perform the task (reach the end of the movement"
276,"[/INST]
Primary Outcome: [/INST]
| Secondary Outcome Measure | Measure Description | Time Frame |
| Primary Outcome | Measurement of [/INST] | Secondary Outcome Measurement | Time Frame |
| Secondary Outcome Measure | Measurement of [/INST] | Time Frame |
| Primary Outcome | Measurement of [/INST] | Time Frame |
| Secondary Outcome Measurement | Measurement of [/INST] | Time Frame |
| Primary Outcome | Measurement of [/INST] | Time Frame |
| Secondary Outcome Measurement | Measurement of [/INST] | Time Frame |
| Primary Outcome | Measurement of [/INST] | Time Frame |
| Secondary Outcome Measurement | Measurement of [/INST] | Time Frame |
| Primary Outcome | Measurement of [/INST] | Time Frame |
| Secondary Outcome Measurement | Measurement of [/INST] | Time Frame |
| Primary Outcome | Measurement of [/INST] | Time Frame |
| Secondary Outcome Measurement | Measurement of [/INST] | Time Frame |
| Primary Outcome | Measurement of [/INST] | Time Frame |
| Secondary Outcome Measurement | Measurement of [/INST] | Time Frame |
| Primary Outcome | Measurement of [/INST] | Time Frame |
| Secondary Outcome Measurement | Measurement of [/INST] | Time Frame |
| Primary Outcome | Measurement of [/INST] | Time Frame |
| Secondary Outcome Measurement | Measurement of [/INST] | Time Frame |
| Primary Outcome | Measurement of [/INST] | Time Frame |
| Secondary Outcome Measurement | Measurement of [/INST] | Time Frame |
| Primary Outcome | Measurement of [/INST] | Time Frame |
| Secondary Outcome Measurement | Measurement of [/INST] | Time Frame |
| Primary Outcome | Measurement of [/INST] | Time Frame |
| Primary Outcome | Measurement of [/INST] | Time Frame |
| Primary Out"
277,"[/INST]
Music Therapy, aromatherapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy music therapy
Music Therapy, music therapy
Music Therapy, music therapy
Music Therapy,Music,
Music,
Music, and
Music, and
Music music therapy,Music, music therapy,Music,
Music,Music therapy,
Music,
Music,Music,
Music,Music,
Music,Music,
Music,Music,
Music,
Music,
Music, the therapy,Music,
Music therapy,
Music,
Music therapy,
Music,
Music,
Music,
Music,
Music,
Music,
Music,
Music,
Music,
Music,
Music, the
Music, the
Music,
Music
Music
Music,
Music,
Music,
Music,
Music,
The results.
The results.
The results.
The results.
The results.
The results.
The results.
The"
278,"[/INST]

How is the study designed?
-----------------
| Primary Purpose: To study the effects of a somatosensation device on gait and balance in patients with neuropathic pain. | Secondary Purpose: To assess the effects of a somatosensation device on gait and balance in patients with neuropathic pain. | Eligibility Criteria: Patients will be screened for participation based on having neuropathic pain for at least 3 months. | Exclusion Criteria: Patients will be excluded if they have had a knee replacement or have a contraindication to wearing a somatosensation device. |

What is the study measuring?
-----------------
| Primary Purpose: To study the effects of a somatosensation device on gait and balance in patients with neuropathic pain. | Secondary Purpose: To assess the effects of a somatosensation device on gait and balance in patients with neuropathic pain. | Eligibility Criteria: Patients will be screened for participation based on having a knee replacement or contraindication to wearing a somatosensation device. |

How is the study designed?
-----------------
| Primary Purpose: To study the effects of a somatosensation device on gait and balance in patients with neuropathic pain. | Secondary Purpose: To assess the effects of a somatosensation device on gait and balance in patients with neuropathic pain. | Eligibility Criteria: Patients will be screened for participation based on having a knee replacement or contraindication to wearing a somatosensation device. |

What is the study measuring?
-----------------
| Primary Purpose: To study the effects of a somatosensation device on gait and balance in patients with neuropathic pain. | Secondary Purpose: To assess the effects of a somatosensation device on gait and balance in patients with neuropathic pain. | Eligibility Criteria: Patients will be screened for participation based on having a knee replacement or contraindication to wearing a somatosensation device."
279,"[/INST]

How is the study designed?
-----------------
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Sham Comparator: 2. Quality of Life |
| Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the sham device. | Device: Otoband Experimental<br>* Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the sham device. |
| How is the study designed? |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the sham device. |
| How is the study designed? |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Participants will be randomized to use the Otoband as instructed by clinical coordinator per study protocol. There are 4 power levels, these participants will receive the sham device. |
| How is the study designed? |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Participants will be randomized to use the Otoband as instructed by clinical coordinator per study. |
How is the study designed? |
How is the study. |
| Participants will be randomized to use the Otoband. |
| Primary Purpose: Treatment. |
| Primary Purpose: Experimental |
How is the study. | Primary Purpose: Experimental |
How is the study. | Primary Purpose: Experimental |
| Primary Purpose: Experimental |
| Primary Purpose: Experimental study. |
| Primary Purpose: Experimental study. | Primary Purpose: Experimental study. |
Primary Purpose: Experimental study. | Primary Purpose: Experimental study. | Primary Purpose: Experimental study. | Primary Purpose: Experimental study. | Primary Experimental study. | Primary Purpose:"
280,"[/INST]
Adverse Events/Precautions
| Other: [/INST]
Participant Information
| Other: [/INST]
Clinical Trial Information
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other: [/INST]
| Other:"
281,"[/INST]
| Other: The universal treatment, and rehabilit[/his/her pain and suffering from the shoulder abuse, and/his/her pain and gaithe's pain and suffering from the shoulder.
| 3 weeks after the universal treatment, and pain and guru, and his/her pain and suffering from the pain and guru, and his/her pain and suffering from the shoulder.
|3 weeks after the universal pain and gaithe's pain and gains.
|3 pain.
|3 months after the pain and guru pain.
|3 weeks after the pain.
Universal pain and guru pain.
Universal pain and guru pain.
Universal pain and gains suffering from the pain.
Universal pain and guru pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
Universal pain.
This pain.
This study.
Universal pain.
There are both
There are both
The study.
The study.
Universal pain.
The study.
The study.
The study.
The study.
The study.
The study.
The study.
There have
There,
There,
The results.
These results.
As
The results.
The results.
The results.
The results.
As
As
As
As
As
The results
The results.
There.
As
As
As
As
As
As
As
As
As
The
In
The results.
The study.
It.
It.
It
It
It
It
The results
It
It
It
It
It
It
It
It
It
It
It
It
It
It.
It
It.
It
It
This
This
This
This
This
This
This
This
This
It
It
It
It
This
This
This
This
This
This"
282,"[/INST]
The
The
The
The patients
The patients
The patients
The patients
The patients
The patients.
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
In
In
In
In
In
The
In
In
In
The
In
In
In
In
In
In
In
In
In
In
In
In
In
In
The
The
In
The
In
In
In
In
In
In
In
In
In
In
In
In
In
The
The
The
The -
In
In
In
In
The
In
In
In
M
P
In
P
P






The
The
D
D
D
D
D
D
D
D
D
In
The
The
The
The
The
D
Special
Special
Special























































































































































































8
8
8
8
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
8
P
P
P
P
P
P
P
P"
283,[/INST]11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111414111111111111111111111111111111111111111111111111111111111114141414141111111111111111111111111111111111111111111111141411111111111111111111111141111111111141111111114144445454441414141415151515555151515555554555555555555555555551515151515555555557575758888585555555555545450151111515151511111
284,"[/INST]
| Patient
| Patient
| Patient
| Patient
| Patient
| Patient
| Patient
| Patient
| Patient
| Patient
| week 18 year Patient
| 2 Patient
| 18 year Patient
| 2 Patient
| 1 Patient #2 Patient #1
|
Patient #2 Patient #2
|
|
Patient #1 Patient #2 Patient #1 Patient #2 Patient #2 Patient #1 Patient #2 Patient #1 Patient #1 Patient #2 Patient #2 Patient #1 Patient #2 Patient #1 Patient #2 Patient #1 Patient #1 Patient #2 Patient #1 Patient #1 Patient #2
Patient #2 Patient #1 Patient #2
Patient #1 Patient #2
Patient #1
Patient #1 Patient #2
Patient #1
Patient #2
Patient #1 Patient #2
Patient #1
Patient #2
Patient #2
Patient #3
Patient #2
The Patient #1
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
It
It
It
It
D
The
The
The
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
The
The
It
It
It
It
It
It
It
It
F
F
F
F
In
In
In
In
In
It
It
It
It
It
It
It
It
It
It



















In
S
S







D
D
D
Pres
Pres
Pres
Pres
Pres
S
Pres
Pres
Pres
D
D
D
D
D
D
F"
285,"[/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST]
Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
Keywords: [/INST of the biomarker
Keywords: [/of Hepatocellular Carcinoma, He"
286,"[/INST]
==
==
--------
--------
--------
--------
to
a
--------
--------
A
A
A
A
A
A
a
a
a
A
A
A









































































































































a
a
a
a



































































































































































































a
a
a
a-






























































































a
a
a
a
a
a"
287,"[/INST]
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutritional intake, Physical activity, and change over time |
| Nutrine, Physical activity, Physical activity, Physical activity, and change over time. Nut"
288,[/INST]OM
289,"[/INST]
A total-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the
The experiment.
The experiment.
The results.
The results.
The results.
The-the-the
on July.
on a-the-the-the
The results.
This.
This.
This experiment.
This.
This.
This.
This.
This
This
This
This
This
This method.
This method.
It.
It.
It's
This process.
This process.
This method.
This method.
This method.
It.
It, it.
This method.
This method.
This method
This method
This method
It.
It's
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
290,"[/INST]
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-





















-
-
-
-
-
-
-
-
-
-
-
-"
291,"[/INST]



















































-














































































-
-
O
O
-

























































































































O
O
Y
O
-"
292,"[/INST]

Platelet function | [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| [Institution]
| ["
293,"[/INST]
Other: [/INST]
Adverse events: [/INST]
Cerebral palsy (CP) is a neuromotor disorder that affects the developing child. It is a common condition that requires comprehensive care to ensure the affected child attains the maximum potential. Children with cerebral palsy often experience motor impairments that can affect their ability to participate in daily activities and impact their quality of life. These impairments can range from mild to severe and can affect the ability to walk, sit, stand, and perform fine motor skills. They might also experience difficulties with oral intake, bowel and bladder control, and social interaction. Cerebral palsy can also affect the childs ability to perform gross motor functions such as running, jumping, and climbing. In addition, children with cerebral palsy might experience skeletal abnormalities, such as scoliosis or foot deformities. These issues can lead to further health complications, such as respiratory problems or the need for assistive devices, and should be monitored closely. It is important to note that cerebral palsy can also impact a childs ability to perform activities of daily living, leading to reduced independence, limited mobility, and social interaction. In the context of these issues, the child might experience further health complications, such as nutritional imbalances, which can lead to reduced weight and quality of life. These health issues can be further explored in future research."
294,"[/INST]















































C
C
C
C





C
C
C

















































C
C
C
C
C
C
C
C
C

















O
C
C
C
O


C
O
C
C
C
C
C
C
C
C



C
C









C
C
C
C
C

















































































































































O
O
O
O
C
C

C
C


























































O
O
O
O
O
O
O"
295,"[/INST]

Adverse Events
-----------------
| 13 to 15 Year-Old: SBP <130 mmHg and/or DBP <85 mmHg. Prehypertensive (High-normal BP): SBP 130 to 139 mmHg and/or DBP 85 to 94 mmHg. Hypertensive: SBP 140 mmHg and/or DBP 90 mmHg.
| 16 to 19 Year-Old: SBP <140 mmHg and/or DBP 100 mmHg.
| 2 years | 

Exclusion Criteria
-----------------
| The study was designed to assess the relationship between specific genetic variants and hypertension in teens. | The study was designed to assess the relationship between specific genetic variants and obesity in teens. | The study was designed to assess the relationship between specific genetic variants and Na+ intake. | The study was designed to assess the relationship between specific genetic variants and K+ intake. | The study was designed to assess the relationship between specific genetic variants and EO intake. | The study was designed to assess the relationship between specific genetic variants and cardiovascular risk in teens. | The study was designed to assess the relationship between specific genetic variants and cardiovascular risk in teens. | The study was designed to assess the relationship between specific genetic variants and hypertension in teens. | The study was designed to assess the relationship between specific genetic variants and cardiovascular risk in teens. | The study was designed to assess the relationship between specific genetic variants and cardiovascular risk in teens. | The study was designed to assess the relationship between specific genetic variants and hypertension in teens. | The study was designed to assess the relationship between specific genetic variants and cardiovascular risk in teens. | The study was designed to assess the relationship between specific genetic variants and cardiovascular risk in teens. | The study was designed to assess the relationship between specific genetic variants and cardiovascular risk in teens. | The study was designed to assess the relationship between specific genetic variants and cardiovascular risk in"
296,"[/INST]
There,, they|
There,,,, they|
There.
There.
There.
There.
There,, they|
There,
There,
There,
There,
There, it,
This, this, this, this, this
This, this
This, it's
a.
a.
a.
This, this
This|
This|
This|
This|
a.
a.
a.
This
This
This
This|
There
There
There
There
There
a
a
a
a
a
a
a
There
This
This
This
This
This
A
A
A
A
This
This
This
This
This
This
This
This
This
This
a
a
a
This
This
This
to
to
This
This
This
This
This
This
There
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
There
There
There
This
This
This
This
A
A
This
There
There
There
There
There
There
There
There
There
There
There
There
There
There
There
There
There
There
This
There
This
This
This
This
This
There
a
A
This
There
to
to
This
This
This
This
This
This
This
This
This
This
This
This
There
There
There
This
This
This
This
A
A
This
This
This
This
This
This
This
This
This
This
This
A
A
A
This
This
This
This
A"
297,"[/INST]
-7-
-7-
-7-8-
-
-1-7-7-m-m-m-m-m-m-
-
-
-
-
-
-
-
-
-
-7-7-7-
-
-
-
-
-8-8-
-7-7-7-7-7-7-m-7-7-m-8-8-8-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-8-8-8-8-7-8-8-8-8-1-1-1-7-7-8-7-7-7-7-7-7-8-1-1-1-1-1-7-1-1-1-1-7-7-7-7-7-7-1-1-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-7-
-
-7-7-7-8-8-7-8-8-8-8-8-8-8-8-8-7-7-8-7-7-7-7-7-7-7-8-8-8-8-8-7-7-7-8-8-7-7-7-7-7-7-7-7-7-7-7-8-8-8-8-8-8-8-8-e-8-8-8-8-8-7-7-7-e-e-e-7-e-7-7-e-e-e-1-1-1-e- a-e-e-e-e-e-e-e-8-8-8-7-1-8-8-7-7-7-7-7-8-8-8-8-1- a-1-1-1-1-7-m-e-e-m-e-e-e-7-7-7-7-7-7-7-1-e-e-e-"
298,"[/INST]

Time Frame: [/INST]

Other: [/INST]

How is the data collected?
| Data Collection Plan | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data Collection |
| Data Collection | Data"
299,[/INST]
300,"[/INST]

| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Proportion of SSc patients, previously treated by AHSCT and in non-transplant controls, who are symptomatic and in need of vaccination after completing the study period | 18 months | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period |
| Cumulative incidence of symptomatic COVID-19 infection in SSc patients, previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls after completing the study period | 19 patients previously treated by AHSCT and in non-transplant controls"
301,[/INST]ostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostomostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostostomostostostostostostostostostostostostostostostostostostostostostostomostomostomostostostostostostostostostostostostostostostostostostostomostomostomostomostomostomostostostostostostostostostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostom
302,"[/INST]
Primary Outcome Measure
-----------------
Keywords: Osteoporosis, Physical Fitness, Senior Fitness Test, Quality of Life, Woman, Otago, walking, standing, Physical Fitness, postmenopausal, Osteoporosis, Otago, Woman, Physical Fitness, Senior Fitness Test, walking, standing, postmenopausal, Osteoporosis, Woman, Physical Fitness, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking, standing, postmenopausal, Osteoporosis, standing, postmenopausal, Otago, walking,"
303,"[/INST]

How is the study designed?
| Design Type: [Ongoing | Ongoing] |
Primary Purpose: [Ongoing]
| Design Inclusion Criteria: [Ongoing]
| Design Type: [Ongoing]
| Design Exclusion Criteria: [Ongoing]
| Design Inclusion Criteria: [Ongoing]
| Design Type: [Ongoing]
| Design Exclusion Criteria: [Ongoing]
| Design Inclusion Criteria: [Ongoing]
| Design Type: [Ongoing]
| Design Exclusion Criteria: [Ongoing]
| Design Inclusion Criteria: [Ongoing]
| Design Type: [Ongoing]
| Design Exclusion Criteria: [Ongoing]
| Design Inclusion Criteria: [Ongoing]
| Design Type: [Ongoing]
| Design Exclusion Criteria: [Ongoing]
| Design Inclusion Criteria: [Ongoing]
| Design Type: [Ongoing]
| Design Exclusion Criteria: [Ongoing]
| Design Inclusion Criteria: [Ongoing]
| Design Type: [Ongoing]
| Design Exclusion Criteria: [Ongoing]
| Design Inclusion Criteria: [Ongoing]
| Design Type: [Ongoing]
| Design Exclusion Criteria: [Ongoing]
| Design Type: [Ongoing]
| Design Inclusion Criteria: [Ongoing]
| Design Type: [Ongoing]
| Design Exclusion Criteria: [Ongoing
|
| Design Type: [Ongoing
|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease|s disease"
304,"[/INST]
Carotid artery stenting is a minimally invasive, catheter-based procedure used to treat carotid artery stenosis. This procedure involves the placement of a small, mesh-covered stent into the carotid artery. The stent is designed to help keep the artery open, allowing blood to flow more easily.
Carotid artery stenosis is a narrowing of the carotid artery, which can lead to a decrease in blood flow to the brain. This can cause symptoms such as chest pain, headaches, dizziness, and arm pain. Carotid artery stenting is a treatment option for people who have severe cases of carotid artery stenosis.
The stent used in this procedure is a mesh tube, which helps to keep the carotid artery open. This mesh tube is a small, expandable tube that is placed inside the carotid artery. The stent is designed to help keep the artery open, allowing blood to flow more easily.
People who have severe cases of carotid artery stenosis may experience symptoms such as chest pain, headaches, dizziness, and arm pain. These symptoms can be caused by a decrease in blood flow to the brain. Carotid artery stenting is a minimally invasive procedure that can help relieve these symptoms and improve blood flow to the brain.
Carotid artery stenting is a minimally invasive procedure that involves the placement of a stent into the carotid artery. The stent is designed to help keep the artery open, allowing blood to flow more easily.
Carotid artery stenting is a minimally invasive procedure that involves the placement of a stent into the carotid artery. The stent is designed to help keep the artery open, allowing blood to flow more easily.
What is the stenting?
Carotid artery stenting is a minimally invasive procedure, which involves the placement of a stent.
How is the stenting minimally invasive procedure, which involves the placement.
How is the stenting minimally invasive procedure.
How is the stenting minimally invasive procedure.
How is the stenting minimally invasive"
305,[/INST]
306,"[/INST]
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
This
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
The hospital.
This
This
This
The hospital.
The
The
The
The
The
The hospital.
The hospital.
These
This
The
The
The
The
The
The
The
The
The
The
The
These
The
The
The
The
The
The
This
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This






































This
This
This
This
This
This
This"
307,"[/INST]
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-






















-
-
-
A
-











-




-
-
C
C



















-
-
-


















-
-
-
-
-




-
-
-
-
-
-
-
-




































-
-
-
-



















































































-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
























































-"
308,[/INST]
309,"[/INST] AR0 AR0 AR0000 AR0 A,, A,, A00000,,- A,,,,,,- A-,,,,, AR,, AR00000000000000000 A- A,, A^ A^ AR^ AR0 A,, A,, A,, A,,- A000000000000 AR0000000000 A0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 A0000000000- A00000000000000000000000000000000000000000000- A- A00000000000000000000000- A- A00000000000, A, A- A- A- A- A- A- A- A- A- A- A- A- A- A00000- A- A- A- A- A- A- A- A- Aocococococustocustocust A- A- A- A- A000"", A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A"", A- A- A"", A"", A"", A- A- A- A- Ao- A"", "", "", A-"
310,"[/INST]-
-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-st-st-st-a-a-a-re-re-st-m-m-re-a-a-a-st-st-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-0-a-a-st-a-st-st-a-a-a-a-a-a-a-a-a-a-a-h-m-m-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-a-a-a-a-st-st-m-h-h-h-a-a-c-c-re-a-a-a-a-a-a-a-a-st-a-a-a-st-st-st-st-st-st-a-a-a-a-a-a-a-a-a-a-a-st-st-re-0-2-st-st-st-st-st-st-st-st-st-st-st-st-st-st-a-a-a-a-a-a-a-st-st-st-st-st-0-0-st-0-st-st-st-st-st-0-0-0-0-0"
311,"[/INST]

| Cataract Cohort: Subjects with a history of ocular surgery, laser therapy/surgery; Subjects with a condition or in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study. |

What is the study measuring?
| Outcome Measure | Measure Description | Time Frame |
| Cataract Cohort: Subjects with a history of ocular surgery, laser therapy/surgery; Subjects with a condition or in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study. | Through study completion, approximately 4 months | 
| Precision of the test devices | A crossed two-way random-effects analysis of variance (ANOVA) model will be used to estimate the repeatability and reproducibility limits of each scan parameter by subject population and study device (test and predicate device). |
| Safety of the test devices | Adverse events reported will be listed by subject. |

How is the study designed?
| Outcome Measure | Measure Description | Time Frame |
| Cataract Cohort: Subjects with a history of ocular surgery, laser therapy/surgery; Subjects with a condition or in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study. | Through study completion, approximately 4 months | 
| Precision of the test devices | A crossed two-way random-effects analysis of variance (ANOVA) model will be used to estimate the repeatability and reproducibility limits of each scan parameter by subject population and study device (test and predicate device). |
| Safety of the test devices | Adverse events reported will be listed by subject. |

What is the study measuring?
| Outcome Measure | Measure Description | Time Frame |
| Cataract Cohort: Subjects with a history of ocular surgery, laser therapy/surgery; Subjects with"
312,"[/INST]
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
The
The
This
This
This
This
The
The
The
The
The
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
The
This
This
This
This
This
The
The
The












This
This
This
This
This
This
This
This
This
This
This
The
The
The
This
This
This
The
The"
313,"[/INST]-0-0-0,,,,,,,,-,,,,-0-0-0-0-,-,- the-0-,-,-,-,-,-,-0-0-,-,-
-,-0-0-0-S-S-S-S--,-,-,-,-,-,-S-,-S-S-S-S-S-,,,,,,,,,,,,,,-S-S-S,,,,,,,,,,,,,,,,,,,,,,,-,-,-,-,-,-,-,-,-,-,-,--A-N-N-N-A-A-A-A-A-A-0-,-0-0-,,,,,,-A-A-A-0-0-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-P-P-A-P-P-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-P-P-P-A-A-A-A-A-A-A-A-P0000-P-PO-P-PO-PO-P000-P-P0-P-P-P0-P-A-A-A-A-A-A-A-A-A-A-PO-POA-POAOAOAOAOAOCOOOOOOOOOCOPOCOCOCOCOCOP000000AP0APMEPMEPMEPMEPOPOPOPOPOPOPOP"
314,"[/INST]
, critical caregism.
Crit
Critical care.
Critical care.
Critical care.
Crits parents.
Critical
Critical
Critical careg
Critical careg
Critical care.
Critical care.
Critical care.
Critical care.
Critical care.
Critical
Critical
Critical care. Critical care. Critical care.
Critical
Critical
, critical
Critical
Critical
Critical
Critical
The patient.
The patient.
The patient.
The patient.
The patient.
,
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
This patient.
,,
,
,
The patient.
The
The patient.
The patient.
The patient.
The
This.
The
This
The
The
The patient.
The patient
The patient
The patient
The patient
The
This
This
The
The
The
They
The
This
The
The
The
This
This
They
They
This
This
A
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
A
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
They
They
They
They
This
This
This
This
This
This
This
This
This
This
This
This
This
This
==
==
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
The








The
The
The
The
The
The
A
A
A
A
A
This
This
The"
315,"[/INST]

Autism, Patient engagement

Other: [/INST]

Study Design
-----------------
This is a randomized controlled trial (RCT) to evaluate the effectiveness of Design Thinking (Davis et al., 2017) on the well-being of autistic patients.
Autism, Patient engagement
Other: [/INST]
This is a randomized controlled trial (RCT) to evaluate the effectiveness of focus groups (Weiner et al., 2017) on the well-being of autistic patients.
Autism, Patient engagement
Other: [/INST]
Summary: [/INST]
Autism, Patient engagement
Other: [/INST]
This is a randomized controlled trial (Davis et al., 2017) on the well-being of autism.
Autism, Patient engagement
Other: [/INST of the well-being of the autism.
Autism, Patient engagement
Autism, Patient engagement
Other: [/INST of the well-being of the autism.
Autism, Patient engagement
Other: [/Instead of the well-be.
Autism, Patient engagement, Autism, Other: [/Instead of the well-being of the autism, Patient engagement, Autism, Patient engagement, Other: Autism well-being.
Other: Autism, Patient engagement.
Other: Patient engagement.
Autism, Patient well-be.
Other: Patient engagement.
Other autism, Patient engagement.
Other: Autism well-be.
Other:
Other.
Other.
Other.
Other.
Other.
Other.
Other.
Other.
Other.
Other.
Other.
Other.
Other.
Other.
Other.
Other.
Other.
Other.
Other.
Other.Other.Other.Other.Other.Other.
Other.Other.Other.
Other.Other.
Other.
Other.
Other.Other.
Other.Other.
Other.Other.
Other.
Other.
Other.
Other.Other.Other.
Other.Other.
Other"
316,"[/INST]
| Secondary Smoking abst
| Secondary Outcome smoking
| Secondary Outcome smoking
|
Secondary Smoking
|
Secondary Smoking
|
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Secondary Smoking
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second
Second.
Second.
Second
Second
Second
Second.
Second
Second
The
*
*
*
*
*
*
*
*
The
The
The
The
The
The
The
The
*
**
**
**
**
It.
It.
It.
It.
**
**
*
*
==
==*
==
==
==
==
==
==
==
==
==
==
==
==
--------
--------
--------
--------
--------.
--------.
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
Ob
Ob
Ob
==,
==
==
==
==
==
==
==
==
==
==
In
==
==
==
==
**
**
**
This
This
f
f
This
This
This
==
==
==
==
==
==
==
==
==
==
**
**
**
**
**
**
**
**
**
**
R
R
R
R
R
R
R
R
R
R
R
R"
317,"[/INST]


Adverse Events
-----------------

Other: Flipped Classroom Model
| Experimental: Other |


| Course success | 11/12/2023 | Other: Flipped Education Model |
  Experimental: The effect of the Inside Out Education Model on the course success of nursing students. |
  Time Frame: 11/12/2023 | Other: Flipped Education Model |
  Keywords: 11/12/2023 | Other: Flipped Education Model |
  Terms related to the study of nursing students"
318,"[/INST]

Study Drug(s)
| Available as an investigational drug for patients with seizures.
| REMI is an investigational device for ambulatory EEG monitoring of seizure activity.
| Patients must agree to use REMI for a minimum of 90 days.
| REMI is an investigational device for ambulatory EEG monitoring of seizure activity.
| REMI is manufactured by Remi, Inc.
| REMI is an investigational device for prolonged use.
| REMI is an investigational device for ambulatory EEG monitoring of seizure activity.
| REMI is manufactured by Remi, Inc.
| REMI is an investigational device for prolonged use.
| REMI is an investigational device for ambulatory EEG monitoring of seizure activity.
| REMI is an investigational device for prolonged use.
| REMI is an investigational device for ambulatory EEG monitoring of seizure activity.
| REMI is an investigational device for prolonged use.
| REMI is an investigational device for ambulatory EEG monitoring of seizure activity.
| REMI is an investigational device for prolonged use.
| REMI is an investigational device for ambulatory EEG monitoring of seizure activity.
| REMI is an investigational device for prolonged use.
| REMI is an investigational device for ambulatory EEG monitoring of seizure activity.
| REMI is an investigational device for prolonged use.
| REMI is an investigational device for ambulatory EEG monitoring of seizure activity.
| REMI is an investigational device for prolonged use.
| REMI is an investigational device for ambulatory EEG monitoring of seizure activity.
| REMI is an investigational device for prolonged use.
| REMI is an investigational device for ambulatory EEG monitoring of seizure activity.
| REMI is an investigational device for prolonged use.
| REMI is an investigational device for ambulatory EEG monitoring of seizure activity.
| REMI is an investigational device for prolonged use.
| REMI is an investigational device for ambulatory EEG monitoring of seizure activity."
319,"[/INST]

















































,












































































































-





























































































































,
,,,
,
,
,










,
,
,,,
,
























,
,
,
,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,














,
,



















,
,,,,,,,,,,,,,,,,,,







,,,,,,"
320,"[/INST]
| Preoperative fasting time
| Postoperative nausea or vomiting
| Surgical complications
| Length of surgery
| Outcome: Preoperative oral carbohydrate tolerance | Length of surgical stay
| Postoperative complications
| Surgical outcome
| Other: Surgical complications
| Preoperative oral carbohydrate tolerance | Length of surgical stay
| Postoperative complications
| Surgical outcome
| Other: Preoperative oral carbohydrate tolerance | Length of surgical stay
| Postoperative complications
| Surgical outcome
| Other: Preoperative oral carbohydrate tolerance | Length of surgical stay
| Postoperative complications
| Surgical outcome
| Other: Preoperative oral carbohydrate tolerance | Length of surgical stay
| Postoperative complications
| Surgical outcome
| Other: Preoperative oral carbohydrate tolerance | Length of surgical stay
| Postoperative complications
| Surgical outcome
| Other: Preoperative oral carbohydrate tolerance | Length of surgical stay
| Postoperative complications
| Surgical outcome
| Other: Preoperative oral carbohydrate tolerance | Length of surgical stay
| Postoperative complications
| Surgical outcome
| Other: Preoperative oral carbohydrate tolerance | Length of surgical stay
| Postoperative complications
| Surgical outcome
| Other: Preoperative oral carbohydrate tolerance | Length of surgical stay
| Postoperative complications
| Surgical outcome
| Other: Preoperative oral carbohydrate tolerance | Length of surgical stay
| Postoperative complications
| Surgical outcome
| Other: Preoperative oral carbohydrate tolerance | Length of surgical stay
| Postoperative complications
| Surgical outcome
| Other: Preoperative oral carbohydrate tolerance | Length of surgical stay
| Postoperative complications
| Surgical outcome
| Other"
321,"[/INST]

| Keywords: [provided by] [mentored by] [the study conducted at] [the start of the] [mentoring sessions ending at 9 months. |


Other: [provided by] [the study conducted at] [the start of the] [mentoring sessions ending at 9 months when the reinforcement program ends. |


| Other: [provided by] [the study conducted at] [the start of the] [mentoring sessions ending at 9 months when the reinforcement program ends. |



| Other: [provided by] [the study conducted at] [the start of the] [the reinforcement program ending at 9 months when the study conducted by] [the start of the] [the study conducted at the start of the] [the reinforcement ending at 9 months later. |






| Other: [provided by] [the study conducted at the start of the] [the study conducted at the start of the] [the study conducted at the start of the study conducted at the start of the study conducted at the start of the study conducted at the start of the study conducted at the start of the study conducted at the start of the study conducted at the start of the study conducted at the start of the study conducted at the start of the study conducted at the start of the study conducted at the start the study conducted at the start the study conducted at the start the study conducted at the start the study conducted at the start the study conducted at the start the study, the start the study conducted at the start the study, the study conducted the start the study, the study, the study the start the study the start the study the start the study the start the study the start the study the start the study the start the study the start the study the start the study the study the start the study the start the study the start the study the start the start the study the start the study the start the study the start the study the start the start the study the start the start the start the start the start the start the study the start the study the start the study the start the start the start the start the start the start the start the start the start the start the start the start the start the start the start the start the start the start the
The M the start the
The M.
The rate, the
The M."
322,"[/INST]
Adverse events
| Other: virtual reality, ice massage, cervical dilatation, supportive care
| labor pain, ice massage, cervical dilatation, supportive care
| birth satisfaction, ice massage, cervical dilatation, supportive care
| labor pain, ice massage, cervical dilatation, supportive care
| birth satisfaction, ice massage, cervical dilatation, supportive care
| labor pain, ice massage, cervical dilatation, supportive care
| birth satisfaction, ice massage, cervical dilatation, supportive care
| labor pain, ice massage, cervical dilatation, supportive care
| birth satisfaction, ice massage, cervical dilatation, supportive care
| labor pain, ice massage, cervical dilatation, supportive care
| birth satisfaction, ice massage, cervical dilatation, supportive care
| labor pain, ice massage, cervical dilatation, supportive care
| birth satisfaction, ice massage, cervical dilatation, supportive care
| labor pain, ice massage, cervical dilatation, supportive care
| birth satisfaction, ice massage, cervical dilatation, supportive care
| labor pain, ice massage, cervical dilatation, supportive care
| birth satisfaction, ice massage, cervical dilatation, supportive care
| labor pain, ice massage, cervical dilatation, supportive care
| birth satisfaction, ice massage, cervical dilatation, supportive care
| labor pain, ice massage, cervical dilatation, supportive care
| birth satisfaction, ice massage, cervical dilatation, supportive care
| labor pain, ice massage, cervical dilatation, supportive care
| birth satisfaction, ice massage, cervical dilatation, supportive care
| labor pain, ice massage, cervical dilatation, supportive care
| birth satisfaction, ice massage, cervical dilatation, supportive care
| labor pain, ice massage, cervical dilatation, supportive care
| birth satisfaction, ice massage, cervical"
323,"[/INST]

How is the study designed?
| Participant group |
| Have known CMV reactivation prior to transplantation. |
| Willingness to be followed up within 22 months after liver transplantation |
| Children, ages 18-21 |
| Loss to follow-up survey |
| Adults, ages 22-28 |

What is the study measuring?
| Primary Outcome Measures |
| Have known CMV reactivation prior to transplantation. |
| Children, ages 18-21 |
| Adults, ages 22-8 |

How is the study designed?
| Participant group |
| Have known CMV reactivation prior to transplantation. |
| Children, ages 18-21 |
| Adults, ages 22-8 |

What is the study measuring?
| Primary Outcome Measures |
| Have known CMV reactivation prior to transplantation. |
| Children, ages 18-21 |
| Adults, ages 22-8 |

How is the study structured?
| Secondary Outcome Measures |
| Have known CMV reactivation prior to transplantation. |
| Children, ages 18-21 |
| Adults, ages 22-8 |

What is the study designed to measure?
| Primary Outcome Measures |
| Have known CMV reactivation prior to transplantation. |
| Children, ages 18-21 |
| Adults, ages 22-8 |

How is the study structured?
| Secondary Outcome Measures |
| Have known CMV reactivation prior to transplantation. |
| Children, ages 18-21 |
| Adults, ages 22-8 |

What is the study designed to measure?
| Primary Outcome Measures |
| Have known CMV reactivation prior to transplantation. |
| Children, ages 18-21 |
| Adults, ages 22-8 |

How is the study structured"
324,"[/INST]

Prism Adaptation Therapy
-----------------
Primary Purpose: Diagnostic
Intervention Model: Non-randomized
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Spatial neglect, as assessed by the Behavioral Inattention Test-conventional subtest (BIT-c) | This variable (max value 30, min value 0, higher is abnormal) examines the severity of spatial neglect as measured by a functionally-valid assessment, the Behavioral Inattention Test-conventional subtest (BIT-c; min value 146, min value 0, perception needs assessment). Functionally-valid spatial neglect assessments predict independence for activities of daily living, and care needs. | 5 weeks after enrollment | 
Secondary Outcome Measures
-----------------
Prism Adaptation Therapy
-----------------
Primary Purpose: Diagnostic
Intervention Model: Non-randomized
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Spatial neglect, as assessed by the Behavioral Inattention Test-conventional subtest (BIT-c) | This variable (max value 30, min value 0, higher is abnormal) examines the severity of spatial neglect as measured by a functionally-valid assessment, the Behavioral Inattention Test-conventional subtest (BIT-c; min value 146, min value 0, perception needs assessment). Functionally-valid spatial neglect assessments predict independence for activities of daily living, and care needs. | 5 weeks after enrollment | 
Secondary Outcome Measures
Prism Adaptation Therapy
-----------------
Primary Purpose: Diagnostic
Intervention Model: Non-randomized
| Outcome Measure | Measure Description | Time Frame |
| Spatial neglect, as assessed by the Behavioral Inattention Test-conventional subtest (BIT) | This variable (max value 30, min value 146, perception needs assessment. |
Prism Adaptation Therapy
Primary Purpose: Diagnostic
| Spatial neglect, as assessed by the Behavioral Inattention, the severity, and"
325,"[/INST]

Primary Outcome: Glioma, by means of a contrast-enhanced magnetic resonance procedure, and the results of the biopsies taken from patients with this type of tumor.


Secondary Outcome: [/INST]"
326,"[/INST]


















































































































































































































































































































-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-



-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-"
327,"[/INST]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|"
328,"[/INST]
Primary Outcome Measures
-----------------
| Secondary Outcome Measures
| Participants will be enrolled in the study. | Measured by Positron, 6 months. | Baseline, 3 months. | Participants will be enrolled in the study. | Measured by CM-only. | Secondary Outcome Measured. | Participants will be enrolled in the study. | Participants will be enrolled in the study. | Secondary Outcome will be enrolled in the study. | Participants will be enrolled in the study. | Secondary Outcome will be enrolled in the study. | Secondary Outcome will be enrolled in the study. | Secondary Outcome will be enrolled in the study. | Secondary Outcome will be enrolled in the study. | Secondary Outcome will be enrolled in the study. | Secondary Outcome will be enrolled in the study. | Secondary Outcome will be enrolled in the study. | Secondary Outcome will be enrolled in the study. | Secondary Outcome will be enrolled in the study. Secondary Outcome will be enrolled in the Secondary Outcome will be enrolled in the study. | Secondary Outcome will be enrolled in the study. | Secondary Outcome will be enrolled in the study. Secondary. | Secondary. Secondary.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
== ->
==
==
==
== //
== //
== //"
329,"[/INST]
The clin-with a   
The clinical   0, with a   1, the
The treatment.
The treatment.
The treatment.
The treatment.
The treatment.
The treatment
The treatment
The treatment.
The treatment.
The   ........
The   ........
The   
The   
The   
The   ........
The   ........
It   ........
It.
It.
It.
It.
The
The
The
The
The   
The   
The   
The   
The   
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
This
This
The
This
This
This
This
This
This
and
with
and
This
A
A
A
A
H
This
This
This
This
This
This
This
This
This
This
H
This
This
P
















































f
f
f
f




f

f



































































f


















f
f
f
f
f
f
f
f
f"
330,"[/INST]
This
This
This
This
This
This
The
The
The
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The






















































































































































































































































































































































8"
331,"[/INST]

Other: [/INST]

Data related to the study
| Data related to the air traps |
| Data related to the patient |
| Data related to the venous air trap |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |
| Data related to the patient |
| Data related to the air traps |"
332,"[/INST]
1.
1.
1.
1.
1.
1.
1.
2.
1.
2.
2.
2.
2.
2.
2.
2.
2.
2.
2.
3.
3.
This will
This is
This is
This is
This is
This will
4.
This is
This is
4.
This is
The
4.
This will
This will
This will
This
This
This
This
This will
This will
This will
This will
This
This
This
This
The
The
The
The
The
The
The
The
The
The
The
The
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This
==
This
This.
This.
This.
This.
This.
====.
In.
In.
In.
In.
In.
In.
In.
In.
In.
In.
In.
In.
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
This
In
This
This
This
This
In
In
In
In
In
In
In
In
In
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
333,"[/INST]
Pancreatic transverse section, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the pancreatic duct, pancreatic duct exploration and the"
334,"[/INST]
| Aging, Physical activities, Functional capacity, Physical fitness, Physical training, Exercise, Strength training, Healthy diet, Balanced diet, Nutrition, Physical therapy, Rehabilitation, Seniors, Geriatrics, Seniors' physical condition, Physical rehabilitation, Physical reconditioning, Physical fitness, Physical training, Physical therapy, Rehabilitation, Seniors' physical condition, Physical reconditioning, Geriatrics, Healthy diet, Balanced diet, Nutrition, Physical activities, Physical training, Physical rehabilitation, Seniors' physical condition, Physical therapy, Physical reconditioning, Geriatrics, Healthy diet, Seniors, Physical training, Physical rehabilitation, Physical therapy, Balanced diet, Nutrition, Seniors' physical condition, Physical reconditioning, Geriatrics, Healthy diet, Physical training, Physical rehabilitation, Seniors' physical condition, Balanced diet, Physical therapy, Physical rehabilitation, Geriatrics, Healthy diet, Physical training, Physical reconditioning, Seniors' physical condition, Balanced diet, Physical therapy, Physical rehabilitation, Geriatrics, Healthy diet, Physical training, Physical reconditioning, Seniors' physical condition, Balanced diet, Physical therapy, Physical rehabilitation, Geriatrics, Healthy diet, Physical training, Physical reconditioning, Seniors' physical condition, Balanced diet, Physical therapy, Physical rehabilitation, Geriatrics, Healthy diet, Physical training, Physical reconditioning, Seniors' physical condition, Balanced diet, Physical therapy, Physical rehabilitation, Geriatrics, Healthy diet, Physical training, Physical reconditioning, Seniors' physical condition, Balanced diet, Physical therapy, Physical rehabilitation, Geriatrics, Healthy diet, Physical training, Physical reconditioning, Seniors' physical condition, Balanced diet, Physical therapy, Physical rehabilitation, Geriatrics,"
335,"[/INST]

Primary Purpose: Prevention
-----------------
Participants in the control group will receive usual care. | At either the end of the fourteen-day period or when the patient is discharged from the Intensive Care Unit (ICU), whichever comes first; through study completion, an average of 6 month |"
336,"[/INST]

| Other names: surgical fixation | intervention

| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention
| thoracic pain |
| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention
| thoracic pain |
| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention
| thoracic pain |
| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention
| thoracic pain |
| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention
| thoracic pain |
| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention
| thoracic pain |
| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention
| thoracic pain |
| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention
| thoracic pain |
| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention
| thoracic pain |
| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention
| thoracic pain |
| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention
| thoracic pain |
| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention
| thoracic pain |
| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention
| thoracic pain |
| Procedure: surgical fixation of multiple fractured ribs |
| Other names: surgical ventilation | intervention"
337,"[/INST]

Secondary Outcome Measures

Behavioral: [Participant Group] | --- | Behavioral: TSST<br>* Participants randomized to the TSST will be exposed to a traditional psychological stress test consisting of a 5-minute preparation phase (immediately after acute psychological stress and 60 minutes after the test) | Change from 5 minutes pre to peak stress test (STAI-S) using a telemetric scale. |
| Salivary cortisol (sAA) | Changes in the concentration of free salivary alpha amylase (SAA) before and after the stress test using ELISA. |
| Heart rate | Continuous measurement of heart rate will be assessed using a telemetric chest strap. |
| State anxiety | assessed using the state scale of the STAI-S, consisting of a 20-item scale for measuring the intensity of anxiety as an emotional state (STAI-S) |
| Salivary cortisol (sAA) | Change from 5 minutes pre to peak stress test (STAI-S) using a telemetric scale. |
| Change from 30 minutes pre to 60 minutes after the stress test using a telemetric chest strap. |

Primary Outcome Measures
-----------------

Secondary Outcome Measures
| --- | --- |
| State anxiety inventory (STAI-S) using the Yale-Brown scale |
| Salivary cortisol (sAA) | Change from 5 minutes pre to peak stress test (STAI-S) using a telemetric chest strap. |
| Heart rate | Continuous measurement of heart rate will be assessed using a telemetric chest strap. |
| Salivary alpha amylase (sAA) | Change from 30 minutes pre to peak stress test (STAI-S) using a telemetric chest strap. |
| State anxiety | assessed using the state scale of the STAI-S, consisting of a 20-item scale for measuring the intensity of anxiety as an emotional state (STAI-S) |
| Salivary cortisol"
338,"[/INST]






























































































































































































































































































-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-









-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-



-
-








-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-"
339,"[/INST]

Virtual reality therapy, Sickle Cell Crisis and time study team will interact with the patient is estimated to be 30 minutes.

Primary Outcome Measure
Virtual reality therapy, Sickle Cell Crisis and time study team will interact with the patient is estimated to be 30 minutes.
Secondary Outcome Measure
Virtual reality therapy, Sickle Cell Crisis and time study team will interact with the patient is estimated to be 30 minutes.
Primary Outcome Measure
Virtual reality therapy, Sickle Cell Crisis and time study team will interact with the patient is estimated to be 30 minutes.
Secondary Outcome Measure
Virtual reality therapy, Sickle Cell Crisis and time study team will interact with the patient is estimated to be 30 minutes."
340,"[/INST]
The
The
The
The
The
The
The
The
The
The
S"
341,"[/INST]

Primary Purpose: Diagnostic
Interventional Model: Butterfly IQ, Pocket sized ultrasound exam of both elbows, Pediatric elbow fracture, negative and positive X-ray
Secondary Purpose: Butterfly IQ, Pocket sized ultrasound of both elbows, negative and acceptability of pediatric elbow fracture, positive and negative X-ray
Primary Purpose: Diagnostic
Interventional Model: Pocket sized ultrasound exam of both elbows, negative and acceptability of pediatric elbow fracture, positive and negative X-ray
Secondary Purpose: Butterfly IQ, Pocket sized ultrasound of both elbows, negative and acceptability of pediatric elbow fracture, positive and negative X-ray
Primary Purpose: Diagnostic
Interventional Model: Pocket sized ultrasound exam of both elbows, negative and acceptability of pediatric elbow fracture, positive and negative X-ray
Secondary Purpose: Butterfly IQ, Pocket sized ultrasound of both elbows, negative and acceptability of pediatric elbow fracture, positive and negative X-ray
Primary Purpose: Diagnostic
Interventional Model: Pocket sized ultrasound exam of both elbows, negative and acceptability of pediatric elbow fracture, positive and negative X-ray
Secondary Purpose: Butterfly IQ, Pocket sized ultrasound of both elbows, negative and acceptability of pediatric elbow fracture, positive and negative X-ray
Primary Purpose: Diagnostic
Interventional Model: Pocket sized ultrasound exam of both elbows, negative and acceptability of pediatric elbow fracture, positive and negative X-ray
Secondary Purpose: Butterfly IQ, Pocket sized ultrasound of both elbows, negative and acceptability of pediatric elbow fracture, positive and negative X-ray
Primary Purpose: Diagnostic
Interventional Model: Pocket sized ultrasound exam of both elbows, negative and acceptability of pediatric elbow fracture, positive and negative X-ray
Secondary"
342,"[/INST]-a-a-a-a-a-a-a-f-f-a-f-a-a-a-a-a-a-a-a-a-a-a-a-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-a-
-
-
-
-
-
-
-
-f-f-f-f-f-f-a-f-f-f-f-f-f-f-f-f-f-f-f-re-s-s a-s-s-re-re-re-re-f-re-f-ch-s-s a-s-f-f-f-f-s-s a-s-f-re-re-7-a-a-a-f-f-8-8-8-a-a-8-a-a-a-8-f-f-f-f-f-f-f-f-a-a-a-a-a-a-a-f-f-f-f-7-f-f-f-7-7-7-f-f-f-m-m-m-m-f-f-f-f-f-f-st-st-st-f-f-f-re-f-st-st-7-7-7-7-e-e-e-8-8-7-7-7-ch-7-7-c-8-p-f-8-7-7-re-re-re-7-7-7-7-e-e-f-m-8-8-8-f-f-e-8-e-e-e-e-e-e-e-e-e-e-e-e-e-e-8-8-8- an- an- an- an- an an an an an an an an an an an an an an an-8- an--------8-7-7-7-7- an-7-A-7------------------------"
343,"[/INST]

Procedure: Pharyngeal flap

How is the surgery performed?
-----------------
Velopharyngeal insufficiency, Speech function will be evaluated through parent- and child-reported outcome measures.
| Procedure: Pharyngeal flap

How is the surgery performed?
-----------------
Speech function in children | Parents of children with velopharyngeal insufficiency

How is the surgery performed?
-----------------
Speech function in children | Parents of children with velopharyngeal insufficiency

How is the surgery performed?
| Procedure: Pharyngeal flap

How is the surgery performed?
| Children with velopharyngeal insufficiency | Parents of children with cleft palate

How is the surgery performed?
| Procedure: Pharyngeal flap

How is the surgery performed?
| Children with velopharyngeal insufficiency | Parents of children with cleft palate

How is the surgery performed?
| Procedure: Pharyngeal flap

How is the surgery performed?
| Children with velopharyngeal insufficiency | Parents of children with cleft palate

How is the surgery performed?
| Procedure: Pharyngeal flap

How is the surgery performed?
| Children with velopharyngeal insufficiency | Parents of children with cleft palate

How is the surgery performed?
| Procedure: Pharyngeal flap

How is the surgery performed?
| Children with velopharyngeal insufficiency | Parents of children with cleft palate

How is the surgery performed?
| Procedure: Pharyngeal flap

How is the surgery performed?
| Children with velopharyngeal insufficiency | Parents of children with cleft palate

How is the surgery performed?
| Procedure: Pharyngeal flap

How is the surgery performed?
| Children with velopharyngeal insufficiency | Parents of children with cleft palate"
344,[/INST]0000uliteululululiteuliteuliteuliteuliteuliteulite0000000000ululululul0000000000000000000000000000000000000000000000000000000000000000000ulululululiteuliteuliteuliteuliteuliteulululululululul00000000ululululululightulululululululululululululululululululululululululululululululululululilililulululililulululululightilililightilightililiteiliteilililiteiliteilululomedayrdululululululululululululululululululululululomeilililililomeilightilightilightonicledayilitedayobulobulobulobobilobulululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululululightulightililululululululululululululululululululululightulightulululululight000000000ululululululululululululululululul0000ulululululululululululululightulightulightulightulightulightulightulightulightulululightulululululululululululightulightulululululululululululululululululululululul
345,"[/INST]
Primary Outcome Measure
| Vaginal cuff dehiscence | Days after surgery | 
| Vaginal cuff complications | 90 days after surgery | 
| Sexual function | Days after surgery | 
| Hospital stay | 
Secondary Outcome Measure
| Vaginal cuff dehiscence | Days after surgery | 
| Vaginal cuff complications | 90 days after surgery | 
| Sexual function | Days after surgery | 
| Hospital stay |
| Vaginal cuff complications | 
| Vaginal cuff dehiscence | 90 days after surgery | 
| Sexual function | Days after surgery | 
| Vaginal cuff complications | 
| Hospital stay |
| Vaginal cuff dehiscence | 
| Sexual function | Days after surgery | 
| Vaginal cuff complications | 
| Hospital stay |
| Vaginal cuff dehiscence | 
| Sexual function | Days after surgery | 
| Vaginal cuff complications | 
| Hospital stay |
| Vaginal cuff dehiscence | 
| Sexual function | Days after surgery | 
| Vaginal cuff complications | 
| Hospital stay |
| Vaginal cuff dehiscence | 
| Sexual function | Days after surgery | 
| Vaginal cuff complications | 
| Hospital stay |
| Vaginal cuff dehiscence | 
| Sexual function | Days after surgery | 
| Vaginal cuff complications | 
| Hospital stay |
| Vaginal cuff dehiscence | 
| Sexual function | Days after surgery | 
| Vaginal cuff complications | 
| Hospital stay |
| Vaginal cuff dehiscence | 
| Sexual function | Days after surgery | 
| Vaginal cuff complications | 
| Hospital stay |
| Vaginal cuff dehiscence | 
| Sexual function | Days after surgery | 
| Vaginal cuff complications | 
| Hospital stay |
|"
346,"[/INST]
Other: gambling addiction, fMRI, amygdala, emotional states, DSM-5, problem, EMA, gambling behavior, striatal response, BOLD, facial recognition, emotional stimuli, amygdala response, problem gambling, DSM-5, EMA, gambling behavior, amygdala, emotional states, problem, fMRI, gambling addiction, striatal response, EMA, facial recognition, amygdala, gambling behavior, DSM-5, problem, EMA, emotional states, amygdala response, gambling behavior, striatal response, facial recognition, amygdala, gambling addiction, DSM-5, EMA, emotional states, gambling behavior, amygdala response, facial recognition, gambling addiction, DSM-5, EMA, emotional states, amygdala response, gambling behavior, facial recognition, DSM-5, gambling addiction, amygdala response, EMA, emotional states, gambling behavior, striatal response, facial recognition, amygdala, gambling addiction, EMA, emotional states, gambling behavior, amygdala response, facial recognition, gambling addiction, DSM-5, gambling behavior, EMA, emotional states, gambling behavior, gambling, facial recognition, gambling, gambling, and the investigators, gambling behavior, gambling, facial recognition, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, facial recognition, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling, gambling,"
347,"[/INST]
Primary Purpose: To measure the effect of the study.
| Secondary Outcome Measures |
What is the study measuring?
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Outcome of the study |

What is the study measuring?
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Outcome of the study |

What is the study measuring?
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Outcome of the study |

What is the study measuring?
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Outcome of the study |

What is the study measuring?
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Outcome of the study |

What is the study measuring?
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Outcome of the study |

What is the study measuring?
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Outcome of the study |

What is the study measuring?
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Outcome of the study |

What is the study measuring?
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Outcome of the study |

What is the study measuring?
| Outcome Me"
348,"[/INST]

Secondary Objectives

Participant Group
| --- | --- |
| 1-year progression-free survival | the time from study entry to the time of disease progression as determined by the investigator (by clinical, radiological or pathological means) | 
| 1-year from start of treatment | 
| Quality of life score | the time from study entry to the time of disease progression as determined by the investigator (by clinical, radiological or pathological means) | Every 3 month until 2 years from start of treatment | 
| the Rates of AE and SAE | Frequency of adverse events according to the investigator's assessment, and the time of death | 


Secondary Outcome Measures

| --- | --- |
| 1-year progression-free survival | the time from study entry to the time of disease progression as determined by the investigator (by clinical, radiological or pathological means) | 
| Quality of life score | Observed length of life from start of treatment | Every 3 month until 2 years from start of treatment | 



Secondary Outcome Measures

| --- | --- |
| 1-year progression-free survival | the time from study entry to the time of disease progression as determined by the investigator (by clinical, radiological or pathological means) | Every 3 month until 2 years from start of treatment | 
| Quality of life score | Observed length of life from start of treatment |"
349,"[/INST]

Adverse Events
-----------------
Related Studies
-----------------
Study Design
-----------------
Study Population / Eligible Patients
-----------------
Study Intervention
Study Comparators
Study Outcome
Study Intervention
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Study Design
Study Population / Eligible Patients
Study Intervention
Study Outcome
Stud"
350,"[/INST]
Behavioral: [INST] Exercise program lasted for 5 days, PRE was similar to the HIE program, pain severity was assessed using a visual analogue scale, maintaining a range between 6 and 20 RPE (16).
Primary Intervention: [INST] High Intensity Exercises program lasted for 5 days, pain severity was assessed using a visual analogue scale, maintaining a range between 6 and 20 RPE (16).
Secondary Outcome Measure: [INST] High Intensity Exercises program lasted for 5 days, pain severity was assessed using a visual analogue scale, maintaining a range between 6 and 20 RPE (16).
Behavioral: [INST] Exercise program lasted for 5 days, pain severity was assessed using a visual analogue scale, maintaining a range between 6 and 20 RPE (16).
Exercise intensity was similar to the HIE program, pain severity was assessed using a visual analogue scale, maintaining a range between 6 and 20 RPE (16).
Behavioral: [INST] Exercise program lasted for 5 days, pain severity was assessed using a visual analogue scale, maintaining a range between 6 and 20 RPE (16).
Secondary Outcome Measure: [INST] High Intensity Exercises program lasted for 5 days, pain severity was assessed using a visual analogue scale, maintaining a range between 6 and 20 RPE (16).
Behavioral: [INST] Exercise program lasted for 5 days, pain severity was assessed using a visual analogue scale, maintaining a range between 6 and 20 RPE (16).
Primary Intervention: [INST] High Intensity Exercises program lasted for 5 days, pain severity was assessed using a visual analogue scale, maintaining a range between 6 and 20 RPE (16).
Secondary Outcome Measure: [INST] Exercise program lasted for 5 days, pain severity was assessed using a visual analogue scale, maintaining a range between 6 and 2"
351,"[/INST]
| What is the study measuring?
| How is the study designed?
| What are the study's primary and secondary outcome measures?
| How are the study's primary and secondary outcome measures related to the
| Intervention's primary and secondary outcome measures?
| What is the study's primary and secondary outcome measures?
| How are the study's primary and secondary outcome measures related to
| the Intervention's primary and secondary outcome measures?
| How are the study's primary and secondary outcome measures related to
| the Intervention's primary and secondary outcome measures?
| What is the study's primary and secondary outcome measures?
| How are the study's primary and secondary outcome measures related to
| the Intervention's primary and secondary outcome measures?
| What is the study's primary and secondary outcome measures?
| How are the study's primary and secondary outcome measures related to
| the Intervention's primary and secondary outcome measures?
| What is the study's primary and secondary outcome measures?
| How are the study's primary and secondary outcome measures related to
| the Intervention's primary and secondary outcome measures?
| What is the study's primary and secondary outcome measures?
| How are the study's primary and secondary outcome measures related to
| the Intervention's primary and secondary outcome measures?
| What is the study's primary and secondary outcome measures?
| How are the study's primary and secondary outcome measures related to
| the Intervention's primary and secondary outcome measures?
| What is the study's primary and secondary outcome measures?
| How are the study's primary and secondary outcome measures related to
| the Intervention's primary and secondary outcome measures?
| What is the study's primary and secondary outcome measures?
| How are the study's primary and secondary outcome measures related to
| the Intervention's primary and secondary outcome measures?
| What is the study's primary and secondary outcome measures?
| How are the study's primary and secondary outcome measures related to
| the Intervention's primary and secondary outcome measures?
| What is the study's primary and secondary outcome measures?
| How are the study's primary and secondary outcome measures related to
| the Intervention's primary and secondary outcome measures?
| What is the"
352,"[/INST],,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, the, the -A A, A, A,,,,,,,,,,,,,,,,,-p-p-p-p-p-p-p-O,,,,,,,,,,,,,, the,,,,,,,,,,,,,,,,,,,,-p-p-p-p-M,,,,-M-M-M-M,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, the, the, the the the the the, the, the,,,,,,,,,,,,,,,, the, the, the, the, the,,,,,,,,,,,-M-M-M,,, the, the,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-M-M-M-M-M,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,.,.,.,.,,,,,,,,,,,,,,,,,,,,"
353,"[/INST]
| Diagnostic Test: Magnesium |
| Diabetes Mellitus |
| Type 2 Diabetes Mellitus |
| Patients on Mg supplementation |
| Diabetes Controlled with Mg |
| Renal failure patients |
| Diabetes Controlled with Mg |
| Type 2 Diabetes Mellitus |
| Diabetes Controlled with Mg |
| Renal failure patients |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |
| Diabetes Controlled with Mg |"
354,"[/INST]

How is the study designed?
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophiochepalus striatus extract
| Designed by: Ophio"
355,"[/INST]

Chronic Pain Feasibility Study
-----------------
| Primary Purpose: Treatment | Intervention Model: Parallel Group |
| Secondary Outcome Measure | Treatment as usual |
| Pain Function | Intervention as usual |
| Patient Health Questionnaire 9 (GAD) | will be measured at baseline, 1 month, 3 months, and 6 months after enrollment (and start of intervention in the intervention arm) | 
| Generalized anxiety symptom measure; scores range from 0-21 | will be measured at baseline, 1 month, 3 months, and 6 months after enrollment (and start of intervention in the intervention arm) | 

Secondary Outcome Measures
| Pain Function | Intervention as usual |
| Patient Health Questionnaire 9 (GAD) | will be measured at baseline, 1 month, 3 months, and 6 months after enrollment (and start of intervention in the intervention arm) | 

Chronic Pain Feasibility Study
-----------------
| Primary Purpose: Treatment | Intervention Model: Parallel Group |
| Pain Function | will be measured at baseline, 1 month, 3 months, and 6 months after enrollment (and start of intervention in the intervention arm) | 
| Patient Health Questionnaire 9 (GAD) | will be measured at baseline, 1 month, 3 months, and 6 months after enrollment (and start of intervention in the intervention arm) | 

Secondary Outcome Measures
| Pain symptom measure; scores range from 0-21 | will be measured at baseline, 1 month, 3 months, and 6 months after enrollment (and start of intervention in the intervention arm) | 

Chronic Pain Feasibility Study
-----------------
| Primary Purpose: Treatment | Intervention Model: Parallel |
| Pain Function | will be measured at baseline, 1 month, 3 months, and 6 months after enrollment (and start of intervention in the intervention arm) | 

Secondary Outcome Measures
| Pain symptom measure; scores range"
356,"[/INST]

* Preoperative complications: Robot assisted radical cystectomy with mono J ureteral stent placement<br>Postoperative complications: FloRIN<br>Treatment of bladder tumor with/without ureteral mono J stent placement<br>Preoperative complications: Robot assisted radical cystectomy with/without ureteral mono J stent placement<br>Postoperative complications: FloRIN<br>Treatment of bladder tumor with/without ureteral mono J stent placement<br>Preoperative complications: Robot assisted radical cystectomy with/without ureteral mono J stent placement<br>


How is the study designed?
| Design Type: Parallel Assignment | Design Unit: FloRIN<br>Treatment of bladder tumor with/without ureteral mono J stent placement<br>

How is the study conducted?
| Conduct Type: Parallel Assignment | Conducted by: FloRIN<br>Treatment of bladder tumor with/without ureteral mono J stent placement<br>

How are the study results analyzed?
| Analysis Type: Parallel Assignment | Analysis Unit: FloRIN<br>Treatment of bladder tumor with/without ureteral mono J stent placement<br>

What are the risks or potential complications?
| Risks: FloRIN<br>Treatment of bladder tumor with/without ureteral mono J stent placement<br>

What are the study results compared with?
| Comparison: FloRIN<br>Treatment of bladder tumor with/without ureteral mono J stent placement<br>

How are the study results generalizable to other similar conditions or diseases?
| Generalizability Type: FloRIN<br>Treatment of bladder tumor with/without ureteral mono J stent placement<br>

Who is the study designed for?
| Eligibility"
357,"[/INST]
This
This
This
This
This
This
This
This
This
This
This
This
This.
This.
This
This
This
This
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
The
This
This
This
This
This
This
This
This
This
This
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
A
A
A
This
This
This
This
This
This
This
This
This
A
A
A
The
The
The
The
This
This
This
This
This
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
The
The
The
The
The
The
A
A
A
A
A
A
A
A
A
A

































































































































the
the
the
the
the
st
st
st"
358,"[/INST]
be
be
be
be
be
be
be
be
be
be
be
be
be
be
be
be
be
be
C
C
C















--------
--------
C
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
--------
be
--------
--------
--------
C
C
C
C
C
C
C
A
A
A
A
A
A
A
A


















C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
A
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C









C
C
C
C
C
C
C
C



C
C
C
C
C

















C
be
A
A
be
be
be
C
C
C
C





be
C






C
C



C
C
C
C
C
C
C
C
A
A
A
A"
359,"[/INST]
| Inclusion Criteria | Exclusion Criteria |
| Primary Outcome Measure | Secondary Outcome Measure | Tertiary Outcome Measure |
| 6 hours | 
| Dietary Supplement: 1,3-Butanediol | 6 hours | 
| Secondary Outcome Measure | 6 hours | 
| Dietary Supplement: 1,3-Butanediol | 6 hours | 
| Stroke volume | 6 hours | 
| Dietary Supplement: 1,3-Butanediol | 6 hours | 
| Secondary Outcome Measure | 6 hours | 
| Dietary Supplement: 1,3-Butanediol | 6 hours | 
| Stroke volume | 6 hours | 
| Dietary Supplement: 1,3-Butanediol | 6 hours | 
| Secondary Outcome Measure | 6 hours | 
| Dietary Supplement: 1,3-Butanediol | 6 hours | 
| Stroke volume | 6 hours | 
| Dietary Supplement: 1,3-Butanediol | 6 hours | 
| Secondary Outcome Measure | 6 hours | 
| Dietary Supplement: 1,3-Butanediol | 6 hours | 
| Stroke volume | 6 hours | 
| Dietary Supplement: 1,3-Butanediol | 6 hours | 
| Secondary Outcome Measure | 6 hours | 
| Dietary Supplement: 1,3-Butanediol | 6 hours | 
| Secondary Outcome Measure | 6 hours | 
| Dietary Supplement: 1,3-Butanediol | 6 hours | 
| Secondary Outcome Measure | 6 hours | 
| Dietary Supplement: 1,3-Butanediol | 6 hours | 
| Secondary Outcome Measure | 6 hours | 
| Dietary Supplement: 1,3-Butanediol | 6 hours | 
| Secondary Outcome Measure | 6 hours | 
| Dietary Supplement: 1,3-But"
360,"[/INST]
macromastia, pain management

Other Terms: [/INST]
Keywords: [INST]
macromastia, pain management
Other Terms: [INST]
macromastia, pain management
Keywords: [INST]
macromastia, pain management
Other Terms: [INST]
macromastia, pain management
macromastia, pain management
Other Terms: [INST]
macromastia, pain management
macastia, pain management
macromastia, pain management
Other Terms: [INST]
macromastia, pain management
macastia, pain management
macastia, pain management
Other Terms: [INST]
macromastia, pain management
macia, pain management
macromastia, pain management
macrine, pain management
Other Terms: [INST]
macromastia, pain management
macromastia, pain management
macromastia, pain management
Other Terms: [INST macromastia, pain management
macrine, pain management
macromastia, pain management
Other Terms: [INST macromastia, pain management
macromastia, pain management. Other Terms: [INST macromacine, pain management.
Other Terms: macromacine, pain management.
Other Termin macromacine, pain management.
Other Termin, macromastine, pain management.
Other Terms: macroma, pain management.
Other Terms: macroma.
Other Termin, pain management.
Other Termin, macromaxim, pain management.
Other Terms: Other pain management.
Other Terms: macromel.
Other Terms: Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain management.
Other pain.
The pain.
Other pain.
Other pain."
361,[/INST]
362,"[/INST]
| Infertility |
| Treatment Group |
| Inclusion / Exclusion Criteria |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment Group |
| Treatment"
363,"[/INST]
-
-
-
-
-
-
-
-A
-
-
-
-
-
-
-
-
-

-
-
-
-
-
O
O

















O
O
P
P
CT
CT
CT
P
P
A
A
A
A
A
A
A
P
CT
CT
CT
CT
O
O
P
P
P
O
P
P
P
P
P
P
P
P
P
P
P
A


P














P
O

O
O
O
A
A
P
P
P
P
O
P
O"
364,"[/INST]
A
A
A
The
The
The
The
The
The
The
The
The
The
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
The
The
The
The
The
The
The
The
The
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A







































































A
be




















A
A
A
A
A
A
A
A
A
A
A-
A
A
A
A
A-
A-
A-
A-
A
A
A
A-
A
A-
A-
A
A:
A-
A-
A-
A-
A-
A-
A-
-
A-
-
-
-
-
-
-
-
8-
8-
-
-
-
-
-
-a-a-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-a-a-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-"
365,[/INST]-a-f-C-C-C-C-C-C-C---C-C-C-C-C--C---C- -------------------------- -- -- ------f--f-f-f- --C--------- -----f-y-f-f- -- -- -- -- ---------f--f-f-re-re-re-C-C-----C-a-p--p-p-a-a-a-C-a-C-a-a-a-a-a-C-C-C-C-C-C-C-C-C-a-a-a-a-f-f-a-a-C-C-a-a-a-a-a-a-a-a-a-a-a---C-C-C-C-a-C-C-C-C-a-a-C-C-C-a-a-a-a-a-a-a-a-a-a-a-a-a-a-C-a-C-C-a-f-f-a-a-a-a-a-a-a-a-C-a-a-a-a-a-s-a-a-a-a-a-C-C-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-s-C-C-C-C-C-a-a-a-a-a-a-a-a-a-a-s-a-a-A-a-a-a-a-a-a-a-a-a-a-a-a-a-C-a-a-a-a-a-a-s-s-s-a-a-a-a-a-a-a-a-a-s-s-s-s-s-a-a-a
366,"[/INST]
This
This
This
This
The
The
The
The
The
The
The
This
This
This
This
This
This
This
This
The
The
This
This
This
This
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The











































































A
A
A"
367,"[/INST]
Other related words:
Cognitive decline, Cognitive functioning

Primary Outcome Measure
-----------------
| Other: Quality of Life Surveys, Cognitive functioning
Secondary Outcome Measure
-----------------
| Other: Quality of Life Surveys, Cognitive functioning
Primary Outcome Measure
-----------------
| Other: Quality of Life Surveys, Cognitive functioning
Secondary Outcome Measure
-----------------
| Other: Quality of Life Surveys, Cognitive functioning
Primary Outcome Measure
-----------------
| Other: Quality of Life Surveys, Cognitive functioning
Primary Outcome Measure
-----------------
| Other: Quality of Life Surveys, Cognitive functioning
Primary Outcome Measure
| Other: Quality of Life Surveys, Cognitive functioning
Primary Outcome
| Other: Quality of Life Surveys, Cognitive functioning
Primary Outcome
| Other: Quality of Life Surveys, Cognitive functioning
Primary Outcome: Quality of Life Surveys, Cognitive functioning
Primary Outcome: Quality of Life Surveys, Cognitive functioning
Primary Outcome: Quality of Life Surveys, Cognitive functioning
Primary Outcome: Quality of Life Surveys, Cognitive functioning
Primary Outcome: Quality of Life Surveys, Cognitive functioning
Primary Outcome: Quality of life.
Primary Outcome Quality of the quality of life.
Primary Outcome Quality of the cognitive functioning.
Primary Outcome. Primary Outcome Quality of the quality of life. Primary Outcome. Primary Outcome.
Primary Outcome.
Primary Outcome.
Primary Outcome.
Primary Outcome. Primary Outcome Quality of the quality of the quality. Primary Outcome.
Primary Outcome. Primary Outcome. Primary Outcome.
Primary Outcome.
Primary Outcome. Primary Outcome. Primary Outcome. Primary Outcome. Primary Outcome. Primary Outcome.
Primary Outcome. Primary Outcome. Primary Outcome.
Primary Outcome. Primary Outcome.
Primary Outcome.
Primary Outcome.
Primary Outcome.
Primary Outcome."
368,"[/INST]
It.
It
It.
It
It
It
It
It
It
It
It
It
It
It
The
It
It
It
It
It
It
It
It
It
It
In
The
The
It
It
It
This
This
This
It
by
by
by
It
The
The
The
The
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
The
The
The
The
The
The
The
This
The
The
The
The
The
The





This.
p
p.
This
This
This
This
This
p"
369,"[/INST]

How is the study designed?
-----------------
Primary Purpose: To measure health literacy in children with type 1 diabetes.
Secondary Purpose: To measure the effect of the intervention on health literacy in children with type 1 diabetes.
Tertiary Purpose: To measure the impact of the intervention on the acute complications of diabetes in children.
Quaternary Purpose: To measure the impact of the intervention on the health literacy of children with type 1 diabetes.
| Eligibility Criteria: Children with type 1 diabetes aged 8-12 years.
| Interventions: The first interview will be carried out with the children and their parents. The data will be collected at the beginning of the study and 4 weeks after the training. The Literacy Scale for Acute Complications of Diabetes for Children with type 1 diabetes (8-12 years) will be applied to the participants at the first meeting and the final evaluation will be carried out by experts.
| Outcome Measures: The data will be collected at the beginning of the study and 4 weeks after the training.
| Keywords: Health Literacy, Diabetes, Board Game, Children with type 1 diabetes.
| Evaluation: The data will be collected at the beginning of the study and 4 weeks after the training.
| Secondary Outcome Measures: Diabetes health literacy in children with type 1 diabetes.
| Eligibility Criteria: Children with type 1 diabetes aged 8-12 years.
| Interventions: The first interview will be carried out with the children and the Literacy Scale for Acute Complications of Diabetes for Children with type 1 diabetes (8-12 years) will be applied to the participants at the beginning and 4 weeks after the training.
| Primary Purpose: To measure the impact of the intervention on health literacy in children with type 1 diabetes.
| Secondary Outcome Measures: Diabetes health literacy in children with type 1 diabetes aged 8-12 years.
| Eligibility Criteria: Children with type 1 diabetes aged 8-12 years.
| Interventions:"
370,"[/INST]
The (the clinic surge.
The (the clinic.
The months after the clinic surge.
The (the patients.
The clinic.
The clinic.
The clinic.
The clinic.
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
The clinic.
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
The.
The.
The.
The.
The.
The
The
The patients.
The patient.
The
The
in
in
in
in
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The patient.
The patient.
The.
The.
The.
The.
The clinical
The
==
==
==
==
The
The
In
It
It
The
In
The
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
The
==
==
The
The
The
The
In
The
In
In
In
In
The
The
This
The
The
The
The
The
The
In
In
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
in
in
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
The
The
The
The
This
==
==
==
==
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
C
This
This
C
C
This
This
This
This
C
C
C






















C
C
C
C
C
C
C
C
C
C"
371,"[/INST]

Primary Outcome: Rosemary

Study Design: [/INST]

Inclusion / Exclusion Criteria
-----------------
How is the study designed?
| Primary Outcome: Rosemary
| Secondary Outcome: Frankincense
| tertiary Outcome: no data available |
| Eligibility Criteria: Rosemary
| Inclusion / Exclusion Criteria: Frankincense
| Secondary Outcome: pain level, before procedure, during procedure extraction and immediately after procedure extraction |
| Primary Outcome: Rosemary
| Secondary Outcome: Frankincense
| Eligibility Criteria: Rosemary
| Inclusion / Exclusion Criteria: Frankincense
| pain level, before procedure, during procedure extraction and immediately after procedure extraction and immediately before the procedure of a primary molar |
| Eligibility Criteria: Rosemary
| pain level, before procedure, during procedure extraction and immediately after procedure extraction and immediately before the procedure of a primary molar |
| Inclusion / Exclusion Criteria: Rosemary
| pain level, before procedure, during procedure extraction and immediately after procedure extraction and immediately before the procedure of a primary molar |
| Eligibility Criteria: Rosemary
| pain level, before procedure, during procedure extraction and immediately after procedure extraction and immediately before the procedure of a primary molar |
| Inclusion / Exclusion Criteria: Rosemary
| pain level, before procedure, during procedure extraction and immediately after procedure extraction and immediately before the procedure of a primary molar |
| Eligibility Criteria: Rosemary
| pain level, before procedure, during procedure extraction and immediately after procedure extraction and immediately before the procedure of a primary molar |
| Inclusion / Exclusion Criteria: Rosemary
| pain level, before procedure, during procedure extraction and immediately after procedure extraction and immediately before the procedure of a primary molar |
| Eligibility Criteria: Rosemary
| pain level, before procedure, during procedure extraction and immediately after procedure extraction and immediately before the procedure of a primary molar |
| Inclusion / Exclusion Criteria: Rosemary
| pain level, before procedure, during procedure extraction and immediately after procedure extraction and immediately before the"
372,"[/INST]

Adverse Events
-----------------

Other: The effect of puzzles on students' course success


| Experimental: Students' course success<br>The effect of puzzles on students' course success<br>Other: The effect of puzzles on students' course success<br>Time Frame: 5 weeks |

Adverse Events: [/INST]

Other: The effect of puzzles on students' course success<br>The effect of puzzles on students' course success<br>Time Frame: 5 weeks |


Adverse Events: [/INST]

Other: The effect of puzzles on students' course success<br>The effect of puzzles on students' course success<br>Time Frame: 5 weeks |


Adverse Events: [/INST]

Other: The effect of puzzles on students' course success<br>The effect of puzzles on students' course success<br>Time Frame: 5 weeks |

Adverse Events: [/INST]

Other: The effect of puzzles on students' course success<br>The effect of puzzles on students' course success<br>Time Frame: 5 weeks |

Adverse Events: [/INST]

Other: The effect of puzzles on students' course success<br>The effect of puzzles on students' course success<br>Time Frame: 5 weeks |

Adverse Events: [/INST]

Other: The effect of puzzles on students' course success<br>The effect of puzzles on students' course success<br>Time Frame: 5 weeks |

Adverse Events: [/INST]

Other: The effect of puzzles on students' course success<br>The effect of puzzles on students' course success<br>Time Frame: 5 weeks |

Adverse Events: [/INST]

Other: The effect of puzzles on students' course success<br>The effect of puzzles on students' course success<br>Time Frame: 5 weeks |

Adverse Events: [/INST]

Other: The effect of puzzles on students' course success<br>The effect of puzzles on students' course success<br>Time Frame: 5 weeks |

Adverse Events: [/INST]

Other: The"
373,[/INST]-0-7-7-a-O-O-a-a-0-a-a-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-cure-a-0-0-0-a-0---7-a-7-7-7-7-a-7-7-O-a-0-0-O-O-na-na-na-na-na-re-re-0-0-na-na-na-na-na-re-e-e-e-a-O-O-re-re-re----8-na-na-na-na-smur-O-O-O-smur-re-D-re-O-O-O-a-Dna---------ve-e-e-Dur-Dur-Dur-disive-dison-dis-dis-Dur-m-m-m-D-D-Dur-dis-smur-a-a-smur-smur-a-a-a-a-a-a-a-sm-sm-sm-sm-sm-7-sm-sm-D-sm-smur-sm-a-a-a-a-smur-sm-sm-smur-sm-smive-smive-smur-smur-smur-smur-sm-sm-sm-smive-smive-sm
374,"[/INST]
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Skin, Ivermectin
Rosacea, laser
Rosacea, laser
Rosacea, laser
Rosace, laser
Rosace, laser
Rosace, laser
Rosace, laser
Rosace, laser
Rosace, laser
Rosace, laser
Rosace, laser
Rosace, laser
Rosace, laser, laser
Rosace, laser, laser
Rosace, laser, laser
Rosace, laser, laser
Rosace, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser, laser"
375,"[/INST]

How is the study funded?
-----------------
| FDG PET |

Funding for the study is provided by the National Institute of Health.

Characteristics of the study population
-----------------
| Clinical trials |

How is the study population defined?
| Patients with neurodegenerative diseases |
| Diagnosis of the disease |
| Other characteristics of the study population examined in previous studies |

What is the time frame for the study?
| Start of the study in 2014 |
| FDG PET to measure brain activity in patients with neurodegenerative diseases.

What is the time frame for the intervention?
| FDG PET to measure brain activity in patients with neurodegenerative diseases.
| Start of the study in 2014 |

How is the study designed?
| FDG PET to measure brain activity in patients with neurodegenerative diseases.
| Start of the study in 2014 |

How is the study designed to address the primary outcome?
| FDG PET to measure brain activity in patients with neurodegenerative diseases.
| Start of the study in 2014 |

How is the study designed to address the secondary outcome measures?
| FDG PET to measure brain activity in patients with neurodegenerative diseases.
| Start of the study in 2014 |

How is the study designed to address the secondary outcome measures?
| FDG PET to measure brain activity in patients with neurodegenerative diseases.

What is the study designed to measure?
| FDG PET to measure brain activity in patients with neurodegenerative diseases.
| Start of the study in 2014 |

How is the study designed to measure the primary outcome?
| FDG PET to measure brain activity in patients with neurodegenerative diseases.

How is the study designed to measure the secondary outcome?
| FDG PET to measure brain activity in patients with neurodegenerative diseases.

What is the study designed to measure?
| FDG PET to measure brain activity in patients with neurode"
376,"[/INST]
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| SARS-CoV-2 seropositivity, clinical symptoms and clinical outcomes in pwCF | detectable seropositivity of anti-SARS-CoV-2 antibodies following vaccination. | 3-year period (comprising a 1-year enrollment period and a 2-year follow-up) | 
| Longitudinal comparison of the detection of anti-SARS-CoV-2 antibodies in pwCF following routine care. |
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| SARS-CoV-2 seropositivity, clinical symptoms and clinical outcomes in pwCF following vaccination. | detectable seropositivity of anti-SARS-CoV-2 antibodies in pwCF according to routine care. | 3-year period (comprising a 1-year enrollment period and a 2-year follow-up) | 
| Serum proteomic and genomic responses of pwCF who are SARS-CoV-2 seropositive and seronegative. | Measuring detectable seropositivity of anti-SARS-CoV-2 antibodies in pw according to routine care. |
| Terms related to the study
Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| SARS-CoV-2 seropositivity, clinical symptoms and clinical outcomes in pwCF following vaccination. | detectable seropositivity of anti-SARS-CoV-2 antibodies in pw according to routine care. | 3-year period (comprising a 1-year enrollment period and a 2-year follow-up) | 
| Longitudinal comparison of the detection of anti-SARS-CoV-2 antibodies in pwCF following routine care. |"
377,"[/INST]

Explanation of Study Measures
-----------------
| Other: Symptomatic Group | Diagnostic Test: Duplex ultrasound of the left common iliac vein<br>Participants in the vascular ultrasound department |
| Primary Purpose: Diagnostic Test of the left common iliac vein |
| Intervention: Symptomatic Group | Other: Vascular ultrasound of the left common iliac vein |
| Participation Criteria: Participants must be at least 18 years of age and have provided appropriate informed consent |
| Exclusion Criteria: Participants must be able to provide appropriate informed consent |
| Other: Asymptomatic Group | Diagnostic Test: Duplex ultrasound of the left common iliac vein<br>Participants in the vascular ultrasound department |
| Primary Purpose: Diagnostic Test of the left common iliac vein |
| Intervention: Symptomatic Group | Other: Vascular ultrasound of the left common iliac vein |
| Primary Purpose: Diagnostic Test of the left common iliac vein |
| Intervention: Symptomatic Group | Other: Vascular ultrasound of the left common iliac vein |
| Primary Purpose: Diagnostic Test of the left common iliac vein |
| Intervention: Symptomatic Group | Other: Vascular ultrasound of the left common iliac vein |
| Primary Purpose: Diagnostic Test of the left common iliac vein |
| Intervention: Symptomatic Group | Other: Vascular ultrasound of the left common iliac vein |
| Primary Purpose: Diagnostic Test of the left common iliac vein |
| Intervention: Symptomatic Group | Other: Vascular ultrasound of the left common iliac vein |
| Primary Purpose: Diagnostic Test of the left common iliac vein |
| Intervention: Symptomatic Group | Other: Vascular ultrasound of the left common iliac vein |
| Primary Purpose: Diagnostic Test of the left common iliac vein |
| Intervention: Symptomatic Group | Other: Vascular ultrasound of the left common iliac ve"
378,"[/INST]
| The health of patients with symptomatic convergence insufficiency who had received visual training |
| Patients who had not received monocular vision training |
| Visual acuity of patients with symptomatic convergence insufficiency |
| Patients who had not received monocular vision training |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyperopia |
| Patients who had not received training in hyper"
379,"[/INST]

How is the study designed?
-----------------
| Data collection at time of surgery | 
| Sensitivity, Specificity, and Negative Predictive Value using ICG Dye for sentinel lymph nodes. | Create a 2x2 contingency table for SLNs using blue dye. | Data collection at time of surgery | 
| Use a paired t-test or McNemar's test to compare the proportions of SLNs within each hemi-pelvis. | Report the correlation between SLNs using blue dye for sentinel lymph node mapping. |

What is the study measuring?
-----------------
| Sensitivity, Specificity, and Negative Predictive Value using ICG Dye for sentinel lymph nodes. | Create a 2x2 contingency table for SLNs using blue dye. Report the correlation between SLNs using the Wald test or likelihood ratio. | Data collection at time of surgery | 

How is the study designed?
-----------------
| Sensitivity, Specificity, and Negative Predictive Value using ICG Dye for sentinel lymph nodes. | Create a 2x2 contingency table for SLNs using blue dye. | Data collection at time of surgery | 

What is the study measuring?
-----------------
| Sensitivity, Specificity, and Negative Predictive Value using ICG Dye for sentinel lymph nodes. | Create a 2x2 contingency table for SLNs using blue dye. | Data collection at time of surgery | 

How is the study designed?
-----------------
| Sensitivity, Specificity, and Negative Predictive Value using ICG Dye for sentinel lymph nodes. | Create a 2x2 contingency table for SLNs using blue dye. | Data collection at time of surgery | 

How is the study designed?
-----------------
| Sensitivity, Specificity, and Negative Predictive Value using ICG Dye for sentinel lymph nodes. | Create a 2x2 contingency table for SLNs using blue dye. | Data collection at time of surgery |"
380,"[/INST]
Second, and third-10101010100000000000001.
Second, and third.
Second, and third.
Second, third.
Second, third.
Second, third.
Second, third.
Second, third.
Second, third.
Second, third.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
This.
This.
This
====
====
====
====.
This.
====
This
It.
It.
It.
It's
In
In
In
This
==
==
==
==
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
381,"[/INST]
| 12 weeks after the cross-over
| 12 weeks after the cross-over
| 12 weeks after the cross-over
| 12 weeks after the cross-over
| 12 weeks after the cross-over
| 12 weeks after the cross-over
| 12 weeks after the cross-over
| 12 weeks after the cross-over
| 12 weeks after the cross-over
| 12 weeks after the cross-over
| 12 weeks after the cross-over
| 12 weeks after the cross-over
| 12 weeks after the cross-over
| 1
| 1
| 12 weeks after the cross-over
| 1
| 1
| 1
| 1
| 1
| 1
| 2
| 1
| 1
| 1
| 1
| 1
| 1
| 1
| 2
| 1
| 1
| 2
| 1
| 2
| 1
| 1
| 1
| 1 year old
| 1
| 2
| 1
| 2
| 1
| 1
| 1
|
|
|
|
|
|
|
| 2
| 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
and
and
This
Ob
This
Pres
This
This
This
This"
382,"[/INST]

How is the study designed?
-----------------
Primary Purpose: Prevention
Intervention Model: Single Group Assignment
| Experimental: Genetic<br>Participants will have their DNA tested and this data alongside lifestyle data will personalize the information they receive | Genetic: Genetic<br>* A saliva sample test will be undertaken by all participants in order to analyze their DNA for personalizing their recommendations. The Global Screening Array (GSA) will be used to measure well-being. This uses a Likert Scale from 0 ('At no time') to 5 ('All of the time'). Measurements taken at baseline, 3 weeks following receiving personalized recommendations, and at 3 month follow-up | 

Secondary Outcome Measures
| How sustainable are the personalized recommendations | A questionnaire that will cover whether recommendations were followed (Yes/No), for how long (1-5 days, 1-2 weeks, 3-4 weeks, 1 month, > 2 months), and how easy participants found implementing the recommendations. | Measurements taken at 3 month follow-up | 


Terms related to the study
-----------------
Primary Purpose: Prevention
Intervention Model: Single Group Assignment
| Experimental: Genetic<br>Participants will have their DNA tested and this data alongside lifestyle data will personalize the information they receive | Genetic: Genetic<br>* A saliva sample test will be undertaken by all participants in order to analyze their DNA for personalizing the recommendations. The Global Screening Array (GSA) will be used to measure well-being. This uses a Likert Scale from 0 ('At no time') to 5 ('All of the time'). Measurements taken at baseline, 3 weeks following receiving personalized recommendations, and at 3 month follow-up | 


Secondary Outcome Measures taken at baseline, 3 weeks following receiving personalized recommendations, and at 3 month follow-up | How sustainability of the Global Screening Test. This uses a Liked DNA to measure of the recommendations.
Primary Purpose: Genetic<br>




How is it be sustain the DNA



How"
383,"[/INST]O,-a,OO,O-a-a-a,-h-h-h-h-h-a-a-a-a hO h-a-a h-a h-h-h-h-h-h-h-h-h-h h-a h-h-C-C-C-C-h-C-C-a-a-a-a-a-a-h-h-h-h-h-h-h-h-h-h-h-h-h-C-C-C-C-C-C-C-C-C-a-a-a-a-a-C-C-s-C-C-C-h-h-a-a-a-a-a-a-a-C-C-C-a-a-a-a-a-a-a-a-C-a-a-aCCCCCCCACACAC-aC-a-sC-sC-C-CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCOCMCMC-a-aC-aCCCCCCCCCCCCCCC-aC-C-C-C-C-CCCCCCCCCCC-s-a-a-s-sCCCCCC-sCCC-C-C-CD-C-C-CCCCCCC-CCCC-a-a-aC-aC-aCCCCCCCCCCCCCCCCCCCCCCC-aCC-aC-D-D-D-D-D-a-a-a-a-a-a-a-s-D-D-C-C-C-C-C-C-a-aCA-aD-a-a-D-D-D-D-D-s-s-s-a-a-aD-aDCC-sCACADACACOCOC-"
384,"[/INST]
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
Patient.
Patients.
Patient.
Patient.
Patient.
Patient s.
Patient s.
Patient.
Patient.
Patient.
The patient.
Patient.
Patient.
Patient.
The patient.
The patient.
The patient.
The patient.
The
The patient.
The
The
The patient.
The patient.
The.
In.
In
In
In
In
Patient.
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
The,
The,
Patient
In
In
In
The,
The,
The,
The
The
The
The
The
In
This
In
In
In
In
S
S
S
S
S
S
S
S
S
S
In
In
In
In
In
In
In
In
In
In
In
In
In
This
This
What
F
P
P
P
S
S
S
S
S
S
In
In
In
The
The
The
The
The
The
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
F
F
F
F
S
S"
385,"[/INST] -
* Thoracic paravertebral block: 20 ml. | [/INST]
* Active Comparator: Thoracic paravertebral block: 20 ml. | [/INST]
* Morphine consumption: 20 ml. | [/INST]
* Primary Outcome Measure: Pain will be assessed at the 4th-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain). | 4th-hour after surgery. |
* Secondary Outcome Measure: Morphine consumption will be assessed at the 24th-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain). | 


Thoracic paravertebral block: 20 ml. | [/INST]
* Primary Outcome Measure: Pain will be assessed at the 4th-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain). | 4th-hour after surgery. |
* Morphine consumption: 20 ml. | [/INST]"
386,"[/INST] of Multiple Sclerosis | fatigue, and the Fatigue, and the FIS the subject to the Fatigue, and the FIS the subject to the Fatigue, and the FIS the subject to the FIS the most commonly used to the Fatigue, and the FIS the subject to the Fatigue, and the FIS the subject to the FIS the most commonly used to the Fatigue the symptoms of the Fatigue, and the Fatigue the subject to the Fatigue the symptoms.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The patient|
The patient.
The patient.
The patient.
The patient.
There.
There.
In|.
In.
The patient.
The patient.
There.
There.
There.
There.
There.
The patient.
The patient.
The patient.
In
The patient.
There.
There.
The patient.
The patient.
The.
The.
The disease.
The disease.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The>
The.
The.
The.
This.
The.
The.
The
The.
This.
This"
387,"[/INST]
this"
388,"[/INST]
Other Outcome Measures
| the number of attempts to get five samples | 7 days after lung biopsy |
| the number of attempts to get five samples |
| the number of attempts to get the biopsy sample |
| the number of blood vessels in the biopsy sample is recorded, according to the histological analysis of the biopsy paraffin section. |
| the number of blood vessels in the biopsy sample is measured, according to the histological analysis of the biopsy paraffin section. |
| the number of attempts to get five samples |
| the number of blood vessels in the biopsy sample is recorded, according to the histological analysis of the biopsy paraffin section. |
| the number of blood vessels in the biopsy sample is measured, according to the histological analysis of the biopsy paraffin section. |
| the number of attempts to get five samples |
| the number of blood vessels in the biopsy sample is recorded, according to the histological analysis of the biopsy paraffin section. |
| the number of blood vessels in the biopsy sample is measured, according to the histological analysis of the biopsy paraffin section. |
| the number of attempts to get five samples |
| the number of blood vessels in the biopsy sample is recorded, according to the histological analysis of the biopsy paraffin section. |
| the number of blood vessels in the biopsy sample is measured, according to the histological analysis of the biopsy paraffin section. |
| the number of attempts to get five samples |
| the number of blood vessels in the biopsy sample is recorded, according to the histological analysis of the biopsy paraffin section. |
| the number of blood vessels in the biopsy sample is measured, according to the histological analysis of the biopsy paraffin section. |
| the number of attempts to get five samples |
| the number of blood vessels in the biopsy sample is recorded, according to the histological analysis of the biopsy paraffin section. |
| the number of blood vessels in the biopsy sample is measured, according to the histological analysis of the biopsy paraffin section. |
| the number of attempts to get five samples"
389,"[/INST]


| How is the study structured?
| Diagnostic Test: Ultrasound | 28 weeks of gestation
| Examinees will be recruited from 28 weeks of gestation |
| Prenatal testing of sFGR will be performed at 28 weeks of gestation |
| Diagnostic testing will continue until birth |
| The testing will be performed at 2 years of age |
| Prenatal testing of sFGR will be performed every 2 years |
| Examinees will be tested every 2 years |
| The testing will be performed every 2 years |
| Prenatal testing of sFGR will be performed every 2 years |
| Diagnostic testing of sFGR will be performed every 2 years |
| The testing will be performed every 2 years |
| Prenatal testing of sFGR will be performed every 2 years |
| Examinees will be tested every 2 years |
| Prenatal testing of sFGR will be performed every 2 years |
| The testing will be performed every 2 years |
| Diagnostic testing of sFGR will be performed every 2 years |
| Prenatal testing of sFGR will be performed every 2 years |
| The testing will be performed every 2 years |
| Prenatal testing of sFGR will be performed every 2 years |
| Diagnostic testing of sFGR will be performed every 2 years |
| The testing will be performed every 2 years |
| Prenatal testing of sFGR will be performed every 2 years |
| Diagnostic testing of sFGR will be performed every 2 years |
| The testing will be performed every 2 years |
| Prenatal testing of sFGR will be performed every 2 years |
| Diagnostic testing of sFGR will be performed every 2 years |
| The testing will be performed every 2 years |
| Prenatal testing of sFGR will be performed every 2 years |
| Diagnostic testing of sFGR will be performed every 2 years |
| The testing will be performed every 2 years |
| Prenatal testing of sFGR will be performed every 2 years |
| Diagnostic testing of sFGR will be performed"
390,"[/INST]

Experimental: [/INST]

Primary Outcome Measure
-----------------
Terms related to the study: [/INST]
Behaviors related to the study: [/INST]
Other names: [/INST]

Secondary Outcome Measures
-----------------
Terms related to the study: [/INST]
Behaviors related to the study: [/INST]
Other names: [/INST]

Primary Outcome Measure
Terms related to the study: [/INST]
Behaviors related to the study: [/INST]
Other names: [/INST]

Secondary Outcome Measure
Terms related to the study: [/INST]
Behaviors related to the study: [/INST]
Other names: [/INST]

Primary Outcome Measure
Terms related to the study: [/INST]
Behaviors related to the study: [/INST]
Other names: [/INST]

Primary Outcome Measure
Terms related to the study: [/INST]
Behaviors related to the study: [/INST]
Other names: [/INST]

Primary Outcome Measure
Terms related to the study: [/INST]
Behaviors related to the study: [/INST]
Other names: [/INST]

Primary Outcome Measure
Terms related to the study: [/INST]
Behaviors related to the study: [/INST]
Other names: [/INST]

Primary Outcome Measure
Terms related to the study: [/INST]
Behaviors related to the study: [/INST]
Other names: [/INST]

Primary Outcome Measure
Terms related to the study: [/INST]
Behaviors related to the study: [/INST]
Other names: [/INST]

Primary Outcome Measure
Terms related to the study: [/INST]
Behaviors related to the study: [/INST]
Other names: [/INST]

Primary Outcome Measure
Terms related to the study: [/INST]
Behaviors related to the study: [/INST]
Other names: [/INST]

Primary Outcome Measure
Terms related to the study:"
391,"[/INST]

Primary Purpose: To assess the impact of the intervention on the outcome.
Secondary Purpose: To determine if the intervention was effective in achieving the desired outcome.
Tertiary Purpose: To determine if the intervention was efficient in achieving the desired outcome.
Quaternary Purpose: To determine if the intervention was effective in achieving the desired outcome.
Interventions: [/INST]
Behavioral: [/INST]
Primary Purpose: To determine if the intervention was effective in changing behavior.
Secondary Purpose: To determine if the intervention was efficient in changing behavior.
Tertiary Purpose: To determine if the intervention was effective in achieving the desired outcome.
Behavioral: [/INST]
Primary Purpose: To determine if the intervention was effective in changing behavior.
Secondary Purpose: To determine if the intervention was efficient in changing behavior.
Tertiary Purpose: To determine if the intervention was effective in achieving the desired outcome.
Interventions: [/INST]
Behavioral: [/INST]
Primary Purpose: To determine if the intervention was effective in changing behavior.
Secondary Purpose: To determine if the intervention was efficient in achieving the desired outcome.
Tertiary Purpose: To determine if the intervention was effective in changing behavior.
Behavioral: [/INST]
Primary Purpose: To determine if the intervention was effective in changing behavior.
Secondary Purpose: To determine if the intervention was efficient in achieving the desired outcome.
Tertiary Purpose: To determine if the intervention was effective in changing behavior.
Interventions: [/INST]
Behavioral: [/INST]
Primary Purpose: To determine if the intervention was effective in changing behavior.
Secondary Purpose: To determine if the intervention was efficient in achieving the desired outcome.
Tertiary Purpose: To determine if the intervention was effective in changing behavior.
Behavioral: [/INST]
Primary Purpose: To determine if the intervention was effective in changing behavior.
Secondary Purpose: To determine if the intervention was efficient in achieving the desired outcome.
Interventions: [/INST]
Behavioral: [/INST]
Primary Purpose: To determine if"
392,"[/INST]
The
The
The
The
The
The
The
The
that
that
that
that
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The





































































































































































































































































































































































































































































A"
393,"[/INST]

Acceptance of the study protocol
-----------------
Primary Outcome: The study will determine whether tFUS increases or decreases the activity between the stimulation target (Nucleus Accumbens) and connected brain regions, including the prefrontal cortex, hippocampus, and sensory areas.
Secondary Outcome Measures
-----------------
Acceptance of the study protocol
Primary Outcome: The study will determine whether tFUS increases or decreases the activity between the stimulation target (Nucleus Accumbens) and connected brain regions, including the prefrontal cortex, hippocampus, and sensory areas.
Secondary Outcome: The study will determine whether tFUS increases or decreases the activity between the stimulation target (Nucleus Accumbens) and connected brain regions, including the prefrontal cortex, hippocampus, and sensory areas.
Experimental: The study will determine whether tFUS increases or decreases the activity between the stimulation target (Nucleus Accumbens) and connected brain regions, including the prefrontal cortex, hippocampus, and sensory areas.
Experimental: The study will determine whether tFUS increases or decreases the activity between the stimulation target (Nucleus Accumbens) and connected brain regions, including the prefrontal cortex, hippocampus, and sensory areas.
Experimental: The study will determine whether tFUS increases or decreases the activity between the stimulation target (Nucleus Accumbens) and connected brain regions, including the prefrontal cortex, hippocampus, and sensory areas.
Experimental: The study will determine whether tFUS increases or decreases the activity between the stimulation target (Nucleus Accumbens) and connected brain regions, including the prefrontal cortex, hippocampus, and sensory areas.
Experimental: The study will determine whether tFUS increases or decreases the activity between the stimulation target (Nucleus Accumbens) and connected brain regions, including the prefrontal cortex, hippocampus, and sensory areas.
Experimental: The study will determine whether tFUS increases or decreases the activity between the stimulation target (Nucleus Accumbens)"
394,"[/INST]
| Other: [/INST]
| --- |

| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Approximately 12 Months | 
| bloodbrain barrier Ktrans |
| Inflammatory markers |
| Appro"
395,"[/INST]

Patients
| Participation Criteria |
-----------------
| Ineligible for study due to age, sex, or smoking status.

Other Terms
-----------------

Patients
| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to age, sex, or smoking status.

| Participation Criteria |
| Ineligible for study due to"
396,"[/INST]
| Bone Graft, Autogenous
| 6 month after the surgery, and 6 month after the bone
| 6 month after the surgery, and 6 month after the bone
| 6 month after the surgery, and 6 month after the bone surgery, 6 month after the surgery, 6 month after the surgery, 6 month after the bone surgery, 6 month after the surgery, 6 month after the surgery, 6 month after the surgery, 6 month after the surgery 6 month surgery, 6 month after the surgery, 6 month surgery, 6 month after the surgery, 6 month surgery, 6 month surgery, 6 month surgery, 6 month surgery 6 month surgery 6 month surgery 6 month surgery 6 month surgery 6 month surgery 6 surgery 6 month surgery 6 surgery 6 month surg 6 month surgery 6 month surgery 6 month 6 month surgery 6 month 6 month surgery 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 month 6 6 month 6 6 month 6 6 month 6 month 6 month 6 month 6 month 6 month 6 6 month 6 month 6 month 6 month 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6.
====. 6.
6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6
====. 6.
== . . .,, this.
This.
====.
====.
====.
====.
====.
====.
This.
This.
Answer.
Answer.
This.
This.
This.
This.
This"
397,"[/INST]
| Explanation of the study's inclusion and exclusion criteria |
| Explanation of the study's terms |
| Participant Group | Explanation of the study's terms |
| Study Design |
| Explanation of the study's terms |
| Participant Group | Explanation of the study's terms |
| Study Design (TBD) |
| Explanation of the study's terms |
| Participant Group (IGRA) |
| Study Design (NAA) |
| Explanation of the study's terms |
| Participant Group (IGRA) |
| Study Design (TBD) |
| Explanation of the study's terms |
| Participant Group (IGRA) |
| Study Design (NAA) |
| Explanation of the study's terms |
| Participant Group (IGRA) |
| Study Design (TBD) |
| Explanation of the study's terms |
| Participant Group (IGRA) |
| Study Design (NAA) |
| Explanation of the study's terms |
| Participant Group (IGRA) |
| Study Design (TBD) |
| Explanation of the study's terms |
| Participant Group (IGRA) |
| Study Design (NAA) |
| Explanation of the study's terms |
| Participant Group (IGRA) |
| Study Design (TBD) |
| Explanation of the study's terms |
| Participant Group (IGRA) |
| Study Design (TBD) |
| Explanation of the study's terms |
| Participant Group (IGRA) |
| Study Design (TBD) |
| Explanation of the study's terms |
| Participant Group (IGRA) |
| Study Design (TBD) |
| Explanation of the study's terms |
| Participant Group (IGRA) |
| Study Design (TBD) |
| Explanation of the study's terms |
| Participant Group (IGRA) |
| Study Design (TBD) |
| Participant Group (IG"
398,"[/INST]
| the seventh, and the pain.
| the seventh, the stimuli, the pain.
| the seventh, the stimuli.
| the seventh, the pain.
| the stimuli.
| the seventh, the stimuli the seventh, the pain.
The stimuli the seventh, the stimuli the seventh, the pain.
Stim, the pain.
Stim, the pain.
Stim, the pain.
Stim, the pain.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.im.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
Stim.
There are
Stim.
Stim.
Stim.
Stim.
There.
There.
There.
There.
There.
There.
Stim.
St.
Stim.
There.
There.
There.
There.
There.
There.
There.
There.
There.
There.
The.
The.
The brain.
This.
This.
Q.
There.
Q.
Q.
There, it.
There, it's.
It.
It.
It.
It.
It.
This.
The.
The.
This.
This.
The presence.
The presence
It.
This
This
it
it
it
it
it
it
it
it
it
it
It
It
It
It
It
It
It
It
It
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
399,"[/INST]

Primary Outcome Measure
-----------------
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Obtain MRE images | MRE images will be processed to estimate global differences in the amplitudes and temporal delays of translation and rotation between the skull and brain. | End of study | 

Secondary Outcome Measures
-----------------
| Outcome Measure | Measure Description | Time Frame |
| Obtain MRE images | MRE images will be processed to estimate global differences in the amplitudes and temporal delays of translation and rotation between the skull and brain. | End of study | 

Study Design
-----------------
| Outcome Measure | Measure Description | Time Frame |
| Obtain MRE images | MRE images will be processed to estimate global differences in the amplitudes and temporal delays of translation and rotation between the skull and brain. | End of study | 

Secondary Outcome Measures
-----------------
| Outcome Measure | Measure Description | Time Frame |
| Obtain MRE images | MRE images will be processed to estimate global differences in the amplitudes and temporal delays of translation and rotation between the skull and brain. | End of study | 

Study Population
-----------------
| Outcome Measure | Measure Description | Time Frame |
| Obtain MRE images | MRE images will be processed to estimate global differences in the amplitudes and temporal delays of translation and rotation between the skull and brain. | End of study | 

Eligibility Criteria
-----------------
| Outcome Measure | Measure Description | Time Frame |
| Obtain MRE images | MRE images will be processed to estimate global differences in the amplitudes and temporal delays of translation and rotation between the skull and brain. | End of study | 

Interventions/treatments
-----------------
| Outcome Measure | Measure Description | Time Frame |
| Obtain MRE images | MRE images will be processed to estimate global differences in the amplitudes and temporal delays of translation and rotation between the skull and brain. | End of study | 

Explanation of the study
-----------------
| Outcome Measure | Measure Description | Time Frame |
| Obtain MRE images | MRE"
400,"[/INST]
The
The
be
be
be-
be-
be-
The
The
The
The
be-



























































































































































































































be-
be-
be-
A-










































































be-
be-
S-
S-
A-
A-
A-















c-
S-
S-
S-
S-
S-
S-
S-
S-
S-
S-
S-
S-
S-
S-
A-
A-
m-
S-
C-
S-
S-
S-
S-
S-h-
S-
-
S-
S-
S-
S-
A-
S-
A-
A-
C-
S-
C-
-
-
O-
O-
C-
C-
O-
C-
C-
O-"
401,[/INST]
402,"[/INST]

Primary Purpose: Treatment
| Outcome Measure | Measure Description | Time Frame |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome Measure | Measure Description |
| effective preparation of bowel | 2 hours after having bowel preparation | 
| Outcome"
403,"[/INST]
Quality of Life: [/INST]
Other: [/INST]
Primary Outcome Measurements
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other: [/INST]
Quality of Life: [/INST]
Other"
404,"[/INST]
-
-







-
-
-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-
-
-
-
-
-
-a-
-
-
-
-
-
-
-
-
-
-
-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-                                                                                                                                                                                                                                                                                                                -a-a-a-a
-a-
-
-
-
-
-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-
-
-
-
-
-a-a-a-a-
-
-a-a-a-a-a-a-a-a-a-
-
-
-
-
-
-
-
-
-
-
-
-a-a-a-a-a-
-
-
-a-
-
-a-a-a-a-a-a-st-st-st-
-
-
-
-a-a-a-a-
-                -a-                -                -                -                -                -a-                -                -|-|-|-|-|-|-|-|-|-|-|-|-|-|-
-                -                -st-st-st-st-
-
-
-
-
-
-
-
-
-
-
-
-
-
-a-a-a-a-a-a-a-a-a-a-a-"
405,[/INST]
406,"[/INST]
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000001.
In.
The.
The.
The treatment.
In.
In.
In.
In.
In.
In.
This.
This.
The treatment.
It.
It.
These.
It.
It.
It.
It.
It.
It.
It.
It's.
It's.
The.
The.
In.
In.
In.
This.
This.
This.
It.
This.
In.
In.
It.
It.
This.
This.
This.
It
This.
This.
This.
This.
This.
This
This
This
This.
This.
This
This
This
This
This
This
This
This
In
This
This
This
This
This
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
407,"[/INST]
| Lung microbiome | 16S1990s in the bronchoalve. | 
| Day 0 (subsequent to study in the ICU. | 16S. | 17. | 190s. | 16S. | 17. | 16. | 17. | 190. | 17. | 16. 17. | 190009019016. 17. 19017. 19016. 19017. 1901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901901990190190199191999991999999999999991991999199999999999999999999999999999999999999999999999999999999999999999999999999999999"
408,"[/INST]

Experimental: [This group will receive 3D Printed Foot Orthoses | Generic Foot Orthosis]
Primary Outcome: [This group will receive Prefabricated Foot Orthoses]
Secondary Outcome: [This group will be measured using the Visual Analog Scale]
Treatment Group: [This group will be measured using the Visual Analog Scale]
Experimental: [This group will be measured using the Visual Analog Scale]

Visual Analog Scale: [This group will be measured using the Quebec questionnaire]

Secondary Outcome: [This group will be measured using the Visual Analog Scale]


Visual Analog Scale: [This group will be measured using the Quebec questionnaire]"
409,"[/INST]

Primary Outcome Measures
-----------------
| Recurrent |

Behavioral: the incisional hernia recurred after surgery repair;
| 2016.1-2023.3 |

Behavioral: the incisional hernia recurred after surgery repair;
| 2016.1-2023.3 |

Behavioral: the incisional hernia recurred after surgery repair;
| 2016.1-2023.3 |

Behavioral: the incisional hernia recurred after surgery repair;
| 2016.1-2023.3 |

Behavioral: the incisional hernia recurred after surgery repair;
| 2016.1-2023.3 |

Behavioral: the incisional hernia recurred after surgery repair;
| 2016.1-2023.3 |

Behavioral: the incisional hernia recurred after surgery repair;
| 2016.1-2023.3 |

Behavioral: the incisional hernia recurred after surgery repair;
| 2016.1-2023.3 |

Behavioral: the incisional hernia recurred after surgery repair;
| 2016.1-2023.3 |

Behavioral: the incisional hernia recurred after surgery repair;
| 2016.1-2023.3 |

Behavioral: the incisional hernia recurred after surgery repair;
| 2016.1-2023.3 |

Behavioral: the incisional hernia recurred after surgery repair;
| 2016.1-2023.3 |

Behavioral: the incisional hernia recurred after surgery repair;
| 2016.1-2023.3 |

Behavioral: the incisional hernia recurred after"
410,"[/INST]
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The.
Mod.
Mod.
Mod.
The.
The.
The,
The,
The,
The.
The.
The,
The, it.
The, it.
The, it.
The, mod.
The.
It.
The.
The.
The.
The patient.
The,
The,
The.
The.
The.
The.
The.
The.
The.
It.
It.
It.
It.
This.
The.
The
The
The
The,
The,
The,
The
The
The
The
In
In
This
This
This
This
This
This
This
The
The
The
The
The
The
The
The
The
This
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
A
The
The
The
The
The
The
The
The
The
The
A
A
A
A
A
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A"
411,"[/INST]
Other related to the study of White matter hyperintensity, cognition, and glymphatics.
Primary Outcome Measures
| Other related to the study of White matter hyperintensity, cognition, and glymphatics.
| at study visit during inclusion up to 3 years | 
| WMH shape on brain MRI as a marker of glymphatics, cognition, and White matter hyperintensity. | at study visit during inclusion up to 3T and cognition, White matter hyperintensity, and glymphatics, and cognition, and White matter, and glymphatics, and cognition, and White matter, and glymphatics, and cognition, and White matter, and glymphatics, and cognition, and White matter, and glymphatics, and cognition, and White matter, and glymphatics, cognition, White matter, cognition, White matter, cognition, White matter, cognition, and White matter, and glymphics, cognition, White matter, cognition, White matter, cognition, White matter, cognition, White matter, cognition, White matter, cognition White matter, cognition White matter, White matter, cognition White matter, cognition White matter, cognition White matter, cognition, White matter, cognition White matter, cognition White matter, cognition White matter, White matter, White matter, White matter, White matter, cognition White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter, White matter. White matter.
White matter.
White matter.
White matter.
White matter.
White matter.
White matter.
White matter.
White matter.
White matter.
White matter.
White.
White.
White.
White."
412,"[/INST]

| Participant Group/Eligibility Criteria | Exclusion Criteria: The researchers calculated the established AI model and compared it with endoscopists of different levels.

How is the study designed?
| Participant Group/Eligibility Criteria | Exclusion Criteria: The researchers calculated the established AI model and compared it with endoscopists of different levels.
| Participant Group/Exclusion Criteria | Inclusion Criteria: The researchers calculated the established AI model and compared it with endoscopists of different levels.

How is the study measured?
| Participant Group/Exclusion Criteria: The researchers calculated the established AI model and compared it with endoscopists of different levels.

What is the study measuring?
| Participant Group/Inclusion Criteria: The researchers calculated the established AI model and compared it with endoscopists of different levels.

How is the study designed?
| Participant Group/Exclusion Criteria: The researchers calculated the established AI model and compared it with endoscopists of different levels.

How is the study measured?
| Participant Group/Inclusion Criteria: The researchers calculated the established AI model and compared it with endoscopists of different levels."
413,"[/INST]
The study.
1.
1.
1.
1.
1.
1.
1.
1.
1.
1.
1.
2.
2.
2.
1.
2.
2.
2.
1.
2.
2.
2.
2.
1.
1.
1.
1.
2.
1.
2.
1.
2.
1.
2.
1.
1.
2.
1.
2.
1.
1.
1.1.
1.
1.
1.
1.
2.
1.
1.
1.
1.
1.
1.
1.
1.
1.
1.
1.
1.
1.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
--------
--------
--------
--------
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
F
F
This
This
This
This
This
F
F
F
F
F
This
This
This
The
This
This
This
This
This
This
This
This
This
This
This
This
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
S
S
S
This
This
This
This
S
S
S
S
S
S
S
S
S
This
S
S
S
S
S
S
S
S
S
S
S
The
The
This
The
The
S"
414,"[/INST]
The process.
The process.
There are many
There are
There.
There.
There.
There.
There.
There.
There.
==
It.
There.
The.
The.
The.
The.
The.
The.
The process.
The
The
The patient.
The patient.
The patient.
The
The
The
The
The
The
The
The
The
The patient.
The patient
The patient
The
The.
It.
The
The
It's
and
and
The
The
The
The
It
It
It
It
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
This
This
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
This
This
This
This
This
This
This
==
==











This
This
This
This
This
This
This
There
There
This
This
This
This"
415,"[/INST]
| Cataract surgery is the most common surgical procedure performed worldwide, with over 20 million cases annually. | Cataract surgery is the most common surgical procedure performed worldwide, with over 20 million cases annually.
| Cataract surgery is the most common surgical procedure performed worldwide, with over 20 million cases annually.
| Cataract surgery is the most common surgical procedure performed worldwide, with over 20 million cases annually.
| Cataract surgery is the most common surgical procedure performed worldwide, with over 20 million cases annually.
| Cataract surgery is the most common surgical procedure performed worldwide, with over 20 million cases annually.
| Cataract surgery is the most common surgical procedure performed worldwide, with over 20 million cases annually.
| Cataract surgery is the most common surgical procedure performed worldwide, with over 20 million cases annually.
| Cataract surgery is the most common surgical procedure performed worldwide, with over 20 million cases annually.
| Cataract, with over 20 million cases annually.
| Cataract, with over 20 million cases annually.
| Cataracts. Cataracts.
| Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts.|s eyes. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Cataracts. Catarq. Catarq. Catarq. Catarq. Catarq. Catarine. Catarq. Catarq. Catarq. Catarq. Catarq. Catarq. Catarq.
|s. Catarq.
Catarq.
Catarq."
416,"[/INST]s symptoms.
Symper.
Symper.
Symmetrics.
Symper.
Symper.
Symphob, it.
The symptoms.
Sym,
Sym,
The symptoms.
Symper.
Sym,
The symptoms.
Symper.
Sympt
Sympt
Sympt
Symper.
There are-
There are-
The-two.
The-two.
The-two.
The-two.
The symptoms.
The-two.
The-two.
The symptoms.
The symptoms.
There are-two
There.
The symptoms.
The symptoms.
The symptoms.
There.
There.
The
The symptinal
The sympt-
The-as
The-itis.
These
These
Ther.
The-like
The-like
The-like
The-the-
The patients.
The-the-all
The-all.
This.
This.
This.
This.
The.
The.
The.
In.
In.
In.
In.
In.
In.
In.
In.
In.
In.
In.
This.
In.
In.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
==.
This
This
This
This
This
This
This
This
This
This
This
==.
==-
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
This
This
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The"
417,"[/INST]

How is the study designed?
-----------------
| Summary of findings on newborn screening in French. | Other: Interview with parents whose child was diagnosed based on clinical signs. | November 2023 | 
| Mixed method design used to measure parental acceptability (by quantitative and thematic content analysis of the free comment areas) | November 2023 | 
| Typology of parental acceptability scores for newborn screening (by quantitative and thematic content analysis of the free comment areas) | November 2023 | 
| Secondary Outcome Measures | Measure Description | Time Frame |
| --- | --- |
| Mixed method design used to measure parental acceptability (by quantitative and thematic content analysis of the free comment areas) | November 2023 | 
| Secondary Outcome Measures | Measure Description | Time Frame |
| --- | --- |
| Mixed method design used to measure parental acceptability (by quantitative and thematic content analysis of the free comment areas) | November 2023 | 
| Typology of parental acceptability scores for newborn screening (by quantitative and thematic content analysis of the free comment areas) | November 2023 | 
| Secondary Outcome Measures | Measure Description | Time Frame |
| --- | --- |
| Mixed method design used to measure parental acceptability (by quantitative and thematic content analysis of the free comment areas) | November 2023 | 
| Secondary Outcome Measures | Measure Description | Time Frame |
| --- | --- |
| Mixed method design used to measure parental acceptability (by quantitative and thematic content analysis of the free comment areas) | November 2023 | 
| Secondary Outcome Measures | Measure Description | Time Frame |
| --- | --- |
| Mixed method design used to measure parental acceptability (by quantitative and thematic content analysis of the free comment areas) | November 2023 | 
| Secondary Outcome Measures | Measure Description | Time Frame |
| --- | --- |
| Mixed method design used to measure parental acceptability (by quantitative and thematic content analysis of the free comment areas"
418,"[/INST]

Primary Outcome: Change in pain intensity from 0 to 100%
Secondary Outcome Measures:
| Change in pain intensity from 0 to 100% |
| Pain intensity at 3 months |
| Change in pain intensity from 0 to 100% |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at 3 months |
| Pain intensity at baseline |
| Pain intensity at"
419,"[/INST]
How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Toxicities related to CAR19 therapy will be reported by Common Terminology for Adverse Events (CTCAE) criteria, as well as American Society for Transplantation and Cellular Therapy (ASTCT) criteria | 12 months | 
| Change in CD4 count | CD4 count on day of leukapheresis, 3 months post CAR19 therapy, 6 months post CAR19 therapy, and 12 months post therapy will be measured | Day 0, 3 months, 6 months, and 12 months post CAR19 therapy | 
| Absolute lymphocyte count | HIV viral load on day of leukapheresis, 3 months post CAR19 therapy, 6 months post CAR19 therapy, and 12 months post therapy will be measured | Day 0, 3 months, 6 months, and 12 months post CAR19 therapy | 
| Overall response | Defined as complete disappearance of all disease | 3 months and 6 months | 
| Leukemia, acute lymphoblastic leukemia, CART cell therapy, and 12 months | 
| Toxicities related to CAR19 therapy will be reported by Common Terminology for Adverse Events (CTCAE) criteria, as well as American Society for Transplantation and Cellular Therapy (ASTCT) criteria | 
| Outcome Measure | Measure Description | Time Frame |
| Toxicities related to CAR19 therapy will be reported by Common Terminology for Adverse Events (CTCAE) criteria, as well as American Society for Transplantation and Cellular Therapy (ASTCT) criteria | 12 months | 
| Change in CD4 count | CD4 count on day of leukapheresis, 3 months post CAR19 therapy, 6 months post CAR19 therapy, and 12 months post therapy will be measured | Day 0, 3 months, 6"
420,[/INST]
421,"[/INST]

How is the study designed?
| Participants | Eligible since 2017 |
| Participants with IBD |
| Surgery at Sahlgrenska University Hospital |
| 2021-2025 |
| This group was operated 2017-2021 |
| Inflammatory Bowel Disease |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital. |
| This group was operated 2017-2021 at Sahlgrenska University Hospital"
422,"[/INST]

Role of Myeloid-Derived Suppressor Cells and Cancer Stem Cells in Non-Small Cell Lung Cancer (NSCLC)
-----------------
These cells play a key role in the immune response to cancer. Myeloid-derived suppressor cells are a type of white blood cell that reside in the tumor microenvironment and critical for the activation of immune responses. These cells are able to inhibit the growth and spread of cancer cells by producing a protein called SCF. In addition, myeloid-derived suppressor cells can inhibit the activation of cancer stem cells. These cells are able to inhibit the growth and spread of cancer by producing a protein called CD73. The mechanism behind this is that myeloid-derived suppressor cells compete with cancer stem cells for the same soluble factors. This competition leads to the development of a tumor microenvironment that is rich in nutrients and able to sustain the growth of cancer cells.
Cancer is a disease caused by abnormal cells that are able to invade and spread to other parts of the body. Cancer stem cells are able to invade other organs and tissues because they have the ability to produce their own blood supply. These cancer cells are able to produce their own growth factors and are therefore able to sustain their own growth and spread. The immune system is able to detect these cancer cells and respond by producing proteins called cytokines. These cytokines are able to activate the immune response and critical for the destruction of cancer cells.
Cancer is a disease caused by abnormal cells that are able to invade and spread to other parts of the body. Cancer stem cells are able to inhibit the growth and spread of cancer by producing their own blood supply. These cells are able to produce a protein called SCF that critical for the activation of immune responses."
423,"[/INST]
| Participants in the study | 0, 12 weeks | 0, 12 weeks |
| Participants in the fasting condition | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 0, 12 weeks | 12 weeks | 0, 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 weeks | 12 | 12 weeks | 12 | 12 weeks | 12 weeks | 12. | 1. | 12. | 1. | 12. | 12. | 12.
| 1.1.1. | 1.1
| 1.1.
The parents.
The parents.
The parents.
The parents.
The parents.
There.
There.
This.
This.
There.
The parents.
These.
The parents.
This.
There.
These.
These.
The.
The.
The
The
These.
These.
These.
The,
This.
This.
This.
This.
It.
This.
It.
It.
This.
This.
In
In
In.
In.
These.
This.
It"
424,"[/INST]
Device: Novosyn Quick is a synthetic absorbable suture material that is available in a range of gauges, from 0 to 100% (e.g. 18 gauge, 20 gauge, 30 gauge). Device: Monosyn Quick is a synthetic absorbable suture material that is available in a range of gauges, from 18 gauge to 100% (e.g. 20 gauge, 30 gauge, 40 gauge).
Device: Novosyn Quick is a synthetic absorbable suture material that is available in a range of gauges, from 18 gauge to 100% (e.g. 20 gauge, 30 gauge, 40 gauge).
Device: Monosyn Quick is a synthetic absorbable suture material that is available in a range of gauges, from 18 gauge to 100% (e.g. 20 gauge, 30 gauge, 40 gauge).
Device: Monosyn Quick is a synthetic absorbable suture material that is available in a range of gauges, from 18 to 100% (e.g. 18 gauge, 30).
Device: Novosyn Quick is a synthetic suture material that is available in a range from 18 to 10% (e. 10% of the suture material that is a synthetic suture material that is a synthetic suture synthetic suture material that is a synthetic suture synthetic suture synthetic suture synthetic material synthetic suture synthetic material synthetic suture synthetic suture synthetic material synthetic suture synthetic suture synthetic material synthetic suture synthetic suture synthetic suture synthetic suture synthetic synthetic suture synthetic synthetic suture synthetic material synthetic suture synthetic suture synthetic synthetic suture synthetic synthetic suture synthetic synthetic suture synthetic synthetic suture synthetic synthetic synthetic synthetic suture synthetic synthetic synthetic synthetic synthetic synthetic synthetic synthetic synthetic synthetic synthetic synthetic synthetic synthetic synth
Syn
Synetic synthetic synthetic synthetic synthetic synthetic synth"
425,[/INST]
426,"[/INST]-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-





-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-h-h-h-
-M-M-M-M-M-M-M-M-M-M-M-M-M-
-
-
-
-
-
-M-M-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-M-M-M-M-M-f-M-M-M-M-
-M-h-f-f-f-f-f-f-f-f-f-"
427,"[/INST]
| surgical wound to be placed surgical site
| abdom
| surgical wound surgical site| surgical wound surgical site| surgical wound surgical site| surgical wound surgical site| 36 surgical wound surgical site surgical wound surgical site.
| surgical wound surgical wound surgical wound surgical wound surgical site surgical wound surgical surgical wound surgical surgical wound surgical surgical wound surgical surgical wound surgical surgical wound surgical surgical wound surgical surgical wound surgical surgical wound surgical surgical surgical surgical wound surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surgical surg
The surgery.
Ab.
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
The.
The patient.
The patient.
The patient.
The patient.
The.
The patient.
The patient.
The patient.
The, it.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
The.
The
The
The
The
The
The
This
This
This
This
This"
428,"[/INST]

Adverse events: [/INST]
Primary Outcome Measures
-----------------
CDK4, 6 inhibitor, Neoadjuvant therapy, Hormone therapy, Other names: Femara; Drug: Letrozole<br>* Endocrine therapy, 6 inhibitor and endocrine therapy; Drug: Abemaciclib<br>* CDK4, 6 inhibitor and endocrine therapy; Other names: Venus;

Secondary Outcome Measures
-----------------
CDK4, 6 inhibitor, Neoadjuvant therapy, Hormone therapy, Other names: Femara; Drug: Letrozole<br>* Endocrine therapy, 6 inhibitor and endocrine therapy;

Adverse events: [/INST]
Primary Outcome Measures
-----------------
CDK4, 6 inhibitor, Neoadjuvant therapy, Hormone therapy, Other names: Femara; Drug: Letrozole<br>* Endocrine therapy, 6 inhibitor and endocrine therapy;

Secondary Outcome Measures
-----------------
CDK4, 6 inhibitor, Neoadjuvant therapy, Hormone therapy, Other names: Femara; Drug: Letrozole<br>* Endocrine therapy, 6 inhibitor and endocrine therapy;

Adverse events: [/INST]
Primary Outcome Measures
-----------------
CDK4, 6 inhibitor, Neoadjuvant therapy, Hormone therapy, Other names: Femara; Drug: Letrozole<br>* Endocrine therapy, 6 inhibitor and endocrine therapy;

Secondary Outcome Measures
-----------------
CDK4, 6 inhibitor, Neoadjuvant therapy, Hormone therapy, Other names: Femara; Drug: Letrozole<br>* Endocrine therapy, 6 inhibitor and endocrine therapy;

Adverse events: [/INST]
Primary Outcome Measures
-----------------
CDK4, 6 inhibitor, Neoadjuv"
429,"[/INST]

Secondary Outcome Measures
-----------------
Examine the effectiveness of the intervention in improving outcomes for caregivers and persons living with dementia.
| How is the effectiveness of the intervention measured? | Measurement of outcomes will include changes in CGs and caregivers well-being. | For the intervention, measures will include changes in CGs well-being and ability to use assessment tools provided for persons living with dementia. | How is the effectiveness of the intervention measured for persons living with dementia? Measurement of outcomes will include changes in the ability of caregivers to provide supportive care and changes in depression and anxiety levels. |
Examine the feasibility of the intervention for caregivers. | How is the intervention feasible for caregivers to implement? Measurement of outcomes will include changes in caregiver ability to use assessment tools and changes in depression and anxiety levels. |
Examine the acceptability of the intervention for caregivers. | How is the intervention acceptable to caregivers? Measurement of outcomes will include changes in caregiver ability to provide supportive care and changes in depression and anxiety levels. |
Examine the impact of the intervention on persons living with dementia. | How is the intervention acceptable to persons living with dementia? Measurement of outcomes will include changes in the ability of persons living with dementia to function in daily life and changes in depression and anxiety levels. |
Examine the cost-effectiveness of the intervention. | How is the cost-effectiveness of the intervention measured? Measurement of outcomes will include changes in CGs ability to provide supportive care and changes in depression and anxiety levels. |
Examine the equity of the intervention. | How is the intervention equitable for caregivers and persons living with dementia? Measurement of outcomes will include changes in caregiver ability to use assessment tools and changes in depression and anxiety levels. |
Examine the safety of the intervention. | How is the intervention safe for caregivers and persons living with dementia? Measurement of outcomes will include changes in caregiver ability to use assessment"
430,"[/INST]
Primary Outcome Measures
Secondary Outcome Measures
Symptoms of depression
Other: [/INST]
Exercise, Twice per week for 8 weeks. Total 16 sessions will be given. | Other: Flexibility training, Twice per week for 8 weeks. The MAPP-QOL is a brief self-report questionnaire that measures quality of life during the general population. | 8 weeks | 
Symptoms of depression
Other: [/INST]
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Symptoms of depression
Primary Outcome Measures
Symptoms of depression
Other: [/INST]
Sympt"
431,"[/INST]

How is the study designed?
-----------------
| Other: surface hardness of denture teeth |
| 3D, 6 months after insertion wear resistance of denture teeth |
| 2D, 3D, 6 months after insertion wear resistance of denture teeth |
| surface hardness test of denture teeth at insertion |
| 3D, 6 months after insertion wear resistance of denture teeth |
| surface hardness of the denture artificial teeth at insertion |
| 2D, 3D, 6 months after insertion wear resistance of denture teeth |
| surface hardness of the denture artificial teeth at insertion |
| 3D, 6 months after insertion wear resistance of denture teeth |
| surface hardness of the denture artificial teeth at insertion |
| 2D, 3D, 6 months after insertion wear resistance of denture teeth |
| surface hardness of the denture artificial teeth at insertion |
| 3D, 6 months after insertion wear resistance of denture teeth |
| surface hardness of the denture artificial teeth at insertion |
| 2D, 3D, 6 months after insertion wear resistance of denture teeth |
| surface hardness of the denture artificial teeth at insertion |
| 3D, 6 months after insertion wear resistance of denture teeth |
| surface hardness of the denture artificial teeth at insertion |
| 2D, 3D, 6 months after insertion wear resistance of denture teeth |
| surface hardness of the denture artificial teeth at insertion |
| 3D, 6 months after insertion wear resistance of denture teeth |
| surface hardness of the denture artificial teeth at insertion |
| 2D, 3D, 6 months after insertion wear resistance of denture teeth |
| surface hardness of the denture artificial teeth at insertion |
| 3D, 6 months after insertion wear resistance of denture teeth |
| surface hardness of the denture artificial teeth at insertion |
| 2D, 3D, 6 months after insertion wear resistance of denture teeth |
| surface hardness of the denture artificial teeth at insertion |"
432,"[/INST]







































































































































































































































































































































A
A













D







D
D
D
D
D
D



































































D D---
D






F D





F
A
A D
A DO DO DO D
A DO D-













O DO QODCODC                 stides m"
433,"[/INST]
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Survival: Sevoflurane, 1-year survival, and 3-year overall survival | Karnofsky performance score | 6-month Karnofsky performance score, from the date of surgery until the date of first documented progression or death | 
| Other names: inhalation anesthesia, assessed up to 36 months |
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Survival: Sevoflurane, 1-year survival, and 3-year overall survival | Karnofsky performance score | 6-month Karnofsky performance score, from the date of surgery until the date of first documented progression or death | 
| Other names: inhalation anesthesia, assessed up to 36 months |
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Survival: Sevoflurane, 1-year survival, and 3-year overall survival | Karnofsky performance score | 6-month Karnofsky performance score, from the date of surgery until the date of first documented progression or death | 
| Other names: inhalation anesthesia, assessed up to 36 months | 
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Survival: Sevoflurane, 1-year survival, and 3-year overall survival | Karnofsky performance score | 6-month Karnofsky performance score, from the date of surgery until the date of first documented progression or death | 
| Other names: inhalation anesthesia, assessed up to 36 months | 
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Survival: Sevoflurane, 1-year survival, and 3-year overall survival | Karnofsky performance score | 6-month Karnofsky performance score, from the date of surgery until the date of"
434,"[/INST]
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
















S
S
S
S
S
S
S
S
S
S
S
















































































































































S
S
S
S
S
S
S

S
S
S
S
S
S

S
S
S
S




S
S
S"
435,"[/INST]
| Improvement of the menstrual cycle |
| Improvement of the inflammatory markers |
| Decrease in the incidence of hyperplasia |
| Decrease in the incidence of anovulation |
| Improvement of the insulin resistance |
| Decrease in the incidence of symptoms such as hirsutism |
| Improvement of the androgen levels |
| Decrease in the incidence of symptoms such as hirsutism |
| Improvement of the women's health |
| Decrease in the incidence of symptoms such as dyspareunia |
| Improvement of the anovulation rates |
| Decrease in the incidence of symptoms such as dysmenorrhea |
| Improvement of the women's health |
| Decrease in the incidence of symptoms such as amenorrhea |
| Improvement of the androgen levels |
| Decrease in the incidence of symptoms such as dysmenorrhea |
| Improvement of the women's health |
| Decrease in the incidence of symptoms such as dyspareunia |
| Improvement of the androgen levels |
| Decrease in the incidence of symptoms such as dysmenorrhea |
| Improvement of the women's health |
| Decrease in the incidence of symptoms such as dyspareunia |
| Improvement of the androgen levels |
| Decrease in the incidence of symptoms such as dysmenorrhea |
| Improvement of the women's health |
| Decrease in the incidence of symptoms such as dysmenorrhea |
| Improvement of the androgen levels |
| Decrease in the incidence of symptoms such as dyspareunia |
| Improvement of the women's health |
| Decrease in the incidence of symptoms such as dysmenorrhea |
| Improvement of the androgen levels |
| Decrease in the incidence of symptoms such as dysmenorrhea |
| Im"
436,[/INST]--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
437,"[/INST]
O
A
A
A
A
A
A
-
A
O
A
O
O
A
A
A
A
A
A
A
A
A
A
A



O
A
A
A
A
A
A
A













A
O
A
A
A
A
A
A
A
A




























-



-
A-
A




































-






























-"
438,"[/INST]

Adverse Events
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes/No |
| Yes"
439,"[/INST]
==
==
==
==
==
==
==
==
==
==
==
==-
==-
==
==
==
==
==
==
==-
==-
==-
==-
==-
==-
==-
==-
==-
==-
==-
==-
==-
==-
==-
==-
==-
==-
==-
==-
==
==-
C-
C-
==-
==-
==-
==-
==-
S
S
S
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
C
==-
==
==
S
S
S
S
S
S
S
S
C
C
C
S
S
S
S
S
S
S
C
C
C
C
C
C
==
C
C
C
--------
C
C
C
--------
C
--------
--------
--------
--------
--------
--------
8
8
........
C
C
C
--------
C
C
--------
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
S
C
C
C
C
C
C
C
C
C
C
C
C-
C
C
C
C
C
C
C
C
C
C
C"
440,"[/INST]
S
------------
S































































































































0
0000000000


























































































































































































































































































































































S
S
S
S"
441,"[/INST]

Secondary Outcome Measures"
442,"[/INST]
| Participant Group | Intervention/Treatment |
| Device: conventional transcranial Doppler probe and wearable ultrasound patch. |
| Blood flow in the brain will be measured by the conventional transcranial Doppler probe and wearable ultrasound patch. |
| Participants will be recruited from the general population. |
| Blood pressure and flow will be measured by the conventional transcranial Doppler probe and wearable ultrasound patch. |
| Participants will be screened according to the inclusion/exclusion criteria. |
| Blood flow in the brain will be measured by the conventional transcranial Doppler probe and wearable ultrasound patch. |
| Primary Outcome: Reduction of systolic blood pressure by at least 5 mmHg. |
| Secondary Outcome: Reduction of diastolic blood flow in the brain by at least 5 mmHg. |
| Tertiary Outcome: Reduction of serum-induced damage to the brain by at least 10 mmHg. |
| Blood flow in the brain will be measured by the conventional transcranial Doppler probe and wearable ultrasound patch. |
| Participants will be recruited from the general population. |
| Blood flow in the brain will be measured by the conventional transcranial Doppler probe and wearable ultrasound patch. |
| Primary Outcome: Reduction of systolic blood pressure by at least 5 mmHg. |
| Secondary Outcome: Reduction of diastolic blood flow in the brain by at least 10 mmHg. |
| Participants will be recruited from the general population. |
| Blood flow in the brain will be measured by the conventional transcranial Doppler probe and wearable ultrasound patch. |
| Primary Outcome: Reduction of systolic blood pressure by at least 5 mmHg. |
| Secondary Outcome: Reduction of diastolic blood flow in the brain by at least 10 mmHg. |
| Participants will be recruited from the general population. |
| Blood flow in the"
443,"[/INST]

Other Measures

Primary Purpose: Other
-----------------
Intervention/Treatment Study
Other Purpose
Secondary Outcome Measure
Terms related to the study
Other Purpose
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Other Purpose
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Other Purpose
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to the study
Primary Purpose: Other
Secondary Outcome Measure
Terms related to"
444,"[/INST]-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-s,-dis-dis-
-
-w-w-w-w-w-dis-dis-dis O-st-st-h-h-h-h-h-re-re-re-re-f-dis-dis-st-st-dis-st-dis-dis-dis-st-st-st-st-st-dis-dis-dis-f-f-f-f-C-O-R-O-dis-dis-dis-dis-dis-dis-dis-dis-dis-st-st-st-st-st-st-st-st-st-st-st-dis-O-st-0-0-st-re-st-st-st-st-dis
-dis-dis-dis-dis-dis-dis-dis-
-
-dis-dis-dis-dis-dis-dis-dis-disure-f-dis-dis-dis-dis-dis-dis r0-f-f-f-f-f-f-f-f-f-f-st-f-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-f-st-st-st-st-st-st-dis-dis-dis-dis-dis-f-st-st-f-f-f-f-dis-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-p-st-dis-dis-dis-dis-dis-dis-dis-dis-dis-p-p-p-p-dis-dis-dis-dis-dis-dis-diso-disy-dis-dis-dis-dis-diso-dis-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-f-"
445,[/INST] p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-st-p-p-p-p-p-st-st-p-st-st-p-p-p-p-p-p-p-st-st-st-st-st-st-st-st-st-st-st pure pids pies pure pure pure pure pure pure pure pure p-p-p-p-p-p-p-p-st-st-st-p-st-st-st-st-p-p-t-t-p-st-st-st-st-st-st-st-st-st-st-st-st-st-p-p-st-st-st-st-st-st-st-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-st-p-p-p-p-p-p-p-a pies pies pies pies p-p-p-p-in-in-a pies pies pies pies pies pies pies pites pites pites pites pites pites pites pites pites pites pised pies pies pies pies pies pies pies pies pies pies pies pry-st-st-p-p-p-p-p-p-p-p-p-p-a-p-p-p-p-p-p-p-p-p-p-p-p-p-s-s-s-p-a-a-p-p-p-p-p-p-p-s-s-s-p-p-p-p-p-p-p-p-p-p-p-p-p-p-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-p-p-p-p-p-p-p-p-a-a-
446,"[/INST]
-----------------
Adverse effects: [/INST]
Other: [/INST]
Primary Outcome: [/INST]
Secondary Outcome Measure: [/INST]
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Changes in clotting time in both groups. | 1 week | 
| Changes in clotting parameters like ESR. | 1 week | 
| Changes in clotting parameters like IL-6. | 1 week | 
| Changes in inflammatory parameters like TNF-alpha. | 1 week | 
| Changes in renal function by s. | 1 week | 
| Changes in inflammatory parameters like VWF. | 1 week | 
| Changes in the albuminome in both the groups | 1 week | 
| Adverse effects of Human Albumin Solution | 1 week | 
| Changes in inflammatory parameters like CRP. | 1 week | 
| Changes in the albuminome in both the groups | 1 week | 
| Duration of hospital stay | 28 days | 
| Changes in inflammatory parameters like PRA. | 28 days | 
| Changes in clotting parameters like TNF-alpha. | 28 days | 
| Changes in the albuminome in both the groups | 28 days | 
| Changes in renal function by s. | 28 days | 
| Changes in inflammatory parameters like IL-6. | 28 days | 
| Changes in the albuminome in both the groups | 28 days | 
| Adverse effects of Human Albumin Solution | 28 days | 
| Changes in clotting parameters like ESR. | 28 days | 
| Changes in inflammatory parameters like VWF. | 28 days | 
| Changes in the albuminome in both the groups | 28 days | 
| Changes in renal function by s. | 28 days | 
| Changes in inflammatory parameters like TNF-alpha. | 28 days | 
| Changes in"
447,"[/INST]
Adverse events associated with the use of this drug include:
| Arms 1For stage III NSCLC patients who underwent complete resection. | Immunotherapy alone or chemotherapy combined with immunotherapy. |
| Arms 2For stage III NSCLC patients who underwent concurrent radio- | Immunotherapy alone or chemotherapy combined with immunotherapy. |
| Follow-up time: 2 years | 
| Disease-free survival (RECIST) of stage III NSCLC patients | follow-up time: 2 years | 
| OS: The survival time from the enrollment to the operation | 
| Disease-free survival (RECIST) of stage III NSCLC patients | follow-up time: 2 years | 
| The prediction of recurrence by positive MRD | 2 years | 
| The survival time from the enrollment to the operation | 
| The prediction of recurrence by positive MRD | follow-up for 2 years | 
| The survival time from the enrollment to the operation | 
| The prediction of recurrence by positive MRD | follow-up for 2 years | 
| The survival time from the enrollment to the operation | 
| The prediction of recurrence by positive MRD | follow-up for 2 years | 
| The survival time from the enrollment to the operation | 
| Disease-free survival (RECIST) of stage III NSCLC patients | follow-up for 2 years | 
| The prediction of recurrence by positive MRD | 2 years | 
| The survival time from the enrollment to the operation | 
| Disease-free survival (RECIST) of stage III NSCLC patients | follow-up for 2 years | 
| The prediction of recurrence by positive MRD | 2 years | 
| The survival time from the enrollment to the operation | 
| Disease-free survival (RECIST) of stage III NSCLC patients | follow-up for 2 years | 
| The prediction of recurrence by positive MRD | 2 years | 
| The survival time from the enrollment to the"
448,"[/INST]
Patient Population
-----------------
Age 18 or older
Secondary Outcome Measures
| Patient #1 | Hypotensive ICU patient | Patient #2 |
| Patient #3 |
| Patient #4 |
| Patient #5 |
| Patient #6 |
| Patient #7 |
| Patient #8 |
| Patient #9 |
| Patient #10 |
| Patient #11 |
| Patient #12 |
| Patient #13 |
| Patient #14 |
| Patient #15 |
| Patient #16 |
| Patient #17 |
| Patient #18 |
| Patient #19 |
| Patient #20 |
| Patient #21 |
| Patient #22 |
| Patient #23 |
| Patient #24 |
| Patient #25 |
| Patient #26 |
| Patient #27 |
| Patient #28 |
| Patient #29 |
| Patient #30 |
| Patient #31 |
| Patient #32 |
| Patient #33 |
| Patient #34 |
| Patient #35 |
| Patient #36 |
| Patient #37 |
| Patient #38 |
| Patient #39 |
| Patient #40 |
| Patient #41 |
| Patient #42 |
| Patient #43 |
| Patient #44 |
| Patient #45 |
| Patient #46 |
| Patient #47 |
| Patient #48 |
| Patient #49 |
| Patient #50 |
| Patient #51 |
| Patient #52 |
| Patient #53 |
| Patient #54 |
| Patient #55 |
| Patient #56 |
| Patient #57 |
| Patient #58 |
| Patient #59 |
| Patient #60 |
| Patient #61 |
| Patient #62"
449,"[/INST]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The baby|
The baby|
The baby|
The baby|
The baby|
The baby|
The baby|
The baby|
The baby|
The baby|
The baby.
The baby.
The baby.
The baby.
The study.
The patient.
The patient.
The study.
The study.
The study.
The study.
The
The patients.
The patient.
The
The
The
The
The patient.
The
The
The
The
The
The
The results.
The
The
The lack
The    //
The    //
The    //
This    //
This    //
The    //
The    //
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
The.
A.
A.
The
This
This
This
This
This
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
This
This
This
This
This
This
This
This
This.
This.
This.
This.
This.
This.
This.
This
This
This
This.
This
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
S
S
S"
450,"[/INST]
Other related keywords: Hair Removal, Diode Laser, Intense Pulsed Light, photoepilation, Diode Laser, intense pulsed light, depilation, axillary, diode laser, photoepilation, intense pulsed light, diode laser, photoepilation, intense pulsed light, diode laser, depilation, intense pulsed light, photoepilation, diode laser, depilation, intense pulsed light, photoepilation, diode laser, depilation, intense, diode laser, photoepilation, diode laser, intense, diode, intense, diode, photoepilation, diode laser, intense, diode, intense, diode, intense, diode, intense, diode laser, intense, diode, intense, diode, intense, diode, intense, diode, intense, diode, intense, diode, intense, diode, intense, diode, intense, diode, intense, diode, intense, diode, intense, diode, intense, diode, intense, diode, intense, diode, intense, diode, intense diode, intense diode, axe, diode, intense diode, intense, diode, intense, diode, intense, diode, axe, diode, intense, diode, axe, diode, diode, axe, diode, axe, diode, axe, diode, diode, axe, diode, axe, diode, axe, diode, axe, diode, diode, axe, diode, diode, diode, axe, diode, diode, axe, diode, diode, diode, diode, diode, diode, diode, diode, diode, diode, diode, diode,
The laser, diet
The laser, and it.
==
==
==
==
==
The treatment.
This will be done.
The patient.
Why.
This will be done.
How.
How.
How.
How."
451,"[/INST]
The-the-the-the-the-
The-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-
There are-based treat-
There are- 1999
The-the-the-the-as
The-as
in-as-as-as.
There,
in-the-as-based
in-as-as-as-as-as-as-as-as
in-as-
in-as-as
in-as-as-as-as-as-as-
The   9
The   1,1.
in.
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
in
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
g
g
g

This
This
This
This
This
This
This
This
This
This
This
This
This
This
this
this
g
g
g
g











g
g"
452,"[/INST]

How is the study designed?
-----------------
| Other: Artificial Intelligent, Contrast-enhanced Ultrasound, Thyroid Nodule, Learning Curve, January 2018, June 2020. | The end of the first (M1), third (M3), and June (M6) 2018 in Sun Yat-sen Memorial Hospital. | Artificial Intelligent, Contrast-enhanced Ultrasound, Thyroid Nodule, Learning Curve, January 2019, June 2020. | Other: Artificial Intelligent, Contrast-enhanced Ultrasound, Thyroid Nodule, Learning Curve, January 2019, June 2020. |

How is the study implemented?
-----------------
| Other: Artificial Intelligent, Contrast-enhanced Ultrasound, Thyroid Nodule, Learning Curve, January 2018, June 2020. | The end of the first (M1), third (M3), and June (M6) 2018 in Sun Yat-sen Memorial Hospital. | Artificial Intelligent, Contrast-enhanced Ultrasound, Thyroid Nodule, Learning Curve, January 2019, June 2020. |
What is the study measuring?
| Other: Artificial Intelligent, Contrast-enhanced Ultrasound, Thyroid Nodule, Learning Curve, January 2019, June 2020. | The end of the first (M1), third (M3), and June (M6) 2018 in Sun Yat-sen Memorial Hospital. | Artificial Intelligent, Contrast-enhanced Ultrasound, Thyroid Nodule, Learning Curve, January 2019, June 2020. |
How is the study reported?
| Other: Artificial Intelligent, Contrast-enhanced Ultrasound, Thyroid Nodule, Learning Curve, January 2019, June 2020. | The end of the first (M1"
453,"[/INST]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
==|
|
|
|
|
|
|
|
|
|
In a|
The results.
Incre.
In.
In a|
In a|
In a|
In a brain.
In|
In|
==.
The process.
The process.
The process.
These.
==.
The.
The brain.
==
==.
This process.
In a mental.
==.
==.
==.
In.
In.
In.
In.
These.
In.
In.
In.
In.
In a.
In a|
In a|
In a|
==.
==
==
== . . .
==.
This
This
a
==
a.
==
==.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
==
==
==
==
==
==
==
==
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
454,[/INST]
455,"[/INST]
Eligibility Criteria
-----------------
Infantile age: 12 months
Primary Purpose: Diagnostic
Intervention: [/INST]
Participation Criteria
Infantile age: 12 months
Exclusion Criteria
Salivary markers: [/INST]
Participation: [/INST]
Intervention: [/INST]
Eligibility Criteria
Salivary markers: [/INST]
Participation: [/INST]
Intervention: [/INST]
Exclusion Criteria
Salivary markers: [/INST]
Participation: [/INST]
Intervention: [/INST]
Salivary markers: [/INST]
Exclusion Criteria
Intervention: [/INST]
Salivary markers: [/INST]
Participation: [/INST]
Intervention: [/INST]
Salivary markers: [/INST]
Exclusion Criteria
Salivary markers: [/INST]
Intervention: [/INST]
Salivary markers: [/INST]
Exclusion Criteria
Salivary markers: [/INST]
Intervention: [/INST]
Salivary markers: [/INST]
Exclusion Criteria
Salivary markers: [/INST]
Intervention: [/INST]
Salivary markers: [/INST]
Exclusion Criteria
Salivary markers: [/INST]
Intervention: [/INST]
Salivary markers: [/INST]
Exclusion Criteria
Salivary markers: [/INST]
Intervention: [/INST]
Salivary markers: [/INST]
Exclusion Criteria
Salivary markers: [/INST]
Intervention: [/INST]
Salivary markers: [/INST]
Exclusion Criteria
Salivary markers: [/INST]
Intervention: [/INST]
Salivary markers: [/INST]
Exclusion Criteria
Salivary markers: [/INST]
Intervention: [/INST]
Salivary markers: [/INST]
Exclusion Criteria
Salivary markers: [/INST]
Intervention: [/INST]
Salivary markers: [/INST]
Exclusion Criteria
Saliv"
456,"[/INST]
Empagliflozin, Dulaglutide, Liver Steatosis
[/INST]
[/SUMMARY]"
457,"[/INST]
[/INST]
[/surgical exposure]
[/open eruption]
[/surgical intervention]
[/open eruption]
[/surgical exposure]
[/open eruption]
[/surgical intervention]
[/surgical exposure]
[/open eruption]
[/surgical intervention]
[/open eruption]
[/surgical exposure]
[/surgical intervention]
[/surgical exposure]
[/open eruption]
[/surgical intervention]
[/surgical exposure]
[/surgical intervention]
[/open eruption]
[/surgical exposure]
[/surgical intervention]
[/open eruption]
[/surgical exposure]
[/surgical intervention]
[/surgical exposure]
[/surgical intervention]
[/surgical exposure]
[/surgical intervention]
[/surgical exposure of the surgical intervention[/surgical exposure of the surgical intervention[/surgical exposure[/surgical intervention[/surgical exposure[/s surgical intervention[/s surgical intervention[/surgical exposure[s surgical intervention[s surgical intervention[s surgical intervention[s surgical intervention[s surgical intervention[s surgical intervention[s surgical intervention[s surgical intervention[s surgical intervention[s.
[s surgical intervention[s surgical intervention[s surgical intervention[s surgical intervention[s surgical intervention[s surgical intervention[s surgical intervention[s surgical intervention[s surgical intervention[s surgical intervention[s.
[s surgical intervention[s.
[s intervention[s surgical intervention[s.
There[s intervention[s.
There[s intervention[s intervention[s intervention[s.
The intervention[s intervention.
The surgery.
There are the surgical[s inter"
458,"[/INST]
| Clinician's Manual | Treatment, Mothers and Infants ages 12-54 months |
| Treatment, Women, Infants and Children, ages 1-5 years |
| Clinician's Manual | Treatment, Mothers and Infants ages 12-54 months |
| Treatment, Women, Infants and Children, ages 1-54 months |
| Treatment, Mothers and Infants ages 12-54 months |
| Treatment, Women, Infants and Children, ages 12-54 months |
| Treatment, Mothers and Infants and Children, ages 12-54 months |
|
| Clinician's Manual | Treatment, Women, Infants and Children, ages 12-54 months |
|
| Clinician's Manual | Treatment, Mothers ages 12-54 months after birth|
| Infants and Infants ages 12-54 months after birth, Infant's Manual, Infant's Manual, Infant's Manual, Infant's Manual, Infant's Manual, Infant's Manual, Infant's Manual, Infant's Manual, Infant's Manual, Infant's Manual, Infant's Manual, Infant's Manual, Infant's Parents
|s Manual
|s Manual
|s Manual Infant
|s Manual
|s Manual
|s Manual
|s Manual|s
|s
|s Manual|s
|s
|s
|s
|s clinic|s
|s clinic|s
|s clinic|s
|s clinic|s clinic|s clinic|s clinic|s clinic|s clinic|s clinic|s
|s clinic|s clinic
|s clinic
|s clinic
The|s parents|s child|s parents|s.
The|s parents|s.
The|s child|s.
The|s parents|
The|
The|
The|"
459,"[/INST] (

(
(
(
(
(
(
(
(
(
(
-
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
(
- (
- (
(
(
(

-
-
-
(
-
(
-
-
-
-
-
-
-
-
-a a a a a a (
-
-
-
-
-
-
-
-
-
-
-
-
-
-



-



-
-













-
-
-
-
-
-
-
-
-a a a a a a a a a ( ( ( (
-
-
-
-
-
-
-
 (
 (
 (
 (
-
-
- ( (
-
-
 ( (
 (
 (
 (
 (
 (
 ( ( ( ( ( ( ( ( ( ( ( ( (
-
-
-
-
- a a a a (- (- ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (- (- ( ( ( ( ( ( (
 (



















































 (
 ( (
 ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (
 (
 ( ( (
 ("
460,"[/INST]
Other: [/INST]"
461,"[/INST]
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It's
in.
in
in
in
in
in
It
It
in
in
in
in
in
in
in
in
in
in
This
This
==
==
in
in
in
in
In
In
In
This
This
This
The
==
==
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
==
==
==
==
==
==
==
==
==
==
==
==
==
==


































The
f
f
f






f







f

f


























































































































8














8
8



8
8
8
8
8
8
8
8




8
8
7
8
8"
462,"[/INST]

Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Primary Diagnosis
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Secondary Diagnosis
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Primary Diagnosis
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Secondary Outcome Measures
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Primary Diagnosis
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Primary Diagnosis
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Primary Diagnosis
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Primary Diagnosis
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Primary Diagnosis
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Primary Diagnosis
Patients with penetrating injuries are at increased risk for developing severe infections.
| Other: Risk Factor
Patients with penetrating injuries are"
463,"[/INST]

Other: [/INST]

Study Design: [/INST]

How is the study designed?
| Primary Outcome: Lumbar Spinal Stenosis Eligible for study involving patients with SS and RA. Inclusion/Exclusion criteria: Patients with LSS and RA, or knee, ankle, and thigh, who agree to wear actigraphs and mobility. Exclusion: Patients with SS and knee, ankle, who agree to wear actigraphs and mobility.
| Other: NIPT, knee, ankle, thigh, who agree to wear actigraphs and mobility.

How is the study designed?
| Primary Outcome: Lumbar Spinal Stenosis Eligible for study involving patients with SS and knee, ankle, who agree to wear actigraphs and mobility.
| Other: NIPT, knee, ankle, thigh, who agree to wear actigraphs and mobility.

How is the study designed?
| Primary Outcome: Lumbar Spinal Stenosis Eligible for study involving patients with SS and knee, ankle, who agree to wear actigraphs and mobility.
| Other: NIPT, knee, ankle, thigh, who agree to wear actigraphs and mobility.

How is the study designed?
| Primary Outcome: Lumbar Spinal Stenosis Eligible for study involving patients with SS and knee, ankle, who agree to wear actigraphs and mobility.
| Other: NIPT, knee, ankle, thigh, who agree to wear actigraphs and mobility.

How is the study designed?
| Primary Outcome: Lumbar Spinal Stenosis Eligible for study involving patients with SS and knee, ankle, who agree to wear actigraphs and mobility.
| Other: NIPT, knee, ankle, thigh, who agree to wear actigraphs and mobility.

How is the study designed?
| Primary Outcome: Lumbar Spinal Stenosis Eligible for study involving patients with SS and knee, ankle,"
464,"[/INST]
Primary Outcome Measure
-----------------
Terms related to the study
Secondary Outcome Measure
-----------------
Patient Information Form
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by the blad
Patient Information Form provided by the blad
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by Centre Hospitalier Valida
Patient Information Form provided by the blad
Patient Information Form provided by the blad
Patient Information Form provided by the patient information provided by the patient information provided by the patient information provided by the patient information provided by the patient information provided by the patient information provided by the patient information provided by the patient information provided by the patient information provided by the patient information provided by"
465,"[/INST]
Genetic and Epigenetic Biomarkers
-----------------
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Adverse Childhood Experiences
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Genetic and Epigenetic Biomarkers
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Adverse Childhood Experiences
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Genetic and Epigenetic Biomarkers
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Adverse Childhood Experiences
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Genetic and Epigenetic Biomarkers
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Adverse Childhood Experiences
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Genetic and Epigenetic Biomarkers
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Adverse Childhood Experiences
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Genetic and Epigenetic Biomarkers
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Adverse Childhood Experiences
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Genetic and Epigenetic Biomarkers
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Adverse Childhood Experiences
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Genetic and Epigenetic Biomarkers
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Adverse Childhood Experiences
| Cancer, Breast, ACEs, Quality of Life, and Resilience
Genetic and Epigenetic Biomarkers
| Cancer, Breast, ACE"
466,"[/INST]

Colorectal cancer, Colonoscopy, AI-assisted polyp detection


What is the study measuring?
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| AI-assisted polyp detector | The AI-assisted polyp detector will be performed by every new colonoscopy (second intervention) with at least one polyp. | up to one month | 
| Diagnostic performance of AI-assisted polyp detector | The diagnostic performance of the AI-assisted system will be assessed by sensitivity, specificity, positive and negative values. |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| AI-assisted polyp detector | The AI-assisted polyp detector will be performed by every new colonoscopy (second intervention) with at least one polyp. | up to one month | 


What is the study measuring?
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| AI-assisted polyp detector | The AI-assisted polyp detector will be performed by every new colonoscopy (second intervention) with at least one polyp. | up to one month | 
| Diagnostic performance of AI-assisted polyp detector | The diagnostic performance of the AI-assisted system will be assessed by sensitivity, specificity, positive and negative values. |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| AI-assisted polyp detector | The AI-assisted polyp detector will be performed by every new colonoscopy (second intervention) with at least one polyp. | up to one month | 


What is the study measuring?
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| AI-assisted polyp detector | The AI-assisted polyp detector will be performed by every new colonoscopy (second intervention) with at least one polyp. | up to one month | 
| Diagnostic performance of AI-assisted polyp det"
467,"[/INST]
Other: [/INST]
Primary Outcome Measure
Seizure frequency in the 9 months prior to pregnancy, and seizures during pregnancy will be compared.
Secondary Outcome Measures
Gut bacteria composition, pre-pregnancy and during pregnancy
Other: [/INST]
Treatment: low glycemic index diet, pregnancy
Primary Outcome Measure
Seizure frequency in the 9 months prior to pregnancy, and seizures during pregnancy will be compared.
Other: [/INST]
Treatment: low glycemic index diet, pregnancy
Secondary Outcome Measures
Seizure frequency in the 9 months prior to pregnancy, and seizures during pregnancy will be compared.
Treatment: low glycemic index diet, pregnancy
Other: [/INST]
Seizure frequency in the 9 months prior to pregnancy, and seizures during pregnancy will be compared.
Treatment: low glycemic index diet, pregnancy
Secondary Outcome Measures
Seizure frequency in the 9 months prior to pregnancy, and seizures during pregnancy will be compared.
Treatment: low glycemic index diet, pregnancy
Other: [/INST]
Seizure frequency in the 9 months prior to pregnancy, and seizures during pregnancy will be compared.
Treatment: low glycemic index diet, pregnancy
Secondary Outcome Measures
Seizure frequency in the 9 months prior to pregnancy, and seizures during pregnancy will be compared.
Treatment: low glycemic index diet, pregnancy
Other: [/INST]
Seizure frequency in the 9 months prior to pregnancy, and seizures during pregnancy will be compared.
Treatment: low glycemic index diet, pregnancy
Secondary Outcome Measures
Seizure frequency in the 9 months prior to pregnancy, and seizures during pregnancy will be compared.
Treatment: low gly"
468,"[/INST]
| Eligible for surgical resection. | 
| 42|
| Patients with pancreasinum. | 
| 42.
| 42.
| Patients with pancreasin.
| 42.
| 10. 42.
| 42. 42. 10. 42. 42. 10. 42. 42. 10. 42. 42. 10. 42. 42. 10. 42. 42. 42. 10. 42. 42. 42. 10. 42. 42. 42. 42. 42. 42. 42. 10. 42. 42. 42. 42. 42. 42. 42. 42. 42. 42. 42. 42. 42. 42. 42. 42. 42. 42. 4. 4. 4. 4. 42. 42. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 42. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4.
There, a.
The   .
The.
The.
The
The
The
The
The
There
There
The
The
The
The
The
There
There"
469,"[/INST]
|s diagnosis.
Second, it.
The presence.
The presence.
The presence.
The presence.
The disease.
The disease.
The presence.
The presence.
The presence.
The disease.
The disease.
The disease.
The presence.
The disease.
The presence.
The breast.
The disease.
The disease.
The breast.
The treatment.
The treatment.
The treatment.
The disease.
The disease.
The disease.
The clinical symptnes.
The treatment.
The breast.
The breast.
The breast.
The breast.
The clinical.
The breast.
The treatment.
The treatment.
The
The treatment.
The bre
The.
The.
The.
The treatment.
The.
The treatment.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
The.
The.
The
The
Th.
Th.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
The
The
The
The
The
The
The
The
The
This
This
This
This
This
This
This
The
The"
470,"[/INST]
Other: [Insert summary here]
Primary Outcome: [Insert outcome here]
Secondary Outcome Measures
-----------------
Inclusion Criteria: [Insert criteria here]
Exclusion Criteria: [Insert criteria here]
* Other: [Insert criteria here]
Primary Outcome: [Insert outcome measures here]
Secondary Outcome Measure: [Insert outcome measures here]
Exclusion Criteria: [Insert outcome measures here]
Inclusion Criteria: [Insert outcome measures here]
Other: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Secondary Outcome Measure: [Insert outcome measures here]
Exclusion Criteria: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Secondary Outcome Measure: [Insert outcome measures here]
Other: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Secondary Outcome Measure: [Insert outcome measures here]
Exclusion Criteria: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Secondary Outcome Measure: [Insert outcome measures here]
Other: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Secondary Outcome Measure: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Secondary Outcome Measure: [Insert outcome measures here]
Other: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Secondary Outcome Measure: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Other: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Secondary Outcome Measure: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Other: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Secondary Outcome Measure: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Other: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Secondary Outcome Measure: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Other: [Insert outcome measures here]
Primary Outcome: [Insert outcome measures here]
Secondary"
471,"[/INST]
| Primary Outcome Measure | Serum concentrations of albumin | 10 weeks |
| Secondary Outcome Measure | Serum concentrations of phosphorous | 10 weeks |
| Primary Outcome Measure | Serum concentrations of albumin | 10 weeks |
| Secondary Outcome Measure | Serum concentrations of phosphorous | 10 weeks |
| Primary Outcome Measure | Serum concentrations of albumin | 10 weeks |
| Secondary Outcome Measure | Serum concentrations of phosphorous | 10 weeks |
| Primary Outcome Measure | Serum concentrations of albumin | 10 weeks |
| Secondary Outcome Measure | Serum concentrations of phosphorous | 10 weeks |
| Primary Outcome Measure | Serum concentrations of albumin | 10 weeks |
| Secondary Outcome Measure | Serum concentrations of phosphorous | 10 weeks |
| Primary Outcome Measure | Serum concentrations of albumin | 10 weeks |
| Secondary Outcome Measure | Serum concentrations of phosphorous | 10 weeks |
| Primary Outcome Measure | Serum concentrations of albumin | 10 weeks |
| Secondary Outcome Measure | Serum concentrations of phosphorous | 10 weeks |
| Primary Outcome Measure | Serum concentrations of albumin | 10 weeks |
| Secondary Outcome Measure | Serum concentrations of phosphorous | 10 weeks |
| Primary Outcome Measure | Serum concentrations of albumin | 10 weeks |
| Secondary Outcome Measure | Serum concentrations of phosphorous | 10 weeks |
| Primary Outcome Measure | Serum concentrations of albumin | 10 weeks |
| Secondary Outcome Measure | Serum concentrations of phosphorous | 10 weeks |
| Primary Outcome Measure | Serum concentrations of albumin | 10 weeks |
| Secondary Outcome Measure | Serum concentrations of phosphorous | 10 weeks |
| Primary Outcome Measure | Serum concentrations of albumin | 10 weeks |
| Secondary Outcome Me"
472,"[/INST]
Patients with:
| Cardiac Surgery |
| AKI |
| Breathing support |
| Cardiopulmonary bypass |
| Goal-directed perfusion |
| Cardiac surgery |
| Hemoglobin (Hb) |
| Blood pressure (BP) |
| Cardiac surgery |
| Hemodynamic (Hb) |
| Cardiopulmonary bypass |
| Goal-directed perfusion |
| Cardiac surgery |
| Hemoglobin (Hb) |
| Blood pressure (BP) |
| Cardiac surgery |
| Hemodynamic (Hb) |
| Cardiopulmonary bypass |
| Goal-directed perfusion |
| Hemoglobin (Hb) |
| Cardiac surgery |
| Blood pressure (BP) |
| Cardiopulmonary bypass |
| Hemoglobin (Hb) |
| Goal-directed perfusion |
| Cardiac surgery |
| Hemodynamic (Hb) |
| Blood pressure (BP) |
| Cardiac surgery |
| Hemoglobin (Hb) |
| Goal-directed perfusion |
| Cardiac surgery |
| Blood pressure (BP) |
| Hemoglobin (Hb) |
| Cardiac surgery |
| Goal-directed perfusion |
| Hemodynamic (Hb) |
| Cardiac surgery |
| Blood pressure (BP) |
| Hemoglobin (Hb) |
| Cardiac surgery |
| Goal-directed perfusion |
| Hemodynamic (Hb) |
| Cardiac surgery |
| Blood pressure (BP) |
| Hemoglobin (Hb) |
| Cardiac surgery |
| Goal-directed perfusion |
| Blood pressure (BP) |
| Cardiac surgery |
| Hemoglobin (Hb) |
| Cardiac surgery |
| Blood pressure (BP) |
| Hemodynamic (Hb) |
| Cardiac surgery |
| Goal-directed perfusion |
| Blood pressure"
473,"[/INST]

How is the study designed?
-----------------
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study designed? |
| Primary Purpose: Basic Science | Eligibility Criteria |
| How is the study"
474,[/INST]luliticlelasicleulululululululustulusticlerdulusticleiticleiticleusticlerdusticlerdusticlerdusticlerdusticlerdulusticlerdullaustullaustullausticlerdullausticlelalalalaustlausticlerditiclerdoniclerditiclerditiclelusticlerditiclerdiclelausticlelausticlelausticlelausticlelausticlelausticlelausticlelausticlelausticlelauticlelausticlelausticlerdiclerditiclerdiclerdiclerdiclerdiclerdiclerdiclerdiclelauticlelauticlelautulululululieduliedlaustiedlausticlelausticlelausticlelaiclelaiclelaiclelaiclelaullausticlelacialiticlenylacialiticlelausticlelausticlerdiclerditiclerditiclerditieditiediticlerduliedrdiedrdieditieditieditieditieditulightlyrditieditiedlyrditieditiedlaightiedulightlyrdiediediediediediediediediediedlylalylalyrdieditieditiedlautlaightititititititititulightulightedulightedulightedulightulightulightulomomuliedomulieditieditiedituliedulieditieditieditiedomitiedomightiedomitlyitieditieditieditiedomitiedomitiedomomiedomomomomomomightlyomitiedomitiedomitiedomullautullaullautullautulightiedulightedulightitulightitieditieditullacialitied9lullautiedomomitiedomitiedomitieditiedonightedonightonitulightiniedomidiedidiediediediediediediedidiediedidiedidulieduliediedidiedidiedoniedoniedoniedidiedidiedidiedidiedlutiedidiedidulidulidulidulidulidulidulitulitulitulitulitulidulitulitulitidulidulidulightit
475,"[/INST]

Adverse Events
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Expected to occur: [/INST]
| Reported adverse events include: [/INST]
| Ex"
476,"[/INST]

Secondary Outcome Measures
-----------------
Exclusion Criteria
| Alcohol Drinking, Binge | Biological: blood microsampling | Phosphatidylethanol, active |
| Alcohol Drinking, Binge | Phosphatidylethanol, blood | Smartphone, healthy |
| Alcohol Drinking, Binge | Phosphatidylethanol, blood |
| Alcohol Drinking, Binge | Phosphatidylethanol, healthy |
| Alcohol Drinking, Binge | Phosphatidylethanol, blood |
| Alcohol Drinking, Binge | Phosphatidylethanol, healthy |
| Alcohol Drinking, Binge | Phosphatidylethanol, blood |
| Alcohol Drinking, Binge | Phosphatidylethanol, healthy |
| Alcohol Drinking, Binge | Phosphatidylethanol, blood |
| Alcohol Drinking, Binge | Phosphatidylethanol, healthy |
| Alcohol Drinking, Binge | Phosphatidylethanol, blood |
| Alcohol Drinking, Binge | Phosphatidylethanol, healthy |
| Alcohol Drinking, Binge | Phosphatidylethanol, blood |
| Alcohol Drinking, Binge | Phosphatidylethanol, healthy |
| Alcohol Drinking, Binge | Phosphatidylethanol, blood |
| Alcohol Drinking, Binge | Phosphatidylethanol, healthy |
| Alcohol Drinking, Binge | Phosphatidylethanol, blood |
| Alcohol Drinking, Binge | Phosphatidylethanol, healthy |
| Alcohol Drinking, Binge | Phosphatidylethanol, blood |
| Alcohol Drinking, Binge | Phosphatidylethanol, healthy |
| Alcohol Drinking, Binge | Phosphatidylethanol, blood |
| Alcohol Drinking, Binge | Phosphatidylethanol, healthy |
| Alcohol Drinking,"
477,"[/INST]
| Type 2 Diabetes Mellitus |
| Inclusion / Exclusion Criteria |
| Eligible for Study |
| Type 1 Diabetes Mellitus |
| Exclusion Criteria: Pregnant or nursing women. |
| Liver disease: Childbearing age 18-25. |
| Type 2 Diabetes Mellitus |
| Inclusion Criteria: Age 18-25. |
| Exclusion Criteria: Pregnant or nursing women. |
| Type 1 Diabetes Mellitus |
| Inclusion Criteria: Childbearing age 18-25. |
| Exclusion Criteria: Pregnant or nursing women. |
| Type 2 Diabetes Mellitus |
| Inclusion Criteria: Liver disease. |
| Exclusion Criteria: Pregnant or nursing women. |
| Type 1 Diabetes Mellitus |
| Inclusion Criteria: Childbearing age 18-25. |
| Exclusion Criteria: Pregnant or nursing women. |
| Type 2 Diabetes Mellitus |
| Inclusion Criteria: Liver disease. |
| Exclusion Criteria: Pregnant or nursing women. |
| Type 1 Diabetes Mellitus |
| Inclusion Criteria: Childbearing age 18-25. |
| Exclusion Criteria: Pregnant or nursing women. |
| Type 2 Diabetes Mellitus |
| Inclusion Criteria: Liver disease. |
| Exclusion Criteria: Pregnant or nursing women. |
| Type 1 Diabetes Mellitus |
| Inclusion Criteria: Childbearing age 18-25. |
| Exclusion Criteria: Pregnant or nursing women. |
| Type 2 Diabetes Mellitus |
| Inclusion Criteria: Liver disease. |
| Exclusion Criteria: Pregnant or nursing women. |
| Type 1 Diabetes Mellitus |
| Inclusion Criteria: Childbear"
478,[/INST]
479,"[/INST]
-----------------
Primary Purpose: Money Management Program
Secondary Purpose: [/INST]
-----------------
Primary Purpose: Money Management Program
Secondary Purpose: [/INST]
-----------------
Primary Purpose: Money Management Program
Secondary Purpose: [/INST]
Primary Purpose: Money Management Program
Secondary Purpose: [/INST]
Primary Purpose: Money Management Program
Secondary Purpose: [/INST]
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program
Secondary Purpose: [/INST]
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program
Secondary Purpose: Money Management Program: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Purpose: Secondary Pur
Secondary Purpose: Secondary Pur
Secondary Pur
Secondary Secondary Secondary Pur
Secondary Pur
Secondary Pur
Secondary Secondary.
Secondary.
Secondary Secondary.
Secondary.
Second.
Second.
Secondary.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
The
The money.
The second.
The
The
The
The"
480,"[/INST]
P
The
The
The
The
The
The
The
P
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S








































































































































































































































































































































































A
A
A-
A-
A-
A-
A-
A-
A-
A-










8-
C-
A-
A
C
C-
C

-
-
-



O





P
P
P
















P-"
481,"[/INST]

Primary Outcome: Diaphragmatic function and conformation
Secondary Outcome Measures: [/INST]
Exclusion Criteria: Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragmatic function and conformation before and after the valves insertion. | Diaphragm"
482,"[/INST]
Primary Outcome: [Patient information redacted]
Secondary Outcome: [Patient information redacted]
Tertiary Outcome: [Patient information redacted]
Quarantine of the study: [Patient information redacted]
Exclusion Criteria: [Patient information redacted]
Inclusion Criteria: [Patient information redacted]
Examine the study for: [Patient information redacted]
Exclusion Criteria: [Patient information redacted]
General anesthetic requirements: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient information redacted]
Examine the study for: [Patient"
483,"[/INST]
-
-
-
-
-
-
-
-
-
-CT
C
C
C
C
C
C
C
C
C
































-"
484,"[/INST]
Other: [/INST]
Primary Outcome: Pain
Secondary Outcome: [/INST]
Treatment: [/INST]
Other: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Other: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Other: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Other: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]
Secondary Outcome: Pain
Treatment: [/INST]"
485,"[/INST]

Adverse Events
| --- | --- |
| Achondroplasia, Drug

TransCon CNP
| Drug

Primary Safety Measure
| Secondary Efficacy Measure

Height Z-score
| Weight

Treatment Completion
| Achondroplasia

Study Design
| Treatment Completion

Masking Description
| Achondroplasia
| TransCon CNP
| Drug

Height Z-score
| Weight
| Through trial completion, an average of 10 years
| Achondroplasia

Secondary Outcome Measures
| TransCon CNP
| Drug

Height Z-score
| Weight
| Through trial completion, an average of 10 years


Treatment Completion
| Achondroplasia
| TransCon CNP
| Drug

Height Z-score
| Weight
| Through trial completion, an average of 10 years


Study Results
| TransCon CNP
| Drug

Height Z-score
| Weight
| Through trial completion, an average of 10 years


Treatment Completion
| Achondroplasia
| TransCon CNP
| Drug

Height Z-score
| Weight
| Through trial completion, an average of 10 years


Study Results
| TransCon CNP
| Drug

Height Z-score
| Weight
| Through trial completion, an average of 10 years


Treatment Completion
| Achondroplasia
| TransCon CNP
| Drug

Height Z-score
| Weight
| Through trial completion, an average of 10 years


Study Results
| TransCon CNP
| Drug

Height Z-score
| Weight
| Through trial completion, an average of 10 years


Treatment Completion
| Achondroplasia
| TransCon CNP
| Drug

Height Z-score
| Weight
| Through trial completion, an average of 10 years


Study Results
| TransCon CNP
| Drug"
486,"[/INST]
| Other: Observational study of patients with paroxysmal atrial fibrillation.
| Inclusion Criteria: Patients with paroxysmal atrial fibrillation.
| Exclusion Criteria: Patients with paroxysmal atrial fibrillation.
| Participation Criteria: Patients able to participate in the study.
| Eligibility Criteria: Patients with paroxysmal atrial fibrillation.
| Exclusion Criteria: Patients unable to participate in the study due to severe illness such as dementia, psychosis, or coma.
| Inclusion/Exclusion Criteria: Patients with paroxysmal atrial fibrillation.
| Participation in the study was limited to patients age 18-75.
| Exclusion Criteria: Patients with paroxysmal atrial fibrillation.
| Other: Observational study of patients with paroxysmal atrial fibrillation.
| Inclusion/Exclusion Criteria: Patients with paroxysmal atrial fibrillation.
| Participation in the study was limited to patients age 18-75.
| Exclusion Criteria: Patients with paroxysmal atrial fibrillation.
| Other: Observational study of patients with paroxysmal atrial fibrillation.
| Inclusion Criteria: Patients with paroxysmal atrial fibrillation.
| Exclusion Criteria: Patients unable to participate in the study due to severe illness such as dementia, psychosis, or coma.
| Other: Observational study of patients with paroxysmal atrial fibrillation.
| Inclusion Criteria: Patients with paroxysmal atrial fibrillation.
| Exclusion Criteria: Patients unable to participate in the study due to severe illness such as dementia, psychosis, or coma.
| Other: Observational study of patients with paroxysmal atrial fibrillation.
| Inclusion Criteria: Patients with paroxysmal atrial fibrillation.
| Exclusion Criteria: Patients unable to participate in the study due to severe illness such as dementia, psychosis,"
487,"[/INST]
| the surgery.
| 18 year old, surgery.
| 18865000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000001
The surgery.
The patient.
The patient.
The patient.
The surgery.
The surgery.
The patients.
The patients.
The surgical.
The surgery.
The surgery.
The surgery.
The patient.
The patient.
The patient.
The patient.
The, the disease.
The patient.
The patient.
The patient.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The//>
The>
The>
The.
The.
The.
The.
The.
The.
As
The
The
The
The
The
The
The
The
The
This
The
The
The
The
The
The
The
The
This
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
488,"[/INST]
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
It.
It.
It.
It.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
S
This
This
This
This
This
This
This
This
This
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
S
S
S
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
S
S
S
S
S
S
S
S
A
A
S
S
S
S
S
S
S
S
S
A
A
A
A
A
S
S
S
S
S
S
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A"
489,"[/INST]

Virtual Reality to Cope with Stress in Academic Life
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 1999)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2001)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2002)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2003)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2004)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2005)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2006)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2007)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2008)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2009)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2010)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2011)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2012)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2013)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2014)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2015)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2016)
Visualization, Virtual Reality to Cope with Stress in Academic Life (Visualization, 2017)
Visualization, Virtual Reality to Cope with"
490,"[/INST]

Remimazolam, Desflurane, Morbid Obesity, Sleeve Gastrectomy


| Primary Outcome: Hypotension event | Secondary Outcome Measure |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction |
| Induction time |

| Secondary Outcome Measure |
| During anesthesia induction"
491,"[/INST]
The.
This.
g
g
g
D
D
D
D
D
D
D
D
f.
g
g
f


f






D
D
D
D
D
D
D
D
D
D











D
D
D
D
















A
A
be
be
be
be
be
be











f
f
f
f
f












f
f
f
f
f
f




















f
be
f
be
be
be
be
be
be
f
f
be
be
f
f
f
be
be
be













g
g
g
g





















f
to
to
f











































C
A"
492,[/INST]
493,"[/INST]
This is a summary of the key issues relating to the use of CFTR modulators in the treatment of cystic fibrosis.
Cystic fibrosis is a genetic disorder which affects the respiratory, digestive and reproductive systems. It is caused by a defect in the CFTR gene which leads to a reduction in the production of the protein that controls the movement of salt and water in the body.
CFTR modulators are drugs which can help to increase the production of the protein, and improve the function of the digestive and reproductive systems. They work by stimulating the CFTR gene, and have been shown to improve lung function and reduce inflammation in people with cystic fibrosis.
There are two CFTR modulators which have been licensed for use in the UK - ivacaftor and tezacaftor. They act in a similar way, but there is currently no evidence to suggest that one is more effective than the other. Both are administered by injection into the vein, and are usually given every four to six weeks.
CFTR modulators have been shown to improve lung function and reduce inflammation in people with cystic fibrosis. They have also been shown to have other benefits, such as improved BMI and reduced rate of hospitalisation.
People with cystic fibrosis may have other medical conditions, such as inflammatory bowel disease or liver disease. It is important to discuss any other medical conditions with a doctor before starting treatment with CFTR modulators.
There is currently no evidence to suggest that CFTR modulators increase the life expectancy of people with cystic fibrosis, but they have been shown to improve quality of life and reduce the need for hospitalisation.
CFTR modulators are not a cure for cystic fibrosis, and it is important to note that they do not correct the genetic defect which causes the condition.
There is currently no evidence to suggest that CFTR modulators are safe for use in children, but they have been shown to be generally well tolerated in adults.
It is important to note that CFTR modulators are not a treatment for cystic fibrosis, and that they should only be used in addition to the ongoing medical treatment which is required for people with the condition."
494,"[/INST]
Other names: [/INST]
Study Start: [INST]
Study Design: [/INST]
Study Population: [/INST]
Study Time: [/INST]
Caution: [INST]
Ethics approval: [INST]
Sponsor: [INST]
Funding: [INST]
Conflict of Interest: [INST]
Contributor: [INST]
Participant Information: [INST]
Research Group: [INST]
Adverse Events: [INST]
Data Safety Monitoring Committee: [INST]
Adverse Events Monitoring Committee: [INST]
Caution: [INST]
Contributor: [INST]
Research Group: [INST]
Contributor: [INST]
Participant Information: [INST]
Data Monitoring Committee: [INST]
Research Group: [INST]
Contributor: [INST]
Research Group: [INST]
Contributor: [INST]
Participant Information: [INST]
Data Safety Monitoring Committee: [INST]
Adverse Events Monitoring Committee: [INST]
Research Group: [INST]
Contributor: [INST]
Participant Information: [INST]
Data Safety Monitoring Committee: [INST]
Adverse Events: [INST]
Research Group: [INST]
Contributor: [INST]
Participant Information: [INST]
Data Safety Monitoring Committee: [INST]
Adverse Events: [INST]
Contributor: [INST]
Research Group: [INST]
Participant Information: [INST]
Data Safety Monitoring Committee: [INST]
Adverse Events: [INST]
Contributor: [INST]
Research Group: [INST]
Participant Information: [INST]
Data Safety Monitoring Committee: [INST]
Adverse Events: [INST]
Contributor: [INST]
Data Safety Monitoring Committee: [INST]
Participant Information: [INST]
Adverse Events: [INST]
Contributor: [INST]
Data Safety Monitoring Committee: [INST]
Participant Information: [INST]
Adverse Events:"
495,"[/INST]
| survival |
| length of hospital stay |
| lung function |
| Lung transplantation has become a standard treatment for patients suffering from end-stage lung diseases. |
| suitability for transplantation of the lungs after 6 hours of EVLP with HDF |
| lung function | 6 hours | 12 hours |
| survival | 12 hours |
| length of hospital stay | 12 hours | 24 months |
| lung function | 24 hours | 12 months |
| suitability for transplantation of the lungs after 24 months | 12 months |
| lung function | 24 hours | 12 months |
| survival | 12 hours |
| length of hospital stay | 12 hours | 24 months |
| lung function | 24 hours | 12 months |
| suitability for transplantation of the lungs after 24 months | 12 months |
| lung function | 24 hours | 12 months |
| survival | 12 hours |
| length of hospital stay | 12 hours | 12 months |
| lung function | 24 hours | 12 months |
| survival | 12 hours |
| length of hospital stay | 12 hours |
| lung function | 24 hours | 12 months |
| survival | 12 hours |
| lung function | 24 hours |
| length of hospital stay | 12 hours |
| survival | 12 hours |
| lung function | 24 hours |
| length of hospital stay | 12 hours |
| survival | 12 hours |
| lung function | 24 hours |
| survival | 12 hours |
| lung function | 24 hours |
| length of hospital stay | 12 hours |
| survival | 12 hours |
| lung function | 24 hours |
| survival | 12 hours |
| lung function | 24 hours |
| survival | 12 hours |
| lung function | 24 hours |
| survival | 12 hours |
| lung function | 24"
496,"[/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Secondary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Tertiary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Secondary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Secondary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Secondary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST]
Behavioral: Multisensorial stimulation, White Noise
Primary Outcome: [/INST"
497,"[/INST]

| Previous Studies |
-----------------

Time Frame: [/INST]

| Previous Research |
-----------------

How is the study designed?
| Previous Studies |
| the whole eyeball |
| those with similar conditions |
| those enrolled in research |
| those who have similar corneal health |
| those who have enrolled in research |
| those who have similar eye health |
| those who have enrolled in research |
| those who have similar corneal health |
| those who have similar histories |
| those who have similar eye health |
| those who have enrolled in research |
| those with similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye conditions |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye conditions |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye conditions |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye conditions |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histories |
| those who have similar eye health |
| those who have similar histor"
498,"[/INST]

Adverse Events
| --- | unknown |
| Unknown
Expected rate of decline in the severity of Oral Mucositis: 1 week after the end of Radiotherapy | 
| Unknown
Primary Safety Measure
Secondary Safety Measure
| Unknown
Primary Purpose: To evaluate the effect of the study on the severity of Oral Mucositis |
| Unknown |
| Unknown
Secondary Outcome Measure
Primary Purpose: To evaluate the effect of the study on the severity of Oral Mucositis |
| Unknown |
| Unknown |
Secondary Outcome Measure
Primary Purpose: To evaluate the effect of the study on the severity of Oral Mucositis |
| Unknown |
| Unknown |
Secondary Outcome Measure
Primary Purpose: To evaluate the effect of the study on the severity of Oral Mucositis |
| Unknown |
| Unknown |
Secondary Outcome Measure
Primary Purpose: To evaluate the effect of the study on the severity of Oral Mucositis |
| Unknown |
| Unknown |
Secondary Outcome Measure
Primary Purpose: To evaluate the effect of the study on the severity of Oral Mucositis |
| Unknown |
| Unknown |
Secondary Outcome Measure
Primary Purpose: To evaluate the effect of the study on the severity of Oral Mucositis |
| Unknown |
| Unknown |
Secondary Outcome Measure
Primary Purpose: To evaluate the effect of the study on the severity of Oral Mucositis |
| Unknown |
| Unknown |
Secondary Outcome Measure
Primary Purpose: To evaluate the effect of the study on the severity of Oral Mucositis |
| Unknown |
| Unknown |
Secondary Outcome Measure
Primary Purpose: To evaluate the effect of the study on the severity of Oral Mucositis |
| Unknown |
| Unknown |
Secondary Outcome Measure
Primary Purpose: To evaluate the effect of the study on the severity of Oral Mucositis |
| Unknown |
| Unknown |"
499,"[/INST]
What is the study measuring?
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Salivary biomarkers | Combination of C-reactive protein (CRP), triggering receptor expressed on myeloid cells-1 (TREM-1), interleukin (IL)-1beta, metalloproteinase (MMP)-8, IL-10, monocyte chemoattractant protein-1 (MCP-1), interferon-gamma (IFN-gamma), osteoprotegerine (OPG), Receptor activator of nuclear factor kappa B ligand (RANKL), Tumor Necrosis Factor-Alpha (TNF-alpha), Macrophage Inflammatory Protein-1 Alpha (MIP-1), interferon-gamma (IFN-gamma), osteoprotegerine (OPG), Receptor activator of nuclear factor kappa B ligand (RANKL), TNF-beta, monocyte chemoattractant protein-1 (MCP-1), interleukin (IL-1), metalloproteinase (MMP-8), IL-6, osteoprotegerine (OPG), and smoking history |
| Patient's age | 
| Habits | Baseline | 
| Patient's weight and height | Baseline | 
| Patient's waist circumference | Baseline | 
| Patient's waist measurement | Baseline | 
| Patient's history of smoking | Baseline | 
| Patient's waist measurement | Baseline | 
| Patient's history of alcohol use | Baseline | 
| Patient's history of smoking | Baseline | 
| Patient's history of alcohol use | Baseline | 
| Patient's history of smoking | Baseline | 
| Patient's history of alcohol use | Baseline | 
| Patient's history of smoking | Baseline | 
| Patient's history of alcohol use | Baseline | 
| Patient's history of smoking | Baseline | 
| Patient's history of alcohol use |"
500,[/INST] a - a - a - a - a - a - a - a - a- a - a - a - a - a - a - a - a - a - a - a - a  a  a  a  a - a - a - a- a- a - a - a  a  a - a - a - a - a - a - a - a - a  a - a- a- a- a- a - a - a - a a a a a a a a a a a a a- a- a- a a- a- a- a- a- a a a a a a a a a a a a a a- a- a- a- a- a- a- a- a- a a a a a- a- a- a- a- a- a- a- a- a- a- a- a- a- a- a- a- a- a-a- a- a- a- a- a- a- a- a- a- a- a- a- a- a- a- a- a a- a- a- a- a- a- a- a a a a a- a- a- a- a- a-a-a- a- a-a-a-a-a-A-A-D-D-D-D-D-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-D-a-a-D-a-a-a-a-D-D-D-D-D-D- a-a-a-a-a-a-a-a-a-a-D-D-D-D-D-D-D-A-a-2-A-A-A-A-A-A-A-a-a-a-a-a-a-a-a-a-D-D-a-D-D-D-D-D-a-a-a-2-2-2- a- a- a-a- a
501,"[/INST]

Other: Music, Neonatal, Pain, heart sound, listening to music, infant crying
Primary Interventions/Treatments
Music, Neonatal, Pain, heart sound, listening to music
Secondary Interventions/Treatments
Music, Neonatal, Pain, heart sound, listening to music
Tertiary Interventions/Treatments
Neonatal, Pain, heart sound, listening to music
Secondary Outcome Measures
Music, Neonatal, Pain, heart sound, listening to music
Tertiary Interventions/Treatments
Neonatal, Pain, heart sound, listening to music
Secondary Outcome Measures
Music, Neonatal, Pain, heart sound, listening to music
Tertiary Interventions/Treatments
Neonatal, Pain, heart sound, listening to music
Secondary Outcome Measures
Music, Neonatal, Pain, heart sound, listening to music
Tertiary Interventions/Treatments
Neonatal, Pain, heart sound, listening to music
Secondary Outcome Measures
Music, Neonatal, Pain, heart sound, listening to music
Tertiary Interventions/Treatments
Neonatal, Pain, heart sound, listening to music
Secondary Outcome Measures
Music, Neonatal, Pain, heart sound, listening to music
Tertiary Interventions/Treatments
Neonatal, Pain, heart sound, listening to music
Secondary Outcome Measures
Music, Neonatal, Pain, heart sound, listening to music
Tertiary Interventions/Treatments
Neonatal, Pain, heart sound, listening to music
Secondary Outcome Measures
Music, Neonatal, Pain, heart sound, listening to music
Tertiary Interventions/Treatments
Neonatal, Pain, heart sound, listening to music
Secondary Outcome Measures
Music, Neonatal, Pain, heart sound, listening to music
Tertiary Interventions/Treatments
Neonatal, Pain, heart sound, listening to music
Secondary Outcome Measures
Music"
502,"[/INST]

Primary Outcome Measure
-----------------
Change from week 1 (baseline) to week 12 (final visit) on the Caregiver Stress Checklist (36 items) | To assess caregiver use of strategies and 85 items, and child's behavior on a 1 to 5 scale. | Week 1 (baseline) versus week 12 (final visit) | 
Secondary Outcome Measure
-----------------
Change from week 1 (baseline) to week 12 (final visit) on the Vineland Adaptive Behavior Scales (72 items) | To assess child's abilities with 15 items, and caregiver use of strategies with 6 items. | Week 1 (baseline) versus week 12 (final visit) | 
Change from week 1 (baseline) to week 12 (final visit) on the Social Competence Scale (36 items) | To assess child's behavior on a 1 to 5 scale and caregiver use of 15 items. |
Secondary Outcome Measure
-----------------
Change from week 1 (baseline) to week 12 (final visit) on the Vineland Adaptive Behavior Scales (72 items) | To assess child's abilities with 15 items, and caregiver use of strategies with 6 items. |
Primary Outcome Measure
-----------------
Change from week 1 (baseline) to week 12 (final visit) on the Social Competence Scale (36 items) | To assess child's behavior on a 1 to 5 scale and caregiver use of 15 items. |
Primary Outcome Measure
-----------------
Change from week 1 (baseline) to week 12 (final visit) on the Vineland Adaptive Behavior Scales (36 items) and caregiver use of 15 items. | To assess child's behavior on a second (15 items. | Change from week 1 (basement, and caregiver of 15 items. | To assess child. | to week 1. | to assessment of the caregiver. | to assessment of 15 items. | to assessment. | to"
503,"[/INST]
-
-
-





























O
O
O
A
A
O
O
O
























0
0
0
0
O
O
O
O
O
A
O
O

O





O















0
0
00000000000
0
8
8
8
8


























0
0
0
00000
0
0
8


8
-
-
-
-
-
-











-
-
8









































O
O
O
O










0











ization
O







0
0
0
0

O
O
O
O
O
O










































8
8
8
8
8"
504,"[/INST]
Adverse Events: [/INST]
Primary Outcome Measure
-----------------
| Verbal testing: Change from baseline of verbal scores for those who underwent hyperbaric oxygen therapy and the control group who did not receive treatment. |
Secondary Outcome Measures
-----------------
| Verbal testing: Change from baseline of verbal scores for those who underwent hyperbaric oxygen therapy and the control group who did not receive treatment. |
Adverse Events: [/INST]
| Verbal testing: Change from baseline of verbal scores for those who underwent hyperbaric oxygen therapy and the control group who did not receive treatment. |
Participants will be randomly assigned to either receive hyperbaric oxygen therapy or the control group who did not receive treatment.
Outcome Measures
-----------------
| Verbal testing: Change from baseline of verbal scores for those who underwent hyperbaric oxygen therapy and the control group who did not receive treatment. |
Adverse Events: [/INST]
Secondary Outcome Measures
-----------------
| Verbal testing: Change from baseline of verbal scores for those who underwent hyperbaric oxygen therapy and the control group who did not receive treatment. |
Participants will be randomly assigned to either receive hyperbaric oxygen therapy or the control group who did not receive treatment.
Adverse Events: [/INST]
| Verbal testing: Change from baseline of verbal scores for those who underwent hyperbaric oxygen therapy and the control group who did not receive treatment. |
Secondary Outcome Measures
-----------------
| Verbal testing: Change from baseline of verbal scores for those who underwent hyperbaric oxygen therapy and the control group who did not receive treatment. |
Adverse Events: [/INST]
| Verbal testing: Change from baseline of verbal scores for those who underwent hyperbaric oxygen therapy and the control group who did not receive treatment. |
Participants will be randomly assigned to either receive hyperbaric oxygen therapy or the control group who did not receive treatment.
Secondary Outcome Measures
-----------------
| Verbal testing: Change from baseline of verbal scores for those who underwent hyperbar"
505,"[/INST]
| knee
| elbow and 24 hours after the frist's knee .|24 hours after the knee|24 hours after the knee|24 hours after the knee|24 hours after the knee.
|24 hours after the knee|24 hours after the knee|24 hours after knee|24 hours after the knee|24 hours after the knee|24 hours after the knee.|24 hours after the knee.|24 hours after the knee.|24 hours after the knee.|24 hours after the knee after the knee.|24 hours after the knee.|24 knee after the knee after the knee after the knee after the knee after the knee after the knee after the knee after the knee after the knee after the knee after the knee after knee after knee after knee after knee after knee after the knee after the knee after the knee after the knee after the knee after the knee after the knee after the knee after the knee after knee after knee after knee after the knee after the knee after the knee after the knee after the knee after the knee.
The knee.
The knee.
The knee.
The knee.
The knee.
The knee.
The knee.
The knee.
The knee.
The knee.
The knee.
The knee.
The knee.
The knee.
The surgery.
The surgery.
The surgery.
The knee.
The knee.
The knee.
The
The.
The surgery.
The knee.
The.
The, this.
The.
The.
The surg
The.
The.
The.
The.
The.
The,.
The.
The.
The.
The.
This
This.
The, this
The, this
The,
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
The
This
This
This
This"
506,"[/INST]

Primary Purpose: Prevention
| Intervention Model: RCT
| Experimental: Lymphatic lymph node dissection and immediate axillary reconstruction
| Procedure: Immediate lymphatic reconstruction, or sentinel lymph node dissection and ILR
| Terminology: Lymphatic lymphedema, or seroma and axillary lymph node dissection
| Experimental: Lymphatic lymph node dissection, or sentinel lymph node biopsy and immediate ILR
| Intervention: Immediate lymphatic lymph node dissection, or sentinel lymphedema and ILR
| Procedure: Immediate lymphatic lymph node dissection, or sentinel lymph node biopsy and ILR
| Terminology: Lymphatic lymphedema, or seroma and axillary lymph node dissection
| Experimental: Lymphatic lymph node dissection, or sentinel lymph node biopsy and immediate ILR
| Procedure: Immediate lymphatic lymph node dissection, or sentinel lymphedema and ILR
| Intervention: Lymphatic lymph node dissection, or sentinel lymph node biopsy and ILR
| Terminology: Lymphatic lymph node dissection, or seroma and axillary lymphaceous lymph
| Procedure: Immediate lymphatic lymph node dissection, or sentinel lymph node biopsy and ILR
| Experimental: Lymphatic lymph node dissection, or sentinel lymph node biopsy and ILR
| Intervention: Immediate lymphatic lymph node dissection, or sentinel lymph node biopsy and ILR
| Procedure: Immediate lymphatic lymph node dissection, or sentinel lymph node biopsy and ILR
| Terminology: Lymphatic lymph node dissection, or seroma and axillary lymphaceous lymph node biopsy and ILR
| Experimental: Lymph"
507,"[/INST]
| Other: Patient #1, #2, #3, #4, #5, #6, #7, #8, #9, #10, #11, #12, #13, #14, #15, #16, #17, #18, #20, #22, #25, #28, #30
| Other: Patient #1, #2, #3, #4, #5, #6, #7, #8, #9, #10, #11, #13, #14, #17, #18, #21, #24, #27, #28, #31
| Other: Patient #1, #2, #3, #4, #5, #6, #7, #10, #11, #13, #14, #17, #20, #21, #24, #27, #21, #28, #30
| Other: Patient #1, #2, #3, #4, #5, #6, #7, #10, #11, #13, #14, #17, #20, #21, #24, #27, #21, #28, #30
| Other: Patient #1, #2, #3, #4, #5, #6, #7, #10, #11, #13, #14, #17, #20, #21, #24, #27, #21, #28, #30
| Other: Patient #1, #2, #3, #4, #5, #6, #7, #10, #11, #13, #14, #17, #20, #21, #24, #27, #21, #28, #30
| Other: Patient #1, #2, #3, #4, #5, #6, #7, #10, #11, #13, #14, #17, #20, #"
508,[/INST]
509,"[/INST]

Patients with early breast cancer
-----------------
Behavioral: Patients with early breast cancer
Quality of Life in Women with early breast cancer
Transcultural adaptation of the PRO questionnaire
| Transplantation: Patients with early breast cancer will be transplanted 17 years after diagnosis.
| Survival at 5 years: PRO will be measured by the PRO questionnaire, which will be administered to patients with early breast cancer.
| Quality of Life: The PRO questionnaire will be administered to patients with early breast cancer.
| Transplantation: Patients with early breast cancer will be eligible for the PRO questionnaire.
| Survival at 5 years: The PRO questionnaire will be administered to patients with early breast cancer.
| Quality of Life: The PRO questionnaire will be administered to patients with early breast cancer.
| Intervention: The PRO questionnaire will be administered to patients with early breast cancer.
| Transplantation: Patients with early breast cancer will be eligible for the PRO questionnaire.
| Screening: The PRO questionnaire will be administered to patients with early breast cancer.
| Outcome: The PRO questionnaire will be administered to patients with early breast cancer.
| Intervention: The PRO questionnaire will be administered to patients with early breast cancer.
| Transplantation: Patients with early breast cancer will be eligible for the PRO questionnaire.
| Screening: The PRO questionnaire will be administered to patients with early breast cancer.
| Outcome: The PRO questionnaire will be administered to patients with early breast cancer.
| Intervention: The PRO questionnaire will be administered to patients with early breast cancer.
| Transplantation: Patients with early breast cancer will be eligible for the PRO questionnaire.
| Screening: The PRO questionnaire will be administered to patients with early breast cancer.
| Outcome: The PRO questionnaire will be administered to patients with early breast cancer.
| Intervention: The PRO questionnaire will be administered to patients with early breast cancer.
| Transplantation: Patients with early breast cancer will be eligible for the PRO questionnaire.
| Screening: The PRO questionnaire will be administered"
510,"[/INST]
1.
Sym
Sympt
Sym
Sympt
Sym
Sympt
Sympt
Sym
Sympt
Symas
Symas
Sym
Sympt
Sym
Sympt
Symper
Sym
Sym
Sym
Sympt
Sym
Sympt
Sym
Sympt
Sym
Sym
Sym
Sympt
Symost
Symost
Symost
Symost
Symost
Symper
Sympt
Sympt
Sympt
Sympt
Sympt
Sympt
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
Sym
The
Sym
The
Sym
The
The
The
The
Sym
Sym
The
The
The
The
The
The
The
The
The
The
It
The
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It.
It
The patient
The patient
The
The psych
It
This
It
It
This
This
This
This
This
This
This
This
This
This
It
This
This
This
This
This
This
This
It
It
It
It
It
It
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
P
P
P
P
P
P
P
P
P
F
S
S
S
S
S
S
S
This
P
M
M
F
F
F
This
This
P
P
P
P
P
P
P
P
P
P
This
This
S
S
Term
Term
C
C
D
C
C
S
P
M
P
P
P
P
P
S
S
S"
511,"[/INST]
The-the-the-the
The treatment.
The-the-the-the-the-the-
The-the-the-this.
The-the-the-the-the
The experiment.
The experiment.
The experiment.
After.
After.
The control.
The control.
The
The
The
The
The
The experiment.
The experiment.
The
The
The
The
The
The
The
The
The
The
The
The
The.
The.
The.
The.
This.
This
This
This.
This.
This.
This
This
This
This
This
This.
The
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This.
This.
This.
This.
The
This.
The.
This.
This.
A.
This.
This.
This.
This.
This.
This.
This
This
This.
A
A
A
A
a
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
This
This
A
This
This"
512,"[/INST]

Adverse Events
| Favorable neurological function: mRS score 3 at 90 days. |
| Procedure: endovascular recanalization via femoral approach at 90 days. |
| Outcome: favorable neurological function at 90 days. |
| Procedure: endovascular recanalization via femoral approach at 90 days. |
| Outcome: neurological function at 90 days. |

Secondary Outcome Measures
-----------------
| Favorable neurological function: mRS score 3 at 90 days. |
| Procedure: endovascular recanalization via femoral approach at 90 days. |
| Outcome: neurological function at 90 days. |

Secondary Outcome Measures
-----------------
| Favorable neurological function: mRS score 3 at 90 days. |
| Procedure: endovascular recanalization via femoral approach at 90 days. |
| Outcome: neurological function at 90 days. |

Secondary Outcome Measures
-----------------
| Favorable neurological function: mRS score 3 at 90 days. |
| Procedure: endovascular recanalization via femoral approach at 90 days. |
| Outcome: neurological function at 90 days. |

Secondary Outcome Measures
-----------------
| Favorable neurological function: mRS score 3 at 90 days. |
| Procedure: endovascular recanalization via femoral approach at 90 days. |
| Outcome: neurological function at 90 days. |

Secondary Outcome Measures
-----------------
| Favorable neurological function: mRS score 3 at 90 days. |
| Procedure: endovascular recanalization via femoral approach at 90 days. |
| Outcome: neurological function at 90 days. |

Secondary Outcome Measures
-----------------
| Favorable neurological function: mRS score"
513,"[/INST]

Other Outcome Measures
-----------------
Primary Outcome Measure
Measure Description | Time Frame |
| --- | --- |
| Perinatal Healthcare Utilization | Baseline, third trimester and postpartum | 
| Depression | Measured with the Patient Health Questionnaire-9 (PHQ-9) | Baseline, third trimester and postpartum | 
| Severe Maternal Morbidity | Composite diagnoses using ICD-10 codes: acute myocardial infarction, aneurysm, cardiac arrest, shock, sickle cell disease, thrombosis, disseminated intravasive shock, air and thrombotic embolism, hysterectomy, temporary tracheostomy, and postpartum | 
| Breastfeeding Initiation | Rates of breastfeeding prior to discharge from the hospital | 
| Trust in Providers | Baseline, third trimester and postpartum | 
| Depression | Measured with the Patient Health Questionnaire-9 (PHQ) | Baseline, third trimester and postpartum | 
| Perinatal Healthcare Utilization | 
| Trust in Providers | Baseline, third trimester and postpartum | 
| Depression | Measured with the Patient Health Questionnaire | 
| Perinatal healthcare utilization, third trimester and postpartum | 
| Trust in Providers | 
| Perinatal healthcare | Baseline, third trimester and postpartum | 
| Perinatal, third trimester, postpartum | 
| Trust in Provider | Perinatal, third trimester, postpartum|s healthcare|s trust|s perinatal|s healthcare providers, third trimester|s: Perinatal|s healthcare|s trust|s healthcare providers.|s: Perinatalists, third trimester|s healthcare providers. Perinatalism.
|s healthcare providers. Perinatalism.
|s. Perinatal|s.
Trust healthcare providers. Perinatalists: Perinatalists. Perinatalist|s. Perinatalist|s. Perinatalist|s. Per"
514,"[/INST]
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The
for.
for.
for.
for.
for.
The
A
A
in
in
in
in
in
in
in
This
in
A
A
A
A
A
A
A
A
A-from-based
A
This
This
This
This
This
This
and
and
and
and
and
and
and
in
in
I
I
I
I
I
I
I
I
I
I
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
for
for
for
comple
comple
comple
comple
and
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A"
515,"[/INST]
The study.
The study.
The study.
The study.
The study.
The study.
The study.
The study.
The study.
The study.
The study.
The study.
The study.
The subjects.
The subjects.
The study.
The study.
The study.
This.
The study.
The National
The National
The study.
The study.
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The experiment
The experiment
The experiment
The experiment
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This











This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
516,"[/INST]
|
| 12 months | 12 months |
| 12 months |
| 12 months | 12 months |
| 12 months after the study | 12 months | 12 months after the baseline | 12 months after the study | 12 months after the baseline | 12 months after the study | 12 months after the baseline | 12 months after the study baseline | 12 months after the baseline | 12 months after the study baseline | 12 months after the study baseline | 12 months after the study baseline | 12 months after the study baseline | 12 months after the baseline | 12 months after the baseline | 12 months after the baseline | 180s baseline months after the study after the baseline months after the study after the baseline. |12 months after the baseline. |12 months after the baseline months after the baseline months after the baseline. |180. |180. |180.
|18 months after the baseline. |18018 baseline. |1801 baseline.19801801 baseline.1801980198010101010101980101980191901010190101010101010101901010101010101010101.
Basia.
Basic.
Basic.101010100000010101.
Basia.
Bas.
Bas.
Bas.
Basic.
Basia.
Bas
Bas.
Bas
Bas
Bas
Basian.
Basian.
Basia.
The surgine.
The surg
The results.
The surg
The,
The,
The
The
The
This
This
This:
This:
The results
The,
The,
The:
The:
This:
This:
This:
This:
The:"
517,"[/INST] g0 g0 g0 g-0 g-0 p-1 p-m-0-0-0-0-m-m-m-m-m-m-m-m-8-8-m-m-m-m-m-0-0-0-0 D-m-m-o-m-m-m-m-m-m-m-m-m-m-m-m-m-m-0 p0 p00000000-0 g0 g0 g0 g0 p-0-0-0-0-m-m-m-m-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0.-0-0--0-0-0-0-0-0-0-0-0-0--------o--o-,- g- g- g- g-0-0-0-0-0-0---0-0-0-0-0-0-0-0--0-0-0-y-y-y-0-0-0-0-0-0-, g-0-,-,-,--------0-0-0-0-0-0-0-0-0------0-0-0-0-0-0-,-,-0-0-0-0-0-0-0-0-0-0-0------------0-0-0-0-0-0-a-a-a------------------y--y-y----------y-y-y-y-y-y---y-a-a-a--y---------0-0-0-a-0-a-a-a-a-y-y-a-a-a-a-a-a-0-0-0-.-.-.---0-0-y-y-y-y-a"
518,"[/INST]

Screening Recommendations
-----------------
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |
| Primary Care Physician |
| Secondary Care Physician |
| Specialist: Colonoscopy |"
519,"[/INST]
A


























A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A
A
A
A


















h













A
h
h
h-
h-
h-
h-
h-
h-
h-
h-
h-
h-
h-
h-
h-
A-
A-
A-
A-
h-
h-
h-
A-
A-
A-
A-



A-
A-
A-
A
A
-
A-
A-
A-
-
-
-h-h-h-h-h-h-h-h-h-h-h-
-h-h-h-h-h-h-h-
-
-
-
-
-
-
-
-
-
-
-
-
-
-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h"
520,"[/INST]
| Primary Outcome | Secondary Outcome | Tertiary Outcome |
| Intermediate Outcome |
| Behavioral |
| Outcome Measure |
| Secondary Outcome |
| Tertiary Outcome |
| Primary Outcome |
| Secondary Outcome |
| Intermediate Outcome |
| Behavioral |
| Primary Outcome |
| Secondary Outcome |
| Tertiary Outcome |
| Intervention |
| Primary Outcome |
| Secondary Outcome |
| Tertiary Outcome |
| Behavioral |
| Primary Outcome |
| Secondary Outcome |
| Tertiary Outcome |
| Intervention |
| Primary Outcome |
| Secondary Outcome |
| Tertiary Outcome |
| Behavioral |
| Primary Outcome |
| Secondary Outcome |
| Intervention |
| Tertiary Outcome |
| Primary Outcome |
| Secondary Outcome |
| Intervention |
| Tertiary Outcome |
| Primary Outcome |
| Secondary Outcome |
| Intervention |
| Tertiary Outcome |
| Primary Outcome |
| Secondary Outcome |
| Intervention |
| Tertiary Outcome |
| Primary Outcome |
| Secondary Outcome |
| Intervention |
| Tertiary Outcome |
| Primary Outcome |
| Secondary Outcome |
| Intervention |
| Tertiary Outcome |
| Primary Outcome |
| Secondary Outcome |
| Intervention |
| Tertiary Outcome |
| Primary Outcome |
| Secondary Outcome |
| Intervention |
| Tertiary Outcome |
| Primary Outcome |
| Secondary Outcome |
| Intervention |
| Tertiary Outcome |
| Primary Outcome |
| Secondary Outcome |
| Intervention |
| Tertiary Outcome |
| Primary Outcome |
| Secondary Outcome |
| Intervention |
| Tertiary Outcome |
| Primary Outcome |
| Secondary Outcome |
| Intervention |
| Tertiary Out"
521,"[/INST]
| Mon.
|
| 8 hours.
| 8 hours.
Mon, it for |
Mon for 8.
Mon, it to 8 hours.
Mon, 8 months. Mon. Mon. Mon.
Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon. Mon.
Mon.
Mon.
Mon.
Mon.
Mon.
Mon.
Mon.
Mon.
Mon.
Mon.
Mon.
Mon.
It.
Mon.
The
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
In
In
It
It
It
It
It
It
It
It
It
It
It
In
In
In
In
In
It
It
It
It
It
It
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
It
It
It
It
It
It
It
In
In
In
In
In
In
In
In
It
It
This
This
This
This
This
A
A
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
This
This
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A"
522,"[/INST]

Other Names: Sinomenine
| Drug: Glucocorticoid
| Participant Group: Knee Osteoarthritis
| Experimental: Sinomenine
| Have: Knee Osteoarthritis
| Participants will receive one injection every 4 months
| Primary Purpose: To compare the change in WOMAC score from baseline to final visit
| Secondary Purpose: To compare the change in tibial cartilage volume from baseline to final visit
| Participants will receive one injection every 4 months
| Have: Knee Osteoarthritis
| Primary Purpose: To compare the change in WOMAC score from baseline to final visit
| Secondary Purpose: To compare the change in tibial cartilage volume from baseline to final visit
| Participants will receive one injection every 4 months
| Have: Knee Osteoarthritis
| Primary Purpose: To compare the change in WOMAC score from baseline to final visit
| Secondary Purpose: To compare the change in tibial cartilage volume from baseline to final visit
| Participants will receive one injection every 4 months
| Have: Knee Osteoarthritis
| Primary Purpose: To compare the change in WOMAC score from baseline to final visit
| Secondary Purpose: To compare the change in tibial cartilage volume from baseline to final visit
| Participants will receive one injection every 4 months
| Have: Knee Osteoarthritis
| Primary Purpose: To compare the change in WOMAC score from baseline to final visit
| Secondary Purpose: To compare the change in tibial cartilage volume from baseline to final visit
| Participants will receive one injection every 4 months
| Have: Knee Osteoarthritis
| Primary Purpose: To compare the change in WOMAC score from baseline to final visit
| Secondary Purpose: To compare the change in tibial cartilage volume from baseline to final visit
| Participants will receive one injection every 4 months
| Have: Knee Osteoarthritis
| Primary Purpose: To compare the change in"
523,"[/INST]
Other: anxiety, dyspnea, virtual reality, breathing exercise, quality of life
====================
Primary Outcome Measure | Secondary Outcome Measure | pretest, week 4, week 8 | Secondary Outcome Measure | pretest, week 4, week 8 | Secondary Outcome Measure | pretest, week 4, week 8 | Secondary Outcome Measure | pretest, week 4, week 8 | Secondary Outcome Measure breathing exercises, pretest, week 4, virtual reality breathing exercises, pretest, week 8 | Secondary Outcome breathing exercises, pretest, week 4, virtual reality breathing exercises, pretest, Secondary Outcome breathing exercises, pretest, pretest, breathing exercises, pretest, breathing exercises, pretest, pretest, breathing exercises, pretest, pretest, breathing exercises, pretest, pretest, pretest, pretest, breathing exercises, pretest, pretest, breathing exercises, pretest, pretest, pretest, pretest, pretest, breathing. Secondary breathing, pretest, pretest, pretest, pretest, pretest, breathing pretest, pretest, pretest, pretest, pretest, pretest, pretest, pretest, pretest, pretest, pretest, pretest pretest, pretest, pretest, pretest, pre-test, pre, pre, pre, pre, pre, pre, pre, pre, pre. Second, pre. Second, pre. Second, pre
Second, pre
Second pretest pretest pretest, pre
, pre
, pre
Second, pre
Second, pre
Second, pre
Second, pre
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
==,, they.
==
==
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The
The
The
The
The
The"
524,"[/INST]
| Participant Group | Eligibility Criteria | Exclusion Criteria |
| Participant will be asked to provide demographic information (e.g., age, sex, height, weight) as part of the study. | Participants will be asked to abstain from alcohol and tobacco. | Participants will be current smokers or former smokers. |
| Participants will be asked to refrain from behaviors that may lead to injury or illness (e.g., horseback riding, scuba diving, skydiving, bungee jumping). | Participants will be asked to provide information on their medical history (e.g., whether they have a history of heart disease, cancer, or thyroid disease). |
| Participants will be asked to refrain from behaviors that may lead to injury or illness (e.g., horseback riding, scuba diving, smoking, consumption of alcohol). | Participants will be asked to abstain from behaviors that may lead to injury or illness (e.g., horseback riding, skydiving, smoking, consumption of alcohol). |
| Participants will be asked to provide information on their medical history (e.g., whether they have a history of cancer, heart disease, or thyroid disease). | Participants will be asked to refrain from behaviors that may lead to injury or illness (e.g., horseback riding, skydiving, smoking, consumption of alcohol). |
| Participants will be asked to abstain from behaviors that may lead to injury or illness (e.g., horseback riding, skydiving, smoking, consumption of alcohol). | Participants will be asked to provide information on their medical history (e.g., whether they have a history of cancer, heart disease, or thyroid disease). |
| Participants will be asked to refrain from behaviors that may lead to injury or illness (e.g., horseback riding, skydiving, smoking, consumption of alcohol). | Participants will be asked to provide information on their medical history (e.g., whether they have a history of cancer, heart disease, or thyroid disease). |
| Participants will be asked to refrain from"
525,"[/INST]
be-












































































































































p


















































































h-
h-



8-





-
8-
8-
8-
8-
8-
8-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
8-
8-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
--
-
-
-
-
-
-
-
-
-
---h---------
-
-
-h-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-----"
526,"[/INST] Tranexamic acid (TXA) vs. placebo.
Adverse Events
-----------------
Patients
Primary Outcome
-----------------
Cardiovascular Surgery
Adverse Events
Secondary Outcome
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Secondary Outcome
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Secondary Outcome
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Secondary Outcome
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiovascular Surgery
Adverse Events
Measurement of primary outcome | Time Frame |
Cardiov"
527,"[/INST]
The, it's .
The most.
In.
In.
In.
In.
It.
It.
in.
in.
It.
in.
In.
In.
It
/>.
/>.
==
==
==
==
== (==
==
==
==.
==
==
==
==
==
==
==
==
==
==
==
==.
==
==
==
==
==
==
==
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
==.
==.
==
This
This
This
This"
528,"[/INST]
| Other: [/INST]

How is the study designed?
| Primary Purpose: Prevention | Intervention: Dumpling suture for ileostomy<br>This study uses stoma suturing with sutures at the skin fold, and the incision is narrowed by 2-3 interrupted sutures at the distal and proximal ends of the skin lesion using traditional suturing method. | Other: Traditional suture of ileostomy using sutures at the skin fold, and the incision is fixed with stoma using sutures. The stoma is then realigned at the right lower abdominal incision with sutures.

How is the study measuring results?
| Primary Outcome Measures: [/INST]
| Other: [/INST]

How is the study designed?
| Primary Purpose: Prevention | Intervention: Dumpling suture for ileostomy<br>This study uses stoma suturing with sutures at the skin fold, and the incision is narrowed by 2-3 interrupted sutures at the distal and proximal ends of the skin lesion using traditional suturing method. | Other: Traditional suture of ileostomy using sutures at the skin fold, and the incision is fixed with stoma realignment and the corresponding lesion using sutures.

What is the study measuring?
| Primary Outcome Measures: [/INST]
| Other: [/INST]

How is the study designed?
| Primary Purpose: Prevention | Intervention: Dumpling suture for ileostomy<br>This study uses stoma suturing with sutures at the skin fold, and the incision is narrowed by 2-3 interrupted sutures at the distal and proximal ends of the skin lesion using traditional suturing method. | Other: Traditional suture of ileostomy using sutures at the skin fold, and the incision is fixed with stoma realignment and the corresponding lesion."
529,"[/INST]
|
| 6-8.
| 6-8 months after the
|
|
| 6-8 years old
|
| 6-8.
| 6-8.
|
|
|
|
|
|
| 6.
| 7.
| 6.
|
| 6.
| 6.
| 6.
| 6.
| 7.
| 7.
| 7.
| 7.
| 7.
| 7.
| 7.
| 7.
| 7.
| 8.
| 7.
| 7.|
| 7.| 7.|
| 7.|
| 7.|
| 7.
| 7.|
| 7.|
|
| 7.|
|
|
|
|
|
|
|
|
|
|
|
|
The patient.
There.
|
|
|
|
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
There,
There,
The patient.
The patient
The patient
The patient
The patient
The
There
There
There
There
There
There
There
There
There
There
There
The
In
In
This
This
The
In
In
In
The
The
The
The
The
The
The
The
The
The
The
Th
The
This
This
This
This
This
This
This
This
This
This
This
The
The
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
530,"[/INST]
| Experimental: Age range of 18 to 44 years old, The initial dose of rocuronium for pre-injection was set at 0.04mg/kg according to previous literature and preliminary test results. The dose of rocuronium in the next patient will be increased until the patient has myofibrillation. | Drug: rocuronium<br>* Advanced intravenous injection of rocuronium before the succinylcholine injection<br>Age range of 18 to 44 years old, The initial dose of rocuronium for pre-injection was set at 0.04mg/kg according to previous literature and preliminary test results. The dose of rocuronium in the next patient will be increased until the patient has myofibrillation."
531,"[/INST]



































































































































,,




,,,,,,,,"
532,"[/INST]

Other: [/INST]
Adverse events: [/INST]
Clinical events: [/INST]
Secondary Outcome Measures
Terms related to the clinical events: [/INST]
| Incidence of a composite of myocardial infarction, stroke, and all-cause mortality in patients with polluted vs non-polluted plaques | Cox models, adjusted for the same variables, will be run to examine the relationship between the burden of microplastics and the incidence of the composite outcome. P values < 0.05 will be considered statistically significant. | 24 months | 


Adverse events related to the study: [/INST]
Secondary Outcome Measures
Terms related to the adverse events: [/INST]
Clinical events: [/INST]
Carotid endarterectomy is performed to assess the presence of microplastics within plaques. Cox models, adjusted for the same variables, will be used to explore the relationship between the burden of microplastics and the incidence of the composite outcome. P values < 0.05 will be considered statistically significant.

Secondary Outcome Measures
Terms related to the clinical events: [/INST]
Carotid endarterectomy is performed to assess the presence of microplastics within plaques. Cox models, adjusted for the same variables, will be used to explore the relationship between the burden of microplastics and the incidence of the composite outcome. P values < 0.05 will be considered statistically significant.


Secondary Outcome Measures
Terms related to the clinical events: [/INST]
Carotid endarterectomy is performed to assess the presence of microplastics within plaques. Cox models, adjusted for the same variables, will be used to explore the relationship between the burden of microplastics and the incidence of the composite outcome. P values < 0.05 will be considered statistically significant.


Secondary Outcome Measures
Terms related to the clinical events: [/INST]
Carotid endarterectomy is performed to assess the presence of microplastics within plaques. Cox models, adjusted for the"
533,"[/INST]

How is the study designed?
-----------------
| Transarterial radioembolization | Colonectomy - CT scan |
| Transhepatic embolization |

How is the study measured?
-----------------
| Transhepatic radioembolization | Colonectomy - CT scan |
| Transhepatic embolization |

How is the study funded?
-----------------
| Transhepatic radioembolization | Colonectomy - CT scan |
| Transhepatic embolization |

How is the study reported?
| Transhepatic radioembolization | Colonectomy - CT scan |
| Transhepatic embolization |

How is the study reported?
| Transhepatic radioembolization | Colonectomy - CT scan |
| Transhepatic embolization |

How is the study reported?
| Transhepatic radioembolization | Colonectomy - CT scan |
| Transhepatic embolization |

How is the study reported?
| Transhepatic radioembolization | Colonectomy - CT scan |
| Transhepatic embolization |

How is the study reported?
| Transhepatic radioembolization | Colonectomy - CT scan |
| Transhepatic embolization |

How is the study reported?
| Transhepatic radioembolization | Colonectomy - CT scan |
| Transhepatic embolization |

How is the study reported?
| Transhepatic radioembolization | Colonectomy - CT scan |
| Transhepatic embolization |

How is the study reported?
| Transhepatic radioembolization | Colonectomy - CT scan |
| Transhepatic embolization |

How is the study reported?
| Transhepatic radioembolization | Colonectomy - CT scan |
| Transhepatic embolization |

How is the study analyzed?
| Transhepatic radioembolization | Colonectomy - CT scan |
| Transhepatic embolization |

How is the study evaluated?
| Transhepatic radioembolization | Colon"
534,"[/INST]
Other: [/INST]
Eligibility Criteria: Age 21 - 45 years.
Experimental: Age 46 years.
Primary Outcome Measure: [/INST]
Clinical performance of chemically cured conventional GICs: [/INST]
Other: [/INST]
Secondary Outcome Measures: [/INST]
Treatment of M2 group: [/INST]
Experimental: KetacTM Universal AplicapTM with light-emitting diode activating the chemically cured conventional GICs |

How is the study designed?
Conventional GICs: [/INST]
Primary Purpose: [/INST]
Experimental: [/INST]
Clinical performance of chemically cured conventional GICs: [/INST]
Secondary Outcome Measures: [/INST]
Treatment of M2 group: [/INST]
Experimental: KetacTM Universal AplicapTM with light-emitting diode activating the chemically cured conventional GICs |

What is the study measuring?
Conventional GICs: [/INST]
Clinical performance of chemically cured conventional GICs: [/INST]
Secondary Outcome Measures: [/INST]
Experimental: KetacTM Universal AplicapTM with light-emitting diode activating the chemically cured conventional GICs |

How is the study designed?
Conventional GICs: [/INST]
Clinical performance of chemically cured conventional GICs: [/INST]
Secondary Outcome Measures: [/INST]
Experimental: KetacTM Universal AplicapTM with light-emitting diode activating the chemically cured conventional GICs |

What is the study measuring?
Conventional GICs: [/INST]
Clinical performance of chemically cured conventional GICs: [/INST]
Secondary Outcome Measures: [/INST]
Experimental: KetacTM Universal AplicapTM with light-emitting diode activating the chemically cured conventional GICs |
How is the study designed?
Conventional GICs: [/INST"
535,"[/INST]


Device: [/INST]"
536,[/INST]
537,"[/INST]

Experimental, Diagnostic Testing: Transient Elastography, Liver function tests
| Primary Outcome: Alcohol use disorders, blood tests
| Secondary Outcome: Liver function tests, Fibroscan
| Tertiary Outcome: Alcohol use disorders, blood sampling
| Quaternary Outcome: Liver function tests, Fibroscan
| Outcome Measurement: Alcohol use disorders, blood sampling
| Primary Outcome: Alcohol use disorders, blood tests
| Secondary Outcome: Liver function tests, Fibroscan
| Tertiary Outcome: Alcohol use disorders, blood sampling
| Experimental: Intervention, Liver function tests
| Primary Outcome: Alcohol use disorders, blood sampling
| Secondary Outcome: Liver function tests, Fibroscan
| Tertiary Outcome: Alcohol use disorders, blood sampling
| Experimental: Intervention, Liver function tests
| Secondary Outcome: Alcohol use disorders, blood sampling
| Primary Outcome: Alcohol use disorders, blood sampling
| Secondary Outcome: Liver function tests, Fibroscan
| Tertiary Outcome: Alcohol use disorders, blood sampling
| Experimental: Intervention, Liver function tests
| Secondary Outcome: Alcohol use disorders, blood sampling
| Primary Outcome: Alcohol use disorders, blood sampling
| Secondary Outcome: Liver function tests, Fibroscan
| Tertiary Outcome: Alcohol use disorders, blood sampling
| Primary Outcome: Alcohol use disorders, blood sampling
| Secondary Outcome: Liver function tests, Fibroscan
| Tertiary Outcome: Alcohol use disorders, blood sampling
| Primary Outcome: Alcohol use disorders, blood sampling
| Secondary Outcome: Liver function tests, Fibroscan
| Tertiary Outcome: Alcohol use disorders, blood sampling
| Primary Outcome: Alcohol use disorders, blood sampling
| Secondary Outcome: Liver function tests, Fibroscan
| Primary Outcome: Alcohol use disorders, blood sampling
| Secondary Outcome: Liver function tests, Fibro"
538,"[/INST]

Etiology of the disease
| Index case: Under 40 years old
| Diagnosis: Syndromic diagnosis suspected but not confirmed by genetic testing
| Other: Non-invasive prenatal diagnosis
| Parents: Majority of index case and parents have reached age 40
| Other: Biological parents have reached age 60

What is the study about?
| Index case: Under 40 years old| Biological parents have reached age 60
| Other: Parents have reached age 60

How is the study designed to address a specific health problem?
| How is the study designed to improve the health of the index case and his/her biological parents?
| How is the study designed to prevent the health problem in the future?
| How is the study designed to prevent the health problem in the general population?
| How is the study designed to prevent the index case from having the same health problem in the future?
| How is the study designed to prevent the health problem in the general population?
| How is the study designed to prevent the index case from having the same health problem in the future?
| How is the study designed to prevent the same health problem in the general population?
| How is the study designed to prevent the index case from having the same health problem in the future?
| How is the study designed to prevent the same health problem in the general population?
| How is the study designed to prevent the index case from having the same health problem in the future?
| How is the study designed to prevent the same health problem in the general population?
| How is the study designed to prevent the index case from having the same health problem in the future?
| How is the study designed to prevent the same health problem in the general population?
| How is the study designed to prevent the index case from having the same health problem in the future?
| How is the study designed to prevent the same health problem in the general population?
| How is the study designed to prevent the index case from having the same health problem in the future?
| How is the study designed to prevent the same health problem in the general population?
| How is the study designed to prevent the index case from having the same health problem in the future?
| How is the study designed to prevent the same health problem in the"
539,"[/INST]


| How is the study designed?
| Designed by: [/INST]
| How is the study structured?
| How is the study designed?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study structured?
| How is the study struct"
540,"[/INST]-p-p-p-p-p-p-p-a-a-a-a-a-a-a-a-a-a-a-a-p-a-a-a-p-a-a-p-p-p-p-p-p-p-p-p-p-p-p-p-a-a-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-a-a-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-a-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-p-a-a-a-a-a-p-a-a-a-a-a-p-p-a-p-a-a-p-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-
-
-
-
-
-
-
-
-p-p-p-p-p-p-p-p-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-a-a-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-"
541,"[/INST]
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It
It.
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
in
It
It
It
It
It
It
It
It
It
It
It
This
It
It
It
It
It
It
It
It
It
It
It
This
This
This
This
This
This
It
It
It
It
It
This
a
a
a
a
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
It
It
It
It
It
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
It
It
It"
542,"[/INST]
I
I
I
-
-
-
-
-
-
-
-
-
-
I-
-
-
-








I


-
-
I
I
I-
I-
I-
I-
I-
I-
-
I-
-
-
-
-
-
-
-
-



-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-









-
-
















-
-
-
-
I-
I-
I-
I-
-
-
-
-


-
-
-
-
-

























-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-











-
-
-
-


I
I





















-
I
I










-
-
-
-
-
-
-
-






















































































































































-
-





-"
543,"[/INST]

Inclusion Criteria
-----------------
The study will include patients with BPD. Exclusion Criteria: Patients will be excluded if they have a history of physical abuse, psychological abuse, or sexual abuse. The study will be conducted in a hospital setting, and patients will be followed up every 6 months.

Quality of Life
-----------------"
544,"[/INST]
in
in
in
It
It
The
The
The
The
The
The
The
The
The
The
The
It
It
S
S
The
in
in
in
in
in
in
in
in
in
It
It
It
in
in
A
A
A
A
A
g.
It
It
It
It
It
It
fraction
in
s
s
a
a
in
A
A
A
A
A
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in








































































































































































































































































































h
h
h
h-
h-
h-

h






h
h
h
h
h
h"
545,"[/INST]
S.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The therapy.
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
In
In
In
The
In
In
The
The
The
In
The
In
The
In
In
In
In
In
In
Th
Th
This
This
This
This
This
This
This
The
The
Th
Th
This
This
This
This
This
This
This


























This
This.
This.
This.
This
This
This
This
This
This
This
This"
546,"[/INST]
| Immune of the emerging from the emerging from the emerging from the study.
| Immune of the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emerging from the emergency.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre
Tre
Tre.
Tre.
Tre.
Tre.
This.
This.
Tre.
Tre.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
S
S
S
S
S
S
S
This
This
This
This
This"
547,"[/INST]
A



















































-
































A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A-
A-
-
A
A
A-
A
A
A-
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-
A-a-a-a-a-A-A-A-p-p-p-p-p-p-p-A-A-A-A-A-a-a-a-a-a-a-a-A-A-A-A-A-
-
-
-
-
-
-
-
-A-A-A-A-A-A-A-
-
-A-A-A-A-"
548,"[/INST]

Change From Baseline in the Mean Monthly Physical Impairment Domain Score of the AIM-D | The AIM-D is an 11-item daily diary measure that assesses the impact of migraine and is comprised of two domains that evaluate performance of daily activities (7 items) and physical impairment using a 6 point rating scale ranging from Not difficult at all to I could not do it at all. Scores range from 0-100 scale, with higher scores indicating greater impact of migraine.
Other Migraine Terms
Aspartame, Frenquency of Episodic Migraine, Prosac, The AIM-D, SSRI, 5-HT1A, 5-HT2A, 5-HT3A, 11-item daily diary, Physical Impairment, Migraine, SSRI, Psychotropic, Frenquency of Episodic Migraine, 2-item daily diary, Physical Impairment, Migraine, Psychotropic, Prosac, Frenquency of Episodic Migraine, 5-HT1A, 5-HT2A, The AIM-D, SSRI, Psychotropic, 11-item daily diary, Physical Impairment, Migraine, Psychotropic, Frenquency of Episodic Migraine, 2-item daily diary, Physical Impairment, Migraine, Psychotropic, 5-HT1A, SSRI, Frenquency of Episodic Migraine, Psychotropic, The AIM-D, SSRI, 11-item daily diary, Physical Impairment, Migraine, Psychotropic, Frenquency of Episodic Migraine, 2-item daily diary, Physical Impairment, Migraine, Psychotropic, SSRI, Frenquency of Episodic Migraine, Psychotropic, The AIM-D, SSRI, 11-item daily diary, Physical Impairment, Migraine, Psychotropic, Frenquency of Episodic Migraine, 2-item daily diary, Physical Impairment, Migraine, Psychotropic, SSRI, Frenquency of Episodic Migraine, Psychotropic, The AIM-D, SS"
549,"[/INST]
| 4, 24, 48, 24, 24, 4, 24, 25, 24, 25, 24, 25, 24, 25. 25, 24, 25, 25, 24, 25, 25, 26, 25, 26, 25, 25, 26, 25, 25, 25, 25, 26, 25, 27, 25, 25, 25, 26, 25, 25, 25, 25, 26, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25.
The 26. 25. 25. 25.
The 25.
The 25.
The 2.
The 2.
The 2.
The study.
The study.
The study.
The study.
The study.
The study.
The study.
There.
There.
There.
This will be
This.
The study.
The doctor.
The doctor.
The patient.
The.
The patient.
The patient.
The doctor.
The doctor.
The patient.
This patient
This.
This.
This
This
This
This
B.
It
It.
It.
It.
It.
It.
It.
It.
It.
The   
In
The
In
In
In
In
In
In
This
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
550,"[/INST]

Suspected cases leading to hospitalization
-----------------
Symptoms of COVID-19
Severe respiratory failure
Hypoxemia
Hypoxemia leading to hospitalization
Use of mechanical ventilation
Use of positive end-expiratory and low pressure ventilation
Use of high-flow cannula
Use of intravenous fluids
Use of high-flow cannula
Use of intravenous fluids
Use of high-flow cannula
Use of positive pressure ventilation
Use of intravenous fluids
Use of high-flow cannula
Use of intravenous fluids
Use of positive pressure ventilation
Use of intravenous fluids
Use of high-flow cannula
Use of positive pressure ventilation
Use of intravenous fluids
Use of high-flow cannula
Use of positive pressure ventilation
Use of intravenous fluids
Use of high-flow cannula
Use of positive pressure ventilation
Use of intravenous fluids
Use of high-flow cannula
Use of positive pressure ventilation
Use of intravenous fluids
Use of high-flow cannula
Use of positive pressure ventilation
Use of intravenous fluids
Use of high-flow cannula
Use of positive pressure ventilation
Use of intravenous fluids
Use of high-flow cannula
Use of positive pressure ventilation
Use of intravenous fluids
Use of high-flow cannula
Use of positive pressure ventilation
Use of intravenous fluids
Use of high-flow cannula
Use of positive pressure ventilation
Use of intravenous fluids
Use of positive pressure ventilation
Use of intravenous fluids
Use of positive pressure ventilation
Use of intravenous fluids
Use of positive pressure ventilation
Use of intravenous fluids
Use of positive pressure ventilation
Use of intravenous fluids
Use of positive pressure ventilation
Use of intravenous fluids
Use of positive pressure ventilation of positive pressure
Use of intra
Use of positive pressure ventilation of intra
Use of positive pressure
Use of positive pressure ventilation of intra
Use of positive pressure positive pressure vent"
551,"[/INST]
* Drug: MTX monotherapy<br>Combined treatment with letrozole add-on<br>* MTX in a single dose of 100 mg intravenously and 50 mg orally, followed by hysteroscopic evacuation of POC and letrozole add-on<br>* Drug: MTX monotherapy<br>Combined treatment with letrozole add-on<br>* MTX in a single dose of 100 mg intravenously and 50 mg orally, followed by hysteroscopic evacuation of POC and letrozole add-on<br>* Drug: MTX monotherapy<br>Combined treatment with letrozole add-on<br>* MTX in a single dose of 100 mg intravenously and 50 mg orally, followed by hysteroscopic evacuation of POC and letrozole add-on<br>* Drug: MTX monotherapy<br>Combined treatment with letrozole add-on<br>* MTX in a single dose of 100 mg intravenously and 50 mg orally, followed by hysteroscopic evacuation of POC and letrozole add-on<br>* Drug: MTX monotherapy<br>Combined treatment with letrozole add-on<br>* MTX in a single dose of 100 mg intravenously and 50 mg orally, followed by hysteroscopic evacuation of POC and letrozole add-on<br>* Drug: MTX monotherapy<br>Combined treatment with letrozole add-on<br>* MTX in a single dose of 100 mg orally and 50 mg and 50 mg orally, followed by hysteroscopic evacuation of POC and letrozole add-on<br>* Drug: MTX monotherapy followed by hysterical<br>
* Drug: MTX in a single dose, followed by hyster<br>
* Drug: M"
552,"[/INST]
Primary Purpose: To transplant livers from deceased donors into recipients.
Secondary Purpose: To study the effects of different blood products on recipients.
Explanation of the study's purpose:
| Donor blood transfusion. | Recipient: None. |
| Donor blood collection. |
| Primary outcome: Survival of liver transplant recipients. | Secondary outcome: Hemoglobin level in donor blood. |
| Explanation of the study: We transplant livers from deceased donors into recipients. |
| Recipient's hemoglobin level. |
| Blood collection from donors. |
| Transfusion: None. |
| Primary purpose: To study the effects of different blood products on hemoglobin level in recipients. |
Secondary Purpose: To study the effects of different blood products on hemoglobin level in donors. |
| Recipient: None. |
Explanation of the study: We transplant livers from deceased donors into recipients. |
| Primary outcome: Survival of liver transplant recipients. | Secondary outcome: Hemoglobin level in donor blood. |
| Recipient's blood collection. |
| Transfusion: None. |
Explanation of the study: We transplant livers from deceased donors into recipients. |
| Primary outcome: Survival of liver transplant recipients. | Secondary outcome: Hemoglobin level in donor blood. |
| Recipient: None. |
| Transfusion: None. |
Explanation of the study: We transplant livers from deceased donors into recipients. |
| Primary outcome: Survival of liver transplant recipients. | Secondary outcome: Hemoglobin level in donor blood. |
| Recipient: None. |
Explanation of the study: We transplant livers from deceased donors into recipients. |
| Primary outcome: Survival of liver transplant recipients. | Secondary outcome: Hemoglobin level in donor blood. |
| Recipient: None. |
Explanation of the study: We transplant livers from deceased don"
553,"[/INST]

Efficacy of the study: Subcutaneous versus sublingual immunotherapy
Primary Purpose: Treatment
| Active Comparator: Subcutaneous immunotherapy
| Intervention Model: Subcutaneous immunotherapy
| Drug: Allergen immunotherapy
| Active Comparator: Sublingual immunotherapy
| Intervention Model: Subcutaneous allergen immunotherapy
| Drug: Allergen immunotherapy
| Intervention Model: Subcutaneous allergen immunotherapy
| Active Comparator: Sublingual immunotherapy
| Drug: Allergen immunotherapy
| Intervention Model: Subcutaneous allergen immunotherapy
| Active Comparator: Sublingual immunotherapy
| Drug: Allergen immunotherapy
| Intervention Model: Subcutaneous allergen immunotherapy
| Active Comparator: Sublingual immunotherapy
| Drug: Allergen immunotherapy
| Intervention Model: Subcutaneous allergen immunotherapy
| Drug: Allergen immunotherapy
| Intervention Model: Subcutaneous allergen immunotherapy
| Active Comparator: Sublingual immunotherapy
| Drug: Allergen immunotherapy
| Intervention Model: Subcutaneous allergen immunotherapy
| Drug: Allergen immunotherapy
| Intervention Model: Subcutaneous allergen immunotherapy
| Active Comparator: Sublingual immunotherapy
| Drug: Allergen immunotherapy
| Intervention Model: Subcutaneous allergen immunotherapy
| Drug: Allergen immunotherapy
| Intervention Model: Subcutaneous allergen immunotherapy
| Active Comparator: Sublingual immunotherapy
| Drug: Allergen immunotherapy
| Intervention Model: Subcutaneous allergen immunotherapy
| Drug: Allergen immunotherapy
| Intervention Model: Subcutaneous allergen immunotherapy
| Active Comparator: Sublingual immunotherapy
| Drug: Allergen immunotherapy
| Intervention Model: Subcutaneous allergen immunotherapy
| Active"
554,"[/INST]
Primary Outcome Measure
| Secondary Outcome Measure | Time Frame |
| Diagnostic Test: Contrast Enhanced Stereotactic Biopsy |
| The investigators will undergo Mammography, scoring the pain associated with this intervention on a 0-10 scale (0 no pain, 10 worst pain ever) |
| Secondary Outcome Measure | Time Frame |
| Diagnostic results of the biopsies performed using CEM |
Secondary Outcome Measure
| The investigators will undergo Mammography, scoring the pain associated with this intervention on a 0-10 scale (0 no pain, 10 worst pain ever) |
| Diagnostic Test: Contrast Enhanced Stereotactic Biopsy |
| The investigators will undergo Mammography, scoring the pain associated with this intervention on a 0-10 scale (0 no pain, 10 worst pain ever) |
| Secondary Outcome Measure | Time Frame |
| Diagnostic results of the biopsies performed using CEM |
| The investigators will undergo Mammography, scoring the pain associated with this intervention on a 0-10 scale (0 no pain, 10 worst pain ever) |
| Diagnostic Test: Contrast Enhanced Stereotactic Biopsy |
| The investigators will undergo Mammography, scoring the pain associated with this intervention on a 0-10 scale (0 no pain, 10 worst pain ever) |
| Secondary Outcome Measure | Time Frame |
| Diagnostic results of the biopsies performed using CEM |
| The investigators will undergo Mammography, scoring the pain associated with this intervention on a 0-10 scale (0 no pain, 10 worst pain ever) |
| Diagnostic Test: Contrast Enhanced Stereotactic Biopsy |
| The investigators will undergo Mammography, scoring the pain associated with this intervention on a 0-10 scale (0 no pain, 10 worst pain ever) |
| Secondary Outcome Measure | Time Frame |
| Diagnostic results of the biopsies performed using CEM |
| The investigators will undergo Mammography, scoring the pain associated"
555,"[/INST]
Other: [/INST]
Keywords: Knee osteoarthritis, Quadriceps, Kinesiotaping, knee extension, knee flexion, knee osteoarthritis, knee surgery, knee arthroscopy, knee ligament, knee osteoarthritis, knee surgery, knee osteoarthritis, knee arthroscopy, knee surgery, knee osteoarthritis, knee surgery, knee osteoarthritis, knee surgery, knee osteoarthritis, knee surgery, knee osteoarthritis, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surgery, knee surg"
556,"[/INST]

Family therapy training and implementation
-----------------
Family therapy training and implementation
Family Systems Theory
Family therapy training and implementation
Family Systems Theory
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family therapy training and implementation
Family ther"
557,"[/INST]
Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.


Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.


Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.

Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.

Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.

Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.

Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.

Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.

Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.

Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.

Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.

Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.

Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.

Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.

Herpes zoster pain, neck, back and temporal. Hyaluronan injection was used to dissolve the pain trough the pain scale.

Herpes zoster pain, neck, back and temporal. Hyal"
558,"[/INST]
-----------------
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
Terms related to the study: [/INST]
Secondary Outcome: [/INST]

How is the study measuring?
-----------------
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
How is the study measuring?
-----------------
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
How is the study measuring?
-----------------
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
How is the study measuring?
Secondary Outcome: [/INST]
How is the study measuring?
Secondary Outcome: [/INST]
How is the study measuring?
Secondary Outcome: [/INST]
How is the study measuring?
Secondary Outcome: [/INST]
How is the study measuring?
Secondary Outcome: [/INST]
How is the study measuring?
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST]
Secondary Outcome: [/INST
Secondary Outcome: [/INST
Secondary Outcome: [/INST
Secondary Outcome: [/INST
Secondary Outcome: [/INST
Secondary Outcome: [/INST
Secondary Outcome: [/INST
Secondary Outcome: Patient [/Institution: Secondary Outcome:
Second Outcome: Patient [/Institution: Secondary Outcome: Patient [/Institute: Secondary Outcome: Patient [/Institution: Secondary Outcome: Secondary Outcome: Secondary Outcome: Patient: Secondary Outcome:
Second: Secondary Outcome: Patient: Secondary Outcome: Patient: Secondary Outcome: Patient: Secondary Outcome: Patient: Secondary Outcome: Patient: Secondary Outcome: Patient: Secondary: Patient: Patient: Secondary Outcome: Patient: Secondary Outcome: Secondary Outcome: Secondary: Secondary: Secondary: Patient: Patient: Patient: Patient: Second: Secondary: Patient: Secondary"
559,"[/INST]
| Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of symptoms : dyspnoea scale 0 to 5 / Higher score mean worse outcome | 3 months, 6 months | 
| Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of symptoms : dyspnoea scale 0 to 5 / Higher score mean worse outcome | 3 months, 6 months | 
| Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of specifics symptoms : dyspnoea scale 0 to 5 / Higher score mean worse outcome | 3 months, 6 months | 
| Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of symptoms : dyspnoea scale 0 to 5 / Higher score mean worse outcome | 3 months, 6 months | 
| Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of symptoms : dyspnoea scale 0 to 5 / Higher score mean worse outcome | 3 months, 6 months | 
| Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of symptoms : dyspnoea scale 0 to 5 / Higher score mean worse outcome | 3 months, 6 months | 
| Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of symptoms : dyspnoea scale 0 to 5 / Higher score mean worse outcome | 3 months, 6 months | 
| Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of symptoms : dyspnoea scale 0 to 5 / Higher score mean worse outcome | 3 months, 6 months | 
| Evaluation of the effectiveness of a respiratory training to cardiac coherence on the decrease of symptoms : dyspnoea scale 0 to 5 / Higher score mean worse outcome | 3 months, 6 months | 
| Evaluation of"
560,"[/INST]

Secondary Outcome Measures
-----------------

Patients who have developed atrial fibrillation
| Other: no history of atrial fibrillation


How is the study designed?
-----------------
| Patient #1 | Other: Patient #2
| Patient #3

How is the study conducted?
| Patient #1 | Other: Patient #2
| Patient #3 |

How is the study funded?
| Patient #1 | Other: Patient #2 |
| Patient #3 |
| Patient #4 |
| Patient #5 |
| Patient #6 |
| Patient #7 |
| Patient #8 |
| Patient #9 |
| Patient #10 |
| Patient #11 |
| Patient #12 |
| Patient #13 |
| Patient #14 |
| Patient #15 |
| Patient #16 |
| Patient #17 |
| Patient #18 |
| Patient #19 |
| Patient #20 |
| Patient #21 |
| Patient #22 |
| Patient #23 |
| Patient #24 |
| Patient #25 |
| Patient #26 |
| Patient #27 |
| Patient #28 |
| Patient #29 |
| Patient #30 |
| Patient #31 |
| Patient #32 |
| Patient #33 |
| Patient #34 |
| Patient #35 |
| Patient #36 |
| Patient #37 |
| Patient #38 |
| Patient #39 |
| Patient #40 |
| Patient #41 |
| Patient #42 |
| Patient #43 |
| Patient #44 |
| Patient #45 |
| Patient #46 |
| Patient #47 |
| Patient #48 |
| Patient #49 |
| Patient #50 |
| Patient #51 |
| Patient #52 |"
561,"[/INST]
| Other: [/INST]
How is the study designed?
| Participants: [/INST]
| How is the study designed? |
| Designed to measure changes in blood pH. |
| How is the study designed to measure changes in blood pH? |
| What is the study designed to measure? |
| How is the study designed to measure changes in blood pH? |
| What is the primary outcome for the study? |
| How is the study designed to measure the primary outcome? |
| What is the secondary outcome for the study? |
| How is the study designed to measure the secondary outcome? |
| What is the study designed to measure? |
| How is the study designed to measure changes in the secondary outcome? |
| How is the study designed to measure the primary outcome? |
| What is the study designed to measure? |
| How is the study designed to measure changes in the secondary outcome? |
| How is the study designed to measure the primary outcome? |
| What is the study designed to measure? |
| How is the study designed to measure changes in the secondary outcome? |
| How is the study designed to measure the primary outcome? |
| What is the study designed to measure? |
| How is the study designed to measure changes in the secondary outcome? |
| How is the study designed to measure the primary outcome? |
| What is the study designed to measure? |
| How is the study designed to measure changes in the secondary outcome? |
| How is the study designed to measure the primary outcome? |
| What is the study designed to measure? |
| How is the study designed to measure changes in the secondary outcome? |
| How is the study designed to measure the primary outcome? |
| What is the study designed to measure? |
| How is the study designed to measure changes in the secondary outcome? |
| How is the study designed to measure the primary outcome? |
| What is the study designed to measure? |
| How is the study designed to measure changes in the secondary outcome? |
| How is the study designed to measure the primary outcome? |
| What is the study designed to measure? |
| How is the study designed to measure changes in the secondary outcome? |
| How is the study designed to measure the primary outcome? |"
562,[/INST]
563,"[/INST]


-----------------

Procedure: percutaneous coronary intervention, gastrointestinal bleeding, percutaneous coronary intervention, moderate risk of cardiovascular clinical complex, non-fatal myocardial infarction, coronary artery bypass grafting, oral antiplatelet drugs, or pretreatment of ischemic stroke"
564,"[/INST]
Acceptance of the study: [/INST]
Participation: [/INST]
Primary Outcome Measure: [/INST]
Acceptance of the study: [/INST]
Participation: [/INST]
Secondary Outcome Measure: [/INST]
Acceptance of the study: [/INST]
Participation: [/INST]
Acceptance of the study: [/INST]
Secondary Outcome Measure: [/INST]
Acceptance of the study: [/INST]
Participation: [/INST]
Acceptance of the study: [/INST]
Secondary Outcome Measure: [/INST]
Acceptance of the study: [/INST]
Participation: [/INST]
Acceptance of the study: [/INST]
Secondary Outcome Measure: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]
Acceptance of the study: [/INST]"
565,"[/INST]
Other: [/INST]
How is the study designed?
Primary Purpose: To measure the effects of vertical sitting versus supine lying traction on pain, range of motion, and function in patients with chronic lumbar disc disorders.
Population: [/INST]
Sample Size: [/INST]
Inclusion Criteria: [/INST]
Exclusion Criteria: [/INST]
Time Frame: [/INST]
Keywords: [/INST]
Population: [/INST]
Sample Size: [/INST]
How is the study designed?
Primary Purpose: [/INST]
Sample Size: [/INST]
Time Frame: [/INST]
Keywords: [/INST]
Sample Size: [/INST]
How is the study designed?
Population: [/INST]
Sample Size: [/INST]
How is the study designed?
Keywords: [/INST]
Sample Size: [/INST]
How is the study designed?
Keywords: [/INST]
Sample Size: [/INST]
How is the study designed?
Keywords: [/INST]
How is the study designed?
How is the study designed?
Keywords: [/INST]
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?"
566,"[/INST]

Device: Dry Needling
-----------------
Primary Outcome Measure
| change in pain intensity | the intensity of your pain using the Visual Analog Pain Scale (VAS), which scores your current pain with scores between 0 and 10. Zero is no pain and 10 is considered unbearable pain and greater function. | evaluation before treatment, immediately at the end of treatment and 12 weeks post treatment | 
| change in hip function | In each assessment, participants will perform the Timed Up And Go Test (TUG) | evaluation before treatment, immediately at the end of treatment and 12 weeks post treatment | 
| change in lower limb function | In each assessment, participants will perform the 30'' Sit To Stand Test. | evaluation before treatment, immediately at the end of treatment and 12 weeks post treatment | 
| change in hip function | In each assessment, participants will perform the 30'' Sit To Stand Test. | evaluation before treatment, immediately at the end of treatment and 12 weeks post treatment | 
| change in lower limb function | In each assessment, participants will perform the 30'' Sit To Stand Test. | evaluation before treatment, immediately at the end of treatment and 12 weeks post treatment | 

Secondary Outcome Measure
=================
Device: Dry Needling
| change in pain intensity | the intensity of your pain using the Visual Analog Pain Scale (VAS), which scores your current pain with scores between 0 and 10. Zero is no pain and 10 is considered unbearable and greater function. | evaluation before treatment, immediately at the end of treatment and 12 weeks post treatment | 
| change in hip function | In each assessment, participants will perform the 30'' Sit To Stand Test. | evaluation before treatment, immediately at the end of treatment and 12 weeks post treatment | 
| change in lower limb pain | the intensity using the Visual Analog Pain Scale (VAS, which scores between 0 and 10 and 12 weeks post treatment | the end immediately at the end of treatment and 10. |
| change in lower limb pain using the Visual Analog, immediately at the end of treatment|
| change in the Visual Analog.|
| change in"
567,"[/INST]

Rapid EMA assay for intestinal anti-transglutinase antibodies | Diagnostic accuracy of rapid EGD assay for intestinal serology | Sensitivity and specificity of the rapid anti-TG2 test on mechanically lysed intestinal biopsies compared to the reference standard (serology + histopathology) | At the time of endoscopic examination |
| Exclusion Criteria: None specified |

Outcome Measures
-----------------
Sensitivity and specificity of rapid anti-TG2 test on mechanically lysed intestinal biopsies compared to the reference standard (serology + histopathology) | At the time of endoscopic examination |
| Secondary Outcome Measures |

Primary Outcome Measures
-----------------
Sensitivity and specificity of rapid anti-TG2 test on mechanically lysed intestinal biopsies compared to the reference standard (serology + histopathology) | At the time of endoscopic examination |
Secondary Outcome Measures
-----------------
Sensitivity and specificity of rapid anti-TG2 test on mechanically lysed intestinal biopsies compared to the reference standard (serology + histopathology) | At the time of endoscopic examination |

Secondary Outcome Measures
-----------------
Sensitivity and specificity of rapid anti-TG2 test on mechanically lysed intestinal biopsies compared to the reference standard (serology + histopathology) | At the time of endoscopic examination |

Secondary Outcome Measures
-----------------
Sensitivity and specificity of rapid anti-TG2 test on mechanically lysed intestinal biopsies compared to the reference standard (serology + histopathology) | At the time of endoscopic examination |

Secondary Outcome Measures
-----------------
Sensitivity and specificity of rapid anti-TG2 test on mechanically lysed intestinal biopsies compared to the reference standard (serology + histopathology) | At the time of endoscopic examination |


Terms related to the study
intestinal serology, rapid anti"
568,"[/INST]
| anxiety | measured by 36-Item Short Form Health Survey before and after the intervention, and at 20 weeks | 6 months |
| sleep quality | measured by 36-Item Short Form Health Survey before and after the intervention, and at 20 weeks | 
| depression | measured by 36-Item Short Form Health Survey before and after the intervention, and at 6 months | 
| sleep quality | measured by 36-Item Short Form Health Survey before and at 20 weeks | 
| anxiety | measured by 36-Item Short Form Health Survey before and at 6 months | 
| depression | measured by 36-Item Short Form Health Survey before and at 20 weeks | 
| sleep quality | measured by 36-Item Short Form Health Survey before and at 6 months | 
| anxiety | measured by 36-Item Short Form Health Survey before and at 20 weeks | 
| depression | measured by 36-Item Short Form Health Survey before and at 6 months | 
| sleep quality | measured by 36-Item Short Form Health Survey before and at 20 weeks | 
| anxiety | measured by 36-Item Short Form Health Survey before and at 6 months | 
| depression | measured by 36-Item Short Form Health Survey before and at 20 weeks | 
| sleep quality | measured by 36-Item Short Form Health Survey before and at 6 months | 
| anxiety | measured by 36-Item Short Form Health Survey before and at 20 weeks | 
| depression | measured by 36-Item Short Form Health Survey before and at 6 months | 
| sleep quality | measured by 36-Item Short Form Health Survey before and at 20 weeks | 
| anxiety | measured by 36-Item Short Form Health Survey before and at 6 months | 
| depression | measured by 36-Item Short Form Health Survey before and at 20 weeks | 
| sleep quality | measured by 36-Item Short Form Health Survey before and at 6 months | 
| anxiety | measured by 36-Item Short Form Health Survey before and at 20 weeks |"
569,[/INST]
570,"[/INST]
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
















C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C














C
C
C
C
C
C
C
C

































C
C
C
C
C
C
C
C
C
C
C








C
C
C
C
C
C
C
C












C
C
C
C
C
C
C
C


























































A
A
A
C
C
C
A




C
C





C
C
C
C































C

















O
O
O
O
C
C
C
C
A
C
C
C
C
P
P
P
C
C
C

C
















C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C


C

C
C
C
C
C
C
C
C
C
C
C"
571,"[/INST]
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF |
| HFNC, NIV |
| NIV, type2 RF"
572,"[/INST]
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
This
The
The
The
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
The



































This
f
f"
573,"[/INST]






































































































































































-
-



-
-
-
-
-
-


-
-
-
-
-
-
-
-
-
-
-


-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
C
C
C
C


-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-











-
-
-
-
-
-
-
-
-
-
-





-







-
-
-






-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
























-
-


-
-















-
-
-
-
-
-
-
-
-
-
-
-"
574,"[/INST]

| Patient #1 | Treatment decision for malignant hormone-sensitive prostate cancer |
| Patient #2 | Apalutamide and health-related quality of life |

Other Health Conditions
-----------------

Secondary Outcome Measures

| Patient #3 | Apalutamide and health-related quality of life |

| Patient #4 | Metastatic hormone-sensitive prostate cancer |
| Patient #5 | Apalutamide and cognitive function |

Other Drugs
| Patient #6 | Apalutamide and cognitive function |

| Patient #7 | Metastatic hormone-sensitive prostate cancer |
| Patient #8 | Apalutamide and health-related quality of life |

| Patient #9 | Metastatic hormone-sensitive prostate cancer |

| Patient #10 | Apalutamide and cognitive function |

| Patient #11 | Metastatic hormone-sensitive prostate cancer |
| Patient #12 | Apalutamide and health-related quality of life |

| Patient #13 | Metastatic hormone-sensitive prostate cancer |
| Patient #14 | Apalutamide and cognitive function |

| Patient #15 | Metastatic hormone-sensitive prostate cancer |
| Patient #16 | Apalutamide and health-related quality of life |

| Patient #17 | Metastatic hormone-sensitive prostate cancer |
| Patient #18 | Apalutamide and cognitive function |

| Patient #19 | Metastatic hormone-sensitive prostate cancer |
| Patient #20 | Apalutamide and health-related quality of life |

| Patient #21 | Metastatic hormone-sensitive prostate cancer |
| Patient #22 | Apalutamide and cognitive function |

| Patient #23 | Metastatic hormone-sensitive prostate cancer |
| Patient #24 | Apalutamide and health-"
575,"[/INST]
Other: [0.045% Tazarotene/0.01% Halobetasol lotion]
Primary Outcome: Hair growth
Secondary Outcome: Scalp itch
Tertiary Outcome: Other names: Tazarotene/Halobetasol lotion
Exclusion Criteria: [0.045% Tazarotene/0.01% Halobetasol lotion]
Subjects with known allergies to ingredients in the study medications
Subjects currently participating in another clinical study of psoriasis
Exclusion Criteria: [0.045% Tazarotene/0.01% Halobetasol lotion]
Masking: Other
Primary Outcome: Hair growth
Secondary Outcome: Scalp itch
Tertiary Outcome: Other names: Tazarotene/Halobetasol lotion
Exclusion Criteria: [0.045% Tazarotene/0.01% Halobetasol lotion]
Subjects with known allergies to ingredients in the study medications
Subjects currently participating in another clinical study of psoriasis
Exclusion Criteria: [0.045% Tazarotene/0.01% Halobetasol lotion]
Primary Outcome: Hair growth
Secondary Outcome: Scalp itch
Tertiary Outcome: Other names: Tazarotene/Halobetasol lotion
Exclusion Criteria: [0.045% Tazarotene/0.01% Halobetasol lotion]
Subjects with known allergies to ingredients in the study medications
Subjects currently participating in another clinical study of psoriasis
Exclusion Criteria: [0.045% Tazarotene/0.01% Halobetasol lotion]
Primary Outcome: Hair growth
Secondary Outcome: Scalp itch
Tertiary Outcome: Other names: Tazarotene/Halobetasol lotion
Exclusion Criteria: [0.045% Tazarotene/0.01"
576,"[/INST],-M-M-M-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O M-M-O-O-M-O-O-O-O-O-M-O-M-M-M-M-M-M-O-O-O-O-O-O a. -O........
..
....-a-a-hO-hO-O-O-O-O-O-O-O-a-O-O-O-O-O-O...... a.....O-O-O-O-O-O-OOOOOO DO DO DO DO.... DO.O.O.O DO DO DO DO DO..O.O.O.O.O.O DO DO DO DO DO DO DO DO. - a. D-D. DO. DO DO DO DO DO DO DO-O-O-O-O-O-O-O DO DO DO DO DO D- D- D- D-B DO DO DO DO DO DO DO DO DO DO DO DO DO DO DO DO DO DO DO DO DO BO BO DO B- B- B-A DO DO D D D D D D D D D D DO D D D DO DO DO DO DO DO DO DO DO DO. DO DO DO DO DO DO DO DO DO DO D D D D D D D D DO DO DO DO DO DO DO DO DO DO DO DO DO DO D- DO DO-A DO DO DO D D DO DO D D D D DO DO DO DO DO DO DO DO DO DO DO DO DO DO DO DO DO DO DO D"
577,"[/INST]
| Active Comparator: Procedure; volar approach. |
| Wrist pain: dorsal approach. |
| Hand grip: general anesthesia. |
| Wrist pain: Henry approach. |
| Procedure: volar approach. |
| Hand grip: dorsal approach. |
| Wrist pain: general anesthesia. |
| Procedure: Henry approach. |
| Hand grip: volar approach. |
| Wrist pain: dorsal approach. |
| Procedure: Henry approach. |
| Hand grip: volar approach. |
| Wrist pain: dorsal approach. |
| Procedure: Henry approach. |
| Hand grip: volar approach. |
| Wrist pain: dorsal approach. |
| Procedure: Henry approach. |
| Hand grip: volar approach. |
| Wrist pain: dorsal approach. |
| Procedure: Henry approach. |
| Hand grip: volar approach. |
| Wrist pain: dorsal approach. |
| Procedure: Henry approach. |
| Hand grip: volar approach. |
| Wrist pain: dorsal approach. |
| Procedure: Henry approach. |
| Hand grip: volar approach. |
| Wrist pain: dorsal approach. |
| Procedure: Henry approach. |
| Hand grip: volar approach. |
| Wrist pain: dorsal approach. |
| Procedure: Henry approach. |
| Hand grip: volar approach. |
| Wrist pain: dorsal approach. |
| Procedure: Henry approach. |
| Hand grip: volar approach. |
| Wrist pain: dorsal approach. |
| Procedure: Henry approach. |
| Hand grip: volar approach. |
| Wrist pain: dorsal approach. |
| Procedure: Henry approach. |
| Hand grip: volar approach. |
| Wrist pain: dorsal approach. |
| Procedure: Henry approach. |
| Hand grip: volar approach. |
| Wrist pain: dorsal approach. |
| Procedure: Henry approach. |
| Hand"
578,"[/INST]-p-p-p-p-p-p-p-p-p-p-p-st-st-st-st-st-p-p-p-p-p-p-st-p-p-p-p-p-st-st-f-f-f-st-p-st-p-st-st-st-st-st-st-st-st-st-e-e-p-p-p-p-p-p-st-st-st-e-e-s-s-s,-s,-p-p-p-to-to-st-st-f-f-f-e-p-p-p-p-p-e-p-st-st-st-p-p-p-s-s-p-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-A-s-s-s-s-s-D-D-D-D-D-s-s-e-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s-s,-s,-s-s-s-s-s-s-s-s-s-s-s-s-s-s-e-s-s-s-s-s-s-s-s-s-s-s-s-s,-s,-s,-s-s-s,-s,-s,-s,-e-e-e-s,-s,-s,-s,-s,-s,-s,-s-s-s-s-s-s-s-s-s,-s,-s,-s,-s,-s,-s,-s,-s,-s,-s,-s,-s,-s,-s-s-s-s-s-s,-s,-s,-s,-s,-s,-s-s-s-s-s-s-s,-"
579,"[/INST]
Other: [/INST]
Primary Outcome Measurement
-----------------
Participants will be asked to stand with their heels together and their command 'start' will be stopped by touching a finish line.
Change from Baseline 6MWT at 12 weeks | Participants will be asked to walk at a comfortable pace while their heels are together and the command 'start' will be stopped by touching a finish line.
| Other: [/INST]
Primary Outcome Measurement
-----------------
Participants will be asked to stand with their heels together and the command 'start' will be stopped by touching a finish line.
Change from Baseline 6MWT at 12 weeks | Participants will be asked to walk at a comfortable pace while their heels are together and the command 'start' will be stopped by touching a finish line.
| Other: [/INST]
Primary Outcome Measurement
-----------------
Participants will be asked to stand with their heels together and the command 'start' will be stopped by touching a finish line.
Change from Baseline 6MWT at 12 weeks | Participants will be asked to walk at a comfortable pace while their heels are together and the command 'start' will be stopped by touching a finish line.
| Other: [/INST]
Primary Outcome Measurement
-----------------
Participants will be asked to stand with their heels together and the command 'start' will be stopped by touching a finish line.
Change from Baseline 6MWT at 12 weeks | Participants will be asked to walk at a comfortable pace while their heels are together and the command 'start' will be stopped by touching a finish line.
| Other: [/INST]
Primary Outcome Measurement
-----------------
Participants will be asked to stand with their heels together and the command 'start' will be stopped by touching a finish line.
Change from Baseline 6MWT at 12 weeks | Participants will be asked to walk at a comfortable pace while their heels are together and the command 'start' will be stopped by touching a finish line.
| Other: [/INST]
Primary Outcome Measurement
-----------------
Participants will be asked to stand with"
580,"[/INST]

How is the study designed?
| How is the study measuring up?
| How are the participants doing?
| How many outbreak participants have joined the cohort?
| How many have seroconverted against a non-seasonal influenza virus?
| What percentage of the study participants have become seropositive against a non-seasonal avian influenza virus?
| How are the veterinarians working in the poultry farms doing?
| What is the morbidity/mortality like among the study participants?
| How many have been lost to the cohort?
| How many have died of a non-seasonal respiratory virus?
| What is the name of the virus?
| How is it characterized?
| What are the clinical features among the study participants?
| How is the study being received by the general public?
| What is the level of awareness like among the study participants?
| How many have been reached by the study?
| How are they adapting to the new circumstances?
| What is the name of the wild bird?
| How is it being received by the general public?
| How is it being characterized by pathologists?
| What is the diagnosis like among the study participants?
| How is the study being received by the pathologists?
| What is the diagnosis like among the study participants?
| How is the study being received by the general public?
| What is the level of awareness like among the pathologists?
| How are they adapting to the new circumstances?
| How are they being received by the general public?
| What is the diagnosis like among the study participants?
| How is the study being received by the general public?
| What is the level of awareness like among the pathologists?
| How are they adapting to the new circumstances?
| How are they being received by the general public?
| What is the diagnosis like among the study participants?
| How is the study being received by the general public?
| How are they adapting to the new circumstances?
| What is the level of awareness like among the pathologists?
| How are they being received by the general public?
| How are they adapting to the new circumstances?
| How are"
581,"[/INST]

Other: [/INST]



Adverse Events
-----------------
| Adverse Events will be monitored by project staff using an adverse events checklist. | Adverse Events will be reported to the youth's health care provider on a weekly basis. | Youth will be monitored for adverse events using an adverse events checklist. | Adverse Events will be reported to the health care provider on a daily basis. | Youth will be monitored for adverse events using an adverse events checklist. |



Primary Purpose: [/INST]
| Other: [/INST]
| Secondary Outcome Measures | Other will be monitored by project staff using an adverse events checklist. |
| Change from baseline to up to 1-month post intervention |
| Other: [/INST]
|
| Secondary Outcome Measures will be reported to the health care provider on a daily basis. | Other will be monitored for adverse events using an adverse events checklist. |







































































































































































































































































The
The
The
The
The
The
The
The
The
The
The"
582,"[/INST]
How the 18-19 to be measured.
|
|
| 18.
| 18.
| 18.
| 18.
How the 18.|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.|18.
|18.|18.
|18.
|18.
|18.
|18.|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
|18.
9.
9.
|18.
|18.
9|18.
9.
9.|18.
9.|18.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9.
9
9
9
9
9
9
9
This
This
This
This
This
This
9
9
9
9
9
9
9
--------
--------
--------
in
in
in
--------|
==|
in
in
in
--------
--------
--------
==|
in
in
in
in
==
==
==
==
==
==
This
This
This
This
This
This
This
This
This
This
This
This"
583,"[/INST]

Experimental Protocol
| Primary Purpose |
| Other: Insertion of peripheral venous catheter | Normal care
| No Intervention: Arm training program | Normal care
| Other: Insertion of peripheral venous catheter | Measured at baseline | 
| Vein status | Normal care
| Other: Insertion of peripheral venous catheter | Measured at baseline | 

Training Program
| Other: Insertion of peripheral venous catheter | Measured at baseline | 
| Vein status | Normal care
| Other: Insertion of peripheral venous catheter | Measured at baseline | 

| Primary Purpose |
| Other: Insertion of peripheral venous catheter | Measured at baseline | 
| Vein status | Normal care
| Other: Insertion of peripheral venous catheter | Measured at baseline | 

Secondary Outcome Measures
| Primary Purpose |
| Other: Insertion of peripheral venous catheter | Measured at baseline | 
| Vein status | Normal care
| Other: Insertion of peripheral venous catheter | Measured at baseline | 

Training Program
| Primary Purpose |
| Other: Insertion of peripheral venous catheter | Measured at baseline | 
| Vein status | Normal care
| Other: Insertion of peripheral venous catheter | Measured at baseline | 

Secondary Outcome Measures
| Primary Purpose |
| Other: Insertion of peripheral venous catheter | Measured at baseline | 
| Vein status | Normal care
| Other: Insertion of peripheral venous catheter | Measured at baseline | 

Training Program
| Primary Purpose |
| Other: Insertion of peripheral venous catheter | Measured at baseline | 
| Vein status | Normal care
| Other: Insertion of peripheral venous catheter | Measured at baseline | 

Secondary Outcome Measures
| Primary Purpose |
|"
584,"[/INST]
| Diagnosis |
| 31 May 2028 |
| 31 May 2028 |
| 31 May 2028 | 31 | 31 May 2028 | 31 | 31 May 2028 | 31 May 31 | 31 May 2028 | 31 | 31 May 2028 | 31 May 31 | 318 | 318, 20218, 318 | 31 May 2028, 318, 318 | 20218. | 318. | 20218, 3118, 3118, 20208, 318, 2018, 318, 2018, 2018, 2018, 2018, 2018, 2018, 2018, 2018, 2018, 2018, 2018, 2018, 201118, 2018, 2018, 2018, 2018, 2018, 2018, 2019, 2018, 2018, or 2018, or 2019, 20198, or 2018, 201818, 2019,, 20198.
The 2019.
The 20198.
It 20198.
It.
It.
It.
It.
It's 201999.
It.
It.
It.
Why.
Why.
It.
It.
It's.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It's
It's's"
585,"[/INST]
| Primary Safety Measure | [/INST]
| Secondary Safety Measure | [/INST]
| Exploratory Safety Measure | [/INST]
| Tertiary Safety Measure | [/INST]
| Quaternary Safety Measure | [/INST]
| Other Safety Measures | [/INST]
| Neutral Safety Measure | [/INST]
| Non-Clinical Safety Measure | [/INST]
| Clinical Safety Measure | [/INST]
| Pharmacokinetic Safety Measure | [/INST]
| Pharmacodynamic Safety Measure | [/INST]
| Pharmacological Safety Measure | [/INST]
| Toxicology Safety Measure | [/INST]
| Pharmacological Effectiveness Safety Measure | [/INST]
| Pharmacological Efficacy Safety Measure | [/INST]
| Pharmacological Equivalence Safety Measure | [/INST]
| Pharmacological Acceptability Safety Measure | [/INST]
| Pharmacological Effectiveness in a Specific Population | [/INST]
| Pharmacological Safety in a Specific Disease | [/INST]
| Pharmacological Efficacy in a Specific Disease | [/INST]
| Pharmacological Effectiveness in a Specific Disease | [/INST]
| Pharmacological Safety in a Specific Disease | [/INST]
| Pharmacological Effectiveness in a Specific Population | [/INST]
| Pharmacological Efficacy in a Specific Disease | [/INST]
| Pharmacological Acceptability in a Specific Disease | [/INST]
| Pharmacological Effectiveness in a Specific Population | [/INST]
| Pharmacological Safety in a Specific Disease | [/INST]
| Pharmacological Efficacy in a Specific Disease | [/INST]
| Pharmacological Effectiveness in a Specific Population | [/INST]
| Pharmacological Safety in a Specific Disease | [/INST]
| Pharmacological Efficacy in a Specific D"
586,[/INST]0cyocyocyocyocyocyocyocyocyocyocyoopularcyoopitopitopitularcyrdustularcyrdustrycycycycycycyocyocycycycyocyocyocyocyocyocyocyocyocyocyoopostomostomostopnyoisternycyrdustnyocyrdustnyocyrdustcyrdustomistercyrdustustularcyrdustularcyrdulcyocyrdulcyrdustularcyocyrdustularcyrdustuckery000rdusteryrdustryrdustryrdustuckeryoledustryrdustryrdustustryrdustustustustustomistercyocyrdustustustustustustustustustocyoustomostoromister00000000ustomostomisterlyoledomistercyrdustonisteronisternyonustustustustustustustomisterocyrdulistercyrdulisterlyonopulisterlyomostly00000000ustlyustlyoustustustomisterlyocyocyomisterlyomisterlycycycycyrdullyrdiallyomostomostomostomisterlyomisterlyooplyapullyomoporopularlyomomomomomomomomomomomomomostomomomomomostomostomostomostomomostomostomostomostomomostlyomlyomlylylylyomullyomularlyomostlyomostlyomlyomlyomlyomlyomlyomlyomlyaplyomomomomomomomomomomomomomomomlyomlyomlyomlyomlyomlyomlyomomomomomomomomomomomomomomomomlyomlyomlyomlyomlyomlyomlyolyoomomomlyomiallyomlyomlylylylylylylylylylyustlylylyiedlyomustlyomitlyomlylylylylylylylylylylylylylylylylylylyomlylylyomlyomoply111111
587,[/INST]
588,"[/INST]-
-
-
-
-


-
-
-
-
-
-
-
-
-



-
-
-
-
-
-
-



-
-
-
-
-five
-five,
-p-
-
-
-

















	
	
	
	
	
	
	
	




































































-









-p-p-p-
-
-



-











-
-
-"
589,"[/INST]
Patient #1: [Age] years old, [Sex] years old, [Weight lb] before index, [Height cm] before index, [Marital Status] before index, [SARS-CoV] years old, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Height cm] before index, [Marital Status] years old, [Weight lb] before index, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index, [Marital Status] years old, [Height cm] before index, [Weight lb] before index"
590,"[/INST]
R
R
R
S
S
S
S
S
S
S
S
S
S
The
The
S
S
P
P
P
P
S
S
S
S
R
R
R
S
S
R












S
S
S
S
S
S
S
S
S






































































































































S
S
S
S
S
S
S"
591,"[/INST]

Data Collection
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Collection Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis
Time Frame: [/INST]
Data Analysis"
592,"[/INST]
Episodic Migraine, Atogepant, QULIPHA, AGN-241689
=================
Keywords Provided by Centre Hospitalier Valida
=================
Episodic Migraine, Atogepant, QULIPTA, AGN-241689
=================
Keywords Provided by Centre Hospitalier Valida
Episodic Migraine, Atogepant, QULIPTA, AGN-241689
=================
Keywords Provided by Centre Hospitalier Valida, Atogepant, QULIP
=================
================
=================
Keywords Provided by Centre Hospitalier Valida, Atogepant, QULI, Atogepant, QULI, Atogepant, QULI, AGN, Atogepant, QULI, Atogepant, Valida, QULI, Atogepant, QULI, Atogepant, QULI, Atogepant, QULI, Atogepant, QULI, Atogepant, Valium, QULI, Atogepant, QU, Atogepant, QU, Lili, Atogepant, QU, Lili, Atogepant, QU, Atogepant, QU, Atogepant, Atogepant, Atogepant, QU, Atog, QU, Atog, Atog, QU, Atogepant, QU, Atog, QU, Atog, Atog, QU, Atog, QU, Atog, QU, Atog, QU, Atog, QU, Atog, QU, Atog, QU, Atog, QU, Atog, QU, Atog, QU, Atog, QU, Atog, QU, QU, QU, QU, Atog, QU, Atog, QU, Atog, QU, Atog, QU, QU, Atog, QU, QU, QU, QU,
================, QU, QU, QU, QU, QU,
================, QU,.
================,.
================.
================."
593,"[/INST]
| The investigational behavior.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
| the intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The intervention.
The.
The intervention.
The therapy.
The.
The.
The intervention.
The.
The inter
The inter-.
The intervention.
The patients.
The.
The.
The.
The.
The.
The patient.
The patient.
The patient.
The.
The.
The.
The|>
The|
The| a|
The| a|
The| a| a| a|
In.
In a|
In|
In|
The|
In a|
The|
The>
The>
The>
In a|
In.
This.
The.
The.
The.
The.
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The"
594,"[/INST]
The mother.
The mother.
The mother.
The mother.
The mother.
The mother.
The mother.
The mother.
The symptoms.
The symptoms.
The mother.
The mother.
The mother.
The mother.
The mother.
The mother.
The mother.
The mother.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The
The patients.
The patients.
The patients.
The patients.
The.
The patients.
==
The patients.
The patients.
The patients.
It's
It's
The
The
The
It.
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
In
In
In
In
In
The
The
The
Thomas
The
The
The
The
Th
The
The
The
The
The
The
The
The
The
The   
The    psych
C
C
C
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
The
The
The
The
The
In
In
A
This
The
The
The
The
The
The
The
The
The




The
The










P




The
The
A
A
A
The
The
A
A
A
A
A
A

























A
A
The
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A"
595,"[/INST] a a a a a a a a a a a a a a a a
































0
0
0
0
0










0



0
0
0
0
0
0



 A D0.
istic A
0.
 a a a a a a a a a a a g0000000000 a a a a a mister a m7 a m70000 r0 mister a mors a mors a D0 a mors a mister a a mistic a r000000000 a D0 a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a mO a c0-st-st-st-st-st. a D0-st-st-re a a a a a a a a D0-stive a D0-stive a a a a a a a-st-st-st-st-stive D0-stive D0-stive a D0-st-st-st-st-st-st-st-st-stive a a a a a a a a a-st0000000000000000000-stive a-st-st-st-st-st-st-st-st0-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-m-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st0-st0-st-A-A-stive a-st-st-st0-st-st0-st"
596,"[/INST]

| Outcome Measures | Measurement Description | Time Frame |
| Outcome of the study | Measured using the Rivermead Global Health Scale | Through study completion, an average of 1 year | Participants will be assessed using the PROMIS Global Health Scale at 3 months after their final OMT session | 
| Outcome of the study will be the ability to work without physical or psychological sequelae |
| Outcome of the study will be the ability to return to work without psychological sequelae |
| Through study completion, an average of 1 year | Participants will be assessed using the Rivermead Global Health Scale at 3 months after their final OMT session
| Outcome of the study will be the ability to return to work without psychological sequelae |
| Outcome of the study will be the ability to work without physical or psychological sequelae |
| Through study completion, an average of 1 year | Participants will be assessed using the Rivermead Global Health Scale at 2 months after their final OMT session |
| Outcome of the study will be the ability to work without psychological sequelae |
| Outcome of the study will be the ability to return to work without physical or psychological sequelae |
| Through study completion, an average of 1 year | Participants will be assessed using the Rivermead Global Health Scale at 2 months after their final OMT session
| Outcome of the study will be the ability to work without psychological sequelae |
| Through study completion, an average of 1 year | Participants will be assessed using the Rivermead Global Health Scale at 3 months after their final OMT session |
| Outcome of the study will be the ability to work without psychological sequelae |
| Through study completion, an average of 1 year | Participants will be assessed using the Rivermead Global Health Scale at 2 months after their final OMT session |
| Outcome of the study will be the ability to work without psychological sequelae |
| Through study completion, an average of 1 year | Participants will be assessed using the Rivermead Global Health Scale at 3 months after their final OMT session |
| Outcome of the"
597,"[/INST]
Data provided by: Centre Hospitalier, Indocyanine Green, Angiography, ICG, thrombolysis, and hypothesize that these two imaging modalities (conventional angiography and used in close association with nephrotoxicity and other risks) will be concordant in demonstrating the ischemic tissue present in severe frostbite.
Data provided by: Centre Hospitalier, Indocyanine Green, Angiography, ICG, thrombolysis, and hypothesize that these two imaging modalities (conventional angiography and used in close association with nephrotoxicity and other risks) will be concordant in demonstrating the ischemic tissue present in severe frostbite.
Data provided by: Centre Hospitalier, Indocyanine Green, Angiography, ICG, thrombolysis, and hypothesize that these two imaging modalities (conventional angiography and used in close association with nephrotoxicity and other risks) will be concordant in demonstrating the ischemic tissue present in severe frostbite.
Data provided by: Centre Hospitalier, Indocyanine Green, Angiography, ICG, thrombolysis, and hypothesize that these two imaging modalities (conventional angiography and used in close association with nephrotoxicity and other risks) will be concordant in demonstrating the ischemic tissue present in severe frostbite.
Data provided by: Centre Hospitalier, Indocyanine Green, Angiography, ICG, thrombolysis, and hypothesize that these two imaging modalities (conventional angiography and used in close association with nephrotoxicity and other risks) will be concordant in demonstrating the ischemic tissue present in severe frostbite.
Data provided by: Centre Hospitalier, Indocyanine Green, Angiography, ICG, thrombolysis, and hypothesize that these two imaging modalities (conventional angiography and used in close association with nephrotoxicity and other risks) will be concordant in demonstrating the ischemic tissue present in severe frostbite.
Data provided by: Centre Hospitalier"
598,"[/INST]
-----------------
Other: [/INST]
Admission to the Elderly Care Unit, [INST]
Patient status: [/INST]
Functional ability: [INST]
Change in functional status between groups | Other: [INST]
Patient satisfaction: [INST]
Other: [INST]
Change in weight between groups | Other: [INST]
Patient status: [INST]
Functional ability: [INST]
Change in functional status between groups | Other: [INST]
Patient satisfaction: [INST]
Other: [INST]
Change in weight between groups | Other: [INST]
Patient status: [INST]
Functional ability: [INST]
Change in functional status between groups | Other: [INST]
Patient satisfaction: [INST]
Other: [INST]
Change in weight between groups | Other: [INST]
Patient status: [INST]
Functional ability: [INST]
Change in functional status between groups | Other: [INST]
Patient satisfaction: [INST]
Change in weight between groups | Other: [INST]
Patient status: [INST]
Functional ability: [INST]
Change in functional status between groups | Other: [INST]
Patient satisfaction: [INST]
Change in weight between groups | Other: [INST]
Patient status: [INST]
Functional ability: [INST]
Change in functional status between groups | Other: [INST]
Patient satisfaction: [INST]
Change in weight between groups | Other: [INST]
Patient status: [INST]
Functional ability: [INST]
Change in functional status between groups | Other: [INST]
Patient satisfaction: [INST]
Change in weight between groups | Other: [INST]
Patient status: [INST]
Functional ability: [INST]
Change in functional status between groups | Other: [INST]
Patient satisfaction: [INST]
Change in weight between groups | Other: [INST]
Patient status: [INST]
Functional ability: [INST]
Change in functional status between groups | Other: [INST]
Patient satisfaction: [INST]
Change in weight between groups | Other: [INST]
Patient status: [INST]
Functional ability: [INST]
Change in functional status between groups | Other: [INST"
599,"[/INST]
| Patients receiving study treatment will be monitored for evidence of disease progression. |
| Patients receiving study treatment up to 1 month | 
| Other names will be used to determine significance. |
| Patients receiving study will be monitored continuously. |
| Patients receiving study. |
| Patients will be monitored for evidence of disease. |
| Patients receiving study. | Patients will be monitored for evidence of disease. |
| Patients receiving study. | Patients will be monitored for evidence. |
| Patients receiving study. | Patients will be monitored for evidence. | Patients receiving study. | Patients receiving study. | Patients will be monitored for the study. | Patients receiving study. | Patients receiving study. | Patients will be monitored. | Patients receiving study. | Patients receiving study. | Patients will be monitored. | Patients receiving study. | Patients receiving study. | Patients receiving study. | Patients receiving study. | Patients receiving study. | Patients receiving study. | Patients will be monitored. | Patients receiving study. Patients receiving study. | Patients receiving study. | Patients receiving study. Patients receiving study. Patients receiving study. Patients receiving study. | Patients receiving study. | Patients receiving study. Patients receiving study. Patients receiving study. Patients receiving study. Patients receiving study. Patients receiving study. Patients receiving study. Patients receiving study. Patients receiving study. Patients receiving radiology. Patients receiving study. Patients receiving study. Patients receiving treatment. Patients receiving treatment. Patients receiving treatment. Patients receiving study. Patients receiving study. Patients receiving study. Patients receiving study. Patients receiving study. Patients receiving study. Patients receiving treatment. Patients receiving treatment. Patients receiving treatment. Patients. Patients.
The patients. Patients.
Patients. Patients.
Patients.
Patient.
Patient. Patients.
Patients.
Patients.
Patients.
Patients. Patients.
Patient. Patients.
Patient. Patients.
Patients.
----------------.
The patients.
The patients.
In.
In.
In.
In.
In.
In. Patients"
600,"[/INST]
The
The
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S






S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S"
601,"[/INST]
Other names: 19F MRI, ventilation, pediatrics
Terms related to the study: 19F MRI, ventilation, pediatrics
Keywords: 19F MRI, ventilation, pediatrics
Other names: 19F MRI, ventilation, pediatrics
Terms related to the study: 19F MRI, ventilation, pediatrics
Other names: 19F MRI, ventilation, pediatrics
Terms related to the study: 19F MRI, ventilation, pediatrics
19F MRI, ventilation, pediatrics
Terms related to the study: 19F MRI, ventilation, pediatrics
19F MRI, ventilation, pediatrics
Terms related to the study: 19F MRI, ventilation, pediatrics
19F MRI, ventilation, pediatrics
Terms related to the study: 19F MRI, ventilation, pediatrics
19F MRI, ventilation, pediatrics
Terms related to the study: 19F MRI, ventilation, pediatrics
19F MRI, ventilation, pediatrics
Terms related to the study: 19F MRI, ventilation, pediatrics
19F MRI, ventilation, pediatrics
Terms related to the study: 19F MRI, ventilation, pediatrics
19F MRI, ventilation, pediatrics
Terms related to the study: 19F MRI, ventilation, pediatrics
19F MRI, ventilation, pediatrics
19F MRI, ventilation, pediatrics
Terms related to the study: 19F MRI, ventilation, pediatrics
19F MRI, ventilation, pediatrics
19F MRI, pediatrics
Terms related to the study. 19F MRI, pediatrics
Terms related to the study. 19F MRI, pediatrics
19F MRI, pediatrics
Terms related to the study, pediatrics
19F MRI, pediatrics
Terms related to the"
602,"[/INST]
Other: [/CC]

Statistical Method
Open kinetic chain exercises
Closed kinetic chain exercises
Outcome Measures:
Pain at the knee
Balance at the knee
Statistical Method:
Numerical Pain Rating Scale
Closed kinetic chain exercises
Outcome: Pain at the knee
Balance at the knee
Statistical Method:
Numerical Pain Rating Scale
Closed kinetic chain exercises
Outcome: Pain at the knee
Balance at the knee
Statistical Method:
Numerical Pain Rating Scale
Closed kinetic chain exercises
Outcome: Pain at the knee
Balance at the knee
Statistical Method:
Numerical Pain Rating Scale
Closed kinetic chain exercises
Outcome: Pain at the knee
Balance at the knee
Statistical Method:
Numerical Pain Rating Scale
Closed kinetic chain exercises
Outcome: Pain at the knee
Balance at the knee
Statistical Method:
Numerical Pain Rating Scale
Closed kinetic chain exercises
Outcome: Pain at the knee
Balance at the knee
Statistical Method:
Numerical Pain Rating Scale
Closed kinetic chain exercises
Outcome: Pain at the knee
Balance at the knee
Statistical Method:
Numerical Pain Rating Scale
Closed kinetic chain exercises
Outcome: Pain at the knee
Balance at the knee
Statistical Method:
Numerical Pain Rating Scale
Closed kinetic chain exercises
Outcome: Pain at the knee
Balance at the knee
Statistical Method:
Numerical Pain Rating Scale
Closed kinetic chain exercises
Outcome: Pain at the knee
Balance at the knee
Statistical Method:
Numerical Pain Rating Scale
Closed kinetic chain exercises
Outcome: Pain at the knee
Balance at the knee"
603,"[/INST]
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-st-st-st-st-h-st-
-
-
-
-
-
-
-
-
-
-
-
-
-































-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-st-st-st-st-st-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-a-
-
-a-st-st-st-st-st-st-st-st-st-st-f--
-
-f-
- g-st-st-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-st-st-
-
-
-
-
-
-
-
-
-
----
-
-
-
-f-
-
-
-st-st-st-st-st-st-st-
-st--
------
-
--st-----
----------------st-st-st,,,,, M-st M-st M-e M- M-st-st-st-st-- M-st-st- M-st M- M-- M- M- M--------st----- M--"
604,"[/INST]
Device: [/INST]
| The incidence of the procedure-related complication | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications | The incidence of the procedure-related complications | 1 year | 
| The incidence of the procedure-related complications"
605,"[/INST]
| Experimental: CSX-1004<br>Single dose of nicotine | Biological: CSX-1004<br>* Maximum serum concentration | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 | 6 months | 
| Infusion site visit | 4 months | 
| Treatment phase of 1004 |"
606,"[/INST]

Other: [/INST]"
607,"[/INST]

How is the study measuring?
-----------------
| Change in FLVlongtau2 occurring with a protocol-defined CF pulmonary exacerbation | Difference in FLVlongtau2 between baseline and exacerbation visit 1, expressed as a percentage of total lung volume. | Day 1 to Day 365 (+/- 30 days) | 
| Change in FLVlongtau2 occurring with a protocol-defined CF pulmonary exacerbation | Difference in FLVlongtau2 between baseline and exacerbation visit 1, expressed as a percentage of total lung volume. | Day 1 to Day 14 (+/- 30 days) | 
| Change in MRI severity score with VDP at baseline. | Baseline is a mean of the VDP scores from Day 1 and Day 14 (expressed as a percentage of lung). |
| Change in MRI severity score with FLVlongtau2 at baseline. | Difference in FLVlongtau2 between Day 1 and Day 14, expressed as a percentage of total lung volume. | Day 1 to Day 365 (+/- 30 days) | 
| Change in FLVlongtau2 occurring with a protocol-defined CF pulmonary exacerbation | Difference in FLVlongtau2 between baseline and exacerbation visit 1, expressed as a percentage of total lung volume. | Day 1 to Day 14 (+/- 30 days) | Change in FLVlongtau2 occurring with a protocol-defined CF pulmonary exacerbation | Day 1 to Day 14 (+/- 30 days) | Change in FLVlongtau2 occurring with a protocol. | Day 1 to Day 1 to Day 14 (+/- 30 days. | Change in FLVlongtau2 occurring with a protocol. | Day 1 to Day 1 to Day 1, expressed as a protocol. | Day 1 to Day 1, expressed as a protocol. | Day 1 to Day 1 to Day 1, expressed as a protocol. | Day 1 to Day 1 to Day 1, expressed as a protocol. | Day 1, expressed as"
608,"[/INST]
S"
609,"[/INST]
| Disengage the breathing circuit when the patient is changed from the supine to the lateral decubitus position. | Anesthesiologists will score the quality of lung collapse using a four-point ordinal scale (1=extremely poor-no collapse of lung, 2=poor partial collapse, 3=good total collapse, but the lung had some residual air; 4=excellent collapse). |
| Primary Outcome: lung collapse is optimal |
| Secondary Outcome: the patient is awake and the lung has no residual air |
| Tertiary Outcome: the patient is transferred from the supine to the lateral decubitus position |
| Quaternary Outcome: the patient is extubated |
| Outcome Measure |
| Primary Outcome: lung collapse is optimal |
| Secondary Outcome: the patient is awake and the lung has no residual air |
| Tertiary Outcome: the patient is transferred from the lateral decubitus to the supine position |
| Quaternary Outcome: the lung has no residual air |
| Outcome Measure |
| Primary Outcome: lung collapse is optimal |
| Secondary Outcome: the patient is awake and the lung has no residual air |
| Tertiary Outcome: the patient is transferred from the lateral decubitus to the supine position |
| Quaternary Outcome: the lung has no residual air |
| Primary Outcome: lung collapse is optimal |
| Secondary Outcome: the patient is awake and the lung has no residual air |
| Tertiary Outcome: the patient is transferred from the lateral decubitus to the supine position |
| Quaternary Outcome: the lung has no residual air |
| Primary Outcome: lung collapse is optimal |
| Secondary Outcome: the patient is awake and the lung has no residual air |
| Tertiary Outcome: the patient is transferred from the lateral decubitus to the supine position |
| Quaternary Outcome: the lung has no residual air |
| Primary Outcome: lung collapse is optimal |
| Secondary Outcome: the patient is awake and the lung has no"
610,"[/INST]
| Other: [Diabetes Distress Scale]
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
| Diabetes Control |
|"
611,"[/INST]



































|
|
|
|
|
|
|
|
|
O



















|
|








|
|
|
||||||||||
|
|
|


















|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|



|
|
|
|
|
|
|
||
|
||
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||	|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
||||"
612,"[/INST]

Surgical resection is the gold standard for treating soft tissue lesions.
Benign lesions are not cancer and do not require treatment.
Soft tissue lesions are not cancer and are not treated with surgery.
A gold standard for diagnosing soft tissue lesions is biopsy and surgical resection.
AIs are not cancer and do not require treatment.
Sensitivity and specificity of the algorithms are not cancer and do not require treatment.
Classification of soft tissue lesions is not an AI algorithm.
Grading of soft tissue lesions is not cancer and do not require treatment.
Soft tissue lesions are not cancer and do not require surgery.
A gold standard for diagnosing soft tissue lesions is biopsy and surgical resection.
Sensitivity and specificity of the algorithms are not cancer and do not require treatment.
Soft tissue lesions are not cancer and do not require surgery.
A gold standard for diagnosing soft tissue lesions is biopsy and surgical resection.
Sensitivity and specificity of the algorithms are not cancer and do not require treatment.
Soft tissue lesions are not cancer and do not require surgery.
A gold standard for diagnosing soft tissue lesions is biopsy and surgical resection.
Classification of soft tissue lesions is not an AI algorithm.
Soft tissue lesions are not cancer and do not require treatment.
Sensitivity and specificity of the algorithms are not cancer and do not require treatment.
Soft tissue lesions are not cancer and do not require surgery.
A gold standard for diagnosing soft tissue lesions is biopsy and surgical resection.
Sensitivity and specificity of the algorithms are not cancer and do not require treatment.
Soft tissue lesions are not cancer and do not require surgery.
A gold standard for diagnosing soft tissue lesions is biopsy and surgical resection.
Sensitivity and specificity of the algorithms are not cancer and do not require treatment.
Soft tissue lesions are not cancer and do not require surgery.
A gold standard for diagnosing soft tissue lesions is biopsy and surgical resection.
Sensitivity and specificity of the algorithms are not"
613,"[/INST]

Inclusion Criteria:
Males and non-smokers
Exclusion Criteria: Females and smokers
Intervention Model: Microneedling alone
Comparison: Microneedling along with HA
Primary Outcome Measure: Gingival thickness (GT) will be measured at baseline and 9 months.
Secondary Outcome Measure: Gingival thickness (GT) will be measured at 9 and 18 months.
Tertiary Outcome Measure: Gingival thickness (GT) will be measured at 27 and 36 months.
Quaternary Outcome Measure: Gingival thickness (GT) will be measured at baseline and 3 years.
Fifth Outcome Measure: Gingival thickness (GT) will be measured at 5 years.
Sixth Outcome Measure: Gingival thickness (GT) will be measured at 10 years.
Seventh Outcome Measure: Gingival thickness (GT) will be measured at 10 years and at 15 years.
Eighth Outcome Measure: Gingival thickness (GT) will be measured at 15 years and at 20 years.
Ninth Outcome Measure: Gingival thickness (GT) will be measured at 20 years and at 25 years.
Tenth Outcome Measure: Gingival thickness (GT) will be measured at 25 years and at 30 years.
Eleventh Outcome Measure: Gingival thickness (GT) will be measured at 30 years and at 35 years.
Twelfth Outcome Measure: Gingival thickness (GT) will be measured at 40 years and at 45 years.
Thirteenth Outcome Measure: Gingival thickness (GT) will be measured at 45 years and at 50 years.
Fourteenth Outcome Measure: Gingival thickness (GT) will be measured at 55 years and at 60 years.
Fifteenth Outcome Measure: Gingival thickness (GT) will be measured at 65 years and at 75 years.
Sixteenth Outcome Measure: G"
614,"[/INST]

Inclusion Criteria
-----------------
Primary Inclusion Criteria | Participant Group, defined as the mean and median number of patients who will undergo the surgical procedure/treatment (Surgical Group) or the investigators (March 2022). Exclusion Criteria: Colorectal surgical group, defined as the mean and median number of patients who will undergo the surgical procedure/treatment (March 2022). | at the time of tissue analysis, usually 1 month after surgery | Colorectal surgical group, defined as the mean and median number of patients who will undergo the surgical procedure/treatment (March 2022).
| at the time of tissue analysis, usually 1 month after surgery |

Exclusion Criteria: Colorectal surgical group, defined as the mean and median number of patients who will undergo the surgical procedure/treatment (March 2022). | at the time of tissue analysis, usually 1 month after surgery |


Participant Eligibility Criteria
-----------------
| Participant Group, defined as the mean and median number of patients who will undergo the surgical procedure/treatment (March 2022). | at the time of tissue analysis, usually 1 month after surgery |

Exclusion Criteria: Colorectal surgical group, defined as the mean and median number of patients who will undergo the surgical procedure/treatment (March 2022). | at the time of tissue analysis, usually 1 month after surgery |


Participant Eligibility Criteria
-----------------
| Participant Group, defined as the mean and median number of patients who will undergo the surgical procedure/treatment (March 2022). | at the time of tissue analysis, usually 1 month after surgery |


Participant Eligibility Criteria
-----------------
| Participant Group, defined as the mean and median number of patients who will undergo the surgical procedure/treatment (March 2022). | at the time of tissue analysis, usually 1 month after surgery |


Participant El"
615,"[/INST]
Other
| migraine, oculomotor
| Cervical, migraine
| migraine, oculomotor
| Other
| migraine, oculomotor
| migraine, cervical, oculomotor
| migraine, oculomotor
| migraine, cervical, migraine, oculomotor
| migraine, cervical, migraine, oculomotor
| migraine, cervical, migraine, migraine, cervical, migraine, migraine, migraine, migraine, migraine, cervical, migraine, migraine, migraine, migraine, migraine, migraine, cervical, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, migraine, mig, mig.
|
|
|
|
Otherwise.
|
|
|
|
|
Other symptoms, it may be|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
==|
==|
==|
==|
==|
==|
==|
by|.|
In|.|
==.|
The patient.|
The patient|
The patient|
This.|
The patient|
The patient.|
The patient.|
The patient.|
The patient.|
The patient.
==.
==.
==.
==.
==.
==.
==.
==.
====.
====.
==.
==."
616,[/INST]
617,"[/INST]

Adverse Events
-----------------
Volunteers

Comments
-----------------

Shamrock, trident, ultrasound, day 0, the projection of line, depth of lumbar plexus, and presence of vessels.

Comments related to the study provided by trident and shamrock techniques.

Volunteers

Comments related to the study provided by trident and shamrock techniques.

Informed consent provided by trident and shamrock techniques.

Volunteers

Comments related to the study provided by trident and shamrock techniques.

Shamrock, trident, ultrasound, the projection of line, depth of lumbar plexus, and presence of vessels.

Comments related to the study provided by trident and shamrock techniques.

Volunteers

Comments related to the study provided by trident and shamrock techniques.

Shamrock, trident, ultrasound, the projection of line, depth of lumbar plexus, and presence of vessels.

Volunteers

Comments related to the study provided by trident and shamrock techniques.

Shamrock, trident, ultrasound, the projection of line, depth of lumbar plexus, and presence of vessels.

Volunteers

Comments related to the study provided by trident and shamrock techniques.

Shamrock, trident, ultrasound, the projection of line, depth of lumbar plexus, and presence of vessels.

Volunteers

Comments related to the study provided by trident and shamrock techniques.

Shamrock, trident, ultrasound, the projection of line, depth of lumbar plexus, and presence of vessels.

Volunteers

Comments related to the study provided by trident and shamrock techniques.

Shamrock, trident, ultrasound, the projection of line, depth of lumbar plexus, and presence of vessels.

Volunteers

Comments related to the study provided by trident and shamrock techniques.

Shamrock, trident, ultrasound, the projection of line, depth of lumbar plexus, and presence of vessels."
618,"[/INST]

How is the study designed?
| Designed by: Detailed Description of Study Design | Allocation: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized |
| Designed by: Randomized"
619,"[/INST]
-----------------
Adverse drug reaction, older people, hospitalized patients, computerized decision support for the alert, stepped-wedge, hospitalized patients, cost-effectiveness of the pharmaceutical intervention, time spent, average of 20 days
-----------------
Evaluation of the study: [/INST]
Adverse drug reaction, older people, hospitalized patients, stepped-wedge, time spent, average of 20 days | through study completion, time spent
-----------------
Evaluation of the study: [/INST]
Adverse drug reaction, older people, hospitalized patients, stepped-wedge, time spent, average of 20 days | through study completion, time spent
-----------------
Evaluation of the study: [/INST]
Adverse drug reaction, older people, hospitalized patients, stepped-wedge, time spent, average of 20 days | through study completion, time spent
-----------------
Evaluation of the study: [/INST]
Adverse drug reaction, older people, hospitalized patients, stepped-wedge, time spent, average of 20 days | through study completion, time spent
-----------------
Evaluation of the study: [/INST]
Adverse drug reaction, older people, hospitalized patients, stepped-wedge, time spent, average of 20 days | through study completion, time spent
-----------------
Evaluation of the study: [/INST]
Adverse drug reaction, older people, hospitalized patients, stepped-wedge, time spent, average of 20 days | through study completion, time spent
-----------------
Evaluation of the study: [/INST]
Adverse drug reaction, older people, hospitalized patients, stepped-wedge, time spent, average of 20 days | through study completion, time spent
-----------------
Evaluation of the study: [/INST]
Adverse drug reaction, older people, hospitalized patients, stepped-wedge, time spent, average of 20 days | through study completion, time spent
-----------------
Evaluation of the study: [/INST]
Adverse drug reaction, older people, hospitalized patients, stepped-wedge, time spent, average of 20 days | through study completion, time spent
-----------------
Evaluation of the study: [/INST]
Adverse drug reaction, older people, hospital"
620,"[/INST]

Definitions
-----------------
| CD patients |
| Control group |
| Inflammatory Bowel Disease |
| at inclusion |
| CD patients requiring surgical intervention |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surgical intervention |
| at inclusion |
| Control group |
| at inclusion |
| CD patients requiring surg"
621,"[/INST]

Experimental: LY3437943 (Part A)<br>LY3437943 administered IV<br>|
Primary Purpose: LY3437943 (Part A)<br>Experimental: LY3437943 (Part B)<br>PK: LY3437943 administered IV<br>|
Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Part A: LY3437943 (Part B)<br>PK: LY3437943 administered IV<br>|
| Part B: PK: LY3437943 administered IV<br>|

How is the study funded?
-----------------
| Funding Source: National Institute of Health<br>| Part A: National Health Insurance Program<br>| Part B: National Health Insurance Program<br>| Part C: Smithsonian Institute<br>| Part D: Private funding

How is the study designed?
| Designed by: HH
| Primary Purpose: LY3437943 (Part A)<br>Designed by: HH"
622,"[/INST]

How is the study designed?
-----------------
Patients with pituitary tumours

What is the primary outcome measure?
How is it defined?
What is the time frame for the study?
What is the secondary outcome measure?
How is it measured?
What is the relationship between the primary and secondary outcome measures?
How are they collected?
How are they analysed?
How are the results reported?
Who is responsible for reporting the results?
How are the results disseminated?
How are the results interpreted?
What is the relationship between the primary and secondary outcomes?
How do we know we are studying the right patients?
How are the inclusion and exclusion criteria defined?
How are the inclusion and exclusion criteria applied?
Who is eligible for the study?
What are the inclusion and exclusion criteria?
How are they defined?
How are they applied?
What is the relationship between the inclusion and exclusion criteria?
How are the inclusion and exclusion criteria applied?
Are the inclusion and exclusion criteria applied consistently?
Are there any specific safety precautions for this study?
Are the inclusion and exclusion criteria applied consistently?
Are the inclusion and exclusion criteria applied in a timely manner?
Are the inclusion and exclusion criteria applied consistently across the included patient population?
Are the inclusion and exclusion criteria applied consistently across the included patient population?
Are the inclusion and exclusion criteria applied in a timely manner?
Are the inclusion and exclusion criteria applied consistently?
Are the inclusion and exclusion criteria applied in a timely manner?
Are the inclusion and exclusion criteria applied consistently?
Are the inclusion and exclusion criteria applied in a timely manner?
Are the inclusion and exclusion criteria applied consistently?
Are the inclusion and exclusion criteria applied in a timely manner?
Are the inclusion and exclusion criteria applied consistently?
Are the inclusion and exclusion criteria applied in a timely manner?
Are the inclusion and exclusion criteria applied consistently?
Are the inclusion and exclusion criteria applied in a timely manner?
Are the inclusion and exclusion criteria applied in a timely manner?
Are the inclusion and exclusion criteria applied in a timely manner?
Are the inclusion and exclusion criteria applied in a timely manner?
Are the inclusion and exclusion criteria"
623,"[/INST]
| 12 weeks after the age | 12 weeks after the age.
| 12 weeks after the age.
| 12 weeks after the age.
| 12 weeks after the age.
| 12 weeks after the age.
| 12 weeks after the age.
| 12 weeks after the age.
| 12 weeks after the age.
| 12 weeks after the age.
|12 weeks after the age.|2 weeks after the age.| 1 year.
| months after the age.
| months after the age.
| months after the age.
| months after the age.
The study.
|1 year.
The months after the age.
The months after the age.
The months after the age.
The months after the months after the age.
The months after the age.
The months after the age.
The months after the
The months after the
The months.
The months.
The months after the months.
The months.
The months after the years.
The study.
The months.
The months.
The months.
The months.
The months.
The months.
The months.
The months.
The months.
The clinic.
The months.
The clinic.
The clinic.
The dose.
The patients.
The patients.
The patients.
The patients.
The clinic.
The clinic.
The patients.
The patients.
The patients.
The patients.
The treatment.
The patients.
The patients.
The patients.
The patients.
The.
The patients.
The patients.
The patients.
The patients.
In the disease.
In.
In.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
624,"[/INST]
Primary treatment of the 1.
Primary treatment of the 1.
Colon
The 1.
Colon't
Colon't
Colon
Colon
Colon't
Colon's
Colon
The 1.
Colon
Primary
Colon
Colon
Colon
Colon
Colon
Colon
Colon
Colon
Colon
Primary
Colon
Colon
Colon
Colon
Colon
Colon
Cola
Colon
Colon
Colon
Colon
Colon
Colon
Cola
Colomb
Cola
Cola
The surg
Cola
The 101
Colomb.
Colomb.
Colomb.
Colomb.
Colomb.
The
The
The patient.
Cola
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient
The patient
The patient
The patient
The patient
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The
The patient.
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
S
The
The.
The.
In
The.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This.
This
This
This
This
This
in
The
The
S
The 6
S
S
F
F
S
S
S.
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S"
625,"[/INST] I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I, I, I I I, I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II II II II II II II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I, I, I I I I I I I I I I I I I I I I I I I I I I I"
626,"[/INST]
Other relevant information
ClinicalTrials.gov number: NCT02457087
Title: Efficacy and Safety of White Kidney Bean Extract in the Treatment of Obesity: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial"
627,"[/INST]
| Treatment of the total behavior and the maximum score
| 12. Terms related to the total behavior associated with the total behavior
| 3 months after the total behavior associated with the total behavior
| 18. Terms related to the total behavior
| 3 months associated with the total behavior
| 18. Terms related to the total behavior associated with the total behavior
| 18 months total behavior associated with the total behavior total behavior associated with the total behavior total behavior associated with the total behavior total behavior associated with the total behavior total behavior associated with the total behavior total behavior total behavior associated with the total behavior total behavior total behavior total behavior associated with the total behavior total behavior associated with the total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior total behavior. total behavior. total behavior.
====. total behavior. total behavior. total behavior. total.
The behavior. total.
The behavior.
The behavior.
====.
====.
====.
====.
====.
====.
The behavior
The behavior
The
The
The
The
The
--------
--------
--------
--------
--------
--------
(when
(when
(before
(before
(before
(before
The
--------.
--------.
--------
--------
--------
--------
The
The
The
The
The
This
The
In
In
In
In
(including
(including
In
In
This
This
This
This
In
In
In
This
This
In
==
==
==
In
In
In
In
In
In
In
In
In
In
In"
628,"[/INST]
================="
629,"[/INST]
The
The
The
The
The
F
F
F
F
F
F
F
F
F
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
















































































































































































































































































































































R-
R-




-
-































A
A
A
A
A
A
A

R
R
-
R
R
R
R-
R-
R-
R-
R
R
R
R
R
R-
R-
h-
h-
h
h
R-
h-"
630,"[/INST]
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
-
-
-
-
-
-
-
-
-
-
This
This
This
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-











The
The
The
The
The
The
The
-

















































































-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
D
D
D






The


-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
D
-
-
-
-
-
-
-
-
-
P
P
P
P
P
P
P-
-
A
P-"
631,"[/INST]
The.
The.
The treatment.
The-based
A.
The clinical
A.
The.
The.
The hospital.
As
As
As
As
As
The
The
This
The clinical
The clinical
The clinical
The particular
The patient
The patient
The.
The clin-based
The clinement
The particular.
The particular.
This
This
This
This particular.
This.
This.
This.
This.
This.
This.
== this.
== .
==
==
This.
This.
This.
This
This
This
This
The
This
This
This
This
This
This
This
This
The
The
This
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
A
This
This
This
This
The
The
The
The
The"
632,"[/INST]
| Other names: Paravertebral block versus Erector spinea block versus quadratus lamborum block;|
| Primary Outcome: [INSTANCE]
| Secondary Outcome: [/INSTANCE]
| Tertiary Outcome: [/INSTANCE]
| Quadratus lamborum block<br>Erector spinea block versus thoracic paravertebral block;|
| Other names: Paravertebral block versus Erector spinea block versus quadratus lamborum block;|

How is the study designed?
| Designed by: [/INSTANCE]
| Other names: Paravertebral block versus Erector spinea block versus quadratus lamborum block;|
| Primary Outcome: [/INSTANCE]
| Secondary Outcome: [/INSTANCE]
| Tertiary Outcome: [/INSTANCE]
| Other names: Paravertebral block versus Erector spinea block versus quadratus lamborum block;|
| Primary Outcome: [/INSTANCE]
| Secondary Outcome: [/INSTANCE]
| Tertiary Outcome: [/INSTANCE]
| Other names: Paravertebral block versus Erector spinea block versus quadratus lamborum block;|
| Primary Outcome: [/INSTANCE]
| Secondary Outcome: [/INSTANCE]
| Tertiary Outcome: [/INSTANCE]
| Other names: Paravertebral block versus Erector spinea block versus quadratus lamborum block;|
| Primary Outcome: [/INSTANCE]
| Secondary Outcome: [/INSTANCE]
| Tertiary Outcome: [/INSTANCE]
| Other names: Paravertebral block versus Erector spinea block versus quadratus lamborum block;|
| Primary Outcome: [/INSTANCE]
| Secondary Outcome: [/INSTANCE]
| Tertiary Outcome: [/INSTANCE]
| Other names: Paravertebral block versus Erector spinea block versus quadratus lamborum block;|
| Primary Outcome: [/INSTANCE]
| Secondary Outcome: [/INSTANCE]
| Tert"
633,"[/INST]
^
ive	^
ities
ities	ry	^	^	^	^	ry	-
^	-
^-
-
^
^
^
^
ities cure	^
^
ities cure	ry	ry	ry	ry cure cure cure	ry	ry	ry	ry	ry	ry c-	ry	ry	ry	ry	ry cure m8	ive	ry	ry	ry	ry	ry	ive	^	ry	^	-
	-
	-	-	-	-
-
istic	ry	ry	ry	ry	^
^
^
	ry	ry	ry	-st
-st-st-|-|-|-|-|-|-|-st -stive	ry	ry	ry	ry mister	ry	-sture	ure	ure mure mure m-st -st -st -|-st m-st m- - - - -st 	- r8	-8	- - - - -8 - - m8 m8 8 murities mure mure mure mure mister ive 8 ry mister -st murities mors mors mors mors  m8  mors  murities murities m-
 murities -8 murities ristic rities rities r8 r8 r8 -8 -8 - m- c- m- m8 mure mure murities murities mure mure murities cure  murities 	-  rites c- 
    
 
 
 
 m- ristic rities c-  m- c- c- c- ristic  ristic ristic rist c- - - - c--- cure cure cure ristic c- c- c- c- c- c- r- r- r- r-"
634,"[/INST]

Carcinoma, NSCLC, Ovarian Cancer, Hypothalamic Hamartomas, Head and Neck Cancer, Brain Cancer, Kidney Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Lung Cancer, Thyroid Cancer, Parathyroid Cancer, Breast Cancer, Stomach Cancer, Cervical Cancer, Prostate Cancer, Bladder Cancer, Testicular Cancer, Mesothelioma, Thyroid Lobe Cancer, Medullary Cancer, Laryngeal Cancer, Melanoma, Retroperitoneal Cancer, Ovarian Cancer, Peritoneal Cancer, Kidney Cancer, Thyroid Cancer, Parathyroid Cancer, Head and Neck Cancer, Liver Cancer, Colorectal Cancer, Brain Cancer, Pancreatic Cancer, Lung Cancer, Breast Cancer, Cervical Cancer, Prostate Cancer, Bladder Cancer, Stomach Cancer, Thyroid Cancer, Medullary Cancer, Testicular Cancer, Melanoma, Thyroid Cancer, Laryngeal Cancer, Parathyroid Cancer, Ovarian Cancer, Breast Cancer, Cervical Cancer, Head and Neck Cancer, Colorectal Cancer, Pancreatic Cancer, Mesothelioma, Kidney Cancer, Thyroid Cancer, Laryngeal Cancer, Ovarian Cancer, Testicular Cancer, Brain Cancer, Cervical Cancer, Head and Neck, Thyroid Cancer, Ovarian Cancer, Colorecter of the neck, Ovaries breast, Laryn's disease.
What is known as the time.
What is known as the time.
How is known as the time.
How is known as the time.
How is known as the time.
How is known as the time.
How is known as the time known as the time known as the time. How is known as the time.
How is known as the time.
How is known as the time. How is known as the time.
How is the time. How is the time known as the"
635,"[/INST]
| 0-6 months after hospital discharge, 14-60. | 
| 
| 0-6 months after hospital discharge, 14-60.
| 0-6 months after hospital discharge.
| 0-60.
| 14-60.
| 0-60.
| 0-60.
| 0-60.
| 0-60.
| 0-60.
| 0-60.
| 0-60.| 0-60.| 0-60.|0.
| 0.
| 0.
| 0.
| 0.
| 0.
| 0.
| 0.
| 0.| 0.
| 0.| 0.
| 0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|0.|
The disease.|0.|.
The patient|.
The patient|.|.




The brain.
The brain.
The brain.
The brain.
The patient.
The brain.
The brain.
The brain.
The brain.
The patient.
The patient.
The patient.
The%
The%
This.
The%
The%
This.
The patient
The//
This.
This
This
This
This
This.
This
This
This
This
This
It
It
It"
636,"[/INST]
| Participants will be weighed to the nearest 0.1 kg. | Participants will be weighed to the nearest 0.1 month | Participants will be weighed to the nearest 0.1 month | Participants will be weighed to the nearest 0.1 month | Participants will be weighed to the nearest 0.1 month | Participants will be weighed to the nearest 0.1 month | Participants will be weighed to the study will be weighed to the nearest 0. Participants will be weighed to the study will be weighed to the study will be weighed to the study will be weighed to the study. Participants will be weighed to the study. Participants will be weighed to the study. Participants will be weighed to the study will be weighed to the study will be weighed to the study will be weighed to the study will be weighed to the study will be weighed to the study will be weighed to the study will be weighed to the study will be weighed to the study will be weighed to the study will be weighed to the study will be weighed will be weighed will be weighed will be weighed will be weighed will be weighed.
The study will be weighed will be weighteen will be weighed will be weighed will be
The study will be weighed will be weighed will be weighed will be
The study will be weighed will be
The study will be
The study will be
The study will be
The study will be
The study will be
The study will be
The study will be
The study will be
The study
The study
The study
The study.
The study.
The study.
The study.
The study.
The study.
The study.
The study.
The A.
The A.
The A.
As.
As.
As
As
It.
It.
These.
These.
====.
It.
It.
These.
The
The
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It."
637,"[/INST]
How is the study designed?
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |
| Patients with GIST and negative circulating TKI resistance |
| Drug Holiday with minimal residual disease and negative circulating TKI resistance |"
638,"[/INST]
Other: [/INST]
Acceptance Criteria: [/INST]
Adverse events: [/INST]
Exclusion Criteria: [/INST]
Keywords: [/INST]
Other: [/INST]
Primary Purpose: [/INST]
Acceptance Criteria: [/INST]
Other: [/INST]
Exclusion Criteria: [/INST]
Keywords: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Primary Purpose: [/INST]
Acceptance Criteria: [/INST]
Other: [/INST]
Keywords: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Primary Purpose: [/INST]
Acceptance Criteria: [/INST]
Other: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Acceptance Criteria: [/INST]
Primary Purpose: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Acceptance Criteria: [/INST]
Other: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Acceptance Criteria: [/INST]
Primary Purpose: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Acceptance Criteria: [/INST]
Other: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Acceptance Criteria: [/INST]
Exclusion Criteria: [/INST]
Acceptance Criteria"
639,"[/INST]

Study Design
-----------------
Primary Purpose: Prevention
Intervention/Treatment: Control | Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/Treatment: Control | Primary Purpose: Prevention
| Study Design: Prevention
| Intervention/"
640,"[/INST]











































































































































































































































O
O
O
-
O
-
-














-
-
-
-


































































-
8
8
8
8
O-
-
-
-
8
8





C
C
C
C
C
C
C
O
C
O
O




O
O
O
O
O
O
O
C-
O
O
O
O
O
O-
O
O
O
-
-
-
-
C
C
C
O
-
O
O-
O
O
O
O
O

C
C
-
-
-
-
-
-
-
-
-
-






















O
-"
641,"[/INST]
Other: [/INST]
Adverse events: [/INST]
Secondary Outcome Measures
Gastric volume (ml/kg) | measurements are done with USG and calculated with this formula CSA=(AP(anterior -posterior) diameter x CC(craniotomy-caudal ) diameter x 3.14)/4 | preoperative | 
| measurements are done with USG and calculated with this formula CSA=(AP(anterior -posterior) diameter x CC(craniotomy-caudal ) diameter x 3.14)/4 | 10 minutes before extubation | 
| blood volume in suction system | weighing sponge, pad, and blood volume in the aspirator | intraoperative | 
| the time from the start of the surgery to the end of the surgery |
| blood volume in the aspirator | measurements are done with USG and calculated with this formula CSA=(AP(anterior -posterior) diameter x CC(craniotomy-caudal ) diameter x 3.14)/4 | 10 minutes before extubation | 
| blood volume in the aspirator | measurements are done with USG and calculated with this formula CSA=(AP(anterior -posterior) diameter x CC(craniotomy-caudal ) diameter x 3.14)/4 | 
| the time from the start of the surgery to the end of the surgery |
| blood volume in the aspirator | weighing sponge, pad, and blood volume in the aspirator | 
| the time from the start of the surgery to the end of the surgery |
| blood volume in the aspirator | measurements are done with USG and calculated with this formula CSA=(AP(anterior -posterior) diameter x CC(craniotomy-caudal ) diameter x 3.14)/4 | 
| blood volume in the aspirator | weighing sponge, pad, and blood volume in the aspirator | 
| the time from the start of the surgery to the end of the surgery |
| blood volume in the aspirator | measurements are done with USG and calculated with this formula C"
642,"[/INST]
The
A
A
A
A
A
A
The



































































































































































































c
c
c






























































































































































































































































C
C"
643,"[/INST]
S
S
S
S
S
The
The
The
The
The
The
The
The"
644,"[/INST]

Primary Outcome Measure
-----------------
Latent: [/INST]
Intervention: [/INST]

Experimental: [/INST]

Subjects: [/INST]

Other: [/INST]

Primary Outcome Measure
Latent: [/INST]
Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Experimental: [/INST]

Latent: [/INST]

Intervention: [/INST]

Latent:"
645,"[/INST]

| Outcome: Mycophenolate mofetil in refractory gastrointestinal Henoch-Schnlein purpura| steroids: MMF, other names, gastrointestinal involvement, organ transplant surgery, immune deficiency, heart failure, bloody stools |

Adverse Events
|---|
| Expected to occur during the course of the study.
| Patients may experience the following adverse events: MMF, mycophenolate mofetil, gastrointestinal involvement, heart failure, immune deficiency, organ transplant surgery, bloody stools |
| Other names: steroids, refractory gastrointestinal purpura, mycophenolate mofetil, heart failure, immune deficiency, organ transplant surgery |
| Expected to occur during the course of the study.
| Patients may experience the following adverse events: MMF, gastrointestinal involvement, heart failure, immune deficiency, bloody stools |
| Other names: steroids, gastrointestinal involvement, organ transplant surgery, mycophenolate mofetil, refractory purpura |
| Expected to occur during the course of the study.
| Patients may experience the following adverse events: MMF, gastrointestinal involvement, heart failure, immune deficiency, organ transplant surgery, bloody stools |
| Other names: steroids, gastrointestinal involvement, mycophenolate mofetil, refractory purpura, immune deficiency, organ transplant surgery |
| Patients may experience the following adverse events: MMF, gastrointestinal involvement, heart failure, immune deficiency, bloody stools |
| Other names: steroids, gastrointestinal involvement, organ transplant surgery, mycophenolate mofetil, refractory purpura |
| Expected to occur during the course of the study.
| Patients may experience the following adverse events: MMF, gastrointestinal involvement, heart failure, immune deficiency, organ transplant surgery"
646,"[/INST]

Device: Transcranial Magnetic Stimulation, EEG-enhanced, Veterans RAND 36-item health survey (VR-36)

Device: Transcranial Magnetic Stimulation, EEG-enhanced, Veterans RAND 36-item health survey (VR-36)

Device: Transcranial Magnetic Stimulation, EEG-enhanced, Veterans RAND 36-item health survey (VR-36)

Device: Transcranial Magnetic Stimulation, EEG-enhanced, Veterans RAND 36-item health survey (VR-36)

Device: Transcranial Magnetic Stimulation, EEG-enhanced, Veterans RAND 36-item health survey (VR-36)

Device: Transcranial Magnetic Stimulation, EEG-enhanced, Veterans RAND 36-item health survey (VR-36)

Device: Transcranial Magnetic Stimulation, EEG-enhanced, Veterans RAND 36-item health survey (VR-36)

Device: Transcranial Magnetic Stimulation, EEG-enhanced, Veterans RAND 36-item health survey (VR-36)

Device: Transcranial Magnetic Stimulation, EEG-enhanced, Veterans RAND 36-item health survey (VR-36)

Device: Transcranial Magnetic Stimulation, EEG-enhanced, Veterans RAND 36-item health survey (VR-36)

Device: Transcranial Magnetic Stimulation, EEG-enhanced, Veterans RAND 36-item health survey (VR-36)


Device: Transcranial Magnetic Stimulation, EEG-enhanced, Veterans RAND 36-item health survey (VR-36)


Device: Transcranial Magnetic Stimulation, EEG-enhanced, Veterans RAND 36-item health survey (VR-36)"
647,"[/INST]

How is the study designed?
----------------
| The Primary Outcome Measure is progression-free survival (PFS).
| The Secondary Outcome Measure is time to disease progression.
| The tertiary Outcome Measure is death.

How is the study structured?
----------------
| The Primary Structure is a multi-institutional, open-label, retrospective study. The Secondary Structure is a multi-institutional, open-label, retrospective study. The Tertiary Structure is a multi-institutional, open-label, retrospective study.
| The Primary Outcome is progression-free survival (PFS). The Secondary Outcome is time to disease progression.
| The tertiary Outcome is death.

How is the study designed?
| The Primary Outcome Structure is progression-free survival (PFS). The Secondary Outcome Structure is time to disease progression.
| The tertiary Outcome Structure is death.

What is the study addressing?
| The Primary Outcome addresses progression-free survival (PFS). The Secondary Outcome addresses time to disease progression.
| The tertiary Outcome addresses death.

How is the study organized?
| The Primary Outcome is progression-free survival (PFS). The Secondary Outcome is time to disease progression.
| The tertiary Outcome is death.

What is the study addressing?
| The Primary Outcome is progression-free survival (PFS). The Secondary Outcome is time to disease progression.
| The tertiary Outcome is death.

How is the study structured?
| The Primary Outcome is progression-free survival (PFS). The Secondary Outcome is time to disease progression.
| The tertiary Outcome is death.

What is the study addressing?
| The Primary Outcome is progression-free survival (PFS). The Secondary Outcome is time to disease progression.
| The tertiary Outcome is death.

How is the study designed?
| The Primary Outcome is progression-free survival (PFS). The Secondary"
648,"[/INST]
| Inclusion Criteria | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome MeasureMENTENT | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome MeasureMENTENT | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements | Exclusion Criteria |
| Outcome Measurements | Time Frame |
| Outcome Measurements"
649,[/INST]
650,"[/INST]
Other: [synovial tissue]
Terms related to the study of:
synovial tissue

Psychiatric hospital

Other: [hospital]
synovial tissue

Psychiatric hospital

Other: [hospital]

Terms related to the study of:
synovial tissue

Psychiatric hospital

Other: [hospital]
synovial tissue

Psychiatric hospital

Other: [hospital]
synovial tissue

Psychiatric hospital
Other: [hospital]
synovial tissue

Psychiatric hospital
Other: [hospital]
synovial tissue

Psychiatric hospital
Other: [hospital]
synovial tissue
Psychiatric hospital
Other: [hospital]
synovial tissue
Psychiatric hospital
Other: [hospital]
synovial tissue
Psychiatric hospital
Other: [hospital]
synovial tissue
Psychiatric hospital
Other: [hospital]
synovial tissue
Psychiatric hospital
Other: [hospital
Psychiatric hospital
Psychiatric hospital
Other: [hospital
Psychiatric hospital
Psychiatric hospital
Other: [hospital
Psychiatric hospital
Psychiatric hospital
Other: [hospital
Psychiatric hospital
Other: [hospital
Psychiatric hospital
Ps
Other: [hospital
Psychiatric hospital
Other: [hospital
Ps Synovial hospital
Other: [hospital
Other: Psychiatric hospital
Other: [hospital
Other: Psychiatric hospital
Other: [hospital
Other: Psychiatric hospital
Other: [hospital
Other: Psychiatric hospital
Other: [patient
Other: Synovel
Other: [patient hospital
Other: Psychiatric hospital
Other: Psychiatric hospital
Other: Psychiatric hospital
Other: Psychiatric hospital
Other: Ps
Other: Synov
Other: Other: Ps
Other"
651,"[/INST]

Patients receiving radioactive iodine will have artificial tears.



| Participants receiving artificial tears will be monitored for development of NLDO.

| Cancer of the nasolacrimal duct: rare, aggressive
| Prior use of radioactive iodine
| Treatment of choice for thyroid cancer
| Artificial tears will be administered to participants in this arm
| Nasolacrimal duct obstruction
| Participants will be monitored for development of NLDO
| Cancer of the nasolacrimal duct
| Artificial tears will be administered to participants in this arm
| Prior use of radioactive iodine
| Treatment of choice for thyroid cancer
| Artificial tears will be administered to participants in this arm
| Nasolacrimal duct obstruction
| Participants will be monitored for development of NLDO
| Cancer of the nasolacrimal duct
| Artificial tears will be administered to participants in this arm
| Prior use of radioactive iodine
| Treatment of choice for thyroid cancer
| Artificial tears will be administered to participants in this arm
| Nasolacrimal duct obstruction
| Participants will be monitored for development of NLDO
| Cancer of the nasolacrimal duct
| Artificial tears will be administered to participants in this arm
| Prior use of radioactive iodine
| Treatment of choice for thyroid cancer
| Artificial tears will be administered to participants in this arm
| Nasolacrimal duct obstruction
| Participants will be monitored for development of NLDO
| Cancer of the nasolacrimal duct
| Artificial tears will be administered to participants in this arm
| Prior use of radioactive iodine
| Treatment of choice for thyroid cancer
| Artificial tears will be administered to participants in this arm
| Nasolacrimal duct obstruction
| Participants will be monitored for development of NLDO
| Cancer of the nasolacrimal duct
| Artificial tears will be administered"
652,"[/INST]
|.
Primary prevention.
|s disease.
Primary therapy.
|.
Primary therapy.
Primary therapy.
Primary therapy.
|.
Primary prevention.
Second therapy.
Primary therapy.
Second therapy.
Secondary prevention.
Secondary prevent the development.
Secondary prevent the therapy.
Second therapy.
Second therapy.
Second therapy.
Second prevent the primary prevent the development.
Second therapy.
Second therapy.
Second therapy.
Second prevent the therapy.
Second therapy.
Second therapy.
Second therapy.
Second therapy.
Second therapy.
Second therapy.
Second therapy.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
The
The patients.
In.
Second.
In.
In.
In.
The.
The.
The.
The.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
In.
The
The
In.
The.
The.
The.
The
The
This.
This.
In.
In
In
In
In
In
In
In
The.
The.
In
In
In
In
In
In
The
The
The
The
The
The
This
This
This
This
This
This
f
f
in
in
in
This
in
comple
in
in
in
The
The
The
in
The
The
in
The
The
The
The
This
The
The"
653,"[/INST]
to (
In (
be
c
c
c
The
The
The
The
The
The
The
This
This
The
The
Al
Al
Al
Al
Al
------------
------------
------------
------------
------------
------------
------------
------------
------------
------------
------------
------------
------------
C
C
C
C
C
C
C
C
C"
654,"[/INST]
Text messaging, Behavioral economics, older adults, Mobile Health

Text messaging, Behavioral economics, older adults, Mobile Health
Text messaging, Behavioral economics, older adults, Mobile Health
Text messaging, Behavioral economics, older adults, Mobile Health
Text messaging, Behavioral economics, older adults, Mobile Health
Text messaging, Behavioral economics, older adults, Mobile Health
Text messaging, Behavioral economics, older adults, Mobile Health
Text messaging, Behavioral economics, older adults, Mobile Health
Text messaging, Behavioral economics, older adults, Mobile Health
Text messaging, Behavioral economics, older adults, Mobile Health
Text messaging, Behavioral economics, older adults, Mobile Health
Text messaging, Behavioral economics, older adults, Mobile Health
Text messaging, Behavioral economics, older adults, Mobile Health
Text messaging, older adults, Mobile Health
Text messaging, older adults, Mobile Health
Text messaging, older adults, Mobile Health
Text messaging, older adults, Mobile Health
Text messaging, older adults, Mobile Health
Text messaging, older adults, Mobile Health
Text messaging, older adults, older adults, Mobile Health
Text messaging, older adults, older adults, Mobile Health
Text messaging, older adults. Text messaging, older adults.
Text messaging, older adults. Text messaging, older adults. Text messaging, older adults. Text messaging, older adults. Text messaging, older adults.
Text mess. Text messaging, older adults. Text messaging, older adults, older adults, older adults.
Text mess. Text mess.
Text mess. Text mess. Text. Text.
Text. Text.
Text.
Text mess.
Text mess.
Text mess.
Text mess.
Text mess.
Text mess.
Text mess.
Text.
Text.
Text.
Text.
Text.
Text.
Text.
Text.
Text.
Text.
Text.
Text.
Text.
Text.
Text.
The text.
Text.
The"
655,"[/INST]
| Participants will receive a single intravenous bolus injection of 10 mCi 20% of [18F]-Fluselenamyl, and undergo an 18F-PIB PET scan. | Whole-body PET imaging (skull vertex to proximal thighs) in healthy volunteers will be conducted using [11C]-PIB tracer. | Participants with mild cognitive impairment will receive a single IV injection of 10 mCi 20% of [18F]-Fluselenamyl, and undergo an 18F-PIB PET scan. |
| Primary Outcome Measures: [18F]-Fluselenamyl will be administered IV, and PET imaging will be conducted in healthy volunteers using [11C]-PIB tracer. | Secondary Outcome Measures: To assess the distribution of [18F]-Fluselenamyl in human plasma using PET imaging, and conduct a comparative analysis of PET images in healthy volunteers.
| Time Frame: 1 year
Adverse Events: [18F]-Fluselenamyl will be administered IV, and PET imaging will be conducted in healthy volunteers using [11C]-PIB tracer. | Primary Outcome Measures: To assess the distribution of [18F]-Fluselenamyl in human plasma using PET imaging, and conduct a comparative analysis of PET images in healthy volunteers.
| Secondary Outcome Measures: To assess the safety of [18F]-Fluselenamyl in human subjects, and conduct a comparative analysis of PET imaging in healthy volunteers using [11C]-PIB tracer.
| Primary Outcome Measures: To assess the safety of [18F]-Fluselenamyl in human subjects, and conduct a comparative analysis of PET imaging in healthy volunteers using [11C]-PIB tracer.
| Secondary Outcome Measures: To assess the distribution of [18F]-Fluselenamyl in human plasma using PET imaging, and conduct a"
656,"[/INST]
Primary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Secondary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Primary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Secondary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Primary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Secondary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Primary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Secondary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Primary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Secondary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Primary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Secondary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Primary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Secondary Outcome: Transcranial magnetic stimulation (TMS) using theta burst protocol over the left dorsolateral prefrontal cortex.
Primary Outcome: Transcranial magnetic stimulation (TMS"
657,"[/INST]
-
-
-
-
-
-
-
-
-
-
-
-
-
-



















-
-
-
0
0
0
-
-










-
-
-
-
-
-
-
-









































































0





























































































































0
0
0
0













































































































































































































7"
658,"[/INST]

==================

1.  The study is designed to measure [/INST] inflammation
2.  The study is designed to measure [/INST]
3.  The study is designed to measure [/INST]
4.  The study is designed to measure [/INST]
5.  The study is designed to measure [/INST]
6.  The study is designed to measure [/INST]
7.  The study is designed to measure [/INST]
8.  The study is designed to measure [/INST]
9.  The study is designed to measure [/INST]
10.  The study is designed to measure [/INST]
11.  The study is designed to measure [/INST
12.  The study is designed to measure [/INST
2.  The study is designed to measure [/INST
3.  The study is designed to measure [/INST
4.  The study is designed to measure [/INST
1.  The study is designed to measure [/INST
1.  The study is designed to measure [/INST
2. 1. 1. 2. 1. 1. 1. 2. 1. 1. 2. 1. 1. 2. 1. 1. 1. 1. 2. 1. 1. 1. 1. 1. 1. 1. 1. 1. 2. 1. 1. 1. 2. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 2. 1. 2. 1. 1. 1. 2. 1. 1. 2. 1. 1. 1. 1. 1. 2. 1. 2. 1. 2. 1. 1. 1. 2. 1. 2. 1. 2. 1. 1. 1. 1. 2. 2. 2. 1. 1. 2. 1. 1. 1. 1. 2.
The sympt"
659,"[/INST]
Other: [/INST]
Primary Outcome: [/INST]
Change in self-reported level of nutrition security after enrollment [/INST]
Secondary Outcome: [/INST]
Change in diabetes-related quality of life after enrollment [/INST]
Primary Outcome: [/INST]
Change in self-reported level of nutrition security after enrollment [/INST]
Secondary Outcome: [/INST]
Change in diabetes-related quality of life after enrollment [/INST]
Primary Outcome: [/INST]
Change in self-reported level of nutrition security after enrollment [/INST]
Secondary Outcome: [/INST]
Change in diabetes-related quality of life after enrollment [/INST]
Primary Outcome: [/INST]
Change in self-reported level of nutrition security after enrollment [/INST]
Secondary Outcome: [/INST]
Change in diabetes-related quality of life after enrollment [/INST]
Primary Outcome: [/INST]
Change in self-reported level of nutrition security after enrollment [/INST]
Secondary Outcome: [/INST]
Change in diabetes-related quality of life after enrollment [/INST]
Primary Outcome: [/INST]
Change in self-reported level of nutrition security after enrollment [/INST]
Secondary Outcome: [/INST]
Change in diabetes-related quality of life after enrollment [/INST]
Primary Outcome: [/INST]
Change in self-reported level of nutrition security after enrollment [/INST]
Secondary Outcome: [/INST]
Change in diabetes-related quality of life after enrollment [/INST]
Primary Outcome: [/INST]
Change in self-reported level of nutrition security after enrollment [/INST]
Secondary Outcome: [/INST]
Change in diabetes-related quality of life after enrollment [/INST]
Primary Outcome: [/INST
Secondary Outcome: [/INST
Primary Outcome: [/INST
Secondary Outcome: [/"
660,"[/INST]
The.
The patients.
The patients.
The patients.
The patients.
The patients.
The patients.
The.
The.
The.
The.
The.
The.
The clin-
The.
The patients.
The.
The.
The.
The.
The.
The.
The study.
The .
The.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
The
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This
This
This
This
This
This
This
This
This
This
This
This
















this
this
this
this
this
this
this
this
this
this
this
this
this
this
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
661,"[/INST]


 D-
-A 7 7 7 7 7
-m-8
8
-
-
-
-97 D7-
-
7
-
-
-7 7 7 7 7 7 7 7 7-7-8
-f-8 7 7



-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-A-A-A-
-
-
-














-



-
7 7 



















7
7
-
-




-
-
-
-





7
7
7
-
-

















-
-
-
-
-
-
-
-
-






 D























-
-
-
-
-














































-
-
-























-

-
-















-
-
-
-
-























































































































-"
662,"[/INST]
| Work Ability, Senior workers, Physical capacity, and Musculoskeletal pain
| Baseline | 
| Work Ability, Senior workers, Physical capacity, and Musculoske's pain
| Baseline | 
| Senior workers, Physical capacity, and Musculos's pain
| The study, and Senior workers, Physical capacity, and pain
| 
| 
| 555 years old, and Senior pain
| 60 years old, and Senior pain
| 55 years old, and Senior pain
| 55 years old pain
| 55 years old pain
| 55 years old pain
|55 years old pain
|55 years old pain
|55 years old pain
|55 years old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old pain old.
The project old.
The pain old.
The project.
The relationship old.
The relationship.
The relationship old.
The relationship old.
==s.
==
==s.
The relationship.
The relationship.
The relationship.
The relationship.
The relationship.
This.
This.
This.
This.
This.
This.
on.
on.
in.
This
This
This.
The.
The.
The,
The project
This.
This.
This.
This.
It
It.
This.
This"
663,"[/INST]
O
-
-
-
-
-
-
-
-
-
-
O
O
O
O
O
O
O
O
O
O
O
-
-
-
O
O
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-











































































-








-
-
-
-
-
-
-
-"
664,"[/INST]

Secondary Outcome Measures
-----------------

Primary Outcome Measure"
665,[/INST]
666,"[/INST]
Evaluation of PIK3CA mutations using sequencing analysis.
Stage I: up to approximately 6 years
Stage II: up to approximately 6 years
Stage III: up to approximately 6 years
Stage IV: up to approximately 6 years
Stage V: up to approximately 6 years
Stage VI: up to approximately 6 years
Stage VII: up to approximately 6 years
Stage VIII: up to approximately 6 years
Stage IX: up to approximately 6 years
Stage X: up to approximately 6 years
Stage XI: up to approximately 6 years
Stage XII: up to approximately 6 years
Stage XIII: up to approximately 6 years
Stage XIV: up to approximately 6 years
Stage XV: up to approximately 6 years
Stage XVI: up to approximately 6 years
Stage XVII: up to approximately 6 years
Stage XVIII: up to approximately 6 years
Stage XIX: up to approximately 6 years
Stage XX: up to approximately 6 years
Stage XXI: up to approximately 6 years
Stage XXII: up to approximately 6 years
Stage XXIII: up to approximately 6 years
Stage XXIV: up to approximately 6 years
Stage XXV: up to approximately 6 years
Stage XXV: up to approximately 6 years
Stage XXVI: up to approximately 6 years
Stage XXVII: up to approximately 6 years
Stage XXVIII: up to approximately 6 years
Stage XXIX: up to approximately 6 years
Stage XXX: up to approximately 6 years
Stage XXXI: up to approximately 6 years
Stage XXXII: up to approximately 6 years
Stage XXXIII: up to approximately 6 years
Stage XXXIV: up to approximately 6 years
Stage XXXV: up to approximately 6 years
Stage XXXV: up to approximately 6 years
Stage XXXVI: up to approximately 6 years
Stage XXXVII: up to approximately 6 years
Stage XXXVIII: up to approximately 6 years
Stage XXXIX: up to approximately 6 years
Stage XL: up to approximately 6 years
Stage XLI: up to approximately 6 years
Stage L: up to approximately 6 years
Stage LI: up to approximately 6 years
Stage LII: up to approximately 6 years
Stage LII: up to approximately"
667,"[/INST]

Primary Outcome Measure
-----------------
Sleep Spindle
| Inclusion Criteria: Male, age 18-24 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 24 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21 | Exclusion Criteria: None |
| Primary Purpose: Male, age 5 | Inclusion Criteria: Female, age 21"
668,"[/INST] I I I I I I IO IO IO I-I-P-P-P-P-P IO IO IO II II II IIIIIIIIIII-P-P-P II IIOIOIIIIIIIPIPIPI IP II I IO II II II II II I I I I I I I I I I IO IO IOIPIPIIPIII IPIPIPIPIPIPIPIPIPIPIIIIIIIIIIIIIIHIOIOIOIOIOIOIOI IIIIIIIIIIII II IIII II II I I I II II
 II II II I
 I
 IO IO IP I







I
I
IPIPI
IPIOIOIOIIIIIIPIIIIIIIP
IPIPOIPIPIPIPIPIPIPIPIPIPIPIPIPIPIP IP I













I
I
I
I
I I
I
I I
I II I
I
I
I
I I
I
I
I I I I I I I I II II II II IIIII II II II II II I I I I I I II II II II II II I I I I I I I I I I I I I II II II I II II I II II I I I I I II II II IIIIIIIIIIII II II II I I I I I I I I I I I I I I I I I I II II I I I I I I I I I I II II I ya I ya I"
669,"[/INST]
Other: real time MRI, Cleft palate anatomy
Primary Purpose: Other
Secondary Purpose: real time MRI, Cleft palate anatomy
Tertiary Purpose: real time MRI, Cleft palate anatomy
Quaternary Purpose: real time MRI, Cleft palate anatomy
Decennial Purpose: real time MRI, Cleft palate anatomy
Quinary Purpose: real time MRI, Cleft palate anatomy
Decennial+1/2: real time MRI, Cleft palate anatomy
Quaternary Purpose: real time MRI, Cleft palate anatomy
Secondary Outcome Measures
Terms related to the study
Other: real time MRI, Cleft palate anatomy
Quaternary Purpose: real time MRI, Cleft palate anatomy
Decennial+1/2: real time MRI, Cleft palate anatomy
Quaternary Purpose: real time MRI, Cleft palate anatomy
Secondary Outcome Measures
Decennial+1/2: real time MRI, Cleft palate anatomy
Quaternary Purpose: real time MRI, Cleft palate anatomy
Secondary Outcome Measures
Decennial+1/2: real time MRI, Cleft palate anatomy
Quaternary Purpose: real time MRI, Cleft palate anatomy
Secondary Outcome Measures
Decennial+1/2: real time MRI, Cleft palate anatomy
Quaternary Purpose: real time MRI, Cleft palate anatomy
Secondary Outcome Measures
Decennial+1/2: real time MRI, Cleft palate anatomy
Quaternary Purpose: real time MRI, Cleft palate anatomy
Secondary Outcome Measures
Decennial+1/2: real time MRI, Cleft palate anatomy
Quaternary Purpose: real time MRI, Cleft palate anatomy
Secondary Outcome Measures
Decennial+1/2: real time MRI, Cleft palate anatomy
Quaternary Purpose"
670,"[/INST]
."
671,"[/INST]
| Keywords: [/INST]"
672,"[/INST]
|
|
Secondary surgery.
|
Second surgery.
| uter.
Second surgery.
|
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.Second surgery.Second surgery.
Second surgery.
Second surgery.Second surgery.
Second surgery.Second surgery.Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second surgery.
Second, it.
Second surgery.
Second, it.
The surgery.
The surgery.
Second.
Second.
Second.
Second, it.
The surgery.
The surgery.
The surgery.
The surgery.
The surgery.
It.
The surgery.
The surgery.
The surgery.
The surgery.
It, it.
It, it.
It, it.
It.
It.
It.
It.
It.
It.
It.
It's.
It.
It.
It.
It.
It   ==//<<
It.
It.
it.
it.
it.
it.
it.
it.
it.
it.
it.
it.
This is
It.
It
It
It
It
It
It
It
in
in
in
in
in
in
in
it
It
It
in
in
in
in
in
in
in
in
It
The
The
The
This
This
This
This
This
This
in
in
The
The
The
The
The
The
The
This
This
The
This
This
This
This
The"
673,"[/INST]
| 2 years after the diagnosis| 2 years after the diagnosis.
| 2 years after the asth
| 2 years after the diagnosis.
| 2 years after the diagnosis.
| 2 years after the diagnosis.
Patients with the diagnosis.
Patients with the diagnosis.
Patients with the diagnosis.
Patients will be the patient.
Patient history.
Patients will be treated.
Patients will be the patient.
Patients will be treated.
Patients will be treated.
Patients will be the patient.
Patients will be the patients.
Patients will be treated.
Patients will be treated.
Patient will be treated.
Patients will be
Patients will be treated.
Patient will be treated.
Patient will be treated.
Patients will be|1 patient.
Patient.
Patient will be treated.
Patient will be performed.
Patients will be done.
Patient will be done.
Patient will be done.
The patient.
The patient.
The patients.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The process.
The.
The   6.
The   7.
The   7.
The.
The   7.
The   
The   
The.
The.
The.
The.
The.
The   7.
In.
In.
This.
In.
The.
The.
The.
The.
The.
The.
The.
In
The
The
The
The
The
The
The
The
The
The
This
This
P
This
P
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The"
674,"[/INST]


Experimental: [/INST]






How is the study designed?
-----------------
Primary Purpose: To measure changes in bench press strength after the intervention.
Intervention: split-body resistance training.
Other: cricket, Strength
Experimental: cricket, Strength
Primary Purpose: To measure changes in bench press strength after the intervention.
Intervention: split-body resistance training.
Other: cricket, Strength




How is the study designed?
-----------------
Primary Purpose: To measure changes in bench press strength after the intervention.
Intervention: split-body resistance training.
Other: cricket, Strength
Experimental: cricket, Strength




How is the study designed?
-----------------
Primary Purpose: To measure changes in bench press strength after the intervention.
Intervention: split-body resistance training.
Other: cricket, Strength
Experimental: cricket, Strength



How is the study designed?
-----------------
Primary Purpose: To measure changes in bench press strength after the intervention.
Intervention: split-body resistance training.
Other: cricket, Strength
Experimental: cricket, Strength



How is the study designed?
-----------------
Primary Purpose: To measure changes in bench press strength after the intervention.
Intervention: split-body resistance training.
Other: cricket, Strength
Experimental: cricket, Strength



How is the study designed?
-----------------
Primary Purpose: To measure changes in bench press strength after the intervention.
Intervention: split-body resistance training.
Other: cricket, Strength
Experimental: cricket, Strength



How is the study designed?
-----------------
Primary Purpose: To measure changes in bench press strength after the intervention.
Intervention: split-body resistance training.
Other: cricket, Strength
Experimental: cricket, Strength



How is the study designed?
-----------------
Primary Purpose: To measure changes in bench press strength after the intervention.
Intervention: split-body resistance training.
Other: cricket, Strength
Experimental: cricket"
675,"[/INST]

Primary Outcome: Breastfeeding self-efficacy of the mother
Secondary Outcome: Infant's weight, head circumference, breastfeeding practices of the mother
Tertiary Outcome: Paternal attachment to the infant
Questions related to the study:
1. How do you ensure that the mother is providing enough milk for the infant?
2. How do you ensure that the infant is latching on and sucking well?
3. How do you ensure that the infant is gaining weight appropriately?
4. How do you ensure that the mother is receiving the support she needs?
5. What are the breastfeeding practices that are used by the mother?
6. How do you ensure that the mother is well-informed about breastfeeding?
7. How do you ensure that the mother is well-supported by the hospital staff?
8. How do you ensure that the mother is following the recommended schedule of rest?
9. How do you ensure that the mother is receiving the nutrition she needs?
10. How do you ensure that the mother is well-informed about the recommended follow-up schedule?
11. How do you ensure that the infant is receiving the recommended immunizations?
12. How do you ensure that the mother is following the recommended schedule of prenatal and postnatal visits?
13. How do you ensure that the mother is well-informed about the recommended follow-up schedule for her own health?
14. How do you ensure that the infant is receiving the recommended follow-up visits?
15. How do you ensure that the mother is receiving the recommended psychological support?
16. How do you ensure that the mother is well-informed about the recommended referral services?
17. How do you ensure that the infant is receiving the recommended developmental assessments?
18. How do you ensure that the mother is receiving the recommended depression screening and follow-up?
19. How do you ensure that the mother is well-informed about the recommended referral services?
20. How do you ensure that the infant is receiving the recommended developmental assessments?
21. How do you ensure that the mother is receiving the recommended psychological support?
22. How do you ensure that the mother is well-informed"
676,"[/INST]
| Placebo, Nutrilite Lifestyle [/INST]
| EMS (Electric Muscle Stimulation)
| Nutrilite Lifestyle [/INST]
| Placebo, EMS (Electric Muscle Stimulation)
| Nutrilite Lifestyle [/INST]
| Placebo, EMS (Electric Muscle Stimulation)
| Nutrilite Lifestyle [/INST]
| Placebo, EMS (Electric Muscle Stimulation)
| Nutrilite Lifestyle [/INST]
| Placebo, EMS (Electric Muscle Stimulation)
| Nutrilite Lifestyle [/INST
| Placebo, EMS (Electric Muscle Stimulation)
| Nutrilite Lifestyle [/INST of the study
| Placebo, EMS (Electric Muscle [/INST of Nutrilte Lifestyle [/INST of the electric muscle stimulation of the electric muscle stimulation of Nutril, EMS (Electro
| Placebo Nutril of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric muscle stimulation of the electric
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|"
677,[/INST]  Aular  Aular  Aular 1 10ulululululularularularlyoilulularoilularulularularular 10ululululululularularularularularularularularularularularlyorularularularlyonularlyonularularularularularularularularularularululululululululululululululularularularularularularularularularularularularularularularularularularularularularularularularularlyoilularoilularularularularularularularularularularularularularularoilululululululululululululululululululululululululululululomulomulomulomulomulomulomululululululululululululululululululululomulomulululululululululularularomululululululululululomulomululululululululululululululululululululululululululululoruloruloromuloromulilululululululululululululululululululululululululululululululululululululululululululululululululomulomulululululomulomulomilomuloromorororomoromoromoromoromoromoromoromoromoromulomulomulomuloromulororuloruloromuloruloromoromoromomomomomomomostoromomonomonomulomuloromuloromoromorightorightororomorightorightorulorulululorulorululululorulororororororororororororororororororomoromoromoromoromorororororororororulororightorightorightorightorororuloruloromuloromuloromulomulomulomulotsilotsilulilululululoromulomuloromor
678,[/INST] | . | a . . . . . . . . . . .	- . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	- |				- . |	- | . . . . . . . . . . . . . . . . . . . . . . . | . | . | . | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | AO- |- |- |- | AO- | AO- |- | | | | | | | |- |- . - A- . - A- . - | - . |- . |- . - | - | - - - - - - - - - - - - A- . A- . A- . A- . A- . A- . A- . A- a- 1: A- . A- . A- . A- . - A- - A- - A- A- A- - A- - - - - - - - - - A: 1: 1: 1 stite- 1: 1: 1: 1: a- 1: a- 1- - - A-  - A- 1- 1- 1-  -  - - - A- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1 1 1 1 1 1 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1  A  A 1  A 1 1 1 1 1 1 1 1 1 1
679,"[/INST]

Other: [/INST]

Adverse events: [/INST]
Clinical trials: [/INST]
Details of the study: [/INST]
Details of the intervention: [/INST]
Details of the comparison: [/INST]
Details of the study: [/INST]
Details of the intervention: [/INST]
Details of the comparison: [/INST]
Details of the study: [/INST]
Details of the intervention: [/INST]
Details of the comparison: [/INST]
Details of the intervention: [/INST]
Details of the comparison: [/INST]
Details of the intervention: [/INST]
Details of the comparison: [/INST]
Details of the intervention: [/INST]
Details of the comparison: [/INST]
Details of the intervention: [/INST]
Details of the comparison: [/INST]
Details of the intervention: [/INST]
Details of the comparison: [/INST]
Details of the intervention: [/INST]
Details of the comparison: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]
Details of the intervention: [/INST]"
680,"[/INST]

Secondary Outcome Measures

How is the study designed?
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description |"
681,"[/INST]

Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition
Primary Purpose: Health Services Research
-----------------
| Other: Care transition"
682,"[/INST]
What is the difference between the standard of behavioral scale. Patients will be observed during the procedure using the Wong-B. Each face will be observed during the procedure using the standard of the pain scale. Patients will be observed during the procedure. Patients will be observed during the standard of care. Each category.
What is the standard of care. Patients will be observed during the procedure. Patients will be observed during the standard of care. Patients will be observed during the procedure.
What is the standard of care. Patients will be observed during the procedure.
What is the standard of care. Patients will be observed during the procedure.
What is the standard of care.
What is the standard of the procedure.
What is the standard of the standard of the standard of the procedure.
What is the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard the standard the standard the standard the standard the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard of the standard the standard.
The standard.
The parent.
The parent.
The parent.
The parent.
The parent.
The parent.
The parent.
The parent.
The.
The
The parent.
The parent.
The patient.
The patient.
The parent.
The procedure.
The procedure.
The procedure.
The procedure.
The patient.
The patient.
The parent.
The patient.
The patient.
The process.
The process.
The process.
The process.
The process.
The process.
The process.
The process.
The patient.
The.
The"
683,"[/INST]

How is the study designed?
| Designed by colonoscopy |
| Designed by an established PCR, with mutation profiling of colorectal lesions and synchronous surveillance of all patients |
| Designed by an established Centre, with histopathological evaluation of metachronous lesions and personalization of the index |
How is the study implemented?
| Implementation of the study designed to identify patients with high risk of recurrent colorectal lesions and personalization of their surveillance based on mutation profiling of colorectal neoplasia found during index colonoscopy |
How is the study implemented?
| Implementation of the study designed to identify patients with high risk of recurrent colorectal lesions and personalization of their surveillance based on examination of all their index and histopathological evaluation |
How is the study implemented?
| Implementation of the study designed to identify patients with high risk of recurrent colorectal lesions and personalization of their surveillance based on examination of all their index and histopathological evaluation |
How is the study implemented?
| Implementation of the study designed to identify patients with high risk of recurrent colorectal lesions and personalization of their surveillance based on examination of all their index and histopathological evaluation |
How is the study implemented?
| Implementation of the study designed to identify patients with high risk of recurrent colorectal lesions and personalization of their surveillance based on examination of all their index and histopathological evaluation |
How is the study implemented?
| Implementation of the study designed to identify patients with high risk of recurrent colorectal lesions and personalization of their surveillance based on examination of all their index and histopathological evaluation |
How is the study implemented?
| Implementation of the study designed to identify patients with high risk of recurrent colorectal lesions and personalization of their surveillance based on examination of all their index and histopathological evaluation |
How is the study implemented?
| Implementation of the study designed to identify patients with high risk of recurrent colorectal lesions and personalization of their surveillance based on examination of all their index and histopathological evaluation |
How is"
684,"[/INST]
Eligibility Criteria
-----------------
What is the study designed to measure?
| Outcome Measures |
| Primary Outcome Measure | Secondary Outcome Measure | Tertiary Outcome Measure | Quaternary Outcome Measure |
| Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome Measure |
| Primary Outcome Measure |
| Secondary Outcome"
685,"[/INST]

Primary Outcome Measure
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Exercise, Physical Activity, Physical Therapy | Average 1-week MVPA measured every 3-months throughout 12-month study period | 


Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
| Steps per day | Average 1-week MVPA measured every 3-months throughout 12-month study period | 



Primary Outcome Measure
| Outcome Measure | Measure Description |
| Steps per day | Average 1-week MVPA |
|








Primary Outcome Measure | Outcome Measure | Steps per day.
|
| Primary Outcome Measure.
| Primary Outcome.


| Outcome Measure. Steps per day.| Primary Outcome.



Primary Outcome.| Primary Outcome. Steps per day.| Primary Outcome. Steps per day.| Primary Outcome. Steps per day.| Primary Outcome. Primary Outcome.| Primary Outcome. Steps per day. Primary Outcome. Steps per day. Primary Outcome. Primary Outcome. Primary Outcome. Steps per day. Primary Outcome. Primary Outcome. Primary Outcome. Steps per day. Primary Outcome. Primary Outcome. Primary Outcome. Primary Outcome. Primary Outcome. Steps per day. Primary Outcome. Primary Outcome. Primary Outcome. Primary Outcome. Steps per day. Primary Outcome. Primary Outcome. Steps. Primary Outcome. Primary Outcome. Primary Outcome. Primary Outcome. Primary Outcome. Steps. Primary Outcome. Primary Outcome. Primary Outcome. Primary Outcome. Primary Outcome. Primary. Steps. Primary. Primary Outcome. Primary Outcome. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary. The clin
The disease. The disease. The"
686,"[/INST]
Keywords: cerebral oxygenation, neuromonitoring, surgery, anesthesia
-----------------
Cerebral oxygenation (ScO2) in multiple brain regions (beach-chair position) and neuromonitoring (tr-fNIRS) data
Stroke (cerebral oxygenation) and anesthesia
Keywords: surgery, cerebral oxygenation, neuromonitoring, beach-chair position, and delirium
-----------------
Cerebral oxygenation (beach-chair position) and neuromonitoring, surgery
Stroke (cerebral oxygenation) and anesthesia
Keywords: cerebral oxygenation, surgery, neuromonitoring, and delirium
----------------
Stroke (cerectomy.
Keywords: cerebral oxygenation, surgery
Keywords: cerebral neurons, surgery, and anesthesia
-----------------of brain surgery.
-----------------us neuromonium cerectomy, surgery
Keywords: cerectomy, surgery
Stroke cerectomy, surgery
-----------------us neuron surgery, cerectomy
Stroke, neuron surgery.
Stroke, cerectomy, surgery.
Stroke, neuron, surgery.
Stroke, cerectomy, surgery.
Stroke, cerectomy, surgery.
Stroke, cerectomy, surgery.
Stroke, surgery.
Stroke, surgery.
Stroke, surgery, cerectomy, surgery.
Stroke, cerectomy, surgery, stroke, neuron, surgery, stroke, cere, surgery, cere, surgery, surgery, cere, surgery, surgery, surgery, cere, surgery, cere, surgery, surgery, cere, surgery, surgery, surgery, cere, surgery, surgery, cere, it.
Stroke, surgery, surgery, cere, surgery, c, c, the surgery, surgery, surgery, surgery.
Stroke, it may be
Stay, it"
687,"[/INST]
| Keywords related to the study
| 
| MI-E insufflation-exsufflation
| 
| Keywords related to the study
| 
| MI-E insufflation-exsuction
| 
| 
| MI-E insufflation-exsuction
| 
| 1=on the study
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2
| 1=2.| 1=1=1=2.| 1=2=1=2.
| 1=2=1=2.| 1=1=1=2.
| 1=2.| 1=1=1=1=1=2.
| 1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=1=
C=1=1=1=1=
C=1"
688,"[/INST]
| Change of TR to 18 months after 18 months after the echocardiology
| 18 months after the echocardiology
| 18 months after the echocardiology
| 18 months after the heart failure to the heart failure to the echocardiology.
| 18 months after the echocardiology.
| 18 months after the echocardiology.
| 18 months after the echocardiology.
| 18 months after the echocardiology.
| 18 months after the echocardi.
| 18 months after the echocardi.
| 18 months after the echocardi 18 months after the echocardi 18 months after the echocardiology.
| 18 months after the ech088.
Sym.
Symmeters.
Symmeters.
Symmeters.
Sympt.
Sym.
Sympt.
Symper.
Symmetrics.
Sympt.
Sympt.
Sympt.
Sympt.
Symper.
Symper.
Symper.
Symper.
Sympt.
Symport.
Symper.
Symper.
Sym.
Sym.
Symper.
Sym.
Sym.
Sym.
Symper.
Symper.
Sym.
Sym.
Sym.
Sym.
Sym.
Sym.
Sym.
Sym.
Sym.
Sym.
Sym.
A.
A.
S.
The sympt
S.
The sympt
The symptakes.
The symptakes.
The sympt
The sympt
The sympt
The sympt
The sympt.
The symptasts.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
in.
It.
It.
It.
It.
The symptobile
The.
The.
in.
The.
in.
in.
in.
In.
in.
in
in
in
in
in
The.
In
The.
The [][
The [.
The [.
The.
The.
The.
The"
689,"[/INST]

Other Measures
-----------------

Study Design: Other
Primary Purpose: Other
Secondary Purpose: Other
Study Design: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Study Design: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Study Design: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Study Design: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose: Other
Secondary Outcome Measures: Other
Primary Purpose:"
690,"[/INST]

How is the study designed?
----------------
Primary Purpose: Treatment
| Intervention/Treatment | Study Design: Randomized |
| Outcome Measure: Walking test to assess distance traveled while wearing a harness for either body weight support or as a safety precaution while walking on a treadmill | Procedure: Body Weight Supported Treadmill Training<br>This group receives training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill | 
| Outcome Measure: Walking Index to assess distance traveled while wearing a harness | 1-5 days following Intervention | 6-month assessment, 3-month baseline | 12-week training sessions |
| Primary Purpose: Treatment
| Intervention/Treatment | Study Design: Randomized |
| Outcome Measure: Walking test to assess distance traveled while wearing a harness for either body weight support or as a safety precaution while walking on a treadmill | Procedure: Body Weight Supported Treadmill Training<br>This group receives training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill | 
| Outcome Measure: Walking Index to assess distance traveled while wearing a harness for either body weight support or as a safety precaution while walking on a treadmill | 1-5 days following Intervention | 6-month assessment, 3-month baseline | 12-week training sessions |
| Primary Purpose: Treatment
| Intervention/Treatment | Study Design: Randomized |
| Outcome Measure: Walking test to assess distance traveled while wearing a harness for either body weight support or as a safety precaution while walking on a treadmill | Procedure: Body Weight Supported Treadmill Training<br>This group receives training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill | 
| Outcome Measure: Walking Index to assess distance traveled while wearing a harness for either body weight support or"
691,"[/INST]
The
The


































































































































































































































































A
A
A
A
A
A
A
A
A
A
The
The
The
The
The
The
The
The
The
The
The
The
The
A
A
The
A
A
A
A
A-
C-
A-
C
C-
O-
C-
The
C
C
O
O
C
C
C-
C-
C-
C-
C-
C-
O-
C-
O-
O-
O-
C-
C-
O
O
O-
O-
O-
O-h-
O-
O-
O-
O-
O-
O-
O
O-
-
-
O

O
-

O


O
O
O
O
O
O
O
O-
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
A
O
A
O
O
O"
692,"[/INST]
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype |
| biomarkers, phenotype. |
| biomarkers, phenotype.
| biomarkers, phenotype.
|biomarkers, phenotype.
|biomarkers, phenotype.
|biomarkers, phenotype.
|biomarkers, phenotype.
|biomarkers, biomarkers, phenotype.
|biomarkers, phenotype.
|biomarkers, biomarkers, biomarkers, psychiatric|biology.
|biomarkers, psychiatric institutions.
|biomarker.
|biomarker.
|biomarkers.
|biomarkers.
|biomarkers.
|
|
|
The AMP.
The AMP.
The A
biomarkers.
The study.
bi
bi
The study.
The study.
as a
as a
as a
as a
The study.
The study.
The study.
The Aim.
The Aims.
The Aim.
The A"
693,"[/INST]
==
==
==
==s.
==s.
==000000000000000000000000000000000000000000000
==
==
== and//mil.
== and
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
This
This
This
and
and
and
in
==
==
==
==
==
==
==
==
==
==
==
==
==
==
percent
percent
percent
percent
percent
This
This
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
This
This
This
This
a
a
a
a
a
==
==
==
==
==
==
==
and
and
and
==
==
--------
--------
--------
--------
a
a


























a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a"
694,"[/INST]
S
S
S
F
F
F
F
F
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
C
C
C


















































































A
C
A
A
C
C
C
C
C
A
C
C
C
























































































































































































C
C
C
C
C

C
C
C




C
C
C
C
C
C
C
C
C

C
C
C
C
C
C
C
C
C
C
C
C
C
C
C

C
C


C
C
C
C





C
C
C
C
C
P
C
C
C
C
C
C
C
C
C"
695,"[/INST]











CT
CT
CT
CT
CT




CT
CT
C
C




C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
CT
CT
CT
CT
CT
CT
CT
C
C
C
C
C
C
C
C
C
C
CT
CT
CT
CT
CT
CT
C
C
C
C
C
CT
CT
CT

































CT
CT
CT
CT
C
C
S
CT






















C
C
C
C
C
CT












C
C
C
C
C
C










CT
CT
C
C
C























CT
CT
CT
CT
CT
CT






































O
O
O
CT
CT














P
R
R
D
C
C
CT
CT
CT
CT
O
O
O
O
O
R
O
CT
CT
CT
CT
CT
CT
CT
CT
CT
CT
CT
CT
CT
CT
CT
CT
CT








                
CT
CT
O
O
CT
CT
CT
CT
CT
O
O






O
O
O
|
CT
CT"
696,"[/INST] a- 10- 1- 10- 10000- 1 a- 1 nua- 1 ncye- 1 nauo nauo ERcy 1 nau- 1 1 1 1 1 1 ERcye- 1aucyeaucye- 1 a"", a- Acye- A- A nomeo ERcy  A nau 1 1 1 1 1 1000A- 1A 1A 1 Aau- A- A- A- A- A- A- A- A- A- A- A- A- A- (A- (A- (A- A- 1- Ao- Ao- Ao- Ao- A- A- A- A- A- A- A-A-A- A- A- A- A- A- A- 1- A- A- A- A- A- A- A- A- 10000000000000000000000000- (A- (A- (A- (A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A- (100000-A-A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A- A-A-A-A-A-A-A- A- A- A- A- A- A-A-A-A-A-A- A10101110101010- A- A- A-A-A-A-A-A- A- A- A- A- A- A- A- A- A- A100000- A-a- A- A- A- 1- 1- 1- A- A- A- A-a- A- A- 100- 1- 1- 100000-a- 1-a-a-a- 1-a-a-a-A- A-"
697,[/INST]omostomostomostomostomomomomomomomomomomomomomomomomomomomomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomostomomomom0omomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomostomostomomomomomomomomomostomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomostomostomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomomom
698,"[/INST]
Primary Outcome: Survival at Day 28
Secondary Outcome: Ventilation at Day 28
Other Outcome: Survival at Day 28
Terms related to the study: [/INST]
| Other: Survival at Day 28
Secondary Outcome: Ventilation at Day 28
| Other: Survival at Day 28
Terms related to the study: [/INST]
| Other: Survival at Day 28
Secondary Outcome: Ventilation at Day 28
| Other: Survival at Day 28
Terms related to the study: [/INST]
| Other: Survival at Day 28
Secondary Outcome: Ventilation at Day 28
| Other: Survival at Day 28
Terms related to the study: [/INST]
| Other: Survival at Day 28
Secondary Outcome: Ventilation at Day 28
| Other: Survival at Day 28
Terms related to the study: [/INST]
| Other: Survival at Day 28
Secondary Outcome: Ventilation at Day 28
| Other: Survival at Day 28
Terms related to the study: [/INST]
| Other: Survival at Day 28
Secondary Outcome: Ventilation at Day 28
| Other: Survival at Day 28
Terms related to the study: [/INST]
| Other: Survival at Day 28
Secondary Outcome: Ventilation at Day 28
| Other: Survival at Day 28
Terms related to the study: [/INST]
| Other: Survival at Day 28
Secondary Outcome: Ventilation at Day 28
| Other: Survival at Day 28
Terms related to the study: [/INST
| Other: Survival at Day 28
Secondary Outcome: Ventilation at Day 28
| Other: Survival at Day 28
| Other: Survival at Day 28
Secondary Outcome: Survival at Day 28
| Other: Survival"
699,"[/INST]

Adverse Events
-----------------
Experimental: Haitian immigrant to the U.S., non-viral suppression of HIV.
Primary Outcome: Change in viral load.
Secondary Outcome: Change in CD4 count.
Tertiary Outcome: Quality of life.
Adverse Events: Change in viral suppression.
Experimental: Haitian immigrant to the U.S., non-viral suppression of HIV.
Secondary Outcome: Change in CD4 count.
Tertiary Outcome: Quality of life.
Primary Outcome: Change in viral load.
Secondary Outcome: Haitian immigrant to the U.S., non-viral suppression of HIV.
Experimental: Change in CD4 count.
Tertiary Outcome: Quality of life.
Study Design: Experimental study with a single-arm design, Haitian immigrant to the U.S., non-viral suppression of HIV.
Secondary Outcome: Change in CD4 count.
Experimental: Haitian immigrant to the U.S., non-viral suppression of HIV.
Tertiary Outcome: Quality of life.
Study Design: Experimental study with a single-arm design, Haitian immigrant to the U.S., non-viral suppression of HIV.
Primary Outcome: Change in CD4 count.
Secondary Outcome: Haitian immigrant to the U.S., non-viral suppression of HIV.
Experimental: Haitian immigrant to the U.S., non-viral suppression of HIV.
Secondary Outcome: Change in CD4 count.
Tertiary Outcome: Quality of life.
Experimental: Haitian immigrant to the U.S., non-viral suppression of HIV.
Secondary Outcome: Change in CD4 count.
Experimental: Haitian immigrant to the U.S., non-viral suppression of HIV.
Secondary Outcome: Change in CD4 count.
Experimental: Haitian immigrant to the U.S., non-viral suppression of H"
700,"[/INST] in the method.
In,, it.
It.
It.
In, and in the process, its package, it
It, it.
It.
It.
It.
In,, it.
In,, in.
In,,, in the//
In,, this   1
In,
In,
In, in, in, in, in, in,,
In,,,
In
In
In
In
In
S,
In
In
In
In
In
In
In
In
S
S
In
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
Street
This
This
This
This
This
This
This
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S"
701,"[/INST]
| Keywords: radiology, XRays, emergency medicine, artificial intelligence, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine, Fractures | Summary: [/INST]
| Keywords: XR, artificial intelligence, radiology, emergency medicine,"
702,[/INST] - [/SUMMARY]
703,"[/INST]
Other: [/INST]"
704,"[/INST]
It
In
In
This
The
In
==
This
This
This
This
This
It
It
It
This
The
The
The
==
==
==
==
==
0
==
and
and
==
==
==
==
==
==
==
==
==
0
0
This
This
This
The
The
==
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
The
The
The
The
The
This
This
This
This
This
The
The
The
The
The
The
The
The
The
The
This
The
The
The
The
The
The
The
The
The
The
The
The
This
This
The
The
A
A
A
A
A
A
A
This
This
The
The
The
The
The
The
G
G
G
G
G
G
G
G
G
G
The
The
S
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
0
0
0
0
0
0
A
A
A
A
A
A
A
The
The
The
The
The
The
The
A
A
A
A
A
A
-
-
-
0
0
A
A
A
A
The
0
The
The
0
0
The
The
0
The
The
0
The
A
0
0
0-
0-
0-
A
A
A
0-
0"
705,"[/INST]
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
| 
|  | 
| 
|  | 
| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 18| 188| 18888| 188| 188888888.|
| 188888888888888888888888888888888888898888888888.
The pain.
The surgery.
The operation.
The surgery.
The patient.
The patient.
The patient.
The patient.
The patient.
The surgery.
The patient.
The patient.
The operation.
The operation.
The operation.
The operation.
The operation.
The patient.
The operation.
The operation.
The operation.
The surg
The surg.
The surg.
The surg.
The surgera.
The surg.
The surg
In
In it"
706,"[/INST]

How is the study designed?
-----------------
| the mean vertical displacement (in millimeters) measured on the anterior wall of the vagina between rest and maximum pushing effort during dynamic MRI. | the mean vertical displacement (in millimeters) measured on the posterior wall of the uterus between rest and maximum pushing effort during dynamic MRI. | the symptoms of patients with endometriosis are associated with initial dynamic MRI data and post-therapeutic symptoms are associated with dynamic MRI data. | Baseline | 

How is the study designed?
-----------------
| the mean vertical displacement (in millimeters) measured on the anterior wall of the vagina between rest and maximum pushing effort during dynamic MRI. | the symptoms of patients with endometriosis are associated with initial dynamic MRI data and post-therapeutic symptoms are associated with dynamic MRI data. | Baseline | 

How is the study measured?
-----------------
| the mean vertical displacement (in millimeters) measured on the anterior wall of the vagina between rest and maximum pushing effort during dynamic MRI. | the symptoms of patients with endometriosis are associated with initial dynamic MRI data and post-therapeutic symptoms are associated with dynamic MRI data. | Baseline | 

How is the study elicited?
| the mean vertical displacement (in millimeters) measured on the anterior wall of the vagina between rest and maximum pushing effort during dynamic MRI. | the symptoms of patients with endometriosis are associated with initial dynamic MRI data and post-therapeutic symptoms are associated with dynamic MRI data. | Baseline |

How is the study mobility?
-----------------
| the mean vertical displacement (in millimeters) measured on the anterior wall of the vagina between rest and maximum pushing effort during dynamic MRI. | the symptoms of patients with endometriosis are associated with initial dynamic MRI data and post-therapeutic symptoms are associated with dynamic MRI data. | Baseline |

How is the study conducted?
-----------------
| the mean vertical displacement (in millimeters) measured on the anterior wall of the vagina between rest and maximum pushing effort during dynamic MRI. | the symptoms of patients"
707,"[/INST]
Influenza Vaccination in [/INST] Eligible individuals between 6 months and 18 years of age. Admitted Patients receiving influenza vaccine and [/INST]
Primary Outcome: [/INST] Proportion of eligible individuals receiving influenza vaccine and ILI receiving antibiotic prescriptions between 1 September and 30 April the season spans.
Secondary Outcome: [/INST] Proportion of antibiotic prescriptions received by eligible individuals between 1 September and 30 April the season spans.
Influenza Vaccination in [/INST] Eligible individuals between 6 months and 18 years of age.
Primary Outcome: [/INST] Proportion of individuals receiving influenza vaccine and ILI receiving antibiotic prescriptions between 1 September and 30 April the season spans.
Secondary Outcome: [/INST] Proportion of antibiotic prescriptions received by eligible individuals between 1 September and 30 April the season spans.
Influenza Vaccination in [/INST] Eligible individuals between 6 months and 18 years of age.
Primary Outcome: [/INST] Proportion of individuals receiving influenza vaccine and ILI receiving antibiotic prescriptions between 1 September and 30 April the season spans.
Secondary Outcome: [/INST] Proportion of antibiotic prescriptions received by eligible individuals between 1 September and 30 April the season spans.
Influenza Vaccination in [/INST] Proportion of individuals receiving influenza vaccine and ILI between 1 September and 30 April the season spans.
Primary Outcome: [/INST.
Secondary Outcome: Proportion of individuals receiving influenza vaccine and ILI between 1 September the season spans.
Primary Outcome: [/INST the season the influenza the season spans.
Primary Outcome: [/with 1 September the season spans.
Primary Outcome: 1 September the season spans.
Primary Outcome the season, influenza the season.
Primary Outcome the season.
Primary Outcome the season."
708,"[/INST]
Reciting Tang poems, Happiness, Ethnic minorities


Change in the attitude, Happiness, I am confident, I am learning Chinese, I like to recite Tang poems. Tang poems, I am confident, I am learning Chinese, I am learning Tang poems.
=================
Change in the past, I am learning Chinese, I am learning Tang poems.
=================
Change in the poems, I am learning Chinese, I am learning Tang poems.
================-
================-
Change in the poems.
================
==================
================
================
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
Change the poems.
The poems.
The poems.
This is a.
The poems.
The poems.
The poems.
The Chinese poems.
The poems.
The Chinese.
The mother.
The mother.
The psych.
The psych.
The mother.
Their parents.
In their mothers.
In their mothers.
They.
They.
They.
They.
They.
They.
They.
The psych
The psych
The psych.
A.
A.
In a        as a    as a    as
The    as a    as a    as a"
709,"[/INST]
It's mental health issues.
The suicide.
There are-as
There are-as
There are-as a suic
There are-as a suic
There are-as a-as
There are-as
There.
The suic
There.
The suic
The-as-as-as-as-as
It.
The-as-as-as-as
The suic.
It.
It.
There.
The-as
It.
It.
It.
It.
It.
It.
The.
The.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It
It
It.
It.
It.
It.
It.
It
It
It
It
It
This.
This.
The.
The.
It.
This.
This.
This.
This.
This
This
This
This
This
It.
It.
It
It
It.
It.
It.
It.
It.
It.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The"
710,"[/INST]


| Primary Outcome Feasibility Criteria: | Pupil size as measured by pupillometry on Day 1 afternoon, Day 2 morning, and hormone response to light stimuli | Melatonin levels from saliva collection on Night 1 and hormone response to light exposure on Day 1 evening, blue/green light exposure on Night 2 |
| Experimental: Light exposure on night 1 and hormone response to different stimuli | Melatonin levels from saliva collection on Day 2 morning, blue/green light exposure on night 2 |
| Pupillometry to determine circadian timing and hormone response to different light stimuli | Night 1 and blue/green light exposure on Day 2 | 
| Experimental: Light exposure on night 1 and hormone response to different stimuli | Melatonin levels from saliva collection on Day 1 morning, blue/green light exposure on night 2 |
| Pupillometry to determine circadian timing and hormone response to different stimuli | Melatonin levels from saliva collection on Day 1 morning, blue/green light exposure on night 2 |
| Experimental: Light exposure on night 1 and hormone response to different stimuli | Melatonin levels from saliva collection on Day 2 morning, blue/green light exposure on night 2 | 
| Pupillometry to determine circadian timing and hormone response to different stimuli | Melatonin levels from saliva collection on Day 1 morning, blue/green light exposure on night 2 |
| Primary Outcome: Pupil size as measured by pupillometry on Day 1 afternoon, blue/green light exposure on night 2 | Melatonin levels from saliva collection on Day 2 morning, different light stimuli on night 1 |
| Experimental: Light exposure on night 1 and hormone response to different stimuli | Melatonin levels from saliva collection on Day 1 morning, blue/green light exposure on night 2 |
| Pupillometry to determine circadian timing and hormone response to different stimuli | Melatonin levels from saliva collection on Day 1 morning, blue/green light exposure on night 2 |
| Primary Out"
711,"[/INST]


Primary Outcome: Parent training, Parenting skills, Parent behavior, Eyberg Child Behavior Inventory, Child behavior, ADHD, IPSA, Intervention, Treatment, Routine services, Ulf, follow-up, 6 months, 3 months, 1995, Eyberg, 2008, 2018, 2020, 2022, 2022, 2024, 2026, 2028, 2030, 2032, 2034, 2036, 2038, 2040, 2032, 2042, 2036, 2038, 2040, 2036, 208, 2030, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 2036, 206, 2036, 2036, 2036, 2036, 2036, 2036, 206, 20000000000000000000000000000000000000000000000000000000000"
712,"[/INST]

Intervention/Treatment
-----------------
Primary Outcome Measure
-----------------
Intervention/Treatment
-----------------
Adverse Events
-----------------
Secondary Outcome Measures
Adverse Events
-----------------
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Adverse Events
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Measures
Intervention/Treatment
Adverse Events
Secondary Outcome Me"
713,"[/INST]

How is the study designed?
| Design Type: Open-label, single-arm, multi-center, timed | Design Inclusion Criteria: Men and women ages 18-65, with known Primary Progressive Multiple Sclerosis (PPMS) and known history of using Baclofen or Tizanidine for at least 6 months. Exclusion Criteria: Use of Baclofen or Tizanidine in the last 6 months. |
| Design Type: Open-label, single-arm, multi-center, timed | Design Inclusion Criteria: Men and women ages 18-65, with known history of therapeutic use of Baclofen or Tizanidine. Exclusion Criteria: Use of Baclofen or Tizanidine in the last 6 months. |
| Design Type: Open-label, single-arm, timed | Design Inclusion Criteria: Men and women ages 18-65, with known history of therapeutic use of Baclofen or Tizanidine for at least 6 months. Exclusion Criteria: Use of Baclofen or Tizanidine in the last 6 months. |
| Design Type: Open-label, single-arm, timed | Design Inclusion Criteria: Men and women ages 18-65, with known history of therapeutic use of Baclofen or Tizanidine for at least 6 months. Exclusion Criteria: Use of Baclofen or Tizanidine in the last 6 months. |
| Design Type: Open-label, single-arm, timed | Design Inclusion Criteria: Men and women ages 18-65, with known history of therapeutic use of Baclofen or Tizanidine for at least 6 months. Exclusion Criteria: Use of Baclofen or Tizanidine in the last 6 months. |
| Design Type: Open-label, single-arm, timed | Design Inclusion Criteria: Men and women ages 18-65, with known history of therapeutic use of Baclofen or Tizanidine. Exclusion Criteria: Men and women ages 18-65, with known history of"
714,"[/INST]
Other Outcome Measures
-----------------
| response to steroid treatment | prothrombin time at day 7 | Lille score at day 28 |
| death |
| early cirrhosis | alcoholic hepatitis, prothrombin time at day 14 |
| response to medical treatment | Lille score at day 21 |
| death |

Other Interventions
-----------------
| response to steroid treatment | prothrombin time at day 7 | Lille score at day 14 |
| early cirrhosis, alcoholic hepatitis, prothrombin time at day 21 |
| death |

Other Outcome Measures
-----------------
| response to steroid treatment | prothrombin time at day 7 | Lille score at day 14 |
| early cirrhosis, alcoholic hepatitis, prothrombin time at day 28 |
| death |

Other Interventions
-----------------
| response to steroid treatment | prothrombin time at day 7 | Lille score at day 14 |
| early cirrhosis, alcoholic hepatitis, prothrombin time at day 21 |

Other Outcome Measures
-----------------
| response to steroid treatment | prothrombin time at day 7 | Lille score at day 14 |
| early cirrhosis, alcoholic hepatitis, prothrombin time at day 28 |

Other Interventions
-----------------
| response to steroid treatment | prothrombin time at day 7 | Lille score at day 14 |
| early cirrhosis, alcoholic hepatitis, prothrombin time at day 21 |

Other Outcome Measures
-----------------
| response to steroid treatment | prothrombin time at day 7 | Lille score at day 14 |
| early cirrhosis, alcoholic hepatitis, prothrombin time at day 28 |

Other Interventions
-----------------
| response to steroid treatment | prothrombin time at day 7 | Lille score at day 14 |
| early cirrhosis"
715,"[/INST]
Other: [/INST]
Primary Outcome Measure
Cerebral palsy
Other: [/INST]
How is the study designed?
Cerebral palsy
Other: [/INST]
How is the study measuring?
Cerebral palsy
Other: [/INST]
How is the study designed?
Cerebral palsy
Other: [/INST]
How is the study measuring?
Cerebral palsy
Other: [/INST]
How is the study designed?
Cerebral palsy
Other: [/INST]
How is the study measuring?
Cerebral palsy
Other: [/INST]
How is the study designed?
Cerebral palsy
Other: [/INST]
How is the study measuring?
Cerebral palsy
Other: [/INST]
How is the study designed?
Cerebral palsy
Other: [/INST]
How is the study measuring?
Cerebral palsy
Other: [/INST]
How is the study designed?
Cerebral palsy
Other: [/INST]
How is the study measuring?
Cerebral palsy
Other: [/INST]
How is the study designed?
Cerebral palsy
Other: [/INST]
How is the study measuring?
Cerebral palsy
Other: [/INST]
How is the study designed?
Cerebral palsy
Other: [/INST]
How is the study measuring?
Cerebral palsy
Other: [/INST]
How is the study designed?
Cerebral palsy
Other: [/INST]
How is the study measuring?
Cerebral palsy
Other: [/INST]
How is the study designed?
Cerebral palsy
Other: [/INST]
How is the study measuring?
Cerebral palsy
Other: [/INST]
How is the study designed?
Cerebral palsy
Other: [/INST]
How is the study measuring?
Cerebr"
716,"[/INST] -
Primary Outcome Measure
-----------------
Secondary Outcome Measure
How is the study designed?
| ToF primary repair<br>Patients who underwent ToF primary repair<br>* Procedure: ToF primary repair<br> 
| Hospital Length of Stay | TOF primary repair<br> 
| Secondary Outcome Measure |
How is the study measuring?
| ToF primary repair<br>Patients who underwent ToF primary repair<br> 
| Hospital Length of Stay | TOF primary repair<br> 
Secondary Outcome Measure
How is the study measuring?
| ToF primary repair<br>Patients who underwent ToF primary repair<br> 
| Hospital Length of Stay | TOF primary repair<br> 
Secondary Outcome Measure
How is the study measuring?
| ToF primary repair<br>Patients who underwent ToF primary repair<br> 
| Hospital Length of Stay | TOF primary repair<br> 
Secondary Outcome Measure
How is the study measuring?
| ToF primary repair<br>Patients who underwent ToF primary repair<br> 
| Hospital Length of Stay | TOF primary repair<br> 
Secondary Outcome Measure
How is the study measuring?
| ToF primary repair<br>Patients who underwent ToF primary repair<br> 
| Hospital Length of Stay | TOF primary repair<br> 
Secondary Outcome Measure
How is the study measuring?
| ToF primary repair<br>Patients who underwent ToF primary repair<br> 
| Hospital Length of Stay | TOF primary repair<br> 
Secondary Outcome Measure
How is the study measuring?
| ToF primary repair<br>Patients who underwent ToF primary repair<br> 
| Hospital Length of Stay | TOF primary repair<br> 
Secondary Outcome Measure
How is the study measuring?
| ToF primary repair<br>Patients who underwent ToF primary repair<br> 
| Hospital Length of Stay | TOF primary"
717,"[/INST]

| Procedure provided by physician |
| Patient-reported pain level |
| Procedure time |
| Patient-reported interest in subsequent procedure |
| Provider-reported pain level |
| Patient issued procedure prior to the patient leaving the clinic |
| Procedure time |
| Patient-reported pain level |
| Provider-reported pain level prior to the patient leaving the clinic |
| Patient issued procedure prior to the patient leaving the clinic |
| Procedure time |
| Patient-reported pain level |
| Provider-reported pain level prior to the patient leaving the clinic |
| Patient issued procedure prior to the patient leaving the clinic |
| Provider-reported pain level |
| Patient-reported pain level prior to the patient leaving the clinic |
| Procedure time |
| Patient-reported pain level |
| Provider-reported pain level prior to the patient leaving the clinic |
| Patient issued procedure prior to the patient leaving the clinic |
| Provider-reported pain level |
| Patient-reported pain level prior to the patient leaving the clinic |
| Procedure time |
| Patient-reported pain level |
| Provider-reported pain level prior to the patient leaving the clinic |
| Patient-reported pain level |
| Procedure time |
| Patient-reported pain level prior to the patient leaving the clinic |
| Provider-reported pain level |
| Patient-reported pain level prior to the patient leaving the clinic |
| Procedure time |
| Patient-reported pain level |
| Provider-reported pain level prior to the patient leaving the clinic |
| Patient-reported pain level |
| Procedure time |
| Patient-reported pain level prior to the patient leaving the clinic |
| Provider-reported pain level |
| Patient-reported pain level prior to the patient leaving the clinic |
| Procedure time |
| Patient-reported pain level prior to the patient leaving the clinic |
| Provider-reported pain level prior to the patient leaving the clinic |
| Patient-reported pain level |
|"
718,"[/INST]
Other: Screening test for type 1 diabetes and celiac disease.
Eligibility Criteria: Residency in Cantalupo, locality of the Municipality of Cerro Maggiore (MI). Age between 18 and 65 years old.
Exclusion Criteria: No exclusion criteria
Primary Purpose: Other
Interventional Model: Other
Secondary Outcome Measures
| Other: Screening test for type 1 diabetes and celiac disease.
| through study completion, an average of 1 year |
Secondary Interventions: Other
Primary Purpose: Other
Interventional Model: Other
Secondary Outcome Measures
| through study completion, an average of 1 year |
Exclusion Criteria: No exclusion criteria
Primary Purpose: Other
Interventional Model: Other
Secondary Outcome Measures
| through study completion, an average of 1 year |
Exclusion Criteria: No exclusion criteria
Primary Purpose: Other
Interventional Model: Other
Secondary Outcome Measures
| through study completion, an average of 1 year |
Exclusion Criteria: No exclusion criteria
Primary Purpose: Other
Interventional Model: Other
Secondary Outcome Measures
| through study completion, an average of 1 year |
Exclusion Criteria: No exclusion criteria
Primary Purpose: Other
Interventional Model: Other
Secondary Outcome Measures
| through study completion, an average of 1 year |
Exclusion Criteria: No exclusion criteria
Primary Purpose: Other
Interventional Model: Other
Secondary Outcome Measures
| through study completion, an average of 1 year |
Exclusion Criteria: No exclusion criteria
Primary Purpose: Other
Interventional Model: Other
Secondary Outcome Measures
| through study completion, an average of 1 year |
Exclusion Criteria: No exclusion criteria
Primary Purpose: Other
Interventional Model: Other
Secondary Outcome Measures
| through study completion, an average of 1 year |
Exclusion Criteria: No exclusion criteria
Primary Purpose: Other
Interventional Model: Other
Secondary Outcome Measures
| through study completion, an average of 1 year |
Exclusion Criteria"
719,"[/INST]
| 2018, Breast
|
|
|
|
| 2018
|
| 2018
| 201
|19888
|1988
|1988
|1988
|1988
|198
|198
|1988
|1988
|1988
|198
|198
|198
|198
198
198
198
198
198
198
198
198
198
198
198
198
198
198
198
198
198
198
198
198
198
198
198
198
198989800198
19898
19898
1989898
1989898
19898
19801
19898
199999
199999
199999
199
1
1
1999
19
1
1
1
1
199
1
1
1
1
1
1
1999
1
1
1
199
1
1
1
1
1
The
This
1
This
This
In
In
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
S
S
S
S
S
S
S
S
S
This
This
This
This
This
This
This
This
S
S
S
S
S
S
S
S
This
S
S
S
S
S
S
S
S
This
This
This"
720,[/INST] - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -		- - -												P														- - - - - - - - - - - - - - - - - - - -	- - - - - - - -																														P0P0P0000000																																																		- -	0- 90- 9- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -	0000000000XLL999XLL000000000- 1- 	- 	LLLLLLLL					000000000000000000- - - - - - - - - - - - - - - - - - - -	cycycycycycycy99999999cycyrcorsurecyoristryoristryoristryXualiteableXurecy9Xralisticrcualcyralisticialcycycycycycycycycycycycycycyoocyoocyrcistry000000000ralisticcycycy
721,"[/INST]
The patient.
The patients.
The
The
The
The patient
The patient.
The patient.
The patients
The patients
The patients
The patients
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
The
The
The
This
This
This
The
The
The
The
in
in
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
In
This
This
In
This
The
This
S
S
S
The
The
The
The
The
The
in
D
D
D
S
S
The
This
This
The
This
The
The
The
The
This
D
D
S
S
S
S
This
This
S
H
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
F
F
The
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S"
722,"[/INST]
| EEG, electroencephalography, magnetic resonance imaging, functional MRI, neuroimaging |
| psychosis, psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, electroconvulsive therapy, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiatric symptoms, psychotropic medications |
| psychiatric symptoms, neuroimaging |
| psychiat"
723,"[/INST]


















C
A
A
A
A
A












C























































C
C
C


C
C
C
C




C
C
C
f
f

















































C
C
f













































8
8






















8
8
f












8




8
8


7"
724,"[/INST]
The ...
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
The.
This.
This.
This.
This.
This
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This."
725,"[/INST]

How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
| Primary Outcome Measure |
| Whole genome sequencing of the index case and his/her relatives. |
| Other: Skin biopsy of the index case and his/her relatives. |
| Other: High-density microarrays of the pathogen and its relatives. |
| To check the effect of mutations in the pathogen and its relatives. |
| To check the effect of the mutation in the pathogen and its relatives. |
| To check the effect of the mutation in the pathogen and its relatives. |
| Other: Skin biopsy of the index case and his/her relatives. |
| To check the effect of the mutation in the pathogen and its relatives. |
| Other: Whole genome sequencing of the pathogen and its relatives. |
| To check the effect of the mutation in the pathogen and its relatives. |
| Other: Skin biopsy of the index case and his/her relatives. |
| To check the effect of the mutation in the pathogen and its relatives. |
| Other: Whole genome sequencing of the pathogen and its relatives. |
| To check the effect of the mutation in the pathogen and its relatives. |
| Primary Outcome Measure |
| Other: Skin biopsy of the index case and his/her relatives. |
| To check the effect of the mutation in the pathogen and its relatives. |
| Whole genome sequencing of the pathogen and its relatives. |
| To check the effect of the mutation in the pathogen and its relatives. |
| Primary Outcome Measure |
| Other: Skin biopsy of the index case and his/her relatives. |
| To check the effect of the mutation in the pathogen and its relatives. |
| Whole genome sequencing of the pathogen and its relatives. |
| To check the effect of the mutation in the pathogen and its relatives. |
| Primary Outcome Measure |
| Other: Skin biopsy of the index case and his/her relatives. |
| To check the effect of the mutation in the pathogen and its"
726,"[/INST]

Quality of Life Scores
-----------------
How is the study designed?
Quality of Life Scores
Quality of Life Scores
How is the study designed?
Quality of Life Scores
Quality of Life Scores
How is the study designed?
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of Life Scores
Quality of"
727,"[/INST]
Synema.
17 patients.
17.
17.
17.
Syn
Syn
Syn
Syn
Syn
Syn
Syn
17.
17.
17.
Syn
175
17
17
17
17
17.
17
17
17
17
17
17
17
17.
175
1788.
17.
17
17.
17.
17.
17.
The patient.
17.
17.
17.
17.
17
17
17
17
1
1.
1
1
1.
1.
1.
17.
1.
1.
1.
1.
1.
The
The
The    ==
The    ==
The    ==
This
This
This
==
==
==
==
==
It
It
in
C
C
C
C
C
C
C
==
==
==
==
==
==
==
This
This
This
This
This
This
This
This
This
This
This
This
This
This
S
==
==
==
==
==
==
==
S
==
==
==
This
This
This
This
This
This
This
This
This
This
This
This
This
This
in
in
in
in
==
==
==
==.
==
==
==
==
==
==
==
S
S
S
==
==
==.
==
==
==
==
==
==
==
==
==
==
==
==
for
for
for
for
for
for
C
as
as
turn
as
as
for
for
for
for
for
as
for
for
s
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
as
as
as
s
as
s
s"
728,"[/INST]
S
S
S
S
S
This
This
This
This
This
This
This
The
It
It
It
This
This
This
By
By
By
This
This
This
This
C
This
S
S
S
S
S
This
This
This
This
This
This
The
The
The
S
This
This
This
This
This
This
This
This
This
This
This
S
S
This
The
The
This
This
This
The
The
The
The
S
S
S
The
This
This
This
T
T
The
The
The
S
S
The
S
The
The
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S"
729,"[/INST]
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study designed?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
| Cirrhotic patients | Diagnostic Test: stool analysis<br>Non-cirrhotic patients . .
How is the study conducted?
|"
730,"[/INST]
| Primary Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Primary Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Primary Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Primary Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Primary Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Primary Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Primary Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Primary Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame |
| Primary Outcome Measure | Measure Description | Time Frame |
| Outcome Measure | Measure Description | Time Frame | Primary Outcome Measure Description | Time Frame |
| Primary Outcome Measure Description | Time Frame the surgeon's disease | Primary Outcome Measure
| Primary Outcome Measure Description | Time Frame
| Primary Outcome Measure
| Primary Outcome Measure
| Primary Outcome Measure
| Primary Outcome
| Primary Outcome Measure Primary Outcome
| Primary Outcome Measure Primary Outcome
| Primary Outcome
Primary Outcome
| Primary Outcome
Primary Outcome
Primary Outcome
Primary Outcome Measure Primary Outcome
Primary Outcome
Primary Outcome
Primary Outcome Primary Outcome
Primary Outcome Primary Outcome
Primary Outcome
Primary Outcome
Primary Outcome
Primary Outcome Primary Outcome Primary Outcome
Primary Outcome
Primary Outcome
Primary Outcome
Primary Outcome Primary Outcome Primary Outcome
Primary Outcome Primary Outcome Primary Outcome Primary Outcome
Primary Outcome
Primary Outcome primary surg
Primary Outcome Primary Outcome
Primary Outcome
Primary Outcome
Primary
Primary Outcome
Primary surgery
Primary
Primary
Primary
Primary
Primary
Primary
Primary
Primary"
731,"[/INST]
Other: [/INST]
Primary Outcome: Hallux Valgus, Duration, Onset, Sensory block, Peripheral Nerve Block, ropivacaine Onset, Duration, Postoperative pain scores
Secondary Outcome: Hallux Valgus, Duration, Sensory block, Peripheral Nerve Block, ropivacaine Onset, Postoperative pain scores
Tertiary Outcome: Hallux Valgus, Duration, Sensory block, Peripheral Nerve Block, ropivacaine Onset, Postoperative pain scores
Explanation of how the study measures the primary outcome(s)
Explanation of how the study measures the secondary outcome(s)
Explanation of how the study measures the primary outcome
Explanation of how the study measures the secondary outcome(s)
Explanation of how the study measures the primary outcome
Explanation of how the study measures the secondary outcome(s)
Explanation of how the study measures the primary outcome
Explanation of how the study measures the secondary outcome(s)
Explanation of how the study measures the primary outcome
Explanation of how the study measures the secondary outcome(s)
Explanation of how the study measures the primary outcome
Explanation of how the study measures the secondary outcome(s)
Explanation of how the study measures the primary outcome
Explanation of how the study measures the secondary outcome(s)
Explanation of how the study measures the primary outcome
Explanation of how the study measures the secondary outcome(s)
Explanation of how the study measures the primary outcome(s)
Explanation of how the study measures the secondary outcome(s)
Explanation of how the study measures the primary outcome(s)
Explanation of how the study measures the secondary outcome(s)
Explanation of how the study measures the primary outcome(s)
Explanation of how the study measures the secondary outcome(s)
Explanation of how the study measures the primary outcome(s)
Explanation of how the study measures the secondary outcome(s)
Explanation of how the study measures the primary outcome(s)
Explanation of how the study measures the secondary outcome(s)
Explanation of how"
732,"[/INST]

How is the study designed?
| Participant Group/Eligibility Criteria | Intervention/Allocation |
| Primary Purpose: Supportive Care | Participant will be in the compression stockings group | Exclusion Criteria: Pregnant women in the compression stockings group will wear the socks given for 3 weeks. |
| Secondary Outcome Measures |
| Primary Purpose: Supportive Care | Participant will be in the compression stockings group | Exclusion Criteria: Pregnant women in the compression stockings group will wear the socks given for 3 weeks. |
| Secondary Outcome Measures |

How is the study designed?
| Primary Purpose: Supportive Care | Participant will be in the compression stockings group | Exclusion Criteria: Pregnant women in the compression stockings group will wear the socks given for 3 weeks. |
| Secondary Outcome Measures |

How is the study designed?
| Primary Purpose: Supportive Care | Participant will be in the compression stockings group | Exclusion Criteria: Pregnant women in the compression stockings group will wear the socks given for 3 weeks. |
| Secondary Outcome Measures |

How is the study designed?
| Primary Purpose: Supportive Care | Participant will be in the compression stockings group | Exclusion Criteria: Pregnant women in the compression stockings group will wear the socks given for 3 weeks. |
| Secondary Outcome Measures |"
733,"[/INST]
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O

O










O
O
O
O
O
O
O
O
O
O
A
A
A
A
A
A
A
A
A
A
A

































O
O
A




O
O
O
O
O
O




























O
O
O
O
O
O
A
O
O
O
O





O

O
O
O


O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O




























O
O
O
O
O
O
O
O





































































































































































O
O
O
O
O
O
O
O"
734,"[/INST]
| 2018000000001800001800001800000000001010101010101800180010101010101800101010180018001010180010101010180018180180180180180101010101010101010101010101010101018018180101010101010101010101010101010101010101010101010010101001010100100000000100001001001001001001000180001
The surg.1.001.0010101.001.01.01.01.01.01.01.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The.
The.
The.
The.
The, it.
The, it.
The, it.
The, it.
The.
The.
The.
The.
The.
The.
The.
The.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
in
in
in
in
in
in"
735,"[/INST]






How is the study designed?
-----------------
Primary Purpose: To determine the effect of nursing care based on Kolcaba's comfort theory on the satisfaction and sleep quality of intensive care patients.
| Secondary Purpose: To compare the effects of nursing care on comfort and sleep quality in intensive care patients.
| Eligibility Criteria: Individuals who are diagnosed with a sleep disorder and are receiving nursing care.
| Inclusion Criteria: Individuals who are diagnosed with a sleep disorder and are not receiving nursing care.
| Exclusion Criteria: No history of sedative use.
| Comfort Behaviour Checklist: A checklist developed by Katharine Kolcaba to assess comfort. It includes six items (depth of sleep, time to fall asleep, frequency of awakening, quality of sleep and ambient noise level).
| Richard-Campbell Sleep Scale: A scale developed by Richards et al. (1987) to assess sleep quality in intensive care units.
| Other: No history of sedative use.



How is the study designed?
-----------------
Primary Purpose: To determine the effect of nursing care based on Kolcaba's comfort theory on the satisfaction and sleep quality of intensive care patients.
| Secondary Purpose: To compare the effects of nursing care on comfort and sleep quality in intensive care patients.
| Inclusion Criteria: Individuals who are diagnosed with a sleep disorder and are receiving nursing care.
| Exclusion Criteria: No history of sedative use.
| Comfort Behaviour Checklist: A checklist developed by Katharine Kolcaba to assess comfort. It includes six items (depth of sleep, time to fall asleep, frequency of awakening, quality of sleep and ambient noise level)."
736,"[/INST]
Primary Outcome: [/INST]
Other: [/INST]
Health Systems Research, Public Health System, Pediatric Emergency Medicine, Implementation Science
================-
Other: [/INST]
Primary Outcome: [/INST]
Health Systems Research, Pediatric Emergency Medicine, Public Health System, Implementation Science
================-
Other: [/INST]
Primary Outcome: [/INST]
Health Systems Research, Pediatric Emergency Medicine, Public Health System, Implementation Science
Other: [/INST]
Primary Outcome: [/INST]
Health Systems Research, Pediatric Emergency Medicine, Public Health System, Implementation Science
Other: [/INST]
Primary Outcome: [/INST]
Health Systems Research, Pediatric Emergency Medicine, Public Health System, Implementation Science
Other: [/INST]
Primary Outcome: [/INST]
Health Systems Research, Pediatric Emergency Medicine, Public Health System, Implementation Science
Other: [/INST]
Primary Outcome: [/INST]
Health Systems Research, Pediatric Emergency Medicine, Public Health System, Implementation Science
Primary Outcome: [/INST
Other: [/INST
Primary Outcome: [/INST
Other: [/INST
Primary Outcome: Pediatric Medicine, Public Health Systems Research, Implementation Science
Primary Outcome: [/INST
Other: [/INST
Primary Outcome: Pediatric Medicine, Public Health Systems Research, Pediatric Medicine, Public Health Systems Research, Implementation Science, Pediatric Medicine, Public Health Systems Research, Pediatric Outcome, Primary Outcome, Pediatric Medicine, Public Health Systems, Implementation Science, Pediatric Medicine, Public Health Systems, Pediatric Medicine, Pediatric Medicine, Pediatric Medicine, Pediatric Public Health Systems, Pediatric Health Systems, Implementation, Pediatric Medicine, Pediatric Medicine, Implementation, Pediatric Medicine, Pediatric Medicine, Pediatric Medicine, Pediatric Medicine, Pediatric Medicine, Implementation, Pediatric Medicine, Implementation, Pediatric Medicine, Implementation, Pediatric Medicine, Pediatric Medicine, Implementation, Pediatric Medicine, Implementation, Pediatric Medicine, Implementation, Pediatric Medicine, Im"
737,"[/INST]
Other: [/INST]
Participants will be asked to maintain two different postures, at 10 sessions of treatment, and at 30 days after the end of the training.
What is the study assessing?
| Outcome Measure | Measure Description | Time Frame |
| Pain Visual Analogue Scale (VAS) | Change of Pain Visual Analogue Scale (VAS) from baseline, at 10 sessions of treatment, and at 30 days after the end of the training. The VAS consisted of a straight horizontal line of fixed length (100 mm). | Baseline, after 5 weeks of treatment , and 1 month after the end of the training | 
| Pain Visual Analogue Scale (VAS) | Change of Pain Visual Analogue Scale (VAS) from baseline, at 10 sessions of treatment, and at 30 days after the end of the training. The VAS consisted of a straight horizontal line of fixed length (100 mm). | Baseline, after 5 weeks of treatment , and 1 month after the end of the training | 
| Other: Pain Visual Analogue Scale (VAS) | Change of Pain Visual Analogue Scale (VAS) from baseline, at 10 sessions of treatment, and at 30 days after the end of the training. The VAS consisted of a straight horizontal line of fixed length (100 mm). | Baseline, after 5 weeks of treatment , and 1 month after the end of the training | 
| Pain Visual Analogue Scale (VAS) | Change of Pain Visual Analogue Scale (VAS) from baseline, at 10 sessions of treatment, and at 30 days after the end of the training. The VAS consisted of a straight horizontal line of fixed length (100 mm). | Baseline, after 5 weeks of treatment , and 1 month after the end of the training | 
| Pain Visual Analogue Scale (VAS) | Change of Pain Visual Analogue Scale (VAS) from baseline, at 10 sessions of treatment, and at 30 days after the end of the training. The VAS consisted of a straight horizontal line of fixed length"
738,"[/INST]
-----------------
Keywords: [/INST]
Propofol, TCI, TIVA

Summary: [/INST]
Propofol, TCI, TIVA


-----------------
Keywords: [/INST]
Propofol, TCI, TIVA

Summary: [/INST]
Propofol, TCI, TIVA


-----------------
Keywords: [/INST]
Propofol, TCI, TIVA

Summary: [/INST]
Propofol, TCI, TIVA


-----------------
Keywords: [/INST]
Propofol, TCI, TIVA


Summary: [/INST]
Propofol, TCI, TIVA



-----------------
Keywords: [/INST]
Propofol, TCI, TIVA


Summary: [/INST]
Propofol, TCI, TIVA



-----------------
Keywords: [/INST]
Propofol, TCI, TIVA


Summary: [/INST]
Propofol, TCI, TIVA



-----------------
Keywords: [/INST]
Propofol, TCI, TIVA



Summary: [/INST
Propofol, TCI, TIVA












































































































Propof
Propof
Propof
Prop.

Propof
Propof
Propof
Propof
Propof
Propof
Propof
Propof
Propof
Propof
Propof
Propof
Propof
Propof
Propof.
Prop,
Prop,
Prop,
Prop.
Prop.
Prop.
Prop.
Prop.
Prop.
Prop.
Prop,
Prop,
Prop."
739,"[/INST]
This
D
F
F
F
F








F


D
D
D
D
D




F
F"
740,"[/INST]
Second|s surgery.
Second|s surgery.
Second|s.
Second|s.
Second|s.
Second|s surgery.
Second|s surgery.
Second|s.
Second.
Second.
Second.
Second.
Second.
Second|s.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
Second.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient|
The patient.
The patient.
This
This will be
This
This procedure.
The procedure.
The
The
The
This
This
This
This
This
The
The
The
The
The
This
This
This
This
This
This
This     
It         
It
It
It
It
This
This
This
This
This
This
This
This
This
This
This
The
The
The         ::
This   6777
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
0
0
0
088
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
741,"[/INST]
Rad
Rad
Rad
Rad
Rad
Rad
Rad
Rad
Rad
Rad
Rad
Rad
Rad
Rad
Rad
This
This
This
This
This
This
This
This
This
Rad
This
Rad
Rad
This
This
This
Rad
Rad
Rad
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
Rad
Rad
This
This
This
This
This
This
This
This
This"
742,"[/INST] C-
 C-
 C-
 C-
 C-
-
 C-
 C-
 C-



 C
 C-
 C-
-
, an ,,,
-
















































-a
-e
-





















































































































































-C
-e
C
C
C

-C
O
O
O
O
O
O
C
C
C
C
O
































































C
C
C

C
C
C
C
C
C
C
C
C
C
CO
CCC
C
C





















C
C
C











C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C"
743,"[/INST] of the stomach.
| 3, 189471.
|10.
|10.
|10101.
|101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010100000000000000000000000000000000000101010111010100100100100000001011010100000000000001.
The symptisms.
The disease.
The disease.
The sympt.
The sympt.
The sympt.
The sympt.
The sympt.
The disease.
The sympt
The.
The sympt
The.
The.
The sympten.
The sympten.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
The.
The.
It.
The.
The.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
in.
This"
744,"[/INST]
Adverse Events and Precautions
| Agreement of the parties |
| Participants: Single blinded |
| Agreement of the parties |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |
| Participants will be monitored by the researchers |"
745,[/INST]
746,"[/INST]-
-
-
-
-
-a-a-a-a-a-
-
-a-
-a-a-a-
-a-a-0-0-0-0-0-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-0-0-0-0-0-0-0-0-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-C-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-s-s-s-s-s-s-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a-a"
747,"[/INST]
-----------------
| Terms related to the study. | 10 years | 
| Terms related to the diagnosis. | 10 years |
| Terms related to the severity of the disease. | 10 years |
| Terms related to the study. | 10 years |
| Terms related to the diagnosis. | 10 years |
| Terms related to the treatment. | 10 years |
| Terms related to the clinical manifestations. | 10 years |
| Terms related to the diagnosis. | 10 years |
| Terms related to the study. | 10 years |
| Terms related to the clinical manifestations. | 10 years |
| Terms related to the diagnosis. | 10 years |
| Terms related to the treatment. | 10 years |
| Terms related to the diagnosis. | 10 years |
| Terms related to the clinical manifestations. | 10 years |
| Terms related to the diagnosis. | 10 years |
| Terms related to the study. | 10 years |
| Terms related to the diagnosis. | 10 years |
| Terms related to the clinical manifestations. | 10 years |
| Terms related to the diagnosis. | 10 years |
| Terms related to the study. | 10 years |
| Terms related to the diagnosis. | 10 years |
| Terms related to the study. | 10 years |
| Terms related to the diagnosis. | 10 years |
| Terms related to the study. | 10 years |
| Terms related to the diagnosis. | 10 years |
| Terms related to the study. | 10 years |
| Terms related to the diagnosis. | 10 years |
| Terms related to the study. | 10 years |
| Terms related to the diagnosis. | 10 years |
| Terms related to the study. | 10 years |
| Terms related to the diagnosis. | 10 years |
| Terms related to the study. | 10"
748,[/INST]
749,"[/INST]
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-




















-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-























-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-






-
-
-
-










-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-










































-
-
-
-
-























-

-
-
-
-
-
-
-
-
-
-"
750,"[/INST]1-1-1-1-1-1-1-1-1-1-1-
-1-1-1-1-1-1-1 a-1-1-1-a-a-a-a-1-1-1-a-a-a-1-1-1-1-a-1-1-1-1-1-1-1000000000000000-1-1-1-1-10-1-1-1-1 a a-1 a-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-0-1-1-1-1-1-1 a a a a a a a a a a-1-1-1-1 a a a a a a a a-0-1 a a-1-1-p-st-0-st-0-0-0-0-1-1-1-1-1-1-1-0-0-0-0-0-0-0-0-0-0-0-0-0-000000000000000000000-0-00000000000-00-0-0-0-0-0-0-0-0-0-0-0-0-0- a- a- a- a- a- a- a a- a- a-1- a- a a a a a a a a a a-1-1-1-1-0-0-0-0-0-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1 a-1 a-1-1-1-1-0"
751,"[/INST]
Primary safety measure: Sinus, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Secondary safety measure: Pit-picking, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Tertiary safety measure: Sinus, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Quaternary safety measure: Pit-picking, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Fifth safety measure: Sinus, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Sixth safety measure: Pit-picking, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Seventh safety measure: Sinus, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Eighth safety measure: Pit-picking, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Ninth safety measure: Sinus, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Tenth safety measure: Pit-picking, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Eleventh safety measure: Sinus, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Twelfth safety measure: Pit-picking, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Thirteenth safety measure: Sinus, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Fourteenth safety measure: Pit-picking, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Fifteenth safety measure: Sinus, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Sincer of the Dutchess of the skin, Laser-assisted therapy, Minimally invasive surgery
Primary safety measure: Sinus, Laser-assisted therapy, SiLaC, Minimally invasive surgery
Secondary safety measure: Sinus, Laser-ass"
752,"[/INST]
Adverse events: [/INST]
Data about adverse events among patients with substance use disorder attending addiction treatment unit.
| One week |
Data about adverse events among patients with substance use disorder attending addiction treatment unit.
| To identify the common adverse events among patients with substance use disorder: Shortness of breath, chest pain, bradycardia, hypotension, shock, coma, ...etc.
| To identify the common presenting symptoms among patients with substance use disorder: Agitation, disorientation, diaphoresis, ...etc.
| To identify the common presenting symptoms among patients with substance use disorder: Shortness of breath, chest pain, ...etc.
| To identify the common risk factors among patients with substance use disorder: Psychiatric history, family history, ...etc.
| To identify the common risk factors among patients with substance use disorder: Psychiatric history, family history, ...etc.
| To identify the common risk factors among patients with substance use disorder: Psychiatric history, family history, ...etc.
| To identify the common risk factors among patients with substance use disorder: Psychiatric history, family history, ...etc.
| To identify the common risk factors among patients with substance use disorder: Psychiatric history, family history, ...etc.
| To identify the common risk factors among patients with substance use disorder: Psychiatric history, family history, ...etc.
| To identify the common risk factors among patients with substance use disorder: Psychiatric history, family history, ...etc.
| To identify the common risk factors among patients with substance use disorder: Psychiatric history, family history, ...etc.
| To identify the common risk factors among patients with substance use disorder: Psychiatric history, family history, ...etc.
| To identify the common risk factors among patients with substance use disorder: Psychiatric history, family history, ...etc.
| To identify the common risk factors among patients with substance use disorder: Psychiatric history, family history, ...etc.
| To identify the common risk factors among patients with substance use disorder: Psychiatric history, family history, ...etc.
| To identify the common risk factors among patients with subst"
753,"[/INST]
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
f"
754,"[/INST]
S
A
A
A
A
A
A
A
A
A
A
A
A










































































































































































































































































































0



0


























































































































0
0
0
0
0






ive







O
0
0
0
0
CT
O
C
C
C
C
CT
CT
C
0
C
C"
755,"[/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Centre Hospitalier: [/INST]
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Keywords: [/INST]
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Volunteers: [/INST]
Extremity arterial structure and hemodynamic changes by high-frequency ultrasound examination.
Volunteers: [/INST"
756,"[/INST]
|
| A slight bleeding
|
|
| A slight bleeding the mouth|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
==.|
==.|
==.
==.
in
There.
There.
in
in
in
in
in
There.
There.
There.
There,
There,
There,
There,
It
It
It.
It
It.
It
It
It.
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
It
This
This
This
This
This
In
This
In
In
The
In
In
In
In
In
In
In
In
In
In
In
In
This
This
This
This
This
This"
757,"[/INST]
|
|
Symmeters.
|
|
|
|
|
|
|
Symmeters.
Sympt
Sympt
|
|
|
Symmeters.
|
Sympt
Symmeters.
Sympt
|
|
|
|
|
|
|
Symic|
Symic|
Symic|
Symic|
Symic|
|
|
|
|
Symic|
Symic|
|
|
|
Symic|
|
|
|
|
|
The|
The|
The|
The symptles.|
|
|
|
The mind.
The brain.
The brain.
The brain.
There.|
The|
The mind.
The pain.
The brain.
The brain.
The brain.
The brain.
The brain.
The
The
The
The psych
It.
It
==|                
==|                
==|                .
It
It.
It.
It.
It.
It
It
It
It
It
It
It
It
It
It
It
It
We
We
We
We
It
It
It
It
It
in
in
in
in
in
in
in
in
in
in
It
It
It
in
in
in
This
We
We
We
in
in
in
in
in
in
in
in
in
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
==
==
==
==
==
==
==
==.
This
This
This
This
This
This
This
This
This
This
This
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
It
It
It
It
It
It
It
It
It
It
It
It
It
It
The
The
It
It"
758,"[/INST]

Cardiac Sarcoidosis
Cardiac sarcoidosis is a rare disease that affects the heart. It is characterized by the formation of granulomas in the myocardium, which are areas of abnormal growth of cells that look like grains of sand. These granulomas can cause the heart to become enlarged and heavy, and may interfere with its normal function. Cardiac sarcoidosis can lead to symptoms such as shortness of breath, fatigue, and swelling in the legs and ankles. It can also cause irregular heart rhythms, known as arrhythmias.
Cardiac sarcoidosis is most commonly diagnosed using 64CuDOTATATE PET/CT scanning, which allows imaging of the myocardium with 64CuDOTATATE PET/CT. This non-invasive imaging technique uses a low-energy tracer to determine whether the myocardium is being affected by cardiac sarcoidosis.
Cardiac sarcoidosis can also cause neurological symptoms, which can manifest as shortness, fatigue, swelling in the legs and ankles.
Cardiac sarcoidosis can also cause symptoms such as shortness, fatigue, and swelling in the legs and ankles.
Cardiac sarcoidosis is most commonly diagnosed using 64CuDOTATATE PET/CT, which allows imaging of the myocardium.
Cardiac sarcoidosis is most commonly diagnosed using 64CuDOTATATE PET/CT, which allows imaging of the myocardium.
Cardiac sarcoidosis most commonly diagnose using 64CuD, which allows imaging of the myocardism.
Cardiac sarcoidosis most commonly diagnosis using 64C, which allows imaging.
Cardiac sarcoidosis most commonly diagnosis.
Cardiac sarcoidosis most commonly diagnosis.
Cardiac sarcoidosis most commonly diagnosis.
Cardiac sarco.
Cardiac sarco.
Cardiac sarco.
Cardiac symptoms.
Cardiac sarco.
Cardiac diagnosis.
Cardiac sarco.
Cardiac diagnosis.
Cardiac symptoms."
759,"[/INST]
Primary Outcome: [Inflammatory Biomarkers]
Secondary Outcome: [Renal Transplantation]
Treatment of inflammatory biomarkers including TNF, IFN, IL-6, MMP, and TGF with probiotics.
Other: [Renal Transplantation]
Primary Outcome: [Inflammatory Biomarkers]
Secondary Outcome: [Renal Transplantation]
Other: [Inflammatory Biomarkers]
Primary Outcome: [Renal Transplantation]
Secondary Outcome: [Inflammatory Biomarkers]
Other: [Renal Transplantation]
Primary Outcome: [Inflammatory Biomarkers]
Secondary Outcome: [Renal Transplantation]
Other: [Inflammatory Biomarkers]
Primary Outcome: [Renal Transplantation]
Secondary Outcome: [Inflammatory Biomarkers]
Other: [Renal Transplantation]
Primary Outcome: [Inflammatory Biomarkers]
Secondary Outcome: [Renal Transplantation]
Other: [Inflammatory Biomarkers]
Primary Outcome: [Renal Transplantation]
Secondary Outcome: [Inflammatory Biomarkers]
Other: [Renal Transplantation]
Primary Outcome: [Inflammatory Biomarkers]
Secondary Outcome: [Renal Transplantation]
Other: [Inflammatory Biomarkers]
Primary Outcome: [Renal Transplantation]
Secondary Outcome: [Inflammatory Biomarkers]
Other: [Renal Transplantation]
Primary Outcome: [Inflammatory Biomarkers]
Secondary Outcome: [Renal Transplantation]
Other: [Inflammatory Biomarkers]
Primary Outcome: [Renal Transplantation]
Secondary Outcome: [Inflammatory Biomarkers]
Other: [Renal Transplantation]
Primary Outcome: [Inflammatory Biomarkers]
Secondary Outcome: [Renal"
760,"[/INST]
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
P
P
S
P
P
P
P
P
P
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S"
761,"[/INST]
----------------
SS
SS
SS
SS
SS
A
A
A
mass
mass
mass
mass
mass
mass
mass
SS
SS
SS
SS
SS
SS
SS
SS
mass
mass
mass
mass
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
SS
----------------
----------------
----------------
----------------
----------------
----------------
--------
--------
The"
762,"[/INST]

Secondary Outcome Measures
-----------------
How is the study designed?
| Number of participants in the study | 16 years old or older Ages: 16-24 years old, single, never married, no children, no interest in injection treatment (open to men and women) | Other: Holistic, injection treatment, including peer navigation and aftercare
| Primary outcome measures include: (1) Diagnosis and treatment of injection-related infections; (2) Participants will be offered a one-stop, holistic approach to address their addiction; (3) Peer navigation and aftercare; (4) Other. | No specifics, please.
How is the study designed?
| Number of participants in the study: 16 years old or older Ages: 18-24 years old, single, never married, no children Ages: 16-24 years old, no interest in injection treatment; Other: Holistic, including aftercare and peer navigation. | Within 6 months of initial treatment, program enrolment, and after completing the intended course of antibiotics.
| Primary outcome measures include: (1) Diagnosis and treatment of injection-related infections; (2) Participants will be offered a one-stop, holistic approach to address their addiction; (3) Peer navigation and aftercare; (4) Other. | No specifics, please.
How is the study designed?
| Number of participants in the study: 16 years old or older Ages: 24-year-old, single, no interest in injection treatment; Other: Holistic, including aftercare and peer navigation. | Primary outcome measures include: (1) Diagnosis and treatment of injection-related infections; (2) Participants will be offered a one-stop, holistic approach to address their addiction; (3) Peer navigation and aftercare; (4) Other. | No specifics, please.
How is the study designed?
| Number of participants in the study: 16 years old or older Ages: 24-year-old, single, no interest in injection treatment; Other: Holistic, including aftercare and peer navigation. | Primary outcome measures include: (1) Diagnosis and treatment of injection-related infections"
763,"[/INST]

Participants
| Primary Outcome |
| Secondary Outcome |
| Tertiary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - - |
| Primary Outcome |
| Secondary Outcome |
| - - - -"
764,[/INST]PCMCMCMCPCMCMCMCMCMCMCMCMCMCMCMCMCCCCCCCCCCCCMCMCMCMCMCMCMCMCMCCCMCMCMCMCMCMCMCMCMCMCMCCCCMCCCCDrCDrCDrCDrCDrCMCMC-.P-.-.-.-.-.-.-.-.-.-.-.Dr-.-.M-.M-.MCMCM-.M-.-.-.-.-.EXEM-.Dr-.Em-.Em-.-.-.-.-.-.-.-.-M-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.M-.M-.M-.C-.C-.C-.C-.C-.C-.C-.C-.-.-.C-.C-.-M-M-P-ME-A-a-.-a-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.P-.C-.C-.P-.P-.-.-.-.-.-.-.-.-.X-.C9XC-.-.-.-.C-.-.C-..C9.C-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-a-a-.-ME-.-.-.-.-.-.-.9999-.-.-.-.-.-.-.-a-.-a-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.99999949444444949-.-.-.-.-.49499-a.-a-a.-a.1.1.14949999999-.-.-.-.-.-.-.1492999999999-.-.-.-.-.-..19111414149499999999999.9.1.1.99
765,"[/INST]
Primary Outcome: Comfort
Secondary Outcome Measure: Anxiety
Tertiary Outcome Measure: Pain
How is the study designed?
What is the primary purpose of the study?
How is the study designed?
How is the study measured?
How is the study designed?
How is the study measured?
How is the study designed?
How is the study measured?
How is the study designed?
How is the study measured?
How is the study designed?
How is the study measured?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is the study designed?
How is"
766,"[/INST]
| Other names: general anesthesia, surgical procedure<br>* Procedure: per-oral endoscopic myotomy<br>* Patients with normal autonomic function<br> 
| Achalasia patients without autonomic dysfunction in the heart rate variability test performed preoperatively. |
| Other names: general anesthesia, surgical procedure<br>* Procedure: per-oral endoscopic myotomy<br>* Patients with normal autonomic function<br> 
| Achalasia patients without autonomic dysfunction in the heart rate variability test performed preoperatively. |
| Other names: general anesthesia, surgical procedure<br>* Patients with normal autonomic function<br> 
| Achalasia patients without autonomic dysfunction in the heart rate variability test performed preoperatively. |
| Wobble of SAP will be calculated according to the following formula. Performance Error (PEi, i = 1, 2, 3, N) = measured SAP  100/reference SAP. |
| Other names: general anesthesia, surgical procedure<br>* Patients with normal autonomic function<br> 
| Achalasia patients without autonomic dysfunction in the heart rate variability test performed preoperatively. |
| Wobble of SAP will be calculated according to the following formula. Performance Error (PEi, i = 1, 2, 3, N) = measured SAP  100/reference SAP. |
| Other names: general anesthesia, surgical procedure<br>* Patients with normal autonomic function<br> 
| Achalasia patients without autonomic dysfunction in the heart rate variability test performed preoperatively. |
| Wobble of SAP will be calculated according to the following formula. Performance Error (PEi, i = 1, 2, 3, N) = measured SAP  100/reference SAP. |
| Other names: general anesthesia, surgical procedure<br>* Patients with normal autonomic function<br> 
| Achalasia patients without autonomic dysfunction in the heart rate variability test performed preoperatively"
767,"[/INST]
==
==
This
This
This
and
and
This
This
This
This
This
This
This
This
This
This
This
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
The
This
This
This
This
This
This
==
==
==
==0
==00000
==
==
==
==
==
==
==
==
==
This
This
This
This
This
This
==
==
==
==
==
==8
==8
==9
This
This
==8
==
==
==
==
This
==
==
The
The
The
The
A
A






























==
==
==
==
==
==












==
==
==




==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
------------
------------
------------
------------
------------
/>
0
A
A
A
















































































s
A
A
A









A
s
A
A
A
A
A
A

















































-
-



0
0
0
0






0
0
0"
768,"[/INST]
| 1. Provided by the therapist. | 2. Treatment completion at 12 weeks. | 6. | A self-report on the child and parent. | 12. | 10. | 6 months after the treatment. | 12. | 12. | 1. | 1.
| 1. | 1.
| 1.
| 1. Provided by the therapist. | 12. | 12. | 1.
| 1. 1. 1. 1. 1. 2. 1. 1. 1. 1. 1. 2. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
The psych.
The, the psychiat
Ther.
The parent
The parent
The parent
A."
769,"[/INST]
The,
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
D
D
This
This
This
This
This
This
This
This
This
D
This
The
The
The
The
The
The
F
F
F
F
F
F









S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S"
770,"[/INST]

Behavioral Problems
-----------------
Active Comparator: [/INST]
Behavioral Problems
-----------------
Primary Outcome: [/INST]
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavioral Problems
Active Comparator: [/INST]
Patient Health Status
Behavior"
771,"[/INST]
This.
This
This
This
This
A
This.
This.
A.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
in
in
This
This
f
This
This
f
f
This
This
This
This
This
in
This
This
f
This
f
f
f
f
f
This
in
in
A
A
A
S
S
S
S
This
S
S
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
S
S
S
in
comple
comple
comple
comple
in
in
in
S
S
S
in






























































































































































































A
A
A"
772,"[/INST]
| Terms related to the study, High flow nasal cannism, and the incidence of the infant, and the nasal oxygen, and the intubation, and the incidence of the infant, and the nasal preoxic, and pediatrics, and the incidence of the infant.
|s parents, and the incidence of the infant nasal preoperative incubator status.
|s parents, and the infant.
|s parents.
|s condition.
|s parents.
|s parents.
|s parents.
|s parents.
|s parents.
|s parents.
|s parents.
|s parents.
|s parents.
|s parents.
|s parents.
|s parents.
|s parents.|s parents.|s parents.|s parents.
|s parents.
|s parents.|s parents.|s parents.|s parents.|s parents.|s parents.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|s.|
The surgical|s.|
The surgery.|s.|
The patient.
The patient.
The patient.|s surgery.|.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The surgery.
The patient.
The patient.
The patient.
The patient.
The surgery.
The surgery.
The surgery.
The surgery.
The process.
The surgere
The surgery.
The process.
The, this.
The, this.
The process.
The process.
The.
The.
The process
The
The|this
The, this
The, this
The, it
The, a
The, //
This"
773,"[/INST]































































O
O
O
O
O





O
O
O
O
O
O DO
O











O D
D
D
DO DO DO DO DO DO D	


 D
 D
 D
 D
 D
 D
 D
 D
 D





 D
 D
 D
 h D
 hO hO DO DO DO DO D					
		
 DO DO DO D DO DO DO DO
	











	                 DO DO DO DO D							
	
					,  , 
   
   
																																															O DO DO	O		O DO D																																																																				 D	 D	  D	  D	  D	 D	 D	 D  D  D  D - DO DO D D D	 D	 D																								      D"
774,"[/INST]
, and
, physical activity.
, and
, and
, and
, and
, and
, and it to the second.
, physical.
, and it.
, and it.
, and it.  It.  It.  It.
, and
, second.
, and it.
, second.
The second.
The second.
The second.
This will be
This will be
This will be
This will,
There will
There will
There will
2
2
2
This will
This will
This will
This will
This will
This will be
This will be
This will be
This will be
This will be
This will be
This will
This will be
This will be
This will be
This will be
This will be
This will
==
==
==
==
The second.
This will be
This,
This,
The initial-like
The results.
The results.
The
This will be
This,
This will be
This will
This will be
The study.
This.
This.
This.
This.
This.
This.
This.
==
==
==
==
==
==
This   
This.
This.
This.
This.
This.
This.
This.
This   
This|
This|
==
==
==.
==
This
This
This>,
This>,
==
==
==
==
==
==
This U-turn
This U-turn
This U-turn
This U-turn
This U
This U
This U.
This U
This U.
This U-
This U
This
This
This
This
This
This
This U
This U
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This
This
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
775,"[/INST]

Primary Outcome Measurements: [/INST]
Secondary Outcome Measurements
-----------------
Exercise: Aerobic, with use of sleeping medication, Antenatal depression, Primigravida females, the use of sleeping medications, the symptoms of depression, the Pittsburgh Sleep Quality Scale (PSQI) was used to measure sleep quality. This scale consists of seven areas including: subjective sleep quality, sleep latency, sleep duration, and daytime dysfunction (disturbances to sleeping medication, the use of sleeping medications). Higher scores indicate poorer sleep quality. Scoring of answers was based on a scale of 0 to 3 (total score of 21).
Other: Aerobic exercises, Antenatal depression, the symptoms of depression, the use of sleeping medications, the Pittsburgh Sleep Quality Scale (PSQI) was used to measure sleep quality. This tool consists of seven areas including: subjective sleep quality, sleep latency, sleep duration, and daytime dysfunction (the use of sleeping medications, the symptoms of depression) | 8 weeks | 

Exclusion Criteria: [/INST]
Primary Outcome Measurements: [/INST]
Secondary Outcome Measurements: [/INST]
Exercise: Aerobic, Antenatal depression, the symptoms of depression, the use of sleeping medications, the Pittsburgh Sleep Quality Scale (PSQI) was used to measure sleep quality. This tool consists of seven areas including: subjective sleep quality, sleep latency, sleep duration, and daytime dysfunction (the use of sleeping medications, the symptoms of depression) | 8 weeks | 

Primary Outcome Measurements: [/INST]
Secondary Outcome Measurements: [/INST]
Exercise: Aerobic, Antenatal depression, the symptoms of depression, the use of sleeping medications, the Pittsburgh Sleep Quality Scale (PSQI) was used to measure sleep quality. This tool consists of seven areas including: subjective sleep quality, sleep latency, sleep duration, and daytime dysfunction (the use of sleeping medications,"
776,"[/INST]

Other: [/INST]
Accepts Healthy Volunteers
| the control group<br>swaddled and made to inhale mother's breast milk odour<br>the 2nd experimental group were both swaddled and made to inhale mother's breast milk odour<br>Infants in the control group were laid under a radiant heater for the insertion of peripheral intravenous catheter.

Other: [/INST]
Accepts Healthy Volunteers
| the control group<br>swaddled and made to inhale mother's breast milk odour<br>the 2nd experimental group were swaddled and made to inhale mother's breast milk odour<br>Infants in the control group (Inhaling mother's breast milk odour) were laid under a radiant heater for the insertion of peripheral intravenous catheter.

Other: [/INST]
Accepts Healthy Volunteers
| the control group<br>swaddled and made to inhale mother's breast milk odour<br>the 2nd experimental group were swaddled and made to inhale mother's breast milk odour<br>Infants in the control group (Inhaling mother's breast milk odour) were laid under a radiant heater for the insertion of peripheral intravenous catheter.

Other: [/INST]
Accepts Healthy Volunteers
| the control group<br>swaddled and made to inhale mother's breast milk odour<br>the 2nd experimental group were swaddled and made to inhale mother's breast milk odour<br>Infants in the control group (Inhaling mother's breast milk odour) were laid under a radiant heater for the insertion of peripheral intravenous catheter."
777,"[/INST]
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
==
==
==
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
A
A
A
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
S
This
This
This
This
This
This
This
This
This
This
This
S
S
S
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
P
The
The
P
P
P
This
This
This
This
This
This
P
P
P
The
The
This
This
This
This
This
This
This
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
P
P
P
The
The
The
The
The
The
The
The
The
The
The
The
P-
P-
A
The
The
The
The
The
The
The
The
P-
P-
P-
P-
A
A
A
A
A
A"
778,"[/INST]
Primary Outcome Measure | To assess the sensitivity of systemic injection of 1111In-panitumab for identifying sentinel lymph nodes | Will compare the sensitivity of panitumab for identifying sentinel lymph nodes. | Up to five years | 
Primary Outcome of systemic injection of 1111In-panitumab.
| Will compare the sensitivity of sentinel lymon.
| Will assess the sensitivity of 11111.
Primary Outcome of 1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"
779,"[/INST]
Generalized Anxiety Disorder
-----------------
Primary Purpose: To evaluate the effectiveness of transcutaneous vagus nerve stimulation in the treatment of Generalized Anxiety Disorder.
Participants: Patients diagnosed with Generalized Anxiety Disorder.
Exclusion Criteria: Patients who are currently participating in vagus nerve stimulation, those who are planning to become pregnant, those who are breastfeeding, and those who have organic brain lesions.
Intervention: Transcutaneous vagus nerve stimulation.
Comparison: medication-combined sham stimulation.
Outcome Measures: Changes in the Hamilton Anxiety Scale.
* Changes in the Generalized Anxiety Scale at Baseline and Week 2 of the treatment.
* Incidence of adverse events.
* Transcutaneous vagus nerve stimulation is an experimental intervention.
* medication-combined sham stimulation is an intervention commonly used in clinical practice.
* Those who are planning to become pregnant, those who are breastfeeding, and those with organic brain lesions are excluded from this study.
* Changes in the Generalized Anxiety Scale at Baseline and Week 2 of the treatment.
* medication-combined sham stimulation is an intervention commonly used in clinical practice.
* Those who are participating in vagus nerve stimulation, those who are planning to become pregnant, and those with organic brain lesions are excluded from this study.
* Changes in the Generalized Anxiety Scale at Baseline and Week 2 of the treatment.
* medication-combined sham stimulation is an intervention commonly used in clinical practice.
* Those who are planning to become pregnant, those who are breastfeeding, and those with organic brain lesions are excluded from this study.
* Changes in the Generalized Anxiety Scale at Baseline and Week 2 of the treatment.
* medication-combined sham stimulation is an intervention commonly used in clinical practice.
* Those who are planning to become pregnant, those who are breastfeeding, and those with organic brain lesions are excluded from this study."
780,"[/INST]
Other Outcome Measures
| Primary Outcome Measure: Cumulative success rate of DLDO within 2 years of follow-up of the study. | Secondary Outcome Measure: Cumulative success rate of Dacryoendoscopy within 2 years of follow-up of the study. | Tertiary Outcome Measure: Quality of life of patients undergoing Dacryoendoscopy. | Time Frame: 2 years | 
Adverse Events/Serious Adverse Events
| Primary Outcome Measure: Cumulative incidence of Dacryoendoscopy within 2 years of follow-up of the study. | Secondary Outcome Measure: Cumulative incidence of patients undergoing laser dacryoplasty within 2 years of follow-up of the study. | Tertiary Outcome Measure: Quality of life of patients undergoing laser endoscopy. | Time Frame: 2 years | 
Secondary Outcome Measures: Cumulative incidence of patients undergoing laser dacryoplasty within 2 years of follow-up of the study. | Primary Outcome Measure: Cumulative incidence of Dacryoendoscopy within 2 years of follow-up of the study. | Secondary Outcome Measure: Quality of life of patients undergoing laser endoscopy. | Time Frame: 2 years | 
Secondary Outcome Measure: Cumulative incidence of patients undergoing laser dacryoplasty within 2 years of follow-up of the study. | Primary Outcome Measure: Cumulative incidence of Dacryoendoscopy within 2 years of follow-up of the study. | Secondary Outcome Measure: Quality of life of patients undergoing laser endoscopy. | Time Frame: 2 years | 
Secondary Outcome Measure: Cumulative incidence of patients undergoing laser dacryoplasty within 2 years of follow-up of the study. | Primary Outcome Measure: Cumulative incidence of patients undergoing laser endoscopy. | Primary Outcome Measure: Cumulative incidence of the study. | Primary Outcome: laser endoscopy. | Secondary Outcome: Cum lacr"
781,"[/INST]
The.
This.
This.
It's.
This.
It.
It.
It.
This.
This.
This.
This.
in.
in.
in.
in.
in.
in.
In
in
In
in
in
in
in
in
in
This
This
This
This
This
This
This
by
by
by
in
in
This
It
It
It
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
a
a
a
This
This
This
This
This
This
This
==
==
==
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
in
This
This
This
in
in
in
in
This
This
This
This
This
This
This
==
==
==
==
==
This
This
This
This
This
This
This
This
==
==
==
==
==
This
This
This
This
This
This
This
This
This
This
This
This
A
A
A


A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
gm





















































==
==
==
==
==
==
------------
------------
------------
------------
--------
------------
------------
------------
mil
==
mil




mil



































































00"
782,"[/INST]
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
8
This
8
8







This
This
This
This
This
This
This
This
This
This
This
This
This
This
This





This
This
This"
783,"[/INST]

Device: Implantable STARGRAFT-3 shunt for hemodialysis access.
Primary Purpose: To evaluate the effect of STARGRAFT-3 on survival at 1 and 2 years post implantation.
Secondary Outcome Measures: Survival of STARGRAFT-3 shunt. Frequency of interventions related to the use of STARGRAFT-3.
Experimental: Implantation of STARGRAFT-3 shunt.
Time Frame: 1, 2, 4, 6, 9, and 12 months post implantation.
Interventions: Frequency of interventions related to the use of STARGRAFT-3 shunt.
Data provided by Centre Hospitalier Valida.
Outcome Measures: Survival of STARGRAFT-3 shunt.
Device: Implantable STARGRAFT-3 shunt.
Time Frame: 1, 2, 4, 6, 9, and 12 months post implantation | 
Secondary Outcome Measures: Survival of STARGRAFT-3 shunt.
Data provided by Centre Hospitalier Valida.
Interventions: Frequency of interventions related to the use of STARGRAFT-3 shunt.
Time Frame: 1, 2, 4, 6, 9, and 12 months post implantation | 
Outcome Measures: Survival of STARGRAFT-3 shunt.
Data provided by Centre Hospitalier Valida.
Interventions: Frequency of interventions related to the use of STARGRAFT-3 shunt.
Time Frame: 1, 2, 4, 6, 9, and 12 months post implantation | 
Secondary Outcome Measures: Survival of STARGRAFT-3 shunt.
Data provided by Centre Hospitalier Valida.
Interventions: Frequency of interventions related to the use of STARGRAFT-3 shunt.
Time Frame: 1, 2, 4, 6, 9, and 12 months post implantation | 
Outcome Measures"
784,"[/INST]
C"
785,"[/INST]
It's.
There.
There.
There are.
In.
There.
There.
There.
In.
In.
In.
In.
In.
In.
In.
In.
It.
In.
In.
The treatment.
The treatment.
This.
This.
This.
It's.
This.
This.
The.
In.
It.
It.
It's.
This.
This.
This.
This.
This.
In.
In.
In.
In.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This   
This
This
This
This
This
In
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
A
A
A
This
This
This
This
This
This
A
This
This
This"
786,"[/INST]0-s-h-h-h-h-h-h-h-h-0-000000-0-h-h-h-in-in-in-in-in-in-in-in-in-s,-in-in-in-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-a-a-a,,,,,,-h-h-h-h-h-h-h-h-h-0-000-0-h-h-h-h-h-h--0-0-0000000000000--h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-h-
-
-- D- D-h-h-h-h-h-h-h-
-
-----h-h---h-h-h-h-h-h-h-h-h-h-h-h-h-D- D-D- A D-D- A D-D-D-D-D-D-D-D-D-D-D-D-D-D-D-D-D-D-D-D-D in D-D-D-D- D-y D-y D-D-- D- D- D-
 D-
 D- D-
 D
 D
 D
 D
 D
 D
 D
 D- D- D- D- D- D- D- D- D- D- D- D-
 D- D- D- D- D- D- D- D- D8 D8 D8 D8 D-
 D-
 D-"
787,"[/INST]
A
A
A
P
P
P
P
P








A
A
A
A
A
A
A
A
A
S
S



A
A
A
A
A
A
A
A
A
A
A




A
A
A
A
A






-
-
A
A
A
be-
-
-
-
-
-
-
-
-
-
-
-
-


be-
be-
be-
be-
be-









be-
be-
be-
be-
be-
be-
be
be-
be-
be-
be-
be-
be-
be-
be-
be-
-
-
-
be-
be-
be-
be-
be-
be-
be-
be-
be-
be-
be-
be-
be-
A





















































































A
A
A
A
A-
A
A
A
A
A
A
A
A
A-
A
A
A
A
A
A
A
A
A
A
A-
A-
A-
A-
A-
A-
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A
A
A
h
h
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A"
788,"[/INST]

Secondary Outcome Measures
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------"
789,"[/INST]
| Eligible for Study
| Keywords related to the study
| Participant will be hospitalized for the study
| Participant will be hospitalized for the study
| Eligible for the study
| Participant will be hospitalized for the study
| Participant will be hospitalized for the study
| Eligible for the study
| Participant will be hospitalized for the study
| Participant will be hospitalized for the study
| Participant will be hospitalized for the study
| Participant will be hospitalized for the study
| Participant will be hospitalized for the study
| Participant will be hospitalized for the study
| Eligible for the study
| Participant will be hospitalized for the study
| Participant will be hospitalized for the study
| Participant will be hospitalized for the study
| Participant will be hospitalized for the study
| Eligible will be hospitalized for the study will be hospitalized for the study will be hospitalized for the study
| Participant will be hospitalized for the study will be hospitalized for the study will be hospitalized for the study will be hospitalized for the study will be hospitalized for the study will be hospitalized for the study will be hospitalized for the study
| Participant will be hospital
| Participant will be hospital
| Participant will be hospitalized
| Part
| Part
| Part
| Part
| Part
| Part
| Treatment
|
|
Treat the
|
Tre
|
|
|
|
Tre.
Tre.
Tre.
Tre.
Tre.
Tre mental health
Tre medicine
Tre medication| year.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre.
Tre
Tre
Tre
Tre.
Tre.
Tre.
====*
Tre.
Tre.
Tre*
Tre
in
in*
in*
in*
These
Tre
These
These
These
These
====*
====*
====*
in*
in"
790,"[/INST]

Peripheral Neuropathy
| Breast Cancer
| Paclitaxel
| Peripheral neuropathy
| Chemotherapy-induced nausea and vomiting
| Cancer treatment
| Biopsy-induced neuropathy
| Oncology group
| Paclitaxel
| Peripheral neuropathy
| Chemotherapy-induced nausea and vomiting
| Biopsy-induced neuropathy
| Cancer treatment
| Oncology group
| Paclitaxel
| Peripheral neuropathy
| Chemotherapy-induced nausea and vomiting
| Biopsy-induced neuropathy
| Cancer treatment
| Peripheral neuropathy
| Paclitaxel
| Chemotherapy-induced nausea and vomiting
| Biopsy-induced neuropathy
| Oncology group
| Peripheral neuropathy
| Paclitaxel
| Chemotherapy-induced nausea and vomiting
| Biopsy-induced neuropathy
| Cancer treatment
| Peripheral neuropathy
| Paclitaxel
| Chemotherapy-induced nausea and vomiting
| Biopsy-induced neuropathy
| Oncology group
| Peripheral neuropathy
| Paclitaxel
| Chemotherapy-induced nausea and vomiting
| Biopsy-induced neuropathy
| Cancer treatment
| Peripheral neuropathy
| Paclitaxel
| Chemotherapy-induced nausea and vomiting
| Biopsy-induced neuropathy
| Oncology group
| Peripheral neuropathy
| Paclitaxel
| Chemotherapy-induced nausea and vomiting
| Biopsy-induced neuropathy
| Cancer treatment
| Peripheral neuropathy
| Paclitaxel
| Chemotherapy-induced nausea and vomiting
| Biopsy-induced neuropathy
| Oncology group
| Peripheral neuropathy"
791,"[/INST]

Experimental Group
| Comparison Group | Controlled Experiment | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the drug | Comparison of the"
792,"[/INST]

Adverse events are any unfavorable effects that may occur as a result of receiving the study drug.
Common adverse events of ciclosporin include nephrotoxicity, hepato-toxicity, and hematopoietic system disorders.
Less common adverse events of AVA include symptoms of hyperglycemia, hypoglycemia, and symptoms of thrombocytopenia or neutropenia.
Uncommon adverse events of ciclosporin include gastrointestinal bleeding, hyperpigmentation, and hepato-toxicity.
More common adverse events of AVA include symptoms of hypoglycemia, neutropenia, and symptoms of thrombocytopenia or symptoms of hyperpigmentation.
Very common adverse events of ciclosporin include symptoms of hepato-toxicity, nephrotoxicity, and symptoms of hyperglycemia or symptoms of thrombocytopenia.
Common adverse events of AVA include symptoms of hypoglycemia, hyperpigmentation, and symptoms of neutropenia or symptoms of thrombocytopenia.
Less common adverse events of ciclosporin include symptoms of gastrointestinal bleeding, hyperpigmentation, and symptoms of hepato-toxicity or symptoms of thrombocytopenia.
More common adverse events of AVA include symptoms of hypoglycemia, hyperpigmentation, and symptoms of neutropenia or symptoms of thrombocytopenia.
Common adverse events of ciclosporin include symptoms of hepato-toxicity, hyperpigmentation, and symptoms of neutropenia or symptoms of thrombocytopenia.
Less common adverse events of AVA include symptoms of hypoglycemia, hyperpigmentation, and symptoms of thrombocytopenia or symptoms of neutropenia.
Common adverse events of ciclosporin include symptoms of hepato-toxicity, hyperpigmentation, and symptoms of thrombocytopenia.
Less common adverse events of AVA"
793,"[/INST]

How is the study designed?
| Primary Purpose: To assess the sensitivity of 89Zr-panitumumab | Secondary Outcome Measures: The specificity of 89Zr-panitumumab will be compared to the specificity of standard of care imaging modalities, including MRI, CT, and/or 18F-FDG PET/CT. | Up to 7 years | 
| Primary Purpose: To assess the sensitivity of 89Zr-panitumumab | Secondary Outcome Measures: The specificity of 89Zr-panitumumab will be compared to the specificity of standard of care imaging modalities, including MRI, CT, and/or 18F-FDG PET/CT. | Up to 7 years | 

How is the study designed?
| Primary Purpose: To assess the sensitivity of 89Zr-panitumumab | Secondary Outcome Measures: The specificity of 89Zr-panitumumab will be compared to the specificity of standard of care imaging modalities, including MRI, CT, and/or 18F-FDG PET/CT. | Up to 7 years | 
How is the study designed?
| Primary Purpose: To assess the sensitivity of 89Zr-panitumab | Secondary Outcome Measures: The specificity of 89Zr-panitumab will be compared to the specificity of standard of care imaging modalities, including MRI, CT, and/or 18F-FDG PET/CT. | Up to 7 years | 
How is the study designed?
How is the study designed?
How is the sensitivity of 89Zr-panitumab's sensitivity of 89Zr-panitumab's sensitivity of 89Zr-panitumab's sensitivity of 89Zr-panitumab's sensitivity of 89Z.
How is the sensitivity of 89Zr-panitumab's sensitivity of 89Z.
How is the sensitivity of 89Z.
How"
794,"[/INST]


| Prophylactic central neck dissection performed for the ipsilateral lesion |
| control group: prophylactic central neck dissection |
| recurrence: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection |
| control group: prophylactic central neck dissection"
795,"[/INST]
| Over one year follow up, malaria, malaria, Anopheles circumsporters, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria, malaria.
Mal malaria, mal
Mal malaria, mal
Mal malaria, malaria, malaria. malaria. mal
Mal
Mal
Mal. mal
Mal. mal
Mal. mal
Mal. malay,
Mal. mal
Mal.
Mal.
Mal.
Mal.
Mal.
Mal.
There.
There.
There.
There.
There.
There.
There.
There.
There.
As a major.
There.
There.
There.
There.
There.
There.
There.
There.
It.
It.
There.
It.
There.
There.
There.
There.
There.
There.
There.
There
There.
In a>
There.
There
There
There
In.
There
There
There
There
There
There"
796,"[/INST]





-
-
-





-
-
-
-
 a to a to a to a to a to a to a to a to (

























-
-
-
-
-























 a to a to a to a to a to a to a to a to a to a to a to a to a to a to a to to to to to to to to to to to to to to to to to to to to a to a to a to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to a to a to a to a to a to a to a to a to a to a to a to to to a to a to a to a to a to a to a to to to to to to to to to to to to to a to a to a to a to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to a to a to a to a to to to to to to to a to a to a to a to the to the to the to the to the to the to the to the to the to the to the to a to the to the to a to a to the to a to a to a to a to a to a to a to a to a to a to a to a to a to to to to to to to to-D-D-D-D-D-D-Dur-Dur-Dur-Dur-Dur-D-D-D-Dur-Dur-
-y-Dur-Dur-Dur-Dur-e-e,,,,,,,,,,,,,,,,-Fur-S,-Dur-Dur-S to-Dur to the to the to the to a to-Dur-e-st-st-st-re-re-A-re-A-A-Dry-Dry-Dur"
797,"[/INST]

Primary Outcome: [/INST]

Low-level laser, Mini-implants, Deep bite, Root resorption

Keywords: [/INST]

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Keywords: [/INST]

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption

-----------------

Low-level laser, Mini-implants, Deep bite, Root resorption"
798,"[/INST]
Other Outcome Measures
| the study of the anatomical variants of the vessels and the possible effects of the surgical procedure on the patients enrolled in the study. | 6 months
Primary Outcome Measure
| the study of the anatomical variants of the vessels and the possible effects of the surgical procedure on the patients enrolled in the study. | the anatomical variants of the vessels and the possible effects of the surgical procedure on the patients enrolled in the study. | 6 months
Secondary Outcome Measure
Other Outcome Measure
| the anatomical variants of the vessels and the possible effects of the surgical procedure on the patients enrolled in the study. | 6 months
Surgical anastomosis of the vessels and the possible effects of the surgical procedure on the patients enrolled in the study.
| the anatomical variants of the vessels and the possible effects of the surgical procedure on the patients enrolled in the study. | 6 months
Terms related to the study
Right hemicolectomy, Colon cancer, Lymphadenectomy
Secondary Outcome Measure
Other Outcome Measure
| the anatomical variants of the vessels and the possible effects of the surgical procedure on the patients enrolled in the study. | 6 months
Primary Outcome Measure
| the anatomical variants of the vessels and the possible effects of the surgical procedure on the patients enrolled in the study. | the anatomical variants of the vessels and the possible effects of the surgical procedure on the patients enrolled in the study. | 6 months
Secondary Outcome Measure
Other Outcome Measure
| the anatomical variants of the vessels and the possible effects of the surgical procedure on the patients enrolled in the study. | 6 months
Primary Outcome Measure
| the anatomical variants of the vessels and the possible effects of the surgical procedure on the patients enrolled in the study. | the anatomical variants of the vessels and the possible effects of the surgical procedure on the patients enrolled in the study. | 6 months
Other Outcome Measure
| the anatomical variants of the vessels and the possible effects of the surgical procedure on the patients enrolled in the study. | 6 months
Primary Outcome Measure
| the anatomical variants of the"
799,[/INST]
800,"[/INST]
It.
It.
It.
It.
It.
It.
== .
==
==
It.
It.
In.
In.
==
==
==
==
==
==
==
==
==
This.
This
This
This
This
This
This
==
==
==
This
This
This
This
This
This
This
This
This
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This.
This.
This
This
This
This
This
This
This
==
==
==
==
==
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
The
The
The
The
The
This
This
This
This
This
This
This
This
This
This
The
The
This
This
This
This
This
This
This
This
The
The
The
The
The
The
This
The
This
This
The
The
The
The
The
The
The
The
The
This
This
This
This
This
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The"
801,"[/INST]
Primary Inclusion Criteria
-----------------
Age 18 or older
| Sex: Male
| No known history of distal radius malunion
| Known to be pregnant
| No known history of distal radius malunion
| Known to be symptomatic
| No known history of bone grafting
| Known to be cost effective
| Active Comparator: Bone grafting, open wedge osteotomy, and plate fixation
| Known to be symptomatic
| Cost effectiveness analysis, Quality of life, objective functional outcomes, and known to be subjective
| Known to be pregnant
| No known history of distal radius malunion
| Known to be cost effective
| Active Comparator: Bone grafting, open wedge osteotomy, and plate fixation
| Known to be symptomatic
| Cost effectiveness analysis, objective functional outcomes, Quality of life, and known to be subjective
| Known to be pregnant
| Known to be cost effective
Secondary Exclusion Criteria
| Known to be symptomatic
| Active Comparator: Bone grafting, open wedge osteotomy, and plate fixation
| Known to be cost effective
| Known to be symptomatic
| Objective functional outcomes, Quality of life, and known to be subjective
| Known to be pregnant
| Cost effectiveness analysis, objective functional outcomes, Quality of life, and known to be subjective
| Known to be cost effective
Secondary Outcome Measures
Time Frame: [/INST]
| Known to be symptomatic
| Active Comparator: Bone grafting, open wedge osteotomy, and plate fixation
| Known to be cost effective
| Objective functional outcomes, Quality of life, and known to be subjective
| Known to be pregnant
| Cost effectiveness analysis, objective functional outcomes, Quality of life, and known to be subjective
| Known to be cost effective
Secondary Outcome Measures
| Known to be symptomatic
| Active Comparator: Bone grafting, open wedge osteotomy, and plate fixation
| Known"
802,[/INST] 10000000999999usticlelausticleustorneyoisteroisteroisteroisteroisteroisteroisteroisteroightneyightneyightneyoisteroisteroightneyoightneydydydydydydydydydydydydydydydydyoisteroisteroightoightoustoustoustousticleousticleusticleustoustoustoustoustoustolaustorustorustoustoustoustoustustustusticleusticleustorustorustousticleousticleousticleneyusticledydayustidaydayusticledydyusticledyulidaydydydydydydydydydydydydydydydydydydydydydydyustoustorustorightoightoightustainustainidaydyustidaydyightdyightdyightulightulightlylustulightlydydydydydyulightulightdylaustulustorustorustoightoightoightoightoightoightoightoightdayightdayightulightulightidaydyightidaydyightidaydyightidaydyneightdaydyneightdaydyneightiddustightustustightustiddustainneightustaindyneightustainustainustainustainightainightaindyustainustainustainustaindyustainobainobainidainidainidesystemainidainidainidustaindyustaindyustaindydydydydydydyidesystemidesystemidesystemdyidesystemidesystemainightaindydyaindyaindyaindyaindyaindyainainainorainightainightainightainightainightainogustorainidainidulidustorainidulustorainorainidulightainustainightainightainightainightainainightainidainidainidainidainustainustainustainustainightoightocialustocialustoiduliduldyoidulightoidaindyneightoightoidentainidainidainidainidainightoidustainightidulidulidustidaindydydydyidainidainidainidulidainidainidain
803,"[/INST]
|
Key words
Virtual reality
Virtual reality
Virtual reality
|
Keywords
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Keywords
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual reality
Virtual
Virtual reality
Virtual
Virtual reality
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
The
The
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
The
The
The
The
It
It
It
It
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
Virtual
The
==
The
This
==
==
In
In
In
In
In
The
The
In
In
In
In
In
S
S
S
S
S
S
S
S
S
Ang
Ang
S
This
This
This
M
In"
804,[/INST]
805,"[/INST]

| PPROM, speculum exam, preterm birth, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes, preterm prelabor neonatal death, preterm prelabor rupture of membranes,"
806,"[/INST]
Primary Outcome Measures
| Disease-free survival(OS) | To describe the tumor-free survival in patients with liver cirrhosis with HCC treated with sequential adult left lateral lobe liver transplantation. | 1 month, 3 months, 6 months, 1 year, 2 years after the operation | 
Secondary Outcome Measures
| Disease-free survival(OS) in patients with liver cirrhosis with HCC | 1 month, 3 months, 6 months, 1 year, 2 years after the operation| Liver transplantation, with sequential left lateral lobe liver resection. | Patients with liver cirrhosis with HCC. | Patients with liver transplantation. | The operation.
Primary Outcome Measures
| Disease, liver transplantation. Liver cirrhosis with HCC.
Primary Outcome, the operation|s disease.
Primary Outcome liver transplant operation.
Primary liver disease.
Primary liver disease.
Primary liver disease.
Primary liver disease.
Primary liver.
Primary liver disease.
Primary liver disease.
Primary liver disease.
Primary liver disease.
Primary liver disease. Primary liver disease. Primary liver disease. Primary liver disease. Primary liver.
Primary liver disease. Primary liver disease. Primary liver. Primary liver disease. Primary liver disease. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary liver. Primary. Primary. Primary. Primary. Primary. Primary. Primary. Primary liver. Primary liver. The liver. The liver. The liver.
Primary.
Pr
Pr.
The liver.
In the patients.
The operation.
The.
The.
The.
in.
in.
In the treatment"
807,"[/INST]

How is the study designed?
----------------
| Patient Group | Healthy Volunteers | Diagnostic Test: Dexterity Assessment Tool<br>Measurements of dexterity will be taken in healthy participants at two time points, when the participant is recruited. | Diagnostic Test: Dexterity Assessment Tool<br>Measurements of dexterity will be taken in healthy participants at one time point, when the participant is recruited. | Dexterity will be assessed in healthy participants at two time points, once when the participant is recruited. | Diagnostic Test: Dexterity Assessment Tool<br>Measurements of dexterity will be taken in healthy participants at two time points, when the participant is recruited. | Diagnostic Test: Dexterity Assessment Tool<br>Measurements of dexterity will be taken in healthy participants at two time points, when the participant is recruited. | Dexterity will be assessed in healthy participants at two time points, once when the participant is recruited. | Diagnostic Test: Dexterity Assessment Tool<br>Measurements of dexterity will be taken in healthy participants at two time points, when the participant is recruited. | Diagnostic Test: Dexterity Assessment Tool<br>Measurements of dexterity will be taken in healthy participants at two time points, when the participant is recruited. | Diagnostic Test: Dexterity Assessment Tool<br>Measurements of dexterity will be taken in healthy participants at two time points, when the participant is recruited. | Diagnostic Test: Dexterity Assessment Tool<br>Measurements of dexterity will be taken in healthy participants at two time points, when the participant is recruited. | Diagnostic Test: Dexterity Assessment Tool<br>Measurements of dexterity will be taken in healthy participants at two time points, when the participant is recruited. | Diagnostic Test: Dexterity Assessment Tool<br>Measurements of dexterity will be taken in healthy participants at two time points, when the participant"
808,"[/INST]

How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Decentration of intraocular lens (IOL) (mm) | 4 m | Visit 1 | 
| Monocular uncorrected distance visual acuity (UCDVA) (66 cm) | 1 | 
| Manifest refraction/Manifest refraction spherical equivalent (MRSE) (D) | 1 | 

Terms related to the study

Primary Outcome Measures
| Participant Group/Arm | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Decentration of intraocular lens (IOL) (mm) | 4 m | Visit 1 | 
| Monocular uncorrected distance visual acuity (UCDVA) (66 cm) | 1 | 
| Manifest refraction/Manifest refraction spherical equivalent (MRSE) | 1 | 

Secondary Outcome Measures
What is the study designed to measure?
| Participant Group/Arm | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Decentration of intraocular lens (IOL) (mm) | 4 m | Visit 1 | 
| Monocular uncorrected distance visual acuity (UCDVA) (D) | 1 | 
| Manifest refraction/Manifest refraction spherical equivalent (MRSE) | 1 | 

Terms related to the study

How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Decentration of intraocular lens (IOL) (mm) | 4 m | Visit 1 | 
| Monocular uncorrected distance visual acuity (UCDVA) (66 cm) | 1 | 
| Manifest refraction"
809,"[/INST]
Breast Diseases
Mastectomy and axillary lymph node dissection, Serratus posterior superior interfascial plane block
Primary Purpose: To compare the effects of mastectomy and axillary lymph node dissection on postoperative pain scores. | Secondary Purpose: To evaluate the dermatomal coverage of SPSIPB in Group S. The dermatomal coverage will be evaluated with a pinprick test. | Postoperative 1st hour | 
Serratus posterior superior interfascial plane block, Breast Diseases
Primary Purpose: To compare the effects of mastectomy and axillary lymph node dissection on postoperative pain scores. | Secondary Purpose: To evaluate the dermatomal coverage of SPSIPB in Group S. The dermatomal coverage will be evaluated with a pinprick test. | Postoperative 1st hour | 
Serratus posterior superior interfascial plane block, Breast Diseases
Primary Purpose: To compare the effects of mastectomy and axillary lymph node dissection on postoperative pain scores. | Secondary Purpose: To evaluate the dermatomal coverage of SPSIPB in Group S. The dermatomal coverage will be evaluated with a pinprick test. | Postoperative 1st hour | 
Serratus posterior superior interfascial plane block, Breast Disease the dermatology and axillary lymph. | Secondary Purpose: To compare the effects of maste, Serratus. | Postoperative 1sthe serratus. |
Primary Purpose: To compare the effects of maste, Serratus. | Secondary Purpose: To compare the effects of maste, Serr. | Primary Purpose: To compare the serr. | Serr. Secondary effects. | Serr.
Primary Purpose: To compare the effects. Serr. Serr. Secondary effects.
Primary Purpose: Serr. Serr. Serr. Secondary effects. Serr. Serr. Serr. Serr. Secondary effects. Serr. Serr. Serr. Serr. Serr. Serr. Serr. Serr. Serr. Serr. Secondary Serr."
810,"[/INST]
Other relevant information: [/INST]"
811,"[/INST]

| Terminology used in this study |
| Provided by: Centre Hospitalier de Valence |
| Transplantation: July 2021 |
| Patient #1 |
| Aged 65 |
| No known risk factors |
| Survived 4 years |
| Transplantation failure: July 2021 |
| Patient #2 |
| Heart failure: July 2021 |
| Patient #3 |
| Survived 4 years |
| Transplantation failure: July 2021 |
| Patient #4 |
| Heart failure: July 2021 |
| Patient #5 |
| Survived 4 years |
| Transplantation: July 2021 |
| Patient #6 |
| Heart failure: July 2021 |
| Patient #7 |
| Survived 4 years |
| Transplantation: July 2021 |
| Patient #8 |
| Heart failure: July 2021 |
| Patient #9 |
| Survived 4 years |
| Transplantation: July 2021 |
| Patient #10 |
| Heart failure: July 2021 |
| Patient #11 |
| Survived 4 years |
| Transplantation: July 2021 |
| Patient #12 |
| Heart failure: July 2021 |
| Patient #13 |
| Survived 4 years |
| Transplantation: July 2021 |
| Patient #14 |
| Heart failure: July 2021 |
| Patient #15 |
| Survived 4 years |
| Transplantation: July 2021 |
| Patient #16 |
| Heart failure: July 2021 |
| Patient #17 |
| Survived 4 years |
| Transplantation: July 2021 |
| Patient #18 |
| Heart failure: July 2021 |
| Patient #19 |
| Survived 4 years |"
812,"[/INST]
pelvic floor, urinary incontinence, pelvic floor training, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle training, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle training, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle training, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle training, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle training, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle training, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle training, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle training, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle training, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle training, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incontinence, pelvic floor muscle, urinary incont"
813,"[/INST]

How is the study designed?
-----------------
Alcohol and substance misuse treatment, treatment engagement

Primary Outcome: [/INST]
Behavioral: Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency
Secondary Outcome: [/INST]
Alcohol and substance misuse treatment, treatment engagement
Treatment of alcohol and substance misuse: [/INST]
Behavioral: Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency
Secondary Outcome: [/INST]
Alcohol and substance misuse treatment, treatment engagement
Behavioral: Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency
Primary Outcome: [/INST]
Alcohol and substance misuse treatment, treatment engagement
Behavioral: Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency
Secondary Outcome: [/INST]
Alcohol and substance misuse treatment, treatment engagement
Behavioral: Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse frequency
Primary Outcome: [/INST]
Alcohol and substance misuse treatment, treatment engagement
Behavioral: Community Wise, a multi-level manualized behavioral intervention to decrease alcohol and substance misuse
Secondary Outcome: [/INST. Alcohol and substance misuse treatment, treatment
Behavioral: Community Wise, a multi-level behavioral intervention to decrease alcohol and substance misuse
Primary Outcome: [/INST. Alcohol and substance misuse treatment, treatment
Primary Outcome, behavioral intervention, treatment
Primary Outcome, substance misuse
Behavioral intervention, substance misuse treatment, behavioral intervention
Primary Outcome, substance misuse, alcohol and substance misuse, intervention, behavioral intervention, behavioral substance misuse, substance misuse, substance misuse, behavioral intervention, substance misuse, substance misuse, intervention, behavioral substance misuse, substance misuse"
814,[/INST]
815,"[/INST]
| This is the first group. | Other names: lateral internal sphincterotomy; Procedure: Internal sphincterotomy; Hemorrhoids: Botox injection;|
| This group will undergo hemorrhoidectomy. |
| Other names: Lateral internal sphincterotomy;|
| This group will have botox injection in the internal sphincter.|
| This group will undergo hemorrhoidectomy.|
| Other names: Lateral internal sphincterotomy;|
| This group will have botox injection in the internal sphincter.|
| This group will have hemorrhoidectomy.|
| Other names: Lateral internal sphincterotomy;|
| This group will have botox injection in the internal sphincter.|
| This group will undergo hemorrhoidectomy.|
| Other names: Lateral internal sphincterotomy;|
| This group will have botox injection in the internal sphincter.|
| This group will have hemorrhoidectomy.|
| Other names: Lateral internal sphincterotomy;|
| This group will have botox injection in the internal sphincter.|
| This group will undergo hemorrhoidectomy.|
| Other names: Lateral internal sphincterotomy;|
| This group will have botox injection in the internal sphincter.|
| This group will have hemorrhoidectomy.|
| Other names: Lateral internal sphincterotomy;|
| This group will have botox injection in the internal sphincter.|
| This group will have hemorrhoidectomy.|
| This group will have botox injection in the internal sphincter.|
| Other names: Lateral internal sphincterotomy;|
| This group will have hemorrhoidectomy.|
| This group will have botox injection in the internal sphincter.|
| This group will have hemorrhoidectomy.|
| Other names: Lateral internal sphincterotomy;|
| This group will have botox injection in the internal sphincter.|"
816,"[/INST]

Colorectal cancer, Fruquintinib

Adverse events related to the study:
| Drug: Fruquintinib
Primary Outcome Measure
| To evaluate 2-year disease-free survival rate, and metastasis in patients accepting fruquintinib maintenance therapy.
Secondary Outcome Measures
| Drug: Fruquintinib
Adverse events related to the study:
| Drug: Fruquintinib
Colorectal cancer, Fruquintinib
| Drug: Fruquintinib
Adverse events related to the study:
| Drug: Fruquintinib
Primary Outcome Measure
| To evaluate 2-year disease-free survival rate, and metastasis in patients accepting fruquintinib maintenance therapy.
| Drug: Fruquintinib
Secondary Outcome Measures
| Drug: Fruquintinib
Adverse events related to the study:
| Drug: Fruquintinib
Colorectal cancer, Fruquintinib
| Drug: Fruquintinib
Adverse events related to the study:
| Drug: Fruquintinib
Primary Outcome Measure
| Drug: Fruquintinib
Adverse events related to the study:
| Drug: Fruquintib
| Treatment of the study.
| Drug: Fruquintib.
| Drug: Fruquintib.
| Colorectomy.
| Drug: Fruquintib.
| Drug: Fruquintib.
| Treatment.
| Drug: Fruquintib.
| Drug: Fruquintib.
| Drug: Fruquintib.
| Drug: Fruquintib.
| Treatment.
| Drug.
Colon.
| Treatment.
| Drug.
Colon.
| Drug.
Colon.
Primary Outcome. Drug.
| Treatment. Drug.
| Treatment.
Primary Outcome.
Primary Outcome.
Primary Outcome.
Colon"
817,"[/INST]
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
This
This
This
This
This
This
The
The
The
The
The
The
A
This
In
in
in
in
In
In
In
In
A
A
A
A
A
A
A
A
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
This
This
This
The
The
The
The



















The
The
The
The
The
The
The
The
The
The









The
The
The
The
The
The
The
The
p"
818,"[/INST]

Terms related to the study
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using continuous thermodilution | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using Youden Index | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using continuous thermodilution | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using Youden Index | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using continuous thermodilution | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using Youden Index | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using continuous thermodilution | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using Youden Index | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using continuous thermodilution | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using Youden Index | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using continuous thermodilution | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using Youden Index | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using continuous thermodilution | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using Youden Index | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using continuous thermodilution | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using Youden Index | 3 months |
| Diagnostic Test: Coronary flow reserve | Diagnostic of microvascular function using continuous thermodilution | 3 months |
| Diagnostic Test: Coronary flow"
819,"[/INST]
A
M
M
M
M
M
M
A
A
A




A
A
M
M
M
M
M
M
M
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
a
a
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
h
h
A
A
A
A
h
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A



















































A

A"
820,"[/INST]

Adverse Events
| --- |
| Irritable bowel syndrome patients with diarrhea-predominant irritable bowel syndrome |
| Participation Criteria: Patients with diarrhea-predominant irritable bowel syndrome |
| Exclusion Criteria: Patients with diarrhea-predominant irritable bowel syndrome |
| Inclusion Criteria: Patients with diarrhea-predominant irritable bowel syndrome |
| Exclusion Criteria: Patients with diarrhea-predominant irritable bowel syndrome |
| Participation Criteria: Patients with diarrhea-predominant irritable bowel syndrome |
| Inclusion/Exclusion Criteria: Patients with diarrhea-predominant irritable bowel syndrome |
| Exclusion/Inclusion Criteria: Patients with diarrhea-predominant irritable bowel syndrome |
| Outcome Measure: Fecal microbiome |
| Outcome: Fecal microbiota |
| Symptoms: Irritable bowel syndrome |
| Outcome: Fecal microbiome |
| Symptoms: Irritable bowel syndrome |
| Outcome: Fecal microbiome |
| Symptoms: Irritable bowel syndrome |
| Outcome: Fecal microbiome |
| Symptoms: Irritable bowel syndrome |
| Outcome: Fecal microbiome |
| Symptoms: Irritable bowel syndrome |
| Outcome: Fecal microbiome |
| Symptoms: Irritable bowel syndrome |
| Outcome: Fecal microbiome |
| Symptoms: Irritable bowel syndrome |
| Outcome: Fecal microbiome |
| Symptoms: Irritable bowel syndrome |
| Outcome: Fecal microbiome |
| Symptoms: Irritable bowel syndrome |
| Outcome: Fecal microbiome |
| Symptoms: Irritable bowel syndrome |
| Outcome: Fecal microbiome |"
821,"[/INST]

Other relevant terms:
-----------------
Primary Purpose: Other
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Proportion of patients who filled Bricanyl Rx change | Proportion of patients who filled Bricanyl Rx change within 30 days of the clinic | 30 days |
| Rate of patients who filled Bricanyl Rx change within 30 days | 30 days |
| Proportion of patients who changed inhalers for environmental reasons | Proportion of patients who filled Bricanyl Rx change within 30 days | 30 days |
| Patients' willingness to change inhalers for environmental reasons | Patients' willingness to change inhalers for environmental reasons |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Patients' willingness to change inhalers for environmental reasons | Patients' willingness to change inhalers for environmental reasons |
| Proportion of patients who filled Bricanyl Rx change | Proportion of patients who filled Bricanyl Rx change within 30 days | 30 days |
| Patients' willingness to change inhalers for environmental reasons | Patients' willingness to change inhalers for environmental reasons |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Patients' willingness to change inhalers for environmental reasons | Patients' willingness to change inhalers for environmental reasons |
| Proportion of patients who filled Bricanyl Rx change | Proportion of patients who filled Bricanyl Rx change within 30 days | 30 days |
| Patients' willingness to change inhalers for environmental reasons | Patients' willingness to change inhalers for environmental reasons |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Patients' willingness to change inhalers for environmental reasons | Patients' willingness to change inhalers for environmental reasons |
| Proportion of patients who filled Bricanyl Rx change | Proportion of patients who filled Bricanyl"
822,"[/INST]
h
h
h
h
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
h
A
A
h
h
h
h
h
A
A
A
A
h
hO
h
hC
hO
A
A
A
A
A
h
A
h
h
h
h
A
A
A
A
A
A


A
A
A
A
A
A
A
A
A
R
O
R"
823,"[/INST]
|s.
|s.
|s.
|s.
|s.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Cancer.
Essy.
E.
Cancer.
Cancer.
Can be treated.
Cancer.
THE.
These diseable.
This.
The symptoms.
There.
There.
There.
There.
In their
In their
As a severe.
as a significant.
As
As a
In
These.
These.
These.
as
as
as
As
As
As
As a|as
These as a|
As aSS
As a|
As a|
As a|
This.
These
This will
a
a|
This.
This
This
This
This
This
This
This
This
These
This
This
As
As
This
This
As
a
a
a
a
a
a
This
This
As
As
As
As
As
As
As
As
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
A
a
a
a
a
a
a
a
This
This
This
This
This
This
This
This
a
a
This
This
a
This
This
a
a
a
a
a
a
by
by
by
by
by
by
by
by
by
by
by"
824,"[/INST]

Results from the systematic review of the use of neoadjuvant chemotherapy and Trastuzumab in patients with HER2-positive breast cancer.

How is the study designed?
| Participants receiving neoadjuvant chemotherapy and Trastuzumab<br>* Drug: Trastuzumab was given at dosage of either 4mg/kg or 8mg/kg at mostly a weekly interval (but differs among the different studies)<br>|
How is the study measuring results?
| Pathological Complete Response (pCR) was the absence of invasive cancer in the breast and lymph nodes at 5 years | Drug: Trastuzumab was given at dosage of either 4mg/kg or 8mg/kg at mostly a weekly interval (but differs among the different studies)"
825,"[/INST]
The program.
The program.
The program.
The program.
The program.
The program.
The benefits.
These two.
The results.
The Chat.
The program.
The program.
This program.
This.
These.
This.
The.
The program.
The program.
These.
These.
This.
The program.
The program.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
These.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
Thomas.
This.
This.
This.
This.
This.
This.
This.
This
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This.
This.
The.
This.
This.
This.
This.
This.
This.
This.
The.
The.
This.
This.
This.
This.
This.
This.
The.
The.
This
This
This
This
This
be
be
This
This
be
be
be
be
This
This
This
This
This
be
be"
826,"[/INST]
Progressive Muscle Relaxation Exercises (PMRE) were developed by the researcher and were given to the patients in this group. The importance of regular exercise was explained to the patients, and they were asked whether they continued the exercises during the study period.
Primary Intervention: [/INST]
Secondary Prevention of COPD was developed by the researcher and was given to the patients in this group. The importance of regular exercise was explained to the patients, and correct exercise technique was taught.
Secondary Prevention of Asthma was developed by the researcher and was given to the patients in this group. The patients were asked whether they continued the exercises during the study period.
Tertiary Prevention of COPD was developed by the researcher and was given to the patients in this group. The importance of regular exercise was explained to the patients, and correct exercise technique was taught.
Primary Prevention of Asthma was developed by the researcher and was given to the patients in this group. The patients were asked whether they continued the exercises during the study period.
Secondary Prevention of COPD was developed by the researcher and was given to the patients in this group. The importance of regular exercise was explained to the patients, and correct exercise technique was taught.
Primary Prevention of Asthma was developed by the researcher and was given to the patients in this group. The patients were asked whether they continued the exercises during the study period.
Primary Prevention of COPD was developed by the researcher and was given to the patients in this group. The importance of regular exercise was explained to the patients, and correct exercise technique was taught.
Secondary Prevention of Asthma was developed by the researcher and was given to the patients in this group. The patients were asked whether they continued the exercises during the study period.
Primary Prevention of COPD was developed by the researcher and was given to the patients in this group. The importance of regular exercise was explained to the patients, and correct exercise technique was taught.
Primary Prevention of Asthma was developed by the researcher and was given to the patients in this group. The patients were asked whether they continued the exercises during the study period.
Primary Prevention of COPD was developed by the researcher and was given to the patients in this group. The importance of"
827,"[/INST]
| Diagnostic accuracy of UFR in predicting functionally significant coronary stenosis at the patient level, using FFR as the reference standard | Diagnostic accuracy is defined as the proportion of UFFR (0.80 or >0.80) in vessels with hemodynamically significant stenosis as measured by FFR (FFR 0.80); specificity is defined as the proportion of UFFR >0.80 in patients without hemodynamically significant stenosis as measured by FFR (FFR 0.80). | Immediately after the procedure | 
| Sensitivity is defined as the proportion of UFFR (0.80 or >0.80) to identify hemodynamically significant coronary stenosis at the patient level, using FFR as the reference standard | Diagnostic accuracy is defined as the proportion of UFFR (0.80 or >0.80) to identify hemodynamically significant coronary stenosis at the vessel level, using FFR as the reference standard | Immediately after the procedure | 
| Sensitivity is defined as the proportion of UFFR (0.80 or >0.80) to identify hemodynamically significant coronary stenosis at the patient level, using FFR as the reference standard | Diagnostic accuracy is defined as the proportion of UFFR (0.80 or >0.80) in vessels with hemodynamically significant stenosis as measured by FFR (FFR 0.80). | Immediately after the procedure | 
| Diagnostic accuracy of UFR in predicting functionally significant coronary stenosis at the patient level, using FFR as the reference standard | Diagnostic accuracy is defined as the proportion of UFFR (0.80 or >0.80) in vessels with hemodynamically significant stenosis as measured by FFR (FFR 0.80). | Immediately after the procedure | 
Primary Outcome Measures
| Diagnostic accuracy of UFR in predicting functionally significant coronary stenosis at the patient level, using FFR as the reference standard | Diagnostic accuracy is defined as the proportion of UFFR (0.80 or >0.80) in"
828,"[/INST]

Primary Purpose: [/INST]

Secondary Outcome Measures
| Maslach Burnout Inventory-Human Services Survey (MBI-HSS) subscale emotional exhaustion (MBI-EE; 9 items), depersonalization (DP; 5 items), and personal accomplishment (PA; 8 items). The scoring range for each item is 0 (never felt) to 6 (felt every day). The first time for participants in both groups was assessed the MBI-PA questionnaire at baseline. | Maslach Burnout Inventory-Human Services Survey (MBI-HSS) subscale depersonalization (MBI-EE; 9 items), depersonalization (DP; 5 items), and personal accomplishment (PA; 8 items). The scoring range for each item is 0 (never felt) to 6 (felt every day)."
829,"[/INST]

How is the study designed?
-----------------
| Primary Purpose: To determine whether acupuncture is effective in treating SARS-CoV-2 infection in people with long-term abstinence from alcohol. | Secondary Purpose: To determine whether acupuncture is effective in treating SARS-CoV-2 infection in people with long-term abstinence from alcohol. | Experimental: Acupuncture and TCM-based lifestyle management for people with SARS-CoV-2 infection. |
| Experimental: Acupuncture and TCM-based lifestyle management for people with long-term abstinence from alcohol. |
| Inclusion Criteria: Participants will be current drinkers of alcohol. |
| Experimental: Acupuncture and TCM-based lifestyle management for people with SARS-CoV-2 infection. |
| Secondary Outcome Measures: Psychological outcomes include depression, anxiety, and cognitive function. |
| Primary Purpose: To determine whether cognitive behavioral therapy is effective in treating SARS-CoV-2 infection in people with long-term abstinence from alcohol. | Secondary Purpose: To determine whether acupuncture is effective in treating SARS-CoV-2 infection in people with long-term abstinence from alcohol. |
| Experimental: Acupuncture and TCM-based lifestyle management for people with SARS-CoV-2 infection. |
| Inclusion Criteria: Participants will be current drinkers of alcohol. |
| Experimental: Acupuncture and TCM-based lifestyle management for people with SARS-CoV-2 infection. |
| Primary Purpose: To determine whether cognitive behavioral therapy is effective in treating SARS-CoV-2 infection in people with long-term abstinence from alcohol. | Secondary Purpose: To determine whether acupuncture is effective in treating SARS-CoV-2 infection in people with long-term abstinence from alcohol. |
| Primary Purpose: To determine whether cognitive behavioral"
830,"[/INST]

Other: [cancer, relapsed/refractory]

Primary Outcome Measure
| Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Patient Demographics (Sex) | Patient Demographics (Ethnicity) | Approximately 24 months | 
| Patient Demographics (Type of Cancer) | Type of Cancer | Approximately 24 months | 
| Patient Demographics (Age) | Age |
| Patient Demographics (Placement of Orders) | Placement Within Orders | Approximately 24 months | 
| Patient Demographics (Cancer, Ethnicity) | Cancer, Ethnicity |
| Patient Demographics (Type of Cancer) | Type of Cancer |
| Patient Demographics (Age) | Age |
| Patient Demographics (Cancer, Ethnicity) | Cancer, Ethnicity |
| Patient Demographics (Type of Cancer) | Type of Cancer |
| Patient Demographics (Placement of Orders) | Placement Within Orders | Approximately 24 months | 
| Patient Demographics (Age) | Age |
| Patient Demographics (Cancer, Ethnicity) | Cancer, Ethnicity |
| Patient Demographics (Type of Cancer) | Type of Cancer |
| Patient Demographics (Age) | Age |
| Patient Demographics (Cancer, Ethnicity) | Cancer, Ethnicity |
| Patient Demographics (Type of Cancer) | Type of Cancer |
| Patient Demographics (Placement of Orders) | Placement Within Orders | Approximately 24 months | 
| Patient Demographics (Age) | Age |
| Patient Demographics (Cancer, Ethnicity) | Cancer, Ethnicity |
| Patient Demographics (Type of Cancer) | Type of Cancer |
| Patient Demographics (Age) | Age |
| Patient Demographics (Cancer, Ethnicity) | Cancer, Ethnicity |
| Patient Demographics"
831,"[/INST]
Behavioral: Cognitive Stimulation Therapy, Dementia, Apathy, Anxiety, Loneliness, Geriatric Anxiety Scale, Activities of Daily Living, Standardized Mini Mental Test, Cognitive Stimulation Therapy, Dementia, Apathy, Anxiety, Loneliness, Geriatric Anxiety Scale, Cognitive Stimulation Therapy, Dementia, Apathy, Anxiety, Loneliness, Geriatric Anxiety Scale, Cognitive Stimulation Therapy, Dementia, Apathy, Anxiety, Loneliness, Geriatric Anxiety Scale, Cognitive Stimulation Therapy, Dementia, Apathy, Anxiety, Loneliness, Geriatric Anxiety Scale, Cognitive Stimulation Therapy, Dementia, Apathy, Anxiety, Loneliness, Geriatric Anxiety Scale, Cognitive Stimulation Therapy, Dementia, Apathy, Anxiety, Loneliness, Geriatric Anxiety Scale, Cognitive Stimulation Therapy, Dementia, Apathy, Anxiety, Loneliness, Cognitive Stimulation Therapy, Dementia, Apathy, Anxiety, Geriatric Anxiety, Apathy, Dementia, Apathy, Anxiety, Cognitive Stimulation Therapy, Dementia, Apathy, Anxiety, Apathy, Dementia, Apathy, Anxiety, Geriatric Anxiety, Apathy, Anxiety, Apathy, Geriatric Anxiety, Apathy, Anxiety, Apathy, Apathy, Anxiety, Apathy, Apathy, Anxiety, Apathy, Geriatric Anxiety, Anxiety, Anxiety, Apathy, Geriatric Anxiety, Apathy, Anxiety, Apathy, Anxiety, Geriatric Anxiety, Anxiety, Anxiety, Anxiety, Anxiety, Anxiety, Anxiety, Anxiety, Anxiety, Anxiety, Anxiety, Anxiety, Anxiety, An"
832,"[/INST]
Acceptance of the study
Primary Purpose: To determine the effect of counselling on the behaviours of the study population related to early diagnosis of breast cancer.
Secondary Purpose: To determine the effect of counselling on the study population related to breast cancer.
Tertiary Purpose: To determine the effect of counselling on the behaviours of the study population related to breast cancer, symptoms of breast cancer, screening programmes and feedback.
Experimental Group: A randomised controlled experimental study.
Inclusion Criteria: Female administrative staff working at Mersin University who accept to be a part of the study and have previously been diagnosed with breast cancer.
Experimental Group: A randomised controlled experimental study.
Masking: This is a randomised controlled experimental study.
Behaviours: This is a 5-question form consisting of information on the subject consulted, the number of consultations, the status of the referral and the outcome.
Time Frame: 6 months |
Healthy Lifestyle Behaviours: This is a 6-question form consisting of the titles of 'health responsibility', physical activity, nutrition, interpersonal relationships and stress management.
Outcome Measure: The outcome of the study will be the number of referrals to health institutions after the counselling.
Counselling: This is a 1-hour counselling session.
Secondary Outcome Measure: To determine the effect of counselling on the behaviours of the study population related to breast cancer, symptoms of breast cancer, screening programmes and feedback.
Tertiary Outcome Measure: This is a 1-hour counselling session.
Experimental Group: A randomised controlled experimental study.
Behaviours: This is a 5-question form consisting of information on the subject consulted, the number of consultations, the status of the referral and the outcome.
Time Frame: 6 months |
Outcome: This is a 1-hour counselling session.
Masking: This is a randomised controlled experimental study.
Behaviours: This is a 5-question form consisting of information on the subject consulted, the number of consultations, the status of the referral and the outcome.
Time Frame: 6 months"
833,"[/INST]
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
The
The
The
The
The
This
This
This

























The
The"
834,"[/INST]

Follow Up
-----------------
Experimental group received 50 g mangrove sword each day during 15 days. Control group consumed 50 g sword each day during 15 days.

Adverse events
-----------------
Follow Up: Balanced diet consumed by both groups.
Experimental group received 50 g mangrove sword each day during 15 days. Control group consumed 50 g sword each day during 15 days.

Other names: Balanced diet consumed by both groups.

Final Results
-----------------
Mangrove sword bean food bar on the weight of older people
Primary Purpose: Prevention of landslide disaster, control group consumed sword food bar each day.
Secondary Purpose: Balanced diet of older people, control group consumed sword each day.
Other names: Balanced diet consumed by both groups.
Final Results: The treatment group received 50 g mangrove sword each day during 15 days.

Other names: Balanced diet consumed by both groups.
Final Results: The treatment group received 50 g mangrove sword each day during 15 days.

Primary Purpose: Prevention of landslide disaster, control group consumed 50 g sword each day during 15 days.
Other names: Balanced diet consumed by both groups.
Final Results: The treatment group received 50 g mangrove sword each day during 15 days.

Secondary Outcome Measures
-----------------
Experimental group received 50 g mangrove sword each day during 15 days. Control group consumed 50 g sword each day during 15 days.
Other names: Balanced diet consumed by both groups.
Final Results: The treatment group received 50 g mangrove sword each day during 15 days.

Primary Purpose: Prevention of landslide disaster, control group consumed 50 g sword each day during 15 days.
Other names: Balanced diet consumed by both groups.
Final Results: The treatment group received 50 g mangrove sword each day during 15 days.

Primary Purpose: Prevention of landslide disaster, control group consumed 50"
835,"[/INST]


Pain Management: [/INST]
-----------------

| Other: No intervention."
836,"[/INST]
| Primary Outcome: Percentage of participants with clinical success after one treatment cycle of TARA-002 compared to baseline | 8 weeks after last injection | 32 weeks after last injection |
| Secondary Outcome: Percentage of participants with clinical success after one treatment cycle of TARA-002 compared to baseline | 8 weeks after last injection | 32 weeks after last injection |
| Primary Outcome: Percentage of participants with clinical success after one treatment cycle of TARA-002 compared to baseline | 8 weeks after last injection | 32 weeks after last injection |
| Secondary Outcome: Proportion of participants with macrocystic LM or mixed cystic LM with clinical success after one treatment cycle of TARA-002 compared to baseline | 8 weeks after last injection | 32 weeks after last injection |
| Primary Outcome: Percentage of participants with clinical success after one treatment cycle of TARA-002 compared to baseline | 8 weeks after last injection | 32 weeks after last injection |
| Secondary Outcome: Proportion of participants with macrocystic LM or mixed cystic LM with clinical success after one treatment cycle of TARA-002 compared to baseline | 8 weeks after last injection | 32 weeks after last injection |
| Primary Outcome: Percentage of participants with clinical success after one treatment cycle of TARA-002 compared to baseline | 8 weeks after last injection | 32 weeks after last injection |
| Secondary Outcome: Proportion of participants with macrocystic LM or mixed cystic LM with clinical success after one treatment cycle of TARA-002 compared to baseline | 8 weeks after last injection | 32 weeks after last injection |
| Primary Outcome: Percentage of participants with clinical success after one treatment cycle of TARA-002 compared to baseline | 8 weeks after last injection | 32 weeks after last injection |
| Secondary Outcome: Proportion of participants with macrocystic LM or mixed cystic LM with clinical success after one treatment cycle of TARA-002 compared"
837,"[/INST]
| Type 2 DM, Chiglitazar, Randomized, Double-blind, Placebo, Combined with metformin and sitagliptin, with the exception of the baseline | 
| Type 2 DM, Chiglitazar, Randomized, Placebo, Combined with metformin and sitagliptin, with the exception of the baseline | 
| Type 2 DM, Chiglitazar, Randomized, Placebo, Combined with metformin and sitagliptin, with the exception of the baseline | 
| Type 2 DM, Chiglitazone, Randomized, combined with metformin, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the exception of the baseline, with the baseline, the baseline, the exception the baseline, with the baseline, with the baseline, with the exception.
|s baseline, with the baseline, the baseline, with the baseline, with the baseline, the baseline.
|s baseline.
|s baseline.
|s baseline.
|s baseline.
Chigline the baseline.
|s baseline.
Chol.
The baseline.
The baseline.
Chigline.
The baseline.
Chig.
The baseline.
The baseline.
Basia.
Basement.
Chigline.
Basement.
Basement.
The baseline.
The baseline.
The baseline.
The baseline.
The baseline.
Chig.
The treatment.
Chig.
The treatment.
The treatment.
The baseline.
The basement.
The basement.
The treatment.
The patients.
The treatment.
The patients.
The patients.
The"
838,"[/INST]
The







































































































































































































































































































































































-





















































































-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-"
839,"[/INST]
A
C
The
A
C
D
D
D


















A
A
A
A
A
A
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D



























































































































































































































































































8









8




8
8
8
8
8




























8
8
8"
840,"[/INST]

Adverse Events
| --- |
| Active Comparator: cartilage regeneration technique<br>35 patient will have knee arthroscopy and high tibial osteotomy | Procedure: cartilage regeneration technique<br>* autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu<br>|

How is the study designed?
| Eligibility Criteria: cartilage regeneration technique<br>35 patient will have knee arthroscopy and high tibial osteotomy | Procedure: cartilage regeneration technique<br>* autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu<br>|

How is the study designed?
| Primary Purpose: cartilage regeneration technique<br>35 patient will have knee arthroscopy and high tibial osteotomy | Procedure: cartilage regeneration technique<br>* autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu<br>|

How is the study designed?
| Eligibility Criteria: cartilage regeneration technique<br>35 patient will have knee arthroscopy and high tibial osteotomy | Procedure: cartilage regeneration technique<br>* autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu<br>|

How is the study designed?
| Primary Purpose: cartilage regeneration technique<br>35 patient will have knee arthroscopy and high tibial osteotomy | Procedure: cartilage regeneration technique<br>* autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu<br>|

How is the study measuring?
| Primary Purpose: cartilage regeneration technique<br>35 patient will have knee arthroscopy and high tibial osteotomy | Procedure: cartilage regeneration technique<br>* autologous adipose t"
841,"[/INST]
Primary Outcome Measurements
-----------------
Secondary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Exercise training, Performance, Cardiometabolic health, Immune response
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measurements
Exercise training, Performance, Cardiometabolic health, Body composition
Primary Outcome Measure"
842,"[/INST]
The brain.
The brain.
The brain.
There, it.
There, it.
The patients.
The patients.
The presence.
The presence.
The treatment.
The treatment.
The treatment.
In the treatment.
The psych.
The.
The psych.
The psych.
There, it.
There, it.
The psych
The, it.
There, it.
There, it.
There, it.
There, it.
There, it.
There
There
There
There, it.
There, it.
There, it.
This, it,
This.
There, it.
In
In
In
In
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
843,"[/INST]

Risk Factors
-----------------
| Diagnostic Test: Weight-bearing MRI |
| Knee Osteoarthritis |
| Inability to stand for 15 minutes |
| Lateral knee space |

Adverse Events
-----------------

Interventions
| Diagnostic Test: Weight-bearing MRI |
| Knee Osteoarthritis |
| Inability to stand for 15 minutes |
| Lateral knee space |
| Diagnostic Test: Weight-bearing MRI |

Other Important Information
-----------------

Arms and Interventions
| Diagnostic Test: Weight-bearing MRI |
| Knee Osteoarthritis |
| Inability to stand for 15 minutes |
| Lateral knee space |
| Diagnostic Test: Weight-bearing MRI |
| Interventions: Knee Osteoarthritis |
| Lateral knee space |

Other Name
| Diagnostic Test: Weight-bearing MRI |
| Knee Osteoarthritis |
| Inability to stand for 15 minutes |
| Lateral knee space |

Terms related to the study
| Diagnostic Test: Weight-bearing MRI |
| Knee Osteoarthritis |
| Interventions: Knee Osteoarthritis |
| Lateral knee space |

Other Name
| Diagnostic Test: Weight-bearing MRI |
| Knee Osteoarthritis |
| Inability to stand for 15 minutes |
| Lateral knee space |

Adverse Events
| Diagnostic Test: Weight-bearing MRI |
| Knee Osteoarthritis |
| Interventions: Knee Osteoarthritis |
| Lateral knee space |

Other Important Information
-----------------

Arms and Interventions
| Diagnostic Test: Weight-bearing MRI |
| Knee Osteoarthritis |
| Lateral knee space |

Adverse Events
| Diagnostic"
844,[/INST]
845,"[/INST]
A"
846,"[/INST]


























-





-
-


























































































































































-"
847,"[/INST]
| Other: Observational Cohort Study | Incidence rate of new onset HF |
| No intervention given |
| To develop and validate a predictive model for new onset HF |
| Observational cohort used for prediction of incident HF |
| All patients will be followed up at 3, 6, and 9 months |
| No intervention given |
| Other: Observational cohort used for prediction of new onset HF |
| To develop and validate a model for incident HF |
| Incidence rate of new onset HF |
| Observational cohort used for prediction of incident HF |
| No intervention given |
| To develop and validate a model for predicting new onset HF |
| Incidence rate of new onset HF |
| Observational cohort used for prediction of incident HF |
| Other: Observational cohort used for prediction of new onset HF |
| To develop and validate a model for predicting incident HF |
| Incidence rate of new onset HF |
| No intervention given |
| To develop and validate a model for predicting incident HF |
| Observational cohort used for prediction of new onset HF |
| Incidence rate of new onset HF |
| Other: Observational cohort used for prediction of incident HF |
| To develop and validate a model for predicting new onset HF |
| No intervention given |
| To develop and validate a model for predicting incident HF |
| Observational cohort used for prediction of new onset HF |
| Incidence rate of new onset HF |
| Other: Observational cohort used for prediction of incident HF |
| To develop and validate a model for predicting new onset HF |
| No intervention given |
| To develop and validate a model for predicting incident HF |
| Observational cohort used for prediction of new onset HF |
| Incidence rate of new onset HF |
| Other: Observational cohort used for prediction of incident HF |
| To develop and validate a model for predicting new onset HF |
| No intervention given |
| To develop and validate a model for predicting incident HF |
| Observ"
848,"[/INST] Provide details of the study design, including the primary outcome measure(s).
Details of the study design, including the primary outcome measure(s) and time frame(s).
| Other: The study design is a randomized controlled trial. | One year
Details of the study intervention(s), including the primary outcome measure(s) and time frame(s).
| Other: The study intervention(s) include sexual activity, which is measured using the FSFI score. | One year
Details of the study intervention(s), including the primary outcome measure(s) and time frame(s).
| Other: The study intervention(s) include sexual activity, which is measured using the FSFI score. | One year
Details of the study intervention(s), including the primary outcome measure(s) and time frame(s).
| Other: The study intervention(s) include sexual activity, which is measured using the FSFI score. | One year
Details of the study intervention(s), including the primary outcome measure(s) and time frame(s).
| Other: The study intervention(s) include sexual activity, which is measured using the FSFI score. | One year
Details of the study intervention(s), including the primary outcome measure(s) and time frame(s).
| Other: The study intervention(s) include sexual activity, which is measured using the FSFI score. | One year
Details of the study intervention(s), including the primary outcome measure(s) and time frame(s).
| Other: The study intervention(s) include sexual activity, which is measured using the FSFI score. | One year
Details of the study intervention(s), including the primary outcome measure(s) and time frame(s).
| Other: The study intervention(s) include sexual activity, which is measured using the FSFI score. | One year
Details of the study intervention(s), including the primary outcome measure(s) and time frame(s).
| Other: The study intervention(s) include sexual activity, which is measured using the FSFI score. | One year
Details of the study intervention(s), including the primary outcome measure(s) and time frame(s).
| Other: The study intervention(s"
849,"[/INST]
-----------------1
-----------------1
-----------------1
-----------------1
The-1
-----------------1
-----------------1
-----------------1
-----------------1
-----------------1
-----------------1
The-1
-----------------1
-----------------1
-----------------1
-----------------1
The
The-1
The-1
The-1
The-1
The-1
The-1
The-1
The-1
The-1
The-1
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
**
**
**
**
**
**
**
**
**
**
**
==
==
==
==
==
==
==
==
==
==
This.
This.
This.
==
==
==
This
This
This
This
This
This
This
This
**
**
**
**
**
**
**
**
**
**
**
**
*
*
*
*
*
*
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
**
R
P
R
R
P
R
P
R
R
R
R
R
R
P
R
S
S
R
R
S
S
R
P
P
R
P
S
S
S
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P"
850,"[/INST]

How is the study to be analyzed?
-----------------
Data Analysis
| Data | Data collected through the study will be analyzed with ELISA.|
| Data on which the study was performed will be analyzed with ELISA.|
| Data on which the study was completed will be analyzed with ELISA.|
| Other data will require different analysis.|

How are the data to be presented?
| Visualized | The data will be presented in graphs and tables.|
| Other formats may be used, as long as they are able to visualize the information collected.|
How are the data to be interpreted?
| The data will be interpreted according to the study protocol.|
What are the implications of the study findings?
| The study findings will have implications for the prevention of dengue and the monitoring of other flaviviruses.|
Who will be responsible for overseeing the study?
| The study will be overseen by the principal investigator, who will be a physician specializing in dengue.|
What are the risks associated with the study?
| The risks associated with the study were determined through a risk assessment protocol.|
Who will be at risk of developing dengue if they participate in the study?
| People who agree to participate in the study will be at risk of developing dengue.|
What are the risks associated with not participating in the study?
| Not participating in the study will result in missing data.|
How will the study be generalized?
| The study will be generalized according to the data collected.|
How will the study be applied?
| The study will be applied to the prevention of dengue.|
How will the study be applied to other diseases?
| The study may have implications for other diseases, as well.|
How will the study be funded?
| The study will be funded according to the budget approved by the National Health Council.|
How will the study be disseminated?
| The study will be disseminated through the media, including television, radio, and print.|
What are the implications of the study for public policy?
| The study will have implications for public policy, in particular with regard to dengue.|
How will the study be evaluated"
851,"[/INST]

Rapid Testing for SARS-CoV-2 Antigen
-----------------
| Rapid Testing for SARS-CoV-2 Antigen | Time Frame: 6 months |
| Performance Characteristics of the Rapid Tests |
| Sensitivity: 80% (1) | Specificity: 95% (1) |
| Cost per test: $50 (1) |

Rapid Testing for SARS-CoV-2 Antigen
-----------------
| Rapid Testing for SARS-CoV-2 Antigen | Time Frame: 6 months |
| Performance Characteristics of the Rapid Tests |
| Sensitivity: 80% (1) | Specificity: 95% (1) |
| Cost per test: $50 (1) |

Study Population / Eligibility Criteria
-----------------
| The SD Biosensor COVID-19 Ag test kit | Time Frame: 6 months |
| Performance Characteristics of the SD Biosensor compared to the reference standard when used at ports of entry |
| Sexes Eligible for Study: Men and Women |
| The SD Biosensor COVID-19 Ag test kit | Time Frame: 6 months |
| Performance Characteristics of the SD Biosensor compared to the reference standard when used at ports of entry |
| Cost per test: $50 (1) |

Study Population / Eligibility Criteria
-----------------
| The SD Biosensor COVID-19 Ag test kit | Time Frame: 6 months |
| Performance Characteristics of the SD Biosensor compared to the reference standard when used at ports of entry |
| Sexes Eligible for Study: Men and Women |
| The SD Biosensor COVID-19 Ag test kit | Time Frame: 6 months |
| Performance Characteristics of the SD Biosensor compared to the reference standard when used at ports of entry |
| Cost per test: $50 (1) |

Interventions / Treatments
-----------------
| The SD Biosensor COVID-19 Ag test kit | Time Frame: 6 months |
| Performance Characteristics of the SD Biosensor compared to the reference standard when"
852,"[/INST]
This
This
This
This
This
This
This
This
This
to
This
This
This
This
This
to
S






































The
The
The
F
The
The













S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S




S
S









S
S












































S
S
A
A-
A
A



































































































s
A
A
A-














s
s
m-
m-
m-
A-












A-
m-
m-


h-







































s
s
s
A-
m-
A










S
S
S


















S
S
C
A
A
C
A
C
m
m
C"
853,"[/INST]

What is the study measuring?
[/INST]

Primary Outcome Measure
[/INST]

What is the study measuring?
[/INST]

What is the study measuring?
[/INST]

What is the study measuring?
[/INST]

What is the study measuring?
[/INST]

What is the study measuring?
[/INST]

What is the study measuring?
[/INST]

What is the study measuring?
[/INST]

What is the study measuring?
[/INST]

What is the study measuring?
[/INST]

What is the study measuring?
[/INST]

What is the study measuring?
[/INST]

What is the study measuring?
[/INST]
What is the study measuring?
[/INST]
[/INST]
[/INST]
[/TYPE measuring?
[/INST]
[/INST]
[/the study measuring?
[/INST]
[/the study measuring?
[/INST.
[/the study measuring?
[/with the study measuring?/with the study.
[/the study.
[/the study.
[/with the study.
[/with the study.
[/with the study.
[/with the study.
[/with the study.
[/with the study.
[/with the study.
[/with the study.
[/with the study.
[/with the study.
[/with the study.
[/with the study.
[/with the study.
[/with the study.
/with the study.
/with the study.
/with the study.
/with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study.
with the study."
854,"[/INST]

Primary Purpose: Prevention
-----------------
Intervention/Treatment
-----------------
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related to the study
Participant characteristics
Primary Purpose: Prevention
Intervention/Treatment
Terms related"
855,"[/INST]
-----------------
1. Phantom limb pain is a complex problem.
2. Operant conditioning is an effective approach to manage phantom limb pain.
3. Electrodes were placed on the scalp to record brain activity.
4. EEG readings indicate the level of pain.
5. The patient's perception of their pain was assessed with the West Haven Scale.
6. Household chores were not completed.
7. Activities away from home were not included in the assessment.
8. Brain-computer interface is not recommended.
9. Event-related potentials were not recorded.
10. Tactile sense, Instrumental learning, Electroencephalography, Event-related potentials were not assessed.
11. This is a complex problem.
























































































































































































































































































Tre.







Be
Be
Be
Be
Be
Be
Be
Be
Be
Be
Be
Be
Be
Be
Be
Be
Be
Be
Be
Be"
856,"[/INST]
Primary Outcome Measure
| Secondary Outcome Measure | Measure Description | Time Frame |
| Puncture complications after axillary vein catheterization | 2021-10-1 2023-04-30 | 
| Trauma/injury to the thoracic duct during TICU stay | 2021-10-1 2023-04-30 | 
| Traveling to the operating room for invasive hemodynamic monitoring | 2021-10-1 2023-04-30 | 
| Placement of the CVC catheter tip after TICU stay | 2021-10-1 2023-04-30 | 
| Traveling to the operating room for thromboembolism related to the thoracic duct after TICU stay | 2021-10-1 2023-04-30 | 
| Traveling to the operating room for placement of the thoracic duct after TICU stay | 2021-10-1 2023-04-30 | 
| Traveling to the operating room for invasive hemodynamic monitoring | 2021-10-1 2023-04-30 | 
| Traveling to the operating room for thromboembolism related to the thoracic duct after TICU stay | 2021-10-1 2023-04-30 | 
| Traveling to the operating room for placement of the thoracic duct after TICU stay | 2021-10-1 2023-04-30 | 
| Traveling to the operating room for invasive hemodynamic monitoring | 2021-10-1 2023-04-30 | 
| Traveling to the operating room for thromboembolism related to the thoracic duct after TICU stay | 2021-10-1 2"
857,"[/INST]
C
C
C
C
C
C
C
O
O
C
O
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C00000-h-
C
C
C
C
C
C
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A
A
A
A
A
A
A
A
A
A
A
A
A
st-st-st-st-st-st-st-st-st-
A
A-
CT-
A
O
O
O-
CT
A
O
O
O
O
O
O-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st0000-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-"
858,"[/INST]

Accepts Healthy Volunteers
| Primary Purpose: Supportive Care
| Accepts Healthy Volunteers
| Intervention Model: Parallel assignment
| Experimental: RUSI guided ultrasonography imaging<br>on abdomen and diaphragm muscle the transducer was placed perpendicular to the surface of the skin in a transverse plane halfway between the ribs and the lower ribs | Other: device and exercise<br>* cavitation ultrasonography imaging guided exercise
| Primary Purpose: Supportive Care
| Intervention Model: RUSI guided ultrasonography imaging<br>on abdomen and diaphragm muscle the transducer was placed perpendicular to the surface of the skin in a transverse plane halfway between the ribs and the lower ribs | Other: device and exercise<br>* cavitation ultrasonography imaging guided exercise
| Experimental: RUSI guided ultrasonography imaging<br>on abdomen and diaphragm muscle the transducer was placed perpendicular to the surface of the skin in a transverse plane halfway between the ribs and the lower ribs | Other: device and exercise<br>* cavitation ultrasonography imaging guided exercise
| Primary Purpose: Supportive Care
| Intervention Model: RUSI guided ultrasonography imaging<br>on abdomen and diaphragm muscle the transducer was placed perpendicular to the surface of the skin in a transverse plane halfway between the ribs and the lower ribs | Other: device and exercise<br>* cavitation ultrasonography imaging guided exercise
| Primary Purpose: Supportive Care
| Intervention Model: RUSI guided ultrasonography imaging<br>on abdomen and diaphragm muscle the transducer was placed perpendicular to the surface of the skin in a transverse plane halfway between the ribs and the lower ribs | Other: device and exercise<br>* cavitation ultrasonography imaging guided exercise
| Primary Purpose: Supportive Care
| Intervention Model: RUSI guided ultrasonography imaging<br>on abdomen and diaph"
859,"[/INST]

Patient #1: Male, age 58, with ischemic stroke, due to limited studies in search of cryptogenic ischemic stroke (AF), documented by brain imaging (cerebral angioscan, MRI or gadolinium injection)

Other: No history of atrial fibrillation"
860,"[/INST]
A
A
A






















































































































A
A
A
A
A
A



C




































CT"
861,"[/INST] a-st-st-st-st D-st-st-s (-s (-A (-s-h-h-s (-s (-st-R-R-R-R-R-R-st-R-h-st-st-st-s-st-st-st-C-C-st-st-st-s-s-y-y-a-a-y-y-y-y-y-t-t-a-e-A-A-A-e-e-R-R-R-R-R-A-C-A,,,,,,,,,-s-s-e- D-R-a-a-R-R-R-R-R-R-R-s- D- D- D- D- D- D- D- D- D...............-R-C-C... D.... (-C-C-C- D- D- D-C-C-C- D- D- D- D- D- D-D-D-D-D-R-R D-R-R D. D. D. D. D. D-D-D-D-D-D-D-D-D-D-D-D-D-D. D-D. D-D. D-D. D-D. D. D-C D. D- D- D-R-C-D-D-D-R-R D-R D-R D-D-D-D-D- D- D- D- D D D D D D D D ( D ( D ( D ( D ( D-e D-e D-e D-e-e p-e D- ( D- (- (- (- (- (-e-R-R-R-R an. an D. an D. an D. an D-C-C. D. D. D. c. c. c..... (. D-C. D-C-e. c-R. c. c-e. c- c- c. c. c. c-e. c. c. c-e. c-e. c"
862,"[/INST]
Primary symptoms of AR, and 10=6
Primary Rhinosa, 10% of the case, 10% of the nose, and 10% of the nose, 10% of the case, 10% of the nose, 10% of the nose, 10% of the 10% of the nose, 10% of the nose, 10% of the nose, 10% of the nose, 10% of the 10% of the symptoms of the 10% of the 10% of the 10% of the 10% of the 10% of the 10% of the 10% of the 10% of the 10% of the 10% of the 10% of the 10% of the%s symptoms 10% of the% of the 10% of the 10% of the 10% of the 10% of the% of the% of the 10%
10%s symptoms.
10%s symptoms.
10%
2%
Sym disease.
2%
2%
2%
2%
2%
2%
2%
Sym
Sym
Sym syndrome.
Sym syndrome.
Sym
Sym.
Sym
Sym.
Sym
Sym
Sym.
The symptoms.
Sym.
The symptoms.
Sym
Sym.
Sym.
It.
Sym.
The symptoms.
There.
There.
Sym
It.
It.
It.
It.
It.
It.
It.
It.
It.
Q.
Q.
Q.
==
==
It.
It.
It.
It.
It.
It.
It.
It.
It's.
Q
Q
It's.
It.
It.
It.
It.
It.
It.
It's.
It's
It
It
It
It
It
It
It
Q
Q
It
It
It
It
This
This
This
It
It
Q
Q
Q
Q
Q"
863,"[/INST]













































































































































































































































































-
-



























































































































































































|"
864,"[/INST]

How is the study designed?
-----------------
| Summary: [/INST]
| Designed as an open label proof of concept study, using a single center, randomized | 2 years
| Designed as an open label proof of concept study using a single center, randomized | 4 years
| Designed as an open label proof of concept study using a single center, randomized | 2 years
| Designed as an open label proof of concept study using a single center, randomized | 4 years
| Designed as an open label proof of concept study using a single center, randomized | 2 years
| Designed as an open label proof of concept study using a single center, randomized | 4 years
| Designed as an open label proof of concept study using a single center, randomized | 2 years
| Designed as an open label proof of concept study using a single center, randomized | 4 years
| Designed as an open label proof of concept study using a single center, randomized | 2 years
| Designed as an open label proof of concept study using a single center, randomized | 4 years
| Designed as an open label proof of concept study using a single center, randomized | 2 years
| Designed as an open label proof of concept study using a single center, randomized | 4 years
| Designed as an open label proof of concept study using a single center, randomized | 2 years
| Designed as an open label proof of concept study using a single center, randomized | 2 years
| 4 years
| 2 years
| 2 years
| 2 years old proof of concept study using a single center, randomized| 2 years old proof of concept study using a single center, randomized| 2 years old proof of concept study using a single center, randomized| 2 years old proof of randomized proof of random proof of random proof of random proof of random proof of random proof of
| 2 years old proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof of random proof"
865,[/INST]
866,"[/INST]

| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of good quality blastocysts fertilized |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/ICSI cycle |
| Number of women undergoing ovarian stimulation |
| Number of women undergoing IVF/"
867,"[/INST]
Patient diagnosis
Sympt
Patient s.
Patient s.
Patient diagnosis.
Patient
Sympt
Sympt
Sympt
Sympt
Sympt
Symfine.
Symedic.
Sym.
Sym.
Symdom.
Symdom.
Symdom.
Patient.
Sym.
Patient.
Sym.
Sym.
Sym.
Sym.
Sym.
Sym.
Sym.
Patient.
S.
Surg
Surg
Surg
Patient.
It.
It.
It.
It.
It.
It
It
It
It
It
It's mother
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It.
It
It
It
The
The
The
The
The
The
The
The
The
A
It
It
This
It
It
It
This
This
This
It
It
The
The
S
S
S
S
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
This
S"
868,"[/INST]
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |
| somatostatin analogues, neuroendocrine tumor | somatostatin analogues, neuroendocrine tumor |"
869,"[/INST]
This.
This.
This.
This.
This.
This.
This.
This.
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This.
This, this
This, this
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This.
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
870,"[/INST]
Other: [/INST]
Primary Outcome: [/INST]
Other: [/INST]

Secondary Outcome: [/INST]
Other: [/INST]

How is the study designed?
| Design Type: [Institutional Review Board/Single center] | Design Type: [Institutional Review Board/Single center]
| Design: [Institutional Review Board/Single center]
| Design Type: [Institutional Review Board/Single center]
| Design: [Institutional Review Board/Single center]
| Design Type: [Institutional Review Board/Single center]
| Design: [Institutional Review Board/Single center]
| Design Type: [Institutional Review Board/Single center]
| Design: [Institutional Review Board/Single center]
| Design Type: [Institutional Review Board/Single center]
| Design Type: [Institutional Review Board/Single center]
| Design: [Institutional Review Board/Single center]
| Design Type: [Institutional Review Board/Single center]
| Design Type: [Institutional Review Board/Single center]
| Design Type: [Institutional Review Board/Single center]
| Design Type: [Institutional Review Board/Single center]
| Design Type: [Institutional Review Board/Single center]
| Design Type: [Institutional Review Board/Single center]
| Design Type: [Institutional Review Board/Single center]
| Design Type: [Institutional Review Board/Single center]
| Design Type: [Institutionalized people]
| Design Type: [Institutionalized people]
| Mobility, and motor vehicles]
| Mobility, and motor vehicles]
|'s symptoms of multiple sclerosis.|s symptoms, including multiple sclerosis, and symptoms of the brain damage to the brain.|s brain damage to the brain damage to the brain damage to the brain damage to the brain damage to the brain damage to the symptoms, including multiple scleros with multiple scleros with brain damage to the brain damage to the brain damage to the brain.|s symptoms.|s symptoms.|s symptoms. Multiple scleros with brain damage to the symptoms. Multiple symptoms. Multiple scl"
871,"[/INST]
| Secondary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Primary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Secondary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Photograph | Measurement of CLEFT-Q before and after surgery. |
| Health care professionals |
| Secondary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Primary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Health care professionals |
| Secondary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Primary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Secondary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Health care professionals |
| Secondary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Primary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Secondary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Health care professionals |
| Primary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Secondary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Health care professionals |
| Primary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Secondary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Primary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Secondary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Health care professionals |
| Primary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
| Secondary Outcome Measure | Measurement of CLEFT-Q before and after surgery. |
|"
872,"[/INST]
Primary Outcome Measure
| Other: [/INST]
Adverse Events: [/INST]
Comments: [/INST]
* Other: [/INST]
Adverse Events: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]
Comments: [/INST]
* Other: [/INST]"
873,"[/INST]
-


-
A
A
A
A
A
A
















A
A
A
A
A




A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A-
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
-
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A
A
A-
A-
A-
A-
A
A
A
A
A
A
A
A
A
A
A
A
















A







A
A
A
A
A
A
A
A
A
A
A-
A-
A
A
A
A
A
A
A
A
A
A
A-
A
A
A
A-
A
A
A
A
A
A
A
A
A
A
A
A
A
-
A
-
A
0
0
-
-
-
A-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-















-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-f-f-
-
-
-
-
-
-
-
-"
874,[/INST]
875,"[/INST]

| Participant Characteristics | [Institutional Setting]
-----------------
Small Cell Lung Cancer
| Serplulimab plus chemotherapy
| Female, 60 years old, with extensive history of small cell lung cancer
| No history of autoimmune diseases or other cancer
| No previous chemotherapy or immunotherapy
| No previous organ transplantation
| No known contraindications to study drug
| Known pregnancy or breastfeeding
| No known family history of small cell lung cancer
| No known gender or race
| No known prior use of study drug
| No known prior organ transplantation
| No known history of prior use of Serplulimab
| No known pregnancy or breastfeeding
| No known history of autoimmune diseases or other cancers
| No known gender or race
| Known pregnancy or organ transplantation
| No known history of small cell lung cancer
| Serplulimab plus chemotherapy
| Female, 60 years old, with extensive history of small cell lung cancer
| No known pregnancy or breastfeeding
| No known family history of autoimmune diseases or other cancers
| No known history of organ transplantation
| Serplulimab plus chemotherapy
| Female, 60 years old, with extensive history of small cell lung cancer
| No known pregnancy or breastfeeding
| No known history of autoimmune diseases or other cancers
| Known pregnancy or organ transplantation
| Serplulimab plus chemotherapy
| Female, 60 years old, with extensive history of small cell lung cancer
| No known gender or race
| No known family history of autoimmune diseases or other cancers
| Serplulimab plus chemotherapy
| Female, 60 years old, with extensive history of small cell lung cancer
| No known pregnancy or breastfeeding
| No known history of autoimmune diseases or other cancers
| Serplulimab plus chemotherapy
| Female, 60 years old, with extensive history of small cell lung cancer
| No known gender or race
| No known family history of autoimmune diseases or other can"
876,"[/INST]
| Other: [/INST]
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Exercise capacity | Incremental cycle ergometry test | 10 weeks | 
| Physical activity behaviour | Moderate to vigorous physical activity (MVPA) | 10 weeks | 
| Smoking | Smoking level in kg | 10 weeks | 
| Health-related quality of life | EQ-5D Questionnaire | 10 weeks | 
| Patient safety | Adverse events reporting (number and severity of adverse events) | 10 weeks | 
| Secondary Outcome Measures |
| Other: [/INST]
| Physical activity behaviour | Moderate to vigorous physical activity (MVPA) | 10 weeks | 
| Smoking | Smoking level in kg | 10 weeks | 
| Health-related quality of life | EQ-5D Questionnaire | 10 weeks | 
| Patient safety | Adverse events reporting (number and severity of adverse events) | 10 weeks | 
| Other: [/INST]
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Exercise capacity | Incremental cycle ergometry test | 10 weeks | 
| Physical activity behaviour | Moderate to vigorous physical activity (MVPA) | 10 weeks | 
| Smoking | Smoking level in kg | 10 weeks | 
| Health-related quality of life | EQ-5D Questionnaire | 10 weeks | 
| Secondary Outcome Measures |
| Other: [/INST]
| Physical activity behaviour | Moderate to vigorous physical activity (MVPA) | 10 weeks | 
| Smoking | Smoking level in kg | 10 weeks | 
| Health-related quality of life | EQ-5D Questionnaire | 10 weeks | 
| Patient safety | Adverse events reporting (number and severity of adverse events) | 10 weeks | 
| Other: [/INST]
| Primary Outcome Measure | Measure Description | Time Frame |
| --- | --- |"
877,"[/INST]
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose: Experimental |
| Intervention Model: Crossover Assignment |
| Primary Purpose: Treatment |
| Secondary Purpose:"
878,"[/INST]
Other Outcome Measures
-----------------
Keywords: [premature birth, neonatal abdominal assessment, neonatal physiotherapy]
Secondary Outcome Measures
Physiotherapy, neonatal abdominal massage
Terms related to the study: [premature birth, neonatal physiotherapy]
Keywords: [premature birth, neonatal abdominal assessment, neonatal physiotherapy]
Other Outcome Measures
Physiotherapy, neonatal abdominal massage
Terms related to the study: [premature birth, neonatal physiotherapy]
Secondary Outcome Measures
Physiotherapy, neonatal abdominal massage
Terms related to the study: [premature birth, neonatal physiotherapy]
Physiotherapy, neonatal abdominal massage
Secondary Outcome Measures
Physiotherapy, neonatal abdominal massage
Terms related to the study: [premature birth, neonatal physiotherapy]
Physiotherapy, neonatal abdominal massage
Secondary Outcome Measures
Physiotherapy, neonatal abdominal massage
Terms related to the study: [premature birth, neonatal physiotherapy]
Physiotherapy, neonatal abdominal massage
Secondary Outcome Measures
Physiotherapy, neonatal abdominal massage
Terms related to the study: [premature birth, neonatal physiotherapy]
Physiotherapy, neonatal abdominal massage
Secondary Outcome Measures
Physiotherapy, neonatal abdominal massage
Terms related to the study: [premature birth, neonatal physiotherapy]
Physiotherapy, neonatal abdominal massage
Secondary Outcome Measures
Physiotherapy, neonatal abdominal massage
Terms related to the study: [premature birth, neonatal physiotherapy]
Physiotherapy, neonatal abdominal massage
Secondary Outcome Measures
Physiotherapy, neonatal abdominal massage"
879,[/INST] Empowered Relief
880,[/INST]
881,"[/INST]
Primary Purpose: Treatment
-----------------
Study Design and Interventions
| Experimental: MSCs treatment group | Biological: those with poor graft function; age <18; those who are participating in clinical trials, and have been injected with PGF | Interventions: Conventional, with age <20; those who have undergone allogeneic stem cell transplantation, and have been hospitalized for at least 60 days; no response (age 20-40) |
Secondary Purpose: Those with poor graft function; age 60-80, with platelet transfusion; further hospitalization for at least 80 days; no response (age 80)
| Outcome: Survival rate of patients with graft function after treatment; further hospitalization for at least 60 days; no response (age 80)
-----------------
Secondary Outcome Measures
| Experimental: MSCs treatment group | Biological: those with poor graft function; age <20, with platelet transfusion | Further hospitalization for at least 60 days; no response (age 80)
| survival rate: Those with poor graft function; age 80-100
-----------------
Secondary Outcome Measures
| Experimental: MSCs treatment group | Biological: those with poor graft function; age <20, with platelet transfusion | Further hospitalization for at least 60 days; no response (age 80)
| survival rate: Those with poor graft function; age 100
-----------------
Secondary Outcome Measures
| Experimental: MSCs treatment group | Biological: those with poor graft function; age <20, with platelet transfusion | further hospitalization for at least 60 days; no response (age 80)
| survival rate: Those with poor graft function; age 100
-----------------
Secondary Outcome Measures
| Experimental: MSCs treatment group | Biological: those with poor graft function; age <20, with platelet transfusion | further hospitalization for at least 60 days; no response (age 80)"
882,"[/INST]




























































A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
M
A
A
A
P
A
A
A
A
A
A
A
C
C
A
A
A
A
A
A
A
A
A
A
A
C
C
A
A
A
A
C
C
C
C
C
C
C
C
A
C
C
A
A
A
A
A
A
A
C
C
A
C
A
A
C
C
C
-
C
C
C
C
-
C
A
A
A
A
A
A
A











C
M
M
M
O
A
C
-
-
O
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-








































-
-
-
-








































-
-
-
-
-"
883,"[/INST]
| Other: Randomized controlled trials using alcohol |
| Baseline to 6-months post-treatment.
| Other: Randomized trials using alcohol |
| Experimental: Quit Genius, in the study.
| Other: Randomized.
| Alcohol use among patients.
| Baseline to 6-month.
| Other: Quit using alcohol.
|
| Other: Alcohol.
|
| Alcoholism among patients.
| Other: Alcoholism among alcohol.
| Other: Alcoholism.
Primary Outcome| Other: Alcoholism among alcoholism among patients.
| Other: Alcoholism among alcohol.
| Basis among alcoholism.
| Other: Alcoholism.
| Other: Alcoholism.
Primary prevention.| Other: Alcoholism.
|s.
|s.
|s diagnosis.
|s diagnosis.
|s.
Alcoholism.
Other: Alcoholism.
Other: Alcoholism.
Other: Alcoholism.
Alcoholism. Other: Alcoholism. Other: Alcoholism. Other: Alcoholism. Other: Alcoholism. Other: Alcoholism. Other: Alcoholism. Other: Alcoholism. Other: Alcoholism. Other: Alco
Other Alcoholism. Other: Alcoholism.
Other Alcoholism. Other: Alco
Other: Basis.
Other: Basis
Other Alcoholism.
Other Alco
Other Alco
Other:
Other Alco
Other Alcoholism.
Other Alcoholism.
Other Alco
Other Alco
Other Alco
Other:
Other
Alco
==
==
==
==
==
==
The treatment.
The clin
Al.
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
Al
in
,
Alle.
Al
Al
,
in
in
in
In
A
The
==
==
==
The.
The
The"
884,[/INST]IOIIIIIIIIIIIIIIIIIII II IIIIII II IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII II II II II IIIIIIIIIIIIIIIIIIIIIIIIIAIAIIIIIIIIIIIIIIII II II II II II II II IIIIIIIIIIIEIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIEIEIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII II II IIIII II IE II II II II II IIIIIIIIIIIIIIIIIIIIIIII II IIIII II II II III II II II II II II II II II IIIIII II mostI most II mostI mostI mostoIOIO00000IOIOIOIOIO- II IIOIOIIIOIOIIIOIOIOIO- IO- IAI0000000000I II- (I0000000000000000000000000000000000000000000000-
885,"[/INST]
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embryo transfer, uterine lining |
How is the study designed?
| Other: Frozen embry"
886,"[/INST]
| 1.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|2.|1.|1.|2.|2.|2.|2.|
In.|2.|2.|1.|1.|2.|2.|2.|
In.|2.|1.|1.|
In|1.|1.|1.|
In|1.|1.|1.|1.|
In|1.|1.
in.
It.
In.
It.
It.
It.
in.
in.
in.
In.
in.
in.
It.
In.
in.
It.
It.
It.
in.
in.
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in"
887,"[/INST]
1. Preterm birth; children will be subjected to careful follow-up to determine the mode of delivery.
2. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
3. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
4. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
5. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
6. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
7. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
8. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
9. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
10. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
11. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
12. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
13. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
14. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
15. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
16. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
17. Preterm birth complications will be carefully followed using a scale; the value will be plotted on the WHO growth chart.
18. Preterm birth complications will be carefully followed using a scale"
888,"[/INST]
The.
The.
The.
The.
The.
As.
As.
As.
As.
As.
In a.
As.
In a.
in.
in.
in.
The.
in.
in.
in.
in
as
as
as
As
As
As
in
in
in
in
in
In
In
in
in
in
In
In
In
In
The
The
The
As
As
in
As
This
This
This
As
As
As
As
As
In
In
In
In
In
In
In
In
In
In
In
In
This
This
This
As
As
This
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
In
a
a
This
This
This
This
This
This
This
This












































































































































































































0
0
0"
889,"[/INST]

Patients with Urinary Bladder Cancer
-----------------

Patients with Urinary Bladder Cancer
-----------------

Patients with Urinary Bladder Cancer
-----------------

Patients in Darfur

Time Frame: From 2020 to 2022

Patients with Urinary Bladder Cancer

Patients in Darfur

Patients with Urinary Bladder Cancer

Time Frame: From 2020 to 2022

Patients with Urinary Bladder Cancer

Patients in Darfur

Patients with Urinary Bladder Cancer

Time Frame: From 2020 to 2022

Patients with Urinary Bladder Cancer

Patients in Darfur

Patients with Urinary Bladder Cancer

Time Frame: From 2020 to 2022

Patients with Urinary Bladder Cancer

Patients in Darfur

Patients with Urinary Bladder Cancer

Time Frame: From 2020 to 2022

Patients with Urinary Bladder Cancer

Patients in Darfur

Time Frame: From 2020 to 2022

Patients with Urinary Bladder Cancer

Patients in Darfur

Time Frame: From 2020 to 2022

Patients with Urinary Bladder Cancer

Patients in Darfur

Time Frame: From 2020 to 2022

Patients with Urinary Bladder Cancer

Patients in Darfur

Time Frame: From 2020 to 2022

Patients with Urinary Bladder Cancer

Patients in Darfur

Time Frame: From 2020 to 2022

Patients with Urinary Bladder Cancer

Patients in Darfur

Time Frame: From 2020 to 2022

Patients with Urinary Bladder Cancer

Patients in Darfur

Time Frame: From 2020 to 202"
890,"[/INST]

Participants
-----------------

Colonoscopy

Participants
-----------------

Screening Questionnaire
-----------------

Participants
-----------------

Screening Questionnaire
-----------------

Participants
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire
-----------------

Screening Questionnaire"
891,"[/INST] a-a-a-a-a-a-s-s-s-s-s-s-s-s-s-e-e-e- a- a-s,-s,-s,-s,,,,,, a, a, a-a- a-m-m-s,-s, a-s,-s,-a,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,-s,-s-s-s a- a- a- a-a- a- a- a- a- a- a- a- a- a- a,- a- a-a- a- a- a- a-s,-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
,
-
-
-
-
-
-
,,-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-



























-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-"
892,"[/INST]
Autism, Teen's sexual health behaviors.
| 18-year-old, and teen's sexual health behaviors.
How to treatments.
Autism, and teen sexual health behaviors.
Primary caregism, Autism, teen sexual health behaviors.
Primary caregism, Autism, teen sexual health behaviors.
Primary caregism, Autism, teen sexual health behaviors.
Primary caregism.
Autism, teen.
Primary caregism.
Primary caregism.
Primary caregism.
Primary caregism.
Primary caregism.
Primary caregism.
Primary caregism.
Primary caregism.
Primary caregism.
Primary caregism.
Autism.
Primary caregism.
Primary caregism.
Autism.
Primary caregism.
Autism.
Primary caregism.
Autism.
Primary caregism.
Autism.
Primary caregism.
Primary caregism.
Autism.
Autism.
Autism.
Autism.
Autism.
Autism.
Autism.
Primary care.
Autism.
Autism.
Autism.
Autism.
Autism.
Autism.
Autism.
Autism.
Autism.
Autism.
Autism.
Autism.
==
==
==.
==.
==.
==.
==.
==.
==.
==
==.
==.
====.
====.
==.
== for.
====.
====.
====.
====.
== for.
==.
==.
==.
The.
The.
The year.
The year.
====.
==
==
==.
==.
The.
====.
====.
==
==.
==.
==.
a.
==.
==.
The.
The.
The.
as (as.
The.
The.
The.
The.
==.
==.
==.
==.
==.
==.
The.
The.
==.
==.
==.
==.
==.
==.
The"
893,"[/INST]

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------

Patients
-----------------"
894,"[/INST]
-----------------

Patients
-----------------
Liver Transplantation

Terms related to the study

Adverse Events
-----------------

Patients with
Liver Transplantation

Adverse Events following liver transplantation

Patients with
Failure of Liver Transplantation

Adverse Events following liver transplantation

Patients with
Olthoff Disease

Adverse Events following liver transplantation

Patients with
Bilirubin levels above 2 mg/dL

Adverse Events in the first 24 hours following liver transplantation

Patients with
INR < 1.3

Adverse Events in the first 7 days following liver transplantation

Patients with
Olthoff Disease

Bilirubin levels < 2 mg/dL

Adverse Events in the first 24 hours following liver transplantation

Patients with
INR < 1.3

Bilirubin levels < 2 mg/dL

Adverse Events in the first 7 days following liver transplantation

Patients with
Olthoff Disease

INR < 1.3

Bilirubin levels < 2 mg/dL

Adverse Events in the first 2 weeks following liver transplantation

Patients with
Olthoff Disease

INR < 1.3
Bilirubin levels < 2 mg/dL

Adverse Events in the first 7 days following liver transplantation

Patients with
Olthoff Disease

INR < 1.3
Bilirubin levels < 2 mg/dL

Adverse Events in the first 2 weeks following liver transplantation

Patients with
Olthoff Disease

INR < 1.3
Bilirubin levels < 2 mg/dL

Adverse Events in the first 7 days following liver transplantation

Patients with
Olthoff Disease

INR < 1.3
Bilirubin levels < 2 m"
895,"[/INST]

Adverse events |
| Placebo: 10mg/dose, 3 times a day, for 28 consecutive days (as a cycle), for 6 cycles |
| Experimental: 10mg/dose, three times a day, for 28 consecutive days (as a cycle), for 6 cycles |
| Drug: 10mg/dose, three times a day, for 28 consecutive days (as a cycle), for 6 cycles |
| Placebo: 10mg/dose, three times a day, for 28 consecutive days (as a cycle), for 6 cycles |
| Experimental: 10mg/dose, three times a day, for 28 consecutive days (as a cycle), for 6 cycles |
| Drug: 10mg/dose, three times a day, for 28 consecutive days (as a cycle), for 6 cycles |
| Placebo: 10mg/d, three times a day, for 28 consecutive days (as a cycle, for 6 cycles |
| Experimental: 10mg/d, three times a day, for 28 consecutive days, for 6 cycles |
| Placebo: 10mg/day, three times a day, for 28 consecutive days, for 10mg, three times a day, three times a day, three times a day, three times a day.
| Experimental: 10mg, three times a day.
| three times a day.
| three times a day.
| three times a day.
| three times a day.
| three times a day.
Primary care.
Primary care. 10.
| three times a day.
Primary care. 10.
Primary care. 10.
Primary care. 10.
Primary care. 10.
Primary care. 10. 10. 10. 10. 10. 10. 10. 10. 10. 10. 10. 10. 0. 0. 10. 0. 10. 0. 0. 0"
896,"[/INST]
== .
== .
The patient.
The patient.
The patient.
The, it.
The, the, the,
The, the.
The, the.
The patient.
The patient.
The, the.
The, the.
The doctor.
The.
The, the.
The, it.
==
==
==
==
==
==
==
The, the.
The,
The, the,
The,
The.
The,
The,
The 
The.
The, the,
The, the, the
The, the //
The.
The,
The,
The,
The,
==
==
==
==
==
==
==
==.
==.
==.
==.
==.
The
The
The
The
The
S
The
F.
The
The
The
==.
==.
==
==
This
This
This
This
The
This
This
This
This
This
==.
==.
==.
==.
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
P
P
S
S
S
S
S
S
S
S
P
P
P
P
S
S
S
S
S
S
S
S
P
P
P
P
P
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
P
P
P
P
P
P
P
S
P
P









P
P
P
S
S
S
P












P
P
P
P




















P
P
P
P









P"
897,"[/INST]
This
m
This
This


































































































































































































































































































































































































8










-
-

-














-
-
-
-
-
-
-
-
-
8
-
8
-
-
-
-
-
-
-
-
-
-
-







-
C
O
-
-
-
-
-












-
-"
898,"[/INST]
| Primary Outcome: Neonatal abstinence syndrome | Secondary Outcome: Infant exposed to magnesium sulfate since birth | Tertiary Outcome: Buccal swab at 60 hours of life and at discharge |
| Primary Outcome: Opioid-exposed neonates at 24 hrs of life | Secondary Outcome: Salivary microRNA levels let-7a |
| Primary Outcome: Infant at 60 hours of life | Secondary Outcome: Buccal swab at discharge |
| Primary Outcome: Neonatal abstinence from magnesium since 24 hrs of life | Secondary Outcome: Salivary microRNA-146 at 48 hrs of life and at discharge |
| Primary Outcome: Opioid-exposed neonates at 24 hrs of life | Secondary Outcome: Buccal swab at discharge |
| Primary Outcome: Infant at 60 hours of life | Secondary Outcome: Salivary microRNA-146 at discharge |
| Primary Outcome: Opioid-exposed neonates at 24 hrs of life | Secondary Outcome: Buccal swab at discharge |
| Primary Outcome: Infant at 60 hours of life | Secondary Outcome: Salivary microRNA-146 at discharge |
| Primary Outcome: Opioid-exposed neonates at 24 hrs of life | Secondary Outcome: Buccal swab at discharge |
| Primary Outcome: Infant at 60 hours of life | Secondary Outcome: Salivary microRNA-146 at discharge |
| Primary Outcome: Opioid-exposed neonates at 24 hrs of life | Secondary Outcome: Buccal swab at discharge |
| Primary Outcome: Infant at 60 hours of life | Secondary Outcome: Salivary microRNA-146 at discharge |
| Primary Outcome: Opioid-exposed neonates at 24 hrs of life | Secondary Outcome: Buccal swab at discharge"
899,"[/INST]
In.
The control.
It's.
It.
It.
It.
It.
In.
In.
In.
In.
In.
In.
It.
It.
In.
In.
In.
In
In
It
In
In
is
is
is
is
The
The
The
In
In
In
In
In
in
in
in
in
in
in
in
in
in
In
In
in
In
In
In
In
In
In
In
The
The
The
In
In
The
The
The
The
The
The
The
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
In
In
In
This
This
This
This
This
This
In
0
0
This
This
This
This
00
This
This
This
This
The
The
The
The
This
This
This
This
This
The
The
The
The
The
The
The
The
The
In
In
In
In
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
A
A
A
A
A
A
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The"
900,"[/INST]
| Induction success | Days 0 through 4 |
| Recovery success | Days 0 through 7 |
| Treatment adherence | Days 0 through 4 |
| Induction success | Days 0 through 7 |
| Recovery success | Days 0 through 4 |
| Treatment adherence | Days 0 through 7 |
| Induction success | Days 0 through 4 |
| Recovery success | Days 0 through 7 |
| Treatment adherence | Days 0 through 4 |
| Induction success | Days 0 through 7 |
| Treatment adherence | Days 0 through 4 |
| Recovery success | Days 0 through 7 |
| Induction success | Days 0 through 4 |
| Treatment adherence | Days 0 through 7 |
| Recovery success | Days 0 through 4 |
| Induction success | Days 0 through 7 |
| Treatment adherence | Days 0 through 4 |
| Recovery success | Days 0 through 7 |
| Induction success | Days 0 through 4 |
| Treatment adherence | Days 0 through 7 |
| Recovery success | Days 0 through 4 |
| Induction success | Days 0 through 7 |
| Treatment adherence | Days 0 through 4 |
| Recovery success | Days 0 through 7 |
| Induction success | Days 0 through 4 |
| Treatment adherence | Days 0 through 7 |
| Recovery success | Days 0 through 4 |
| Induction success | Days 0 through 7 |
| Treatment adherence | Days 0 through 4 |
| Recovery success | Days 0 through 7 |
| Induction success | Days 0 through 4 |
| Treatment adherence | Days 0 through 7 |
| Recovery success | Days 0 through 4 |
| Induction success | Days 0 through 7 |
| Treatment adherence | Days 0 through 4 |
| Recovery success | Days 0"
901,"[/INST]
How is the study designed?
-----------------
Patient having a thoracic outlet syndrome
Diagnostic Test: Transcutaneous oximetry
| Outcome: TcpO2 measurement
Examination of the thoracic outlet is suspected to have been carried out
| Patient is a minor, non-French speaker
| Diagnostic Test: Transcutaneous oximetry
| Outcome: TcpO2 measurement
| Patient is a minor, non-French speaker
| Diagnostic Test: Transcutaneous oximetry
| Outcome: TcpO2 measurement
| Patient is a minor, non-French speaker
| Diagnostic Test: Transcutaneous oximetry
| Outcome: TcpO2 measurement
| Patient is a minor, non-French speaker
| Diagnostic Test: Transcutaneous oximetry
| Outcome: TcpO2 measurement
| Patient is a minor, non-French speaker
| Diagnostic Test: Transcutaneous oximetry
| Outcome: TcpO2 measurement
| Patient is a minor, non-French speaker
| Diagnostic Test: Transcutaneous oximetry
| Outcome: TcpO2 measurement
| Patient is a minor, non-French speaker
| Diagnostic Test: Transcutaneous oximetry
| Outcome: TcpO2 measurement
| Patient is a minor, non-French speaker
| Diagnostic Test: Transcutaneous oximetry
| Outcome: TcpO2 measurement
| Patient is a minor, non-French speaker
| Diagnostic Test: Transcutaneous oximetry
| Outcome: TcpO2 measurement
| Patient is a minor, non-French speaker
| Diagnostic Test: Transcutaneous oximetry
| Outcome: TcpO2 measurement
| Patient is a minor, non-French speaker
| Diagnostic Test: Transcutaneous oximetry
| Outcome: TcpO2 measurement
| Patient is a minor, non-French speaker
| Diagnostic Test: Transcutaneous oximetry
| Outcome: TcpO2 measurement
| Patient is a minor, non-French speaker
| Diagnostic Test: Transcutaneous oximetry
| Outcome:"
902,"[/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Other: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Other: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST]
Symptoms: [/INST]
Feasibility: [/INST
Symptoms: [/INST.
Symptoms: [/INST.
Symptoms: [/INST
Symptoms: [/INST
Feasibility: [/INST
Symptoms: [/INST
Symptoms: [/INST
Feasibility: [/INST
Symptoms: Symptoms [/INST
Symptoms: Symptoms: Patients [/INST
Feasian symptoms: Patient [/INST
Symptoms: Patient [/Symptoms, including [/with symptoms.
Feasian symptoms.
Symptoms: [/INST
Symptoms: Patient [/Instead, symptoms.
Patients [/Instead, it is a rare ["
903,"[/INST] - The investigator who conducted the study.
| Degree of success: [/INST] - those who experienced anal fissure and were discharged home safely.
| No. of patients included in the study: [/INST] - those who developed anal fissure and need surgical intervention.
| How many patients were enrolled in the study? [/INST] - those who received surgical intervention.
| How many developed anal fissure? [/INST] - those who didn't experience any symptoms and needed no intervention.
| Exclusion Criteria: [/INST] - those who didn't develop anal fissure and received medical treatment only.
| Risk factors associated with development of anal fissure among those who received surgical intervention.
| How many of these patients died? [/INST] - those who didn't experience resolution of symptoms and needed further intervention.
| Expected Outcome: [/INST] - those who experienced anal fissure and received medical treatment.
| How many of these patients were discharged home safely? [/INST] - those who didn't develop anal fissure and needed further intervention.

Analysis
-----------------
Analysis of covid-19 patients' data showed that those who developed anal fissure during the follow up needed surgical intervention.
| How many of these patients were discharged home safely? [/INST] - those who didn't experience resolution of symptoms and needed further observation.
| No. of patients included in the study: [/INST] - those who developed anal fissure during the follow up and needed surgical intervention.
| How many of these patients died? [/INST] - those who didn't develop anal fissure and needed further medical treatment."
904,"[/INST]
| tissue thickness | tissue thickness was measured with B-mode ultrasonography | at baseline immediately after the operation, on days 3, 14, 30, 90 | 
| tissue thickness was measured with ultrasonography | at baseline immediately after the operation, days 3, 14, 10, 30, 14, 10, 100000. | ultrason, 14, 1000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000"
905,"[/INST]

Advanced Recovery Care
-----------------
Provided by [insert institution name]

Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]


Advanced Recovery Care
-----------------
Provided by [insert institution name]

Advanced Recovery Care
-----------------
Provided by [insert institution name]

Advanced Recovery Care
-----------------"
906,"[/INST]
-
8-
8
8
8
-
8
8
8
8888888
8
8
8
8
8
8
8
8
8-
8-
8
8
8
8
8
8
8
8-
8-
8-
8-
888-
8-
8-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-s (h-s (h-s (h-h--
-
-
-
---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-----h-h-f-f-f-f-f-f-f-s-s-y-h-h-h-h-p-f-f-p-8-p-p-f-f--
-
-
-
-
-f-f-f-f-f-
-
-p-p-p-f-f-f-f-f-f-f-m-m-f-m-m-f-f-f---f-f-f-f-s-f-f-f-f-f-f-f-m-f-f-f-f-f-f-f-f-f-f-f-h-f-f-f-f-f-st-st-st-s-s-s-s-
-
-f-f-s-s-s-m-f-f-m-f-f-f-f-f-f-f-f-f-f-s-p-s-s-s-s-s-h-st-st-st-st-p-f-s-s-f-f-f-f-8-re-8-8-8-f-f-f-f-f-re-re-re-0-0-0-re-1-re-1-f-"
907,"[/INST]
| Diagnostic Test: Clinical |
| Questionnaire |
| Questionnaire |
| Diagnostic Test: Clinical |
| Questionnaire |
| Diagnostic Test: Clinical |
| Questionnaire |
| Diagnostic Test: Clinical |
| Questionnaire |
| Diagnostic Test: Clinical |
| Questionnaire |
| Diagnostic Test: Clinical |
| Questionnaire |
| Diagnostic Test: Clinical |
| Questionnaire |
| Diagnostic Test: Clinical |
| Questionnaire |
| Diagnostic Test: Clinical |
| Questionnaire |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
| Diagnostic Test: Clinical |
|"
908,"[/INST]
-----------------
Primary Outcome: Pre-term birth, between 32 and 33 weeks.
Secondary Outcome: Pre-term birth, between 32 and 36 weeks.
Tertiary Outcome: Pre-term infants, between 32 and 36 weeks.
Quaternary Outcome: Pre-term birth, between 32 and 36 weeks.
Interventions: [/INST]
Comments: [/INST]
Primary Outcome: Pre-term birth, between 32 and 36 weeks.
Secondary Outcome: Pre-term infants, between 32 and 36 weeks.
Tertiary Outcome: Pre-term birth, between 32 and 36 weeks.
Comments: [/INST]
Primary Outcome: Pre-term birth, between 32 and 36 weeks.
Secondary Outcome: Pre-term infants, between 32 and 36 weeks.
Interventions: [/INST]
Comments: [/INST]
Primary Outcome: Pre-term birth, between 32 and 36 weeks.
Secondary Outcome: Pre-term infants, between 32 and 36 weeks.
Comments: [/INST]
Primary Outcome: Pre-term birth, between 32 and 36 weeks.
Secondary Outcome: Pre-term infants, between 32 and 36 weeks.
Comments: [/INST]
Primary Outcome: Pre-term birth, between 32 and 36 weeks.
Secondary Outcome: Pre-term infants, between 32 and 36 weeks.
Comments: [/INST]
Primary Outcome: Pre-term birth, between 32 and 36 weeks.
Secondary Outcome: Pre-term infants, between 32 and 36 weeks.
Comments: [/INST]
Primary Outcome: Pre-term birth, between 32 and 36 weeks.
Secondary Outcome: Pre-term infants, between 32 and 36 weeks.
Comments: [/INST]
Primary Outcome: Pre-term birth, between 32 and 36 weeks.
Secondary"
909,"[/INST]


































































-"
910,"[/INST]
| 3 years.
| 3.
| 2.
| 3.
| 3.
|4.
|5.
|4.
|5.
|6.
|4.
|5.
|6.
|1.|1.|1.|1.|1.|1.|4.|1.|2.|1.|2.|2.|1.|2.|1.|1.|1.|1.|1.|1.|1.|1.|1.|1.|1.|1.|1.|1.|1.|1.|1.|1.|1.|1.|1.|
The.
The.
The process.
The process.
The process.
There.
The process.
In.
There.
The process.
The.
The.
The process.
The process.
The.
The.
The
The
The
The
The
The
The process.
The process.
The.
The.
This.
In
In
In
The
The
The
The
The
The
After
After
The
The|
The|
The|
The
The|
The|
The|
The|
The
The
In
In
In
In
This
This
This
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
This
The
The
The
The
The
The
The
The
This
The
The
The
The
The
The
The
The
The
The
The
The
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The"
911,"[/INST]
| Diagnostic Test: Genotyping. |
| Intervention: Biofeedback. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genotyping. |
| Nerve Growth Factor serum level. |
| Diagnostic Test: Genot"
912,"[/INST]

Inclusion and Exclusion Criteria
-----------------
| Participants will be community-dwelling older adults age 60 and older. | Exclusion criteria: major neurological disorders (i.e., stroke, dementia, or cognitive impairment), or symptomatic drug abuse, homebound status, psychiatric hospitalization, or clinically significant medical illness (i.e., cancer, renal failure, or hemodialysis). | Participants will be instructed to regularly engage in mindfulness-based intervention for 8 weeks. | Participants will be instructed to regularly engage in yoga and meditation for 8 weeks. | Participants will be instructed to regularly engage in body scan and yoga for 8 weeks. | Participants will be instructed to regularly engage in sitting meditation for 8 weeks. | Participants will be instructed to regularly engage in body scan and yoga for 8 weeks. | Participants will be instructed to regularly engage in sitting meditation for 8 weeks. | Participants will be instructed to regularly engage in body scan and yoga for 8 weeks. | Participants will be instructed to regularly engage in sitting meditation for 8 weeks. | Participants will be instructed to regularly engage in body scan and yoga for 8 weeks. | Participants will be instructed to regularly engage in sitting meditation for 8 weeks. | Participants will be instructed to regularly engage in body scan and yoga for 8 weeks. | Participants will be instructed to regularly engage in sitting meditation for 8 weeks. | Participants will be instructed to regularly engage in body scan and yoga for 8 weeks. | Participants will be instructed to regularly engage in sitting meditation for 8 weeks. | Participants will be instructed to regularly engage in body scan and yoga for 8 weeks. | Participants will be instructed to regularly engage in sitting meditation for 8 weeks. | Participants will be instructed to regularly engage in body scan and yoga for 8 weeks. | Participants will be instructed to regularly engage in sitting meditation for 8 weeks. | Participants will be"
913,"[/INST]
Exclusion Criteria
| prevalence of MG infection | detection of MG in self-collected samples divided by the total number of samples reported by the clinic | 1 year | 
| prevalence of CT infection | detection of CT in self-collected samples divided by the total number of samples reported by the clinic | 1 year | 
| prevalence of NG infection | total number of reported NG diagnosis divided by the total number of samples tested for MG infection | 1 year | 
| prevalence of syphilis in self-collected samples | total number of reported syphilis diagnosis divided by the total number of samples tested for MG infection | 1 year | 
Secondary Outcome Measures
-----------------
Acceptance of the study protocol
| prevalence of MG infection | detection of MG in self-collected samples divided by the total number of samples reported by the clinic | 1 year | 
| prevalence of CT infection | total number of reported CT diagnosis divided by the total number of samples tested for MG in the clinic | 1 year | 
| prevalence of syphilis in self-collected samples | total number of reported syphilis diagnosis divided by the total number of samples reported by the clinic | 1 year | 
Secondary Outcome Measures
| prevalence of CT infection | total number of reported CT diagnosis divided by the total number of samples reported by the clinic | 1 year | 
| prevalence of MG infection | total number of reported MG diagnosis divided by the total number of samples reported by the clinic | 1 year | 
| prevalence of CT infection | total number of reported CT diagnosis divided by the total number of samples reported by the clinic | 1 year | 
Secondary Outcome Measures
| prevalence of CT infection | total number of reported CT diagnosis divided by the total number of samples reported by the clinic | 1 year | 
| prevalence of MG infection | total number of reported MG diagnosis divided by the total number of samples reported by the clinic | 1 year | 
| prevalence of syphilis in self-collected samples | total number of"
914,"[/INST]
|
Second, the breast, the use of |
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second,
Second
Second
Second
Second
Second
Second,
Second
Second
Second
Second
Second
Second
Second
Second,
Second,
Second,
Second,
Second
Second
Second
Second
Second
Second
In
The breast
Second
Second
The breast.
The breast.
Second
Second.
The breast.
In
In
In
In
In
The breast.
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
It
It
It
It
It
In
In
In
In
In
In
The
The
The
It
In
The
The
In
In
In
In
In
In
In
In
The
The
The
It
It
It
In
In
In
In
In
In
It
It
It
It
It
It




S
In
In
In
In
In
In
In
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
915,"[/INST]
X
Patient
The
The
The
The
The
The
The
The
In
In
In
The
The
The
The
The
In
In
The
The
The
The
The
The
The
P
P
The
In
P
In
The
The
In
In
In
In
In
In
In
In
In
In
In
In
In
The
The




The -
In
In
This
F
F.
F.
This.
This.
This
This
This
F.
F.
F
F
D
D
D
F
D
D
D
D
D
D
D,
D
D
D
D
D
D
F
F
F
F
F
F
F
F
F
D
D
D
D
D
F
F
F
F
F
F
F
F
F
F
D
D
F
F
F
F
F
S
F
F
F
F
S
S
S
S
S
S
S
S
D
D
D
S
S
D
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
The
The
The
The
The
The
The
The
The
S
The
S
S
F
F
F
F
F
F
F







S
S
S




















S
S
S
S
S
F
L
L
L
L
L
L
The
S
L
S
S
S
S
S
S
F
F
S
S
S
S
S
S
S
S
S
S
S
F
L
L
S
S
S
S
S
S
S
S
S
S
S
S"
916,"[/INST]
Other: [/INST]

Data Analysis and Interpretation
Data Analysis Plan: [/INST]
Data Analysis: [/INST]
Data Interpretation: [/INST]
Data Analysis: [/INST]
Data Interpretation: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST]
Data Analysis: [/INST"
917,"[/INST]
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard vital signs monitor
| Patient: newborn
| Device: neoGuard"
918,"[/INST] - Patient information document for a phase II/III clinical trial. [/INST]
Elderly population, aged 70 years. [/INST]
Soft tissue sarcoma in the trunk. [/INST]
Procedure: [/INST] - Patient information document for a phase III clinical trial. [/INST]
Soft tissue sarcoma in the trunk. [/INST]
Patients with performance status  ECOG 65 years. [/INST]
Procedure: [/INST] - Patient information document for a phase III clinical trial. [/INST]
Soft tissue sarcoma in the trunk. [/INST]
Patients with performance status  ECOG 65 years. [/INST]
Procedure: [/INST] - Patient information document for a phase III clinical trial. [/INST]
Soft tissue sarcoma in the trunk. [/INST]
Patients with performance status  ECOG 65 years. [/INST]
Procedure: [/INST] - Patient information document for a phase III clinical trial. [/INST]
Soft tissue sarcoma in the trunk. [/INST]
Patients with performance status  ECOG 65 years. [/INST]
Procedure: [/INST] - Patient information document for a phase III clinical trial. [/INST]
Soft tissue sarcoma in the trunk. [/INST]
Patients with performance status  ECOG 65 years. [/INST]
Procedure: [/INST] - Patient information document for a phase III clinical trial. [/INST]
Soft tissue sarcoma in the trunk. [/INST]
Patients with performance status  ECOG 65 years. [/INST]
Procedure: [/INST] - Patient information document for a phase III clinical trial. [/INST]
Soft tissue sarcoma in the trunk. [/INST]
Patients with performance status  ECOG 65 years. [/INST]
Procedure: [/INST] - Patient information document for a phase III clinical trial. [/INST]"
919,"[/INST]
| Full Name: Head and Neck Cancer | Hospital: Army Hospital | Treatment provided by: Department of ENT, Head and Neck Cancer | Data was collected from May 2022 to April 2023 | Histopathology of HNC was done according to the protocol of Army Hospital | Data was analyzed using SPSS version 22 |
| Outcome: Survival rate of HNC was calculated from the medical records of Army Hospital | Data was collected from May 2022 to April 2023 |
| Expected Outcome: Survival rate of HNC was calculated from the medical records of Army Hospital |
| Data was collected from May 2022 to April 2023 |
| Data was collected from the medical records of Army Hospital |
| Data was collected from May 2022 to April 2023 |
| Data was collected from the medical records of Army Hospital |
| Data was collected from May 2022 to April 2023 |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the medical records of Army Hospital |
| Data was collected from the"
920,[/INST]
921,"[/INST]

Clinical Response is defined as the proportion of patients achieving a HBI of 50% for both very soft and liquid stool and symptom relief.
[/INST]

Other Outcome Measures
-----------------
Acceptable range for Crohn's disease symptom relief: 0 - 19.
Symptom relief is defined as a decrease of  3 points in the Crohn's Disease Symptom Severity Scale (CDAI).
Patients will receive up to 2 points for symptom relief per day.
Patients will receive up to 2 points for symptom relief per day.
Symptom relief is defined as a decrease of  3 points in the Crohn's Disease Symptom Severity Scale (CDAI).
Patients will receive up to 2 points for symptom relief per day.
Acceptable range for Crohn's disease symptom relief is 0 - 4.
Symptom relief is defined as a decrease of  3 points in the Crohn's Disease Symptom Severity Scale (CDAI).
Patients will receive up to 2 points for symptom relief per day.
Symptom relief is defined as a decrease of  3 points in the Crohn's Disease Symptom Severity Scale (CDAI).
Patients will receive up to 2 points for symptom relief per day.
Acceptable range for Crohn's disease symptom relief is 0 - 4.
Symptom relief is defined as a decrease of  3 points in the Crohn's Disease Symptom Severity Scale (CDAI).
Patients will receive up to 2 points for symptom relief per day.
Symptom relief is defined as a decrease of  3 points in the Crohn's Disease Symptom Severity Scale (CDAI).
Patients will receive up to 2 points for symptom relief per day.
Symptom relief is defined as a decrease of  3 points in the Crohn's Disease Symptom Severity Scale (CDAI).
Patients will receive up to 2 points for symptom relief per day.
Symptom relief is defined as a decrease of"
922,"[/INST]
| Summary of the study | This is a summary of the study that should include the following: 1. What is the study measuring? 2. Time frame of the study? 3. Who is included in the study? 4. How many questions are there? 5. How many questions should be answered? 6. What is the main outcome of the study? 7. How should the study be interpreted? 8. Other outcomes of the study? 9. Strengths & difficulties subscale | This is a 5 question survey that asks the caregiver to rate the child's attentional behavior. This survey should take about 5 minutes to complete. | 5 minutes | 
| Strengths & difficulties subscale | This is a 12 question survey that asks the caregiver to rate the child's ability to adapt to change. This survey should take about 5 minutes to complete. | 5 minutes | 
| Ego Resiliency Scale | This is a 11 question survey that asks the caregiver to rate the child's ability to regulate emotions. This survey should take about 5 minutes to complete. | 5 minutes | 

| Outcome: The child's ability to regulate emotions | This is a 12 question survey that asks the caregiver to rate the child's attentional behavior. This survey should take about 5 minutes to complete. | 5 minutes | 
| Strengths & difficulties subscale | This is a 11 question survey that asks the caregiver to rate the child's ability to adapt to change. This survey should take about 5 minutes to complete. | 5 minutes | 
| Ego Resiliency Scale | This is a 12 question survey that asks the caregiver to rate the child's ability to regulate emotions. This survey should take about 5 minutes to complete. | 5 minutes | 

| Summary of the study | This is a 12 question survey that asks the caregiver to rate the child's ability to adapt to change. This survey should take about 5 minutes to complete. | 5 minutes | 
| Strengths & difficulties subscale | This is a 11 question survey that asks the caregiver to rate the child's ability to regulate"
923,"[/INST]

Primary Outcome Measure
-----------------
Recovery from Severe Mental Illness
Secondary Outcome Measures
-----------------
Recovery from Severe Mental Illness
Peer support, provided by the INSPIRE program
Recovery from Severe Mental Illness
Secondary Outcome Measures
-----------------
Recovery from Severe Mental Illness
Peer support, provided by the INSPIRE program
Recovery from Severe Mental illness
Secondary Outcome Measures
-----------------
Recovery from Severe Mental illness
Peer support, provided by the INSPIRE program
Recovery from Severe Mental illness
Secondary Outcome Measures
-----------------
Recovery from Severe Mental illness
Peer support, provided by the INSPIRE program
Recovery from Severe Mental illness
Secondary Outcome Measures
-----------------
Recovery from Severe Mental illness
Peer support, provided by the INSPIRE program
Recovery from Severe Mental illness
Secondary Outcome Measures
-----------------
Recovery from Severe Mental illness
Peer support, provided by the INSPIRE program
Recovery from Severe Mental illness
Secondary Outcome Measures
-----------------
Recovery from Severe Mental illness
Peer support, provided by the INSPIRE program
Recovery from Severe Mental illness
Secondary Outcome Measures
-----------------
Peer support, provided by the INSPIRE program
Recovery from Severe Mental illness
Secondary Outcome Measures
-----------------
Peer support, provided by the INSPIRE program
Recovery from Severe Mental illness
Secondary Outcome Measures
-----------------
Peer support, provided by the INSPIRE program
Recovery from Severe Mental illness
Secondary Outcome Measures
-----------------
Peer support, provided by the INSPIRE program
Recovery from Severe Mental illness
Secondary Outcome Measures
-----------------
Peer support, provided by the INSPIRE program
Recovery from Severe Mental illness
Secondary Outcome Measures
-----------------
Peer support, provided by the INSPIRE program
Recovery"
924,"[/INST]
-----------------
Trauma Center, Vascular surgeon, CT-scan, and graft patency.

Primary Outcome Measure
-----------------
Time Frame: 3 years
Examine graft patency at 3, 6 and 12 months after trauma.
Trauma, Vascular surgeon, CT-scan, and graft patency at 3, 6 and 12 months after trauma.
Secondary Outcome Measures
-----------------
Trauma, Vascular surgeon, CT-scan, and graft patency at 3, 6 and 12 months after trauma.
Examine graft patency at different time points.
Trauma, Vascular surgeon, CT-scan, and graft patency at 3, 6 and 12 months.
Trauma, Vascular surgeon, CT-scan, and graft patency at 3, 6 and 12 months.
Trauma, Vascular surgeon, CT-scan, and graft patency at 3, 6 and 12 months.
Trauma, Vascular surgeon, CT-scan, and graft patency at 3, 6 and 12 months.
Trauma, Vascular surgeon, CT-scan, and graft patency at 3, 6 and 12 months.
Trauma, Vascular surgeon, CT-scan, and graft patency at 3, 6 and 12 months.
Trauma, Vascular surgeon, CT-scan, and graft patency at 3, 6 and 12 months.
Trauma, Vascular surgeon, CT-scan, and graft patency at 3, 6 and 12 months.
Trauma, Vascular surgeon, CT-scan, and graft patency at 3, 6 and 12 months.
Trauma, Vascular surgeon, CT-scan, and graft patency at 3, 6 and 12 months.
Trauma, Vascular surgeon, CT-scan, and graft patency at 3, 6 and 12 months.
Trauma, Vascular surgeon, CT-scan, and gra"
925,"[/INST]
Other Outcome Measures
| --- | --- |
| Summary: [/INST]
Device: [/INST]
| Summary: [/INST]
Adverse Events
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary: [/INST]
| Device: [/INST]
| Summary"
926,"[/INST]
This
This
This
This
This
This
This
This
A
A
This
This
This
This
This
This
This
This
This
This
This
A
A
A
A
A
A
A
A
A
A
This
This
A
A
A
A
A
A
A
A
A
A
This
This
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
f
f
f



be
be
be
be
A










A
A
A
A
A
A
A
A
A
A




A
A
The
The
The
The
The
The
The
The
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
f
f
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A"
927,"[/INST]
| Blood Flow Restriction | creatine, exercise
| Blood Flow Restriction | creatine, exercise
| Blood Flow Restriction | creatine, exercise
| Blood Flow Restriction | creatine, exercise
|
| Blood Flow Restriction | creatine, exercise
|
| Blood Flow Restriction | creatine, exercise
|
| Blood Flow Restriction | creatine, exercise
|
| Blood Flow Restriction | creatine, exercise
|
| Blood Flow Restriction | creatine, exercise
|
|
| Blood Flow Restriction | creatine, exercise
|
|
|
| creatine, exercise
| creatine, exercise
| creatine, exercise
| creatine, blood flow restriction| creatine exercise
| creatine, exercise
| creatine, exercise
| creatine, exercise
| creatine, creatine exercise| creatine, exercise.| creatine, creatine exercise.| creatine exercise.| creatine exercise.| creatine exercise.| creatine exercise.| creatine exercise.| creatine exercise.| creatine exercise.| creatine.| creatine exercise.| creatine exercise.| creatine exercise creatine exercise creatine exercise.| creatine exercise creatine exercise.| creatine exercise.| creatine exercise creatine creatine exercise creatine exercise creatine exercise creatine exercise creatine exercise creatine exercise creatine exercise creatine exercise creatine exercise creatine exercise creatine exercise creatine exercise creatine exercise creatine exercise creatine exercise creatine exercise creatine creatine exercise creat
| creatine exercise creatine exercise creat
| creatime creatime creatime creatine creat
| creatine creat
| creat
| creat
| creat
| creat
| creat
| creat
| creat
| creat
| creat
cre
cre
cre
cre
cre
cre
cre.
cre.
crew.
The creat.
crew.
cre.
crew.
crew.
crew.
The"
928,"[/INST]

Secondary Outcome Measures
-----------------
What is the study measuring?
| Outcome Measure | Time Frame |
| Growth Differentiation Factor-15 (GDF-15) (pg/ml) | Comparison of GDF-15 (pg/ml) level in the cerebrospinal fluids of AN patients and normal-weight controls. | one time assessment 3 weeks after screening | 
| Growth Differentiation Factor-15 (GDF-15) (pg/ml) | Comparison of GDF-15 (pg/ml) level in the cerebrospinal fluids of AN patients and normal-weight controls. |
-----------------
Exercise: [/INST]
Primary Outcome Measures
| Growth Differentiation Factor-15 (GDF-15) (pg/ml) | Comparison of GDF-15 (pg/ml) level in the cerebrospinal fluids of AN patients and normal-weight controls. | one time assessment 3 weeks after screening | 
| Growth Differentiation Factor-15 (GDF-15) (pg/ml) | Comparison of GDF-15 (pg/ml) level in the cerebrospinal fluids of AN patients and normal-weight controls. |
Terms related to the study
Secondary Outcome Measures
What is the study measuring?
| Growth Differentiation Factor-15 (GDF-15) (pg/ml) | Comparison of GDF-15 (pg/ml) level in the cerebrospinal fluids of AN patients and normal-weight controls. | one time assessment 3 weeks after screening | 
| Growth Differentiation Factor-15 (GDF-15) (pg/ml) | Comparison of GDF-15 (pg/ml) level in the cerebrospinal fluids of AN patients and normal-weight controls. |
Exercise: [/INST]
Primary Outcome Measures
| Growth Differentiation Factor-15 (GDF-15) (pg/ml) | Comparison of GDF"
929,"[/INST]

Patient Information
-----------------

Procedure: [Institution]

Patient Information: [Institution]

Procedure: [Patient Information]

Patient Information: [Institution]

Procedure: [Patient Information]

Patient Information: [Institution]

Procedure: [Patient Information]

Patient Information: [Institution]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure: [Patient Information]

Procedure:"
930,"[/INST]
| Artificial Intelligence, Proportional Hazards, Coronary Computed Tomography, Major adverse cardiovascular events, angina-like symptoms | 
| Prospective cohort of patients | 
| Artificial Intelligence, Proportional Hazards, Coronary Computed Tomography Angiography, Major adverse cardiovascular events | 
| Prospective cohort of patients | 
| Artificial Intelligence, Proportional Hazards, Coronary Computed Tomography Angiology, Major adverse cardiovascular events | 
| Prospective cohort of patients | 
| Artificial Intelligence, Proportion of patients | 
| Artificial Intelligence, Coronary Computed Tomography, Coronary Computed Tomography, Major adverse cardiovascular events | 
| Prospective Hazards, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Computed, Pros, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Tomography, Coronary Computed Tomography, Coronary Computed Tomography, Coronary Tomography, Coronary Tomography, Coronary Tomography, Coronary Tomography, Coronary Tomography, Coronary Tomography, Coron.
|
The majority Tom
The most Tom
The most physi
The most patients with a patient Tom
Coronol
The risk.
Coronol.
Coronists.
The risk.
The risk.
The risk.
The Tom.
The Tom.
The goal.
The goal.
The Tom.
The Tom.
The patients with a patient.
The patient.
The Tom.
The Tom.
The Tom.
The Tom.
The patients.
The patient.
The patient.
The patient"
931,"[/INST]
S
S
S
S
S
S
S
The
The
The
The
The
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
The
The
The






The



The
The
The
The"
932,"[/INST]




















































0




0
0




































0
0
0




0
0
0

0
0
0
0
8
8
8
8
8
-
-
-
-
-
-
-
-
-
0
0
0
0
0
0000000000000
0
0
0
-
0
0
0
0
0

-
0
0
0
0
0
0
0000000000000000-
0-
0-
0000000-
-
-
-
-
-
-
-
-
-
-
-
0000000000000000-0-
-000000000-
-
-
-
-
-
-
-
-
-
0000000000000000000-
-0-0-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-000000000-0-
0
0
0
-
-
0000000000000000-
-
-
-
-000000000-0-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0-
0-
0-
-
-
-
0-
0-
0-
0-
0-"
933,"[/INST]
-----------------

Adverse Events
-----------------
Decision-Making
-----------------
Behavioral performance will be assessed in terms of well-known metrics such as selective attention and inhibitory control.
Standard EEG/MEG acquisition and analysis will be used to detect brain activity associated with decision-making and executive performance.
-----------------
Primary Outcome Measure
Decision-Making Skills
Behavioral performance will be assessed in terms of well-known metrics such as selective attention and inhibitory control.
Standard EEG/MEG acquisition and analysis will be used to detect brain activity associated with decision-making and executive performance.
Secondary Outcome Measure
Decision-Making
Behavioral performance will be assessed in terms of well-known metrics such as selective attention and inhibitory control.
Standard DTI acquisition and analysis will be used to detect brain activity associated with decision-making and executive performance.
Adverse Events
Decision-Making
Behavioral performance will be assessed in terms of well-known metrics such as selective attention and inhibitory control.
Standard EEG/MEG acquisition and analysis will be used to detect brain activity associated with decision-making and executive performance.
Secondary Outcome Measure
Decision-Making
Behavioral performance will be assessed in terms of well-known metrics such as selective attention and inhibitory control.
Standard DTI acquisition and analysis will be used to detect brain activity associated with decision-making and executive performance.
Adverse Events
Decision-Making
Behavioral performance will be assessed in terms of well-known metrics such as selective attention and inhibitory control.
Standard EEG/MEG acquisition and analysis will be used to detect brain activity associated with decision-making and executive performance.
Adverse Events
Decision-Making
Behavioral performance will be assessed in terms of well-known metrics such as selective attention and inhibitory control.
Standard DTI acquisition and analysis will be used to detect brain activity associated with decision-making and executive performance.
Adverse Events
Decision-Making
Behavioral performance will be assessed in terms of well-known metrics such as selective attention and inhibitory control.
Standard DTI acquisition and analysis will be used to detect brain activity associated with decision-making and"
934,"[/INST]
| Participant Group | Eligibility Criteria |
| --- | --- |
| Participants will be asked to complete a questionnaire related to key safety information. | Participants will be asked to complete a questionnaire related to key safety information. | 2 months |
| Participants will be asked to complete a questionnaire related to key safety information. | Participants will be asked to complete a questionnaire related to key safety information. | 2 months |
| Participants will be asked to complete a questionnaire related to key safety information. | Participants will be asked to complete a questionnaire related to key safety information. | 2 months |
| Participants will be asked to complete a questionnaire related to key safety information. | Participants will be asked to complete a questionnaire related to key safety information. | 2 months |
| Participants will be asked to complete a questionnaire related to key safety information. | Participants will be asked to complete a questionnaire related to key safety information. | 2 months |
| Participants will be asked to complete a questionnaire related to key safety information. | Participants will be asked to complete a questionnaire related to key safety information. | 2 months |
| Participants will be asked to complete a questionnaire related to key safety information. | Participants will be asked to complete a questionnaire related to key safety information. | 2 months |
| Participants will be asked to complete a questionnaire related to key safety information. | Participants will be asked to complete a questionnaire related to key safety information. | Participants will be asked to complete a questionnaire related to key safety information. | 2 months |
| Participants will be asked to complete a questionnaire related to key safety information. | Participants will be asked to complete a questionnaire related to key safety information. | Participants will be asked to complete a questionnaire related to key safety information. | 2 months |
| Participants will be asked to complete a questionnaire related to key safety information. | Participants will be asked to complete a questionnaire related to key safety information. | Participants will be asked to complete a questionnaire related to key safety information. | 2 months |
| Participants will be asked to complete a questionnaire related to key safety information."
935,"[/INST]
Primary Outcome Feedback
[/INST]
Secondary Outcome Feedback
[/INST]
gait, walking, wearing, feedback, motivation, push-off, 3 months, 6 months, 1 year [/INST]
[/ST]
Secondary Outcome Feedback
[/INST]
gait, walking, wearing, feedback, motivation, push-off, 3 months, 6 months, 1 year [/INST]
[/ST]
Secondary Outcome Feedback
[/INST]
gait, walking, wearing, feedback, motivation, push-off, 3 months, 6 months, 1 year [/INST]
[/ST]
Secondary Outcome Feedback
[/INST]
gait, walking, wearing, feedback, motivation, push-off, 3 months, 6 months, 1 year [/INST]
[/ST]
Secondary Outcome Feedback
[/INST]
gait, walking, wearing, feedback, motivation, push-off, 3 months, 6 months, 1 year [/INST]
[/ST]
Secondary Outcome Feedback
[/INST]
gait, walking, wearing, feedback, motivation, push-off, 3 months, 6 months, 1 year [/INST]
[/ST]
Secondary Outcome Feedback
[/INST]
gait, walking, wearing, feedback, motivation, push-off, 3 months, 6 months, 1 year [/INST]
[/ST]
Secondary Outcome Feedback
[/INST]
gait, walking, wearing, feedback, motivation, push-off, 3 months, 6 months, 1 year [/INST]
[/ST]
Secondary Outcome Feedback
[/INST]
gait, walking, wearing, feedback, motivation, push-off, 3 months, 6 months, 1 year [/INST]
[/ST]
Secondary Outcome Feedback
[/INST]
gait, walking, wearing, feedback, motivation, push-off, 3 months, 6 months, 1"
936,"[/INST]
8-1.
8.
8.
8.
8.
, 1-8.
8.
8.
9.
10.
8.
9.
10, 9.
9.
10.
9.
9.
10.
9.
10.
10.
10, 9.
1.
9.
9.
10.
9.
10.
9.
10.
9.
10.
9.
10
10
9
9
9
9
9
9
9
9
10
10
9
10.
1.
1.
9.
9
9
9
9
10
9
1
1.
9
9
9
9
9
9
9
9
9
1.
1.
1.
9
This
9
9
9
9
9
9
9
9
9
The
The
==
==
==
==
==
==
==>
==
==>
==>
This
This
This
/>
/>
/>
==
This
It
It
It
==
==
==
==
==
==
A
A
A
A
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==.
==.
A
A
This
A
==
==
==
==
==
==
==
This
This
This
This
This
This
This
This
This
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
/>
a
This
This
a
a
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
==
A
A
A
by
by a"
937,"[/INST]

Experimental: printed decision aid
| South Asian, aged 25-64 |
| screening decision, cervical cancer, ethnic minority |
| unsure of the screening decision |
| Choice question, cervical cancer screening |
| screening decision, ethnic minority |
| unsure of the screening decision |
| cervical cancer, screening decision, ethnic minority |
| Choice question, cervical cancer screening |
| screening decision, ethnic minority |
| unsure of the screening decision |
| cervical cancer, screening decision, ethnic minority |
| Choice question, cervical cancer screening |
| screening decision, ethnic minority |
| unsure of the screening decision |
| cervical cancer, screening decision, ethnic minority |
| Choice question, cervical cancer screening |
| screening decision, ethnic minority |
| unsure of the screening decision |
| cervical cancer, screening decision, ethnic minority |
| Choice question, cervical cancer screening |
| screening decision, ethnic minority |
| unsure of the screening decision |
| cervical cancer, screening decision, ethnic minority |
| Choice question, cervical cancer screening |
| screening decision, ethnic minority |
| unsure of the screening decision |
| cervical cancer, screening decision, ethnic minority |
| Choice question, cervical cancer screening |
| screening decision, ethnic minority |
| unsure of the screening decision |
| cervical cancer, screening decision, ethnic minority |
| Choice question, cervical cancer screening |
| screening decision, ethnic minority |
| unsure of the screening decision |
| cervical cancer, screening decision, ethnic minority |
| Choice question, cervical cancer screening |
| screening decision, ethnic minority |
| unsure of the screening decision |
| Choice question, cervical cancer screening |
| screening decision, ethnic minority |
| unsure of the screen"
938,"[/INST]

Examine the effects of the interventions on the primary and secondary outcomes.
-----------------
Temporomandibular disorder, Pain, Traction, conservative management
Primary Outcome: [/INST]
Secondary Outcome: [/INST]
Examine the effects of the interventions on the primary and secondary outcomes.
Temporomandibular disorder, Pain, Traction, conservative management
Secondary Outcome: [/INST]
Examine the effects of the interventions on the primary and secondary outcomes.
Temporomandibular disorder, Pain, Traction, conservative management
Primary Outcome: [/INST]
Examine the effects of the interventions on the primary and secondary outcomes.
Temporomandibular disorder, Pain, Traction, conservative management
Secondary Outcome: [/INST]
Examine the effects of the interventions on the primary and secondary outcomes.
Temporomandibular disorder, Pain, Traction, conservative management
Primary Outcome: [/INST]
Examine the effects of the interventions on the primary and secondary outcomes.
Temporomandibular disorder, Pain, Traction, conservative management
Secondary Outcome: [/INST]
Examine the effects of the interventions on the primary and secondary outcomes.
Temporomandibular disorder, Pain, Traction, conservative management
Primary Outcome: [/INST]
Examine the effects of the interventions on the primary and secondary outcomes.
Temporomandibular disorder, Pain, Traction, conservative management
Secondary Outcome: [/INST]
Examine the effects of the interventions on the primary and secondary outcomes.
Temporomandibular disorder, Pain, Traction, conservative management
Primary Outcome: [/INST]
Examine the effects of the interventions on the primary and secondary outcomes.
Temporomandibular disorder, Pain, Traction, conservative management
Secondary Outcome: [/INST]
Examine the effects of the interventions on the primary and secondary outcomes.
Temporom"
939,"[/INST]
Inclusion Criteria: Moderate Acne Vulgaris
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B Once-daily Dapsone gel for 03 months
Experimental: Group A Clindamycin and Dapsone gel<br> Group B"
940,"[/INST]
| What is the study measuring? | Measure Description | Time Frame |
| --- | --- |
| Differences in Muscle Activation Patterns by Tear Size | Identification of differences in muscle activation patterns between varying tears (small, medium, large, and massive). | baseline |

| What is the study measuring? | Measure Description | Time Frame |
| --- | --- |
| Differences in Muscle Activation Patterns by Tear Size | Identification of differences in muscle activation patterns between varying tears (small, medium, large, and massive). | baseline |

| What is the study measuring? | Measure Description | Time Frame |
| --- | --- |
| Differences in Muscle Activation PatternS by Tear Size | Identification of differences in muscle activation patterns between varying tears (small, medium, large, and massive). | baseline |

| What is the study measuring? | Measure Description | Time Frame |
| --- | --- |
| Differences in Muscle Activation PatternS by Tear Size | Identification of differences in muscle activation patterns between varying tears (small, medium, large, and massive). | baseline |

| What is the study measuring? | Measure Description | Time Frame |
| --- | --- |
| Differences in Muscle Activation PatternS by Tear Size | Identification of differences in muscle activation patterns between varying tears (small, medium, large, and massive). | baseline |

| What is the study measuring? | Measure Description | Time Frame |
| --- | --- |
| Differences in Muscle Activation PatternS by Tear Size | Identification of differences in muscle activation patterns between varying tears (small, medium, large, and massive). | baseline |

| What is the study measuring? | Measure Description | Time Frame |
| --- | --- |
| Differences in Muscle Activation Patterns by Tear Size | Identification of differences in muscle activation patterns between varying tears (small, medium, large, and massive). | baseline |

| What is the study measuring? | Measure Description | Time Frame |
| --- | --- |
| Differences in Muscle Activation PatternS by Tear Size | Identification of"
941,"[/INST]


















































































































































































































































































































































-
















-


























-

























-
-
-"
942,"[/INST]
| Kidney Transplant Recipient | Kidney Transplant Recipient
-----------------
| Rejection of kidney transplantation | Clinical diagnosis of kidney transplantation | Prediction of rejection of kidney transplantation | Rejection of kidney transplantation | Prognosis of kidney transplantation | Prediction of rejection of kidney transplantation | Development of donor-specific cellular markers after kidney transplantation | Rejection of kidney transplantation | Clinical diagnosis of acute rejection of kidney transplantation | Development of donor-specific cellular markers after kidney transplantation | Rejection of kidney transplantation | Prognosis of kidney transplantation | Prediction of rejection of kidney transplantation | 90 days after kidney transplantation | Rejection of kidney transplantation | Development of donor-specific cellular markers after kidney transplantation | 120 days after kidney transplantation | 90 days of hospitalization | Rejection of kidney transplantation | 180 days after hospitalization | 90 days of therapeutic use of antibodies | 120 days of hospitalization | 90 days of therapeutic use of antibodies | 180 days of kidney transplantation | 90 days of therapeutic use of antibodies | 120 days of hospitalization | 90 days of therapeutic use of antibodies | 180 days of hospitalization | 90 days of therapeutic use of antibodies | 120 days of hospitalization | 90 days of therapeutic use of antibodies | 180 days of hospitalization | 90 days of therapeutic use of antibodies | 120 days of hospitalization | 90 days of therapeutic use of antibodies | 180 days of hospitalization | 90 days of therapeutic use of antibodies | 120 days of hospitalization | 90 days of therapeutic use of antibodies | 120 days of hospitalization |"
943,"[/INST]

Secondary Outcome Measures
-----------------

Change in Stair Climb Test (SCT) score
Time Frame: 18 months
| Vitamin B12 group | Vitamin B12 group
| Drug: Vitamin B12
| Experimental: Vitamin B12 group
| Vitamin B12 group

Change in Sensory Motor Test (SMT) score
Time Frame: 18 months
| Vitamin B12 group | Vitamin B12 group
| Drug: Vitamin B12
| Experimental: Vitamin B12

Change in Sensory Motor Test (SMT) score
Time Frame: 18 months
| Vitamin B12 group | Vitamin B12 group
| Drug: Vitamin B12
| Experimental: Vitamin B12

Change in Sensory Motor Test (SMT) score
Time Frame: 18 months
| Vitamin B12 group | Vitamin B12 group
| Drug: Vitamin B12
| Experimental: Vitamin B12

Change in Cognitive Motor Test (CMTT) score
Time Frame: 18 months
| Vitamin B12 group | Vitamin B12 group
| Drug: Vitamin B12
| Experimental: Vitamin B12

Change in Cognitive Motor Test (CMTT) score
Time Frame: 18 months
| Vitamin B12 group | Vitamin B12 group
| Drug: Vitamin B12
| Experimental: Vitamin B12

Change in Cognitive Motor Test (CMTT) score
Time Frame: 18 months
| Vitamin B12 group | Vitamin B12 group
| Drug: Vitamin B12
| Experimental: Vitamin B12

Change in Cognitive Motor Test (CMTT) score
Time Frame: 18 months
| Vitamin B12 group | Vitamin B12 group
| Drug: Vitamin B12
| Experimental: Vitamin B12

Change in Cognitive Motor Test (CMTT) score
Time Frame: 18 months
| Vitamin B12 group | Vitamin B12"
944,"[/INST]

How is the study designed?
| Invasive disease-free Survival | Disease-free survival time is defined as the time from enrollment until the first disease recurrence or death from any cause. | Enrollment until time of events up to 5 years | Disease-free survival time is defined as the time from enrollment until the first disease recurrence or death from any cause. | Invasive disease-free Survival time is defined as the time from enrollment until the first disease recurrence or death from any cause. |

How is the study designed?
| Invasive disease-free Survival | Disease-free survival time is defined as the time from enrollment until the first disease recurrence or death from any cause. | Enrollment until time of events up to 5 years | 

How is the study measuring?
| Invasive disease-free Survival | Disease-free survival time is defined as the time from enrollment until the first disease recurrence or death from any cause. | Enrollment until time of events up to 5 years | 

How is the study measuring?
| Invasive disease-free Survival | Disease-free survival time is defined as the time from enrollment until the first disease recurrence or death from any cause. | Enrollment until time of events up to 5 years | 

How is the study designed?
| Invasive disease-free Survival | Disease-free survival time is defined as the time from enrollment until the first disease recurrence or death from any cause. | Enrollment until time of events up to 5 years | 

How is the study measuring?
| Invasive disease-free Survival | Disease-free survival time is defined as the time from enrollment until the first disease recurrence or death from any cause. | Enrollment until time of events up to 5 years | 

How is the study designed?
| Invasive disease-free Survival | Disease-free survival time is defined as the time from enrollment until the first disease recurrence or death from any cause. | Enrollment until time of events up to 5 years |"
945,"[/INST]
8
8
8



8
8
8


8
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A























































































8
ine
8
8
8
8
8
8
8







































ine
ive
ive
ive
ive
ive





ive
ive
ive
ive
ive
8
























































































































































































ized"
946,"[/INST]
In|
In|>
in.
in.
in.
In.
In.
In.
In.
In
in.
In//
In//
in//
in
In
In
In
In
In
In
in
in a->
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
0
0
0
in
in
in
in
.
.
.
.
.
.
.
.
.
.
In
In
In
In
This
This
In
In
000000
0
In
This
This
This
This
This
This
This
in
This
This
This
in

























































































































































































































































0000000000000000
0
0
0
0
000000000
0
0
0
0

0
0
0
0
00
00000
0

0"
947,"[/INST]
Other names: Arm swing, gait, Timed Up and Go (TUG)
Primary Outcome Measures
Keywords: arm swing, gait, Timed Up and Go (TUG)
Other names: arm swing, gait, Timed 25Foot Walk Test (T25FW)
Primary Outcome Measures
Other names: arm swing, gait, Timed Up and Go (TUG)
Other names: arm swing, gait, Timed 25Foot Walk Test (T25FW)
Other names: arm swing, gait, Timed Up and Go (TUG)
Other names: arm swing, gait, Timed 25Foot Walk Test (T25FW)
Other names: arm swing, gait, Timed Up and Go (TUG)
Other names: arm swing, gait, Timed 25Foot Walk Test (T25FW)
Other names: arm swing, gait, Timed Up and Go (TUG)
Other names: arm swing, gait, Timed 25Foot Walk Test (T25FW)
Other names: arm swing, gait, Timed Up and Go (TUG)
Other names: arm swing, gait, Timed 25Foot Walk Test (T25FW)
Other names: arm swing, gait, Timed Up and Go (TUG)
Other names: arm swing, gait, Timed 25Foot Walk Test (T25FW)
Other names: arm swing, gait, Timed Up and Go (TUG)
Other names: arm swing, gait, Timed 25Foot Walk Test (T25FW)
Other names: arm swing, gait, Timed Up and Go (TUG)
Other names: arm swing, gait, Timed 25Foot Walk Test (T25FW)
Other names: arm swing, gait, Timed Up and Go (TUG)
Other names: arm swing, gait, Timed 25Foot Walk Test (T25FW)
Other names: arm swing, gait, Timed Up and Go (TUG)
Other names: arm swing, gait, Timed 25Foot Walk Test (T25"
948,"[/INST]

Primary Purpose: To measure the effect of the study.
| Secondary Outcome Measures |

Terms related to the study

| Drug: Capecitabine, Pyrotinib; other names: endocrine drugs, Po, for postmenopausal patients.|

| Drug: anastrozole, for premenopausal patients, after chemotherapy, and letrozole (2.5 mg, po, qd for 5 years) or exemestane (1 mg, po, qd for 5 years).|


| Drug: Capecitabine, for premenopausal patients, after chemotherapy, and anastrozole (1 mg, po, qd for 5 years) or letrozole (2.5 mg, po, qd for 5 years) or tamoxifen (60 mg, po, qd for 5 years) or toremifene (1 mg, po, qd for 5 years) or exemestane (2.5 mg, po, qd for 5 years).|


| Drug: anastrozole, for premenopausal patients, after chemotherapy, and letrozole (2.5 mg, po, qd for 5 years) or tamoxifen (1 mg, po, qd for 5 years) or toremifene (60 mg, po, qd for 5 years) or exemestane (1 mg, po, qd for 5 years) or anastrozole (1 mg, po, qd for 5 years).|



| Drug: anastrozole, for premenopausal patients, after chemotherapy, and letrozole (2.5 mg, po, qd for 5 years) or tamoxifen (1 mg, po, qd for 5 years) or toremifene (60 mg, po, qd for 5 years) or exemestane (1 mg, po, qd for 5 years) or anastrozole (1 mg, po, qd for 5 years) or letrozole (2.5 mg, po, qd"
949,"[/INST]
Primary Outcome Measure
| Dyspnea Index (DI) | This is a 10-item questionnaire with scores that range from 0-40, with 40 representing the greatest possible severity of symptoms. The DI is a clinical assessment tool that was designed and validated specifically for patients with upper airway obstruction, including patients with PVFM. The primary outcome measure will be the change in the Dyspnea Index (DI) between the two groups. | pre and 1 month post treatment | 
| Dyspnea Index (DI) | This is a 10-item questionnaire with scores that range from 0-40, with 40 representing the greatest possible severity of symptoms. The DI is a clinical assessment tool that was designed and validated specifically for patients with upper airway obstruction, including patients with PVFM. The primary outcome measure will be the change in the Dyspnea Index (DI) between the two groups. | pre and 3 months post treatment | 
| Dyspnea Index (DI) | This is a 10-item questionnaire with scores that range from 0-40, with 40 representing the greatest possible severity of symptoms. The DI is a clinical assessment tool that was designed and validated specifically for patients with upper airway obstruction, including patients with PVFM. The primary outcome measure will be the change in the Dyspnea Index (DI) between the two groups. | 1 month and 3 months post treatment | 
| Dyspnea Index (DI) | This is a 10-item questionnaire with scores that range from 0-40, with 40 representing the greatest possible severity of symptoms. The DI is a clinical assessment tool that was designed and validated specifically for patients with upper airway obstruction, including patients with PVFM. The primary outcome measure will be the change in the Dyspnea Index (DI) between the two groups. | pre and 1 month post treatment | 
| Dyspnea Index (DI) | This is a 10-item questionnaire with scores that range from 0-40, with 40 representing the greatest possible severity of symptoms. The DI is a clinical assessment tool that was designed and valid"
950,"[/INST]
Sleep Disorders in Critically Ill Patients: Effect of the Multidisciplinary Sleep Protocol (MSc thesis, 2019)"
951,"[/INST]
The

























































A
A
A
s
s
s
s
s
































































































































































































































































g
g
g
g
g
g
g
g
























g
g
g
g



g
g
g
g
g
g
g
g
g
8
8
g
g
g
g
g
8
g
g
g
g
g












g
g
g
g
g
g
g
A"
952,"[/INST]
As.
In.
In.
In|s.
In a|s.
In|s.
In a|c.
As a|c.
As to to.
In to to improve to improve.
As.
In.
In.
, it.
,
In.
In.
In.
In
In
In
This
In
This
As
As
This
This
This
This
In
In
This
It
It
in
in
in
as
as a
as
as
as
as
as
as
as
in
in
in
to
to
in
in
in
in
in
in
in
in
in
This
This
This
This
This
This
This.
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
In
This
as
as
as
as
as
as
as
as
as
to
to
to
to
to
to
to
This
This
This
This
This
This
This
This
This
This
This
This
A



as
simp
simp
simp
c
in
in
in
A
A
A
c
A









































































































































































8
8"
953,"[/INST]
|
| 3 months after the
| 18 months after the
|18 months
|18 months
|1 year|1 year|1 year|18 months
|18 years
|18 months after the
|18 months
|18 months
|18 months
|18 months
|18 months
|18 months
|18 months
|18 months
|18 months
|18
|18
|18
|18
|18
|18
|18
|18
|18
|18
|18.
|18.
|18.
|18.
|18.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The patient|
This
|
|
|
|
|
|
|
|
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient
The patient|
The patient|
The patient
The   
|
|
|
in
in
in
This
This
This
In
This
The
|
|
This
This
This
This
This
==

|
|
|
|
==
==
==
==
in
in
in
in
This
This
This
in
in
in
This
This
in
in









This
This
This
This
in
in
in
in
in
in
in
in
in
in
tre
tre
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
be
f
F
f
f
f
f
in
in
in
in
in
in
This
This
This
This
This
This
This
This
This
This
This
in
in
f
F
F
F
F
F
f"
954,"[/INST]
Adverse Events
-----------------
Experimental: Social Engage Coaching (S-ENG) involves psychoeducation on social isolation, ambulatory monitoring of smartphone use, and behavioral sensing on conversations with others. S-ENG is a stepped, ambulatory program on social isolation, active monitoring of smartphone use, and behavioral sensing on conversations with others. The primary intervention is social engagement (S-ENG) on smartphones, which involves psychoeducation on social isolation, passive monitoring of smartphone use, and behavioral sensing on conversations with others. The secondary intervention is social engagement (S-ENG) on smartphones, which involves psychoeducation on social isolation, active monitoring of smartphone use, and behavioral sensing on conversations with others. The tertiary intervention is social engagement (S-ENG) on smartphones, which involves psychoeducation on social isolation, active monitoring of smartphone use, and behavioral sensing on conversations with others.
Primary Outcome Measures
-----------------
Experimental: Social Engage Coaching (S-ENG) involves psychoeducation on social isolation, active monitoring of smartphone use, and behavioral sensing on conversations with others. The primary intervention is social engagement (S-ENG) on smartphones, which involves psychoeducation on social isolation, active monitoring of smartphone use, and behavioral sensing on conversations with others. The tertiary intervention is social engagement (S-ENG) on smartphones, which involves psychoeducation on social isolation, active monitoring of smartphone use, and behavioral sensing on conversations with others.
Adverse Events: [/INST]
Experimental: Social Engage Coaching (S-ENG) involves psychoeducation on social isolation, active monitoring of smartphone use, and behavioral sensing on conversations with others. The primary intervention is social engagement (S-ENG) on smartphones, which involves psychoeducation on social isolation, active monitoring of smartphone use, and behavioral sensing on conversations with others. The tertiary intervention is"
955,"[/INST]
The symptoms.
The, the
The
The symptoms.
The symptoms.
The symptoms.
The patient.
The
The
The symptoms.
The symptoms.
The symptoms.
The patient
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
The patient.
--------
--------
The patient.
The patient.
In
*
*
*
*
*
*
*
*
The patient
in
in
in
in
In
In
In the particular
in
in
in
in
in
in
in
In
In
In
In
In
In
In
In
In
In
In
in
in
in
in
In
in
in
in
in
in
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
In
This
This
This
This
P
































P
P
P
P"
956,[/INST]
957,"[/INST]
| The amount of drug excreted in urine at t hours after administration | day3 to day3 to day3
| The amount of drug excretion at t hours after administration | day3 to day3 to day3 to
| The amount of drug excretion at t hours after administration | day3 to day3 to day3
| The amount of drug excretion at day3 to day3 to day3 to
| day3 to day3 to
| day3 to day3 to
| The amount of drug excretion at day3 to day3 to day3 to day3
| day3 to day3 to day
| day3 to day
| day3 to day
| day
| day
| day
| day
| day
| day
| day3 day
| day
| day
| day day
| day3 day
| day
| day|3 day|3 day|3 day
| day
| day
| day|3 day|3 day|3 day|3 day|3 day|3 day|3 day|3 day|3 day|3 day|3 day|3|3 day|3 day|3|3 day|3 day|3|3 day|3 day|3|3 day|3 day|3 day|3 day|3 day|3 day
|3 day|3|3|3|3 day|3|3|3 day|3|3|3|3|3|3|3|3|3
|3|3|3|3|3|3|3|3
|3
|3|3|3
|3|3
|3|3|300000000000000001
|   3|
|
Term
Term
Term
Term
M,*
----------------|
----------------
----------------
----------------|
Patient
The patient
The patient
----------------
----------------
----------------
----------------
----------------
Patient
Patient
Patient*
Patient
Patient
Patient*
Patient*
----------------
Pat
----------------
This
It's
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This
This"
958,"[/INST]
Adverse events associated with the use of urolithin A in middle-aged adults with obesity will be listed here.
| Ages: 40-64 years old, exclusively breastfeeding men.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated adverse events.
| Other: No information provided on the anticipated ad"
959,"[/INST]
What is the study related to the neck pain?
| Other: [/INST]
What is the study related to the neck pain?
| 10 minutes | 10 minutes | 12 seconds after reversing the scale.
| 10 minutes after reversing the neck pain.
What is the study related to the neck pain.
| 10 minutes after reversing the pain.
What is the neck pain.
What is the neck pain.
| 10 minutes after reversing the neck pain.
What is the neck pain.
What is the neck pain.
What is the study related to the neck pain.
What is the study related to the neck pain.
What is the study related to the neck pain.
What is the neck pain.
What is the study related to the neck pain.
What is the study related to the neck pain.
What is the study related to the neck pain.
What is the study related to the neck pain related to the study related to the study related to the neck pain related to the study related to the neck pain related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study related to the study.
What is the study related to the study.
What is the study.
What is the study.
What is the study.
What the study.
What is the study.
What is the study.
What.
What.
What is the study.
What is the study.
The study.
The study.
How.
How.
The results.
The results.
The
The
The
The
In
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The.
In.
In.
In.
The
The
The
The.
The.
The.
It.
The.
It.
It"
960,"[/INST]
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
THE
The













































































The
THE
THE
THE




















































































































































































































































































































































a
a
a
a
a"
961,"[/INST]
-





A
A
A
A
A


A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A-
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A
A
A-
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A














A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A



























































































































A
A

























































































C
C
C
C
C

















C
C
C



C
C
C
C
C
C
C
C
C
C
C"
962,"[/INST]
The











































--------

















--------
--------
--------
--------
--------







The
The
The
The
The
the
the
mil
mil












































two
two
two
two
two
two























































































































































mil
mil
s

s























s
s
s
s


































































S
S
m
















h
h
s
s
s
s
s
s
S
S
S
S
S
m
h
h
m
m
h
m
m
h
h
h
S
h
S
S
h
S
S
S
The
The
S
S
S
S
S"
963,"[/INST]
| Laryngectomy | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Laryngectomy | Intervention/Treatment |
| Summary of the study provided by the hospital. | 4 months | 
| Laryngectomy | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Laryngectomy | Intervention/Treatment |
| Summary of the study provided by the hospital. | 4 months | 
| Laryngectomy | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Laryngectomy | Intervention/Treatment |
| Summary of the study provided by the hospital. | 4 months | 
| Laryngectomy | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Laryngectomy | Intervention/Treatment |
| Summary of the study provided by the hospital. | 4 months | 
| Laryngectomy | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Laryngectomy | Intervention/Treatment |
| Summary of the study provided by the hospital. | 4 months | 
| Laryngectomy | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Laryngectomy | Intervention/Treatment |
| Summary of the study provided by the hospital. | 4 months | 
| Laryngectomy | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Laryngectomy | Intervention/Treatment |
| Summary of the study provided by the hospital. | 4 months | 
| Laryngectomy | Intervention/Treatment |
| Outcome Measure | Measure Description | Time Frame |
| Laryngectomy | Intervention/Treatment |
|"
964,"[/INST]
S
C
C
S
S
A
A
C
C
S
S
S
S
S
S
S
S
S
A
A
A
A
C
A
C
C
C
C
C
C
A
A
A
S
S
S
S
S
S
S
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
S
S
S












































C
A
A
A
A
A
A
A
A
A




C
A
A
A
A
A
A
A
C
C






C
C



























C
F
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C


C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C"
965,"[/INST]

How is the information being gathered?
-----------------
| Summary of findings from the study.
| Inclusion/Exclusion Criteria |
| Exclusion Criteria |
| Such as age, gender, race/ethnicity, education level |
| Provides information about how the data is being gathered.
| How many people are being studied.
| How is the data being analyzed?
| What kind of tests are being done?
| How are the tests being scored?
| What kind of scores are being looked at?
| How are the scores being compared to one another?
| How are the scores being interpreted?
| How are the scores being presented? Graphs? Tables?
| How are the scores being presented?
| What kind of graphs are being used?
| How are the scores being presented in the graphs?
| What kind of graphs are being used?
| How are the scores being compared to one another?
| How are the scores being presented in the graphs?
| What kind of graphs are being used?
| How are the scores being displayed?
| How are the scores being presented in the graphs?
| What kind of graphs are being used?
| How are the scores being displayed in the graphs?
| How are the scores being compared to one another?
| What kind of scales are being used?
| How are the scores being interpreted?
| How are the scores being presented in the graphs?
| What kind of scales are being used?
| How are the scores being compared to one another?
| How are the scores being presented in the graphs?
| What kind of scales are being used?
| How are the scores being compared to one another?
| How are the scores being interpreted?
| What kind of scales are being used?
| How are the scores being presented in the graphs?
| How are the scores being compared to one another?
| What kind of scales are being used?
| How are the scores being presented in the graphs?
| How are the scores being compared to one another?
| What kind of scales are being used?
| How are the scores being presented in the graphs?
| How are the scores being compared to one another?
| What kind of scales are being used?
| How are the scores being presented in the graphs?
| How are the scores being"
966,"[/INST]
Primary Purpose: Treatment
-----------------
| Secondary Purpose: Treatment of low molecular weight heparin | Active Comparator: Tinzaparin Prefilled Syringe<br>* Patients will be allocated to either dalteparin or heparin. Clusters are timeframes of 1 hour<br>| 30 days; 30-day mortality of heparin induced thrombocytopenia in patients with indications of low molecular weight heparin. | 30 days; 
| 30-day mortality of heparin induced thrombocytopenia in patients with low molecular weight heparin. | 30 days; 
| 30-day mortality of heparin induced thrombocytopenia in patients with indications of low molecular weight heparin. | 30 days; 
| 365-day mortality of heparin induced thrombocytopenia in patients with low molecular weight heparin. | 365 days; 
| 30-day mortality of heparin induced thrombocytopenia in patients with indications of low molecular weight heparin. | 30 days; 
| 365-day mortality of heparin induced thrombocytopenia in patients with indications of low molecular weight heparin. | 30 days; 
| 30-day mortality of heparin induced thrombocytopenia in patients with indications of low molecular weight heparin. | 30 days; 
| 30-day mortality of heparin induced thrombocytopenia in patients with indications of low molecular weight heparin. | 30 days; 
| 30-day mortality of heparin induced thrombocytopenia in patients with indications of low molecular weight heparin. | 30 days; 
| 30-day mortality of heparin induced thrombocytopenia in patients with indications of low molecular weight heparin. | 30 days; 
| 30-day mortality of heparin induced"
967,"[/INST]
Primary Outcome Measure
| Secondary Outcome Measure | Measure Description | Time Frame |
| --- | --- |
| Secondary Outcome Measure | Measure Description | Time Frame |
| Inspiratory muscle strength | It was measured using the maximum inspiratory pressure (MIP) with a pressure measurer (Elka PM-15, Labolier, S.A., Barcelona, Spain). Unit of measure, centimeter of water (cmH2O). | 8 weeks. | 
| Expiratory muscle strength | It was measured using the maximum expiratory pressure (MIP) with a pressure measurer (Elka PM-15, Labolier, S.A., Buckingham, England). Unit of measure, centimeter of water (cmH2O). | 8 weeks. | 

Terms related to the study
| Inspiratory muscle strength | It was measured using the maximum inspiratory pressure (MIP) with a pressure measurer (Elka PM-15, Labolier, S.A., Buckingham, England). Unit of measure, centimeter of water (cmH2O). | 8 weeks. | 
| Expiratory muscle strength | It was measured using the maximum expiratory pressure (MIP) with a pressure measurer (Elka PM-15, Labolier, S.A., Buckingham, England). Unit of measure, centimeter of water (cmH2O). | 8 weeks. | 

Secondary Outcome Measure
| Inspiratory muscle strength | It was measured using the maximum inspiratory pressure (MIP) with a pressure measurer (Elka PM-15, Labolier, S.A., Buckingham, England). Unit of measure, centimeter of water (cmH2O). | 8 weeks. | 
| Expiratory muscle strength | It was measured using the maximum expiratory pressure (MIP) with a pressure measurer (Elka PM-15, Labolier, S.A., Buckingham, England). Unit of measure, centimeter of water (cmH2O). | 8 weeks. | 

Secondary Outcome Measure
| Inspiratory muscle strength | It was measured using the maximum inspiratory pressure (MIP) with a"
968,"[/INST]









































































































































-








































































-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-e-|-|-|-|-
-|-|-|-|-|-|-|-|-                -                -                                                                -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-"
969,"[/INST]

Patients
-----------------

Time Frame: [/INST]


Patients diagnosed with Thrombotic Microangiopathies


Time of diagnosis and treatment of TMA


Patients with a predictive probability of < 90%


Time Frame: 18 Years

Patients with a history of TMA

Time Frame: 18 Years

Patients diagnosed with Thrombotic Microangiopathies

Predictive probability of < 90%

Patients with a history of TMA

Time Frame: 18 Years

Patients diagnosed with Thrombotic Microangiopathies

Predictive probability of < 90%

Patients with a history of TMA

Time Frame: 18 Years

Patients diagnosed with Thrombotic Microangiopathies

Predictive probability of < 90%

Patients with a history of TMA

Time Frame: 18 Years

Patients diagnosed with Thrombotic Microangiopathies

Predictive probability of < 90%

Patients with a history of TMA

Time Frame: 18 Years

Patients diagnosed with Thrombotic Microangiopathies

Predictive probability of < 90%

Patients with a history of TMA

Time Frame: 18 Years

Patients diagnosed with Thrombotic Microangiopathies

Predictive probability of < 90%

Time Frame: 18 Years

Patients with a history of TMA

Predictive probability of < 90%

Patients diagnosed with Thrombotic Microangiopathies

Time Frame: 18 Years

Patients with a history of TMA

Predictive probability of < 90%

Patients diagnosed with Thrombotic Microangiopathies

Time Frame: 18 Years

Patients with a history of TMA

Predictive probability of < 90%

Patients diagnosed with Thrombotic Microangiopathies

Time Frame: 18 Years

Patients with a history of T"
970,"[/INST]

Access-H20: Smart Faucet
-----------------
Primary Purpose: To provide water to individuals impacted by spinal cord injury Secondary Purpose: To provide water to individuals who are quadriplegic so they can groom and hydrate. Experimental: A prototype of the faucet was provided to quadriplegics so they can operate the fountain to provide water for grooming and rinsing.
Tertiary Purpose: To determine if the faucet can be activated by an individual who is paralyzed so they can receive water from the fountain for grooming and rinsing.
Quaternary Purpose: To develop a device that will allow an individual who is paralyzed to receive water from the fountain for grooming and rinsing.
Fifth Purpose: To determine if the faucet can be activated by an individual who is paralyzed so they can receive water from the fountain for grooming and rinsing.
Sixth Purpose: To develop a device that will allow an individual who is paralyzed to receive water from the fountain for grooming and rinsing.
Seventh Purpose: To determine if the faucet can be activated by an individual who is paralyzed so they can receive water from the fountain for grooming and rinsing.
Eighth Purpose: To develop a device that will allow an individual who is paralyzed to receive water from the fountain for grooming and rinsing.
Ninth Purpose: To determine if the faucet can be activated by an individual who is paralyzed so they can receive water from the fountain for grooming and rinsing.
Access-H20: A prototype of the fountain was provided to quadriplegics so they can receive water from for grooming and rinsing."
971,"[/INST]
Other: [/INST]
Primary Outcome Measures
-----------------
Change in Physical Activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
-----------------
Other: [/INST]
Physical Activity: [/INST]
Change in Habitual physical activity
Physical Activity: [/INST]
Change in Habitual physical activity
Physical Activity: [/INST]
Change in Habitual physical activity
Physical Activity: [/INST
Physical Activity: [/INST
Physical Activity: [/INST"
972,"[/INST]
| Keywords: [Kidney, Lung]
| Blood Pressure, Hemodynamics, Non-invasive, Continuous
| Autonomic Function Testing
| Lung Disease, Hemodynamics, Non-invasive, Continuous
| Blood Pressure, Hemodynamics, Lung Disease
| Autonomic Function Testing
| Keywords: [Kidney, Lung]
| Blood Pressure, Hemodynamics, Non-invasive, Continuous
| Lung Disease, Hemodynamics, Autonomic Function Testing
| Blood Pressure, Hemodynamics, Lung Disease
| Keywords: [Kidney, Lung]
| Blood Pressure, Hemodynamics, Non-invasive, Continuous
| Lung Disease, Hemodynamics, Autonomic Function Testing
| Blood Pressure, Hemodynamics, Lung Disease
| Keywords: [Kidney, Lung]
| Blood Pressure, Hemodynamics, Non-invasive, Continuous
| Lung Disease, Hemodynamics, Autonomic Function Testing
| Blood Pressure, Hemodynamics, Lung Disease
| Keywords: [Kidney, Lung]
| Blood Pressure, Hemodynamics, Non-invasive, Continuous
| Lung Disease, Hemodynamics, Autonomic Function Testing
| Blood Pressure, Hemodynamics, Lung Disease
| Keywords: [Kidney, Lung]
| Blood Pressure, Hemodynamics, Non-invasive, Continuous
| Lung Disease, Hemodynamics, Autonomic Function Testing
| Blood Pressure, Hemodynamics, Lung Disease
| Keywords: [Kidney, Lung]
| Blood Pressure, Hemodynamics, Non-invasive, Continuous
| Lung Disease, Hemodynamics, Autonomic Function Testing
| Blood Pressure, Hemodynamics, Lung Disease
| Keywords: [Kidney, Lung]
| Blood Press"
973,"[/INST]
The-based-
The-based-
The-
The-
The-based-
The-based
Ther.
The-based
The-based
Thomas.
Th.
Third-based
This A
Thames
This A-based
This A
This-
The-based-
This-based-
This-
This-based-based-
This-based-
This
This
This
This
This
This
This
This
This
This
This
This
The-based
This-based-based-
This-based-
This-
This-
This-
The-
The-
The-
The-
The-
The-
The-
This-
This-
This-
This-
This-
This-
This-
This-based-
This-
This-
This-
This-
This-
This-
This-
This-
This-
This-
This-
The-
The-
This-
This-
This-
The-
This-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The
The-
The-
The-
The
The
The
The
The
The
The
The
The
The
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
The-
--------
--------
--------
The-
The-
The-
The-
The-
The
The
The
The
The
The-
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The
The










The
The










The
A
A
A
A
A
A
The
The
A
A"
974,"[/INST]
| Primary Purpose: Treatment of cutaneous warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of cutaneous warts. | Secondary Purpose: Treatment of facial warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. | Secondary Purpose: Treatment of cutaneous warts. |
| Primary Purpose: Treatment of facial warts. |"
975,"[/INST]
Adverse Events
| Experimental: methotrexate<br>The first group will receive a single dose of 50 mg/m2 of letrozole The beta-hcg level is routinely measured on the first day, and the hcg serum level is measured on the fourth, seventh, and fourteenth day. | Drug: methotrexate<br>The first group will receive letrozole is given in the form of 2.5 mg tablets three times a day for 5 days, and hCG levels are measured on the first day, seventh, and fourteenth day. | Experimental: Letrozole TDS<br>letrozole is given in the form of 2.5 mg tablets three times a day, and hCG levels are measured on the first day, seventh, and fourteenth day.
| Primary Purpose: To evaluate the efficacy of Letrozole in the treatment of ectopic pregnancy. |
Secondary Outcome Measures
Adverse Events: nausea, vomiting
| Experimental: nausea, vomiting
| Primary Purpose: to evaluate the efficacy of Letrozole in the treatment of ectopic pregnancy.
| Experimental: nausea, vomiting
| Secondary Outcome Measures
Adverse Events: nausea, vomiting
| Primary Purpose: to evaluate the efficacy of Letrozole in the treatment of ectopic pregnancy.
| Experimental: nausea, vomiting
| Primary Outcome Measures
| Secondary Outcome Measures
Adverse Events: nausea, vomiting
| Primary Purpose: to evaluate the efficacy of Letrozole in the treatment of ectopic pregnancy.
| Experimental: nausea, vomiting
| Primary Outcome Measures
| Secondary Outcome Measures
Adverse Events: nausea, vomiting
| Primary Purpose: to evaluate the efficacy of Letrozole in the treatment of ectopic pregnancy.
| Experimental: nausea, vomiting
| Primary Outcome Measures
| Secondary Outcome Measures
Adverse Events: nausea, vomiting
| Primary Purpose: to evaluate the efficacy"
976,"[/INST]
Primary Outcome Measure
-----------------
Left Ventricular Diameter, Atrial septal defect closure with fenestrated patch
Secondary Outcome Measure
Left Ventricular Diameter, Atrial septal defect closure with non-fenestrated patch
Tertiary Outcome Measure
Left Ventricular Diameter, Atrial septal defect closure with non-fenestrated patch
Quaternary Outcome Measure
Left Ventricular Diameter, Atrial septal defect closure with non-fenestrated patch
Fenestrated patch
Left Ventricular Diameter, Atrial septal defect closure with non-fenestrated patch
Secondary Outcome Measure
Left Ventricular Diameter, Atrial septal defect closure with fenestrated patch
Tertiary Outcome Measure
Left Ventricular Diameter, Atrial septal defect closure with non-fenestrated patch
Left Ventricular Diameter, Atrial septal defect closure with fenestrated patch
Secondary Outcome Measure
Left Ventricular Diameter, Atrial septal defect closure with non-fenestrated patch
Left Ventricular Diameter, Atrial septal defect closure with fenestrated patch
Secondary Outcome Measure
Left Ventricular Diameter, Atrial septal defect closure with non-fenestrated patch
Left Ventricular Diameter, Atrial septal defect closure with fenestrated patch
Secondary Outcome Measure
Left Ventricular Diameter, Atrial septal defect closure with non-fenestrated patch
Left Ventricular Diameter, Atrial septal defect closure with fenestrated patch
Secondary Outcome Measure
Left Ventricular Diameter, Atrial septal defect closure with non-fenestrated patch
Left Ventricular Diameter, Atrial septal defect closure with fenestrated patch
Secondary Outcome Measure
Left Ventricular Diameter, Atrial septal defect closure with non-fenestrated patch
Left Ventricular Diameter, Atrial septal defect closure with fenestrated patch
Secondary Outcome Measure
Left Ventricular Diameter, Atrial septal defect closure with non-fenestrated patch
Left Ventricular Diameter, Atrial septal defect closure with fenestrated patch
Secondary Outcome Measure
Left Ventricular Diam"
977,"[/INST]

Inclusion Criteria
-----------------
Patients with papillary thyroid cancer.
Participation in the study is limited to adults 18-65 years of age.
Exclusion Criteria
-----------------
Patients with papillary thyroid cancer.
Participation in the study is limited to adults 18-65 years of age.
Normal thyroid function will be measured by immunofluorescence assay.
months 1-24 |
Outcome Measures
-----------------
Participation in the study is limited to adults 18-65 years of age.
months 1-24 |
Normal thyroid function will be measured by immunofluorescence assay.
Outcome Measures
-----------------
Participation in the study is limited to adults 18-65 years of age.
months 1-24 |
Normal thyroid function will be measured by immunofluorescence assay.
Outcome Measures
-----------------
Participation in the study is limited to adults 18-65 years of age.
months 1-24 |
Normal thyroid function will be measured by immunofluorescence assay.
Outcome Measures
-----------------
Participation in the study is limited to adults 18-65 years of age.
months 1-24 |
Normal thyroid function will be measured by immunofluorescence assay.
Outcome Measures
-----------------
Participation in the study is limited to adults 18-65 years of age.
months 1-24 |
Normal thyroid function will be measured by immunofluorescence assay.
Outcome Measures
-----------------
Participation in the study is limited to adults 18-65 years of age.
months 1-24 |
Normal thyroid function will be measured by immunofluorescence assay.
Outcome Measures
-----------------
Participation in the study is limited to adults 18-65 years of age.
months 1-24 |
Normal thyroid function will be measured by immunofluores"
978,"[/INST]








































































































































































































-
-
-
-
-"
979,"[/INST]

















































































































-













-
-
-
-
-
-
-
-
-





-
-
-
-
-
-
-
-
-




-
-
-
-
-
-
-



-
-
-
-




-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-




-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-


-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-










-
-
-
-

-
-
-






-
-
-
-
-
-
-
-
-

















O
O










































O
O
O
O






O
O
O
O
O














O
O
O
O
O
O
O
O
O
O
O
O
O
O

O
O
O"
980,"[/INST]
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intrathoracic | Other: No intervention
Sarcoidosis - intr"
981,"[/INST]

Study Design
-----------------
| Single | Interventional
| Randomized
| Sham
| Not blinded
| Not masked
| Not peer reviewed
| Not implemented
| Not standardized
| Not audited
| Not monitored
| Not reported
| Not tracked
| Not measured
| Not analyzed
| Not evaluated
| Not discussed
| Not considered
| Not thought about
| Not planned
| Not budgeted for
| Not a priority
| Not part of the agenda
| Not on the radar
| Not on the horizon
| Not a concern
| Not a priority
| Not a focus
| Not a goal
| Not a target
| Not a KPI
| Not a metric
| Not a measure of success
| Not a part of the Balanced Scorecard
| Not a target
| Not a KPI
| Not a metric
| Not a part of the Balanced Scorecard
| Not a goal
| Not a target
| Not a measure
| Not a KPI
| Not a part of the strategy
| Not a target
| Not a measure
| Not a KPI
| Not a part of the Balanced Scorecard
| Not a goal
| Not a target
| Not a measure
| Not a KPI
| Not a part of the strategy
| Not a target
| Not a measure
| Not a KPI
| Not a part of the Balanced Scorecard
| Not a goal
| Not a target
| Not a measure
| Not a KPI
| Not a part of the strategy
| Not a target
| Not a measure
| Not a KPI
| Not a part of the Balanced Scorecard
| Not a goal
| Not a measure
| Not a target
| Not a KPI
| Not a part of the strategy
| Not a measure
| Not a target
| Not a KPI
| Not a part of the Balanced Scorecard
| Not a goal
| Not a measure
| Not a target
| Not a KPI
| Not a part of the strategy
| Not a measure
| Not a target
| Not a KPI
| Not a part of the Balanced Scorecard
| Not a goal
| Not a measure
| Not a"
982,"[/INST]

How is the study designed?
-----------------
Patients receiving immunotherapy for the first time were included in the study.

What is the study measuring?
-----------------
Patients receiving immunotherapy for the first time were included in the study.

How is the study designed?
-----------------
Patients receiving immunotherapy for the first time were included in the study.

What is the study measuring?
| Drug: Solid tumor patients receiving immunotherapy for the first time were included in the study| Baseline information before treatment (including demographic characteristics, medical history, etc.) and follow-up information after treatment (including quality of life, etc.) |

How is the study designed?
-----------------
Patients receiving immunotherapy for the first time were included in the study.

What is the study measuring?
| Drug: Solid tumor patients receiving immunotherapy for the first time were included in the study| Baseline information before treatment (including demographic characteristics, medical history, etc.) and follow-up information after treatment (including quality of life, etc.) |

How is the study designed?
-----------------
Patients receiving immunotherapy for the first time were included in the study.

What is the study measuring?
| Drug: Solid tumor patients receiving immunotherapy for the first time were included in the study| Baseline information before treatment (including demographic characteristics, medical history, etc.) and follow-up information after treatment (including quality of life, etc.) |

How is the study designed?
-----------------
Patients receiving immunotherapy for the first time were included in the study.

What is the study measuring?
| Drug: Solid tumor patients receiving immunotherapy for the first time were included in the study| Baseline information before treatment (including demographic characteristics, medical history, etc.) and follow-up information after treatment (including quality of life, etc.) |

How is the study designed?
-----------------
Patients receiving immunotherapy for the first time were included in the study.

What is the study measuring?
| Drug: Solid tumor patients receiving immunotherapy for the first time were included in the study| Baseline information before treatment (including demographic characteristics"
983,"[/INST]
A
A
8
8
A
A
A
A
A
A
A
A
A
A
A
A
A
A-
A-
A-
A-
A-
A-
A-
A
A
A
A-
A-
A-A-A-A-A-A-
A-
A-
A-
A-A-A-A-A-A-A-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
A-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-A-A-A-A-A-A-A-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-
-A-A-
-
-A-A-A-A-A-A-A-A-A-
-A-
-A-A-A-A-A-8-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-0-0-000-0-0-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A"
984,"[/INST]
| Active Comparator: Card referrals alone
| Control arm | Card referrals alone
| Participants will be offered confidential HIV testing | Control arm referrals alone
| Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Control arm referrals alone
| Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card referrals alone
| Control arm referrals alone
| Participants will be offered confidential HIV testing | Card refer"
985,"[/INST]
| Experimental: Paroxetine<br>40mg, single dose a day, for 05 consecutive days or 24 hours |
| Placebo: 40mg, single dose a day, for 05 consecutive days or 24 hours |
| Experimental: Paroxetine<br>40mg, single dose a day, for 05 consecutive days or 24 hours |
| Cumulative vasopressor dose of 120 hours, for 90 days | Dose of infused norephineprine and/or vasopressin during 120 hours |
| Total sequential organ failure assessment score varies between 0 and +2 points, higher scores meaning worse dysfunction | 120 hours |
| Mortality during the stay in the ICU | 90 days |
| Cumulative vasopressor dose for 120 hours, for 90 days | Dose of infused norephineprine and/or vasopressin during 120 hours |
| Total sequential organ failure assessment score varies between 0 and +2 points, higher scores meaning worse dysfunction | 120 hours |
| Experimental: Paroxetine<br>40mg, single dose a day, for 05 consecutive days or 24 hours |
| Cumulative vasopressor dose of 120 hours, for 90 days | Dose of infused norephineprine and/or vasopressin during 120 hours |
| Total sequential organ failure assessment score varies between 0 and +2 points, higher scores meaning worse dysfunction | 120 hours |
| Mortality during the stay in the ICU | 90 days |
| Experimental: Paroxetine<br>40mg, single dose a day, for 05 consecutive days or 24 hours |
| Total sequential organ failure assessment score varies between 0 and +2 points, higher scores meaning worse dysfunction | 120 hours |
| Mortality during the stay in the ICU | 90 days |
| Cumulative vasopressor"
986,"[/INST]
Primary Outcome Measure
psychoeducation
Secondary Outcome Measure
psychoeducation
Experimental: [/INST]
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychoeducation
psychotherapy
psychoeducation
psychotherapy
psychology
psychoeducation
psychotherapy
psychoeducation
psychotherapy
psychotherapy
psychotherapy
psychotherapy
psychotherapy
psychotherapy
psychotherapy
psychotherapy
psychotherapy
psychotherapy
psychotherapy
psychotherapy
psychildren
psychildren
psychildren
psychildren
psychildren, psychotherapy, psychotherapy, psychotherapy, psychotherapy, and psychotherapy, and the patient
psychild, psychotherapy, and the psychother, psychother, psychother, psychother, psychother, psychother, psychother, psychother, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychotherapy, this psychology, this psychology, this psychology, this psychology, this psychology, this psychology,"
987,"[/INST]

How is the study designed?
-----------------
| Eligibility Criteria | Participation in the study | Exclusion Criteria |
| Inclusion Criteria | Participation in the study | Exclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Exclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Time Frame |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Primary Outcome | Secondary Outcome |
| Exclusion Criteria |
| Inclusion Criteria |
| Time Frame |
| Primary Outcome"
988,"[/INST] g-m-m-m-A-A-A, A-m-m-m-m-m-A D-m-A D-A D-A-A-A A-st-st-st-st-m-st-st-st-st-A-A-st-a-a-a-a-A-A-A-A- a- a- a-A-A-A-A-A-st-st-m-m-st-A-A-A-A-A-A-A-m-st-a-A-A-A-A D-A-A-A-st-m-st-m-st-m-st-m-st-A-A-A-A-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-st-dis-dis-A-A-dis-A-A-A-A-A-A-st-st-st-st-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-a-a-a-a-a-a-a-a-a-A-A-A-a-a-a-a-a-a-A-A-A-A-A-A-A-A-A-a-A-A-A-A-A-A-A-A-A-a-A-A-A-A-a-a-a-a-a-a-A-a-a-a-a-a-a-a-a-a-a-a-a-A-a-a-A-A-A-A-A-A-h-a-a-a-h-h-A-A-A-A-A-st-st-st-st-a-A-A-A-A-A-A-A-m-g-s.-s.-a.-a. a. a.-a-a-a-a-a-a-a-A, a, a, a,.,."
989,"[/INST]
-p-p-p-p-p-p-
-
-
-
-
-
-


















0






































-
-
-
-
-
-C-C-C
-
-
-

-
-
-p-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-C-C-
-C-
-
-
-
-
-
-
-C-C-C-
-
-
-
-
-
-
-
-
-
-
-
O
C
C
C
O
-
-
C-
O-
O
O-
O
O
O
O
O
O
-
-
C
C
O-
C-
-
-
-
-
C
C
C
C
C





-
-

















0

O
-
O



















C
-
C-
C
C
O
O
O
O
O
C
C
C000
C0
C0
O
O
O
O
O
O
O
O
O
C














































C
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O"
990,"[/INST]
Adverse Events and Precautions
| Headache | Nausea | Diarrhea | Asthenia |
| Muscle cramps | Fatigue | Change from baseline in weight | 
| Skin rash | Change from baseline in appearance of skin lesions | 
| Itching | Change from baseline in the number of semen | 
| Runny nose | Sneezing |
| Other adverse events as observed during the study |
| Other laboratory abnormalities as observed during the study |
| Changes in vital signs as observed during the study |
| Physical exam as observed during the study |
| Weight as measured at baseline and at End of the study | 
| Change from baseline in weight | 
| Change from baseline in waist circumference | 
| Change from baseline in hip circumference | 
| Change from baseline in thigh circumference | 
| Change from baseline in calf circumference | 
| Other physical exam as observed during the study |
| Other laboratory abnormalities as observed during the study |
| Other adverse events as observed during the study |
| Changes in vital signs as observed during the study |
| Physical exam as observed at the end of the study |
| Weight as measured at baseline and at End of the study | 
| Change from baseline in weight | 
| Change from baseline in waist circumference | 
| Change from baseline in hip circumference | 
| Change from baseline in thigh circumference | 
| Other physical exam as observed during the study |
| Other laboratory abnormalities as observed during the study |
| Changes in vital signs as observed during the study |
| Physical exam as observed at the end of the study |
| Change from baseline in weight | 
| Change from baseline in waist circumference | 
| Change from baseline in thigh circumference | 
| Other physical exam as observed during the study |
| Other laboratory abnormalities as observed during the study |
| Changes in vital signs as observed during the study |
| Physical exam as observed at the end of the study |
| Other laboratory abnormalities as observed during the study |
| Change from baseline in weight"
991,"[/INST]
Primary Outcome Measure
-----------------
| Secondary Outcome Measure | Time Frame |
| Outcome Measure | Measure Description |
| Secondary Outcome Measure | Time Frame |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Secondary Outcome Measure | Time Frame |
Terms related to the study: [/INST]
Secondary Outcome Measure
-----------------
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
Terms related to the study: [/INST]
Secondary Outcome Measure
-----------------
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
Terms related to the study: [/INST]
Secondary Outcome Measure
-----------------
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
Terms related to the study: [/INST]
Secondary Outcome Measure
-----------------
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
Terms related to the study: [/INST]
Secondary Outcome Measure
-----------------
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
Terms related to the study: [/INST]
Secondary Outcome Measure
-----------------
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
Terms related to the study: [/INST]
Secondary Outcome Measure
-----------------
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
| Outcome Measure | Measure Description |
Terms related to the study: [/INST]
Secondary Outcome Measure
-----------------
| Outcome Measure | Measure Description |
| Outcome Me"
992,"[/INST]

| Drug: VyndaMx Capsules |
| Patients with ATTR-CM |
| India-based study of Tafamidis |
| Hereditary transthyretin amyloid cardiomyopathy |
| Case report form |

| Transthyretin-based study of VyndaMx Capsules |
| Patients with cardiomyopathy |

| Tafamidis, India-based study of VyndaMx Capsules |
| Hereditary transthyretin amyloid cardiomyopathy |
| Case report form |

| Transthyretin-based study of VyndaMx Capsules |
| Patients with ATTR-CM |
| Hereditary transthyretin amyloid cardiomyopathy |
| Case report form |

| Tafamidis, India-based study of VyndaMx Capsules |
| Patients with ATTR-CM |
| Hereditary transthyretin amyloid cardiomyopathy |
| Case report form |

| Tafamidis, India-based study of VyndaMx Capsules |
| Patients with ATTR-CM |
| Hereditary transthyretin amyloid cardiomyopathy |
| Case report form |

| Tafamidis, India-based study of VyndaMx Capsules |
| Patients with ATTR-CM |
| Hereditary transthyretin amyloid cardiomyopathy |
| Case report form |

| Tafamidis, India-based study of VyndaMx Capsules |
| Patients with ATTR-CM |
| Hereditary transthyretin amyloid cardiomyopathy |
| Case report form |

| Tafamidis, India-based study of VyndaMx Capsules |
| Patients with ATTR-CM |
| Hereditary transthyretin amylo"
993,"[/INST]
Primary Outcome Measures
-----------------
Surgical wound infection | 6 months after surgery
Secondary Outcome Measures
Surgical wound infection | 6 months after surgery
Sternal halves union | 6 months after surgery
Sternal integrity | 6 months after surgery
Keywords: Surgical wound infection, sternotomy
=================
Surgical wound infection | 6 months after surgery
Secondary Outcome Measures
Sternal halves union | 6 months after surgery
Surgical wound infection | 6 months after surgery
Sternal halves union | 6 months after surgery
Keywords: Surgical wound infection, sternotomy
Surgical wound infection | 6 months after surgery
Secondary Outcome Measures
Surgical wound infection | 6 months after surgery
Sternal halves union | 6 months after surgery
Surgical wound infection | 6 months after surgery
Secondary Outcome Measures
Surgical wound infection | 6 months after surgery
Surgical wound infection | 6 months after surgery
Sternal halves union | 6 months after surgery
Surgical wound infection | 6 months after surgery
Surgical wound infection | 6 months after surgery
Surgical wound infection | 6 months after surgery
Surgical wound infection | 6 months after surgery
Surgical wound infection | 6 months after surgery
Surgical wound to be surgery
Surgical wound to be surgical wound to be surgical wound, surgical wound to be surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surgical wound, surg"
994,"[/INST]
| Pain will be assessed using the lumbar and hip extension exercises, and will be asked to respond to the post-intervention questionnaire. | The Global Perceived musculoskeletal pain and sitting position, break and will be assessed using the lumbar and hip extension exercises. |


Active Break
| Pain will be assessed using the post-intervention questionnaire. |
| The Global Perceived musculoskeletes and hip extension exercises, and will be assessed using the post-intervention questionnaire. |
| Pain will be assessed using the lumbar and hip extension, and sitting position, and will be assessed using the post-intervention. |
| Pain will be assessed using the post-intervention. |
| The Global pain will be assessed using the post-intervention. | Pain will be assessed using the post-intervention. |
|
Active pain will be assessed using the post-intervention. |
|
|
| The Global pain assessed pain. |
|
|
Active pain will be assessed the pain. |
|
|
Active pain will be assessed the pain assessed the pain assessed pain
|
Active pain will be assessed pain. |
Active pain. |
|
Active pain.
Active pain.
|
Active pain.
|
|
Active pain.
|
|
Active pain.
Active pain.
Active pain.
Active pain.
|
|
|
|
Active pain.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|   988
|   99
==es.
|
|
|
|
|
|
|
|
These
These
These
|
|
|
|"
995,"[/INST]
, the mother-the-the-the-the-the-the-the-the-text, it-.
, the-the-text.
, teen.
, it.
, it.
, the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-the-.
, the-the-the-the-.
, the-the.
, the-the.
, the-the.
The symptine.
and.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The.
The, it.
The.
The.
The.
The.
The.
be.
The.
It.
It.
It.
It.
It.
It.
It.
It.
It.
g
g
The,
The,
The,
The,
and
and.
==
==
==
==
==
is
is
is
is
is
is
is
is
is
is
is
==
==
The
St
St
St
St
and
and
is
is
is
is
is
is
st
st
and
and
and
and
and
and
st
==
==
==
st
st
st
st
st
st
st
st
st
==
==
St
St
st
st
st
st
st
st
st
st
st
st
st"
996,"[/INST]
Secondary Outcome Measures
-----------------
Patients with secondary erythrocytosis
Exclusion Criteria: [/INST]
History of thrombosis
Patients with polycythemia vera will be included as controls and will be recruited from Sohag university hospital, especially internal medicine department and chest department.
How is the study designed?
Patients with polycythemia vera will be included as controls and will be recruited from Sohag university hospital, especially internal medicine department and chest department.
What is the study measuring?
Patients with polycythemia vera will be included as controls and will be recruited from Sohag university hospital, especially internal medicine department and chest department.
How is the study designed?
Patients with polycythemia vera will be included as controls and will be recruited from Sohag university hospital, especially internal medicine department and chest department.
What is the study measuring?
Patients with polycythemia vera will be included as controls and will be recruited from Sohag university hospital, especially internal medicine department and chest department.
How is the study designed?
Patients with polycythemia vera will be included as controls and will be recruited from Sohag university hospital, especially internal medicine department and chest department.
What is the study measuring?
Patients with polycythemia vera will be included as controls and will be recruited from Sohag university hospital, especially internal medicine department and chest department.
How is the study designed?
Patients with polycythemia vera will be included as controls and will be recruited from Sohag university hospital, especially internal medicine department and chest department.
What is the study measuring?
Patients with polycythemia vera will be included as controls and will be recruited from Sohag university hospital, especially internal medicine department and chest department.
How is the study designed?
Patients with polycythemia vera will be included as controls and will be recruited from Sohag university hospital, especially internal medicine department and chest department.
How is the study designed?
Patients with polycythemia vera will be included as controls and will be recruited from Sohag university hospital, especially internal"
997,"[/INST]
Adult patients with dyspnea
| Exclusion Criteria: Patients with known vascular disease, peripheral artery disease, or trauma due to the emergency triage status
| Inclusion Criteria: Patients over the age of 18 years with dyspnea, whose perfusion index could not be measured at the time of first admission to the emergency department
| Exclusion Criteria: Patients with known vascular disease, whose perfusion index could not be completed due to hospitalization or discharge
| Participation Criteria: Adult patients with dyspnea, whose perfusion index could not be measured at the time of first hour
| Exclusion Criteria: Patients with known vascular disease, whose perfusion index could not be completed due to trauma status
| Inclusion Criteria: Patients with dyspnea, whose perfusion index could not be measured at the time of the second hour after hospitalization
| Exclusion Criteria: Patients with known vascular disease, whose perfusion index could not be completed due to trauma status
| Participation Criteria: Adult patients with dyspnea, whose perfusion index could not be measured at the time of first admission to the emergency department
| Exclusion Criteria: Patients with known vascular disease, whose perfusion index could not be measured at the time of the second hour after hospitalization
| Inclusion Criteria: Patients with dyspnea, whose perfusion index could not be measured at the time of first admission to the emergency department
| Exclusion Criteria: Patients with known vascular disease, whose perfusion index could not be measured at the time of the second hour after hospitalization
| Participation Criteria: Adult patients with dyspnea, whose perfusion index could not be measured at the time of first admission to the emergency department
| Exclusion Criteria: Patients with known vascular disease, whose perfusion index could not be measured at the time of the second hour after hospitalization
| Inclusion Criteria: Patients with dyspnea, whose perfusion index could not be measured at the time of first admission to the emergency department
| Exclusion Criteria: Patients with known vascular disease, whose perfusion index could not be measured at the time"
998,"[/INST]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The study.
The study.
|
|
The study.
----------------
----------------
----------------
----------------
----------------
----------------
----------------
----------------
The study.
The study.
The
The
The
The study.
The study.
The patient
The patient
The patient
The patient
The patient
The patient
The patient.
The patient.
The patient
The patient
The patient.
The patient.
The patient
----------------
----------------
----------------
----------------
------------
------------
------------
------------
in
in
in
in
in
==
This
This
This
------------
------------
------------
----------------
----------------
----------------
------------
----------------
----------------
----------------
--------
--------
--------
--------
This
This
in
in
in
in
in
in
in
in
This
This
This
This
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
in
This
This
This
This
This
This
in
This
This
This
This
This
This
This
in
in
in
in
in
in
in
in
in
in
in
in
in
in
This
This
in
in
in
This
This
This
This
This
This
This"
999,"[/INST]
prenatal education, perinatal outcomes, text messaging, mobile health, birth, mental health, behaviour, and [INST]
prenatal education, perinatal outcomes, text messaging, mobile health, behaviour, birth, mental health, and [INST]
Summary: [/INST]
prenatal education, perinatal outcomes, text messaging, mobile health, behaviour, birth, mental health, and [INST]
prenatal education, perinatal outcomes, text messaging, mobile health, behaviour, birth, mental health, and [INST]
Summary: [/INST]
prenatal education, perinatal outcomes, text messaging, mobile health, behaviour, birth, mental health, and [INST]
prenatal education, perinatal outcomes, text messaging, mobile health, behaviour, birth, mental health, and [INST]
Summary: [/INST]
prenatal education, perinatal outcomes, text messaging, mobile health, behaviour, birth, mental health, and [INST]
prenatal education, perinatal outcomes, text messaging, mobile health, behaviour, birth, mental health, and [INST]
prenatal education, perinatal outcomes, text messaging, behaviour, birth, mental health, mobile health, behaviour, text messaging, perinatal education, perinatal education, text messaging, behaviour, mental health, text messaging, perinatal education, text messaging, perinatal education, text messaging, birth, mental health, text messaging, perinatal education, text messaging, perinatal education, text messaging, birth, text messaging, perinatal education, text messaging, perinatal education, text messaging, perinatal education, text messaging, perinatal education, text messaging, birth text messaging, perinatal education, text messaging, perinatal education, text messaging, text messaging, perinatal education text messaging, text messaging, text messaging, text messaging, perinatal education text messaging, text messaging, text messaging, text messaging, text messaging, text messaging, text messaging, text messaging, text messaging, text messaging, text messaging, text messaging, text messaging, text messaging, text mess"
